<SEC-DOCUMENT>0001731122-24-002041.txt : 20241223
<SEC-HEADER>0001731122-24-002041.hdr.sgml : 20241223
<ACCEPTANCE-DATETIME>20241223163033
ACCESSION NUMBER:		0001731122-24-002041
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241223
DATE AS OF CHANGE:		20241223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				980608404
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		241574057

	BUSINESS ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111
		BUSINESS PHONE:		844-689-3939

	MAIL ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e6219_10-k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:avxl="http://anavex.com/20240930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_035_avxl_anavex.com_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20231001_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000005" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-09-30" id="xdx2ixbrl0084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-09-30" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2023-10-01to2024-09-30" id="xdx2ixbrl0158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-10-01to2024-09-30" id="xdx2ixbrl0170" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2023-10-01to2024-09-30" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-09-30" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-01to2024-09-30" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2024-09-30" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-09-30" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-09-30" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-10-012023-09-30" id="xdx2ixbrl0868" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" contextRef="From2023-10-01to2024-09-30" id="xdx2ixbrl0873" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-10-01to2024-09-30" id="xdx2ixbrl0891" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20240930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-10-01to2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_MichaelJFoxFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_PurchaseAgreement2020Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2020Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-242022-03-25_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-24</xbrli:startDate>
        <xbrli:endDate>2022-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20231001__20240930_zhXoq1C9Tvc"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000011" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 12pt Courier New, Courier, Monospace; margin: 0; text-align: center"><span id="xdx_90E_edei--DocumentAnnualReport_c20231001__20240930_zhZYK0hOhqXd"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_902_edei--DocumentPeriodEndDate_c20231001__20240930_zUYPGJ8eJvv"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20231001__20240930_zOw3IJXkvlde"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">September 30</ix:nonNumeric></span>, <span id="xdx_901_edei--DocumentFiscalYearFocus_c20231001__20240930_zMgORIAhD0Vf"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000015" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_90C_edei--DocumentTransitionReport_c20231001__20240930_zFOXdtbQA1kj"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ______________ to________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number<b>: <span style="text-decoration: underline"><span id="xdx_90F_edei--EntityFileNumber_c20231001__20240930_zFAw29SvJUp2"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000017" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityRegistrantName_c20231001__20240930_zhKL351b7M44"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000018" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 57%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20231001__20240930_zhAnjTtwErrb"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20231001__20240930_zoQi8U2qerB1"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000020" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction of incorporation or organization)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--EntityAddressAddressLine1_c20231001__20240930_zZiNZB3eilsa"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000021" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20231001__20240930_zgOv7DwfeSP8"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000022" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20231001__20240930_zezg98TBPs2g"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000023" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20231001__20240930_z51hosMAEU19"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000024" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressCountry_c20231001__20240930_z6xsaWEzfi3f"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000025" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20231001__20240930_zuYOSKZJb07k"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000026" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code <span style="text-decoration: underline">1-<span id="xdx_907_edei--CityAreaCode_c20231001__20240930_zg9NTA2J65Gf"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000027" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20231001__20240930_zq32WDapXS93"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000028" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered under Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--Security12bTitle_c20231001__20240930_zH4uvh4Zya0g"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000029" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--TradingSymbol_c20231001__20240930_zjG5IQfUFZAg"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000030" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--SecurityExchangeName_c20231001__20240930_zZrDq3L6rKBf"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Trading Symbol</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(g) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of class)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityWellKnownSeasonedIssuer_c20231001__20240930_zWVQtlv9thyb"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric></span>&#160;&#9746;
No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Yes&#160;&#9744;
<span id="xdx_903_edei--EntityVoluntaryFilers_c20231001__20240930_zwDFhUwb4ybk"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityCurrentReportingStatus_c20231001__20240930_zpATUAsAiuJ4"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;
No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityInteractiveDataCurrent_c20231001__20240930_zYtnlP5XawJ8"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;
No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding: 0pt; width: 28%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Large
    accelerated filer &#9744;</span></td>
    <td style="padding: 0pt; vertical-align: top; width: 37%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: top; width: 35%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Accelerated
    filer &#9744;</span></td></tr>
  <tr>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityFilerCategory_c20231001__20240930_zxB6rR2EqBjh"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Smaller
    reporting company <span id="xdx_90A_edei--EntitySmallBusiness_c20231001__20240930_za21br9jwWLi"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; vertical-align: top; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Emerging
    growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20231001__20240930_zw8WX4euOsL3"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal controls over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Yes&#160;&#9744;
<span id="xdx_90E_edei--IcfrAuditorAttestationFlag_c20231001__20240930_zs1Ms8g9p8S8"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--DocumentFinStmtErrorCorrectionFlag_c20231001__20240930_zELtLE9FnzBd"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Yes&#160;&#9744;
<span id="xdx_904_edei--EntityShellCompany_c20231001__20240930_zKKNFbNsvN1l"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Courier New, Courier, Monospace; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">State the aggregate market value of the voting and
non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average
bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal
quarter: $<span id="xdx_901_edei--EntityPublicFloat_iI_pn6n6_c20240331_z8E6Xy76SJNf"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-03-31" id="Fact000042" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">412</ix:nonFraction></span> million based on a price of $5.09 per share, being the closing price of the registrant&#8217;s common stock on March 31,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of each
of the registrant&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20241223_zmoA84gCws4c"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-12-23" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,815,517</ix:nonFraction></span> issued and outstanding as of December
23, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">TABLE OF CONTENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="width: 90%; text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_001">PART I</a></td>
    <td style="width: 10%; text-align: right; padding-top: 0cm; padding-bottom: 0pt">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_002">ITEM 1. BUSINESS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_003">ITEM 1A. RISK FACTORS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_004">ITEM 1B. UNRESOLVED STAFF COMMENTS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_005">ITEM 1C. CYBERSECURITY</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_006">ITEM 2. PROPERTIES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_007">ITEM 3. LEGAL PROCEEDINGS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_008">ITEM 4. MINE SAFETY DISCLOSURES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0cm"><a href="#a_009">PART II</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_010">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_012">ITEM 7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_013">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_014">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">F-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_015">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_016">ITEM 9A. CONTROLS AND PROCEDURES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_017">ITEM 9B OTHER INFORMATION</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_018">ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0cm"><a href="#a_019">PART III</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_020">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_021">ITEM 11. EXECUTIVE COMPENSATION</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">77</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_022">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">83</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_023">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">86</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_024">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">87</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 0cm"><a href="#a_025">PART IV</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">88</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_026">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">88</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0cm; padding-left: 10pt"><a href="#a_027">ITEM 16. FORM 10-K SUMMARY</a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0cm">89</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward Looking Statements.</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
&#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;would&#8221;, &#8220;will&#8221;, &#8220;suggest,&#8221; &#8220;plan&#8221;
and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include,
without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">volatility in our stock price and in the markets
in general;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to successfully conduct preclinical
studies and clinical trials for our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to raise additional capital on favorable
terms and the impact of such activities on our stockholders and stock price;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to generate any revenue or to continue
as a going concern;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to execute our research and development
plan on time and on budget;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our product candidates&#8217; ability to demonstrate
efficacy or an acceptable safety profile;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to obtain the support of qualified
scientific collaborators;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability, whether alone or with commercial
partners, to successfully commercialize any of our product candidates that may be approved for sale;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to identify and obtain additional
product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our reliance on third parties in non-clinical
studies and clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to defend against product liability
claims;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to safeguard against security breaches;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to obtain and maintain sufficient
intellectual property protection for our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to comply with our intellectual property
licensing agreements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to defend against claims of intellectual
property infringement;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to comply with the maintenance requirements
of the government patent agencies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to protect our intellectual property
rights throughout the world;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">competition;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the anticipated start dates, durations and completion
dates of our ongoing and future clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the anticipated designs of our future clinical
trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our ability to attract and retain qualified employees;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the impact of Fast Track designation on receipt
of actual FDA approval;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our anticipated future regulatory submissions
and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast Track
designations; and </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our anticipated future cash position and ability
to obtain funding for our operations. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.65pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements largely
on our current expectations and projections about future events, including the responses we expect from the U.S. Food and Drug Administration,
(&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may affect our financial condition, results
of operations, business strategy, preclinical studies and clinical trials, and financial needs. These forward-looking statements are subject
to a number of risks, uncertainties and assumptions including, without limitation, the risks described in &#8220;Risk Factors&#8221; in
Part I, Item 1A of this Annual Report on Form 10-K. These risks are not exhaustive. Other sections of this Annual Report on Form 10-K
include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive
and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk
factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as
required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Annual Report on Form 10-K, the terms
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221; and &#8220;Anavex&#8221; mean Anavex Life Sciences Corp.,
unless the context clearly requires otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_001"></span>PART I</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_002"></span>ITEM 1. BUSINESS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview and Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage biopharmaceutical
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two seed programs.
Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="image_001.jpg" alt="" style="height: 414px; width: 1000px"/><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying in sigma-1
receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone protein with
important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope and restores
homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds to activate quantitatively
the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography (PET) imaging scan in
mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) target engagement or receptor occupancy with SIGMAR1
in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 310pt; width: 468pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Source: Reyes S et al., Sci Rep. 2021 Aug 25;11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused by chronic
homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile spasms, chronic cellular
stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such as Alzheimer&#8217;s and
Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic
cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons
and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy, a characteristic found in Alzheimer&#8217;s
and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.
The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in
nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, and neurofibrillary
tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation
of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73 (blarcamesine), our approach is to
restore cellular balance (i.e. homeostasis). Therapies that correct defects in cellular homeostasis might have the potential to halt or
delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73 (blarcamesine)-specific
Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we have incorporated
a genomic analysis to better understand potential populations for whom our clinical programs might benefit. In our clinical trials, a
full genomic analysis of Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) has helped us identify
actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine)
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73
(blarcamesine) specific biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73
(blarcamesine), which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points,
provides support for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) by using genetic
biomarkers identified within the trial population itself to either confirm the mechanism of action of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine)
or target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) treatment. We may in the future utilize
such an approach in Alzheimer&#8217;s disease as well as indications like Parkinson&#8217;s disease dementia in which ANAVEX<sup>&#174;</sup>2-73
(blarcamesine) is currently being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the safety
and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic (&#8220;PK&#8221;)
and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect relationship between
ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated in the entire 57 weeks include
exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the clinical trial appeared
to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which also targets the SIGMAR1
receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase 2a
trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing these Phase
2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department
of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
trial of ANAVEX<sup>&#174;</sup>2-73 in early Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 trial enrolled 508 patients,
which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized 1:1:1 to two different
ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and Australia. Primary and
secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s Disease Assessment
Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily
Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (&#8220;CDR-SB&#8221;). In
addition to these endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses related
to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a clinical trial. The
trial was completed in mid-2022 and, in December 2022, the Company presented topline results from the Phase 2b/3 clinical trial. All statistical
analyses were performed by outside consultancy companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, all pre-specified clinical endpoints were analyzed using a mixed model
for repeated measures (MMRM). Under the multiplicity control rule, a trial is successful in meeting the co-primary endpoints if the significance
of each endpoint is P &lt; 0.05, or if the significance of only one co-primary endpoint is P &lt; 0.025. If only one primary endpoint
is significant at an &#945; level of 0.025, then the secondary endpoint will be evaluated at the same level of 0.025. The trial was successful,
the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the ANAVEX<sup>&#174;</sup>2-73 and placebo groups
for ADAS-Cog13 was significant at a level of P &lt; 0.025 and for CDR-SB was significant at a level of P &lt; 0.025, in the patients with
early Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The comparison of individual dose groups vs placebo
also supports blarcamesine&#8217;s efficacy. For the primary endpoint ADAS-Cog13, blarcamesine is significantly better than placebo (&#8722;2.027;
P = 0.0079) as well as for both the 50 mg (&#8722;2.149; P = 0.021) and the 30 mg (&#8722;1.934; P = 0.026) blarcamesine dosage groups
at Week 48, representing that blarcamesine slowed clinical progression at 48 weeks by 36.3% and by 38.5% and 34.6% in 50 mg and 30 mg
groups vs. placebo, respectively. The functional co-primary endpoint, ADCS-ADL, was trending in a positive direction but did not reach
significance at Week 48. The key secondary endpoint CDR-SB was significantly improved vs. placebo (&#8722;0.483, P = 0.0104) as well as
in both 50 mg (&#8722;0.465; P = 0.045) and 30 mg (&#8722;0.502; P = 0.020) groups at Week 48. Clinical Global Impression &#8211; Improvement
(&#8220;CGI-I&#8221;) was also significantly improved vs. placebo (&#8722;0.278, P = 0.004) as well as in both the 50 mg (&#8722;0.314;
P = 0.008) and the 30 mg (&#8722;0.248; P = 0.024) groups at Week 48. The findings are supported by biomarkers, including plasma A&#946;42/40-ratio
and reduction of brain atrophy. Blarcamesine significantly slowed brain atrophy in key regions of interest, including the whole brain
by 37.6%, total grey matter by 63.5%, and lateral ventricles by 25.1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the respective safety population, common treatment-emergent
adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred in 120 participants (35.8%)
during titration and in 76 participants (25.2%) during maintenance with ANAVEX<sup>&#174;</sup>2-73 and 10 (6.0%) during titration and
9 (5.6%) during maintenance with placebo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, we announced the submission of a
Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for ANAVEX<sup>&#174;</sup>2-73 for the treatment of
Alzheimer's disease and, in December 2024, the EMA accepted the submission for scientific review. The MAA, if approved, would allow direct
market access throughout the European Union for oral ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) for the treatment of Alzheimer&#8217;s
disease.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A subsequent long-term open label extension study
of ANAVEX<sup>&#174;</sup>2-73, referred to as the ATTENTION-AD trial, was initiated for patients who completed the 48-week Phase 2b/3
placebo-controlled trial referenced above. This trial extension for a duration of up to 96/144 additional weeks was completed in June
2024. The trial extension will provide additional longer-term safety and efficacy data of ANAVEX<sup>&#174;</sup>2-73 in persons with early
Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related significant
improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes neurological symptoms
that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January
2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase 2
clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The clinical
trials were conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation
of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001),
which took place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety,
tolerability, PK and efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome
over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The primary endpoint
of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional PK. All secondary
efficacy endpoints of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome Behaviour Questionnaire
(&#8220;RSBQ&#8221;) response, when compared to placebo, in the intent to treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011).
66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant improvement in RSBQ response as compared to 10%
of the subjects on placebo in the ITT cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained
improvement in CGI-I response throughout the 7-week clinical trial, when compared to placebo in the ITT cohort (all participants, p =
0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated
with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified efficacy endpoints. No other clinical trials with
ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome have been conducted in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June
2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett
syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Based
upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001), we updated the endpoints for
the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful outcome following International
Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory authorities in the U.K. and in
Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released in February
2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy
endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, Anxiety, Depression, and Mood Scale (ADAMS) (p = 0.010) and CGI-I
(p = 0.037) response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome
symptoms. Convenient once daily oral liquid doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol and subsequent Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The very first trial of ANAVEX<sup>&#174;</sup>2-73
in pediatric Rett syndrome patients, the EXCELLENCE trial, completed enrollment in February 2023. This randomized, double-blind, placebo-controlled
Phase 2/3 trial in pediatric patients with Rett syndrome included trial sites in Canada, Australia, and the United Kingdom. 92 pediatric
patients with Rett syndrome between the ages of 5 through 17 years were treated daily with up to 30 mg ANAVEX<sup>&#174;</sup>2-73. Participants
were randomized 2:1 (ANAVEX<sup>&#174;</sup>2-73:placebo) for 12 weeks, followed by a week 16 safety visit and topline results from this
trial were announced in early January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After 12 weeks, the study showed improvement on the
key co-primary endpoint RSBQ, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients&#8217;
caregivers. The other co-primary endpoint, the CGI-I, which represents a less granular assessment by the site investigators using a seven-point
scoring (one=&#8220;very much improved&#8221; to seven=&#8220;very much worse&#8221;), was not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In an ad-hoc analysis, using the predefined mixed-effect
model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX<sup>&#174;</sup>2-73-treated patients improved LS Mean (SE)
-12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated patients. The LS Mean
difference (SE) of -4.61 (2.439) points between treated and placebo groups did not reach statistical significance (n=77; p=0.063). ANAVEX<sup>&#174;</sup>2-73-treated
patients demonstrated a rapid onset of action with improvements at 4 weeks after treatment with a RSBQ total score LS Mean (SE) -10.32
(2.086) points in the drug-treated group compared to a LS Mean (SE) -5.67 (2.413) points in placebo-treated patients. The LS Mean difference
of -4.65 (2.233) points between treated and placebo groups was statistically significant (n=77; p=0.041).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key secondary endpoint, the ADAMS, trended favorably.
In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study. Collectively, the RSBQ and ADAMS
demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive behaviors,
and social avoidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preliminary review of the safety results indicates
there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile observed with ANAVEX<sup>&#174;</sup>2-73
to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All patients who participated in the trial were eligible
to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol, which was completed in June 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A high enrollment rate in the Open Label Extension
(&#8220;OLE&#8221;) of over 91% and the high level of requests for the Compassionate Use Program (93%) provide solid numerical evidence
for the reported positive Real World Evidence (RWE) from patients with Rett syndrome under Compassionate Use Authorization. Families whose
children were previously on drug or placebo in the placebo-controlled trial commented favorably on the improvement of their child&#8217;s
daily life due to ANAVEX<sup>&#174;</sup>2-73 treatment in the Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements on behavioral,
histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data announced in
October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism. We believe the encouraging
results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind, randomized,
placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia in Spain and Australia,
to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 trial enrolled
approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30 mg and 50 mg, or placebo.
The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis. Treatment with ANAVEX<sup>&#174;</sup>2-73
also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson&#8217;s disease symptom severity,
MDS-Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221;) total score on top of standard of care including dopaminergic
therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability
of slowing and reversing symptoms that progress in Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine
approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 48-week OLE ANAVEX2-73-PDD-EP-001 Phase 2 trial
was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase 2 trial discussed above.
The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson&#8217;s Disease Rating Scale Parts
I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), CGI-I, as well as cognitive efficacy endpoint Montreal Cognitive
Assessment (MoCA) over a 48-week period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we reported the preliminary ANAVEX2-73-PDD-EP-001
OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX<sup>&#174;</sup>2-73 on the pre-specified primary and secondary
objectives. Preliminary analysis reveals that ANAVEX<sup>&#174;</sup>2-73 was found to be generally safe and well tolerated, and safety
findings in this trial were consistent with the known safety profile of ANAVEX<sup>&#174;</sup>2-73. In respect to efficacy, across all
efficacy endpoints, patients performed better while on ANAVEX<sup>&#174;</sup>2-73. While all patients were on drug holiday due to COVID-19
between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including the MDS-UPDRS Part II + III and CGI-I, measured
at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were worsening, as expected in a progressive disease like
Parkinson&#8217;s. However, when patients resumed daily oral ANAVEX<sup>&#174;</sup>2-73 treatment, a consistent improvement was observed
during the extension phase from OLE Baseline through OLE Week 24, and OLE Week 48, respectively. These results are consistent with the
pattern observed for all efficacy measures in the extension phase. The two endpoints, MDS-UPDRS Part II + III and CGI-I measured in this
study are the planned primary and key secondary endpoints in our forthcoming &gt;6-month Parkinson&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we were awarded a research grant
of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to develop ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target
engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Schizophrenia, Frontotemporal Dementia and Alzheimer&#8217;s
disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation for the treatment
of Frontotemporal Dementia (&#8220;FTD&#8221;) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered small molecule targeting
sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase 1
clinical trial was a prospective double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male and female
subjects were included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability,
and PK of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial met
its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities observed.
ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to
200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71 exhibited linear
PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no
effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective of characterizing the effect of
ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically significant ECG parameters throughout
the trial. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In October 2023
a peer-reviewed publication in the journal <i>Neurobiology of Aging</i>, titled &#8216;<i>Early treatment with an M1 and sigma-1 receptor
agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology</i>&#8217;, featured the orally
available small molecule ANAVEX<sup>&#174;</sup>3-71 (AF710B). The preclinical study described the potential disease-modifying properties
of ANAVEX<sup>&#174;</sup>3-71 on Alzheimer&#8217;s disease pathology as a possible drug candidate for a potential once daily oral preventive
strategy for Alzheimer&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In January 2024,
in another peer-reviewed publication in the journal <i>Clinical Pharmacology in Drug Development</i>, entitled, &#8216;<i>Population-Based
Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor
Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease&#8217;</i>, reported the population-based
characterization of the PK and food effect of ANAVEX<sup>&#174;</sup>3-71 as part of the single ascending dose study in healthy participants
with the primary objective of assessing dose proportionality of ANAVEX<sup>&#174;</sup>3-71, and to characterize the effect of food on
the PK of ANAVEX<sup>&#174;</sup>3-71. The results from this PK evaluation demonstrated that ANAVEX<sup>&#174;</sup>3-71, at single ascending
doses of 5 to 200 mg, is linear, dose proportional, and time invariant. Food had no effect on the PK of ANAVEX<sup>&#174;</sup>3-71. This
data also expands the safety objectives met in this first-in-human study of ANAVEX<sup>&#174;</sup>3-71, further supporting its drug development
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71&#8217;s pre-clinical profile, we intend to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>Schizophrenia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In March 2024,
we commenced the U.S. FDA-cleared ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial: a double-blind, placebo-controlled Phase 2 trial in
schizophrenia. The trial consists of two parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day
treatment period in a larger cohort. The trial will utilize standard clinical outcome measures for schizophrenia including the Positive
and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances
in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led
ERP Biomarker Qualification Consortium. In addition to the electrophysiological biomarkers, we are also applying novel neuroinflammatory,
metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX<sup>&#174;</sup>3-71&#8217;s
novel, dual mechanism of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Preliminary
results from Part A of the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, consisting of a multiple ascending dose study in 16 participants,
demonstrated a dose-dependent effect of ANAVEX<sup>&#174;</sup>3-71 on two key EEG biomarkers in patients with schizophrenia. The effects
were most pronounced in the higher dose group indicating a dose-dependent pharmacodynamic effect. The observed changes reversed known
electroencephalography (EEG) and ERP biomarker abnormalities associated with schizophrenia. These EEG biomarkers correlate with positive,
negative, and cognitive symptoms of schizophrenia. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The currently
ongoing Part B of the placebo-controlled Phase 2 study, which includes more participants and a longer treatment duration, will provide
more comprehensive data on the efficacy and safety of ANAVEX<sup>&#174;</sup>3-71 in schizophrenia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73
currently in three different clinical trial indications, and ANAVEX<sup>&#174;</sup>3-71 currently in one clinical trial and several other
compounds in different stages of clinical and pre-clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery Platform
produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may
be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s disease, as well
as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence the functioning
of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple viruses including SARS-CoV-2
(COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular processes, in order to ensure survival
and replication. Hence, it is possible that SIGMAR1 could play a role in modulating the cellular response to viral infection and ameliorate
pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer a
disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73 is
being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule
formulation for diseases such as Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
in liquid form resulted in both significant and dose-related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome
disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic
visual response and respiration tests in 7-month-old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated
fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased
the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73
starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular
coordination, balance, motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease
model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted Orphan
Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In November 2019,
the FDA granted ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of Rett syndrome. The RPD designation
is intended to encourage the development of treatments for rare pediatric diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted Fast Track
designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The FDA Fast Track program
is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of serious
and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates significant
improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant improvements were
seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia, to
study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 trial enrolled approximately
132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30 mg and 50 mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the CDR computerized assessment system analysis. We anticipate conducting further clinical trials of ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s disease dementia after submitting the results of the trial to regulatory authorities to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease animal models, ANAVEX<sup>&#174;</sup>2-73
has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive
therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73
has shown a potential dual mechanism which may impact amyloid, tau pathology and inflammation. In a transgenic Alzheimer&#8217;s disease
animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development of
oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that
is apparently amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals,
regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing, we initiated
and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1 SAD trial, the maximum
tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown to have positive effects in mouse
models of Alzheimer&#8217;s disease. There were no significant changes in laboratory or ECG parameters. ANAVEX<sup>&#174;</sup>2-73 was
well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed adverse events at doses above the maximum
tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen
with drugs that target CNS conditions, including Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed to
assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s disease.
The Phase 2a trial met both primary and secondary objectives of the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated
with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73, among
them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with the common
SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved cognitive (MMSE)
and functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic information in subsequent
clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX<sup>&#174;</sup>2-73
including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. On July 2, 2018, the Human Research
Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety and
efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in Canada, the
United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 trial design incorporates inclusion of genomic precision
medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 14; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies also
supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative diseases
beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X
syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal brain-derived
neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative
pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of
BDNF expression could be a contributing factor for the positive preclinical data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also indicates
that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease. Further,
our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes and oligodendrocyte
precursor cells (&#8220;OPCs&#8221;), as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation
and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73
in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth
of numerous benign tumors in many parts of the body with a high incidence of seizures. The preclinical data demonstrated that treatment
with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is an orally available
clinical drug candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been
shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential
disease modifying treatment for cognitive impairments. We believe it is effective in against the major Alzheimer&#8217;s hallmarks in
transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation
and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71
in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation
with the administration of ANAVEX<sup>&#174;</sup>3-71. In April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71
for the treatment of FTD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.
In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional
preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 has the potential
to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase 1 clinical
trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The trial took place in Australia and was a double-blind, randomized, placebo-controlled, Phase
1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX<span style="background-color: white"><sup>&#174;</sup></span>3-71
including effects of food and gender in healthy volunteers. <span style="background-color: white">The trial met its primary and secondary
endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, </span>as more fully described
above under <i>Clinical Trials Overview &#8211; Schizophrenia, Frontotemporal Dementia and Alzheimer&#8217;s disease</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of this clinical trial and preclinical study could serve as a basis
for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The first of
these trials, the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, commenced in March 2024 and is</span> more fully described above under
<i>Clinical Trials Overview &#8211; Schizophrenia.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist. Pre-clinical
tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41
prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and SIGMAR1 systems through
a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>1-41
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired,
are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic
pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold in the affected paw
to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In
a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and
a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and
a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for the treatment
of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at
nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies,
this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting normal/healthy
cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight the possibility
that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed
in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through
tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates may play an important role in inhibiting
the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation
of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in the pre-clinical
and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown
in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions with
potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further, we may acquire
or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential application
to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alzheimer&#8217;s disease &#8211; In 2024, an estimated
    6.9 million Americans are suffering from Alzheimer&#8217;s disease according to the Alzheimer&#8217;s Association<sup>&#174;</sup>. The
    Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that the annual number of new cases of Alzheimer&#8217;s and other dementias is
    projected to double by 2050. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the
    ability to stop its onset or its progression. We believe that there is an urgent and unmet need for both a disease modifying cure for
    Alzheimer&#8217;s disease as well as for better symptomatic treatments.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s
    disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated
    with degeneration of the basal ganglia of the brain and deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently
    is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease
    market is expected to reach $11.5 billion by 2029, according to GlobalData.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rett syndrome &#8211; Rett syndrome is a rare X-linked
    genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription, which is altered
    and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder
    and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females, boys who have
    the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For females who survive
    infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s life; severe mental retardation,
    their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately
    1 in every 10,000-15,000 females.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Schizophrenia - Schizophrenia is a persistent and
    often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including
    2.8 million people in the U.S., according to the World Health Organization. It is characterized by three symptom domains: positive symptoms
    (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment (deficits
    in memory, concentration, and decision-making). In part due to limitations with current treatments, people living with schizophrenia often
    struggle to maintain employment, live independently, and manage relationships. While current treatments can be effective in managing select
    symptoms, approximately 34% of people do not respond to therapy, with an additional 50-60% experiencing only a partial improvement in
    symptoms or unacceptable side effects.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fragile X &#8211; Fragile X syndrome (FXS) is
the most prevalent genetic form of intellectual disability and autism spectrum disorder, primarily affecting boys. As with most neurodevelopmental
disorders, FXS is considered a condition of synaptic development and function. The disease has a range of clinical presentations depending
on the specific genetic changes associated with an &#8220;expansion&#8221; of the FMR1 gene. The disease is characterized by deficits
in long-term potentiation and homeostatic plasticity. FXS has been detected in all populations and ethnic groups. Researchers do not
know the exact number for how many Americans could have full mutation FXS. Studies estimate that the disease affects approximately 1:4,000
males and 1:6,000 females. Worldwide, more than 1,400,000 people could be affected by FXS.</p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 17; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depression &#8211; Depression is a major cause of
    morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 billion
    by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands.
    However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Epilepsy &#8211; Epilepsy is a common chronic neurological
    disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or
    synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4
    million Americans. Today, epilepsy is often controlled, but not cured, with medications that are categorized as older traditional anti-epileptic
    drugs and second-generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used
    in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market Research Future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.7 billion by 2027.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Competition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The drug discovery and development industry is very
competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential. Any product
candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies that may become available
in the future. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that
are more effective, have fewer side effects, are more convenient or are less expensive than any products that we may develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe our approach to the treatment of Alzheimer&#8217;s
disease and other CNS diseases differs from our competitors. Our platform may offer a disease-modifying approach in neurodegenerative
and neurodevelopmental diseases by activation of SIGMAR1. In our preclinical studies, when activated by SIGMAR1 agonists, such as ANAVEX<sup>&#174;</sup>2-73,
SIGMAR1 demonstrated reduced cellular stress before and after RNA gene transcription. Our studies confirm the potential existence of a
predictive biomarker of response established through SIGMAR1 mRNA expression that could be used in future clinical trials. Because of
its role in maintaining neuronal homeostasis, we believe sigma receptors show significant promise as viable targets for therapeutic molecules
in an effort to treat Alzheimer&#8217;s disease and other CNS diseases and disorders, including Parkinson&#8217;s disease and Rett syndrome,
by restoring healthy gene expression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At this time, our competitors are primarily other
biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer&#8217;s disease
and other CNS diseases, and those companies already doing so. We also face competition from academic institutions and government agencies,
both in the United States and abroad.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors may have significantly greater financial
resources, an established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing,
may be in the process of obtaining regulatory approvals and marketing of approved products. These competitors also compete with us in
recruiting and retaining qualified scientific and technical personnel, establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring or developing technologies complementary to, or necessary for, our programs. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional discussion of the risks related to
competition, see Item 1A &#8220;Risk Factors.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to twenty-five
(25) U.S. patents, twenty-five (25) U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection,&#8221; which claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent
is expected to expire in June 2034, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;A2-73
crystalline polymorph compositions of matter and methods of use thereof&#8221;. It claims crystals of A2-73 freebase or its fumarate salt,
dosage forms and pharmaceutical formulations. This patent is expected to expire in July 2039, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own four issued U.S. patents each with claims directed
to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these four patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease
using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The second of these
four patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment
for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2036, absent any patent term extension
for regulatory delays. The third of these four patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2036, absent
any patent term extension for regulatory delays. The fourth of these four patents claims method of making certain crystalline forms ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in October 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three issued U.S. patents for seizure
treatment. The first of these three patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose
anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii)
ANAVEX<sup>&#174;</sup>19-144. The second of these three patents further claims a combination seizure treatment involving administration
of an anti-epilepsy drug combined with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73.
The third of these three patents claims a dosage form for seizure reduction, comprising (i) ANAVEX<sup>&#174;</sup>19-144, (ii) ANAVEX<sup>&#174;</sup>2-73,
or (iii) a combination of ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73; and optionally further comprising a low-dose anti-epilepsy
drug. All three patents are expected to expire in October 2035, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own four issued U.S. patents with claims directed
to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder, multiple sclerosis,
their related biochemical and functional abnormalities, or loss-of-function associated with a neurodevelopmental disorder, by administering
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to
ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All four patents are expected to expire in January 2037, absent any patent term
extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we own one issued U.S. patent with claims
directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in February
2030, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we own one issued U.S. patent with claims
directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2038, absent
any patent term extension for regulatory delays. Additionally, we own two issued U.S. patent for the treatment of insomnia, anxiety, or
agitation. The first of the two patents claims methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038. The second of the two patents claims a dosage
form comprising any of, or any combination of ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41.
This patent is expected to expire in July 2038, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we own one issued U.S. patent with claims
directed to a method of treating systolic hypertension using ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2039,
absent any patent term extension for regulatory delays. Additionally, we own one issued U.S. patent with claims directed to pharmaceutical
dosage forms of (-) enantiomer of ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three (3) issued U.S. patents related
to ANAVEX<sup>&#174;</sup>1066. The first of these three patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066
isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer. The third patent
claims dosage forms and pharmaceutical compositions comprising (+) ANAVEX<sup>&#174;</sup>1066 isomer. All three patents are expected to
expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada, China,
Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71, we own
exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound and methods of
treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April 2030, and January 2030,
respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related patents or applications
that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected
to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications and certain
granted foreign patents directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional
protection for one or more of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made with
intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered
processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions
for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse
in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Government regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United States, at the
federal, state and local levels, and other countries extensively regulate, among other things, the research, development, testing, manufacture,
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and
import of products such as those we are developing. A new drug must be approved by the FDA through the NDA or ANDA process before it may
be legally marketed in the United States. We are subject to various government regulations in connection with the development of our pipeline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. Drug Development and Regulation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, the FDA regulates drugs under
the Federal Food, Drug, and Cosmetic Act and its implementing regulations (&#8220;FDCA&#8221;). The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process,
approval process or post approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the
FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, import refusal, a clinical hold, warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect
on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once a drug candidate is identified for development,
it enters the preclinical testing stage and an Investigational New Drug Application (&#8220;IND&#8221;) may be opened for the regulatory
development of the product. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as
other preclinical studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and
analytical data, to the FDA as part of the IND to conduct clinical trials. The sponsor must also include a protocol detailing, among other
things, the objectives of the clinical trials, the parameters to be used in monitoring the safety of the trial, and the effectiveness
criteria to be evaluated should the trial include an efficacy evaluation. Some preclinical testing may continue even after the IND is
filed. The IND automatically becomes effective thirty (30) days after receipt by the FDA, unless the FDA, within the 30-day time period,
places the clinical trial on a clinical hold. Clinical holds also may be imposed by the FDA at any time before or during clinical trials
due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may
not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All clinical trials must be conducted under the supervision
of one or more qualified investigators in accordance with FDA good clinical practice (&#8220;GCP&#8221;) requirements, which include a
requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical
trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection inclusion and exclusion
criteria and the safety and/or effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND,
and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An Institutional
Review Board (&#8220;IRB&#8221;) at each institution participating in the clinical trial must review and approve each protocol before
a clinical trial may commence at the institution and must also approve the information regarding the trial as well as the informed consent
form that must be provided to each trial participant or his or her legal representative, monitor the study until completed and otherwise
comply with all applicable IRB regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Human clinical trials are typically conducted in three
sequential phases that may overlap or be combined in certain cases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 1: The compound is initially introduced into
healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to
gain an early indication of its effectiveness. In most cases, initial Phase 1 clinical trials are conducted with healthy volunteers. However,
where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer, and especially when the
product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be conducted on patients with the
target disease or condition. Sponsors sometimes subdivide their Phase 1 clinical trials into Phase 1a and Phase 1b clinical trials. Phase
1b clinical trials are typically aimed at confirming dosage, PK and safety in a larger number of patients. Some Phase 1b clinical trials
evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 2: This phase involves clinical trials in a
limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product
for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 3: Phase 3 clinical trials are undertaken to
further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed clinical
trial sites. These clinical trials, often referred to as &#8220;pivotal&#8221; or &#8220;confirmatory&#8221; clinical trials, are intended
to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis for product approval and labeling.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA or the sponsor may suspend a clinical trial
at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected, serious harm to study subjects. In
addition, clinical trials may be overseen by an independent group of qualified experts organized by the sponsor, known as a data safety
monitoring board or committee. Depending on its charter, this board or committee may determine whether a trial may move forward at designated
check points based on access to certain data from the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 4: Phase 4 or post-approval trials may also
be conducted after a drug receives initial marketing approval. These trials, often referred to as &#8220;Phase 4&#8221; trials, are used
to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may
mandate the performance of such clinical trials as a condition of approval of continued marketing of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the development of a new drug, sponsors are
given several opportunities to meet with the FDA. These meetings can provide an opportunity for the sponsor to share information about
the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement
on the next phase of development. These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical trials, or
before an NDA is ultimately submitted. Sponsors typically use the meetings at the end of the Phase 2 trials to discuss Phase 2 clinical
results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. Meetings at
other times may be made upon request and are subject to approval by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Concurrent with clinical trials, companies typically
complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physicochemical characteristics
of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the FDA&#8217;s current
Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements. The manufacturing process must consistently produce quality batches of
the drug and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the
final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the
effectiveness of the packaging and that the compound does not undergo unacceptable deterioration over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the IND is active, progress reports summarizing
the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at least
an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected adverse
events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal
or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence of a serious adverse reaction
compared to that listed in the protocol or investigator brochure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are also requirements governing the submission
of certain clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products
are required to register and disclose specified clinical trial registration and results information, which is made publicly available
at www.clinicaltrials.gov. Failure to properly report clinical trial results can result in civil monetary penalties. Disclosure of clinical
trial results can often be delayed until the new product or new indication being studied has been approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. review and approval process </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of product development, preclinical and
other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the
chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application (&#8220;NDA&#8221;).
The submission of an NDA is subject to the payment of substantial user fees; a waiver of which may be obtained under certain limited circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA reviews NDAs to determine, among other things,
whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner, which will assure
and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;),
the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, completed NDA for a new molecular entity to review
and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has
approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review
of all NDAs within the first sixty days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts
it for filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may refer an application for a new drug to
an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that
reviews, evaluates and provides a recommendation as to whether and under what conditions the application should be approved. The FDA is
not bound by the recommendations of such an advisory committee, but it considers advisory committee recommendations carefully when making
decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before approving an NDA, the FDA will also inspect
the facility where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes
and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required
specifications. Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance with GCP requirements
and inspect the clinical trial records.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the FDA evaluates an NDA, it will issue an approval
letter or a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete, and the
application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA
identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming
requirements related to clinical trials, nonclinical studies or product manufacturing. If a Complete Response Letter is issued, the sponsor
must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and
information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. An approval letter authorizes commercial
marketing of the drug with prescribing information for specific indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Pediatric Research Equity Act (&#8220;PREA&#8221;),
requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form,
new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless
the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the
claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for
which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of
the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for
use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before
the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment,
keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a drug receives FDA approval, the approval may
be limited to specific diseases and dosages, which could restrict the commercial value of the product. In addition, the FDA may require
testing and surveillance programs to monitor the safety of approved products which have been commercialized and may require a sponsor
to conduct post-marketing clinical trials (Phase 4 clinical trials), which are designed to further assess a drug&#8217;s safety and effectiveness
after NDA approval. The FDA may also place other conditions on approval, including a requirement for a risk evaluation and mitigation
strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit
a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician
communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescribing or dispensing
of products. Marketing approval may be withdrawn for non-compliance with REMS or other regulatory requirements, or if problems occur following
initial marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Post-approval requirements </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once an approval is granted, the FDA may withdraw
the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market. Later discovery
of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of the drug from the market.
After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing changes and additional
labeling claims, are subject to further FDA review and approval. Manufacturers and other entities involved in the manufacture and distribution
of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any drug product manufactured or distributed by us
pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution
requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements.
FDA strictly regulates labeling, advertising, promotion and other types of information regarding approved drugs that are placed on the
market, and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the
prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known
as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet.
Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions
on the marketing of a product for a certain indication or withdrawal of the product from the market as well as possible civil or criminal
sanctions. Failure to comply with the applicable governmental requirements at any time during the product development process, approval
process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse
publicity. The FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing
clinical trials, enforcement letters, import refusals, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,
restitution, disgorgement of profits, or civil or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Expedited development and review programs </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has a fast track designation program that
is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs
are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may consider for
review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the
submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and
the sponsor pays any required user fees upon submission of the first section of the NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any product submitted to the FDA for approval, including
a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review,
such as priority review and accelerated approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A product is eligible for priority review if it is
intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to currently
marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for
priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within
six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA review goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, a product may be eligible for accelerated
approval. Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination
that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint
that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability
or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval
perform adequate and well-controlled post-marketing clinical trials. Drugs receiving accelerated approval may be subject to expedited
withdrawal procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted
clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval, pre-approval of promotional materials,
which could adversely impact the timing of the commercial launch of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Food and Drug Administration Safety and Innovation
Act (&#8220;FDASIA&#8221;) established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to
receive breakthrough therapy designation. A sponsor may seek FDA designation of a compound as a &#8220;breakthrough therapy&#8221; if
the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes
all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is
a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria
are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast track designation, priority review and breakthrough
therapy designation do not change the standards for approval but may expedite the development or approval process. However, even if a
product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification
or decide that the time period for FDA review or approval will not be shortened.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Orphan drug designation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals
in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the
cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from
sales of the product. Orphan designation must be requested before an NDA is submitted. After the FDA grants orphan designation, the identity
of the therapeutic agent and its potential orphan use are publicly disclosed by the FDA. Orphan designation does not convey any advantage
in or shorten the duration of the regulatory review and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product that has orphan designation subsequently
receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product
exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven
years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability
to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as
opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However, competitors may receive approval
of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for
a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our compounds
for seven years if our compound is determined to be contained within the competitor&#8217;s product for the same indication or disease,
or if a competitor obtains approval of the same drug as defined by the FDA. In addition, if an orphan designated product receives marketing
approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Abbreviated New Drug Applications, 505(b)(2) Applications,
and Marketing exclusivity </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In seeking approval for a drug through an NDA, applicants
are required to list with the FDA each patent with claims that cover the applicant&#8217;s drug or an approved method of use of the drug.
Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug
Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221; Drugs listed in the Orange Book can,
in turn, be cited by competitors in support of approval of an Abbreviated New Drug Application, or ANDA, or a 505(b)(2)&#160;application.
In this case, the original NDA (the&#160;so-called&#160;pioneer drug) is known as the &#8220;listed&#8221; drug or &#8220;reference-listed&#8221;
drug. An ANDA provides for marketing of a drug that has the same active ingredient and the same strength, route of administration and
dosage form as the listed drug and has been shown through testing to be bioequivalent to the listed drug or receives a waiver from bioequivalence
testing. ANDA applicants are generally not required to conduct or submit results of preclinical or clinical tests to prove the safety
or effectiveness of their drug, other than the requirement for bioequivalence testing. Drugs approved in this way are considered therapeutically
equivalent, and are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug. These drugs then generally can be substituted
by pharmacists under prescriptions written for the original listed drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 505(b)(2) application is a type of NDA that relies,
in part, upon data the applicant does not own and to which it does not have a right of reference. Such applications often are submitted
for changes to previously approved drug products, and rely on the FDA&#8217;s prior findings of safety and effectiveness for a third party&#8217;s
NDA to abbreviate the showings the sponsor of the 505(b)(2) application must make to establish that its product is safe and effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ANDA or 505(b)(2)&#160;applicant is required to
certify to the FDA concerning any patents listed for the referenced approved drug in FDA&#8217;s Orange Book. Specifically, for each listed
patent, the applicant must certify that: (1)&#160;the required patent information has not been filed; (2)&#160;the listed patent has expired;
(3)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the
listed patent is invalid, unenforceable or will not be infringed by the new drug. A certification that the new drug will not infringe
the already approved drug&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification.
If the ANDA or 505(b)(2)&#160;applicant does not include a Paragraph IV certification, the ANDA or 505(b)(2)&#160;application will not
be approved until all of the listed patents claiming the referenced drug have expired, except for any listed patents that only apply to
uses of the drug not being sought by the ANDA or 505(b)(2)&#160;applicant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the ANDA or 505(b)(2)&#160;applicant has made a
Paragraph IV certification, the applicant must also send notice of a Paragraph IV Notice Letter to the NDA and patent holders once the
ANDA or 505(b)(2)&#160;application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement
lawsuit in response to the notice of the Paragraph IV Notice Letter. The filing of a patent infringement lawsuit within 45&#160;days of
the receipt of notice of a Paragraph IV Notice Letter automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months,
expiration of the patent, settlement of the lawsuit, modification by a court or a decision in the infringement case that is favorable
to the ANDA or 505(b)(2)&#160;applicant. As discussed below, the ANDA or 505(b)(2)&#160;application also will not be approved until any
applicable&#160;non-patent&#160;exclusivity listed in the Orange Book for the reference-listed drug has expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market exclusivity provisions under the FDCA can delay
the submission or approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity
within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity
if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible
for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated
new drug application (&#8220;ANDA&#8221;), or an NDA submitted under Section 505(b)(2) (a &#8220;505(b)(2) NDA&#8221;), submitted by another
company for another drug containing the same active moiety, regardless of whether the drug is intended for the same indication as the
original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data
required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or
non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDCA alternatively provides three years of marketing
exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were
conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, as, for example, new
indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received
approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs
containing the active ingredient for the original indication or condition of use. Five-year and three-year exclusivity will not delay
the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of
reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pediatric exclusivity is another type of marketing
exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached
to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The
issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity,
as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>United States Patent Term Restoration</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA approval of our future product candidates, some of our United States patents may be eligible for limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review
process for a drug that has not been previously approved for commercial marketing. Patent-term restoration, however, cannot extend the
remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved
drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally&#160;one-half&#160;the
time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the
approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence.
Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior
to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application
for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed
patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors
involved in the filing of the relevant NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Foreign Sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales outside the United States of potential drug
compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing for drugs.
The requirements vary widely from country to country, but typically the registration and approval process takes several years and requires
significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the United States, the potential
drug compound may be exported for sale outside of the United States, only if it has been approved in any one of the following: the European
Union or a country in the European Economic Area (the countries in the European Union and the European Free Trade Association) if the
drug or device is marketed in that country or the drug or device is authorized for general marketing in the European Economic Area, Canada,
Australia, New Zealand, Japan, Israel, Switzerland and South Africa. There are specific FDA regulations that govern this process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. coverage and reimbursement </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will depend in part on
the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such
as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers.
Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge, reduction or denial
by payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether a payor will provide
coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.
A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally,
in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and
approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate
reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory
financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.
In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies
in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended
to obtain regulatory approvals. Third-party payors may not consider our compounds to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally,
we or our collaborators may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests require
coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products.
Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion
diagnostics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fraud and Abuse Laws </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Federal and state health care laws and regulations
restrict business practices in the biopharmaceutical industry. In the biopharmaceutical industry, there are a number of federal and state
health care regulatory requirements that apply to entities, including, but not limited to, the federal and state fraud and abuse laws.
These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims act law, criminal false statement
law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative laws. Health care laws, regulations, and
guidance continuously evolve and are thereby subject to constant change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute, 42 U.S.C. &#167;
1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration,
whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the referral of an individual for
the:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are a number of narrow safe harbors to the Federal
Anti-Kickback Statute. Such safe harbors permit certain payments and business practices that, although they would otherwise potentially
implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements of the specific applicable
safe harbor are met. Actual knowledge of the statute or specific intent to violate it is not required in order for a person or entity
to have committed a violation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute applies to certain
arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts and other
financial incentives offered in connection with the sales of our products. Regulatory authorities may determine that certain marketing,
pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws. Noncompliance with the Federal Anti-Kickback
Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability to operate in certain jurisdictions,
and exclusion from participation in Medicare, Medicaid or other federal healthcare programs. In addition, non-compliance can result in
the need to curtail and/or restructure operations. Any penalties, damages, fines, exclusions, curtailment or restructuring of operations
could adversely affect the ability to operate a business, financial condition, and results of operations. A violation of the Federal Anti-Kickback
Statute can serve as a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;) among other things, enacted numerous provisions that prohibit knowingly and willfully executing, or
attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program,
regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly
and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious
or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
matters. These provisions include 18 U.S.C. &#167;&#167; 286, 287, 669, 1035, 1347, and 1518, all as described further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Ethics in Patient Referrals Act, commonly known
as the &#8220;Stark Law,&#8221; 42 U.S.C. &#167; 1395nn, prohibits a physician from making referrals for certain &#8220;designated health
services&#8221; payable by Medicare to an entity in which the physician or an immediate family member of such physician has an ownership
or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory exception applies.
There are a number of exceptions to the Stark Law. Such exceptions permit certain payments and arrangements that, although they would
otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements of the specific exceptions
are met. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliance arrangement,
civil penalties, damages and exclusion from Medicare or other governmental programs. These requirements are highly technical and there
can be no guarantee that regulatory authorities will not determine or assert that arrangements are in violation of the Stark Law and do
not otherwise meet applicable Stark Law exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal false statements statute, 42 U.S.C. &#167;
1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any materially false statement
in connection with the delivery of health care benefits, items, or services. Similarly, 18 U.S.C. &#167; 1035 prohibits a person or entity,
in any matter involving a health care benefit program, from knowingly or willfully falsifying, concealing, or covering up by any trick,
scheme, or device a material fact; making any materially false, fictitious, or fraudulent statements or representations; or making or
using any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or
entry. In addition to criminal penalties, violation of these statutes may result in collateral administrative sanctions, including exclusion
from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 669 prohibits knowingly and willfully
embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the rightful owner, or intentionally
misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets of a health care benefit program. In addition
to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation
in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The criminal health care fraud statute, 18 U.S.C.
&#167; 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme or artifice
to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations, or promises, any
of the money or property owned by, or under the custody or control of, any health care benefit program, in connection with the delivery
of or payment for health care benefits, items, or services. In addition to criminal penalties, violation of this statute may result in
collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.
A person or entity need not have actual knowledge of this law or specific intent to commit a violation of this law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 1518 establishes criminal liability
for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication of information
or records relating to a violation of a Federal health care offense to a criminal investigator. In addition to criminal penalties, violation
of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other
federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 286 establishes criminal liability
for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or agency thereof, by
obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim. In addition to criminal penalties,
violation of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid
and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. &#167; 287 establishes criminal liability
for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including any department
or agency thereof. In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions, including
exclusion from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal False Claims Act, 31 U.S.C. &#167; 3729,
et seq., provides, in part, that the federal government&#8212;or a private party on behalf of the government&#8212;may bring a lawsuit
against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim for payment, or who
has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation to pay money to the
federal government or who has knowingly retained an overpayment. Knowledge under the Federal False Claims Act means actual knowledge,
deliberate indifference, or reckless disregard. In addition, amendments in 1986 to the Federal False Claims Act have made it easier for
private parties to bring whistleblower lawsuits against companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The civil monetary penalties law, 42 U.S.C. &#167;
1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who presents or causes to
be presented claims to a Federal health care program that the person knows or should know is for an item or services that was not provided
as claimed or is false or fraudulent, or the person has made a false statement or used a false record to get a claim paid. The federal
government may also seek civil monetary penalties for a wide variety of other conduct, including offering remuneration to influence a
Medicare or Medicaid beneficiary&#8217;s selection of providers and violations of the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Violations of the Federal False Claims Act and/or
the Civil Monetary Penalties Law can result in penalties ranging from $12,537 to $25,076 for each false claim violation of the Federal
False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up to three times the amount
of damages that the federal government sustained. In addition, the federal government may also seek exclusion from participation in all
federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">42 U.S.C. Section 1320a-7 provides that individuals
and entities can be mandatorily or permissively excluded from participation in federal health care programs. The grounds for mandatory
exclusion include, but are not limited to, conviction for a criminal offense related to the delivery of an item or service reimbursed
under a federal or state health care program, and a conviction related to health care fraud. The grounds for permissive exclusion include,
but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions related to obstruction of an
investigation or audit, and/or failure to disclose certain required information. Exclusion from federal health care programs&#8212;whether
mandatory or permissive&#8212;may mean that our customers may not be able to get reimbursed by federal and/or state health care programs
for use or dispensing of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>State Fraud and Abuse Provisions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many states have also adopted some form of anti-kickback
and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions that apply regardless of
payer, in addition to items and services reimbursed under Medicaid and other state programs. A determination of liability under such laws
could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate in these jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Corporate liability can be present as a result of
the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates, even if they were
not explicitly authorized. There can be no assurance that all employees, representatives, contractors, collaborators, agents, subsidiaries
or affiliates will comply with the foregoing laws at all times. Violation of the aforementioned and other laws could result in whistleblower
complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting, other enforcement actions, disgorgement
of profits, significant fines, damages, other civil and criminal penalties or injunctions or other administrative remedies, suspension
and/or debarment from contracting with certain governments or other persons, the loss of privileges, reputational harm, contract damages,
adverse media coverage and other collateral consequences. In addition, corporate directors, officers, employees, and other representatives
who engage in violations of these and other laws may face imprisonment, fines, and penalties. If any subpoenas or investigations are launched,
or governmental or other sanctions are imposed, or if a company does not prevail in any possible civil or criminal litigation, business,
financial condition, and results of operations could be materially harmed. In addition, responding to any action will likely result in
a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional
fees. Enforcement actions and sanctions could further harm business, financial condition, and results of operations. Any of the consequences
contained in this paragraph and section could adversely affect the ability to operate the business, financial condition, and the results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sunshine Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sunshine Act requires manufacturers of products
reimbursed by Medicare, Medicaid or the Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) to collect and annually report
detailed data to the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) regarding payments or other transfers of value to
physicians, certain other health care providers (such as physicians assistants and nurse practitioners) and teaching hospitals (&#8220;covered
recipients&#8221;), as well as any ownership or investment interest held by physicians and their immediate family members. The reporting
data must be accompanied by an attestation as to the accuracy of the data and failure to timely and accurately submit required information
may result in civil monetary penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Health Insurance Portability and Accountability
Act </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Besides enacting the program integrity provisions
described above, HIPAA, also created a new set of privacy and security requirements. As amended by the Health Information Technology for
Economic and Clinical Health Act, and implementing regulations thereunder, HIPAA requires certain healthcare providers, health plans and
healthcare clearinghouses who conduct specified electronic healthcare transactions (&#8220;covered entities&#8221;), as well as their
independent contractors and agents who conduct certain activities involving protected health information on their behalf (&#8220;business
associates&#8221;) to comply with enumerated requirements relating to the privacy, security and transmission of protected health information.
Failure to comply with HIPAA can result in corrective action, as well as civil fines and penalties and government oversight. Among other
changes, HITECH made HIPAA security standards directly applicable to business associates, increased the tiered civil and criminal fines
and penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general
new authority to file actions to enforce HIPAA. Further, the breach notification rule implemented under HITECH requires covered entities
to notify affected individuals, the U.S. Department of Health and Human Services Office of Civil Rights (&#8220;OCR&#8221;), the agency
that enforces HIPAA, and for breaches affecting more than 500 individuals, the media, of any breaches of unsecured protected health information.
HIPAA does not create a private right of action for individuals, though individuals may submit complaints related to HIPAA to OCR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Legislative Activities Aimed at Controlling Drug
Costs </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been, and continue
to be proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform
government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order,
&#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s
executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan
for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies
that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">the Inflation
Reduction Act (&#8220;IRA&#8221;) passed on August 16, 2022. The IRA, among other things, (1) directs HHS to negotiate the price of certain
highly-utilized single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part
D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although
they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact
on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing
HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models
for lowering drug costs for Medicare and Medicaid beneficiaries. We expect that additional U.S. federal healthcare reform measures will
be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services,
which could result in reduced demand for our product candidates or additional pricing pressures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, a significant portion of our operating
expenses related to research and development. See our Consolidated Financial Statements contained elsewhere in this Annual Report for
costs and expenses related to research and development, and other financial information for fiscal years 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Scientific Advisors </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are advised by scientists and physicians with experience
relevant to our Company and our product candidates. Our scientific advisors include clinicians and scientists who are affiliated with
a number of highly regarded medical institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employees</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have approximately forty-two full-time
employees, and we retain several independent contractors on a regular or as-needed basis. We believe that we have good relations with
our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Available Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our internet website address is www.anavex.com. Our
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished
pursuant to section 13(a) or 15(d) of the Exchange Act are available there free of charge. We include our website address in this report
only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated
into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_003"></span>ITEM 1A. RISK FACTORS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the risks and uncertainties
that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk
factors contained in this report in their entirety for additional information regarding these risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our history of losses and no revenue raises a risk regarding our ability to continue as a going concern
in the future;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We have a very limited relevant operating history upon which an evaluation of our performance and prospects
can be made. We may never be able to successfully develop marketable products or generate any revenue. If we cannot generate sufficient
revenues, we may suspend or cease operations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our research and development plans will require substantial additional future funding. We may be unable
to raise capital when needed, which would force us to delay, reduce or eliminate our research and development activities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 32; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We will need additional funding and may be unable to raise additional capital when needed, which would
force us to delay, reduce or eliminate our research and development activities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Even if our products are approved, we may not be able to generate significant revenues from or successfully
commercialize them, which will adversely affect our financial results and financial condition and we will have to delay or terminate some
or all of our research and development plans which may force us to cease operations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our research and development plans require substantial additional future funding which could impact our
operations and financial condition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we or any companion diagnostic collaborator of ours are unable to timely develop and obtain regulatory
approval for companion diagnostic tests for our drug candidates, we may not realize the commercial potential of our drug candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy,
time-consuming and inherently unpredictable, which could lead to our inability to generate product revenue;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Regulatory authorities may not accept data from our trials conducted outside the United States;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Fast Track designation or breakthrough therapy designation that we have received or may seek out may not
actually lead to a faster FDA review and approval process;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we fail to demonstrate efficacy in our non-clinical studies and clinical trials our future business
prospects, financial condition and operating results will be materially adversely affected;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If a particular product candidate causes undesirable side effects, then we may be unable to receive regulatory
approval of or commercialize such product candidate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Wea re highly dependent on our key personnel and if we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability
will likely be limited, which would have a material adverse effect on our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may not be able to develop, market or generate sales of our products to the extent anticipated. Our
business may fail and investors could lose all their investment in our Company;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">None of our potential drug compounds may reach the commercial market and our business may fail;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Material modifications in the methods of product candidate manufacturing may result in additional costs
or delay;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our technologies and future products may be rendered undesirable or obsolete if our competitors succeed
in developing products and technologies faster or that are more effective or with a better profile than our own, or if scientific developments
change our understanding of the potential scope and utility of our potential products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We have advanced our research and development efforts on the treatment of neurodegenerative and central
nervous system, or CNS, disorders, a field that has seen very limited success in product development;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our reliance on third parties may result in delays in completing, or a failure to complete, non-clinical
testing or clinical trials if they fail to perform under our agreements with them or non-compliance with regulations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 33; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we fail to compete with respect to partnering, licensing, mergers, acquisitions, joint venture and
other collaboration opportunities, our ability to research and develop our potential drug compounds may be limited;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">The use of any of our products in clinical trials may expose us to liability claims, causing our business
to suffer;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we are unable to safeguard against security breaches with respect to our information systems, our business
may be adversely affected;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Continuing regulatory obligations and ongoing regulatory review may result in additional expense. Our
compounds could be subject to restrictions on marketing or withdrawal from the market, and we may be subject to penalties when and if
any of them are approved;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Changes in funding for the FDA, the SEC and other government agencies could prevent these agencies from
performing normal functions on which the operations of our business may rely, which could negatively affect our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We receive Australian government research and development income tax incentive refunds. Loss of access
to such incentives could have a negative effect on our future cash flows and the funding of future research and development projects;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Operating our business internationally carries various risks which could materially adversely affect our
business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our ability to use our net operating loss carryforwards and tax credit carryforwards may be subject to
limitation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Healthcare laws and regulations could expose us to criminal sanctions, civil and administrative penalties,
contractual damages, reputational harm and diminished profits and future earnings, among other penalties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We expect current and future legislation affecting the pharmaceutical industry, including drug pricing
reform, to impact our business generally, which could adversely affect our business operations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved,
could limit our ability to market those products and decrease our ability to generate product revenue;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Issuing additional shares of common stock will result in the dilution of our existing stockholders and
may cause our stock price to fall. A decline in our stock price could affect our ability to raise further working capital and adversely
affect our operations. Raising funds at lower prices would severely dilute existing or future investors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Our stock price has been volatile and may be volatile in the future and our common stock may become the
target of a &#8220;short squeeze&#8221;;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we fail to maintain an effective system of internal control over financial reporting, we may not be
able to accurately report our financial results or prevent fraud. Our disclosure controls and procedures may not prevent or detect all
errors or acts of fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm
our business and the trading price of our common stock;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Patent terms may be inadequate to protect our competitive position on our product candidates. If we are
unable to obtain and maintain sufficient intellectual property protection for our product candidates, our competitors could develop and
commercialize product candidates similar or identical to ours, and our ability to successfully commercialize our product candidates may
be impaired;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If we fail to comply with our obligations in intellectual property licensing agreements or experience
disruptions to our business relationships with our licensors, we could lose important intellectual property rights. If we are unable to
protect the confidentiality of our trade secrets, our business would be harmed;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 34; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Intellectual property infringement claims may adversely affect our development and commercialization efforts;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may be subject to claims that our employees, consultants or independent contractors have wrongfully
used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets
of their former employers;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may become involved in lawsuits to protect or enforce our patents or other intellectual property;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify">Obtaining and maintaining our patent protection
depends on compliance with various requirements imposed by governmental patent agencies. Changes in patent law could impair our ability
to protect our product candidates; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">We may fail to protect our intellectual property rights or the confidentiality of our trade secrets. Changes
in patent law could diminish the value of our patents and patent applications in general.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to other information in this Annual Report
on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such factors may have a significant
impact on our business, operating results, liquidity and financial condition. As a result of the risk factors set forth below, actual
results could differ materially from those projected in any forward-looking statements. Additional risks and uncertainties not presently
known to us, or that we currently consider to be immaterial, may also impact our business, operating results, liquidity and financial
condition. If any such risks occur, our business, operating results, liquidity and financial condition could be materially affected in
an adverse manner. Under such circumstances, the trading price of our securities could decline, and you may lose all or part of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Company</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have had a history of losses and no revenue,
which raises a risk regarding our ability to continue as a going concern in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception through September 30, 2024, we have
accumulated a deficit of approximately $336 million. We can offer no assurance that we will ever operate profitably or that we will generate
positive cash flow in the future. To date, we have not generated any revenues from our operations. Our history of losses and no revenues
creates a greater risk of our continued ability to continue as a going concern in the future. As a result, our management expects the
business to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might
become profitable. We will need to raise additional funds, and such funds may not be available on commercially acceptable terms, if at
all. If we are unable to raise funds on acceptable terms, we may not be able to execute our business plan, take advantage of future opportunities,
or respond to competitive pressures or unanticipated requirements. This may seriously harm our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are an early clinical stage pharmaceutical
research and development company and may never be able to successfully develop marketable products or generate any revenue. We have a
very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that
our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an early clinical stage company and have not
generated any revenues to date and have no operating history. Moreover, we cannot be certain that our research and development efforts
will be successful or, if successful, that our potential drug compounds will ever be approved for sale to pharmaceutical companies or
generate commercial revenues. We have no relevant operating history upon which an evaluation of our performance and prospects can be made.
We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital
requirements, failure of potential drug compounds either in non-clinical testing or in clinical trials, failure to establish business
relationships and competitive disadvantages against larger and more established companies. If we fail to become profitable, we may suspend
or cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We will need additional funding and may be unable
to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and development activities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have funded our operations primarily through
private placement of our equity securities, through issuances of shares under the Purchase Agreement with Lincoln Park Capital Fund, LLC
(&#8220;Lincoln Park&#8221;) pursuant to which the Company may direct Lincoln Park to purchase shares of common stock registered under
an effective registration statement, or, historically, through draws under our &#8220;at-the-market offering&#8221; in connection with
the Amended and Restated Sales Agreement with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;), pursuant
to which we could offer and sell shares of common stock registered under an effective registration statement from time to time through
the Sales Agents. The Company terminated the Sales Agreement in July 2024. We will need to raise additional funding and the current economic
conditions may have a negative impact on our ability to raise additional needed capital on terms that are favorable to our Company or
at all. We may not be able to generate significant revenues for several years, if at all. Until we can generate significant revenues,
if ever, we expect to satisfy our future cash needs through equity or debt financing. We cannot be certain that additional funding will
be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or
eliminate one or more of our research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we are able to develop our potential
drug compounds, we may not be able to receive regulatory approval, or if approved, we may not be able to generate significant revenues
or successfully commercialize our products, which will adversely affect our financial results and financial condition and we will have
to delay or terminate some or all of our research and development plans which may force us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our potential drug compounds are exclusively
focused on SIGMAR1 which has not previously been the subject of any approved drug products and will require extensive additional research
and development, including non-clinical testing and clinical trials, as well as regulatory approvals, before we can market them. In particular,
human therapeutic products are subject to rigorous non-clinical and clinical testing and other approval procedures of the FDA and similar
regulatory authorities in other countries. Various federal statutes and regulations also govern or influence testing, manufacturing, safety,
labeling, storage, and record-keeping related to such products and their marketing. We cannot predict if or when any of the potential
drug compounds we intend to develop will be approved for marketing. There are many reasons that we may fail in our efforts to develop
our potential drug compounds. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that non-clinical testing or clinical trials may show that our potential drug compounds are ineffective and/or cause harmful side effects;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators may not authorize us to commence or continue a clinical trial or may impose a clinical hold or may limit the conduct of a clinical trial through the imposition of a partial clinical hold;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party contractors, including investigators, may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential drug compounds may prove to be too expensive to manufacture or administer to patients;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our potential drug compounds may fail to receive necessary regulatory approvals from the United States Food and Drug Administration or foreign regulatory authorities in a timely manner, or at all;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if our potential drug compounds are approved, we may not be able to produce them in commercial quantities or at reasonable costs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if our potential drug compounds are approved, they may not achieve commercial acceptance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory or governmental authorities may apply restrictions to any of our potential drug compounds, which could adversely affect their commercial success; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proprietary rights of other parties may prevent us or our potential collaborative partners from marketing our potential drug compounds.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to develop our potential drug compounds,
our financial results and financial condition will be adversely affected, we will have to delay or terminate some or all of our research
and development plans and may be forced to cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our research and development plans will require
substantial additional future funding which could impact our operations and financial condition. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It will take several years before we can develop potentially
marketable products, if at all. Our research and development plans will require substantial additional capital, arising from costs to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct research, non-clinical testing and human clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish pilot scale and commercial scale manufacturing processes and facilities; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and develop quality control, regulatory, marketing, sales, finance and administrative capabilities to support these programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future operating and capital needs will depend
on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pace of scientific progress in our research and development programs and the magnitude of these programs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope and results of pre-clinical testing and human clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved in obtaining regulatory approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved in preparing, filing, prosecuting, securing, maintaining and enforcing patents;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing technological and market developments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish additional collaborations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our existing collaborations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing scale-up; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our commercialization activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We base our outlook regarding the need for funds on
many uncertain variables. Such uncertainties include the success of our research initiatives, regulatory approvals, the timing of events
outside our direct control such as negotiations with potential strategic partners and other factors. Any of these uncertain events can
significantly change our cash requirements as they determine such one-time events as the receipt or payment of major milestones and other
payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional funds may be required to support our operations
and if we are unable to obtain them on favorable terms, we may be required to cease or reduce certain further research and development
programs of our drug product platform, sell some or all our intellectual property, merge with another entity or scale back operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we or any companion diagnostic collaborator
of ours are unable to successfully develop and obtain regulatory approval for companion diagnostic tests for our drug candidates, or experience
significant delays in doing so, we may not realize the commercial potential of our drug candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We analyze genomic data from clinical trials to identify
biomarkers, which we use in the analysis of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Identification of these patients will require the
use and development of companion diagnostics. According to the FDA&#8217;s 2014 guidance document on In Vitro Companion Diagnostic Devices,
for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the
safe and effective use of the corresponding therapeutic product, the premarket application for the companion diagnostic device should
be developed and approved or cleared contemporaneously with the therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have experience or capabilities in developing
or commercializing diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility,
or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from
preclinical studies and early clinical trials appear to support development of a companion diagnostic for a drug candidate, data generated
in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators
may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar
to those we face with respect to our drug candidates, including issues with achieving regulatory clearance or approval, production of
sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to
successfully develop companion diagnostics for our drug candidates, or experience delays in doing so, the development of these drug candidates
may be adversely affected, these drug candidates may not obtain marketing approval, and we may not realize the full commercial potential
of any of these therapeutics that have or may obtain marketing approval. We may not be able to enter into arrangements with another diagnostic
company to develop and obtain regulatory approval for an alternative diagnostic test for use in connection with the development and commercialization
of our drug candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization
of our therapeutic candidates or therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Companion diagnostics are subject to regulation by
the FDA and comparable foreign regulatory authorities as medical devices and will likely require separate regulatory approval prior to
commercialization. If we or third parties are unable to successfully develop companion diagnostics for our drug candidates, or experience
delays in doing so:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of these drug candidates may be delayed because it may be difficult to identify patients for enrollment in our clinical trials in a timely manner;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these drug candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not realize the full commercial potential of these drug candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients or types of tumors targeted by these drug candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if our drug candidates and any associated companion
diagnostics are approved for marketing, the need for companion diagnostics may slow or limit adoption of our drug candidates. Our drug
candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either
due to the additional cost of the companion diagnostic or the need to complete additional prior to administering our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of these events were to occur, our business
and growth prospects would be harmed materially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The regulatory approval processes of the FDA
and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, which could lead to our inability
to generate product revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The time required to obtain approval by the FDA and
comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and
depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. Seeking foreign regulatory
approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical
trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of our product candidates in those countries. In addition, approval policies, regulations or the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions,
which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion
in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require
additional preclinical, clinical or other data. Satisfying these and other regulatory requirements is costly, time consuming, uncertain
and subject to unanticipated delays. Our failure to obtain regulatory approval in any country may delay or have negative effects on the
process for regulatory approval in other countries. Even if we eventually complete clinical testing and receive approval of any regulatory
filing for our product candidates, the FDA and comparable foreign regulatory authorities may approve our product candidates for a more
limited indication or a narrower patient population than we originally requested. If we fail to comply with regulatory requirements in
international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full
market potential of our product candidates will be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our product candidates could fail
to receive regulatory approval for many reasons, including but not limited to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA or comparable international regulatory authorities may disagree with the design, implementation
or results of our clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA or comparable international regulatory authorities may determine that our product candidates are
not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics
that preclude our obtaining marketing approval or prevent or limit commercial use;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the population studied in the clinical program may not be sufficiently broad or representative to assure
efficacy and potency and safety in the full population for which we seek approval;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA or comparable international regulatory authorities may disagree with our interpretation of data
from preclinical studies or clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the data collected from clinical trials of our product candidates may not be sufficient to support the
submission of a Biologics License Application, New Drug Application or other submission or to obtain regulatory approval in the United
States or elsewhere;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we may be unable to demonstrate to the FDA or comparable international regulatory authorities that a product
candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the FDA or comparable international regulatory authorities may fail to approve the manufacturing processes,
test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the approval policies or regulations of the FDA or international foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 39; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to market any product candidates outside
of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety
and efficacy and potency and approval standards. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and
accept the payment of user fees, government shutdowns, including as a result of budget delays or other circumstances like the COVID-19
pandemic and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result.
This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain
regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><b><i>All but one of our clinical
trials to date have been conducted outside the United States, and the FDA and other foreign regulatory authorities may not accept data
from such trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">The acceptance of study data from
clinical trials conducted outside the United States by the FDA may be subject to certain conditions or may not be accepted at all. In
cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the
FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States
population and United States medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant
to good clinical practice regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA,
or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate
means. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable
local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any other foreign regulatory
authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable
foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming
and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization
in the applicable jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have received Fast Track designation for
one of our compounds and may seek such designation or breakthrough therapy and priority review for other compounds in the future. Fast
Track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For some of our compounds, including ANAVEX<sup>&#174;</sup>2-73,
we hope to benefit from the FDA&#8217;s Fast Track and priority review programs. In February 2020, the FDA granted Fast Track designation
for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. Programs with Fast Track designation
may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application
for regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being
studied. If any of our compounds receive Fast Track designation but do not continue to meet the criteria for Fast Track designation, or
if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical
supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the
standards for approval. The receipt of Fast Track designation for a compound may not result in a faster development or regulatory review
or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if any product candidate qualifies for Fast Track designation, the FDA may later decide that the product
candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under FDA policies, a compound is eligible for priority
review, or review within a six-month time frame from the time a complete NDA is accepted for filing, if the compound provides a significant
improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. The FDA determines whether a drug qualifies
for Priority Review after an NDA for such drug is submitted to the FDA. Therefore, until NDAs are submitted for our compounds, we cannot
be assured that they will be granted Priority Review. Additionally, even if Priority Review is granted for one of our compounds, the FDA
does not always meet its six-month PDUFA goal date for Priority Review and the review process is often extended by FDA requests for additional
information or clarification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may seek Breakthrough Therapy designation for one
or more of our current or future compounds. Designation as a Breakthrough Therapy is largely within the discretion of the FDA. Accordingly,
even if we believe that a compound meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine
not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in
a faster development process, review or approval compared to candidate products considered for approval under&#160;non-expedited&#160;FDA
review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more compounds qualify as breakthrough
therapies, the FDA may later decide that the product no longer meets the conditions for qualification and revoke the designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast Track or Breakthrough Therapy designation for
our compounds may not actually lead to a faster review process, and a delay in the review process or in the approval of our compounds
will delay revenue from their potential sales and will increase the capital necessary to fund these compound development programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We have received orphan drug designation for several of our compounds,
but we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing
and making available in the United States a drug for a disease or condition will be recovered from sales in the United States for that
drug. If a product that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including
a full NDA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan drug exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have received orphan drug designation for several
of our compounds, but we may not be able to obtain or maintain orphan drug exclusivity in the United States for those compounds. We may
not be the first to obtain marketing approval of any compound for which we have obtained orphan drug designation for the orphan-designated
indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the
United States may be limited if we seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally,
any compound with orphan drug designation may lose such designation if the FDA later determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety
for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective
or makes a major contribution to patient care.&#160;In addition, others may obtain orphan drug exclusivity for products addressing the
same diseases or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases
or conditions for a significant period of time.<b>&#160;</b><span style="background-color: white">Orphan drug designation neither shortens
the development time or regulatory review time of a drug nor gives the product candidate any advantage in the regulatory review or approval
process or entitles the product candidate to priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition and operating results will be materially adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The success of our research and development efforts
will be greatly dependent upon our ability to demonstrate potential drug compound efficacy in non-clinical studies, as well as in clinical
trials. Non-clinical studies involve testing potential drug compounds in appropriate non-human disease models to demonstrate efficacy
and safety. Regulatory agencies evaluate these data carefully before they will approve clinical testing in humans. If certain non-clinical
data reveals potential safety issues or the results are inconsistent with an expectation of the potential drug compound&#8217;s efficacy
in humans, the regulatory agencies may require additional more rigorous testing before allowing human clinical trials. This additional
testing will increase program expenses and extend timelines. We may decide to suspend further testing on our potential drug compounds
if, in the judgment of our management and advisors, the non-clinical test results do not support further development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, success in non-clinical testing and early
clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical
trials will replicate the results of prior clinical trials and non-clinical testing. The clinical trial process may fail to demonstrate
that our potential drug compounds are safe for humans and effective for indicated uses. This failure would cause us to abandon a drug
candidate and may delay development of other potential drug compounds. Any delay in, or termination of, our non-clinical testing or clinical
trials will delay the filing of an IND and NDA with the FDA or the equivalent applications with pharmaceutical regulatory authorities
outside the United States and, ultimately, our ability to commercialize our potential drug compounds and generate product revenues. In
addition, we expect that our early clinical trials will involve small patient populations. Because of the small sample size, the results
of these early clinical trials may not be indicative of future results. Also, the IND process may be extremely costly and may substantially
delay the development of our potential drug compounds. Moreover, positive results of non-clinical tests will not necessarily indicate
positive results in subsequent clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following successful non-clinical testing, potential
drug compounds will need to be tested in a clinical development program to provide data on safety and efficacy prior to becoming eligible
for product approval and licensure by regulatory agencies. From the first human trial through to regulatory approval can take many years
and 10-12 years is not unusual for certain compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our future clinical development potential
drug compounds become the subject of problems, our ability to sustain our development programs will become critically compromised. For
example, efficacy or safety concerns may arise, whether or not justified, that could lead to the suspension or termination of our clinical
programs. Examples of problems that could arise include, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy or safety concerns with the potential drug compounds, even if not justified;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing difficulties or concerns;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory proceedings subjecting the potential drug compounds to potential recall;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity affecting doctor prescription or patient use of the potential drug compounds;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure from competitive products; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of more effective treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each clinical phase is designed to test attributes
of the drug and problems that might result in the termination of the entire clinical plan can be revealed at any time throughout the overall
clinical program. The failure to demonstrate efficacy in our clinical trials would have a material adverse effect on our future business
prospects, financial condition and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If a particular product candidate causes undesirable
side effects, then we may be unable to receive regulatory approval of or commercialize such product candidate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may experience numerous unforeseen events during,
or as a result of, the testing process that could delay or prevent commercialization of any of our product candidates, including the occurrence
of undesirable side effects. Such side effects could lead to clinical trial challenges, such as difficulties in subject recruitment, retention,
and adherence, potential product liability claims, and possible termination by health authorities. These types of clinical trial challenges
could in turn, delay or prevent regulatory approval of our product candidate. Side effects may also lead regulatory authorities to require
stronger product warnings on the product label, costly post-marketing studies, and/or a REMS, among other possible requirements. If the
product candidate has already been approved, such approval may be withdrawn. Any delay in, denial, or withdrawal of marketing approval
for one of our product candidates will adversely affect our business, including our results of operations and financial position. Even
if one or more of our product candidates receives marketing approval, undesirable side effects may limit such product&#8217;s commercial
viability. Patients may not wish to use our product, physicians may not prescribe our product, and our reputation may suffer. Any of these
events may significantly harm our business and financial prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to compete in the highly competitive biotechnology
and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.
We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers,
other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in
product development and harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competition for skilled personnel in our market is
intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Despite our efforts to
retain valuable employees, members of our management, scientific and development teams may terminate their employment or service with
us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment,
which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our
ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level
and senior scientific and medical personnel in an extremely competitive market for employees and other service providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not obtain the support of qualified
scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material adverse effect on
our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to establish relationships with leading
scientists and research institutions. We believe that such relationships are pivotal to establishing products using our technologies as
a standard of care for various indications. Additionally, although in discussion, there is no assurance that our current research partners
will continue to work with us or that we will be able to attract additional research partners. If we are not able to establish scientific
relationships to assist in our research and development, we may not be able to successfully develop our potential drug compounds. If this
happens, our business will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to develop, market or generate
sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment in our Company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assuming that we are successful in developing our
potential drug compounds and receiving regulatory clearances to market our products, our ability to successfully penetrate the market
and generate sales of those products may be limited by a number of factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors receive regulatory approvals for and begin marketing similar products in the United States, the European Union, Japan and other territories before we do, greater awareness of their products as compared to ours will cause our competitive position to suffer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information from our competitors or the academic community indicating that current products or new products are more effective or offer compelling other benefits than our future products could impede our market penetration or decrease our future market share; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The pricing and reimbursement environment for our future products, as well as pricing and reimbursement decisions by our competitors and by payers, may have an effect on our revenues.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this happens, our business will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>None of our potential drug compounds may reach
the commercial market for a number of reasons and our business may fail.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Successful research and development of pharmaceutical
products is high risk. Most products and development candidates fail to reach the market. Our success depends on the discovery of new
drug compounds that we can commercialize. It is possible that our products may never reach the market for a number of reasons. They may
be found ineffective or may cause harmful side effects during non-clinical testing or clinical trials or fail to receive necessary regulatory
approvals. We may find that certain products cannot be manufactured at a commercial scale and, therefore, they may not be economical to
produce. Our potential products could also fail to achieve market acceptance or be precluded from commercialization by proprietary rights
of third parties. Our patents, patent applications, trademarks and other intellectual property may be challenged, and this may delay or
prohibit us from effectively commercializing our products. Furthermore, we do not expect our potential drug compounds to be commercially
available for a number of years, if at all. If none of our potential drug compounds reach the commercial market, our business will likely
fail and investors will lose all of their investment in our Company. If this happens, our business will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Material modifications in the methods of product
candidate manufacturing may result in additional costs or delay.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As product candidates progress from preclinical studies
to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program,
such as manufacturing methods, materials and processes, are altered along the way in an effort to optimize yield, manufacturing batch
size, minimize costs and achieve consistent purity, identity, potency, quality and results. Such changes carry the risk that they will
not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and could affect
planned or other clinical trials conducted with product candidates produced using the modified manufacturing methods, materials, and processes.
This could delay completion of clinical trials and could require non-clinical or clinical bridging and comparability studies, which could
increase costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our competitors succeed in developing products
and technologies faster or that are more effective or with a better profile than our own, or if scientific developments change our understanding
of the potential scope and utility of our potential products, then our technologies and future products may be rendered undesirable or
obsolete.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We face significant competition from industry participants
that are pursuing technologies in similar disease states to those that we are pursuing and are developing pharmaceutical products that
are competitive with our products. Nearly all of our industry competitors have greater capital resources, larger overall research and
development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval and pharmaceutical
product manufacturing and marketing than we do. With these additional resources, our competitors may be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend
in large part on our ability to maintain a competitive position with respect to these technologies. Rapid technological development, as
well as new scientific developments, may result in our products becoming obsolete before we can recover any of the expenses incurred to
develop them. For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted
therapy like we are developing may limit the drug&#8217;s market potential if it is subsequently demonstrated that only certain subsets
of patients should be treated with the targeted therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have advanced our research and development
efforts on the treatment of neurodegenerative and central nervous system, or CNS, disorders, a field that has seen very limited success
in product development.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have advanced our research
and development efforts on addressing neurodegenerative, neurodevelopmental and CNS disorders. Collectively, efforts by pharmaceutical
companies in the field of neurodegenerative,&#160;neurodevelopmental&#160;and CNS disorders have seen very limited successes in product
development. The development of neurodegenerative and CNS therapies presents unique challenges, including an imperfect understanding of
the biology, the presence of the blood brain barrier that can restrict the flow of drugs to the brain, a frequent lack of translatability
of preclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be
too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our reliance on third parties, such as university
laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing,
or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them or non-compliance
with regulations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of product development, we may engage
university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture drug material
for us to be used in non-clinical and clinical testing and contract research organizations to conduct and manage non-clinical studies
and clinical trials. If we engage these organizations to help us with our non-clinical and clinical programs, many important aspects of
this process have been and will be out of our direct control. If any of these organizations we may engage in the future fail to perform
their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical trials in a satisfactory manner,
we may face delays in completing our clinical trials, as well as commercialization of any of our potential drug compounds. Furthermore,
any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials, regulatory filings and
the potential market approval of our potential drug compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, any of these third parties may engage
in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Misconduct by these parties
could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations
of any regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;
healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information
or data accurately. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to compete successfully with respect
to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability
to research and develop our potential drug compounds.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors compete with us to attract established
biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint ventures or other
collaborations. Collaborations include contracting with academic research institutions for the performance of specific scientific testing.
If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will
then be precluded from pursuing those specific opportunities. Since each of these opportunities is unique, we may not be able to find
a substitute. Other companies have already begun many drug development programs, which may target diseases that we are also targeting,
and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available
opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universities and public and private research institutions
also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary
technology and acquire patent applications and patents that we may need for the development of our potential drug compounds. In some instances,
we will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if
at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we
may be limited in our ability to develop new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The use of any of our products in clinical trials
may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out, causing our business to
suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The nature of our business exposes us to potential
liability risks inherent in the testing, manufacturing and marketing of our products. We currently have one drug compound in clinical
trials; however, when any of our products enter clinical trials or become marketed products, they could potentially harm people or allegedly
harm people possibly subjecting us to costly and damaging product liability claims. Some of the patients who participate in clinical trials
are already ill when they enter a trial or may intentionally or unintentionally fail to meet the exclusion criteria. The waivers we obtain
may not be enforceable and may not protect us from liability or the costs of product liability litigation. Although we intend to obtain
product liability insurance, which we believe is adequate, we are subject to the risk that our insurance will not be sufficient to cover
such claims. The insurance costs along with the defense or payment of liabilities above the amount of coverage could cost us significant
amounts of money and management distraction from other elements of the business, causing our business to suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our information systems or data, or those
of third parties upon whom we rely, are or were compromised, our business may be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of our business, we, or third parties
upon whom we rely, may gather, collect, receive, use, transmit, store/retain or dispose of data and confidential information (such as
confidential employee information or health-related data), sensitive data, intellectual property and trade secrets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Cyberattacks, malicious internet-based
activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive
information and information technology systems, and those of the third parties upon whom we rely. We, and the third parties upon whom
we may rely, may be subject to a variety of these evolving threats.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although we endeavor to protect
confidential information through the implementation of security technologies, processes and procedures, it is possible that an individual
or group could defeat security measures and access sensitive information about our business and employees. The existence of a remote workforce
also poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network
connections outside our premises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any misappropriation, loss or other unauthorized disclosure
of confidential information gathered, stored or used by us or by third parties on our behalf, could have a material impact on the operation
of our business, including damaging our reputation with our employees, third parties and investors. We could also incur significant costs
implementing additional security measures and organizational changes, implementing additional protection technologies, training employees
or engaging consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our contracts with third
parties upon whom we may rely, may not contain limitations of liability, and even where they do, there can be no assurance that limitations
of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security
obligations. In addition, we could incur increased litigation as a result of any potential cyber-security breach and our insurance coverage
may not be adequate or sufficient in type or amount to protect us from or to mitigate liabilities arising out of our privacy and security
practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are not aware that we have experienced any material
misappropriation, loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a cyber-security
breach or other act, however, a cyber-security breach or other act and/or disruption to our information technology systems could have
a material adverse effect on our business, prospects, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we receive regulatory approval for one
or more compounds, we will be subject to continuing regulatory obligations and ongoing regulatory review, which may result in significant
additional expense. Additionally, our compounds, if approved, could be subject to labeling and other restrictions on marketing or withdrawal
from the market, and we may be subject to penalties, if we fail to comply with regulatory requirements or if we experience unanticipated
problems with our compounds, when and if any of them are approved. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following potential approval of any our compounds,
the FDA may impose significant restrictions on a drug&#8217;s indicated uses or marketing or require potentially costly and time-consuming
post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the drug. The FDA may also require
a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) as a condition of approval of one or more of our compounds, which could
include requirements for a medication guide, physician communication plans or additional elements to ensure safe use of the drug. Additional
REMS elements may include restricted distribution methods, patient registries and other risk minimization tools.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if the FDA or a comparable foreign regulatory
authority approves one or more of our compounds, the manufacturing processes, labeling, packaging, distribution, adverse event reporting,
storage, advertising, promotion, import, export and recordkeeping for the approved drug will be subject to additional and potentially
extensive ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports,
establishment registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval.
Later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or
with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among
other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The occurrence of any event or penalty described above
may limit our ability to commercialize our compounds and generate revenue and could require us to expend significant time and resources
in response or generate negative publicity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our compounds are approved, our product
labeling, advertising and promotion will also be subject to regulatory requirements and ongoing regulatory review. The FDA strictly regulates
the promotional claims that may be made about drug products. In particular, a drug may not be promoted for uses that are not approved
by the FDA as reflected in the drug&#8217;s approved labeling. If we receive marketing approval for a compound, physicians may nevertheless
lawfully prescribe it to their patients in a manner that is inconsistent with the approved label. While the FDA recently clarified that
mere knowledge that a physician is prescribing an approved drug for off-label use is not sufficient to constitute unlawful off-label promotion,
if we are found to have actively promoted such off-label uses, we may become subject to significant liability under the FDCA. The federal
government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies
from engaging in off-label promotion. Additionally, promotion for off-label uses could result in significant liability under the False
Claims Act. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional
conduct is changed or curtailed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA&#8217;s and other regulatory authorities&#8217;
policies are subject to change at any time, and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our compounds. If we are unable to timely adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are not able to maintain regulatory compliance post-marketing, we may lose any marketing approval that we may have
obtained, and we may not achieve or sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 47; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Finally, we cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United
States or abroad. It is difficult to predict how any such legislative, administrative or executive actions will be implemented, and the
extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these legislative or executive actions
impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business
may be negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in funding for the FDA, the SEC and
other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services
from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which
the operation of our business may rely, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and
accept payment of user fees, statutory, regulatory and policy changes, and business disruptions, such as those caused by the COVID-19
pandemic. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and
other government agencies on which our operations may rely, including those that fund research and development activities is subject to
the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disruptions at the FDA and other agencies may also
slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our
business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such
as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged
government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions,
which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the
public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We receive&#160;Australian&#160;government research
and development income&#160;tax&#160;incentive refunds. If our research and development expenditures are not deemed to be eligible for
the refund, proposed modifications to the&#160;tax&#160;incentive program are enacted, or the&#160;tax&#160;incentive program is discontinued
by the&#160;Australian&#160;government, it could have a negative effect on our future cash flows and the funding of future research and
development projects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our subsidiary, Anavex Australia Pty Ltd., is incorporated
in Australia where we are currently engaged in research and development activities for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71.
Our subsidiary is eligible to participate in the&#160;Australian&#160;Federal Government&#8217;s Research and Development&#160;Tax&#160;Incentive
program, under which the government provides a cash refund for a portion of eligible research and development expenditures (currently
43.5% to 48.5% depending on the entity&#8217;s corporate tax rate) by small&#160;Australian&#160;entities, which are defined as&#160;Australian&#160;entities
with less than $20 million (Australian) in revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Research and Development&#160;Tax&#160;Incentive
refund is offered by the&#160;Australian&#160;federal government for eligible research and development purposes based on the filing of
an annual application. As part of this program, our subsidiary applied for and received cash refunds from the&#160;Australian&#160;Taxation
Office, or the ATO, for a percentage of the research and development costs expended by our subsidiary in Australia. Since the fiscal year
ended September 30, 2015, we have been receiving Research and Development&#160;Tax&#160;Incentive refunds related to research and development
expenditures made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain research and development expenses incurred
outside of Australia are also eligible for the&#160;Australian&#160;research and development&#160;tax&#160;incentive program, provided
we obtain an Advance Overseas Finding from AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation
and Science (&#8220;AusIndustry&#8221;).&#160;To receive an Advance Overseas Finding, the expenses must have been for eligible research
and development activities, as determined by AusIndustry, and the expenditures must have a scientific link to the&#160;Australian&#160;activities,
be unable to be conducted in Australia and the total actual and reasonably anticipated overseas costs must be expected to be less than
the total actual and reasonably anticipated expenditures for activities conducted within Australia, as determined by AusIndustry at the
time of application for an Advance Overseas Finding (&#8220;OSF&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This OSF binds both AusIndustry
and the Commissioner of Taxation for three income years. However, for compliance purposes, specific issue guidance jointly issued by AusIndustry
and the ATO in 2014 provides that an OSF can apply for the duration of the overseas activity provided the activities are not new or materially
different than the activities described in the OSF. Currently, the Company is outside of the binding three-year period with respect to
OSF applicable to some of its programs being claimed in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent that some or all of our research and
development expenditures are deemed to be &#8220;ineligible,&#8221; then our refunds may decrease or be eliminated. In addition, the&#160;Australian&#160;government
may in the future modify the requirements of, reduce the amounts of the refunds available under, or discontinue the Research and Development&#160;Tax&#160;Incentive
program. Any such change to our anticipated refunds or change to the Research and Development&#160;Tax&#160;Incentive program would have
a negative effect on our future cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A variety of risks are associated with operating
our business internationally which could materially adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are presently conducting clinical development solely
in Australia, United Kingdom, The Netherlands, Germany and Canada and may choose to conduct additional international and U.S. clinical
trials in the future. Additionally, while we have not taken any steps to enter into any non-U.S. markets, we may do so in the future.
Accordingly, we are subject to risks related to operating in foreign countries, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different United States and foreign drug import and export rules;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced protection for intellectual property rights in certain countries;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with the FCPA and other anti-corruption and anti-bribery laws;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign taxes, including withholding of payroll taxes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability resulting from development work conducted by foreign partners;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from natural disasters, outbreaks of contagious diseases, such as COVID-19, or geopolitical actions, including war and terrorism, or systems failure including cybersecurity breaches; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with evolving and expansive foreign regulatory requirements, including data privacy laws (such as the GDPR).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in connection with the ongoing conflict
between Russia and Ukraine, the U.S. government and European Union countries have imposed enhanced export controls on certain products
and sanctions on certain industry sectors and parties in Russia. The U.S. government has also indicated it will consider imposing additional
sanctions and other similar measures in the near future. Although we do not currently conduct any clinical trials in Russia or Ukraine,
further escalation of geopolitical tensions could have a broader impact that expands into other markets where we do business or conduct
certain research and development operations, which could adversely affect our business, our supply chain for our product candidates, our
collaborators or our ability to carry out our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>Our ability
to use our net operating loss (&#8220;NOL&#8221;) carryforwards and certain tax credit carryforwards may be subject to limitation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, we had approximately $128.5
million of U.S. federal and $16.9 million of state and local NOL carryforwards. We had approximately $16.6 million of NOL carryforwards
in Australia as of the same period. Our NOL carryforwards are subject to review and possible adjustment by the U.S. and state tax authorities.
In addition, under Sections 382 and 383 of the Internal Revenue Code and corresponding provisions of state law, if a corporation undergoes
an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year
period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and research and development credits to offset its post-change
income may be limited. This could limit the amount of NOLs or research and development credit carryforwards that we can utilize annually
to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization
of NOLs and research and development credits carried forward may further affect the limitation in future years. In addition, at the state
level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase
state taxes owed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted a Section 382 study during the year ended
September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership which resulted in $25.8
million of federal NOLs being subject to an annual limitation. During the year ended September 30, 2021, we reduced our federal NOLs by
$12.1 million and our research and development tax credit carryforwards by $0.8 million, which are the amount of tax assets that will
expire unutilized pursuant to the Section 382 study. This resulted in a reduction of $2.5 million of NOLs and $0.8 million of research
and development credits and a corresponding reduction in the valuation allowance of $3.3 million, which was recorded in the 2021 fiscal
year. Subsequent ownership changes in future years could trigger additional limitations of our NOLs. During the year ended September 30,
2024 and 2023, we determined that there were no changes in ownership pursuant to Section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to healthcare laws and regulations
which may require substantial compliance efforts and could expose us to criminal sanctions, civil and administrative penalties, contractual
damages, reputational harm and diminished profits and future earnings, among other penalties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare providers, physicians and others will play
a primary role in the recommendation and prescription of our products, if approved. Our arrangements with such persons and third-party
payors and our general business operations will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations
that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our
drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal, state and foreign healthcare laws and regulations
include, but are not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 50; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which impose criminal and civil penalties, including those from civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Stark Law prohibits a physician from making referrals for certain &#8220;designated health services&#8221; payable by Medicare to an entity in which the physician or an immediate family member of such physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory exception applies. There are a number of exceptions to the Stark Law. Such exceptions permit certain payments and arrangements that, although they would otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements of the specific exceptions are met.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, which among other things, created additional federal criminal statutes that impose criminal and civil liability for, such actions as executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating to healthcare matters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The privacy and security provisions of HIPAA, which impose certain requirements on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the Affordable Care Act that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to track and annually report to CMS payments and other transfers of value provided to physicians, certain other healthcare providers (such as physicians assistants and nurse practitioners),and teaching hospitals, as well as ownership and investment interests held by physicians or their immediate family members; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ensuring that our business arrangements with third
parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will
conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual
damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could substantially
disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance
with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded
healthcare programs. We may incur significant costs achieving and maintaining compliance with applicable federal and state privacy, security,
and fraud laws. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our attention from the operation of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 51; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We expect current and future legislation affecting
the pharmaceutical industry, including drug pricing reform, to impact our business generally, which could adversely affect our business
operations. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been, and continue
to be proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform
government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order,
&#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s
executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for
drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of
certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to
penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although
they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact
on the pharmaceutical industry. If any of our products are subject to such negotiation, we may lose a significant amount of the revenues
expected during the full life cycle of these products. Further, the Biden administration released an additional executive order on October
14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged
to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. We&#160;expect that additional U.S. federal healthcare
reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare
products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The coverage and reimbursement status of newly
approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved,
could limit our ability to market those products and decrease our ability to generate product revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will depend in part on
the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such
as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers.
Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge, reduction or denial
by payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether a payor will provide
coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.
A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally,
in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and
approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate
reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory
financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors are increasingly challenging the
price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.
In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies
in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended
to obtain regulatory approvals. Third-party payors may not consider our compounds to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally,
we or our collaborators may develop companion diagnostic tests for use with our product candidates. Companion diagnostic tests require
coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products.
Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion
diagnostics. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for the product candidates,
and for us or our collaborators to obtain coverage and adequate reimbursement for related companion diagnostic tests that may be developed,
could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A decline in the price of our common stock could
affect our ability to raise further working capital and adversely impact our operations and would severely dilute existing or future investors
if we were to raise funds at lower prices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A prolonged decline in the price of our common stock
could result in a reduction in our ability to raise capital. Because our operations have been financed through the sale of equity securities,
a decline in the price of our common stock could be especially detrimental to our continued operations. Any reduction in our ability to
raise equity capital in the future would force us to reallocate funds from other planned uses and would have a significant negative effect
on our business plans and operations, including our ability to develop new products and continue our current operations. If our stock
price declines, there can be no assurance that we can raise additional capital or generate funds from operations sufficient to meet our
obligations. We believe the following factors could cause the market price of our common stock to continue to fluctuate widely and could
cause our common stock to trade at a price below the price at which you purchase your shares of common stock:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our quarterly operating results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of new services, products, acquisitions or strategic relationships by us or our competitors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting treatments or principles;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings estimates by securities analysts and in analyst recommendations; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general political, economic, regulatory and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price for our common stock may also be
affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations, even if minor,
could materially adversely affect the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we issue additional shares of common stock
in the future, it will result in the dilution of our existing stockholders and may cause the share price of our common stock to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have 200,000,000 shares of common stock authorized
for issuance and we also have 10,000,000 shares of preferred stock authorized. Our Board of Directors has the authority to issue additional
shares of preferred and common stock up to the authorized capital stated in the articles of incorporation. Our Board of Directors may
choose to issue some or all such shares of common stock to acquire one or more businesses or to provide additional financing in the future.
The issuance of any such shares of common stock will result in a reduction of the book value or market price of the outstanding shares
of our common stock. If we do issue any such additional shares of common stock, such issuance also will cause a reduction in the proportionate
ownership and voting power of all other stockholders. Further, any such issuance may result in a change of control of our corporation.
In the event we do issue or sell additional shares of common or preferred stock, it may result in stockholder dilution and may cause our
share price to fall.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stock price has been volatile and may be
volatile in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock price has been volatile at certain times
historically, and may be volatile in the future. We may incur rapid and substantial increases or decreases in our stock price in the foreseeable
future that do not coincide in timing with the disclosure of news or developments by us. The stock market in general, and the market for
biotechnology and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating
performance of particular companies. The market price for our common stock may be influenced by many factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of new data, clinical trial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements related to any delays in any preclinical or clinical trials related to our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements related to our products&#8217; ability to demonstrate efficacy or an acceptable safety profile of our product candidates or similar announcements by companies that are perceived to be similar to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet or exceed expectations of analysts or investors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">news that the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions taken by regulatory agencies with respect to our product candidates or the progress of our clinical trials, including with respect to any fast track or orphan drug designations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grants awarded to us or companies that are perceived to be similar to us from outside entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volume of our common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning our collaborations or partners;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the perception of the biotechnology or pharmaceutical industries by the public, legislatures, regulators and the investment community;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or disputes concerning intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant lawsuits, including patent or stockholder litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock by us or our stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declines in the market prices of stocks generally or of companies that are perceived to be similar to us; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, industry and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, companies trading in the stock market
in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of these companies. These broad market and industry factors may seriously harm the market
price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market, securities
class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial
costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial
condition, results of operations and growth prospects. There can be no guarantee that our stock price will remain at current prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our common stock may become the target of a
&#8220;short squeeze.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities of certain companies have experienced significant
and extreme volatility in stock price due to short sellers of shares of common stock, known as a &#8220;short squeeze.&#8221; These short
squeezes have caused extreme volatility in those companies and in the market and have led to the price per share of those companies to
trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased
shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the price
per share has declined steadily as interest in those stocks have abated. There can be no assurance that we will not in the future be a
target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares at a rate that
is significantly disconnected from our underlying value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to maintain an effective system of
internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result,
stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of
our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Section 404 of the Sarbanes-Oxley Act,
our management is required to report upon the effectiveness of our internal control over financial reporting. We cannot assure you that
there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any
failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition,
results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or
if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal
control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market
price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC or
other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement
or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our disclosure controls and procedures may not
prevent or detect all errors or acts of fraud.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to the periodic reporting requirements
of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports
we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal
controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives
of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to
disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls
can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls.
Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Intellectual Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to obtain and maintain sufficient
intellectual property protection for our product candidates, or if the scope of the intellectual property protection obtained is not sufficiently
broad, our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully
commercialize our product candidates that we may pursue may be impaired. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends in large part on our ability to
obtain and maintain protection of our intellectual property, particularly patents, in the United States and other countries with respect
to our product candidates and technology. We seek to protect our proprietary position by filing patent applications in the United States
and abroad related to our product candidates or by in-licensing intellectual property. U.S. patents related to ANAVEX<sup>&#174;</sup>2-73
are directed to ANAVEX&#174;2-73 in its various optical or crystal forms, its therapeutic indications, and dosage forms comprising certain
doses of ANAVEX<sup>&#174;</sup>2-73 combined with another therapeutic agent. We may not be able to obtain broader scope patent protection
for ANAVEX<sup>&#174;</sup>2-73 as a single drug or in other jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 55; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the
subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the
United States, or vice versa. Further, we may not be aware of all third-party intellectual property rights potentially relating to and/or
interfering with our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some
cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or
pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope,
validity, enforceability and/or commercial value of our patent rights are highly uncertain. Our pending and future patent applications
may not result in patents being issued that protect our product candidates, in whole or in part, or which could effectively prevent others
from commercializing competitive product candidates. Even if our patent applications issue as patents, they may not issue in a form that
will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive
advantage. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing
manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, we may be subject to a third-party pre-issuance
submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation,
reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of
others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent
rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in
our inability to manufacture or commercialize drugs without infringing on third-party patent rights. In addition, if the breadth or strength
of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the issuance of a patent is not conclusive
as to its inventorship, scope, validity and/or enforceability, and our patents may be challenged in the courts or patent offices in the
United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar
or identical product candidates, or limit the duration of the patent protection of our product candidates. Given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or
shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude
others from commercializing drugs similar or identical to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to twenty-two
U.S. patents, twenty-three U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates, methods
associated therewith, and to our research programs. Neither patents nor patent applications ensure the protection of our intellectual
property for a number of reasons, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors may interfere with our patenting process in a variety of ways. Competitors may claim that we are not entitled to an issued patent for a variety of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom to operate. If a court or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all of our patent protection. As a company, we have no meaningful experience with competitors interfering with our patents or patent applications.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of a patent may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible for competitors to design products that do not infringe our patent(s).</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are seeking patent protection for a number of indications, combination products and drug regimens. The lack of patent protection in global markets for a specific end product or indication may inhibit our ability to advance our compounds and may make us less attractive to potential partners.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 56; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: justify; width: 5%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defending a patent lawsuit takes significant time and can be very expensive.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a court decides that an Anavex compound, its method of manufacture or use, infringes on a competitor&#8217;s patent, we may have to pay substantial damages for infringement.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A court may prohibit us from making, selling or licensing the potential drug compound unless the patent holder grants a license. A patent holder is not required to grant a license. If a license is available, we may have to pay substantial royalties or grant cross licenses to our patents, and the license terms may be unacceptable.</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally or willfully
disclose our information to competitors. Enforcing a claim that someone illegally obtained and is using our trade secrets, like patent
litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes
less willing to protect trade secrets. Our competitors may independently develop equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also support and collaborate in research conducted
by government organizations, hospitals, universities or other educational institutions. These research partners may be unable or unwilling
to grant us exclusive rights to technology or products derived from these collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual property
licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or even
be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses. There is also a risk
that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration with other parties,
all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patent terms may be inadequate to protect our
competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patents have a limited lifespan. In the United States,
if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents
covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products,
including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product
candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our
owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics
of FDA marketing approval of product candidates that we identify, one of the U.S. patents covering such product candidate or the use thereof
may be eligible for up to five years of patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one
patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent
term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those
claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension
also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted
patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence
during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of
patent protection during any such extension, afforded by the governmental authority could be less than what we request. If we are unable
to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we
will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following
our patent expiration sooner, and our revenue could be reduced, possibly materially.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also, there are detailed rules and requirements regarding
the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the
Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements
for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or
a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product
candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated
new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to comply with our obligations in
the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business
relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are party to an exclusive license agreement with
Life Science Research Israel Ltd., with respect to certain in-licensed intellectual property related to our ANAVEX<sup>&#174;</sup>3-71
product candidate, and we may need to obtain additional licenses from others in the future. Our license agreement with Life Science Research
Israel Ltd. imposes, and we expect that future license agreements will impose, various development, diligence, commercialization, and
other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under
such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and
commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents
fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and
to market, products identical to ours and we may be required to cease our development and commercialization of ANAVEX<sup>&#174;</sup>3-71
or other product candidates covered by any such future licenses. Any of the foregoing could have a material adverse effect on our competitive
position, business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, disputes may arise regarding intellectual
property subject to a licensing agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">the priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the agreements under which we currently
license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible
to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to
be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other
obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results
of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to
maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual property
licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or even
be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses. There is also a risk
that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration with other parties,
all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success will also depend in part on our ability
to commercialize our compounds without infringing the proprietary rights of others. However, our research, development and commercialization
activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled
by third parties. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist
or could be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with
respect to our technology. Because patent applications can take many years to issue, there may be currently pending patent applications
which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the
future and claim that use of our technologies infringes upon these patents. If our compounds or other subject matter are claimed under
other United States patents or other international patents or are otherwise protected by third party proprietary rights, we may be subject
to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights, or we may be required
to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances that we would
be successful in a challenge or be able to obtain such licenses or that such licenses, if available, could be obtained on commercially
reasonable terms. Furthermore, the failure to succeed in a challenge, develop a commercially viable alternative or obtain needed licenses
could be materially adverse. Adverse consequences include delays in marketing some or all of our potential drug compounds based on our
drug technology or the inability to proceed with the development, manufacture or sale of potential drug compounds requiring such licenses.
If we defend ourselves against charges of patent infringement or to protect our proprietary rights against third parties, substantial
costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success.
An adverse outcome could subject us to significant liabilities to third parties and force us to curtail or cease the research and development
of our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties making claims against us may obtain injunctive
or other equitable relief, which could effectively block our ability to further develop and commercialize ANAVEX<sup>&#174;</sup>2-73 or
our other product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would
be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we
may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign
our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary
expenditure. Additionally, parties making claims against us may be able to sustain the costs of complex patent litigation more effectively
than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information
could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could
have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results
of operations, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we use reasonable efforts to protect our trade
secrets, our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing a claim that
someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is
unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Our competitors may
independently develop equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 59; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek to protect our confidential proprietary information,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors
and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements
have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality
of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our
information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary
information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor
from using that technology or information to compete with us, which could harm our competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims that our employees,
consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees
have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not
use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary
information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may infringe our patents or other intellectual
property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to
enforce a patent covering ANAVEX<sup>&#174;</sup>2-73 or our other product candidates, the defendant could counterclaim that the patent
covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging
invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several
statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability
assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or
made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interference or derivation proceedings provoked by
third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents
or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights
to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable
terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation
or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to
raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties,
or enter into development partnerships that would help us bring ANAVEX<sup>&#174;</sup>2-73 or our other product candidates to market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims challenging the
inventorship of our patents and other intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We or our licensors may be subject to claims that
former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual
property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations
of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets
or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to
our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be
a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Periodic maintenance fees, renewal fees, annuity fees
and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent
agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place
to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent
agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help
us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable
rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the
market and this circumstance would have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Filing, prosecuting and defending patents on our product
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not
protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able
to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products
made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and may also export infringing products to territories where
we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in patent law could diminish the value
of our patents and patent applications in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in either the patent laws or interpretation
of the patent laws in the United States and other countries could increase the uncertainties and costs surrounding the prosecution of
patent applications and the enforcement or defense of issued patents. After March 2013, under the Leahy-Smith America Invents Act, or
the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming
that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an
invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application
in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the
invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent
application. Since patent applications in the United States and most other countries are confidential for a period of time after filing
or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our
product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America
Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect
patent litigation. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents,
all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 61; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the patent positions of companies in
the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the
scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination
of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions
by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways
that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property
in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk factors disclosed in this Annual Report on
Form 10-K could materially and adversely affect our business, financial condition and results of operations. The risks described herein
are not the only risks we face. Our operations could also be affected by additional factors that are not presently known to us or by factors
that we currently consider immaterial to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_004"></span>ITEM 1B. UNRESOLVED STAFF
COMMENTS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_005"></span>ITEM 1C. CYBERSECURITY</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risk management and strategy </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have implemented and maintain various information
security processes designed to identify, assess and manage material risks from cybersecurity threats to our cloud networks, third party
hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information
that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have processes designed to protect our information
systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes
the use of third-party IT professionals to assess the effectiveness of our cybersecurity practices for possible cybersecurity threats
and to manage our IT systems to mitigate these threats. We also use multi-factor authentication, maintain logical, physical and technical
controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, we provide periodical cybersecurity reminders
to our employees to emphasize the importance of adherence to our security policies. We also carry a separate cybersecurity commercial
insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our assessment and management of material risks from
cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. We conduct organizational risk assessments
commensurate with our size and complexity of our operations. We are in a continuous process of reviewing and implementing incremental
information technology strategies to mitigate cybersecurity risks as new risks arise and as our operations evolve. This has led us to
engage third party professionals to assist in the implementation of processes to manage these risks. We also use third-party service providers
across a variety of functions throughout our business, such as application providers, hosting companies, contract research organizations,
contract manufacturing organizations, distributors, and supply chain resources. We have a vendor management process to help manage cybersecurity
risks associated with our use of certain of these providers. For certain vendors, these processes include a comprehensive vendor audit
process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this Annual Report, we do not believe
that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect,
our business strategy, results of operations, or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See &#8220;<i>Risk Factors - Risks Related to Our
Business and Operations</i>&#8221; for additional information about the risks to our business associated with cybersecurity or a breach
or compromise to our information security systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Governance </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our board of directors addresses the Company&#8217;s
cybersecurity risk management as part of its general oversight function. The audit committee of the board of directors is responsible
for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity
threats. The audit committee receives periodic reports from senior management concerning the Company&#8217;s significant cybersecurity
threats and risk and the processes the Company has implemented to address them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Currently we have two cybersecurity experts on our
Audit Committee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_006"></span>ITEM 2. PROPERTIES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not own any real property. We maintain a corporate
head office at 630 5th Avenue, 20th Floor, New York, NY, USA. Our lease costs for this office are approximately $11,000 per month. We
believe our offices are suitable and adequate to operate our business currently, as they provide us with sufficient space to conduct our
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_007"></span>ITEM 3. LEGAL PROCEEDINGS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to claims and legal proceedings
that arise during the course of business. The Company is currently subject to the following lawsuits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York. The complaint
is captioned Blum v. Anavex Life Sciences, Corp. et al., case number 1:24-cv-01910, and it named the Company and Christopher Missling
as Defendants. The complaint alleges violations of the Securities and Exchange Act of 1934 associated with disclosures and statements
made with respect to certain clinical trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome (the &#8220;March 2024 Complaint&#8221;).
At a hearing on or about June 13, 2024, the Court named another purported Company shareholder, Quintessa Huey, as lead plaintiff with
respect to the March 2024 Complaint. An Amended Complaint was filed by the appointed lead plaintiff on July 12, 2024, which asserts allegations
related to purported violations of Section 10(b) of the Securities Exchange Act tied to disclosures associated with the same clinical
trials related to Rett Syndrome, and which names the Company and Christopher Missling as defendants. The Amended Complaint seeks unspecified
damages, as well as costs, including counsel and expert witness fees, on behalf of class of investors who purchased stock of the Company
on the NASDAQ during the period February 1, 2022 through January 1, 2024.&#160;The defendants filed a motion to dismiss the complaint.
The motion to dismiss is fully-briefed and awaiting a decision by the Court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing (case no. 1:2024-cv-03529), a purported shareholder of the Company,
against the same defendants as the March 2024 Complaint. The defendants filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed his complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), Christopher Missling, and members of the Company&#8217;s
Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder named Denise Deangelis.&#160;The
complaint asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a) of the Securities Exchange
Act regarding the same or similar allegations at issue in the two purported class action lawsuits related to disclosures and statements
made about certain clinical trials related to Rett Syndrome. The parties are currently due to file a proposed schedule for the anticipated
motion to dismiss by the Company and Christopher Missling (the other named defendants have not been served with the complaint) on or before
January 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
to which our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which
any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 63; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_008"></span>ITEM 4. MINE SAFETY DISCLOSURES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_009"></span>PART II</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_010"></span>ITEM 5. MARKET FOR REGISTRANT&#8217;S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Market information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is quoted on the Nasdaq Global Select
Stock Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;AVXL.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Holders of Common Stock </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 23, 2024, there were approximately
48 stockholders of record, and 84,815,517 shares of our common stock were issued and outstanding. Most of our stockholders hold their
shares in street name.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dividends </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not paid any cash dividends on our common
stock and have no intention of paying any dividends on the shares of our common stock. Our current policy is to retain earnings, if any,
for use in our operations and in the development of our business. Our future dividend policy will be determined from time to time by our
Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Sales of Unregistered Securities </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the beginning of our fiscal year ended September
30, 2024, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported
in a quarterly report on Form 10-Q or in a current report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Repurchases of Equity Securities by Our Company
and Affiliated Purchasers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 6 [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_012"></span>ITEM 7 MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following discussion should be read in conjunction
with our consolidated financial statements and related notes thereto included elsewhere in this report. Past operating results are not
necessarily indicative of results that may occur in future periods. This discussion contains forward-looking statements, which involve
a number of risks and uncertainties. See <i>Forward Looking Statements</i> included elsewhere in this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Operations Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">We are in
the development stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues until we
can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal"></span></p>

<!-- Field: Page; Sequence: 64; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Our operating costs consist primarily of research and development
activities including the cost of clinical studies and clinical supplies as well as clinical drug manufacturing and formulation. Research
and development expenses also include personnel related costs such as salaries and wages, and third-party contract research organization
(CRO) expenses in support of these clinical studies. Personnel costs include salaries and wages, benefits, and non-cash share-based compensation
charges associated with options and other equity awards granted to employees and consultants who are directly engaged in support of our
research and development activities.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">General and administrative expenses consist of personnel costs,
expenses for outside professional services and expenses associated with operating as a public company. Personnel costs consist of salaries
and wages, benefits and share-based compensation for general and administrative personnel. Outside professional services and public company
expenses include expenses related to compliance and reporting, additional insurance expenses, audit and SOX compliance, expenses associated
with patent research, applications and filings, investor and stockholder relations activities and other administrative expenses and professional
services.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>Comparison of year ended September 30, 2024 to year ended
September 30, 2023</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Our operating expenses for fiscal 2024 decreased to $52.9 million,
from $55.8 million in fiscal 2023. The decrease is attributable to a modest decrease in research and development expenses of $1.9 million
(4.3%) to $41.8 million in fiscal 2024 as well as a small decrease in general and administrative expenses of $1.0 million (8.3%) to $11.0
million in fiscal 2024, as more fully described below.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">During fiscal 2024, we experienced an overall decrease
in total research and development expenses over the comparable fiscal 2023 financial year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">The decreases were largely due to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(i)</td><td style="text-align: justify">a decrease in share-based compensation expense of $5.0 million as a result of the vesting of previous
option awards and a change in estimated vesting dates associated with performance-based option awards;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(ii)</td><td style="text-align: justify">a decrease of approximately $3.5 million relating to our Rett syndrome program as a result of the completion
of the EXCELLENCE trial and the respective open label extension; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(iii)</td><td style="text-align: justify">a decrease of approximately $1.2 million in expenditures over the comparable period relating to our Alzheimer&#8217;s
program, as a result of the completion of the Phase 2b/3 clinical trial and its related open label extension.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These decreases were largely offset by the following
increases in research and development expenditures over the comparable fiscal 2023 financial year:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(i)</td><td style="text-align: justify">an increase in personnel costs of $3.4 million related to the addition of new employees including new
additions to the Company&#8217;s leadership team, and expenses related to the engagement of consultants to assist in the preparation of
the submission of our Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA);</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(ii)</td><td style="text-align: justify">an increase of approximately $3.6 million over the comparable period relating to manufacturing activities
of ANAVEX<sup>&#174;</sup>2-73 for potential commercial use, and to support the MAA; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(iii)</td><td style="text-align: justify">an increase of $2.2 million over the comparable period relating to expenditures on the ANAVEX<sup>&#174;</sup>3-71-SZ-001
clinical trial, which trial commenced in the second quarter of fiscal 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt"></p>

<!-- Field: Page; Sequence: 65; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our research and development expenses for
the years ended September 30, 2024, and 2023 (in thousands):</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Costs of external service providers</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">21,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,542</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other common costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">375</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">99</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,838</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,717</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">External service provider cost by product candidate
was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">17,572</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">19,540</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,624</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">504</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">372</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total external service provider costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,974</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,542</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">General and administrative expenses were $11.0 million
for the fiscal 2024 financial year, as compared to $12.0 million in fiscal 2023. The primary reason for the decrease in general and administrative
expenses was a reduction in share-based compensation charges of $1.9 million, as a result of the vesting of previous option awards and
the extended timeline of milestone based vesting awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
expect to see our research and development expenditures increase from current levels as we advance our clinical programs, including continuation
of ANAVEX<sup>&#174;</sup>3-71 trial in Schizophrenia and subsequent advancements, planned advancement of ANAVEX<sup>&#174;</sup>2-73 for
Parkinson</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s disease, planned initiation of an ANAVEX<sup>&#174;</sup>2-73
for a Fragile X clinical trial, and as we continue to grow our staffing to manage and support these clinical initiatives. </span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Net other income for the year ended September 30, 2024 was $9.9
million as compared to $8.3 million for fiscal 2023. The primary reason for the increase in other income was due to a one-time financing
charge of $0.9 million recognized in the comparable year associated with entering into the 2023 Purchase Agreement (as described below),
as well as an increase in interest income in fiscal 2024 earned on cash and cash equivalents, due to an increase in market wide interest
rates year over year.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">During
fiscal 2024, we recorded $2.3 million in research and development incentive income, consisting of the Australian research and development
incentive credit administered through the ATO, in connection with fiscal 2024 eligible expenditures. In comparison, research and development
incentive income for fiscal 2023 was $2.7 million in connection with fiscal 2023 eligible expenditures. This income is driven by the clinical
trial expenditures incurred in Australia, and the decrease is a result of the completion of the EXCELLENCE trial in Rett Syndrome and
the Phase 2b/3 clinical trial in Alzheimer</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s disease, as well as
related open label extension trials, which were completed during fiscal 2024. We expect to continue to receive support from the Australian
government for future clinical trials which we plan to conduct, in part, within Australia. </span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Net loss</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Net loss for fiscal 2024 was $43.0 million, or $0.52
per share, compared to a net loss of approximately $47.5 million, or $0.60 per share for fiscal 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 66; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>Working Capital (in thousands)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">135,567</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">154,386</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,304</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,534</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Working Capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">120,263</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">141,852</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">At September 30, 2024, we had $132.2 million in cash and cash
equivalents, a decrease from $151.0 million at September 30, 2023.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">We intend to continue to use our capital resources to advance
our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and to perform work necessary to prepare for future
development of our pipeline compounds.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><i>Cash Flows </i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-weight: normal">Following is a summary
of sources of cash flows for the years ended September 30, 2024 and 2023 (in thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(30,812</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(27,785</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash flows provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">(Decrease) increase in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18,837</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,866</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Cash flow used in operating activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">There was an increase in cash used in operating activities of
$3.0 million during fiscal 2024. The principal reason for this is an increase in net cash expenses, after taking into account non-cash
share-based compensation, over the comparable period of approximately $3.3 million.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Cash flow provided by financing activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Cash provided by financing activities in fiscal 2024 was $12.0
million, comprised of $11.3 attributable to cash received from the issuance of common shares at various market prices under the 2023 Purchase
Agreement (as defined below) and $0.7 million received pursuant to the exercise of stock options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Cash provided by financing activities in fiscal 2023 was $29.7
million, comprised of $27.9 million attributable to cash received from the issuance of common shares under the 2023 Purchase Agreement
and $1.8 million received pursuant to the exercise of stock options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Other Financings</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>2023 Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant
to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0 million
in value of its shares of Common Stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to certain customary
conditions, the Company may direct Lincoln Park to purchase up to 200,000 shares of Common Stock (such purchases, &#8220;Regular Purchases&#8221;).
The amount of a Regular Purchase may increase under certain circumstances based on the market price of the Common Stock; provided, however,
that Lincoln Park&#8217;s committed obligation under any Regular Purchase shall not exceed $4.0 million. The purchase price of shares
of Common Stock will be based on the then prevailing market prices of such shares at the time of sales as described in the 2023 Purchase
Agreement. There are no limits on the price per share that Lincoln Park may pay to purchase Common Stock under the 2023 Purchase Agreement.
In addition, if the Company has directed Lincoln Park to purchase the full amount of Common Stock available as a Regular Purchase on a
given day, it may direct Lincoln Park to purchase additional amounts as &#8220;accelerated purchases&#8221; and &#8220;additional accelerated
purchases,&#8221; each as set forth in the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement limits the Company&#8217;s
sale of shares of Common Stock to Lincoln Park to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common Stock
outstanding on the date of the 2023 Purchase Agreement unless (i) stockholder approval is obtained to issue more than such amount or (ii)
the average price of all applicable sales of Common Stock to Lincoln Park under the 2023 Purchase Agreement equals or exceeds the lower
of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average
of the closing price of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement also prohibits the Company
from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock
then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership,
at any single point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated pursuant to Section
13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park 75,000 shares of Common Stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
during the year ended September 30, 2023 and agreed to issue up to 75,000 shares pro rata (collectively with the initial commitment shares,
the &#8220;commitment shares&#8221;), when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the $150.0 million aggregate
commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2024, the Company
issued to Lincoln Park an aggregate of 2,455,646 shares of Common Stock under the 2023 Purchase Agreement, including 2,450,000 shares
of Common Stock for an aggregate purchase price of $11.3 million and 5,646 commitment shares. During the year ended September 30, 2023,
the Company issued to Lincoln Park an aggregate of 3,288,943 shares of Common Stock under the 2023 Purchase Agreement, including 3,275,000
shares of Common Stock for an aggregate purchase price of $27.9 million and 13,943 commitment shares as well as the 75,000 initial commitment
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2024, an amount of $110.8 million
remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended and Restated
Sales Agreement (the &#8220;2020 Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;),
pursuant to which we could offer and sell shares of Common Stock registered under an effective registration statement from time to time
through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shares were sold during the years ended September
30, 2024 and 2023 under the 2020 Sales Agreement. The Company terminated the 2020 Sales Agreement on July 24, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Off-Balance Sheet Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no off-balance sheet arrangements that have
or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 68; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities,
revenue and expenses. These estimates and assumptions are affected by management</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with
the following aspects of our financial statements is critical to an understanding of our financial statements.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We base our assumptions and estimates on historical experience
and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances,
politics, global economics, general business conditions and other factors. Our significant estimates are related to the valuation of warrants
and options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">There are accounting policies that we believe are significant
to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research
and development expenses and share-based compensation expense.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>Research and Development Expenses</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and
benefits and share-based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (</span>&#8220;<span style="font-family: Times New Roman, Times, Serif">CROs</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(</span>&#8220;<span style="font-family: Times New Roman, Times, Serif">ASC</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">)
730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended use.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Nonrefundable advance payments for goods or services that will
be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered,
or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation
to external CROs, and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment,
invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. The
Company reviews and accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those
costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion.
Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these
contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion
of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our financial statements
based on actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based
on our estimate of the degree of completion of the event or events specified in the specific clinical trial contract.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">In addition, we incur expenses in respect of the acquisition
of intellectual property relating to patents and trademarks. The probability of success and length of time to develop commercial applications
of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with
respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully
commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<!-- Field: Page; Sequence: 69; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i>Share-based Compensation</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We account for all share-based payments and awards under the
fair value-based method.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of all share purchase options and warrants are
expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest,
in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Compensation costs for share-based payments with graded vesting
are recognized on a straight-line basis. Share-based compensation expense is adjusted for actual forfeitures of unvested awards as they
occur.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We have granted share purchase option awards that vest upon
achievement of certain performance criteria, or milestone-based awards. We estimate an implicit service period for achieving performance
criteria for each award and recognizes the resulting fair value as expense over the implicit service period when we conclude that achieving
the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and conclusions
on achieving the performance criteria. Performance awards vest upon achievement of the performance criteria.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
use the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the date of the grant.
This model requires the input of subjective assumptions, including the expected price volatility, and expected life of each&#160;award.
These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s
judgment. Changes in these assumptions can materially affect the fair value estimates.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">For a discussion of recent accounting pronouncements and their
possible effect on our results, see Note 2 to our Consolidated Financial Statements found elsewhere in this Annual Report.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal"><span id="a_013"></span>ITEM 7A QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Not required for smaller reporting companies.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<!-- Field: Page; Sequence: 70; Value: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal"><span id="a_014"></span>ITEM 8. FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 71; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><br/>
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Board of Directors and Shareholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Opinion on the financial statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated balance sheets of Anavex
Life Sciences Corp. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;) as of September 30, 2024 and 2023, the related
consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows for each of the two
years in the period ended September 30, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September
30, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended September 30, 2024,
in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis for opinion </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control
over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical audit matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Critical audit matters are matters arising from the current period audit
of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts
or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.
We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ <span id="xdx_90B_edei--AuditorName_c20231001__20240930_zg0KWxcfur05"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000044" name="dei:AuditorName">GRANT THORNTON LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90C_edei--AuditorLocation_c20231001__20240930_zD9DLEgLBS68"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000045" name="dei:AuditorLocation">Melville, New York</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">December 23, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span id="xdx_90E_edei--AuditorFirmId_c20231001__20240930_zGOpmTRJixD3" style="display: none"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000046" name="dei:AuditorFirmId">248</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_pn3n3_z0v1fLNbBgbe" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_496_20240930_zcvNJpPHd1bb" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20230930_z903qhi5wKDf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">Anavex Life Sciences Corp.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">Consolidated Balance Sheets</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">(in thousands, except share and per share amounts)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_zw30FO75cNrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrentAbstract_i01B_zMWIN3emL6O2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzZMy_zAi1MilmZLAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" id="Fact000055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesReceivable_i02I_maCzZMy_zGSL9NzlMGTl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2024-09-30" id="Fact000057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,449</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2023-09-30" id="Fact000058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,709</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzZMy_zIDzYam4fme2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">931</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30" id="Fact000061" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">653</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCzZMy_z4qTVF45Grhi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-09-30" id="Fact000063" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,567</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" id="Fact000064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zlXN9uWRiN9i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zsqq74zkxAf5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_maCz0Cc_znwyxQ8LroRb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,627</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz0Cc_zQ7ztcJhd8f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities - Note 3</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredRentCredit_i02I_maCz0Cc_zCIKE2yztqq" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income - Note 4</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredRentCredit" contextRef="AsOf2024-09-30" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">842</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredRentCredit" contextRef="AsOf2023-09-30" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">917</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i02TI_mtCz0Cc_maCzJC3_zcjHU8UKpnl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,304</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,534</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommitmentsAndContingencies_i01I_zDQ6fN81KeA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0084">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20240930_z2nG7gjrZxz" title="Preferred stock, authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20230930_zMbxGSmCeQ8c" title="Preferred stock, authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000087" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20240930_zLBJ7l2kxvOd" title="Preferred stock, par value"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20230930_zwdfxzzwekRb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzWHW_c20240930_z715b5WHRzub" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PreferredStockValue_i01I_pp0p0_maCzWHW_c20230930_zzVM9lco4j37" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240930_zSk33ViW5D51" title="Common shares, authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20230930_zNDsfA4CyIgl" title="Common shares, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000099" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" id="Fact000101" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20240930_za7BxmTobqF7" title="Common shares, par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230930_zd7Bjl8NvJUg" title="Common shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pip0_c20240930_zpfSRbTcuA38" title="Common shares, issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20240930_zR40s7Aaull7" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,795,517</ix:nonFraction></ix:nonFraction></span></span> common shares (2023 - <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pip0_c20230930_z6uaupDQBKhj" title="Common shares, issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20230930_z7UnXFeIl6o5" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,066,511</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CommonStockValue_iI_maCzWHW_c20240930_zmTWneEElNTh" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per Issued and outstanding: 84,795,517 common shares (2023 - 82,066,511)" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CommonStockValue_iI_maCzWHW_c20230930_zGU5ssRU1hOg" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per Issued and outstanding: 84,795,517 common shares (2023 - 82,066,511)" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzWHW_z8oMvmIN75l6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-09-30" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456,249</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-09-30" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434,839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzWHW_zdbrdE0ADlhh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">336,071</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293,069</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_iTI_mtCzWHW_maCzJC3_zLozK1pSlEXe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,263</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,852</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzJC3_zm9KENLCEv46" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,567</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See
Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_pn3n3_zxwuqcFAQZC1" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20231001__20240930_zC4hnuIUtTqg" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221001__20230930_z3CtR85GYSJ6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">Anavex Life Sciences Corp.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">Consolidated Statements of Operations and Comprehensive Loss</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">(in thousands, except share and per share amounts)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Years Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zqCP7rN9jYte" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzeWD_zQYgI7SieWA4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-01to2024-09-30" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,039</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-012023-09-30" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,039</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzeWD_zcaGi7TF7j19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-09-30" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,838</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-012023-09-30" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,717</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtCzeWD_msCz8Vx_zwSya3fyFYZj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-10-01to2024-09-30" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52,877</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-10-012023-09-30" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,756</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_i01T_mtCz8Vx_maCzyS5_zj4mis2q1xq4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-01to2024-09-30" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">52,877</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,756</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zNumjS85zvDe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonOperatingIncomeFromGrants_i01_maCzwDm_zHi3j5vxCYLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-10-01to2024-09-30" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-10-012023-09-30" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzwDm_zAgIXn3YMk05" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-10-01to2024-09-30" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,291</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-10-012023-09-30" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeExpenseNet_i01_maCzwDm_zHPwOAo27OQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-10-01to2024-09-30" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,320</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-012023-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherFinancingExpense_i01N_di_msCzwDm_zmJZIMNQhDvb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other financing expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0158">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-10-012023-09-30" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">964</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzwDm_z7axpFrkyFRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange gain (loss)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-10-01to2024-09-30" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-10-012023-09-30" id="Fact000162" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzwDm_maCzyS5_zec4ZNv116i4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total other income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-10-01to2024-09-30" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,875</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-10-012023-09-30" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzyS5_maCzeh2_zl2gprGwmlgi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-10-01to2024-09-30" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-012023-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,498</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzeh2_z5fIQjdxghY4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense, current</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0170">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-10-012023-09-30" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_mtCzeh2_zffjmo12xdN4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-09-30" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--EarningPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pip0_c20231001__20240930_znill9f8WYmf" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20240930_zGZ2rtkja5ri" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-10-01to2024-09-30" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-01to2024-09-30" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.52</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pip0_c20221001__20230930_zRftcucxlQVe" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20230930_zWPAS02ss9q6" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-10-012023-09-30" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012023-09-30" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.60</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20231001__20240930_zfnX6mubGO6d" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20231001__20240930_zhkMAUGQ4BO7" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-01to2024-09-30" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-01to2024-09-30" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,468,049</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20221001__20230930_zMSkHKJq7wud" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20221001__20230930_zaka2SmGxKak" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012023-09-30" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012023-09-30" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">79,787,596</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See
Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><br/>
</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_pn3n3_zz6twZeBc7f9" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20231001__20240930_zURXn2oUDKXe" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20221001__20230930_z7qO1r3jUPH6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">Anavex Life Sciences Corp.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">Consolidated Statements of Cash Flows</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">(in thousands, except share and per share amounts)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_z353S2Qulum6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_maCzv40_zRYFYprUrcHf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-09-30" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zTR26G4jKwwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--NoncashFinancingRelatedCharges_i01_maCzv40_zORVq0jaytg9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash financing related charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2022-10-012023-09-30" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i01_maCzv40_zvEdiMTodbW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-09-30" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zS2IN9MPRfN" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzv40_zki7nFzP6yHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2023-10-01to2024-09-30" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">260</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-10-012023-09-30" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzv40_zqowW9OGauyc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-01to2024-09-30" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">278</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-012023-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzv40_zXd1bPQ90gg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-01to2024-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,305</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-012023-09-30" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzv40_z4VfL75LtMj4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-01to2024-09-30" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,460</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-012023-09-30" id="Fact000226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredGrantIncome_i02N_di_msCzv40_zoOlDZuiRGJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2023-10-01to2024-09-30" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2022-10-012023-09-30" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzv40_maCzAAZ_zUzpEWr5wc24" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-01to2024-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30,812</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-012023-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">27,785</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zQHOCjzhoI4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzRiu_zkcG4Ql6fiC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-09-30" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,284</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-012023-09-30" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzRiu_zc3qOAFMVyIj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-10-01to2024-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-10-012023-09-30" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,776</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzRiu_maCzAAZ_zvUhiiWZI9K2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-01to2024-09-30" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,975</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-012023-09-30" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzAAZ_ztgi0CnO9mo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">(Decrease) Increase in cash and cash equivalents during the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-01to2024-09-30" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,837</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-012023-09-30" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z6aYJz7PirYk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zaKA3YnB7bX2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of year</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zbxPMmDzhpwf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--CashPaidForStateAndLocalFranchiseTaxes_i01_zm4KxIFJ0pvb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash paid for state and local franchise taxes</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2023-10-01to2024-09-30" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2022-10-012023-09-30" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See
Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_pn3n3_zrdbRI3iLPG4" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z2zTcKmZGCp" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zVEk7dwEbYh5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zbBnqGpeJ3Yb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_zK9sQeu4rPDl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="21" style="font-weight: bold; text-align: center">Anavex Life Sciences Corp.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="21" style="font-weight: bold; text-align: center">Consolidated Statements of Changes in Stockholders&#8217; Equity</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="21" style="font-weight: bold; text-align: center">(in thousands, except share and per share amounts)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional Paid-in</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_430_c20221001__20230930_eus-gaap--StockholdersEquity_iS_zlSmT7kAzu51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 35%; font-weight: bold; text-indent: -10pt">Balance, October 1, 2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOJAqBAB1O8b" title="Balance at beginning, shares" style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">77,942,815</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,977</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">245,564</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142,491</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedUnder2023PurchaseAgreement_z7oqfx2x8uoa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InitialCommitmentShares_zZn1GKKBV8O7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">&#160;Initial Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--InitialCommitmentSharesShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIMUnUhRxc07" title="Initial commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-09-30" id="Fact000276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockRepurchasedDuringPeriodValue_zGuM5cD0Qf2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockRepurchasedDuringPeriodShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgtfLKoKsfk" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,275,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-09-30" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommitmentShares_zr9uTGvM6AJ1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--CommitmentSharesShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuH9pGA4paE" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">13,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zucBCOdvYzV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zveb74SxLuIg" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">759,753</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-09-30" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zXpbHQeyBlB2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-09-30" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zzK2eeKZdFTi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-09-30" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,505</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20231001__20240930_eus-gaap--StockholdersEquity_iS_zHNzYs6VCVai" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, September 30, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziM5nNKm11kf" title="Balance at beginning, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,066,511</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434,839</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293,069</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,852</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedUnder2023PurchaseAgreement_zMZ8utLeB31c" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockRepurchasedDuringPeriodValue_zYrXH3F6iN43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockRepurchasedDuringPeriodShares_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1dMk1aImdA2" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000328" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-10-01to2024-09-30" id="Fact000326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommitmentShares_zmj8nOBzCgqi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--CommitmentSharesShares_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrN6MeLp2LMk" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zfVNtZ1cLVqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4kWiMtZgF3i" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">273,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-01to2024-09-30" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zlvrNqiksWYf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-01to2024-09-30" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zSzrWbjDCMY" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000351" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-09-30" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20231001__20240930_eus-gaap--StockholdersEquity_iE_zF3grFDRY0S9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, September 30, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pip0_c20231001__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrnpFMT0tWpl" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,795,517</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000356" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">336,071</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,263</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 7</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000361" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUbZM51yn049" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_82B_zSWlR6NQYzu5">Business Description and Basis of Presentation</span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000363" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z6slE3KxRmT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2	<span id="xdx_823_z9L3pvings8g">Summary of Significant Accounting Policies</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000365" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_zgBJ5I211vml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_zAPlVc3iYYcf">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zfd2UJ8lJbc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div id="xdx_23A_z6q7U4iL7aHf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zGwybMp6O5qh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zU0mYd0Mu0Vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zK9JXdqsIiQ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_ziW15N6odw07" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zWfTMqgLMsWk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 8</span></p></ix:exclude>


<ix:exclude><p id="xdx_233_zW1mxNn2Ed41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000373" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zSbQAInpEeXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_ztu82Co1Phn3">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000375" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBxoT8ehUmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zI70NBdVOwS5">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_c20240930_pp0p0" title="Federal deposit insurance corporation"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30" id="Fact000377" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>, under current regulations. At September 30, 2024 and 2023, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000379" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8e6NUAU2tYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zesLA3jv5Q2k">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zXtZK6veelfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 78 -->
    <div id="xdx_238_z7gQqe6na0U3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zy9F2zyXgTWg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zH3qHm8RYd3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zIBUaKULl6li" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zN56udBLoDCg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zCGGKWXrRUG" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 9</span></p></ix:exclude>


<ix:exclude><p id="xdx_230_zUBTCUxB2pIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000387" name="us-gaap:RevenueRecognitionIncentives"><p id="xdx_842_eus-gaap--RevenueRecognitionIncentives_zYOO7Un8ukSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zN9aksYH7Hu9">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;) through a program administered through the Australian Tax Office (the
&#8220;ATO&#8221;) and AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;).
The Australia R&amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#8217;s company tax rate in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), since the incentives
are not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000389" name="avxl:LicenseFeesPolicyTextBlock"><p id="xdx_84D_ecustom--LicenseFeesPolicyTextBlock_zvVTlse0Q7E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zgaDCnCdHYPa">License Fees</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.</span></p>

<ix:exclude><p id="xdx_237_zK5VFH7lIdUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zJeM7pEaWzXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 79 -->
    <div id="xdx_238_z2ifsuB0ZNWd" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zFzIvxm9ZAo2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zUSJJ5JqFnYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"></p><ix:exclude><p id="xdx_230_zUVODMlVjCh6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zqbmotQcdCrg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_z4FSTBwMitE3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 10</span></p></ix:exclude>


<ix:exclude><p id="xdx_23B_zV4vKWB6JYI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000398" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zWgq0UJnIPo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zDPBM6FA6BL3">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, diluted loss per share excludes
<span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-09-30" id="Fact000400" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,047,754</ix:nonFraction></span> potentially dilutive common shares (2023 &#8211; <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-012023-09-30" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,271,780</ix:nonFraction></span>) related to outstanding options and warrants, as their effect was
anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000404" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z9ZlJF0Lwhif" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z19xBHj34mV5">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000406" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zuAFu9p1clul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_zVPWAmk5hIua">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000408" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zgEdj1w4tJSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zIbr3fjZhz78">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000410" name="avxl:GrantIncomePolicyTextBlock"><p id="xdx_842_ecustom--GrantIncomePolicyTextBlock_zGwCAdk9hY0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zaw8i3Xa0wN7">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000412" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zXolNW64SI38" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zvqLWhRMJSC1">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<ix:exclude><p id="xdx_232_zAzXJiYlD623" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zN5NLR8G3AWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 80 -->
    <div id="xdx_23C_zaEQRmhQB3yl" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z6BeYU8uNMU6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zJgIycnr2Aji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zaOA107McPZd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zdyLxXMG10p4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z9xkJccCvwW5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 11</span></p></ix:exclude>


<ix:exclude><p id="xdx_23E_zPUOKHuabb8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000421" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zZYtdCIH7Uu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zzz8d0snS2Si">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. The Company&#8217;s historical share option exercise experience does not provide
sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the
expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid
any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist
of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. Changes
in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#8217;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zt8KwuB8Qdrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div id="xdx_23F_z73WCep0QoD6" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_z3rp04hckRS3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_z5tNN046YDi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zYXJPZ6W8yf5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_znughXYRN9g7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zO5i9bFyzy85" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 12</span></p></ix:exclude>


<ix:exclude><p id="xdx_231_zSwym13wTLqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000429" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOMteVA1jZv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_ziRWdPxOyJSl">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024 and 2023, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000431" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8PUyFNhGER7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zI4c0i94DpBe">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October 1, 2022, the Company
adopted Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832) &#8211; Disclosures by Business Entities about Government
Assistance, which requires business entities to disclose information about transactions with a government that are accounted for by applying
a grant or contribution model by analogy. For transactions within scope, the new standard requires the disclosure of information about
the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line
items affected by the transaction. The disclosure of the Company&#8217;s research and development tax incentive income and receivable
is detailed in Note 4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000433" name="avxl:RecentAccountingPronouncementsPolicyTextBlock"><p id="xdx_847_ecustom--RecentAccountingPronouncementsPolicyTextBlock_z1SqSlbs2MCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_865_zX6GA3HUEZHd">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000435" name="avxl:AccuredLiabilitiesTextBlock"><p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zEPbtC6j3LPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_827_zlLjSI9VItkl">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<ix:exclude><p id="xdx_23B_zpSWzem0E58f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zg8A9Ygjp69l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div id="xdx_23F_zT9yvYoQoC0f" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zS5tgudKjVIj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zkiOhJd7HcZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zeYb8Cz7wnLi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zj6YbFKzTEZ5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zcJz0LX6oaif" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 13</span></p></ix:exclude>


<ix:exclude><p id="xdx_232_zc301LuRgW24" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000444" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zbwnkL2K0Ym1" summary="xdx: Disclosure - Accrued Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B5_z2lzU6dypaQd" style="display: none">Schedule of principal components of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240930_z4WLWlnfqNq1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930_zSwhbt41fS56" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_zvn6pZIbv5Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedInvestigatorPayments" contextRef="AsOf2024-09-30" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedInvestigatorPayments" contextRef="AsOf2023-09-30" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,006</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2024-09-30" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-09-30" id="Fact000450" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,360</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FixedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2023-09-30" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2024-09-30" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2023-09-30" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,267</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000458" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,891</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,624</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTIC_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact000462" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,295</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AB_z9vsAXyMD93i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000464" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_808_ecustom--OtherIncomeDisclosureTextBlock_zpl9acj2tuH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_82D_z4iq2194pL1b">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of September 30, 2024,
the Company had received a $<span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20231001__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zUqOPy8iSm9k" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2023-10-012024-09-30_custom_MichaelJFoxFoundationMember" id="Fact000466" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1</ix:nonFraction></span>.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) related to Parkinson&#8217;s
disease. Of the total, $<span id="xdx_906_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zsZM6XiZSJa7" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2022-10-012023-09-30" id="Fact000468" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year ended September 30, 2023 and $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_zNYa628sfExl" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2020-10-012021-09-30" id="Fact000470" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year
ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2024, the Company recognized $<span id="xdx_90F_ecustom--NonOperatingIncomeFromGrant_c20231001__20240930_pn5n6" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-10-01to2024-09-30" id="Fact000472" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75,000</ix:nonFraction></span> (2023: $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20221001__20230930_pn5n6" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-10-012023-09-30" id="Fact000474" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25,000</ix:nonFraction></span>) of this grant on its statements of operations within
grant income. At September 30, 2024 an amount of $<span id="xdx_900_ecustom--DeferredGrantIncome1_c20231001__20240930_pn5n6" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome1" contextRef="From2023-10-01to2024-09-30" id="Fact000476" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million (2023: $<span id="xdx_902_ecustom--DeferredGrantIncome1_c20221001__20230930_pn5n6" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome1" contextRef="From2022-10-012023-09-30" id="Fact000478" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million) of this grant is recorded as deferred grant income,
representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its
statements of operations as the related expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2024, the Company recorded research and development incentive income of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930_zebZr3UeVuh" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-01to2024-09-30" id="Fact000480" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zalCwRRoaIzg" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-09-30_currency_AUD" id="Fact000482" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million) (2023: $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930_zrnuLxk9QHT" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-09-30" id="Fact000484" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zUS5vDVvJrPl" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-09-30_currency_AUD" id="Fact000486" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction></span>
million)) in respect of the Australia R&amp;D credit for eligible research and development expenses incurred during the year. This amount
is included within Other income (expense) on the consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At September 30, 2024, Incentive
and tax receivables includes $<span id="xdx_909_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zS5nTIpYaJU6" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-09-30" id="Fact000488" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million (AUD <span id="xdx_908_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zNvZ2x4TOs3h" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-09-30_currency_AUD" id="Fact000490" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million) (2023: $<span id="xdx_904_eus-gaap--OtherReceivables_iI_pn5n6_c20230930_znwGIkvLBIv6" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-09-30" id="Fact000492" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million (AUD <span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20230930__srt--CurrencyAxis__currency--AUD_zatHjCAGFLH2" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-09-30_currency_AUD" id="Fact000494" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.9</ix:nonFraction></span> million)) relating to Australia R&amp;D credits
earned during the year that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<ix:exclude><p id="xdx_236_zdvA0q6RVcwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zmNYyuao4FHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div id="xdx_23D_zEDcwpEfrYp" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zllyyXtDTjR4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zxv6F5CMsjn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zh5Feu4aKRS9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z5jCioS5jxSi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_z3Pdv2l4PgBb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 14</span></p></ix:exclude>


<ix:exclude><p id="xdx_23B_zLAil9G33Scc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2024 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000503" name="avxl:EquityOfferingTextBlock"><p id="xdx_807_ecustom--EquityOfferingTextBlock_z8uH5AsWqi3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_821_z4UnVL811xpi">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zjBTw7sVBGf4" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000505" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">150</ix:nonFraction></span>.0
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zDtpzYyEJE34" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000507" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVEHO9Ok8nG3" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000509" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zlvesVw4UA3k" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000511" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">150</ix:nonFraction></span>.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_90C_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zJ9cx1I1Uf3j" title="Fair value of the initial commitment"><ix:nonFraction name="avxl:FairValueOfInitialCommitment" contextRef="AsOf2023-09-30" id="Fact000513" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_900_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zuQfWHsPplPj" title="Incurred expenses"><ix:nonFraction name="avxl:IncurredExpenses" contextRef="AsOf2023-09-30" id="Fact000515" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2024, the Company
issued to Lincoln Park an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_z5XyHbAeGon5" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember" id="Fact000517" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,455,646</ix:nonFraction></span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_z9eP1mwZKD7e" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember" id="Fact000519" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,450,000</ix:nonFraction></span> shares
of common stock for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z3vDqP2N5m5a" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,283,200</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zuZAWjOBzDX" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember" id="Fact000523" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,646</ix:nonFraction></span> commitment shares. During the year ended September 30, 2023,
the Company issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zv8LrAnhBMp2" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember" id="Fact000525" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,288,943</ix:nonFraction></span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_z4amQsG4Rn02" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember" id="Fact000527" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,275,000</ix:nonFraction></span>
shares of common stock for aggregate proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zX7Y5ZjfAYx8" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000529" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.9</ix:nonFraction></span> million and&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zvwZfCtAdAej" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember" id="Fact000531" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">13,943</ix:nonFraction></span>&#160;commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024, an amount of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVFXJZstk14i" title="Amount of shares remain available"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000533" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">110.8</ix:nonFraction></span> million
remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2020 Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;2020 Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company could offer and sell shares of common
stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<ix:exclude><p id="xdx_235_zDEEjNOwzdib" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zWCUUxrsL9e1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div id="xdx_235_zIWWisgmANJ1" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zRvMf26bI5Ti" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zRHs2SNQcn8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z91V3c6JvEP3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zqjL7bIcYvu3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zUzihFue46t7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 15</span></p></ix:exclude>


<ix:exclude><p id="xdx_234_zdbG0on5XvF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2024 and 2023,
no shares were sold pursuant to the Offering. At September 30, 2023, an amount of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2020Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrSVeZj0Klw6" title="Amount of shares remain available"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2020Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000542" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">142.4</ix:nonFraction></span> million was registered pursuant to an effective
registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2024, the Company terminated the 2020
Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000544" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsDisclosureTextBlock_zU3MKmk8tD6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_82E_zSxZDr5qZEec">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company leases office space under an operating lease with an initial term of <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zyt4oNkSylq3" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2024-09-30" format="ixt-sec:durmonth" id="Fact000546" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">12</ix:nonNumeric></span> months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
operating lease costs were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000548" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_pn3n3_zo7TtWmPUcw5" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zZE28QeKNvL9" style="display: none">Schedule of operating lease costs</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20231001__20240930_zy0nqCX3Sqqg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20221001__20230930_zOcdnZ1gajT9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zG2OCtLdwmZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-10-01to2024-09-30" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-10-012023-09-30" id="Fact000551" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z6qARMn5koC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company made matching contributions under the 401(k) plan as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000553" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zY74239U5rD7" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zCLJmKfNvB4e" style="display: none">Schedule of contributions under the plan</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231001__20240930_zumtC3qVDoQk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221001__20230930_zkzgsKpX6ZJb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40C_eus-gaap--PensionContributions_zqnvDHsWLGQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-10-01to2024-09-30" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">279</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-10-012023-09-30" id="Fact000556" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zfRQyDHqkRy" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024. The complaint alleges violations
of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect to certain clinical trials for
ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. The complaint seeks unspecified damages, as well as costs, including counsel and
expert witness fees, on behalf of a class of investors.&#160;The Company believes the lawsuit is without merit and the Company denies
any liability or wrongdoing and has filed motions to dismiss the complaints, which is awaiting a decision by the Court. No amount has
been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes
that it is not probable that any loss will occur.</span></p>

<ix:exclude><p id="xdx_23C_zLHgvgSajtC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zvXuhKhp7pQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div id="xdx_23C_zpzsFr6wMgi5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zACMeMBjrNbj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zvOIFu74Hkte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zo3WckdneE8f" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zVoUKZCKuoVe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z0K0sNUQMlS7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 16</span></p></ix:exclude>


<ix:exclude><p id="xdx_233_zHWz1KQKIzuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#8217;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett Syndrome. The Company believes this lawsuit is without merit and the Company denies any liability or wrongdoing.
The parties are currently due to file a proposed schedule for the anticipated motion to dismiss by the Company and the officer of the
Company (the other named defendants have not been served with the complaint) on or before January 15, 2025.&#160;No amount has been recorded
in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is
not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of the Company&#8217;s outstanding
share purchase warrants is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000565" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zVrXB8D2W2el" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zyucDNJtHIe6" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Balance, September 30, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsEaQiiCcKZf" title="Number of warrants outstanding" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-09-30_custom_PurchaseWarrants1Member" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">160,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zkOIgSWK3Ps2" title="Weighted average exercise price" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_custom_PurchaseWarrants1Member" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfWarrantsExpired_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9iODe9gm0d6" title="Number of warrants expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="avxl:NumberOfWarrantsExpired" contextRef="From2023-10-012024-09-30_custom_PurchaseWarrants1Member" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">150,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceExpried_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zGiipVAva5fi" title="Weighted average exercise price expried" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:WeightedAverageExercisePriceExpried" contextRef="From2023-10-012024-09-30_custom_PurchaseWarrants1Member" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Balance, September 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsLjle0jOCG9" title="Number of warrants outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-09-30_custom_PurchaseWarrants1Member" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z8bylO1akFQ8" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_custom_PurchaseWarrants1Member" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zmbBBcE82K9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024, the Company had <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20240930_zRbUQoqcPBh4" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-09-30" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000</ix:nonFraction></span> share
purchase warrants outstanding exercisable at $<span id="xdx_907_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20240930_zuT1PGPuBGF3" title="Warrants outstanding weighted average exercise price"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2024-09-30" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">12.00</ix:nonFraction></span> per share until <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240930_zYam2lj5mBle" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2024-09-30" format="ixt:datemonthdayyearen" id="Fact000583" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYy7f34kF64e" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-09-30_custom_StockOptionPlan2015Member" id="Fact000585" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<ix:exclude><p id="xdx_234_zqHU5Pduqgn" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zbOsdszCsjGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div id="xdx_23F_zjdlFqrXFJZk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zgL76DEpsDQ1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zeI0LBbfI89e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zcLlM59EWnO1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zbD2dKlGD1cb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zLEvXUIR3lO" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 17</span></p></ix:exclude>


<ix:exclude><p id="xdx_234_zoQec685RNXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20231001__20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zjyTf3HUI3qg" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2023-10-012024-09-30_custom_StockOptionPlan2019Member" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zlkcZFkN32gj" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zaMq4gs0d8Dc" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-03-242022-03-25_custom_StockOptionPlan2022Member" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At September
30, 2024, <span id="xdx_90F_ecustom--OptionIssued_pip0_c20231001__20240930_zf4vwFU8Ylt2" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2023-10-01to2024-09-30" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,267,500</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zuhgSy4D4QU4" title="Option available issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-09-30_custom_StockOptionPlan2022Member" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,462,202</ix:nonFraction></span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the years ended September 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000604" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_ztty77jTyIU6" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zWT9kxCLd4y8" style="display: none">Schedule of stock option activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, October 1, 2022</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj2x0XX7LPE5" title="Number of options, Outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">13,169,616</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuf1aIFtmA81" title="Weighted average exercise price, Outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000608" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.61</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlhUTPvaW8Ag" title="Weighted average grant date fair value, Outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000610" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlUHLENQXHdc" title="Aggregate intrinsic value, Outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000612" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,267,309</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNoKqll9fo3h" title="Number of options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,959,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zi1TwIf8oIff" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000616" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgzQ7JpYdPf6" title="Weighted average grant date fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVgAZGD8r8Af" title="Number of options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000620" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">759,753</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z06a8R6hHwP6" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZP9O0acgU" title="Weighted average grant date fair value, Exercised" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziqPF6mfyqq6" title="Aggregate intrinsic value, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000626" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,629,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFy5pRVKYI99" title="Number of options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000628" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">257,083</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNQysIpp47ae" title="Weighted average exercise price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvNZk4PG8T94" title="Weighted average grant date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000632" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRNBDwcTAcAb" title="Number of options, Outstanding beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">14,111,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVCEf3tVsaM2" title="Weighted average exercise price, Outstanding beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000636" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw26BK1vpFz2" title="Weighted average grant date fair value, Outstanding beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTz4uUWMxZyh" title="Aggregate intrinsic value, Outstanding beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,290,069</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znZU3kVlHEO1" title="Number of options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000642" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,860,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM2dLVlLPbD6" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000644" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z03F1sZBGRg4" title="Weighted average grant date fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000646" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4ZomoYX4ICl" title="Number of options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000648" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">273,360</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWjNVYMoyey4" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000650" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqqUr0RdYOm9" title="Weighted average grant date fair value, Exercised" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000652" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdyGr0vXAN6f" title="Aggregate intrinsic value, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000654" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">601,407</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0cHRJXMWav2" title="Number of options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000656" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">661,166</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zALlzza5Em9d" title="Weighted average exercise price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000658" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">11.67</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhkSSkBQ8mua" title="Weighted average grant date fair value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyLucyoiWRHl" title="Number of options, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000662" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,037,754</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbAC367IhERd" title="Weighted average exercise price, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000664" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSsx5kNI3hI2" title="Aggregate intrinsic value, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000666" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,825,791</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, September 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0GduqcpBhGj" title="Number of options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,910,590</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlmzHQ6Ebou3" title="Weighted average exercise price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000670" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.52</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5tBnhyuxDb4" title="Aggregate intrinsic value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000672" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,176,855</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zosVbZGmQpg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at September 30, 2024 by a range of exercise prices:</p>

<ix:exclude><p id="xdx_238_zZRTI8bNI2W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zbxn6rPHCqAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div id="xdx_23C_zPjvOBkf7I5d" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zVzYIaKaea14" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zLR4qazteWEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zKVfUnDuGTT3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zlOmdft6l7Mc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_z1CMnbuKS2I" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 18</span></p></ix:exclude>


<ix:exclude><p id="xdx_234_z5sUbMDz8jV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000681" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2YVgwyiK376" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B7_z68Fo18hTGsi" style="display: none">Schedule of summarizes information about stock options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"/><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">vested</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zKnsCyiAjbw7" title="Range of exercise prices, Lower range limit" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zqSFAzGAh9k4" title="Range of exercise prices, Upper range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDdyTnQoyzci" title="Number of outstanding options" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,015,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjowsLPUAp12" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" id="Fact000689" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.79</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zl8YkrHgTAhg" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000691" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.39</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdwqQ4ozmBqd" title="Number of vested options" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,015,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjEnt80JFkO9" title="Weighted average exercise price options vested" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.39</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zFs6okO3fwEd" title="Range of exercise prices, Lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zqBReWOji9Vj" title="Range of exercise prices, Upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zH8xy90eCWLk" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,267,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ziTWkBIVvmZ4" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" id="Fact000703" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.01</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z1bYzPLt6MA3" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000705" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zv1CWYPyXMSd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,056,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_znR0tyhcDjdi" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHErj6uIlhle" title="Range of exercise prices, Lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvUdvToDrSr" title="Range of exercise prices, Upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000713" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zefhqZJERt9e" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,640,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHu9lRBkqU1b" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" id="Fact000717" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.07</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zAwjOi5bd1He" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zhLOzuGk2cZa" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,473,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zRLtybyWOCw3" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zwgjH4CudMMd" title="Range of exercise prices, Lower range limit" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zHbXDbyucZag" title="Range of exercise prices, Upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zAzTAGC3i8Hc" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,649,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zjtL6f21Ij98" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" id="Fact000731" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zfzOK1oMVFth" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zouJsfyRROXh" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">760,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zJcbeYjhrGt8" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUVTVmMIz5bg" title="Range of exercise prices, Lower range limit" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zTRX6VFAciHc" title="Range of exercise prices, Upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">25.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKia0Yvbyx1b" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,465,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRXry7ZoAYG3" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" id="Fact000745" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.45</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXDhjTnxgqC" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.18</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zExs2DKoYFoc" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">605,001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z3Z0f4RuhDm6" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.47</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7WiabqsG4Pl" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,037,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzOS46JZKPbg" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact000755" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.48</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze3OZD5jIuyh" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zv7ks6Ny45x1" title="Number of vested options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,910,590</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcbaT8u383oe" title="Weighted average exercise price options vested" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.52</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A6_zAufvJUNWIsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested at September 30, 2024 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zPGlJzsx1zL1" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-09-30" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.34</ix:nonFraction></span> (2023: $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zUFUHnNr2KR6" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-09-30" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.94</ix:nonFraction></span>). At September 30, 2024, the weighted average contractual life of options outstanding
was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zHLhZTyCnIo7" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt-sec:duryear" id="Fact000767" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.48</ix:nonNumeric></span> years (2023: <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zRvLLcf6qJWg" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2022-10-012023-09-30" format="ixt-sec:duryear" id="Fact000769" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.0</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zvCl9X5i0juj" title="Options exercisable"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt-sec:duryear" id="Fact000771" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.03</ix:nonNumeric></span> years (2023: <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_z6uUq3cqdtnh" title="Options exercisable"><ix:nonNumeric contextRef="From2022-10-012023-09-30" format="ixt-sec:duryear" id="Fact000773" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.75</ix:nonNumeric></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized share-based compensation
expense of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240930_zmUOLDM5C0Rg" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-01to2024-09-30" id="Fact000775" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.4</ix:nonFraction></span> million during the year ended September 30, 2024 (2023: $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230930_zaAPC60VFCR9" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-09-30" id="Fact000777" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.4</ix:nonFraction></span> million) in connection with the issuance and vesting 	of
stock options in exchange for services. These amounts have been included in general and 	administrative expenses and research and development
expenses on the Company&#8217;s consolidated statements of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000779" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zi2FVOcwWNha" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_z2tVgKm7mwUi" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp9OpXIsV36a" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,625</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFxQwPTmIz11" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyDyahjVnw1c" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000785" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmVbu9HVINJa" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000787" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,812</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zY0w9hpDCWCf" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-09-30" id="Fact000789" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,438</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zqU4aiHPBqac" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-09-30" id="Fact000791" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,370</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zU4EDeUl5dbl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20240930_zGXnFIkhKl2a" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-09-30" id="Fact000793" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.4</ix:nonFraction></span> million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000795" name="avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_ztvANBNBKOd" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zGx432uQE2A4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_zmVvhw0wUJUk" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-10-01to2024-09-30" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.28</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zk9aeGxWv1f6" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-10-012023-09-30" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.70</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zKcOrtuCNxVj" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" format="ixt-sec:duryear" id="Fact000801" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.78</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zvMR7rgFHMMg" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2022-10-012023-09-30" format="ixt-sec:duryear" id="Fact000803" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.64</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_znTGYHoJmyzd" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-10-01to2024-09-30" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.81</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zQyr91zB3pV3" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-10-012023-09-30" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.13</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zDdrcqcPiXgc" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-10-01to2024-09-30" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_zZxC4dNmLus5" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-012023-09-30" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zWu897XZdev9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the years ended September 30, 2024 and 2023 was determined with reference to the quoted market price of the Company&#8217;s shares
on the grant date.</p>

<ix:exclude><p id="xdx_230_zrK8FgKr1dVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zEXxNmQWOnok" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div id="xdx_238_zm76NuW57WY6" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z7O1gGY7J6O4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_z1A5Z4nSaqza" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zgTCi9U70FOk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zNwAZar0zfIj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z1vPDT40cwnc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 19</span></p></ix:exclude>


<ix:exclude><p id="xdx_23A_zHg8sOZwasc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000820" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z8QYnm9qtxSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	 	<span id="xdx_827_zcEPileDpSC2">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s U.S. and foreign loss before income
taxes are set forth below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000822" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zHTmOjgJIYk4" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B1_z7HyZ8TCOyec" style="display: none">Schedule of loss before income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231001_20240930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221001_20230930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-10-01to2024-09-30" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,195</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-10-012023-09-30" id="Fact000825" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">41,198</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-10-01to2024-09-30" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,807</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-10-012023-09-30" id="Fact000828" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,300</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-10-01to2024-09-30" id="Fact000830" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-012023-09-30" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,498</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zPW5pZgLedye" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of net deferred income tax assets as of September 30, 2024
and 2023 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000833" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zRVU4M8bO6H5" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zWHOKKQJ26yf" style="display: none">Schedule of components of net deferred income tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240930_zGRKXFJ26cP3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930_zlqiytEYB4ug" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-09-30" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-09-30" id="Fact000836" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-09-30" id="Fact000838" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-09-30" id="Fact000839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,713</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-09-30" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-09-30" id="Fact000842" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,593</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization" contextRef="AsOf2024-09-30" id="Fact000844" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization" contextRef="AsOf2023-09-30" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2024-09-30" id="Fact000847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2023-09-30" id="Fact000848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-09-30" id="Fact000850" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-09-30" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">593</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zG0mt9nm9ho3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:ForeignExchangeAndOther" contextRef="AsOf2024-09-30" id="Fact000853" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">254</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ForeignExchangeAndOther" contextRef="AsOf2023-09-30" id="Fact000854" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_z6h5f6BjiZC5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-09-30" id="Fact000856" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92,233</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-09-30" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zt8cAN4PUdM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2024
and 2023 is as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000862" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zs1csAl6SFD6" summary="xdx: Disclosure - Income Taxes (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zLKUUUwRbwp9" style="display: none">Schedule of reconciliation of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20231001__20240930_zfSNRerA5OV6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20221001__20230930_zPiGwBdkJhzl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-10-01to2024-09-30" id="Fact000864" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,030</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-10-012023-09-30" id="Fact000865" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,975</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-10-01to2024-09-30" id="Fact000867" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">61</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2023-10-01to2024-09-30" id="Fact000870" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextRef="From2022-10-012023-09-30" id="Fact000871" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">601</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" contextRef="From2022-10-012023-09-30" id="Fact000874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-10-01to2024-09-30" id="Fact000876" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-10-012023-09-30" id="Fact000877" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2023-10-01to2024-09-30" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">860</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextRef="From2022-10-012023-09-30" id="Fact000880" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">37</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-10-01to2024-09-30" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,821</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-10-012023-09-30" id="Fact000883" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,122</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years&#8217; tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2023-10-01to2024-09-30" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,128</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2022-10-012023-09-30" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-10-01to2024-09-30" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,186</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-10-012023-09-30" id="Fact000889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,098</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-10-012023-09-30" id="Fact000892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zXo4lZdi2t5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, the Company had U.S. federal
net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_custom_FederalMember" id="Fact000894" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">128.5</ix:nonFraction></span> million (2023: $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-09-30_custom_FederalMember" id="Fact000896" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">126.3</ix:nonFraction></span> million) of which <span id="xdx_905_ecustom--OperatingLossCarryforwardsDescription_c20231001__20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember" title="Operating loss carryforwards description"><ix:nonNumeric contextRef="From2023-10-012024-09-30_custom_FederalMember" id="Fact000898" name="avxl:OperatingLossCarryforwardsDescription">$37.7 million will begin to expire in
2025 and $90.8 million can be carried forward indefinitely</ix:nonNumeric></span>, state and local net operating loss carryforwards of approximately $ <span id="xdx_900_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember" id="Fact000900" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.9</ix:nonFraction></span> million
(2023: $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-09-30_us-gaap_StateAndLocalJurisdictionMember" id="Fact000902" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.6</ix:nonFraction></span> million) which will begin to expire in <span id="xdx_90E_ecustom--OperatingLossCarryForwardsExpirationYear_c20231001__20240930" title="Operating loss carry forwards expiration year"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000904" name="avxl:OperatingLossCarryForwardsExpirationYear">2036</ix:nonNumeric></span>, and Research and Development tax credits of approximately $<span id="xdx_908_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20231001__20240930_pn5n6" title="Research and Development tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-10-01to2024-09-30" id="Fact000906" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million (2023:
$<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20221001__20230930_pn5n6" title="Research and Development tax credits"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2022-10-012023-09-30" id="Fact000908" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million) which will begin to expire in <span id="xdx_904_ecustom--ResearchAndDevelopmentTaxCreditsYear_c20231001__20240930" title="Research and development tax credits year"><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" id="Fact000910" name="avxl:ResearchAndDevelopmentTaxCreditsYear">2029</ix:nonNumeric></span>. The calculation of the Research and Development tax credits, by their nature, involve
estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these credit
carryforwards would be disputed by the tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember" id="Fact000912" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.6</ix:nonFraction></span> million (approximately
AU$<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD" id="Fact000914" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">23.9</ix:nonFraction></span> million) (2023: $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-09-30_us-gaap_ForeignCountryMember" id="Fact000916" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.9</ix:nonFraction></span> million (approximately AU$<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-09-30_us-gaap_ForeignCountryMember_currency_AUD" id="Fact000918" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.1</ix:nonFraction></span> million)) of net operating loss carryforwards in Australia, which have an
indefinite life, available to offset future taxable income in those jurisdictions.</p>

<ix:exclude><p id="xdx_23C_zGa11OBJBme8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zxBZ4aEHq7Rd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div id="xdx_230_zVsW1wLknKY4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zV9zGSa8ltX4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zG8LwUVT6ij4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zEu6FhFn6Kaj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zp3EtAQkhSHi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zi0ljQPyGtCb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30, 2024 &#8211; Page 20</span></p></ix:exclude>


<ix:exclude><p id="xdx_23B_zQAKlz3Q8YDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its valuation allowance requirements
based on available evidence. When circumstances change, and this causes a change in management&#8217;s judgment about the recoverability
of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income. Because management of the
Company does not currently believe that it is more likely than not that the Company will receive the benefit of these assets, a valuation
allowance has been established at September 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act of 2017 (TCJA) has modified
the IRC 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the TCJA, the Company
must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and
15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development costs in accordance
with IRC 174 has resulted in a gross deferred tax assets at September 30, 2024 of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_c20240930_pn5n6" title="Gross deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-09-30" id="Fact000927" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.1</ix:nonFraction></span> million (2023: $<span id="xdx_902_eus-gaap--DeferredTaxAssetsGross_iI_pn5n6_c20230930_z8yalo9nOo7j" title="Gross deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-09-30" id="Fact000929" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.2</ix:nonFraction></span> million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Uncertain Tax Positions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of the Internal Revenue Code,
the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducted a Section 382 study during the
year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership which resulted
in $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20150930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2015-09-30_custom_FederalMember" id="Fact000931" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.8</ix:nonFraction></span> million of federal NOLs being subject to an annual limitation. During the year ended September 30, 2021, the Company reduced
its federal NOLs by $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zmd7nUtQtTa9" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-09-30_custom_FederalMember" id="Fact000933" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.1</ix:nonFraction></span> million and its Research and Development tax credit carryforwards by $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20210930_z93tCgCjYeK5" title="Research and development tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-09-30" id="Fact000935" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million, which are the amount of tax
assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20210930_zmQtWtpoiQVj" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-09-30" id="Fact000937" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million of NOLs and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20210930_zZeW3liPXk17" title="Research and development tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-09-30" id="Fact000939" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million
of research and development credits and a corresponding reduction in the valuation allowance of $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20201001__20210930_zlq9EDiyUjZi" title="Decrease in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2020-10-012021-09-30" id="Fact000941" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million, which was recorded in the
2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of the Company&#8217;s NOLs<span style="background-color: white">.
During the year ended September 30, 2024 and 2023 the Company determined that there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#8217; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-09-30" escape="true" id="Fact000943" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zLlyvChHMtGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note
8	<span id="xdx_822_zpnru012Oyt9">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#8217;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no subsequent events or transactions that
required recognition or disclosure in the consolidated financial statements.</p>

</ix:nonNumeric><p id="xdx_81E_zKS44TnaU5x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"></span></p>

<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_015"></span>ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not Applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_016"></span>ITEM 9A. CONTROLS AND PROCEDURES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures that
are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the
Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and
to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive officer and
our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our principal executive and principal financial officer, of the effectiveness
of the design and operation of our disclosure controls and procedures, as defined in&#160;Rule&#160;13(a)-15(e) under the Exchange Act.
Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures
were effective as of September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Management&#8217;s Annual Report on Internal
Control over Financial Reporting </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for establishing and
maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act.
Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established
in the framework in&#160;Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the
Treadway Commission (&#8220;COSO&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods
are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on this evaluation, our management concluded
that our internal controls over financial reporting were effective as of September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended September 30, 2024, there
were no material changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules
13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal controls
over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_017"></span>ITEM 9B OTHER INFORMATION</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90A_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240701__20240930_zKybKrH5irv3"><ix:nonNumeric contextRef="From2024-07-012024-09-30" format="ixt:booleanfalse" id="Fact000944" name="ecd:Rule10b51ArrAdoptedFlag">N</ix:nonNumeric></span><span id="xdx_90E_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20240701__20240930_zEZxSYfhzdrg"><ix:nonNumeric contextRef="From2024-07-012024-09-30" format="ixt:booleanfalse" id="Fact000945" name="ecd:NonRule10b51ArrAdoptedFlag">o</ix:nonNumeric></span><span id="xdx_90B_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240701__20240930_z9yIcj2vLNd6"><ix:nonNumeric contextRef="From2024-07-012024-09-30" format="ixt:booleanfalse" id="Fact000946" name="ecd:Rule10b51ArrTrmntdFlag">n</ix:nonNumeric></span><span id="xdx_90F_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240701__20240930_zQsJxfH5whN9"><ix:nonNumeric contextRef="From2024-07-012024-09-30" format="ixt:booleanfalse" id="Fact000947" name="ecd:NonRule10b51ArrTrmntdFlag">e</ix:nonNumeric></span> of our directors or Section 16 officers adopted,
modified or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement&#8221; (in each case,
as defined in Item 408(a) of Regulation S-K) during the three-month period ended September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_018"></span>ITEM 9C DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 91; Options: NewSection; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_019"></span>PART III</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_020"></span>ITEM 10 DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Directors and Executive Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors are to be elected at our annual meeting
and each director elected is to hold office until his or her successor is elected and qualified. Our Board of Directors may remove our
officers at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors and executive officers, their ages,
positions held, and duration of such, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #F2F2F2">
    <td style="border: Black 1pt dotted; padding: 0pt; width: 30%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="border-top: Black 1pt dotted; border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; width: 36%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="border-top: Black 1pt dotted; border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; width: 10%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="border-top: Black 1pt dotted; border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; width: 24%; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date first appointed</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, President, Chief Executive Officer, Secretary</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 5, 2013</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiong Ma, PhD</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chair</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 25, 2021</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 9, 2013</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 2018</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 15, 2015</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 8, 2017</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; border-left: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer</span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43 </span></td>
    <td style="border-right: Black 1pt dotted; border-bottom: Black 1pt dotted; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 1, 2015</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Board Leadership Structure</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors is composed of a majority of
independent directors and the Chief Executive Officer of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors has appointed an independent
Board Chair, Dr. Jiong Ma. As Board Chair, Dr. Ma has the authority, among other things, to call and preside over meetings of our Board,
to set meeting agendas, and to determine materials to be distributed to the Board. The Company believes separation of the positions of
Board Chair and Chief Executive Officer reinforces the independence of our Board in its oversight of the business and affairs of the Company.
In addition, the Company believes that having an independent Board Chair creates an environment that is more conducive to objective evaluation
and oversight of management&#8217;s performance, increasing management accountability and improving the ability of our Board to monitor
whether management&#8217;s actions are in the best interests of the Company and its stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee, Compensation Committee, and Nominating
and Corporate Governance Committee each have oversight over specific areas of responsibility, as discussed further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Board of Directors&#8217; Role in Risk Oversight</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors is responsible for oversight
of the Company&#8217;s risk management process. The Board administers this oversight function directly through the Board of Directors
as a whole, as well as through the committees of the Board. Areas of focus include economic risk, operational risk, financial risk (accounting,
investment or liquidity, and tax), competitive risk, legal and regulatory risk, cybersecurity risk and compliance and reputational risks.
The Board of Directors is supported by regular reporting by management, which is designed to give the Board of Directors visibility over
the Company&#8217;s operations and activities to adequately identify key risks and understand management&#8217;s risk mitigation strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business Experience</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a brief account of the education
and business experience of directors and executive officers during at least the past five years, indicating their principal occupations
during the period, and the names and principal businesses of the organizations by which they were employed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 92; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Christopher Missling, PhD</span>. Christopher Missling
has over twenty years of healthcare industry experience in big pharmaceutical, biotech and investment banking. Most recently, from March
2007 until his appointment by our Company, Dr. Missling served as the head of healthcare investment banking at Brimberg &amp; Co. in New
York, New York. In addition, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ: CRIS) and ImmunoGen, Inc. (NASDAQ:
IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northwestern University Kellogg School of Management
and WHU Otto Beisheim School of Management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Jiong Ma, PhD.&#160;</span>Jiong Ma has over 25 years
of experience in investing, building, and scaling of companies with a focus on innovative product launches in digital health, technology
and the new energy transition. Dr. Ma is a General Partner of Phoenix Venture Partners. She serves as Lead Independent Board Director
of SES AI Corporation (NYSE: SES), Chairs the Compensation Committee, and as a member of Audit, Nominating, and Strategic Investment Committee.
Dr. Ma served as senior partner and a member of the investment committee at Braemar Energy Ventures (&#8220;Braemar&#8221;). While at
Braemar, Dr. Ma led investments in more than 15 companies involved in either resource efficiency, e-mobility, industrial digitalization,
renewable energy, or deep tech, and has achieved multiple successful exits through M&amp;A and IPO. Dr. Ma has significant knowledge and
expertise in the technology industry, including information security. Prior to Braemar Energy Ventures, she was with the Venture Capital
Group at 3i Group, a global private equity firm, where she led investments across multiple stages in Digital Health, TMT and Cleantech.
Preceding the Venture Capital Group at 3i, Dr. Ma held several senior positions at Lucent Technologies and Bell Labs. Her responsibilities
included lead roles in product portfolio strategy, new product launches for Optical and Data Networking, and research and product development.
Dr. Ma was also a founding team member of Onetta Inc., a fiber networks company. She has a PhD in Electrical and Computer Engineering
from the University Colorado Boulder and an MS in Electrical Engineering from Worcester Polytechnic Institute. Dr. Ma is a Kauffman Fellow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Claus van der Velden, PhD</span>. Claus van der Velden,
PhD brings significant expertise in management, accounting, internal controls, information security and risk management. Since May 2021,
he has served as Managing Director (Chief Financial Officer) of NetCologne GmbH, a regional telecommunication provider in Germany. From
July 2011 to May 2021, he served as corporate head of Management Accounting, Internal Audit and Risk Management at Stroeer SE &amp; Co
KGaA, a publicly listed German digital media company. As the prior head of internal audit at Stroeer SE &amp; Co KGaA, Dr. van der Velden
has experience in the area of information security risk assessment, and the internal control tools, processes, and policies needed to
counter information security threats. Previously, Dr. van der Velden served as the Director of Corporate Business Controlling for the
Nutrition &amp; Health business unit at Cognis, a worldwide supplier of global nutritional ingredients and specialty chemicals. In this
position, he was also a compliance representative and a member of the global leadership team. After the acquisition of Cognis by BASF,
he was responsible for the management accounting processes of the BASF Nutrition &amp; Health division, developing and producing mostly
natural-source ingredients for the food and healthcare industries. Dr. van der Velden started his career as a strategy consultant at an
international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University
of Kiel and later obtained his doctorate in business management from the WHU-Otto Beisheim School of Management where he also previously
taught economics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Athanasios Skarpelos</span>. Athanasios (Tom) Skarpelos
is a self-employed investor with over 20 years of experience working with private and public companies with a focus on biotechnology companies
involved in drug discovery and drug development projects. His experience has led to relationships with researchers at academic institutes
in Europe and North America. Mr. Skarpelos is a founder of Anavex.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Steffen Thomas, PhD</span>. Steffen Thomas has over
15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property
law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and
a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately
USD $10 billion. Dr. Thomas&#8217; legal practice covers drafting of patent applications, prosecuting patent applications before national
and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents
before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas
has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 93; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Peter Donhauser, D.O.</span> Peter Donhauser had more
than 20 years of expertise in clinical research prior to practicing osteopathic medicine with an integrated medical approach in private
practice beginning in 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases.
During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp &amp; Dohme,
Merck, Boehringer Mannheim, Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of
Osteopathic Medicine (D.O.) from the German-American Academy for Osteopathy, or DAAO, a member of the European Register for Osteopathic
Physicians, or EROP, at the Philadelphia College of Osteopathic Medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Sandra Boenisch, CPA, CGA.</span> Ms. Boenisch is
a Chartered Professional Accountant (CPA, CGA) with approximately 20 years of accounting, audit and financial reporting experience in
a variety of industries, both in the United States and Canada. Ms. Boenisch was an independent consultant, providing financial reporting
services to a range of public companies in the United States and Canada since January 2012. From 2008 until 2012, Ms. Boenisch was employed
at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant and was later promoted to Manager, Audit Assurance. Ms. Boenisch
specialized in managing assurance engagements for public companies in the United States and Canada. Prior to that, Ms. Boenisch worked
for another public accounting firm from 2001 to 2008. As an independent consultant, Ms. Boenisch has acquired considerable experience
in finance, governance, and regulatory compliance. She holds a BComm from Laurentian University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Family Relationships</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no family relationships between any director
or executive officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Involvement in Certain Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no material proceedings to which any director
or executive officer or any associate of any such director or officer is a party adverse to our Company or has a material interest adverse
to our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Delinquent Section 16(a) Reports </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Section 16(a) of the Exchange
Act requires our officers and directors, and persons who beneficially own more than ten percent (10%) of our outstanding common stock,
to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons are required by SEC regulations to
furnish us with all copies of Section 16(a) forms they file.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Based solely on our review
of the forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable
to our executive officers, directors and persons who own more than 10% of our common stock were complied with in fiscal year 2024, except
for the following late filings:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Form 4 filed January 12, 2024 for Sandra Boenisch;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Form 4 filed January 12, 2024 for Christopher
Missling;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Form 4 filed February 23, 2024 for Athanasios Skarpelos;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Form 4 filed February 23, 2024 for Jiong Ma;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Form 4 filed February 23, 2024 for Steffen Thomas;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Form 4 filed February 23, 2024 for Peter Donhauser; and </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Form 4 filed February 23, 2024 for Claus van der Velden.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white"></p>

<!-- Field: Page; Sequence: 94; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-indent: -18pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business Code of Conduct &amp; Ethics</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board adopted a code of business ethics and conduct
(the &#8220;<span style="text-decoration: underline">Code of Ethics</span>&#8221;), applicable to all of our executives, directors and employees. The Code of Ethics is available
in print to any stockholder that requests a copy. Copies may be obtained by contacting Investor Relations at our corporate headquarters.
Our Code of Ethics is also available on our website at <i><span style="text-decoration: underline">www.anavex.com/corporate-governance</span></i>. We intend to make any disclosures
regarding amendments to, or waivers from, the Code of Business Conduct required under Form 8-K by posting such information on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Insider Trading Policy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have an Insider Trading Policy that provides guidelines
with respect to transactions in our securities by insiders and the handling of our confidential information and the confidential information
of the companies with which we engage in transactions or do business. The policy promotes compliance with U.S. federal, securities laws
that prohibit certain persons who are aware of material non-public information relating to us from (1) purchasing, selling, or otherwise
engaging in transactions in our securities, or (2) providing material non-public information to other persons who may trade on the basis
of that information. In addition, our Insider Trading Policy prohibits our directors, officers, employees and consultants from engaging
in short sales, transactions in publicly traded options such as put, calls or other derivative securities, hedging transactions and other
inherently speculative transactions with respect to our stock at any time. Our policy further prohibits such persons from engaging in
transactions involving any loan, pledge or other transfer of beneficial ownership of the Company&#8217;s securities without obtaining
advance clearance of the proposed transaction from our Insider Trading Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Information Regarding Committees of the Board
of Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has an Audit Committee, a Compensation Committee
and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #D9D9D9">
<td style="border: #BFBFBF 1pt solid; padding: 0pt; text-align: center; width: 49%; vertical-align: bottom"><b>&#160;</b> <b>&#160;</b> <b>Name</b></td>
<td style="border-top: #BFBFBF 1pt solid; border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; width: 15%; vertical-align: bottom"><b>&#160;</b> <b>&#160;</b> <b>Audit Committee</b></td>
<td style="border-top: #BFBFBF 1pt solid; border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; width: 17%; vertical-align: bottom"><b>&#160;</b> <b>&#160;</b> <b>Compensation Committee</b></td>
<td style="border-top: #BFBFBF 1pt solid; border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; vertical-align: bottom; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating and Corporate Governance Committee</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiong Ma, PhD</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X*</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X*</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X*</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; border-left: #BFBFBF 1pt solid; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meetings in 2024</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
<td style="border-right: #BFBFBF 1pt solid; border-bottom: #BFBFBF 1pt solid; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*Committee Chair</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Audit Committee and Audit Committee Financial
Experts </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee is composed of four directors,
each of whom is independent. The Audit Committee operates under a charter that was adopted by our Board of Directors. The Audit Committee
oversees and reports to our Board of Directors on various auditing and accounting-related matters, including, among other things, the
maintenance of the integrity of our financial statements, reporting process and internal controls; the selection, evaluation, compensation
and retention of our independent registered public accounting firm; legal and regulatory compliance, including our disclosure controls
and procedures; and oversight over our risk management policies and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 95; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors has determined that Claus van
der Velden is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC and NASDAQ rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee has reviewed and discussed the
audited consolidated financial statements with management. The Audit Committee has discussed with the Company&#8217;s independent registered
public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight
Board (&#8220;PCAOB&#8221;) and the Securities and Exchange Commission (the &#8220;SEC&#8221;). In addition, the Audit Committee has received
the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the
PCAOB regarding the firm&#8217;s communications with the Audit Committee concerning independence and has discussed with the independent
registered accounting firm its independence from the Company and management. Based on the reviews and discussions referred to above, the
Audit Committee recommended to the Board that the audited consolidated financial statements for the Company for the fiscal year ended
September 30, 2024 be included in this Annual Report on Form 10-K for the year ended September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">The foregoing report has been furnished by the Audit
Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Claus van der Velden (Chairman)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Jiong Ma<br/>
Steffen Thomas<br/>
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee is composed of three directors,
each of whom is independent. The Compensation Committee operates under a charter that was adopted by our Board of Directors. The Compensation
Committee assists our Board of Directors in discharging its responsibilities relating to the compensation of our directors and executive
officers. Its responsibilities include, among other things: reviewing, approving and recommending compensation programs and arrangements
applicable to our officers; determining the objectives of our executive officer compensation programs; overseeing the evaluation of our
senior executives; administering our incentive compensation plans and equity-based plans, including reviewing and granting equity awards
to our executive officers; and reviewing and approving director compensation and benefits. The Compensation Committee can delegate to
other members of our Board of Directors, or an officer or officers of the Company, the authority to review and grant share-based compensation
for employees who are not executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee has the responsibilities
and authority designated by NASDAQ rules and the Compensation Committee Charter. Specifically, the Compensation Committee has the sole
discretion to select and receive advice from a compensation consultant, legal counsel or other adviser and is directly responsible for
oversight of their work. The Compensation Committee must also determine reasonable compensation to be paid to such advisors by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee met two times during fiscal
2024 and acted by written consent as required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Nominating and Corporate Governance Committee
(the &#8220;NCG Committee&#8221;) is appointed by the Board to oversee and evaluate the Board&#8217;s performance and the Company&#8217;s
compliance with corporate governance regulations, guidelines and principles, to identify individuals qualified to become Board members,
to recommend to the Board proposed nominees for Board membership, and to recommend to the Board directors to serve on each standing committee.
The NCG Committee seeks to assemble a Board that possesses the appropriate balance of professional and industry knowledge, financial expertise
and management experience that is necessary to oversee the Company&#8217;s business. The NCG also recognizes the importance of diversity
in board composition, including diversity of experience, gender and ethnicity and seeks to continually strive towards optimal diversity.
The NCG Committee operates under a charter that was adopted by our Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 96; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NCG Committee met one time during fiscal 2024
and also acted by written consent as required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_021"></span>ITEM 11. EXECUTIVE COMPENSATION</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our Executive Compensation Program and Philosophy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The intent of the Company&#8217;s compensation program
for our named executive officers is to attract and retain talent, to create incentives for and to reward excellent performance. We seek
to compensate our named executive officers in a manner that is competitive, rewards performance that creates stockholder value, recognizes
individual contributions, and encourages long-term value creation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee meets at least once per
year to review and evaluate the compensation of our named executive officers and each officer&#8217;s performance. The Compensation Committee
utilizes quantitative and qualitative factors, including the accomplishment of initiatives, attitude, and leadership and applies overall
judgment to assess performance, taking into account the financial condition of the Company. In setting compensation, the Compensation
Committee considers the outcome of the most recent say-on-pay vote, as well as stockholder feedback throughout the year, when making compensation
decisions for our executive officers. In our most recent say-on-pay vote, conducted at our 2024 annual meeting of stockholders, held on
June 18, 2024, our stockholders approved the compensation of our named executive officers on an advisory basis, with 83.8% of the votes
cast in favor of the compensation of our named executive officers. Ultimately, the Compensation Committee seeks to evaluate, based on
the achievement of financial and nonfinancial objectives, the variable compensation, including special awards, of our named executive
officers and decide on the base salary and target discretionary bonus for such persons taking into account relevant benchmark data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee believes that a significant
portion of each named executive officer&#8217;s compensation opportunity should be tied to variable compensation and value creation for
stockholders. The Compensation Committee believes this mix provides an appropriate balance between the financial security required to
attract and retain qualified individuals, and the Compensation Committee&#8217;s goal of ensuring that the compensation of our named executive
officers rewards performance that benefits stockholders over the long term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation Consultants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee makes recommendations to
the Board regarding the compensation of our named executive officers, including the structure and design of the compensation programs.
The Compensation Committee is responsible for retaining and terminating compensation consultants and determining the terms and conditions
of their engagement. During fiscal 2024, the Compensation Committee did not engage any compensation consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Annual Discretionary Cash Bonuses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an annual discretionary cash bonus
program. We provide such bonuses to motivate executive officers to perform on behalf of general corporate goals and to perform in their
areas of responsibility. The Compensation Committee works with the Chief Executive Officer to evaluate the Company&#8217;s financial performance
of the prior year, and overall financial condition of the Company to determine if discretionary bonuses are to be paid. In addition, on
an annual basis, our Compensation Committee independently evaluates the performance of our Chief Executive Officer in the prior year,
as well as the overall financial condition of the Company to determine if a discretionary bonus of up to 20% of base salary shall be paid
to the Chief Executive Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 97; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Clawback Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the Board adopted an executive officer
compensation clawback policy that may be applied in the event of a material financial restatement. The clawback policy covers all of the
named executive officers and includes all incentive-based compensation. Specifically, in the event of an accounting restatement, the Company
must recover, reasonably promptly, erroneously awarded compensation in amounts determined pursuant to the policy. Compensation that may
be recoverable under the policy includes cash or equity-based compensation for which the grant, payment or vesting (or any portion thereof)
is or was predicated upon the achievement of specified financial results that are impacted by the material financial restatement, and
the amount of compensation that may be impacted by the clawback policy is the difference between the amount paid or granted, and the amount
that should have been paid or granted, if calculated on the updated financials. Recovery under the policy with respect to an executive
officer will not require the finding of any misconduct by such executive officer or such executive officer being found responsible for
the accounting error leading to an accounting restatement. Our equity awards provide that the Company may annul an award if the grantee
incurs a separation from service for &#8220;cause&#8221; (as defined in the agreements). In such case, all awards and any amounts or benefits
received or outstanding shall be subject to cancellation, recoupment, rescission, payback and other action in accordance with the terms
of the clawback policy or any applicable law. In addition, in the event of a restatement of the Company&#8217;s financial statements due
to material noncompliance with any financial reporting requirement under the law, whether such noncompliance is the result of misconduct
or other circumstances, an employee shall be required to reimburse the Company for any amounts earned or payable with respect to an award
granted under the Company&#8217;s equity plan to the extent required by law and the Company&#8217;s clawback policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock Ownership Guidelines</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any stock ownership guidelines, ownership
goals or holding requirements. If and as we succeed in achieving approval for and commercializing our product candidates, we expect that
we will adapt the elements of our compensation program as appropriate and may include or substitute other elements in our compensation
program. Changes in the elements of our compensation program may also reflect changes in the importance of tax or accounting treatments
of a particular element of our compensation program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Policies and Practices for Granting Certain Equity
Awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our policies and practices regarding the granting
of equity awards are carefully designed to ensure compliance with applicable securities laws and to maintain the integrity of our executive
compensation program. The Compensation Committee is responsible for the timing and terms of equity awards to executives and other eligible
employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The timing of equity award grants is determined with
consideration to a variety of factors, including but not limited to, the achievement of pre-established performance targets, market conditions
and internal milestones. The Company does not follow a predetermined schedule for the granting of equity awards&#894; instead, each grant
is considered on a case-by-case basis to align with the Company&#8217;s strategic objectives and to ensure the competitiveness of our
compensation packages.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In determining the timing and terms of an equity award,
the Board or the Compensation Committee may consider material nonpublic information to ensure that such grants are made in compliance
with applicable laws and regulations. The Board&#8217;s or the Compensation Committee&#8217;s procedures to prevent the improper use of
material nonpublic information in connection with the granting of equity awards include oversight by legal counsel and, where appropriate,
delaying the grant of equity awards until the public disclosure of such material nonpublic information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is committed to maintaining transparency
in its executive compensation practices and to making equity awards in a manner that is not influenced by the timing of the disclosure
of material nonpublic information for the purpose of affecting the value of executive compensation. The Company regularly reviews its
policies and practices related to equity awards to ensure they meet the evolving standards of corporate governance and continue to serve
the best interests of the Company and its shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 98; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Summary Compensation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The particulars of compensation paid to our named
executive officers for the last three completed fiscal years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">All other</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Option</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Compen-</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name and Principal</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Salary</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Bonus</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">sation</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Position</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Christopher Missling, PhD</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">700,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">140,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,927,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">16,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">2,783,700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">President, Chief Executive Officer, and Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,066,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,894,453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">586,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,045,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,753,643</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,227</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Principal Financial Officer and</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,058</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Treasurer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">452,503</td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 6.6pt"/><td style="width: 21.8pt">(1)</td><td>Comprised of employer matching of defined contribution savings plans.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-indent: -21.8pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 6.6pt"/><td style="width: 21.8pt">(2)</td><td>Compensation to Ms. Boenisch denominated in Canadian Dollars and has been translated to US dollars at an exchange rate of 0.73733
during the year ended September 30, 2024 (2023: 0.7416; 2022: 0.7831).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1cm; text-indent: -21.8pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Christopher Missling</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Dr. Missling entered into an employment agreement
dated July 5, 2013, as amended and extended most recently by the third amendment effective April 7, 2022 (the &#8220;CEO Employment Agreement&#8221;),
whereby we currently pay Dr. Missling an annual base salary of $700,000. In addition, Dr. Missling is eligible to earn an annual cash
bonus for each whole or partial calendar year of up to twenty percent of his base salary, and to participate in our employee benefit plans.
We have agreed to indemnify Dr. Missling in connection with his provision of services to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Sandra Boenisch</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Ms. Boenisch entered into an amended and restated
employment agreement dated October 4, 2017, as amended and extended, whereby we currently pay Ms. Boenisch an annual base salary of $279,840
Canadian dollars. Ms. Boenisch is eligible for discretionary salary increases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Outstanding Equity Awards at Fiscal Year-End
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth for each named executive
officer and director certain information concerning the outstanding equity awards as of September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 99; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="21" style="font-weight: bold; text-align: center">Option Awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Equity</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Incentive</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Plan Awards:</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Securities</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Securities</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Securities</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Underlying</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Underlying</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unexercised</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Option</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unexercisable</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Unearned</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Option</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">(#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">(#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">(#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; width: 29%; text-indent: -10pt">Christopher</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Missling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sept 18, 2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 5, 2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">861,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 18, 2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sept 22, 2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dec 13, 2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct. 1, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">750,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 3, 2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 6, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2, 2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2033</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 20, 2034</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dec 13, 2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct. 1, 2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 4, 2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 6, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2030</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2, 2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2033</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 20, 2034</span></td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 20, 2024, our Compensation Committee granted
options to our Chief Executive Officer and Principal Financial Officer, which vest in four equal tranches based on four performance milestones
including accomplishing (i) Regulatory submission of AD-004 for Alzheimer&#8217;s disease (US or EU), (ii) Publication of a Fragile X
preclinical study (iii) Initiation of new clinical study not yet announced and (iv) Readout of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation of Directors </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the compensation of our directors
who were not our named executive officers for the fiscal year ended September 30, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 100; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Name</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock&#160;<br/> Awards<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>&#160;</b><b>&#160;</b><b>Option&#160;<br/> Awards<br/>
($) <sup>(1)</sup></b></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/>
($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 37%; text-align: left; text-indent: -10pt">Jiong Ma</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">41,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">202,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">243,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Claus van der Velden</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Athanasios Skarpelos</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Steffen Thomas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Peter Donhauser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,200</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Includes stock option awards valued based on the
aggregate grant date fair value of the award computed in accordance with FASB ASC Topic 718. The amounts shown in the table above do not
necessarily reflect the actual value that may be realized by the&#160;non-employee&#160;director upon vesting. On September 30, 2024,
the aggregate number of outstanding vested and unvested stock option awards held by each director was as follows: Dr. Ma possessed options
to purchase 210,000 shares, Dr. van der Velden possessed options to purchase 355,500 shares, Mr. Skarpelos possessed options to purchase
405,500 shares, Dr. Thomas possessed options to purchase 455,500 shares and Dr. Donhauser possessed options to purchase 355,500 shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently compensate non-employee directors $25,000
per year, paid quarterly. We compensate Dr. Ma an additional $4,000 per quarter for acting as Chair. We compensate Claus van der Velden
an additional $4,000 per quarter for performing the functions of Chairman of the Audit Committee, Compensation Committee and Nominating
and Corporate Governance Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regularly grant members of the Board of Directors
awards of options. Each Board member is granted options initially when they join the Board of Directors, which typically vest over a three-year
period. Additionally, we grant awards on an annual basis. Annual awards of options typically vest in full on the first anniversary of
grant date. In 2024, the annual grant was 50,000 options to each director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, directors are entitled to reimbursement
for reasonable travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our Board of Directors. Our
Board of Directors may award further special remuneration to any director undertaking any special services on our behalf other than services
ordinarily required of a director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Retirement or Similar Benefit Plans</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no arrangements or plans in which we provide
retirement or similar benefits for our directors or executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resignation, Retirement, Other Termination,
or Change in Control Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Potential Payments Upon Termination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a party to employment contracts with
our Chief Executive Officer and Principal Financial Officer that contain provisions for payment of severance upon termination by either
the Company without cause or by the employee for good reason. General terms of these arrangements are described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 101; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our CEO Employment Agreement with Dr. Missling contains
provisions regarding our obligations upon his termination and upon a Change in Control. Any capitalized term not defined herein is used
as defined in the CEO Employment Agreement. If Dr. Missling&#8217;s employment is terminated by us without Cause, he is entitled to receive
payments by us consisting of (i) reimbursement of any unpaid business expenses to which he is entitled to reimbursement that were incurred
prior to the effective date of his termination, (ii) all vested compensation and benefits to which he is entitled as of the Termination
Date, (iii) a severance payment consisting of the three times the sum of (a) his annual salary in effect at the time of termination and
(b) the average of the annual Bonuses payable to him for the last three completed calendar years prior to the Termination Date, (iv) all
outstanding and unvested stock options and all options previously vested will become and remain exercisable for no less than three years
from the Termination Date; (v) all of his unvested and outstanding restricted stock, restricted stock units or other equity awards that
are unvested and outstanding as of the Termination Date shall vest and be settled within ten business days after the Termination Date,
(vi) life insurance coverage until the end of the term of the CEO Employment Agreement; and (vii) continued participation in all medical,
dental and hospitalization benefits plans or programs for Dr. Missling and his eligible dependents for 36 months or until he receives
similar benefits at a new employer, at his sole cost. If Dr. Missling&#8217;s employment is terminated by him for Good Reason, he is entitled
to receive the same as the above, however the severance payment will consist of three times his annual salary in effect at the time of
termination and two times the average annual Bonuses payable to him for the last three completed calendar years prior to the Termination
Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Dr. Missling was terminated by the Company without
cause on September 30, 2024, he would have been entitled to a severance payment of $2.5 million. If Dr. Missling terminated his employment
for Good Reason on September 30, 2024, he would have been entitled to a severance payment of $2.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our CFO Employment Agreement with Ms. Boenisch contains
provisions regarding our obligations upon her termination. Any capitalized term not defined herein is used as defined in the CFO Employment
Agreement. Under the CFO Employment Agreement, if Ms. Boenisch is terminated without Cause, the Company shall pay Ms. Boenisch severance
compensation equal to six months base salary payable by the Company for the six-month period following the Termination. In addition, the
Company must provide Ms. Boenisch thirty (30) day notice of her Termination. If the Company opts to have Ms. Boenisch cease providing
services to the Company prior to the expiration of the thirty (30) day notice-period (the &#8220;Notice Period&#8221;), Ms. Boenisch shall
receive the Compensation and Benefits for the full length of the Notice Period as if such period was not waived. In addition, any unvested
stock options or stock awards vesting in the contract year of Termination held by Ms. Boenisch as of the Date of Termination shall immediately
vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Ms. Boenisch was terminated by the Company without
cause on September 30, 2024, she would have been entitled to continued salary payments equal to $0.1 million in total.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents accelerated vesting for
certain equity awards outstanding at the time of the executive&#8217;s termination for each Named Executive Officer, if employment were
terminated by either the Company without cause or by Dr. Missling for good reason on September 30, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Vesting Upon Termination</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Named Executive Officer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unvested Stock Options (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Stock Option Awards</b> <b>&#160;</b> <b>Estimated Benefit ($)<sup>(1)</sup></b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Dr. Christopher Missling</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,375,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">160,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Estimated benefit based on the closing stock price
of $5.68 at September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Ms. Boenisch&#8217;s unvested stock options at
September 30, 2024 all contained performance based vesting conditions, therefore such options would not automatically vest upon Termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Potential Payments Upon Change in Control</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company is subject to a Change in Control,
then the CEO Employment Agreement and the CFO Employment Agreement provide that all previously granted but unvested stock options held
by Dr. Missling and Ms. Boenisch shall vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 102; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents accelerated vesting for
certain equity awards outstanding to the Named Executive Officer, if a change in control had occurred at September 30, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Vesting Due to Change in Control</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Named Executive Officer</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unvested Stock Options (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Stock Option Awards</b> <b>&#160;</b> <b>Estimated Benefit ($)<sup>(1)</sup></b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Dr. Christopher Missling</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2,375,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">160,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sandra Boenisch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Estimated benefit based on the closing stock price
of $5.68 at September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>For a complete description of these terms and conditions please refer
to the CEO Employment Agreement and CFO Employment Agreement (and their amendments) filed as exhibits to this Annual Report on Form 10-K.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_022"></span>ITEM 12. SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth, as of December 23,
2024, certain information with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial
owner of more than 5% of our common stock and by each of our current directors and our named executive officers and by our current directors
and executive officers as a group. We have determined the number and percentage of shares beneficially owned by such person in accordance
with Rule 13d-3 under the Securities Exchange Act of 1934. This information does not necessarily indicate beneficial ownership for any
other purpose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt">Title of class</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Name and address of<br/> beneficial owner</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Amount and nature of<br/> beneficial ownership</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent of<br/> class <sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="11" style="font-weight: bold; text-align: left">Directors and Named Executive Officers</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 22%; text-align: left; text-indent: -10pt">Common Stock</td><td style="width: 5%">&#160;</td>
    <td style="width: 21%; text-align: left; padding-left: 2.25pt">Christopher Missling (CEO/Director)</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">7,363,264</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">8.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">Jiong Ma (Director, Chair)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">Claus van der Velden (Director)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">255,500</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">Athanasios Skarpelos (Director)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,611,958</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">Steffen Thomas (Director)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">360,500</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">Peter Donhauser (Director)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,500</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">Sandra Boenisch (Principal Financial Officer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,262</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Common Stock</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-left: 2.25pt">Directors &amp; Executive Officers as a group (7 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,236,984</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">11.1</td><td style="font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">5% Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">The Vanguard Group &#160; 100 Vanguard Blvd &#160; Malvern, PA 19355</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,360,648</td><td style="text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common Stock</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 2.25pt">BlackRock, Inc. &#160; 55 East 52<sup>nd</sup> Street &#160; New York, NY 10055</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,671,075</td><td style="text-align: left"><sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9</td><td style="text-align: left">%</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">*Less than 1%</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 103; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(1)</td><td style="text-align: justify">Percentage of ownership is based on 84,815,517 of our common stock issued and outstanding as of December
23, 2024. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information
furnished by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where
applicable. Beneficial ownership is determined in accordance with the rules of the Commission and generally includes voting or investment
power with respect to securities. Shares of common stock subject to options or warrants currently exercisable or exercisable within 60
days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants but are
not deemed outstanding for purposes of computing the percentage ownership of any other person.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(2)</td><td style="text-align: justify">Includes options to purchase 500,000 shares of our common stock at $0.92 per share, options to purchase
187,500 shares of our common stock at $5.04 per share, options to purchase 379,625 shares of our common stock at $6.26 per share, options
to purchase 861,429 shares of our common stock at $7.06 per share, options to purchase 500,000 shares of our common stock at $3.28 per
share, options to purchase 450,000 shares of our common stock at $5.92 per share, options to purchase 400,000 shares of our common stock
at $3.30 per share, options to purchase 450,000 shares of our common stock at $2.30 per share, options to purchase 409,500 shares of our
common stock at $2.58 per share, options to purchase 750,000 shares of our common stock at $3.15 per share, options to purchase 550,000
shares of our common stock at $2.96 per share, options to purchase 550,000 shares of our common stock at $5.49 per share and options to
purchase 125,000 shares of our common stock at $10.09 per share that are vested or are vesting within 60 days. Excludes options to purchase
500,000 shares of our common stock at $18.11 per share, options to purchase 500,000 shares of our common stock at $7.54 per share, options
to purchase 375,000 shares of our common stock at $10.09 per share, options to purchase 500,000 shares at $8.57 per share and options
to purchase 500,000 shares of common stock at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(3)</td><td style="text-align: justify">Includes options to purchase 35,000 shares of our common stock at $13.01 per share, options to purchase
25,000 shares of our common stock at $18.11 per share, options to purchase 33,333 shares of our common stock at $10.09 per share and options
to purchase 16,667 shares of our common stock at $8.57 per share that have vested or are vesting within 60 days. Excludes options to purchase
16,667 shares of our common stock at $10.09 per share, options to purchase 50,000 shares of our common stock at $8.57 per share and options
to purchase 50,000 shares of common stock at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(4)</td><td style="text-align: justify">Includes options to purchase 50,000 shares of our common stock at $2.60 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 33,333 shares of our common stock at $10.09 per share and options to purchase 16,667 shares of common stock
at $8.57 per share that have vested or are vesting within 60 days. Excludes options to purchase 16,667 shares of our common stock at $10.09
per share, options to purchase 50,000 shares of our common stock at $8.57 per share and options to purchase 50,000 shares of common stock
at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(5)</td><td style="text-align: justify">Includes options to purchase 100,000 shares of our common stock at $3.28 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 33,333 shares of our common stock at $10.09 per share and options to purchase 16,667 shares of common stock
at $8.57 per share that have vested or are vesting within 60 days. Excludes options to purchase 16,667 shares of our common stock at $10.09
per share, options to purchase 50,000 shares of our common stock at $8.57 per share and options to purchase 50,000 shares of common stock
at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 104; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(6)</td><td style="text-align: justify">Includes options to purchase 50,000 shares of our common stock at $1.76 per share, options to purchase
100,000 shares of our common stock at $3.28 per share, options to purchase 45,500 shares of our common stock at $2.58 per share, options
to purchase 50,000 shares of our common stock at $2.96 per share, options to purchase 35,000 shares of our common stock at $5.49 per share,
options to purchase 25,000 shares of our common stock at $18.11 per share, options to purchase 33,333 shares of our common stock at $10.09
per share and options to purchase 16,667 shares of common stock at $8.57 per share that have vested or are vesting within 60 days. Excludes
options to purchase 16,667 shares of our common stock at $10.09 per share, options to purchase 50,000 shares of our common stock at $8.57
per share and options to purchase 50,000 shares of common stock at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(7)</td><td style="text-align: justify">Includes options to purchase 50,000 shares of our common stock at $5.39 per share, options to purchase
45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, options
to purchase 35,000 shares of our common stock at $5.49 per share, options to purchase 25,000 shares of our common stock at $18.11 per
share, options to purchase 33,333 shares of our common stock at $10.09 per share and options to purchase 16,667 shares of common stock
at $8.57 per share that have vested or are vesting within 60 days. Excludes options to purchase 16,667 shares of our common stock at $10.09
per share, options to purchase 50,000 shares of our common stock at $8.57 per share and options to purchase 50,000 shares of common stock
at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(8)</td><td style="text-align: justify">Includes options to purchase 30,000 shares of our common stock at $3.30 per share, options to purchase
30,000 shares of our common stock at $2.30 per share, options to purchase 27,300 shares of our common stock at $2.58 per share, options
to purchase 35,000 shares of our common stock at $2.93 per share, options to purchase 70,000 shares of our common stock at $2.96 per share,
options to purchase 50,000 shares of our common stock at $5.49 per share and options to purchase 10,000 shares of common stock at $10.09
per share that have vested or are vesting within 60 days. Excludes options to purchase 40,000 shares of our common stock at $18.11 per
share, options to purchase 30,000 shares of our common stock at $10.09 per share, options to purchase 50,000 shares of our common stock
at $8.57 per share and options to purchase 50,000 shares of common stock at $5.36 per share that do not vest within 60 days.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(9)</td><td>Based on Schedule 13G/A as filed with the SEC and dated on February 13, 2024</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">(10)</td><td>Based on Schedule 13G/A as filed with the SEC and dated on January 25, 2024</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Change in Control</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are unaware of any contract or other arrangement, the operation of which
may at a subsequent date result in a change of control of our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Securities Authorized for Issuance under Equity Compensation Plans
or Individual Compensation Arrangements </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes certain information regarding our equity
compensation plan or individual compensation arrangements at September 30, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="font-weight: bold; text-align: left">Equity Compensation Plan Information</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Plan Category</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrants and rights<br/> (a)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights<br/> (b)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of securities remaining available for future issuances under equity compensation plans (excluding securities reflected in column (a))<br/> (c)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Equity compensation plans approved by security holders</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">22,050,553</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">7.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5,462,202</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; font-weight: bold; text-indent: -10pt">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">22,050,553</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7.02</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,462,202</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 105; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, 10,000,000 shares of Common Stock were made available for issuance under the 2022 Plan, in addition to the shares available under
the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;) and the 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;). Any awards
outstanding under a previous stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding
awards under a previous plan that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in
shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purpose of the 2022 Plan is to retain the services
of valued key employees and consultants of our Company and such other persons, and to encourage such persons to acquire a greater proprietary
interest in our Company, thereby strengthening their incentive to achieve the objectives of the shareholders of our Company. The purpose
is also to serve as an aid and inducement in the hiring of new employees and to provide an equity incentive to consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_023"></span>ITEM 13. CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Transactions with related persons</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no transactions, since October 1,
2022, or currently proposed transactions, in which we were or are to be a participant and the amount involved exceeds the lesser of $120,000
or one percent of the average of the smaller reporting company&#8217;s total assets at year end for the last two completed fiscal years,
and in which any of the following persons had or will have a direct or indirect material interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">i.</td><td style="text-align: justify">any director or executive officer of our Company;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">ii.</td><td style="text-align: justify">any beneficial owner of shares carrying more than 5% of the voting rights attached to our outstanding
shares of common stock; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 18pt">iii.</td><td style="text-align: justify">any member of the immediate family (including spouse, parents, children, siblings and in-laws) of any
of the foregoing persons.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation of Named Executive Officers and
Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For information regarding compensation of named executive
officers and directors, please see &#8220;Item 11. Executive Compensation.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Director Independence</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the NASDAQ Stock Market Rules, the Board has
a responsibility to make an affirmative determination that those members of its Board that serve as independent directors do not have
any relationships with the Company and its businesses that would impair their independence. The Board has determined that that Christopher
Missling, PhD is not independent, as that term is defined by NASDAQ 5605(a)(2), because Mr. Missling serves as our President, Chief Executive
Officer, and Secretary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 106; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board has determined that that Claus van der Velden,
Athanasios Skarpelos, Steffen Thomas, Peter Donhauser and Jiong Ma are independent, as that term is defined by NASDAQ 5605(a)(2) and the
applicable rules of the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_024"></span>ITEM 14. PRINCIPAL ACCOUNTING
FEES AND SERVICES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fees Paid to Our Independent Registered Public
Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the aggregate fees
billed or expected to be billed to our Company for professional services rendered by our independent registered public accounting firm,
Grant Thornton, LLP for the fiscal years ended September 30, 2024 and 2023:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Audit Fees</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">446,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">444,098</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Audit Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">446,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">444,098</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Audit Fees.</i></b> Consist of fees billed for
professional services rendered for the audits of our financial statements, reviews of our interim financial statements included in quarterly
reports, services performed in connection with regular filings with the Commission for the fiscal years ended September 30, 2024 and 2023
in connection with statutory and regulatory filings or engagements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Policy on Pre-Approval by Audit Committee of
Services Performed by Independent Registered Public Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee pre-approves all services provided
by our independent registered public accounting firm. All of the above services and fees were reviewed and approved by our Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee has considered the nature and
amount of fees billed or expected to be billed by Grant Thornton LLP and believes that the provision of services for activities unrelated
to the audit was compatible with maintaining Grant Thornton LLP&#8217;s independence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 107; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_025"></span>PART IV</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_026"></span>ITEM 15. EXHIBITS, FINANCIAL
STATEMENT SCHEDULES</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 12%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/>
Number </b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 88%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><br/>
Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3) </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Articles of Incorporation, as amended (incorporated by reference to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000651/e4593_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated <span style="background-color: white">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on April 14, 2023)</span></span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(4)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Instruments Defining the Rights of Security Holders</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">4.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222002062/e4251_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Description of Registrant</span><span style="background-color: white">&#8217;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s Securities (incorporated by reference to our Annual Report on Form 10-K filed on November 28, 2022)</span></span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">4.2</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Registration Rights Agreement, dated February 3, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(incorporated by reference to our Quarterly Report on Form 10-Q filed on February 7, 2023)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10) </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Contracts</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015 Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019 Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, Annex B, dated February 11, 2019, as filed on February 11, 2019)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222000703/e3687_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, dated April 11, 2022, Annex A, filed on April 11, 2022)&#160;</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000106299313004163/exhibit10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of July 5, 2013, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on August 14, 2013)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 7, 2016)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019) </span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/e3692_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to Employment Agreement, dated April 7, 2022 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on April 8, 2022)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Employment Agreement by and between the Company and with Sandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/e1699_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020 (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 6, 2020)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#x5E;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112222000366/e3562_10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 28, 2022 (incorporated by reference to our Current Report on Form 8-K filed on March 4, 2022)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement dated February 3, 2023 by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 7, 2023)</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 108; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code of Ethics</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223002197/e5240_ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics Adopted on August 1, 2023 (incorporated by reference to our Annual Report on Form 10-K filed on November 27, 2023)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e6219_ex19-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(21)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e6219_ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Registrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(23)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consent</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e6219_ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Independent Registered Public Accounting Firm</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(31) </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 302 Certifications</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e6219_ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Christopher Missling, PhD.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e6219_ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification of Sandra Boenisch</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(32) </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section 906 Certifications</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e6219_ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification of Christopher Missling, PhD and Sandra Boenisch</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(97)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy Relating to Recovery of Erroneously Awarded Compensation</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Life Sciences Corp. Compensation Clawback Policy (incorporated by reference to our Annual Report on Form 10-K filed on November 27, 2023)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(101)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XBRL</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">* Filed herewith.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">** The certification attached as Exhibit 32.1 that accompanies
this Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Registrant under the
Securities Act or the Exchange Act, whether made before or after the date of this Form 10-K, irrespective of any general incorporation
language contained in such filing.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#x5E; Denotes a management contract or compensatory plan or arrangement.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal"><span id="a_027"></span>ITEM 16. FORM 10-K SUMMARY</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Not Applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 109; Value: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: white">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date: December 23, 2024</b></span></td>
<td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANAVEX LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="background-color: white">
<td style="width: 50%">&#160;</td>
<td style="width: 7%">&#160;</td>
<td style="width: 43%">&#160;</td></tr>
<tr style="background-color: white">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: Black 1pt solid; vertical-align: top"><i>/s/ Christopher Missling, PhD</i></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
<td style="vertical-align: bottom">Chief Executive Officer (Principal Executive Officer) &#160; &#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; white-space: nowrap; width: 28%; text-indent: 0pt"><b>Signatures</b></td>
<td style="padding: 0pt 0pt 1pt; width: 1%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; white-space: nowrap; width: 43%; text-indent: 0pt"><b>Title(s)</b></td>
<td style="padding: 0pt 0pt 1pt; width: 1%; text-indent: 0pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: center; white-space: nowrap; width: 27%; text-indent: 0pt"><b>Date</b></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt; text-align: center; white-space: nowrap; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-align: center; white-space: nowrap; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-align: center; white-space: nowrap; text-indent: 0pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding: 0pt; text-indent: 0pt"><i>/s/ Christopher Missling, PhD</i></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer) and Director</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0pt; vertical-align: top; text-indent: 0pt"><i>/s/ Sandra Boenisch</i></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer and Treasurer (Principal Accounting Officer)</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0pt; vertical-align: top; text-indent: 0pt"><i>/s/ Jiong Ma, PhD</i></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiong Ma, PhD</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Chair</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0pt; vertical-align: top; text-indent: 0pt"><i>/s/ Claus van der Velden, PhD</i></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0pt; vertical-align: top; text-indent: 0pt"><i>/s/Athanasios Skarpelos</i></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0pt; vertical-align: top; text-indent: 0pt"><i>/s/ Steffen Thomas, PhD</i></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0pt; vertical-align: top; text-indent: 0pt"><i>/s/ Peter Donhauser, D.O.</i></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</span></td></tr>
<tr>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
<td style="padding: 0pt; vertical-align: bottom; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; line-height: 115%; text-indent: 0pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">90</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>








































































































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>e6219_ex19-1.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 19.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-decoration: none">ANAVEX
LIFE SCIENCES CORP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Insider Trading Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 183.6pt 0 183.5pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">Anavex Life Sciences Corp. (&ldquo;<U>Anavex</U>&rdquo;)
has adopted this Insider Trading Policy (the &ldquo;<U>Policy</U>&rdquo;) to promote compliance with federal securities laws by directors,
officers, employees and consultants of Anavex and its affiliates, as well as any immediate family members sharing the household of any
of the foregoing (collectively, the &ldquo;<U>Covered Persons</U>&rdquo;). The Policy also is designed to protect an important corporate
asset: Anavex&rsquo;s reputation for integrity and ethical conduct. The Policy governs transactions in securities of Anavex or any other
issuer where conflicts of interest could arise. As a result of applicable securities laws and the Policy, Covered Persons may, from time
to time, have to forego or delay a desired securities transaction, and may suffer economic loss or forego anticipated profit as a result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>POLICY</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">No Covered Person may trade in Anavex
securities unless certain that he or she does not possess material inside information. No Covered Person may disclose, or &ldquo;tip,&rdquo;
such information to others who might use it for trading or might pass it along to others who might trade.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">Similarly, Covered Persons may not trade
in securities of any other company unless they are certain that they do not possess any material inside information about that company
which they obtained in the course of their employment or consulting relationship with Anavex, such as information about a major contract
or merger being negotiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 6pt; text-align: justify; text-indent: -0.05pt">Inside information
relating to Anavex is the property of Anavex, and the unauthorized disclosure of such information is forbidden.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 6pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>DEFINITIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt; text-align: justify"><U>Securities</U> include common stock and derivative
securities such as put and call options and convertible debentures or preferred stock, as well as debt securities such as bonds and notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.1pt 0 6pt; text-align: justify"><U>Trading</U> includes buying or selling.
It does not include purchasing stock under an employee option or making a gift that does not satisfy a legal obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.1pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 6pt; text-align: justify"><U>Material information</U> is any information
that a reasonable investor would consider important in a decision to buy, sell or hold the securities. Any information that could reasonably
be expected to affect the price of the securities is likely to be considered material. Examples of material information include unexpected
financial results, proposed major mergers and acquisitions, sale of major assets, changes in dividends, an extraordinary item for accounting
purposes, and important business developments such as the entry or exit of a strategic relationship or discoveries or major litigation.
The information may be positive or negative. The public, the media, and the courts may use hindsight in judging what is material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify"><U>Inside</U> means information has not
yet become publicly available. Release of information to the media does not immediately free Covered Persons to trade. Covered Persons
should refrain from trading until the market has had an opportunity to absorb and evaluate the information. If the information has been
widely disseminated, it is usually sufficient to wait at least 24 hours after publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>ADDITIONAL PROHIBITIONS AND GUIDANCE</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><U>Short Sales and Derivatives</U><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">Short sales of Anavex securities (a sale of securities which are
not then owned), including a &ldquo;sale against the box&rdquo; (a sale with delayed delivery) are prohibited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">No Covered Person may <I>ever </I>engage in transactions in <I>publicly
traded </I>options, such as puts, calls and other derivative securities, relating to Anavex. This prohibition also extends to
various forms of hedging transactions or monetization transactions, such as zero-cost collars and forward sale contracts, as they
involve the establishment of a short position in Anavex securities. This prohibition does not prevent employees from exercising
company-issued options, subject to the other restrictions of this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>Standing Orders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt; text-align: justify">Standing orders (except standing orders under
approved Rule 10b5-1 plans, <I>see </I>below) should be used only for a brief period of time. The problem with purchases or sales resulting
from standing instructions to a broker is that there is no control over the timing of the transaction. The broker could execute a transaction
when you are in possession of material inside information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>Margin Accounts and Pledges</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.95pt; text-align: justify">Securities held in a margin account
may be sold by the broker without the customer&rsquo;s consent if the customer fails to meet a margin call. Similarly, securities pledged
as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan or, in many instances, if the value of the collateral
declines. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material inside information regarding
Anavex, Covered Persons are prohibited from holding securities of Anavex in a margin account or pledging such securities as collateral
for a loan. An exception to this prohibition may be permitted in certain limited circumstances with the advance written approval of the
Principal Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>Penalties for non-compliance</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">The following penalties apply under United
States Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) Rule 10b-5, which prohibits trading on material inside information:
(1) imprisonment of up to 20 years, (2) criminal fines of up to $5 million, (3) civil penalties of up to 3 times the profits gained or
losses avoided,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 6.1pt 0 6pt; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">prejudgment
interest, and (5) private party damages. In addition to damage to reputation, violation of this Policy could result in termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.1pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>10b5-1 Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt 0 5.95pt; text-align: justify">Rule 10b5-1 provides a defense from insider
trading liability under SEC Rule 10b-5. To be eligible for this defense, a Covered Person may enter into a &ldquo;10b5-1 plan&rdquo; for
trading in Anavex stock. If the plan meets the requirements of Rule 10b5-1, Anavex stock may be purchased or sold without regard to certain
insider trading restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt 0 5.95pt; text-align: justify">To comply with this insider trading policy,
a 10b5-1 plan must be approved by the Principal Financial Officer and meet the requirements of Rule 10b5-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify">In general, a 10b5-1 plan must be entered
into a time when there is no undisclosed material information. Once the plan is adopted, the Covered Person must not exercise any influence
over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify
the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>Internet and Social Media</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">Because of the potential for abuse of
the prohibition on &ldquo;tipping,&rdquo; Covered Persons are prohibited from posting any information on Internet chat rooms, social media
or other types of public forums where Anavex or Anavex securities are a topic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><U>BLACKOUT POLICY</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">As part of this Policy, Anavex has adopted
a blackout policy that prohibits trading in Anavex securities by officers, directors and certain employees and/or consultants, beginning
on the last day of each fiscal quarter and ending 24 hours after earnings for such quarter are publicly released.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><I>Who is covered by this blackout policy?</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">All Covered Persons</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><I>What transactions are prohibited during
a blackout period?</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Open market purchase or sale of Anavex securities</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase or sale of Anavex securities through a broker</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="padding-right: 39.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise of stock options where all or a portion
of the acquired stock is sold during the blackout period</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 39.9pt 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.95pt"><I>What transactions are allowed during a blackout period?</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.95pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="padding-right: 31.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise of stock options where no Anavex
stock is sold in the market to fund the option exercise</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 31.65pt 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="padding-right: 31.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gifts of Anavex stock, unless you have reason
to believe the recipient intends to sell the shares during the current blackout period</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 31.4pt 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfers of Anavex stock to or from a trust</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="padding-right: 43.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transaction that comply with SEC Rule 10b5-1
pre-arranged written plans (for further information about pre-arranged plans, please contact the Principal Financial Officer)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 43.75pt 0 59.95pt; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt 0 5.95pt; text-align: justify">In addition to the standard end-of-quarter
blackout periods, Anavex may, from time to time, impose other blackout periods upon notice to those persons who are affected. The scope
of persons affected may be broader than, or different from, the persons described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.05pt 0 5.95pt; text-align: justify">Covered Persons not otherwise subject
to this blackout policy are encouraged to refrain from trading Anavex securities during blackout periods to avoid the appearance of improper
trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.05pt 0 5.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>PRE-CLEARANCE OF STOCK TRANSACTIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 6pt; text-align: justify">All Covered Persons must obtain prior
written clearance from Anavex&rsquo;s Principal Financial Officer, or her designee, before he or she makes any purchases or sales of Anavex&rsquo;s
Securities, including any exercise of stock options. Each proposed transaction will be evaluated to determine if it raises insider trading
concerns or other concerns under the federal or state securities laws and regulations. Any advice will relate solely to the restraints
imposed by law and will not constitute advice regarding the investment aspects of any transaction. Clearance of a transaction is valid
only for a 48-hour period. If the transaction order is not placed within that 48-hour period, clearance of the transaction must be re-
requested. If clearance is denied, the fact of such denial must be kept confidential by the person requesting such clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.75pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><U>SECTION 16 REPORTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">Some officers and all Anavex directors
are obligated to file Section 16 reports when they engage in transactions in Anavex securities. Although the Principal Financial Officer&rsquo;s
office will assist reporting persons in preparing and filing the required reports, the reporting persons retain responsibility for the
reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.95pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><I>Who is obligated to file Section 16 reports?</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 17.95pt">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Anavex directors</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 59.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 17.95pt">&#9679;</TD><TD STYLE="padding-right: 16.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Anavex officers designated as &ldquo;executive
officers&rdquo; for SEC reporting purposes by the Board of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 16.35pt 0 59.95pt; text-indent: -17.95pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><U>FORM 144 REPORTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">Anavex directors and certain Anavex officers
designated by the Board of Directors are required to file Form 144 before making an open market sale of Anavex securities. Form 144 notifies
the SEC of your intent to sell Anavex securities. This form is generally prepared and filed by your broker and is in addition to the Section
16 reports filed on your behalf by the Principal Financial Officer&rsquo;s Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">Adopted: August 9, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">4</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>e6219_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF THE REGISTRANT</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Incorporation or Organization</B></FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Australia Pty Limited</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Germany GmbH</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex Canada Ltd.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario, Canada</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>e6219_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">We have issued our report dated December 23, 2024, with respect to the
consolidated financial statements included in the Annual Report of Anavex Life Sciences Corp. on Form 10-K for the year ended September
30, 2024. We consent to the incorporation by reference of said report in the Registration Statements of Anavex Life Sciences Corp. on
Forms S-3 (File No. 333-218292 and File No. 333-281089) and on Forms S-8 (File No. 333-219934, File No. 333-255166 and File No. 333-265537).</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">/s/ GRANT THORNTON LLP</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Melville, New York</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">December 23, 2024</P>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>e6219_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top; font: 11pt Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 23, 2024<BR>
<I><BR>
/s/
Christopher Missling &nbsp;</I></FONT></TD>
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD </FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President, Secretary<BR> (Principal Executive Officer)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>e6219_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
this Annual Report on Form 10-K of Anavex Life Sciences Corp.; &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report; &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have: &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="vertical-align: top; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared; &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles; &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
functions): &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and &nbsp;</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 23, 2024 <BR>
<I><BR>
/s/
Sandra Boenisch &nbsp;</I></FONT></TD>
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer<BR> (Principal Financial and Accounting Officer)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>e6219_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Anavex Life
Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ending September 30, 2024 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of the undersigned, in the capacities and on the date indicated
below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
to the best of his or her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
<TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 23, 2024
&nbsp;</FONT></TD>
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher Missling</I></FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President, Secretary (Principal
Executive Officer)<BR>
<I><BR>
/s/ Sandra Boenisch&#9;</I></FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer<BR> (Principal Financial and Accounting Officer)</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished solely
to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic
version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>avxl-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOa+DKbPtxZ97KekhsmR1bTkKzyIoH2r6OikMjlY28cIK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:avxl="http://anavex.com/20240930" elementFormDefault="qualified" targetNamespace="http://anavex.com/20240930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
          <link:definition>995612 - Disclosure - Business Description and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>995613 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>995614 - Disclosure - Accrued Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
          <link:definition>995615 - Disclosure - Other Income</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
          <link:definition>995616 - Disclosure - Equity Offerings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995617 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>995618 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>995619 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>995620 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>995621 - Disclosure - Accrued Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>995622 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>995623 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>995624 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
          <link:definition>995625 - Disclosure - Accrued Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
          <link:definition>995626 - Disclosure - Other Income (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
          <link:definition>995627 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
          <link:definition>995628 - Disclosure - Commitments and Contingencies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
          <link:definition>995629 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
          <link:definition>995630 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
          <link:definition>995631 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
          <link:definition>995632 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
          <link:definition>995633 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" id="CommitmentsAndContingenciesDetails6">
          <link:definition>995634 - Disclosure - Commitments and Contingencies (Details 6)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>995635 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>995636 - Disclosure - Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>995637 - Disclosure - Income Taxes (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
          <link:definition>995638 - Disclosure - Income Taxes (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>995639 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="avxl_MichaelJFoxFoundationMember" name="MichaelJFoxFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement2023Member" name="PurchaseAgreement2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockIncludingCommitmentSharesMember" name="CommonStockIncludingCommitmentSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockExcludingCommitmentSharesMember" name="CommonStockExcludingCommitmentSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesMember" name="CommitmentSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement2020Member" name="PurchaseAgreement2020Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherFinancingExpense" name="OtherFinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EarningPerShareBasicAndDilutedAbstract" name="EarningPerShareBasicAndDilutedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NoncashFinancingRelatedCharges" name="NoncashFinancingRelatedCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalFranchiseTaxes" name="CashPaidForStateAndLocalFranchiseTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnder2023PurchaseAgreement" name="SharesIssuedUnder2023PurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentShares" name="InitialCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentSharesShares" name="InitialCommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentShares" name="CommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" name="SharesIssuedPursuantToExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureAccruedLiabilitiesAbstract" name="DisclosureAccruedLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccuredLiabilitiesTextBlock" name="AccuredLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LicenseFeesPolicyTextBlock" name="LicenseFeesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_RecentAccountingPronouncementsPolicyTextBlock" name="RecentAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedInvestigatorPayments" name="AccruedInvestigatorPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MilestoneBasedContractAccruals" name="MilestoneBasedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome1" name="DeferredGrantIncome1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FairValueOfInitialCommitment" name="FairValueOfInitialCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncurredExpenses" name="IncurredExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfWarrantsExpired" name="NumberOfWarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageExercisePriceExpried" name="WeightedAverageExercisePriceExpried" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" name="DeferredTaxAssetsResearchAndDevelopmentCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsUnpaidCharges" name="DeferredTaxAssetsUnpaidCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ForeignExchangeAndOther" name="ForeignExchangeAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PermanentDifferencesRelatingToStockBasedCompensation" name="PermanentDifferencesRelatingToStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" name="IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryforwardsDescription" name="OperatingLossCarryforwardsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentTaxCreditsYear" name="ResearchAndDevelopmentTaxCreditsYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>avxl-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheets" xlink:href="avxl-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheetsParenthetical" xlink:href="avxl-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfCashFlows" xlink:href="avxl-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="avxl-20240930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20240930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20240930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20240930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20240930.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20240930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20240930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20240930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20240930.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="995612 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995613 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="995614 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="995615 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="995616 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="995617 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="995618 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="995619 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995620 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="995621 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="995622 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="995623 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995624 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="995625 - Disclosure - Accrued Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="995626 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="995627 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="995628 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995629 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="995630 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="995631 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="995632 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="995633 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:title="995634 - Disclosure - Commitments and Contingencies (Details 6)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995635 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="995636 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="995637 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="995638 - Disclosure - Income Taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="995639 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>avxl-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheets" xlink:href="avxl-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheetsParenthetical" xlink:href="avxl-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfCashFlows" xlink:href="avxl-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="avxl-20240930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20240930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20240930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20240930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20240930.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20240930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20240930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20240930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20240930.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="995612 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995613 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="995614 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="995615 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="995616 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="995617 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="995618 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="995619 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995620 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="995621 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="995622 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="995623 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995624 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="995625 - Disclosure - Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="995626 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="loc_currencyAUD_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredGrantIncome1" xlink:label="loc_avxlDeferredGrantIncome1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome1_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivables_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="995627 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseAgreement2020Member" xlink:label="loc_avxlPurchaseAgreement2020Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2020Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommonStockIncludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockIncludingCommitmentSharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockIncludingCommitmentSharesMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommonStockExcludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockExcludingCommitmentSharesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockExcludingCommitmentSharesMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentSharesMember" xlink:label="loc_avxlCommitmentSharesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommitmentSharesMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlIncurredExpenses_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_120" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="995628 - Disclosure - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995629 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="995630 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NumberOfWarrantsExpired" xlink:label="loc_avxlNumberOfWarrantsExpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlNumberOfWarrantsExpired_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_WeightedAverageExercisePriceExpried" xlink:label="loc_avxlWeightedAverageExercisePriceExpried_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWeightedAverageExercisePriceExpried_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="995631 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="995632 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="995633 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:title="995634 - Disclosure - Commitments and Contingencies (Details 6)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995635 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="995636 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="995637 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="995638 - Disclosure - Income Taxes (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="995639 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FederalMember" xlink:label="loc_avxlFederalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlFederalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="loc_currencyAUD_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="loc_avxlOperatingLossCarryforwardsDescription_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryforwardsDescription_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:label="loc_avxlResearchAndDevelopmentTaxCreditsYear_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlResearchAndDevelopmentTaxCreditsYear_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_180" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>avxl-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="avxl_MichaelJFoxFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxFoundationMember" xlink:to="avxl_MichaelJFoxFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxFoundationMember_lbl" xml:lang="en-US">Michael J Fox Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseAgreement2023Member" xlink:label="avxl_PurchaseAgreement2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement2023Member" xlink:to="avxl_PurchaseAgreement2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement2023Member_lbl" xml:lang="en-US">Purchase Agreement 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommonStockIncludingCommitmentSharesMember" xlink:label="avxl_CommonStockIncludingCommitmentSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockIncludingCommitmentSharesMember" xlink:to="avxl_CommonStockIncludingCommitmentSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockIncludingCommitmentSharesMember_lbl" xml:lang="en-US">Common Stock Including Commitment Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommonStockExcludingCommitmentSharesMember" xlink:label="avxl_CommonStockExcludingCommitmentSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockExcludingCommitmentSharesMember" xlink:to="avxl_CommonStockExcludingCommitmentSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockExcludingCommitmentSharesMember_lbl" xml:lang="en-US">Common Stock Excluding Commitment Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentSharesMember" xlink:label="avxl_CommitmentSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesMember" xlink:to="avxl_CommitmentSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesMember_lbl" xml:lang="en-US">Commitment Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseAgreement2020Member" xlink:label="avxl_PurchaseAgreement2020Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement2020Member" xlink:to="avxl_PurchaseAgreement2020Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement2020Member_lbl" xml:lang="en-US">Purchase Agreement 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FederalMember" xlink:label="avxl_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FederalMember" xlink:to="avxl_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US">Deferred grant income - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per Issued and outstanding: 84,795,517 common shares (2023 - 82,066,511)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OtherFinancingExpense" xlink:label="avxl_OtherFinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_OtherFinancingExpense_lbl" xml:lang="en-US">Other financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EarningPerShareBasicAndDilutedAbstract" xlink:to="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EarningPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss per share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="avxl_NoncashFinancingRelatedCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NoncashFinancingRelatedCharges" xlink:to="avxl_NoncashFinancingRelatedCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NoncashFinancingRelatedCharges_lbl" xml:lang="en-US">Non-cash financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">(Decrease) Increase in cash and cash equivalents during the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:label="avxl_CashPaidForStateAndLocalFranchiseTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:to="avxl_CashPaidForStateAndLocalFranchiseTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalFranchiseTaxes_lbl" xml:lang="en-US">Cash paid for state and local franchise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance at beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:to="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xml:lang="en-US">Shares issued under 2023 Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_InitialCommitmentShares" xlink:label="avxl_InitialCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentShares" xlink:to="avxl_InitialCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentShares_lbl" xml:lang="en-US">&#160;Initial Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_InitialCommitmentSharesShares" xlink:label="avxl_InitialCommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentSharesShares" xlink:to="avxl_InitialCommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentSharesShares_lbl" xml:lang="en-US">Initial commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">&#160;Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentShares" xlink:label="avxl_CommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentShares" xlink:to="avxl_CommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentShares_lbl" xml:lang="en-US">&#160;Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance at ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureAccruedLiabilitiesAbstract" xlink:to="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="avxl_AccuredLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_AccuredLiabilitiesTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="us-gaap_RevenueRecognitionIncentives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionIncentives" xlink:to="us-gaap_RevenueRecognitionIncentives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionIncentives_lbl" xml:lang="en-US">Research and Development Incentive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_LicenseFeesPolicyTextBlock" xlink:label="avxl_LicenseFeesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LicenseFeesPolicyTextBlock" xlink:to="avxl_LicenseFeesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LicenseFeesPolicyTextBlock_lbl" xml:lang="en-US">License Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment and Geographic Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="avxl_GrantIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncomePolicyTextBlock" xlink:to="avxl_GrantIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="avxl_RecentAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RecentAccountingPronouncementsPolicyTextBlock" xlink:to="avxl_RecentAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_RecentAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of principal components of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of contributions under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summarizes information about stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:label="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:to="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of net deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_AccruedInvestigatorPayments" xlink:label="avxl_AccruedInvestigatorPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedInvestigatorPayments" xlink:to="avxl_AccruedInvestigatorPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedInvestigatorPayments_lbl" xml:lang="en-US">Accrued investigator payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="avxl_MilestoneBasedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MilestoneBasedContractAccruals" xlink:to="avxl_MilestoneBasedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MilestoneBasedContractAccruals_lbl" xml:lang="en-US">Milestone-based contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:to="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Non operating income from grant</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredGrantIncome1" xlink:label="avxl_DeferredGrantIncome1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome1" xlink:to="avxl_DeferredGrantIncome1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome1_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FairValueOfInitialCommitment" xlink:label="avxl_FairValueOfInitialCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FairValueOfInitialCommitment" xlink:to="avxl_FairValueOfInitialCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FairValueOfInitialCommitment_lbl" xml:lang="en-US">Fair value of the initial commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_IncurredExpenses" xlink:label="avxl_IncurredExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncurredExpenses" xlink:to="avxl_IncurredExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncurredExpenses_lbl" xml:lang="en-US">Incurred expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NumberOfWarrantsExpired" xlink:label="avxl_NumberOfWarrantsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfWarrantsExpired" xlink:to="avxl_NumberOfWarrantsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfWarrantsExpired_lbl" xml:lang="en-US">Number of warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_WeightedAverageExercisePriceExpried" xlink:label="avxl_WeightedAverageExercisePriceExpried" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageExercisePriceExpried" xlink:to="avxl_WeightedAverageExercisePriceExpried_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageExercisePriceExpried_lbl" xml:lang="en-US">Weighted average exercise price expried</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted average grant date fair value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted average grant date fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, Upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:label="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:to="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization_lbl" xml:lang="en-US">Research and development capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xml:lang="en-US">Unpaid charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible asset costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ForeignExchangeAndOther" xlink:label="avxl_ForeignExchangeAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ForeignExchangeAndOther" xlink:to="avxl_ForeignExchangeAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_ForeignExchangeAndOther_lbl" xml:lang="en-US">Foreign exchange and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at statutory federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign income taxed at other rates</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:label="avxl_PermanentDifferencesRelatingToStockBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:to="avxl_PermanentDifferencesRelatingToStockBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PermanentDifferencesRelatingToStockBasedCompensation_lbl" xml:lang="en-US">Permanent differences relating to share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xml:lang="en-US">Permanent differences relating to GILTI inclusion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:to="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_lbl" xml:lang="en-US">Research and development credits, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Adjustment to true up to prior years&#8217; tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="avxl_OperatingLossCarryforwardsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryforwardsDescription" xlink:to="avxl_OperatingLossCarryforwardsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryforwardsDescription_lbl" xml:lang="en-US">Operating loss carryforwards description</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carry forwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and Development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:label="avxl_ResearchAndDevelopmentTaxCreditsYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:to="avxl_ResearchAndDevelopmentTaxCreditsYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentTaxCreditsYear_lbl" xml:lang="en-US">Research and development tax credits year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Decrease in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherFinancingExpense_2_lbl" xml:lang="en-US">OtherFinancingExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccuredLiabilitiesTextBlock_2_lbl" xml:lang="en-US">AccuredLiabilitiesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:to="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_2_lbl" xml:lang="en-US">ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ForeignExchangeAndOther" xlink:to="avxl_ForeignExchangeAndOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ForeignExchangeAndOther_2_lbl" xml:lang="en-US">ForeignExchangeAndOther</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>avxl-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheets" xlink:href="avxl-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheetsParenthetical" xlink:href="avxl-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfCashFlows" xlink:href="avxl-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="avxl-20240930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20240930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20240930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20240930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20240930.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20240930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20240930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20240930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20240930.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20240930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaapDeferredRentCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_EarningPerShareBasicAndDilutedAbstract" xlink:label="loc_avxlEarningPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_avxlEarningPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalFranchiseTaxes" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalFranchiseTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="995612 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995613 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="995614 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="loc_avxlAccuredLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccuredLiabilitiesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="995615 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="995616 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="995617 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="995618 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="995619 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995620 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="loc_us-gaapRevenueRecognitionIncentives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionIncentives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_LicenseFeesPolicyTextBlock" xlink:label="loc_avxlLicenseFeesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlLicenseFeesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="loc_avxlGrantIncomePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlGrantIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_RecentAccountingPronouncementsPolicyTextBlock" xlink:label="loc_avxlRecentAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlRecentAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="995621 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="995622 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:label="loc_avxlScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="995623 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995624 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="995625 - Disclosure - Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_AccruedInvestigatorPayments" xlink:label="loc_avxlAccruedInvestigatorPayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccruedInvestigatorPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="loc_avxlMilestoneBasedContractAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlMilestoneBasedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="995626 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredGrantIncome1" xlink:label="loc_avxlDeferredGrantIncome1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="995627 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseAgreement2020Member" xlink:label="loc_avxlPurchaseAgreement2020Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2020Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommonStockIncludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockIncludingCommitmentSharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockIncludingCommitmentSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommonStockExcludingCommitmentSharesMember" xlink:label="loc_avxlCommonStockExcludingCommitmentSharesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommonStockExcludingCommitmentSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_CommitmentSharesMember" xlink:label="loc_avxlCommitmentSharesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_avxlCommitmentSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlIncurredExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="995628 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995629 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="995630 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_NumberOfWarrantsExpired" xlink:label="loc_avxlNumberOfWarrantsExpired" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlNumberOfWarrantsExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_WeightedAverageExercisePriceExpried" xlink:label="loc_avxlWeightedAverageExercisePriceExpried" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWeightedAverageExercisePriceExpried" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="995631 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="995632 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="995633 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:title="995634 - Disclosure - Commitments and Contingencies (Details 6)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995635 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="995636 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="995637 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:label="loc_avxlDeferredTaxAssetsResearchAndDevelopmentCapitalization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsResearchAndDevelopmentCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="loc_avxlDeferredTaxAssetsUnpaidCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsUnpaidCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ForeignExchangeAndOther" xlink:label="loc_avxlForeignExchangeAndOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlForeignExchangeAndOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="995638 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_PermanentDifferencesRelatingToStockBasedCompensation" xlink:label="loc_avxlPermanentDifferencesRelatingToStockBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlPermanentDifferencesRelatingToStockBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationGiltiAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:label="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="995639 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_FederalMember" xlink:label="loc_avxlFederalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_avxlFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OperatingLossCarryforwardsDescription" xlink:label="loc_avxlOperatingLossCarryforwardsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryforwardsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_OperatingLossCarryForwardsExpirationYear" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240930.xsd#avxl_ResearchAndDevelopmentTaxCreditsYear" xlink:label="loc_avxlResearchAndDevelopmentTaxCreditsYear" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_avxlResearchAndDevelopmentTaxCreditsYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_L8_%[X:QZ*OC#XD?LW:C);V^FMYD?\ :FER3F2.1/\ EICR_M!C_P"F8BH
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M>#M _P"$0\*Z7I;7E]JRZ;:16_VV]D\VYNBB>7YLC_QR/U)[YKX;_P"&<_\
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M*8TN<>_/_?%?3=>=_LUZI\/;GX/Z78_"W4O#NI>#]$C_ +.M/[%O([FUA\O
MV;XR?G]:]$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^-?^"SOB_Q%
MX6^ GP\M_#?BKQ)X-NO$'Q$TO1KB^T/4)+*Z-O/'<B2,21]N ?\ @%?95?#O
M_!=G0(/%/[/?POTF:2YBMM2^)^D6LKV\GERQ));WL?R'UYH YK]K+]C#Q?\
MLA_L^^)?B-X5_::^.0UCPC9MJ4=OXH\2C4M-OO+Y-N8I(_\ 62_ZM/<CZTMS
M^UWX@\5?M;?L=Z_K?B*\\*:'X]\&WVJZ_IG]HR6.D7-Q)IKR1^9&9/+D'F<Q
M^9S_ *O'->E6/_!%CX*RZC;W&M_\)SXMAM9/-CM-=\27%U:[_P#KGQ7GO[=G
MP4\)_%W_ (*B?LS>"_$6A6>I>%;G1==CETN1-EL8XK.62/&P\>7)''@=.: .
MS_X*Z?M/Z;H/[ 'CJ^\#?$2QL_$\,FG?8KC0]?2*^C_XF%L)/+>!_,'[KS.E
M>A_MQ?M+7'[,/["6N>,H;B3^WVTB.ST<#F2;4;B,1Q'_ &R'?S/^ 5\R_P#!
M7#_@GI\%_@1^P#XY\5>#_A[H?A_Q#I\FG_9[ZW\SS(O,OK>*3_EI_P \Y)*M
M?MMZ?XH_;*_:R^#_ ,$_!.N6>CR?#[1X_B#K=[=6?VVVMIX_+CLO,MSQ)W_=
M^ES0!VG_  2S^(_CSX8_$GQY\"_BUXDU;Q1XR\.V]EXGTS4]5O)+JZN[.YMX
MA<1B21SF.VN/W?U=ZY']J+XFM\8/^"CWB+X6?$'XQ^)_@OX!T+1+.YT1=(U>
M/0SXHFN$C\SS+QQSB0F,1=_+]ZY/]K'X=?%S]B7]H3X8?M&^/OB%I7C^RT'4
M8_"VMR:=X;CTJ2TTNX,N\OY<A\S[\A'_ $T\JO5OC;^TA\'/C#^TGXL^$O[1
M7A7P7I.EZ7;V]WX,\0:U-Y=OK%G/'YDLD5Z=@MSPG^KDY\N3G]W0!V?[*GP7
M^+/[/7[2=QI,?CCQ!\4O@;KFD?:;/5/$.LQWVIZ/?YR(_,_UDD1C''&S]XF.
M]?.G[&GP8U']KRW^)GB#Q9^TE\</"=WHOC_5-&LM-TOQX]C;16D8CDC_ '<G
MF?\ /1Q_VSJ]^RCH?@?X)_\ !3K0/"/[-GBV]\0?#?7-'N[SQOI%OJDFK:/H
M\D<<GV:2.X_>?O#)Y8YD[_?_ 'F*\^_8F^$O[*_CNV^+%U\;KKX?V_BR/XD:
MQ% FM>)?[,NA9_NO+/E_:(_W?F>9^\Q0!]]_L@_LV6WP'O-<N;7XO?$OXIQZ
MI'$GE^*/$O\ :\=@4\S)B_YY^9G_ ,AU-^W-X.^+'Q'^&NC^'OA/K-KX;O-8
MUFWM]<UPR>7=:7IF?W\MO_TUXXK*_8DT']G?X?RZYHOP)U/P3-)=B.\U2TT+
M7!J;_N_W<<DG[R0Q_?QVZUO_ +8'[8NE?L;V'A#4_$6DWUQX=\1:Y%HVH:M$
M^+;01)TN+C_IG0!\U_ 3QCK7P%_X*.>%OA?X6^,/BGXS>#_$>A7EUXCAU[5X
M]:N_"UQ;QR&.3[0G^J\R0"/RS_STY_Y9U]^5^;?B2T^&/PL_X*&? V/]FV^T
MG^V?%%[<?\)G8^&-4^U:9=:.8_-\R\\MWC\P?O'B[\?]<Z_22@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T;J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ^$O^"@.G^)OBM_P44^!WPSTWXB
M?$3P#X?\6:/K%SJ$GA/7)=.FFDMXI)(_5/\ EGWYKBOVM/ _C[_@F"W@/QUX
M9^.7Q2\=6^J>*+/1M1\,>,]7_M8:I!(',GV?."DGR=1_?[5O?\%%O@MI?[0O
M_!4C]GSPEK%UK=C8:IH>N!I]*O#9741CMY)!LD^L=>Q?"?\ X)+?!SX4?$O3
M/%G]G^(/%'B#06\W3[OQ%K-QJ0L9/^>D:2?NQ)[XH XWX3_'N7P]_P %8OCM
MX=\2>-I-/\,6.AZ/)I>F:EK!CL;:62WMS+Y$<DGEI(23GR^N31^W9^T9M_:1
M_9HTWP7XZ/D:QXXCMM8M=%US,=_;XC_=W$<;XDC_ .NG%<#I7[,/@+]IW_@L
M?\?[+Q]X7TWQ3::7H.AW%I'=>9^Z?[';<_(15']L']C?X8_LP_M8?LNW?@#P
M;I/A6YU3X@1QW;VN_P#>1Q^7_?)HN![1_P %4?BMXDL/"_P_^%?@77-4\.^.
M/C'XBM])M]1TZXDBNM,L(I(Y+RYCDC^?,8,>?^F<DE:G_!*KX^ZU\8/V;CH'
MC"ZNKCXA_"_5+CPGXE>[F,ES+-;R8CE=W_>2>9'M_>'_ %DD<M> W_A?XA?M
MZ?\ !2OQUXV^&_C32_!NF_ ^*/PAI>I7NC)JL=U<2>8;WRXWD\L2>9YD?F?\
M\_+IOP>T'QU^P#_P5'T^'XA^+-/\3:;^T98R02ZE:Z6--M6UBVYC_<1\>9_!
MG/[PWOM1<#+^%>MQ?MR?'WXG6OQ1_: \?_#'Q'X=\67FB:)X(T'Q+'X?^QV<
M;GRKG_IXD[>9_P!,_P#II'7LWA30/C9\!_V4_P!H31?'WB*^\0:?X7T35+KP
M+XN;4$75KJW^QW$@,KQOYD<T1$6)#C]*\[T_XL_LW_MQ-XDTW]H[PGX!^'_Q
M6\+ZA/I^IV^K:C_95T8X\E)(KP^5))'Y?3G]'KB?V8;Z'0OA=^V!X-^'?B36
M?&7P(\,^$+L^';Z^E^U16EY)IUS]HM[:3_EK'G?Z?ZN/_GIYD@!T_P"R#^R;
M_P +[_9I\$^+_$7[5'[06FZYXBTJ.]N[6#XAF**&3_<D'F=J^U/V5_@Q;_ W
MX:'1[?QYXP^(L,UV]PNK^)=7_M6^(^1/+$N.8QL/YFOSY_8J^!W[$.O?LI>
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M_P#A'Z?_ /&J]:CB$,>U:Y?_ (63)_T+'B?_ ,!(_P#XY1_PLF3_ *%CQ/\
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M75/!_AG4_"MKL$&C7>EV\MC#Y?W D#IY8Q].*\]_X> ?#O\ Y^]1_P# <?\
MQ='_  \ ^'?_ #]ZC_X#C_XNI_MS+_\ G_#_ ,#B']CYA_SXG_X">Y9;_(KS
M[7OV9/AOXN?69=4^'W@G46\321W6KO=Z!;2'4Y(_]7)<;XSYCIV+Y(KCO^'@
M'P[_ .?O4?\ P''_ ,71_P / /AW_P _>H_^ X_^+H_MS+_^?\/_  .(?V/F
M'_/B?_@+-NT_88^"=A=1SV_P?^%EO/;OYD<D7A/3T>-_4$1=:]7RW^17AO\
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M[_Y^]1_\!Q_\71_;F7_\_P"'_@<0_LC,/^?$_P#P%GN66_R*,M_D5X;_ ,/
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M#>A^/M0\46?A_0;/Q-K$:07^K0V,<=]?1IC9'+/CS' V)P2?]7[#'FW_  \
M^'?_ #]ZC_X#C_XNC_AX!\._^?O4?_ <?_%T_P"W,O\ ^?\ #_P.(?V/F'_/
MB?\ X";NI?L4?"#Q!XJ;7;_X7?#V^UB23S)+N?P]9R2RR<?O')CY?WKJ/B'\
M(?"OQ;\/PZ/XL\-^'_$VDP2+/#8:KI\5[;1R)E0_ER(1D!CR:\Z_X> ?#O\
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M !=']N9?_P _X?\ @<0_LC,/^?$__ 6>Y9;_ "*,M_D5X;_P\ ^'?_/WJ/\
MX#C_ .+H_P"'@'P[_P"?O4?_  ''_P 71_;F7_\ /^'_ ('$/[(S#_GQ/_P%
MGN66_P BC+?Y%>&_\/ /AW_S]ZC_ . X_P#BZ/\ AX!\._\ G[U'_P !Q_\
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MX-7SYOVO_A';/S?,_P">F?+_ -9_M]?>L+_AX!\._P#G[U'_ ,!Q_P#%T?\
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MX=_\_>H_^ X_^+H_MS+_ /G_  _\#B']CYA_SXG_ . L]RRW^11EO\BO#?\
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M /G_  _\#B']D9A_SXG_ . L]RRW^11EO\BO#?\ AX!\._\ G[U'_P !Q_\
M%T?\/ /AW_S]ZC_X#C_XNC^W,O\ ^?\ #_P.(?V1F'_/B?\ X"SW++?Y%&6_
MR*\-_P"'@'P[_P"?O4?_  ''_P 71_P\ ^'?_/WJ/_@./_BZ/[<R_P#Y_P /
M_ XA_9&8?\^)_P#@+/<LM_D49;_(KPW_ (> ?#O_ )^]1_\  <?_ !='_#P#
MX=_\_>H_^ X_^+H_MS+_ /G_  _\#B']D9A_SXG_ . L]RRW^11EO\BO#?\
MAX!\._\ G[U'_P !Q_\ %T?\/ /AW_S]ZC_X#C_XNC^W,O\ ^?\ #_P.(?V1
MF'_/B?\ X"SW++?Y%&6_R*\-_P"'@'P[_P"?O4?_  ''_P 71_P\ ^'?_/WJ
M/_@./_BZ/[<R_P#Y_P /_ XA_9&8?\^)_P#@+/<LM_D49;_(KPW_ (> ?#O_
M )^]1_\  <?_ !='_#P#X=_\_>H_^ X_^+H_MS+_ /G_  _\#B']D9A_SXG_
M . L]RRW^11EO\BO#?\ AX!\._\ G[U'_P !Q_\ %T?\/ /AW_S]ZC_X#C_X
MNC^W,O\ ^?\ #_P.(?V1F'_/B?\ X"SW++?Y%&6_R*\-_P"'@'P[_P"?O4?_
M  ''_P 71_P\ ^'?_/WJ/_@./_BZ/[<R_P#Y_P /_ XA_9&8?\^)_P#@+/<L
MM_D49;_(KPW_ (> ?#O_ )^]1_\  <?_ !='_#P#X=_\_>H_^ X_^+H_MS+_
M /G_  _\#B']D9A_SXG_ . L]RRW^11EO\BO#?\ AX!\._\ G[U'_P !Q_\
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M'_P''_Q=']N9?_S_ (?^!Q#^R,P_Y\3_ / 6>Y9;_(HRW^17AO\ P\ ^'?\
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MC_\ CE'_  V-X:_Z!FO?]^$_^.4?VIA/^?D?O'_9V+_Y]L]<W>XHW>XKR/\
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M?'_\^)_<>Z;O?]*-WO\ I7A/_#PGP-_SQUW_ +]V_P#\=H_X>$^!O^>.N_\
M?NW_ /CM/_6#+/\ G_#_ ,#-/[%Q_P#SXG]Q[MN]_P!* WO^E>#_ /#P[P'_
M ,\M:_[]P?\ QVF_\/$? ?\ SQUK_OW!_P#':7^L&6?\_P"'_@8?V)C_ /GQ
M/[CWM2V?N[13PN!ZUXU\./VR_!_Q5\9V.@Z7#JAO[XR>5YB1B/Y$,AY#^B5[
M(%PG6N["XRAB(>TP\^='#B,+7H3]G7ARL?113)9EA0LWW1768CZ*^+?V5_\
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MBBBX!1111< HHHHN 44447 ****+@%%%%%P"BBBBX!1111< HHHHN 44447
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MD3XA^"NN> Y8O$VDZ_!=:!;C6]/D^UV#W/VB2/S//\M#')YG^M/\8Q0!X_\
M\$^_BCKG_!*?]H7P WBJZD_X57\=_#>GZD]W_P LK622.+]Y_P!=+:23RY?^
MF4OF?\\Z]^_X-K9XX/@W\5I&942/7;:21W_Z]Y*]A^.'_!.>\_:-_P""67@;
MX;:Q80Z?\1O!/AO3_P"S-[Q2?9-0M[:..2W\R/\ =^7)@Q_\\_\ 5R8_=BO
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MV?-!U#X4? +2]4L=:\/Z#JWBK58+^7^V+[[%YUC!)GRX_P#KH!_W[EKR^?\
M:[GO96D?X>_"V21_WDCOH77_ ,B5QGQ4^+VI?%FYTU]0M[&QCTFQ2PM8+2.2
M..-(_P#MI7/'/LOPM2>-A^\G_<A*'_MTBYY'C\7"&&G>,/[\XS_^1ZGO7BCP
MUJGP9_;';Q/X/TE?$6DZM82:TD$,\:QR028^T>7)W_>'S/3]Y'5+X=Z+X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB!J7B#6O'7_".61FTS3H?MNI32>5^\DD\R1,#S/,_P!9(*]%_8M_X*5_#/\
M;R?5K3PA-K6GZQH2[[S2]9M!;W,4?02?NY)(W0D]I#0!]$T5\0^)/^"]OP#\
M.V_B(R3>*KBXT*]^PBU@T]#+J#_O?WD'[P?N_P!W_K)/+_UD?KQN_M&?\%G_
M (,?LU:E8Z7K'_"3ZEXDN+.*\NM%T[3XY+[2/,C$OEW.^2...0?QQ^9D4 ?8
M-%>$_LV_\% _AA^TY\$]8\?:!KGV71O#*22:XNI(;:YT<)&)&\^,YQ^[YW>@
MKP>7_@X0^ </B_[$8/'_ /9?G_9_[9_L5/L'^_CS/M&/^V5 'W=17@/[6/\
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M ( 24O\ PS5X_P#^A/\ $/\ X /7N?\ P])U+_H3;/\ \#Y/_C='_#TG4O\
MH3;/_P #Y/\ XW1_9/"W_0;/_P  #^TN)_\ H%A_X%_P3PO_ (9L^(/_ $)W
MB'_P DI?^&:O'_\ T)_B'_P >O<_^'I.I?\ 0FV?_@?)_P#&Z/\ AZ3J7_0F
MV?\ X'R?_&Z/[)X6_P"@V?\ X ']H\3_ /0+#_P+_@GA?_#-GQ!_Z$[Q#_X
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M9/"W_0;/_P  '_:7$_\ T"P_\"_X)X7_ ,,V?$'_ *$[Q#_X 24O_#-7C_\
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M/_C='_#TG4O^A-L__ ^3_P"-T?V5PM_T&S_\ '_:/$__ $"P_P# O^">%_\
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M/D_^-T?V3PM_T&S_ /  _M+B?_H%A_X%_P $\+_X9L^(/_0G>(?_   DI?\
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MXA_\ 'KW/_AZ3J7_ $)MG_X'R?\ QNC_ (>DZE_T)MG_ .!\G_QNC^R>%O\
MH-G_ . !_:7$_P#T"P_\"_X)X7_PS9\0?^A.\0_^ $E+_P ,U>/_ /H3_$/_
M ( /7N?_  ])U+_H3;/_ ,#Y/_C='_#TG4O^A-L__ ^3_P"-T?V3PM_T&S_\
M #^TN)_^@6'_ (%_P3PO_AFSX@_]"=XA_P# "2E_X9J\?_\ 0G^(?_ !Z]S_
M .'I.I?]";9_^!\G_P ;H_X>DZE_T)MG_P"!\G_QNC^R>%O^@V?_ ( ']I<3
M_P#0+#_P+_@GA?\ PS9\0?\ H3O$/_@!)2_\,U>/_P#H3_$/_@ ]>Y_\/2=2
M_P"A-L__  /D_P#C='_#TG4O^A-L_P#P/D_^-T?V3PM_T&S_ /  _M+B?_H%
MA_X%_P $\+_X9L^(/_0G>(?_   DI?\ AFKQ_P#]"?XA_P# !Z]S_P"'I.I?
M]";9_P#@?)_\;H_X>DZE_P!";9_^!\G_ ,;H_LGA;_H-G_X ']I<3_\ 0+#_
M ,"_X)X7_P ,V?$'_H3O$/\ X 24O_#-7C__ *$_Q#_X /7N?_#TG4O^A-L_
M_ ^3_P"-T?\ #TG4O^A-L_\ P/D_^-T?V3PM_P!!L_\ P /[2XG_ .@6'_@7
M_!/"_P#AFSX@_P#0G>(?_ "2E_X9J\?_ /0G^(?_   >O<_^'I.I?]";9_\
M@?)_\;H_X>DZE_T)MG_X'R?_ !NC^R>%O^@V?_@ ?VEQ/_T"P_\  O\ @GA?
M_#-GQ!_Z$[Q#_P" $E+_ ,,U>/\ _H3_ !#_ . #U[G_ ,/2=2_Z$VS_ / ^
M3_XW1_P])U+_ *$VS_\  ^3_ .-T?V3PM_T&S_\   _M+B?_ *!8?^!?\$\+
M_P"&;/B#_P!"=XA_\ )*7_AFKQ__ -"?XA_\ 'KW/_AZ3J7_ $)MG_X'R?\
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MG_X +^TN)_\ H%A_X%_P3PO_ (9L^(/_ $)WB'_P DI?^&:O'_\ T)_B'_P
M>O<_^'I.I?\ 0FV?_@?)_P#&Z/\ AZ3J7_0FV?\ X'R?_&Z/[)X6_P"@V?\
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M+_H3;/\ \#Y/_C='_#TG4O\ H3;/_P #Y/\ XW1_9/"W_0;/_P  #^TN)_\
MH%A_X%_P3PO_ (9L^(/_ $)WB'_P DI?^&:O'_\ T)_B'_P >O<_^'I.I?\
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M DI?^&:O'_\ T)_B'_P >O<_^'I.I?\ 0FV?_@?)_P#&Z/\ AZ3J7_0FV?\
MX'R?_&Z/[)X6_P"@V?\ X ']I<3_ /0+#_P+_@GA?_#-GQ!_Z$[Q#_X 24O_
M  S5X_\ ^A.\0_\ @ ]>Y_\ #TG4O^A-L_\ P/D_^-T?\/2=2_Z$VS_\#Y/_
M (U1_9/"W_0;/_P /[2XG_Z!8?\ @7_!/G7X@?"7Q5\+O!VJ>(M>\-ZSI.B:
M/;R7%Y=3VDGEVL?_ #TKPV']LSX:WDT:1^(_WDO[O_D'W'_QNOH3_@IA_P %
M!]4^*?[$WC?08=!CT>2^^QD74-^_F0F.]MY,C]W_ +%>N?V;:_\ 0-TS_P
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MGER1_P!GW'_QNN\\*^*K'QKH-GJNFW'VG3[^/S+>3R_+\VOI#-O_ ,^.F_\
M@''_ /&ZCVP?\^.F_P#@OC_^-T8C*<![/]SSAA\ZQ_/^^Y#XS_X;2^&?_0Q_
M^4^X_P#C=>@?\)58_P#"+_VSY_\ Q*_L?VWS_+_Y9^7YGF5]$97_ )\=-_\
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MGF_]^XZ^B)M2_P"G73?_  7V_P#\;H_M%O\ GCIO_@OM_P#XW14RW+/;_;Y
MIYEC_9_8YSYK^'O[0GA'XM:S)IOA_5?MUY%;_:9(_L=Q'^[_ .VD?_32K'Q(
M^/'A7X2W]O!X@U7^S;BZC\R./[/))YO_ '[CKZ(_MB3_ )]]-_\ !?;_ /QN
MH_[8D_Y]]-_\%]O_ /&Z/J66>W^WR#_M''^P^QSGSW\-_CEX9^+4MY'X<U+^
MTI+#R_M'^CR1^5_W\CJO\0?VBO!WPKU[^S=<UC[#>>7YGE_8[B3]W_VSCKZ,
M_MB3_GWTW_P7V_\ \;J+^WI/^??3?_!?;_\ QNL_J66>W^WR%_7<?[#['.>"
M?#?XP>'/BU%>2>'-2_M*.P\O[1_H\D?E?]_(ZR_&W[2W@KX;>(Y-*UC7/L6H
M0^7))']CN)/_ $7'7T9_;T__ #QTW_P7V_\ \;J/_A)+C_GCIO\ X+[?_P"-
MT4\%EGUCW^?D#Z[C_9_N^3G/$_A[\3M#^+6C2:EX?OOMUG%<?9I)/L\D?[S_
M +:?]=*YOQ5^U/X#\$Z]>:5J6N?9M0L)/+N(_L=Q)Y7_ )#KZ,_X22X_YXZ;
M_P""^W_^-T?\))=?\\]-_P# "W_^-UG2PV6>UGS\_(%3&8_V?N<G.>/^"?'F
ME?$CPY'JNCW7V[3Y?,\N3RY(_P#T97'Z]^UI\/?#>LWFFWWB#R[RPN)+:XC_
M +/N/W4D?^L_Y9U]&'Q3='^'3?\ P M__C=1_P#"4W7]S3?_  7V_P#\;HHX
M;+/:3Y^?D-*F)Q_LX<G)SGE?@_QAIOCSPY;ZKI4_VG3[_P#X]Y/+DC\W_OY7
M!S?MF?#6&62.3Q'^\B_=R?\ $ON/_C=?2'_"4W7]S3?_  7V_P#\;J/_ (3"
MZ_N:;_X+[?\ ^-T8:EE,)S]OSA4Q&9\D.3D/-]'UZUU[PY;ZK:S^9I]U;QWL
M;^7_ *V.2/S*\[_X;3^&/_0R?^4^\_\ C=?1'_"8WW_//3?_  7V_P#\;JO_
M ,)M??W--_\ !?;_ /QNL\-3RF'/[?G-,15S/_EQR'G]YXJL=-\+R:Q/-Y>E
MVMG]MDG\O_EGY?F>97G\/[9GPUO)HTC\1_O)?W?_ "#[C_XW7ODWC:^Q_P P
MW_P7V_\ \;H_X3S4?2Q_\%]O_P#&Z,/3RF'\?G#$5,SG_ Y#@_%7BJQ\%:#>
M:KJ5Q]FT^PC\RXD\OS/*KA]'_; ^'.O:I;V-KXC\RXNI(XXX_P"S[C][))_V
MSKW#_A/=1_ZAO_@OM_\ XW4<WQ"U+'_+C_X+[?\ ^-UGA_[)A#]_SFF(J9E.
M?[CD.#\;^/-*^&_AR35=8NOL.GQ>7'))Y<DG_HNO5/V3/C]X1^-G@VXM?#.J
M_P!I7&@_\A"/['<1^5YDDGE_ZR/_ *9R5B?\+"U7_IR_\%]O_P#&Z^K?V"_V
M9/!K>"M2\?3:8UQXE\>F+^UY'?\ =-]C>XM[?RXTXCQ&>U?4<%Y3A,=7J4*4
M_?\ _)3YGBW-,5@X4Z]6'N,X6BOKX?!/PO\ ] 6Q_P"^:/\ A2?A?_H"V/\
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M'%3_ ,0GQ'_/^'_@(?\ $3*/_/@_,>>HYZ_3K_AF[P+_ -"KHW_@.*/^&;O
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M*FF:#Y/C[Q!"]O?:J]Y<3-*CF,N!%)(T4>3&O^K1!@8QCBCGCYE>_P"7EO\
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MQD:4W4G#_P#8.>/%&%DX1I\__P"V>+T5[UXB\&?"_P"&'@7P?/KVD^)-1O\
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MY177_ ?X7?\ "X?B9IVAR2&U@N/,DNI1U2"/]XX_$UW&M?";P;\0_ASK&L>
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M[](^/])V;/D[O'&/^VO?R\59U?XUR:=IGABZCL]1O(_$:>9)LN)/]&_\@?\
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M!(-AQG[E=&'K5*WN4ZQSXNC3PT>>='3U*/@#XKZCXE\40Z?>V"VKRQ7<^/\
M8CGCCC_/+_E7HSM\HR*H:=HZV<N\7%U)_LR/FM&O=P\)PA:H?.XNI"I.]&'(
MCB?VCO\ D@?C;_L WO\ Z)>OR[K]1/VCO^2!^-O^P#>_^B7K\NZ_#O%S_>J'
M^#_VY'ZUX7_[O7_Q+_TEFAX._P"1MTO_ *_(_P#T97T5^T7^U1KGPZ^-^M6.
MEZ7X95K-H_+OI-.,E[S;QG[_ /GBOF6BOSS!9W7PN'GAZ'N<Y]MC\EH8S%4Z
MV(VLU;UM_D?2'@WQW:_#C]G[6/%GC"RG\3:I\3+YX&@^U"SD>U3(>3?'_J_G
MSTQUCKHH=7T?X]^"/ 'B+0=-;2;CP%X@L--GM7N_M$D=H\D6S]Y_RTZQ?^1*
M^3:*]FCQ=.G#ZO4I^YR?C\7/S_XCS:W",&G5IU/WG?R^'DY/\'7YGU]+^V)?
M>#/VHM:\/Z\UC'X>FO9-/CN4A2.>R)'[MS)_B*;#=^)?V7/AK\5+P7BWFJ2:
MC:7%G?7?[S[3'/B/S\?WQR,=/W8KY#HK:/&E9*<ZB]_WN3W_ (.<QEP72O3]
MF_W?N<^GQ\GY'OWQGT2Q_:(\ 6WQ/T*WCBUBS"0>)+&/_EDXQ^__  _S_JY*
M]#^)MXI^,/QVV]&\)1J/^_$?^%?'U%8KBJW[U0_>3^/_ ,!E'_VXU_U5;O3=
M3]W"_)IWG"5O_)?ZL?8'P/\ B5I?QK^%NO:MJC+_ ,)IX:\.76F7,G_/]:R1
M^;')^<8_,_WZR/AAX=^(?ASP=H=]\)M<_P"$@T.^LXY+ZPO9[=_L=U_RTCVR
M?ZN/VC_^O7RM1#-)#_JY/+JX<9*HH1JT_?A]N$^6?]?S&$^$G3E.5*I[D_L3
MASP_KMV/KWQ!K7A?_A97B/P;]HTG1]5\;>'(+:_GL_\ CSAU4>:-G_D3/;./
M[YKB/@S^S5K7P)^(UOXN\;/9Z'H/AMY+@3_:XY)+Y_\ EFB1QU\\T3323C]Y
M)YGE5%;BK#XBO#$5*'OT_P"'_P#;_P#;W^$VH\+5J5/ZO2Q'[NI_$T_+^F?1
MGB#XM7FD?L[:/XLTV18;YO'=WJ"QGNLL<S^7^/F5T'[0FH^'?$G['LOB+0!Y
M*>)/$,&H7=MW@NO+$4B?^0Q7RG16;XPGR3H5(?'#D_[?_G*CPC3C5A4IS^"?
M/\OY#W3]F#PQKFH>![O4OA[XB>S\=6EX4FTF2:-(KRUQ_K=DGW_GSS^%;G[5
MT=]+\&]'N?'EKH]G\1I]1'E0V.PW$EIL/^O,?_33T_\ BZ^;_P#EK1-,\TOF
M2?ZRL:?$%.& ^I^S\OC]S_'R_P QU5,AJ5,?]<]IUO\ ![_^#G_D/?/V?/!.
MH?$;]E?XC:/I-N+K4KB_L/+A+I'CRY!)_'5C2O \O[,7P+\<?\)+<V<.M^*+
M2/3+'34FCDDV8P[OLZ]<Y'I[U\]T5='B##4X0E[/]Y"')\?^+['_ &\36R&O
M5JS7M%[*<^>UM?L];_W>Q]6?$;0;7Q9^TMI\%OXAN/#>LQ^%+5M(N%N/+CEN
MLD)'(._T]*U?$D/C23X2^*HOC/:Z')IMKILG]DWK/;_;);K!V;/+X'\\_C7Q
M]1-+)-]^3_55U1XLI^_4]G\?/]OW/^WX?_LGG_ZIR?)3]K\%OL>_I_)(^T+D
M?%R3X1?#W_A7 C^P_P#"/P?;-QM,^9Y8_P">_P"%8?@[2/%GPG\6>*/B9\4K
M6*XU#0M)2"R19+=#<O(Y2/'DYV'I'SG_ %M?)=%75XPBZD*OLYWA_?\ <^#E
M^'E'1X2:I3I>TA[_ /<]^W/JN?FZGTUX=\1^%_VC/@IXL\':'X>N/#]YI,?]
MN:?!/J4E[]ID0Y?F3GDX'_;0=*W/"6B_$;PAIVE3?"W68/%G@VX@C_<ZC/;R
MFU8??1]VS8.>D?Y5\DU)!-)#YFR23][6,.+D^2I5IWG_ #PGRE5.$9+GA1J6
MA_)-<_Z[GV=X*@M;3]H'XCQ_#]=.CU?_ (18'R[+8+:/4N?N9_=_?\O.?QKS
M_P"+VD_'_5_AKK%MXJ2-O#JP?:+\?Z!@QQ_O./+_ 'G\%?-M%5BN+(XBA[-P
MG#X_@GRP]_\ N\I>&X4E0Q"JQJ0G\'QP]]<G;W]#VK]A^TDU;X@^([.$!IKG
MPQ=6Z*>TDDL==3\ _@AJG[-'C!O&_CAK+2;'1;6<00_:HY9[MY(]FQ-G^<U\
MV45PY;G^&H4J"=/GG3Y^3WSIQW#]:O7J257]W4MSZ:_)W_0^RM'OOBGJW[/'
MP_E^'?EXD@NGU/!M,G]Y^[_U_P#VTZ5D_#S2?B)8?M,Z7??$>.)+^ZT.^M[1
MT^S_ '(U'_/#_KI7R717I2XL4G"K:=X<GV_<]S^[RG%'A6454I7A^\Y_L>_[
M_P#?YNA]6OXWTV3]G5?B9]H/_"41Z#_PB/WN?/\ -\OS/^NFS]Y7>&]UH_$'
MXG2>%VC7Q$VAZ3_9WW/]9LF_YZ?NZ^%J*WAQO*/)>G_Y/_B]_P#K^4Y:G ZG
MM5^]76ZM#?96_$^B/COI7QWU?X:Z@WC18Y/#T#QW,^S[!^[ _P"N?[SO74_$
M[XR6?A#]JC7O#_B+;=^$?%5C:VFIQN>+8_9T\N?^E?)U%>=+BB5.I[2ES_8^
M.?/\'-_\D>C_ *KQJI4JKA]OX(<G\FORY3W;]N_3H])^-OA^TMVWV]CH%I;Q
MO_ST\N62I/VH7$G[<JLOW?[0TS_T7;5X+17/C.(?;U*U3D^.<)_^ '3A<A="
M%.'M/X=.<-OY['V)JNHV/P<^)GQ8^(NK6;7RK<Q:+8V\=SY<ES(\<0?#_P#+
M/Y/+^F)*XZ36_#O[0O[,'B#1M T630;CP&1J]G:27SWGFI^\\\>9)R?^6GYQ
MU\V45W5.+N=3H\G[N?/_ .3?WO\ P'_P$XJ/";A^^]I^\AR6](6^QUVE_P"!
M!1117Q9]B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!](S>(?#OP _9K\,^']?T.3Q%)XT']MW=O%?/
M9^4N8_)S)'^'Y5Z%X=O++XR_&7X6_$S2[7["M\;S2;^&27S)+=X[>Y\OY_X_
M^6GYQU\645]IA^,N2<*7L_<AR?\ DO\ >_\  O\ P(^-Q7"?M/WGM/WE3GOZ
M3_N7T^S_ . GU5^R=\2=.^(WB.'P?XFD_P!.\.ZC)J?AZY/^L(27]Y!^'^/_
M #SJ7XA:[HOP#^&^N1Z]I+ZY-\2->U"YDM$OOL<IM(+@^7F2/MT/!_Y:5\H4
M5<.,YPPOL%3_ 'G\_P#7]WW0J<&TJF+]I[3]WUA_3_F]X^BOV@=8L_C#\$?"
MOQ%\/6K:3<>%Y_[(NX1/]HEMDC)\CY_^6G;_ +^UV'Q#\4Z7I7P?UCXLVLD2
M:YX]T>WTB.-1G[-/DI=_E'&/^_-?(M%8_P"MD^>=3V?OSA_Y/\//_P" FW^J
ME/DIP]I[E.?_ ))\7)_X$?77PI'Q(D_9#\%K\._*^U?:[S[7O,&?*^T2>7_K
MZXSQE\!_BW\9_B/X?L?'GEVT<J2$W)-GFVA3_6/^X[_O(Z^>**53B2G7H0HX
MBG/DAR>YS^Y[G]WE"GP[4P]2=6E4I^_S_8]_W_\ MX^M-4\;^$_VEM)OOA3I
M)^P1^'8X_P#A&+UY<B\DMX_+RW';I[BOG^T^+?C#X<A=&^W?8YM#>2WC2:UM
MY+C37,G[R-))(_,3_MG7%T5RYEQ+7Q?)-^Y/^Y_)]G_P$ZL#PW2PC]F_WE/S
MZ3_^V/J3]G;]GC4_#WP^B^(/]C_\)9XJU("XTJRGN$BCLLY_?R&23YY/QSR.
MG&SSG6M?L? GC36(?BCX*D\2>)KV;[6TPUE[<11R1X\O]Q^[XQ7D-%:5N((/
M#PI4(<CA_AG#_'\/QF5'AZ?UFI5Q%3G53M>#7S4]OS/;_@7J\'@?X6?$SQUI
M]K]CN(T33-(3S/,^S>?)_?\ ^F>8_P#OW6/^S]\+-9\4:3=>)/!NL1Q^,O#\
M_P"XTWRXM\D$D?WTDD_=\^9)[<5Y11#-)#+OCD\N2N>GG%.]#VE/]W3_ /2_
MYS2MD=3][[*IK4\K]/@?<^F/VEO$?A?PYXC\*R>,M L_%'BA]%\O78+6^^Q^
M7/\ N_+=W3^/_68]NG&*;\,_BEIGAKX$_$S6_#'AVQT_3UN=.C@TJ]>34(NJ
MQR??^_\ \]*^::*[*G%U3ZW/$4X?_)_#R_&<JX3IK#TZ%2I^=OCYO@O;R/9/
M#_[2_B3XF_$#PAHMS_96FZ-'KEG.;/3[5+>.5Q<1_P"-=I\1?V0O%7C?X]ZO
MK5XMCI?AN]U$7$NHS7:?Z@#_ )Y[Z^9Z*YZ/$,)4_9X^GS^_S_'_ /:FM?AY
MPJ^URZI[/2WP?\$^Q/%-W)^TUX;^,,/A.&*_:ZU#3;:S_>)&+E(/*\Q_,?C^
M"3K7"Z'X(D_9;^"'C9O%4MFNN>*+>/3+338)HY'V?QN_E]>N<C^M?.M%=F(X
MHI5I_6)T_P!_[_V_<]_F^Q_V\<N'X8K1B\/"HO9ODTM_(H_;O_=['T=^S_\
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M&/\ T _#OY3_ /Q='U/A#_G_ #_\ #ZQQ7_SXA_X%_P3SS_AB[XG?]"G??\
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M#OY3_P#Q='U/A'_G_/\ \ #Z[Q9_SXA_X%_P3SS_ (8N^)W_ $*=]_X$6_\
M\<H_X8N^)W_0IWW_ ($6_P#\<KT/_AYYXQ_Z 7AS\I__ (NC_AYYXQ_Z ?AW
M\I__ (NCZEPC_P _Y_\ @ ?6.*_^?$/_  +_ ()YY_PQ=\3O^A3OO_ BW_\
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MQ._Z%.^_\"+?_P".5Z'_ ,///%W_ $ _#OY3_P#Q='_#SSQ=_P! /P[^4_\
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MG4X3X9_Y_P RO]:,_P#^?,/Z^9X!_P ,5_$[_H4[W_P(M_\ XY1_PQ7\3O\
MH4[W_P "+?\ ^.5)_:W[4G_1S/\ YCK2J]YU;]IWQEJ'PWO-+L[_ $^Q\02Z
M9)9P:[]D\V2VO/+\K[2;?_5_ZS$GE_ZOBG4X3X:_Y_3#_6C/_P#GS#^OF>!?
M\,5_$[_H4[W_ ,"+?_XY1_PQ7\3O^A3O?_ BW_\ CE6;+6_VG(+Z-IOVEOM$
M<+XD3_A7>E1>;7N_Q._:B\:>*_ FJ:;X=O\ 3_">N7=OY=GJR6GV[[!)_P ]
M/+D_=R?2E4X7X9_Y_3#_ %HS_P#Y\P_KYG@'_#%'Q0_Z%.]_\"+?_P".4?\
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M_P# /_M0_M/B?_GQ R?^&)_BA_T*=]_X$6__ ,<I#^Q3\3Q_S*=[_P"!%O\
M_'*Y[XJ?M7?M#^,/'>H:CX<^,5OX2T>ZD_T?2K?P?I]['8?N_P#GI<?O9*[[
MX-_M_?%+X?\ @N+3_%6K:7X^U=9Y'?59],CTV26/M'Y=O^[S[T5,MX/Y/]ZG
M_P" ?_:CIYEQ5_SX@-^&W[(GQ(T?QO9W5UX7N([>+S/,?[1'_P \_P#KI67K
M]G^TIIFO7D%E^SE/J5G%<216]W_PG.G1_:H_^6<GE_\ +.N5'[0O[2'Q(^*-
M\=*^.T?AW3-6N[BXM+%?!&EW4>EQ'S)([822?O'\O C\R2OIKX6_M*^.?!7@
M+2]/\3:II_C#6K6-_MFL-IXL9+X^9C/V>,>7'Q[U]-DV'X7H4[4ISF>!FV)X
MBK5/WE.$##\!_!?XB:[X1L+_ %SP9<>']4N8O-N=-_M&WN?LK_\ //S(_P#6
M5Y#Y7[3W_1L-Q_X<#2JO:YKW[3%SK5Y<6?[1WV&SEG>2WM#X TN7[-&/^69D
M_K7MW@_]J7QMH7P\T_2]5N].UO7+6S^S7.LR6?V:2[N/+S]H^SQ_NX_^N=>G
M37#T/M\YYW_"]/[!@_\ "F_B$? 7V_\ X0V?^W/L'VC^R?[1MO\ CY\K/V;S
M/]7_ *SY/,]*\A\G]I[_ *-CN/\ PO-*H_MO]J0?\W,C_P -WI5>]:Q^U!XV
MO/AO>:9:WEA8^()=,DLX-=^R>;);WGE^6+DV_P#J_P#68D\O_5\>E*G_ *M0
M^.?.*H\^G]CD,/Q)\&/B)H_@Z\OM-\&7&K:Q#;^9;Z;_ &A;VWVJ3_GEYG_+
M/_KI7DFEV'[2U[JEO!=?LVW%E;R2QQ23_P#">Z=+Y4?_ #TIG_"0_M2?]',_
M^8ZTJO>/B;^U;XW\4^!-4T_P_>:?X7URZ@\NSU6.T^V_8)/^>GER?NY/I3IK
MAJ'V^<*CSZ?V.0YSXH?"'XD^$O!5Y>^'O \WB?68_+%MIAU:VL?M?[T"3]Y)
M^[C_ '9>3_@ KSGP?HO[1VN^*-/L]8_9XN-$TNZN(XKR^_X373KG[+'_ ,]/
M+C_UE0>&?&/[26B^*=/O-1_:&BU;3[6XBDN+"3P)I=L+^,2?/'OC_>1^97K7
MQI_:;^(?CGX>W>F^$=<T_P "ZY))&(]:@TR/4I;4>9\^;>X_=GS.V:RI_P"K
M4/W;GSE5/[>G[_(8_P 4OA'\4O"'A*2[\+_#NX\9:IYL<7]F_P!LV^F_)_ST
M\R2N'^'WA_\ :&\1>,K"Q\0?L_W'AK1[F3_2-2_X3'3K[[+^[_YYQ_O)*/AO
M\2OVBO"WCS2]1U_X[1^+-#M;CS+S27\$:?8_;X_^>?F1_O(Z]&^._P"TQ\2_
MB#X*33O!?B?3_A[K!N(Y/[5@TB/4I!&>L?E7'[O\?^F=.G_JU"'L^<K_ (7I
M^_R&+\9?A?\ %WP5HUM<>$?AA<>-KR:X\JXM/[=MM-\J/_GIYDE<_P#"SP?\
M?/%_BR.Q\3? V?PEI?E22R7_ /PEME??/_SS\N.H/A#\4_C[X,^(FGZIXK^-
M4?CCP]:F4W&BR^#-/TV*_)CEC3_2+?\ >1^7(4D_[9UV7[07[1WQ9^)NBZ?;
M^!_&EG\,[RUG>2XNX=$M]7^WQC_EGY=Q_J_K2_XQJ%/V?/\ ]O\ O!_PO3G[
M3D,WXS?#3XR>";6P?P=\*;CQM)=22&XC_P"$@LM-^R_]_/\ 65E?!_P3\=/&
MWBFXM/%WP5G\$Z?#;^;'?_\ "4V6I>;)YD7[ORX_J_\ W[IWP*^-/QT^'?C6
M2^\:?%JW^(.CK;R1C2IO"=GIF)/^>GF6_P"\_#I^\K4_:(_:,^,'Q-.C_P#"
M!^/[/X9_81.+SR-!@U?^U-_E^7_Q\?ZOR_+D_P!7U\RL_P#C&O9^SY_^W_>#
M_A>Y_:<A1^,OP\^-W@O5+./PA\&Y_&]O-%YUQ/\ \)+9:;]E?_GGY<G^LI?@
MU\.?C9XTNM0C\7?"&X\$QVT<8MY/^$DLM2^U?\]/]7_JZ;\ ?CY\;OAOXCO+
MKQO\3;?XCZ?=0>7;6$_ABSTD6DF_'F;[?]Y)]*3]H/\ :!^-WQ'\165UX'^)
MMO\ #C3X8-EQ80>&+/5A=2;\>9ON/WD?';I1_P 8U[/V7/\ ]O\ O#OGW/[3
MD*OQA\!_'3P;XDM[/PG\%9_&MA+;^;)??\)39:;Y4GF2_N_+D^B?]_*TO@S\
M+?C)XVM-0D\7?"FX\$R6LD?V=/\ A(++4OM7_/3_ %?^KJ3]GS]I+XO_  R.
ML?\ "=^/K/XF?;A +(3Z#!I TKR_,\S_ (]_]9YGF1_ZSIY=8_QU^/?QT\?^
M-8[WP7\5[?X>Z.UO'&=*B\)V>IYD_P">GF7'[SUXZ?NZC_C%O9^SY_\ M_WC
M3_C(>?VG(5OB;X,_: \+>,[BQ\-_ FX\5:/%''Y>I?\ "6Z=9>;_ -LY*Z/X
M0_"#XN>+?#EQ=>+/AK-X,U"*Y\J.P.LVVI>;'Y<0\SS(_J__ '[J?]G[]J'X
ML_#/1=0M_''C&S^)=Y=3H]M>3:);Z1]DC/\ RS\NW_UA]ZXWXN?&S]H#QE\1
M-0U3PG\8[;P3H-T8C;Z+!X0T^^BL"(XHW_TBX_>2>9+OD]O,%*I_JM.G[+G_
M .W_ 'A?\9#"?M.0K^-O"7[1>@^+=0M='_9_N-?TNUE\JVOO^$QTZV^U1_\
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M#6;PMJ'F^5]D_MFVOOW?_/3S(Y*X[Q)\#_VC--UZ\M=-^!%WJ6GPR^5;W?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLMZ^[4+CRY+?O'L]?;[E&B_"7X@V>G:3')XCA$UC([7+_:YY3>^F=]<W+/\
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MF!<-T?9^PJ5)^S_D]S_%_)>Q[UX4_:KF^*'A#Q3X;^(^K1M8ZE8[M.NTL/\
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MODU;\2?&2'PMHD=OX5O$DNKV_GO;U_LO_/20[(_WB?Y\NO+JCJJ?$&+A0]A
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M:/P3X3\56.O:_<W%OH?A/4=5LM-TC3_[)CDU&XBCN/[0DN/])_>[Y/+CLO\
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MS_\ /3P[_P"!T_\ \77Q/11_KU3_ .@&C_X '^I=7_H+J?\ @9]L?V%^S/\
M\]/#O_@=/_\ %T?V%^S/_P ]/#O_ ('3_P#Q=?$]%'^O5/\ Z :/_@ ?ZEU?
M^@NI_P"!GVQ_87[,_P#ST\._^!T__P 71_87[,__ #T\._\ @=/_ /%U\3T4
M?Z]4_P#H!H_^ !_J75_Z"ZG_ (&?;']A?LS_ //3P[_X'3__ !=']A?LS_\
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MA?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@
M?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$
M]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,_
M_/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_
M .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&
M?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :
M/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\
MQ=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_8
M7[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/
M3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@N
MI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_
M * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'
M3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\
M71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS
M_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU
M?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^
MO5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T_P#\71_87[,__/3P
M[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']A?LS_P#/3P[_ .!T
M_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@ ?ZEU?^@NI_X&?;']
MA?LS_P#/3P[_ .!T_P#\71_87[,__/3P[_X'3_\ Q=?$]%'^O5/_ * :/_@
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M(+<QQ?N/(MW,;XDCDD\SN9/S^4**/^(@U/\ H$HA_J+#_H+F>T?%CX(/XO\
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M$_P_I<'P]^+VA_"Z\M[EY+N[_L1=;-['WB\NXD C_P#KU\ST4?Z_?]0-'_P
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M3M3NKPR07XTA=$:VM_+ \ORX)").I/F?[=<#\</V:M$\<_$[5=5\&?M(>'_
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M"?\ $Q=0^VOA9J?PE\(_#W1M/\4^.-!\8:]:VPCO-8-N+'[=)WD-O'^[C_\
MK5\Y_P##/WBC_H]/0O\ PVFF_P#QVO,:*/\ B(4_^@6!'^HD/^@N9]M?VK\(
M_P#A5?\ 8_\ PFV@_P#"4?V/]C_MS[./^/OR_+^V?9\^7GS/WGE]/YU\Y?\
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M\0UU#QU^TGH/Q&\/FW>)]''@VUT@R2'[DOVBWD,F1^M>"T4?\1"J?] M'_P
M/]18?]!<SZB_:7\%>#/BA9:/%\./C1H/PMFL'>6_F_L&+6S?I^[V9%PX\OR_
MG_[^GIWP_P!F_P"%VB_#3QO=7WQ$_:&T'XG:+-ITEO#I/_"*VVB&SN-\?^D"
M2W<R?ZN-X_+/_/3\*^>:*/\ B(4_^@6C_P" !_J+#;ZW,^COVE_AQX9^)^NZ
M7+\._CSH7PML[:"2.\MO^$8AUK[<^?\ 6&2XD'EXJ3]FCX=>$_A;>ZPWQ'^.
MF@_%2WOTB&GK_P ([%H?V!_WGFX^SR'S/,_=]?\ GE7S;11_Q$*?_0+1_P#
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M/_7[%_R0*_U,H?\ /P^PO^%^>$?^@[9?]]4?\+\\(_\ 0=LO^^J^.:CGK/\
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M-,_[^5\%U'1_Q$K'_P D!_Z@8/\ GF??'_#37@+_ *&G3/\ OY2?\--^ O\
MH:-,_P"_E? E1ST?\1-QW\D/O8?\0_PG\\S] /\ AIKP#_T-&E?]_!3?^&G_
M  #_ -#3I?\ W\%? ,]1SUG_ ,1.QW\D/Q+_ .(>8/\ Y^3/T"_X:?\  /\
MT-.E_P#?P4W_ (:@^'__ $-.E_\ ?ROS[HH_XB=COY(#_P"(>83^>9^@7_#4
MOP__ .AITG_OX*/^&I?A_P#]#3I/_?T5^?-1UG_Q%3'_ ,D/_)@_XAYA/^?D
MS]"O^&I?A_\ ]#1I/_?P4?\ #4WP^_Z&K2?^_M?GK4='_$5,?_S[A_Y,7_Q#
MO"?\_)_@?H=_PU-\/_\ H;-)_P"_@H_X:I^'W_0V:3_W\%?G;1/6?_$5<?\
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M+_F3T445]H?.!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!0>1110!\8?\%UO!>H>,/^"?VN/IRR2II&H6=[>(G4P"3!_]#%?-W_!%?3O
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MX3>-?AGK.K7GV76M:UE?*T5H1'<6\(R"[^XQ&#_UTKIOB+XG\81_$#Q MO\
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MJX?*O:0?/4;LM83U?^$X#XS?!#_A6'Q8L]!2\^U:;JB6\]C>%,_:().K\?\
M;2M3]J3]F>Z_9Y\0VFR:34-&U)/W-RZ^7B3^..3ZCFO3O%-MH/QJ^ _AC4_"
M\FK7$GPVU2WT^?\ M"-/M1LY)(L_ZOK_ ,L^?^F<E;?C7QO8_$/X\>-OA=XD
MD5=-UZ>%]*NG_P"8;??9X]F/^NG)Q_\ '*]Z?#^7<L^TW#D_\!E[O_@7N_\
M@)X=/B+&\U.V\%/G5M7M[]O\+YCQ?QE^S5+I/[1UA\/]/NIKLWTD'[V2/F*-
MXS)))_VS_K1\;/V?;/X,_%31=+GU::?PWJY@N$OU09">9Y<G(_YY\'\:^CO%
M$>G_  ^^.?CWXDZXUS'I^@V%II5I);+YDAGG2,/Y>_\ Y:)^[/TD_"O,?%]O
MX:^-O[)=Q:^%[C6+R^^&\WVQ?[31/M)MY/,\P?)UCZ_]^JUQ7#>#ITZT(_Q/
M>G#_  0_^2][_P !%@^(L74J4)R;]G:,)NVG//K_ -N^Z>0?&OX,77PF^+UU
MX7@:74-SQ_9&,?\ Q\))_JQ7JFL?LA>$?"*>(IM:\5:A'!X4CL8[]X;;S/+G
MG_@_',7YUV?POM]+^+7@_P #?$K5I(0WPWL[B#6O,_ULOV=-\'Y9$GXUS_P)
M\;:MXQ^#?Q6UR/P_:^*-6U;4[2Y_LNYM_M<=SYDG_//_ *9_^TJSPF28"%?G
M</CYYP_P<G-_Z5[O_;H\9G&83IZ3M[/DA/;6?/;K_=7-_P!O'EOBWPO\,M-L
M;>31_%FO:C/Y\?VF-]-\O]Q_RTDZ5T.K?L8ZA>?%+1=+T&\.J>&?$$']H0:W
ML_=QP?Q[_P#KG_[5CJI\5XO%_C;P_9Z?-\)=.\*K]KC\NZT_P_)9S2R2?NXX
M_,_[:5[=X1.B_#OP79_ _5=<O(M?U[3Y?.NX),QZ;-)CRX ?\_\ D2N;!Y3@
M\57J0KPY(>Y_-#W_ .3WOYCHQ>:8VAAZ=2A/]Y>=_@G[G\_N?RG!_#K]FSP;
MK5U,EG<2>)([F7-E<7)\NW$45Q' <1QS0 _O'D'^L_U<<?[N3?SBW?[.'A6Z
MT6;QA=ZU=>'_  :5(18X7N+AI_/DMY$3OY?[O?P/^6G;RZX^'QWXD_9_N]3\
M&ZC:V=Y'9W8E>WN=_EQO_K?,CD22.3_EG')_W[KK_A9\,]4_:H\0ZEXT\4M>
M7&B:./+:VT^&226Z_P"6GV>!(^?^6G_D3_MI6F'^I8EPP<,+^^_D_P#D_P"[
M'^O/&J\;04\;/$_N]->_HMM?0XCX[_!:W^$L^C7FE:Q_;6A>)+3[78W7V?RY
M < _O$_&H?A;X*\#>(](D?Q3XPO=!OO/\N.&#3)+WS4[2>97=?%3Q3IOB_XC
MP#XB>'?&7A'PO86'V+P_96-I';RQI'Y8_P"6_N/_ $75?]GGPMX3UW]I9;K1
MUU2;POX;M6U8C43&+C,$>#YGE_N_]9S^%>8\MP\<RYJ')R3GR<D^;_P/E^+E
M^(]:.:8AY?;$<_M(0Y^>'+;R7-\/DS1\7?L?:#X<\?:?HY\:K';QZ6^L:M)<
MVA22QAC\OR_DW_?D_>?)_P!,JXSXQ_!+2?"'@?2/%?AGQ!)K_AW6)WL]\\'V
M>YM9X_\ ]51Z+X:US]J;XE^)-6L_L<FK%7U<6<K9DN(X_P#EW3^^/]7'7L'Q
M0O+7Q=^SQX5O_B/H=]X173=8DM8['2X?L<LT,B8WI!)_J_WF.OI_MUVRP&#Q
MM"O*A1]G#[$_>_FC]K[/_P!L<']I8W!XC#PJU_:7^.'NW^T>-?L[?"2R^,_C
M"^L=4U"XT^TTW39]0DG@3S)/W?E?_'*[+PG^SAX%^+/VO3_!WC;4+CQ#:P/<
M06NHZ;Y<=R8_^FF*Z7]FFZ\#Z7\4=9F\'Q>(KR&'PO?2W<&M-;_O/WL7[O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG[R<X^3[]4!JW@KXC:/X/OM6\2R:#=>&[&.PO+5[&2X^TI&X>/9)'_OUN_\
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MDN(O_(E>X-_P3,^("_\ ,3\)_A>3_P#QBA?^"9GQ ;_F)>$Q];R?_P",5O\
MZL\1^S]G[&?W_P#VQBN(^'K\ZE"_I_\ :'@-WXAU"[TB#3YKR\DL;&222"UD
MN)/+MO,_UGEQTZ+Q7J=KX?GTF'4]0CTFXD\R>R2>3[/))_TTC_[9U[[_ ,.R
M_B!_T$_"?_@9/_\ &*3_ (=F?$#_ *"7A/\ \#)__C%9+A//_P#GS/\ K_MX
MV_UHR)JWMH?=_P#:'B]K\7_%6G:,--A\2:Y;Z<O[H6R7\GEC\:R+3Q!J&GZ=
M=6=K>7EO:ZEY?VN%)Y(X[GR_]7YG_/2O?_\ AV9\0/\ H)>$_P#P,G_^,4O_
M  [,^('_ $%/"?\ X&3_ /QBM*O"O$<]Z,_O_P#MC./$?#\-JL/N_P#M#P?_
M (3G6C+ILG]KZMYFD?\ 'A_I<G^@_P"Y_P \ZNZ5\7/%FBQ7$=GXF\06<=U/
M)/)Y.I7$?FO)_K)/]9_K*]K_ .'9?Q _Z"?A/_P,G_\ C%)_P[-^( _YB7A3
M_P #)_\ XQ12X9XCI_PZ,_O_ /MA2XDX>J?%*'W?_:'A_B;XC^(_&%K'#JVN
M:QJEO')YB)>W\EQ%%)_VTK%KZ+'_  3,^(!_YB?A,?6\G_\ C%(W_!,SX@+_
M ,Q+PF?I>3__ !BLZO!^?57[2K1G_7_;QK1XJR.BO9TJT$O3_P"T/G6BOHK_
M (=G?$#_ *"7A7_P,G_^,4?\.SOB!_T$O"O_ (&3_P#QBL?]2\Z_Z!IFO^N.
M4?\ /^'W/_(^=:*^BO\ AV=\0/\ H)>%?_ R?_XQ1_P[.^('_02\*_\ @9/_
M /&*/]2\Z_Z!IC_UQRC_ )_P^Y_Y'SK17T5_P[.^('_02\*_^!D__P 8H_X=
MG?$#_H)>%?\ P,G_ /C%'^I>=?\ 0-,/]<<H_P"?\/N?^1\ZT5]%?\.SOB!_
MT$O"O_@9/_\ &*/^'9WQ _Z"7A7_ ,#)_P#XQ1_J7G7_ $#3#_7'*/\ G_#[
MG_D?.M%?17_#L[X@?]!+PK_X&3__ !BC_AV=\0/^@EX5_P# R?\ ^,4?ZEYU
M_P! TP_UQRC_ )_P^Y_Y'SK17T5_P[.^('_02\*_^!D__P 8H_X=G?$#_H)>
M%?\ P,G_ /C%'^I>=?\ 0-,/]<<H_P"?\/N?^1\ZT5]%?\.SOB!_T$O"O_@9
M/_\ &*/^'9WQ _Z"7A7_ ,#)_P#XQ1_J7G7_ $#3#_7'*/\ G_#[G_D?.M%?
M17_#L[X@?]!+PK_X&3__ !BC_AV=\0/^@EX5_P# R?\ ^,4?ZEYU_P! TP_U
MQRC_ )_P^Y_Y'SK17T5_P[.^('_02\*_^!D__P 8H_X=G?$#_H)>%?\ P,G_
M /C%'^I>=?\ 0-,/]<<H_P"?\/N?^1\ZT5]%?\.SOB!_T$O"O_@9/_\ &*/^
M'9WQ _Z"7A7_ ,#)_P#XQ1_J7G7_ $#3#_7'*/\ G_#[G_D?.M%?17_#L[X@
M?]!+PK_X&3__ !BC_AV=\0/^@EX5_P# R?\ ^,4?ZEYU_P! TP_UQRC_ )_P
M^Y_Y'SK17T5_P[.^('_02\*_^!D__P 8H_X=G?$#_H)>%?\ P,G_ /C%'^I>
M=?\ 0-,/]<<H_P"?\/N?^1\ZT5]%?\.SOB!_T$O"O_@9/_\ &*/^'9WQ _Z"
M7A7_ ,#)_P#XQ1_J7G7_ $#3#_7'*/\ G_#[G_D?.M%?17_#L[X@?]!+PK_X
M&3__ !BC_AV=\0/^@EX5_P# R?\ ^,4?ZEYU_P! TP_UQRC_ )_P^Y_Y'SK1
M7T5_P[.^('_02\*_^!D__P 8H_X=G?$#_H)>%?\ P,G_ /C%'^I>=?\ 0-,/
M]<<H_P"?\/N?^1\ZT5]%?\.SOB!_T$O"O_@9/_\ &*/^'9WQ _Z"7A7_ ,#)
M_P#XQ1_J7G7_ $#3#_7'*/\ G_#[G_D?.M%?17_#L[X@?]!+PK_X&3__ !BC
M_AV=\0/^@EX5_P# R?\ ^,4?ZEYU_P! TP_UQRC_ )_P^Y_Y'SK17T5_P[.^
M('_02\*_^!D__P 8H_X=G?$#_H)>%?\ P,G_ /C%'^I>=?\ 0-,/]<<H_P"?
M\/N?^1\ZT5]%?\.SOB!_T$O"O_@9/_\ &*/^'9WQ _Z"7A7_ ,#)_P#XQ1_J
M7G7_ $#3#_7'*/\ G_#[G_D?.M%?17_#L[X@?]!+PK_X&3__ !BC_AV=\0/^
M@EX5_P# R?\ ^,4?ZEYU_P! TP_UQRC_ )_P^Y_Y'SK17T5_P[.^('_02\*_
M^!D__P 8H_X=G?$#_H)>%?\ P,G_ /C%'^I>=?\ 0-,/]<<H_P"?\/N?^1\Z
MT5]%?\.SOB!_T$O"O_@9/_\ &*/^'9WQ _Z"7A7_ ,#)_P#XQ1_J7G7_ $#3
M#_7'*/\ G_#[G_D?.M%?17_#L[X@?]!+PK_X&3__ !BC_AV=\0/^@EX5_P#
MR?\ ^,4?ZEYU_P! TQ?ZXY/_ ,_X?<_\CQ;1?BOXI\-:;'9Z;XF\0Z?:P\1P
MVNI/''%_VSCDI\WQI\:37.^3Q;XEDD".F^34KC[C_?C_ -9_TSKV;_AV9\0/
M^@EX3_\  R?_ .,4?\.S/B!_T$O"?_@9/_\ &*[O]7.)[>RY)V_K^\<']O\
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ML:1%<'+QV5T]OYA_[9U[O_P[+^('_03\)_\ @9/_ /&*3_AV9\0/^@IX3_\
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MDSR1^8DG^LCD_P"F=?0'_#LSX@8_Y"7A/_P,G_\ C%'_  [,^('_ $$O"?\
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MA_KCE'_/^'W/_(^=:*^BO^'9WQ _Z"7A7_P,G_\ C%'_  [.^('_ $$O"O\
MX&3_ /QBC_4O.O\ H&F'^N.4?\_X?<_\CYUHKZ*_X=G?$#_H)>%?_ R?_P",
M4?\ #L[X@?\ 02\*_P#@9/\ _&*/]2\Z_P"@:8?ZXY1_S_A]S_R/G6BOHK_A
MV=\0/^@EX5_\#)__ (Q1_P .SOB!_P!!+PK_ .!D_P#\8H_U+SK_ *!IA_KC
ME'_/^'W/_(^=:*^BO^'9WQ _Z"7A7_P,G_\ C%'_  [.^('_ $$O"O\ X&3_
M /QBC_4O.O\ H&F'^N.4?\_X?<_\CYUHKZ*_X=G?$#_H)>%?_ R?_P",4?\
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M.O\ H&F'^N.4?\_X?<_\CYUHKZ*_X=G?$#_H)>%?_ R?_P",4?\ #L[X@?\
M02\*_P#@9/\ _&*/]2\Z_P"@:8?ZXY1_S_A]S_R/G6BOHK_AV=\0/^@EX5_\
M#)__ (Q1_P .SOB!_P!!+PK_ .!D_P#\8H_U+SK_ *!IA_KCE'_/^'W/_(^=
M:*^BO^'9WQ _Z"7A7_P,G_\ C%'_  [.^('_ $$O"O\ X&3_ /QBC_4O.O\
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M\*\US_H!ZM_X!R5G]0Q/\L__  "7_P B7]<H_P \#&J.MS_A7FO_ /0#U?\
M\ Y*C_X5YK__ $ ]7_\  .2CZAB?Y9_^ 2_^1-/KE'^>!AT5L?\ "O-?_P"@
M'J__ (!R43?#WQ!_T ]7_P# .2L_[/Q/\L__  "7_P B/ZW1_GA_X&8=1_\
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M3=7%L^W?L=(W=.*^$X_VY/BI"/E\4,/^X;:?_$5]R_M$#_BP?C9?[N@WN/\
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MC\R3RX_,J.[TV?3/+\^"2V\V/S(_,C\OS8Z?^L><6O[>?_@<Q_V'E.WL*?\
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M?^"VT_\ C='_  W5\5O^AJ;_ ,%MI_\ $5Y#11_K+F__ #_G_P"!A_J[E?\
MSXI_^ 'KW_#=OQ6_Z&IO_!;:?_&Z/^&[?BM_T-3?^"VT_P#C=>0T4?ZRYO\
M\_Y_^!A_J[E?_/BG_P" 'KW_  W;\5O^AJ;_ ,%MI_\ &Z/^&ZOBM_T-3?\
M@MM/_B*\AHH_UES?_G_/_P ##_5W*_\ GQ3_ / #U[_ANWXK?]#4W_@MM/\
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MY[2YCCF_U<DD?^MH_M[.?^?U3_P.8?V+E7_/BG_X! ]5_P"&[/BM_P!#4_\
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M_!;:?_&Z/^&[?BM_T-3?^"VT_P#C=>0T4?ZRYO\ \_Y_^!A_J[E?_/BG_P"
M'KW_  W;\5O^AJ;_ ,%MI_\ &Z/^&ZOBM_T-3?\ @MM/_B*\AHH_UES?_G_/
M_P ##_5W*_\ GQ3_ / #U[_ANWXK?]#4W_@MM/\ XW1_PW;\5O\ H:F_\%MI
M_P#&Z\AHH_UES?\ Y_S_ / P_P!7<K_Y\4__   ]>_X;M^*W_0U-_P""VT_^
M-T?\-U?%;_H:F_\ !;:?_$5Y#11_K+F__/\ G_X&'^KN5_\ /BG_ . 'KW_#
M=OQ6_P"AJ;_P6VG_ ,;H_P"&[?BM_P!#4W_@MM/_ (W7D-%'^LN;_P#/^?\
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MO^&[?BM_T-3?^"VT_P#C='_#=OQ6_P"AJ;_P6VG_ ,;KR&BC_67-_P#G_/\
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MZ&IO_!;:?_$5Y#11_K+F_P#S_G_X&'^KN5_\^*?_ ( >O?\ #=OQ6_Z&IO\
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M;_H:F_\ !;:?_&Z/^&[?BM_T-3?^"VT_^-UY#11_K+F__/\ G_X&'^KN5_\
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M_<K]]\,6_P"PZG^-_E$_$_$K_D;0_P "_-DU%%%?JI^>A1110 4444 %%%%
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MNE^*O[0WC+1OV;_AMJMOK]S!J6KF_P#MDR11F2Y\N8"/@\=/2O(/B/-\,O[
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M^*[%+/685E$EM=2?ZO[<G' Z#UX'<9KBIOBQ\.OBGX6T)/&^E>)+36=$M8[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB3X?O<VNJ-IOAW2K'2]23RX_,E"'Y]G[RO+J9C2I0Q5#"U^2%3DY/^WY>_\
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M)IMW_?3S'C^OX?\ 32J'[._Q>T[X(:UK&L3V]Y-K<FG/;Z5LBC\NVFD_C?\
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M_B1:ZEXBUG7->T?$D=]9R77F&1).A\N23R^*TJYEDM#]RI\\*W)#TA"'V_\
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M3VOVN23Y(_\ IG))1X._:"N/ G[06H^,-/6Y6PU74KA[BV8?\?-I))YFQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7G]FWOV/^U[>3SOL\GE??C_Y:4WXS:9ILNL^)GA\/>,X[S[3/(;MYL6)._\
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M>1_9YW>[DDDN8_\ GG)3J<58;^3^OZ^R33X:Q-U^\73]/ZN>O?&'1_%>I_M
MV5YX;AOY--D^R'0[BU_X]8H/+CSL_P"6?EUWWQ8\4^&M1L=-\,7*P1Z!XIO-
M3C2Y3&;*[CN(_+G_ -SS7D_&05\QV'Q US2M*:QMM9U2WLGZ6T%W)'&/^ 5F
M2ZM=7EE;VLUU<26ECYGV>!Y/W<7F?ZSRZYEQ52I^V<(?'_7]?]N_RFW^J]6I
MR*=3^'IH?4>M>%X?AKXKU'7-5U.#1?[)\.VVB6-\8I)(H[R2 YD0)S^[1/\
MR)7G_P 8M/M[KXV>&/%&CW4<^D^++FWG\Z!'CCEG23RYS_\ K_YZ&O*-7\9Z
MUXCLOLNHZQJU[!%)YFR>[DDC\SR_+_\ 1=4QXAU 64%M_:%YY%C)]H@@\^3R
M[63_ )Z1UGC.),/6A[.G#W/C_P"W_P#]GW3; \.XFA4]K.I[_P 'RM_F>^:
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MXZM1J8C%0H_X^I]]P5FV(P=.I'#T)5+]CX;HK[F_X;2^"_\ T#3_ ."A:/\
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M_P!3<L_Z&, _UJS#_H!G_7R/AFBON;_AM+X+_P#0-/\ X*%H_P"&TO@O_P!
MT_\ @H6G_J;EG_0Q@'^M68?] ,_Z^1\,T5]S?\-I?!?_ *!I_P#!0M'_  VE
M\%_^@:?_  4+1_J;EG_0Q@'^M68?] ,_Z^1\,T5]S?\ #:7P7_Z!I_\ !0M'
M_#:7P7_Z!I_\%"T?ZFY9_P!#& ?ZU9A_T S_ *^1\,T5]S?\-I?!?_H&G_P4
M+1_PVE\%_P#H&G_P4+1_J;EG_0Q@'^M68?\ 0#/^OD?#-%?<W_#:7P7_ .@:
M?_!0M'_#:7P7_P"@:?\ P4+1_J;EG_0Q@'^M68?] ,_Z^1\,T5]S?\-I?!?_
M *!I_P#!0M'_  VE\%_^@:?_  4+1_J;EG_0Q@'^M68?] ,_Z^1\,T5]S?\
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M  VE\%_^@:?_  4+1_J;EG_0Q@'^M68?] ,_Z^1\,T5]S?\ #:7P7_Z!I_\
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M_P# 6/\ PH_XA+5_Z"/_ "0/^(H0_P"?'_DW_ /RAHK]7O\ A7NA?] /2?\
MP%C_ ,*/^%>Z%_T ])_\!8_\*/\ B$M7_H(_\D#_ (BA#_GQ_P"3?\ _*&BO
MU>_X5[H7_0#TG_P%C_PH_P"%>Z%_T ])_P# 6/\ PH_XA+5_Z"/_ "0/^(H0
M_P"?'_DW_ /RAHK]7O\ A7NA?] /2?\ P%C_ ,*/^%>Z%_T ])_\!8_\*/\
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M_P"%>Z%_T ])_P# 6/\ PH_XA+5_Z"/_ "0/^(H0_P"?'_DW_ /RAHK]7O\
MA7NA?] /2?\ P%C_ ,*/^%>Z%_T ])_\!8_\*/\ B$M7_H(_\D#_ (BA#_GQ
M_P"3?\ _*&BOU>_X5[H7_0#TG_P%C_PH_P"%>Z%_T ])_P# 6/\ PH_XA+5_
MZ"/_ "0/^(H0_P"?'_DW_ /RAHK]7O\ A7NA?] /2?\ P%C_ ,*/^%>Z%_T
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M*^[O^$.TG_H&6/\ X#I_A1_PAVD_] RQ_P# =/\ "L_^(>S_ .?X_P#79?\
M/L^#:CK[V_X0[2?^@;8_^ Z?X4?\(;I/_0-L?_ =/\*/^(<3_P"?Y?\ KTO^
M?9\"U'7W]_PAVD_] O3_ /OPG^%'_"':3_T"]/\ ^_"?X5/_ !#>?_/\?^O4
M/^?!\ U'7Z!?\(AI/_0+L/\ P'3_  H_X1#1_P#H%Z?_ -^$_P *7_$-Y_\
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M.G^%'_"$:/\ ] ?3?_ =/\*/^(8S_P"@C_R0T_XB%'_GP?F[17Z1?\(1H_\
MT!]-_P# =/\ "C_A"-'_ .@/IO\ X#I_A6?_ !#"?_/_ /\ ) _XB''_ )\'
MYLSU'/7Z5?\ "$:/_P! ?3?_  '3_"C_ (0?1O\ H#Z;_P" Z?X4?\0PG_S_
M /\ R0/^(B1_Y\?B?FC17Z6?\(%HG_0'TO\ \!4_PH_X0+1/^@/I?_@*G^%'
M_$+9?\__ /R0/^(AQ_Y\'YGU'7Z:?\(#HO\ T!M+_P# 9/\ "C_A =%_Z VE
M_P#@,G^%9_\ $+)_\_\ _P D-/\ B)$?^?'XGYEU'7Z<?\(%HO\ T!M+_P#
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M_@S96>DZ3')]G@UZ^M/M%]?=/WD5O)^[C''_ "TCD]_+KZP_X+J>-]0\%_\
M!/\ UV/39)(O[8U"STZ[9.H@DDR?_0!7Y_?\$]/^"8&D_M,?#JS\1>(+K5O+
MU[[1;P6MOY=O<P^7_P OMG)YDD=YY<G^LMY?+D\L>9'YG[OS/:R[#4/9.O7.
MRE3A[/GJ&D/^"O?[2GP&U*SU3Q!XFT7Q9I]]TL=1T>.+'X6\<<B?C)7Z9?\
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M&] T/5KEX+S3=:@C=)X1CRI/+\S8_M7+_8V-]A[?V?N&_P#:V!]O]7]I[_\
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MDGC.!R36.'R/&5X>TA#W#3%9U@L/4]G4J>__ )GD-%=K\3_A3IG@&QM)M/\
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ME_IOB?7+34/$OAW3].\."W-]J<\CBW+R?<3!_P"6@R/S%:4^'\?4I^UIP_\
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MN*#/R?/<?/GUS6YX$^./@SXK7-Q!X4\8>%_$UQ9X^T1Z5JD%X\/^^(W./QH
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MW')<VR<?O'CSO ^=.OJ* -ZBBOCW]J?]JKXV:#^W5X;^#?PEM?A>\FL^%/\
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MK<?ZLZMJ<%D)/IYCC-22?$SPW_PA\?B'^WM%;090ACU+[?']BEWG8/WF=AH
MZ;%&*Y+2OC-X.UOQC<>'-/\ %GAR]\16HQ<:5!JD$E]#_OQ!_,'Y5UM !BC%
M? /P(_:U_:U_:LC\9:IX!TG]GV'P_P"%_$U_X=6/65U2&_EDMS&<_NI)(^8Y
M$KUC]D?]N+Q-\1OC%XC^%/Q6\*VG@?XH>&;*/5!%:7GVC3=<LSC%S;R=!CO&
M7)Q])!& ?4U%<-:?M >!=2O([2W\:>%;B[N;=[N*"/5H))'MX\[Y0-_,?R/^
M\Z#\*W?^$YT/_A$?[>_MG2_[$\KS_P"T_M<?V7R_^>GF?<_'- &Y17-^(OB1
MX;\+^%AK6J^(-&TO19(]ZZC=7L<-KL]?,<[/UJ/PS\4/#?C.[BM]'\0:+K%Q
M<6GVR-+.^CG>2#?Y?FCRR?W>_C>.,T =11BL'Q]X^TOX6^ M8\2:W=+8Z3H-
MI+J%Y,__ "RBC3S'/Y"OCCQK^W_\4/ ?['GPX^)]UH_AJUO/BKX[LK&PTV[M
M99?[+T.\\W[/OV21^9<^6B2>;_J_WG^KX% 'W+BC%<O\6?$MQX#^%7B;6[-8
M9+K1]+N[Z&.8_NW>.)Y &]CBO/OV!?COK7[5'[(?@OQ]X@M].L]7\16TLES!
M81R16T12XDB^3?)(_P#RSSRYZT >TXHQ7RS^UW^UWX\\,_M&^%?@Q\(M!\+Z
MGX^\2Z7)KL]]XEN9(M-TJSCDDC\PQQ?O)'\R-^$]*P?A_P#M7?&[X,?M,>$/
MAO\ '#P_X+N[3X@).FB>)O"'VC[+%<1=8KB.?D9!CY!ZR \\A #[$HQ17Q'\
M<_\ @H/XX\ _"_\ :7\;>'[+PWJ&C?"#5]+\.: +VRE?[5>^9;1ZC]HV2H9/
M+DG_ '?EF.@#[<HKXQ\+>,/VX_%GAK3=6M=/_9?BMM3MXKN,/_;._9)'O_YZ
M>];?QM_:K^*G[-NF_L^Z9XFT[P%=>*_B/XSMO#'B<Z:EW)8P022?ZVSWR>9Y
MGE^7_K?,YS0!]9T5YW^U+\3=0^#'[-/C[QAI,-G-JGAGP]J&KV<=U&\EO));
MV\DJ>9Y?.P[.?\:\!UO]N;Q;X(_9E^!_QBUJWT,>$/%D=DGCI;>V>(Z3]MC0
M17EN[R?NXHKCB1)/,.),9R,T ?86*,4GWQ2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Y7^U_P#LTZ?^UE^SUXD\":C(
M;<:S !;W03_CVN$.^.7'LX!K\L?V7/CW=?\ !(3Q]<>"OBOX6^(&CR?VA)<W
M%QHMS;WNF>(X_P#EG)]GGC\O_MI;21R?\]/^>=?M /F-<_X^^&WA_P"*>A_V
M;XDT/1_$.G,V_P"S:E9QW4)<=]D@(KJP^,Y(>SG\!I3J'E/[(_\ P4&^&7[:
M9U"'P/K-U>:CH\,<]Y8W=G);7$*/T?IL<'U0FO%?V'_^"4T'[+/[9/Q"^(UY
M?6]Y8WEQ.GA6",9>PMK@B23S/^FB?ZL'TR?XZ^I/AU^SA\/?@[JDUYX1\"^#
M_"]]<1^7)/I.BV]C)(G]PO&@)'M7=L >/>LOK'+S*CU#VEO@/EC6YM5O/C7K
M5B[V5KX;OO'5O(\WER2745Q'IUM)'_TS\N3RZXWX>:GKGBWX/ZA-KVH:LR>(
M?A[=:M.#XAO+J:\G0J_VCRQ^[MQ_ 8XY.!\G05<N?C7X?T_X[_%27Q=\4[?P
MW#X*U[^TK?PG#8:0)-2MX-.MKDW.);=[F20?O(]\<@_U6.*ZWP/^TA\/=$\5
M0:%<?"^^\&Z_XUO[/3[BQGTS3A+?1W=O<2QSSR6\LD<D9%O*-A;S!_SSQFO&
MJ9'7Y[G/]7J&O^R7X.L="\;^-'ADU*119:1'_I&IW%SP^GQN?]8Y]:Y>PNAI
MWPON='\,:A_:%OI_AU]=\':W DEO>1V=O<12?8IR<2?P11_]-8P?,YJU=?M[
M^#_ FNZO'I/P_P#%-XUCI]SJFM7>F6NGP_9;/3[V73Y)9?,N(WD\O[.?+CC$
MC^7CCI6%\1/COI&@_$S2=+^''@^;PW8ZIXP30O$OBJTTK3TM;\_V=<7,EOL\
MS[3))_JY/,\K'[O_ %E:_P!CU^3V8?5YF[X>UB\^-=UX'O[S5O$=OH_C;5-6
MU".WM=4N;'%M'!_H\>8Y(SY?[OS/^VE<+XFUV]^)'P%O;[7M:URXN-)\*Z'<
M01C4Y(XI9)+@QR22QQR>7/))Y?\ RU\RN@C_ &P=+^''P%NX]*^'/B8:_P##
M_P (6^O:);ZS;V44NHZ?)FW^V1^7<2>7]S]Y')Y<OS_ZNM+6?C'X+;QY:^'=
M2^$\>M>(K5-/LM&\-P:+I;75B\]E+>21"XDN?LPCCCMY,_ZOH1'YM95,CKSI
M[D?5ZAH>5=W/@Z2^;7?$WG:[XYDT:Z<:Y/%Y5H+V2+RHAYG^C_<'^KQ)6!X=
M?4/&FOZIH]YXB\5-9^'E\3)8^1K=Y'(?L]Z(H/,DCD\R0QCC,OF=JT-5_;J^
M'WB'2;W2E^'/B#5/#L=A;ZYXB']GZ=]ETE+B\EM\7$<EP#+(+BWE\P11R=,\
MU]$Z)\./#ND:9;V^GZ'H]I9PV[VT$<%G&D<<#G+H /X'QT P:=3*ZD/X@?5S
MY;OO$6O^%?#=O9:7K'B*^_X2#PSX<U&:.ZUVY\R6XN+WRKCR[B2222W\R/\
MYY]Z]N_93N[]O#'B2UU*ZDN)--\075HD+ZC+J,EDFR*06QGD_>2&/>XR:[:\
M^&'AK4;-[2XT+19K>2R33GC>RC,9MT^Y 1C'E@](^E:'A/PAI7@31X].T32]
M.T>QA^Y:V-LEO#%]$3 HP^#J0J<[F.G3L<_^T=_R03QM_P!@&]_]$O7Y=U^H
MG[1W_) _&W_8!O?_ $2]?EW7XUXN?[U0_P '_MR/VCPO_P!VK_XE_P"DLDAF
MDL[J.2/_ %D4GF5[Y^SE\</$/Q9_:8\&+XANX[R&QGO)8MMND93S+:3_ ,AX
MKY_K2\&^,=4^'WB2UUG2;G['J5D,03&..3R_W?E_\M*_.\ES2I@Z\)K^'SPY
MS[S.,II8VA.%OWG)H?4GP-U/X>^)_B3KDGA?PJMCXYTT7$^G1ZCJ4LEO<R>H
M.>E<_P"!O$MG9?LR^-+[QGX9D\0-=>+I'O++[5)9_P"D2)%O_P!7Z<_G7SWH
MOBS5/#_BF'6K.YDM]2MY_M"3)W>NV\/_ +7OQ"\,7FI2V.O1V[ZM/]LN]EA9
MGS'\J.+S/]7_ -,Z^HP_%>'Y/]H]SX_@A#D][[?+_,?,8KA;$.K^Z]]>Y\<Y
M7]S=*?9_@9?Q3\5^$?$%A:IX;\$3>%KB.0>?/)JUQ>>9'_SS_>5V7QC8']D_
MX1#N#J>?^_\ 7)_$7]I+QM\5/#W]EZ_K"ZA8EA.4^QV\9+CI_JXZYO5/'FK>
M(/"NE:'>7BOINB[S8PB*/-OYDGF29KQ:F:4/W_LW\</Y(0^U'^4]>CE6)_V=
MU5;V=3^=U/L/JST[]CMML_Q&]_!E^/\ T77C=:OA#QUJO@4:E_95PMI_:UB]
MA=9CCE\R!_\ 61_O*RJ\_$9A3G@Z&'_Y]\__ )/(]'"X.I2QN(Q/_/SDL?1>
MM>-#X,^'OA+1_B1X)LO%FDMIT<FDZM8RR))'!)CRX]Y_Y:?],P?^>=9'QFO+
MG]G'XX>&O$&AZIK%W'<Z;!?0VNJ222W%M _F?Z&_I'^H/YUQ?@#]J3QW\+]#
M32]'\0/'8Q\)"]M'<&/_ *Y^9'7(^,/&VI?$#7YM2UB\GOKRX&&EE& !["OH
M,9Q%AI8=*AS\_N?]N<G]_P"U_P!O'A8+(,1#$/VMN3W_ /M_G_N?8_[=/=?V
M[O&:Z=K]CX.T:SBTS08T_MBYA@'_ !\W$_[S?)^.:] \;>/['6?%>C_#?Q$R
M_P#"/^)_"]C]EFQSI]]^\V.#[\?BHKY.\<>/M7^).N?VAK5U]MN]B6_F>7''
M^[CYC_U='C'QYJWCN^M;K5KP7EQ96J6D#^7''Y:)_JX_W=7+BQ*O6K1^WR?^
M ?RD1X5<J%"A/3DY[_X_YS[$NO"]UX.\=:9HMP8YIM-^%UQ:2%/^6K1R1QUX
MK^PCH6I1?&U=:5+BVT?2K.X;4;J4>7$4\O\ ^.?^BJXZ/]J'QU:>*H-:3Q!)
M_:5O8_V8D[VEO)F#S/,\O_5_^1*9XR_::\=_$'0Y-+U3Q%<7%C<##PI EN9!
M_P!-"D<==N*XFRRI5ABX<_N3]S_R7?\ \!.'"<-YG2H5,,^2U3K?5?%LK?WN
MYZ[<Z]X0TK]D?P#)XDT&[U:QFU2_\B.VN?(DM?\ 29/<>97:ZIJNF>$_&/PC
MM] L;*W^&-U>_:[2ZC:2207<D<L8$F_[G^L]>\G397R/J'CW5M6\&Z;X?NKK
MS-)TEWDM(/+C_=R/_K/WG^LJY%\4M<B^'DGA?^T/^*>DF\[[*\$<GS_],Y/]
M9'6-#C"G%ZP^Q#_R3_VV1M4X1JR5U/7GGU=K3_\ ;X_UW-OXO> ?$=O\>M<T
MV:SU"XUB^U*26W79\]R))/W<L=?5OB#XEM\.O$7Q U96CFU+0M)\.Q:GY;_?
M?SY?,_\ (<E?,-A^U[\1;+0DTZ+Q-<-#&@1'D@26X*#OO\O?GWKD;#XDZ]8Z
M3KVGPZA(8?$AC.I>8D<DER8Y/,_UDG[RLL%Q%@L%4G5PO._:?^2?%_[=(>.X
M=Q^/IPI5_9KV?;K\.^G:.VOJ?7WAGPA:_L__ !-U#4K62*0?$;Q)9P:5(B\_
M97_TF<C_ *9_.4_*N1\;^)/#V@?!7Q!)XB\-R>*+63X@ZBD=LE\]GY<A,N)/
M,C^A_P"^J^>[KXX>*+J[\.23:M+))X3&-*_<I_HW^K_Z9_/]Q/\ 65K^&?VK
MOB!X.BO(]+U\6T>H7+WMP186\AEF?F1_WD=>JN-,![/V4(<D/>^Q"?Q?_;?^
MVG!+A/'M^UJ34Y^[U</AVUMI[MOF9WQ3\2^&?$QL/^$;\'R^%O+\SS_,U*2\
M^T_ZOR_]9_J_^6G_ '\KCZ[/XF?M!^,/BYI$&G^(]6_M"UMYQ.B?8[>/+CI_
MJXZXROS_ #2M3JXCVM/_ -(Y/_)(GWF4T:M+#>SJJW_;_/\ BPHHHKS[G>%%
M%%%P"BBBBX!1111< HHHHN 44447 ****+@%%%%%P"BBBBX!1111< HHHHN
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MW^7#]DMY#%O_ 'G_ "TC]S5R\_;"^(FI:G#?3>(/,O+>-XH)!8V?[O?Y>_\
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M-L;#%XN>(I_U\)]-DN$J8/!T\-4_KX@HHHKRST@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ]:_88_Y.H\)_[]U_Z27%?H]'TK\X
M?V&/^3J/"?\ OW7_ *27%?H]'TK^A/"G_D3S_P"OGZ1/PWQ*_P"1M'_ OU)*
M***_4#\]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHW4;J "BC=1NH **-U&Z@ HHW4;J "BC=1NH Y_XE
M_P#).O$7_8+N/_13U^;?_!+']E;XQ?$[]A'P1K?A7]HK7? OA^^.H"VT*#PM
M9WT5CY>HW,<G[R23S)/,DCDD_P"VAK],]>T:+7M'NK&9F2"]@DMY-IZ"3@_U
MKA/V6/V9]#_9&^!.A_#WPU>:M?:'H/VG[/-J4D4EU*;BXDN)#)Y<<<?^LE?^
M#H: /FW_ (*-Z;X>\+_L^_"KP+\3]0\<?%3Q%?:_;1V&DZ%';V,WC>\MP?DO
M(^B6W[P"3R\??2O!=)\)ZM\-?^"GG[..I-\#_#?P .O2ZK9?8=%U>VO9=8MX
M[+I/%;QQQQX\S_/EU]X?M>?L7>'/VQ-!T&#6M2U[0=8\)ZA_:NB:YHEW]EO]
M+N/6.3M_!VYV#I7G?A__ ()4>$;'XM>%?B%K'COXH^+/'GA._6\MM:UG6X[J
M62/G_0O+,?EQV_[R3B())^\_UAHN!\:>*OV=[KX7>'?BCJ6O?!SP?^T=\._$
MFL:AJ]Q\1/"^MVTGB+38I/WDG[P^9+YD7_/.+]W7H/Q@\(_"[X]?%C]B35-+
MT.W\1>&_$\-YI+2>(+2*ZO;ZSM[)/+M[PD?O#')YF1R/,WU[IXB_X)"^#[W6
M?$:Z#\0OBUX+\*>,KN6\UKPOH7B VND73R#,F(O*_=I)_P M!GD?)TXKM/C7
M_P $VO GQ<^&?@'PWI]]XJ\ P_#&7S/#=[X:U3[/>Z7^[\M\2R"3DCJ_W_?K
MD ^AK.RCLK5(84CACB38B)_RSKXW_P""AO\ RD._8]_[#FN?^DUM7UYH.E_V
M/I%I9O=7%]]E@2+SKA_,DE*8^=SC[Y//UKSKXN?LI>'_ (U_&'X;^.-6OM:A
MU;X7W5W>Z7%:21I;W+W$<<<@G#QDD?N\CRS&>30!X#_P77\,Q^+?V0_#>DO)
M)$FJ^/-(LM\?_+/S#+'_ %KF/V[OV<?@3^S-\%_!G@>Q\$>))6\6^++6YT_P
MCX5F2*7QA>6\?EB*\>0/FV D_>?]=*^K/VF_V7M _:M\&:/H?B*\U>SM-'UN
MTUZW?39(XY&N;<DQ[_,CD&SKD8].>*R?VNOV+/#?[8>A>'X=:U'7]"UCPIJ'
M]JZ)KFB7GV74M+N/6.3MT3Z^6* /@_2_">K?#7_@IY^SCJ+? _P[\ VUZ35;
M+[#HNKVU[+J]O';?\MX[>.../_6=\_\ D.O2/^">_P"S+\/OVU_AE\6O'GQ3
MT#3_ !;XN\3>,=4T[4;K5<7-SH=O;^7%%;6\G_+OY<>/]5BO9/#_ /P2H\(Z
M?\6?"GQ"UCQY\5/%7CSPGJ"7=OK.L:W'=321@'_0GC,7EI;_ +Q_]4$D_>']
MX:/B=_P2G\(^/_'?B;7-!\<_%#X=P^.I?M7B/2_#&N"SL=7E.?,EDCDB?]Y(
M.)#WH ^1?VA;+4/AQX__ &2=*_9N\2_\+0U31M+\6:=X8U/4[VWN0?\ 1O+D
M_>?NX_\ 1HY)/+C_ .F4<=?37_!&6V\%7O[-=WXBTQ=3D^(VI:A)'\0+K67\
MS5Y-83 D24]1&/\ EF@X )S^\\RO4?#O_!/[P#X,\6_"76=!BU725^#%GJ%G
MX?T^VGC-K,+V/R[A[G?&9))#]_(D3]YSS4%S^Q'X<\*_%OXG?$#P[<>+M/U;
MXB:')9:OHVE7EO;V.JW'EG9<Q^8G[N\["0R"/+G/\>0#Z"K\\OVQ?A]XU^)/
M_!9+P'IO@/Q\WPW\0#X9RR#6?['@U8F+[;<^9'Y$O[NOJW]A?X4^(O@K^R5X
M)\+^*KRZOO$6EV;_ &^6XO/MDB222R2>4\O_ "T\OS/+SW\NK6J?LI^']>_:
MQTGXR37VLKXHT70)/#MM:))']@^SO))(7=/+\SS,R'GS /:@#X ^('PS\:0?
MMX^!?AY^U=\3->\:>!]6O(]1\%WEM96^FZ/K.H1?\N]Y;Q1_)(/,\OK_ ,M(
M^?WE>H_MHMX+^(7_  4"M=/L?A3XB^/_ ,0_#OAE$F\+7FH65MX:T&WDD,L<
M\GVA,?:9/,Q^\SP\?X?4W[7O[('A']M;X4IX2\7-J5O:QWL=Y:WVFR1QWUC/
M'G$D4DB/M/+IT/#D>AKSOXG?\$T]%\>?%?3_ !MIOQ$^+'A#QHNBP:'J>NZ'
MJD-K<Z]!%CY[O]QY?F?NT.8P@_V* /B'X4Z1??#G3?V[/"]QX7TOX?+'X'M[
MR3PQI>H"]LM,DDL9>4DXB_C["NP^('P#\._LB?\ !$^/XD>!=%71_'_BSP9I
M%OJGB2%W^W&WU26RDN/WG_;397U+X(_X),?#GX>6_P 0HM.USQZ?^%H^'Y-!
M\0R76KI<RW7F9\R\\R2,R"Y_>2<Y\K]X?W5>P6?[-OA<?LV6'PEU*VN=:\'Z
M?H5OX<>VOI/WMW:Q0)$GF21[/G(0?O(]GS\C&* /S4^-/[,_C/P[^S3X<N/"
MW[./@+X0ZIX1?3[W1_B)%\1]+CNHI/,C_>W$[QQFX\W_ *:2?\M*_6'PU<3Z
MCX=L;BZ2..\F@22=$?>@<ISS7RAHW_!'+P2K:)IVO>/OBQXP\%^&;F.YTSPC
MK.O?:='MO+P(HS%L&^./L":^Q* /RS_X)R^!_P!H+Q-X1^*EQ\+?'?@7POX<
M'Q(UB.>WUG1Y+VZ-S_HV^3S/^>?E^77H7QF_9H\:?L9_LN_'[XR:UX\O/''Q
MB\5Z*EC)K<%I]ABTJS#QQ>7;1Q_ZO"?/YA[Q1^E?6G[+O[*.@?LE>&/$6D>'
MK_6+ZW\3>(+OQ%</J4D<DD5S<>7YB1^7&G[O]V,#MZFN^\8^$M/\>>&=2T/6
M+.VU#2-8MY+*\M)QF.X@D0I)&?J#0!^1^O\ [,/B34/V$]%31_V;? _@Z^M=
M.T_5K#XGO\1-/M[Z*X_=R_;9)Y(XY/WO/[N23]WYE>[?"KPA:_MA?\%'GL?C
M+IVE>*O^$)^&.D7FEZ+=217VFRWEY';RWMY''_JY/WC^7Y@S'_J_^F=>CP_\
M$9/ 4MA9Z%?>.OC!J7P[L9Q<0^";KQ'YFA?ZSS/*V>7YOEY/3S,\_?KT_P#:
M'_8!\*?'3Q9H'B:QU;Q1\/?&'A>S.G:=KGA.[2QNH[3_ )]Y#L.^+_IGTH ^
M(&^#GAOX!?$/]O[PSX1MX[#0;7P)!<6]I$_[JPDN-.EDDCC^LDDE;WQ'N? _
MBKX._L?^'=4\&>,?BYXTM? EGJ.D>!K&>WMM(NH_[-BCDN=0\Q.WEGR_^N<G
MX_2?PX_X)0^ ?ACX?^)EE9^(OB!?R?%[2?[*\0WFH:G%=75QF.59+A)#'GSW
M\UR=^^/('[O&0;GQ)_X)A^$?'>E?#5M+\5>.O"/B+X4Z-%H6A^)-%U".VU+[
M''$(Q'/^Z\J3@'/R)_K)/6@#Y9_9:^'']F?\%9M1\-Z[\(?"?PKTSQE\-+A]
M3\&6-_!JUA=Q_;?]9<1Q1?9M_P"[^Y^/_+2O)8?A_P"'_#?_  0!\::]8Z/I
M-GKFJ>(X[>\OH+>..YN8X]:C\N.23_EIY?\ 2OT&^"__  3%\&_!#]H"P^)U
MIXE^(6M^.(;2>RU#4M9U=+Z378Y#TN=\?_+/">7Y7EX\L<$5RLG_  1X\ CX
M6^//!*>+_BA;^#?'EY'>-HRZO;RVNC2)<BY'V..2W?RLR>N_Y!B@#RG_ (*#
M_L?_  ]_9$_9'\'V7@?PW8Z'-J'COPU;W]VF_P V^-O)+Y;R%R?^>DG_ '\K
MIO!GPM\,_M<_\%6_CE!\2M,L?%%I\,=+T;3O#.C:JGVJQMX[RV\VXN/(D'E^
M89!&,_\ 36OJ+]IS]EO0?VL/!.F:!XBO-6L[32]8M-=BDTV6..0W-N<QY\R.
M0;.O^-<3^T;_ ,$^_#/QX^*%OXZT_P 3>.OAUXYALQISZWX2U,6-U>VX/^JG
M/EN) .,?0==@H /V)?@W\,_V?[OXC>$_AMXJNM6AM]>:\U/P\;V.XM_"=S(,
M"WB0()(T/E_\M"_^KZC%?0U?'/Q:_P""=</P\_85\:?#WX5)XHN/%GBJ^@U"
M;6Y]=2+5+^_-Q"?MEY=R=8X\>9+''@R1B41CS),GZV\/Z=_8^CVMKYDDGV:%
M(_,?_EIQ0!\4_P#!,O6(/"O[:W[5GA'69!:^,+KQF^O1PR'$EUI<A?[,Z?\
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M'4[1,DE!*!S&?2N6^"W_  2_\)?"?XL:5X[\0^+OB-\5/%F@QO'IE]XSUO\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #&*#R***
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M,8?^ !_K'G/_ $ ?^3GQ-17VU_P\[\*?]"[K_P"5O_\ '*/^'G?A3_H7=?\
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M%G/_ $ ?^3GQ+17VS_P\[\*_]"[KWY6__P <H_X>=^%?^A=U[\K?_P".4O\
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MK?\ ^.4?ZKY%_P!#&'_@ O\ 6/.?^@#_ ,G/B:BOMK_AYWX4_P"A=U_\K?\
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M?;7_  \[\*?]"[K_ .5O_P#'*/\ AYWX4_Z%W7_RM_\ XY3_ -6\A_Z&,/\
MP /]8\Y_Z /_ "<^):*^V?\ AYWX5_Z%W7ORM_\ XY1_P\[\*_\ 0NZ]^5O_
M /'*7^J^0_\ 0QA_X '^L><_] '_ ).?$U%?;7_#SOPI_P!"[K_Y6_\ \<H_
MX>=^%/\ H7=?_*W_ /CE/_5O(?\ H8P_\ #_ %CSG_H _P#)SXEHK[9_X>=^
M%?\ H7=>_*W_ /CE'_#SOPK_ -"[KWY6_P#\<I?ZKY#_ -#&'_@ ?ZQYS_T
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M\=_BI]CT<_!ZU^':W D?^U/^$RBNS$8_W?E_9_L;]_WG^L]!1_Q#G!_]!O\
MY('^OV,V^J?^3_\  /ANBOLG]G'X[?'@>.+K_A;EK\(1X;%C(UL/!\5_]N^V
M;X_+$GVA_+\KR_,/KGR^:M_M+?'7XU/KFF_\*=M/A:FEM!(=0'C**_-PLO\
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MVA]27X5WG]EV&GGQO_9<GV3[6)!IG]H>6?+\S_EI]G,N#_ST\NOG^S_:&_;
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MJ(\-QR?V8#YDGE^7]H?S>8O+S_TT\RG_ *A8#_H._P#) _UZQG_0)_Y/_P
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M\?\ \^6?HID_[-&3_LU\U^"/VWYE^&FG?\)-I<9\8"S3^T#IR?\ $M^UE/\
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MD*7^MF4?\_X%?ZLYG:_L3[MV?3\Z-GT_.OBK]I3_ (*!?$;=H9^#^C^"8_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX7D4ZD)Z[/HSY]HKV[X=?!WPMX=^ ^G^./%&D^(/$2ZE=/!';:7)LCLHX_\
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MZ44#I17]"'X@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>Y@,5J\DGR2(DG3]V!WYKJD2W;]I7X5RZE#H]CX^E2\.NQZ9_J1_HTGE[_\
M;_S_ ,\Z^,X9I(9=\<GER45VX?C'DA!NGK[GV_<]R7-[G\LI'#4X1]I.2533
MWU\'O_\ ;_\ ,CZX\5Z?^TAJ]]JD"K;R6-Q(R(I.FY$?:N?\??L_>*OBY^S]
M\+TT/3X[S^R;6[BN_,NDB\L^8!_RT?G_ %;^M?,]%9U>),-7YZ=>G.?/_?\
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M3>[/^>7F:?;RUT%?N.(]IS_O/C/Q>C[/V7N!1114&H4444 %%%%9@1T445H
M4445F:!1110 4445F 5'/4E1ST %1U)4=!H%1U)4= !1110!'1110 4445F
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MF.OCO^WK[_G^OO\ OY)1_P )!??\_P!??^!%'^LF0_\ 0N_\G#_5_//^@_\
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M_P""3MW)#^P!\/\ RY)/^8A_Z<;FOHS[9/\ \_$G_?ROUNMF6#C6D_8'Y?'
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M#J'V>\\,>$/A99R:E=^:DH63,<_F1QQ_\]!TX]:]>^V3_P#/Q)_W\H^V3_\
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M]:T&XGLKOQ%IGPRCM['6MDDF)(XX[C_5^GK7M/\ :<__ #WD_P"_E']IS_\
M/>3_ +^45,VP$_\ EP%/+<9#_E^>5_#C]B'X\?%GP/I_B2W_ &B]?\+QZS%]
MJCTK7OA1I]KJ=@#_ ,LYX_M'R25A^&/VL);'P%IUCJ'P8_:TU37+?3TM[O5A
M\,8[?[7<!,27/V?[1^[\R3]YY=>X?VG/_P ]Y/\ OY4?]IS_ //>3_OY6=3-
ML!/_ )<!3RW&0_Y?GEMO^PG\>[WX<P^)&_:4UJ-)-+&H_P!E/\*-._M.+]WY
MGV?R_M'_ !\#[GE_\]*P=9_:JNKOX=7FFVOP?_:TL?$4FGO!;ZS_ ,*MCD^R
MW>S'VG[/]H\N3]Y^\\NO</[3G_Y[R?\ ?RC[9/\ \_$G_?RBIFV G_RX"GEN
M,A_R_/*O%_[#OQX^'W@"[\53_M%Z]X@BTNU.H2:-IGPITZ74K\?ZS[/'']H_
MUN>,5D^,?VD+WXCZ$WA_PS\+?VK/!.MZK+';6>O7GPQCN+;2_P!Y'^\DCDN/
M]7Q7M?\ :<__ #WD_P"_E1_VG/\ \]Y/^_E%3-L!/_F%"GEN+_Y_GF'Q"_8R
M^-WP(\+OXLU'X^>)_'UCH4D-S=^'O#_PMT^XU+68Q+'OBMT\_J>OMS6)XE^.
M6J?'&'3_  MX1\ _M.?#/6]>U2SLH/$NK?#**YL=+\R>-))+B.2X_P!7CF23
M_EF.:]J^V3_\_$G_ '\H^V3_ //Q)_W\K.IG6 G_ ,PII3RW&?\ /\\M\<_L
MQ_%S]E^UT_Q=XD^,7CCXL:+8WB1W?A?PG\+;*74M1CDSP/+N/W:#'+]JS-3\
M?>)/VH-?T#P=X'\,_M&?!?6+[4!))XE\2_#*WN=-BMX[>7]W)YD_[O\ >>7^
M\]>/^6F:]A_M.?\ Y[R?]_*)M2GS_KY/^_E']M8#GY_JH?V;C.3^.>6^,_@7
M\4OV.]0T?Q%XN^(GQ*^-^B74[V<_A[P;\+K.2^/[N39)))'/^[C&1^?:L^37
M_%'[6'B_1?"_@72_V@_@7>2/-<W&N^*_A=;RZ;,B1X$4DDEQ^[SV]37KW]IS
M_P#/>3_OY1_:<_\ SWD_[^4?VU@.?VGU4/[-QGP>W/+?%?PG^(_[&/B73-4\
M:>,OBE\?-)UB.:V_LGP3\,;+S+&1/+Q+/)'<?(.N#W(-5M'T[QQ^VA\0;;2/
M MQ\</@"NF6$]Y>77C+X7V\MAJGSQ(D<<LD_[N0"0GR^X$G3RZ]7_M.?_GO)
M_P!_*/[3G_Y[R?\ ?RL_[:P'/[3ZJ']DXSD]G[<\OUWPGXZ_8N\6I#X[U;XR
M_M!6NL67FVX\$_#&W$6ER1R?\M)([C_6?],Z;X=\ ^/OVUO&EVW@CQ!\8/@#
M8Z'9H)[;QM\,;,QZI+)))^\MY))_?_5]N*]2_M.?_GO)_P!_*C_M.?\ Y[R?
M]_*/[:P'/[3ZJ7_9.,Y/9^W/+=4TSQ=^Q?XZO-#\>3?'']H(ZGI]O>V%]X+^
M&5M'8Z4=]RDD4DD=Q^\D_=Q_N_\ EF/+/_+2CP9\%_B1^V5XJUS4_!OCGXI?
M ?1M+C@MH](\;?"VS\VYDD\PR26\DEQ^\^X/^N>1ZUZE_:<__/>X_P"_E1_V
MG/\ \]Y/^_E']M8#G]I]5'_9.,Y/9^W/+?[8\2?LH^(]7\*>-](_:$^.%]'(
MES!XA\*?#&WBTU8WCCS$DD=Q^\([^AJYX%_9P^*7[7]SK?BOPK\3OB%\%= C
MU$6,'A;QE\++*.^A\NVMS))'))<?O(Y9'D_>>\D?_+.O0O[3G_Y[R?\ ?RC^
MTY_^>\G_ '\K/^VL!S^T^JA_9.,Y.3VYY=;>-=:_9LU?6?!_C3PO^TA\8]:T
MJ]_Y&CPU\,K>VTRZCD2-Q'!Y=Q^\\O'^L]<BK?PZ_9-^+G[36GZAXKT/XQ^.
M?A7H]]?W$=IX;\5_"RSM]2TZ/C@^9<?O$.>'[UZ%_:<__/>3_OY1_:<__/>3
M_OY1_;6 A/G^JE_V3C/@]N>5:)\7KWX-P7GA/Q5\._VHOB1KGAO4+VRN/$VD
M?#*.WL=9\JYD\N2WCCN/]7Y>P1R?\M,>9]-?X9?L,_&CXV>"[7Q1:?'[Q-X)
ML]8D>YM]"\0_"W3[;4M+C,DG[JXC^T=>?Y5W7]I77_/Q+_W\H_M*Z_Y^+G_O
MY13SO+X?\PH?V3C)_P#+\\I\-?':7P)HZ:'X@^%7[57C'5M++VUWK5I\,H[:
MVU1TDXDCCCN/]76QX#_8$^-WCWX9:;XF_P"&C==TG^TK".\_LK4OA1I]MJ5J
M=F_RI+?S_P!W)ZQ]CQ7=?VE=?\_%S_W\H_M.?_GO)_W\K.GGV7P_YA32IE.-
MG_R_/(_^&AI?^%=_V?\ \*C_ &N/[=_L_P"S?VQ_PJZ/_CXV8^T_9_M'_/3]
MYY=;^N_L!?&[0_A1=>*Q^T9KU\++2'U4:-:_"C3I-7F\N/S/L\4'VC_CX_Y9
M^7_STKN?[3G_ .>\G_?RHYM2NO\ GO<_]_*SIY_ED/\ F%"IE.83_P"7YY?X
MT_:$_P"$@\':K8Z'\'OVNM U>Z@DBL]3?X8QW7V"3_GIY<EQ^\KI/B!^P!\9
M/A!X-O/$UY^T%XB\86NC#[3<:+H7PPLKG4M33S ?*MT^T?ZS_"NL_M*Z_P"?
MBY_[^5'_ &E=?\_%S_W\HIY_ED/^8453*<PG_P OSS+Q5\5KWXMZ=#X;\*_#
M?]J;P#KFM7=O9V_B'4OAE'<V.E^9<QB26XCDN/\ 5^7O'_3//F5O?$']C#XJ
M?LW:##XQU[XT>,OB=H^EWD'VKPUX5^&-E)J>JQ.X3RTV7&1UYD[5U?\ :5U_
MS\7/_?RC^TKK_GXN?^_E%//\LA3Y/JHYY3F$_P#E^>?ZAXLU;]H;4M+\'^$_
M!O[2WPJU;6+U(H_$OB#X8V]SIMC'_&)_,N/D0_\ /3^=:7C_ /9*^*'[*46E
M^+?$OQ4\>_%S0XKS[-=^&_"'PPLY-2N_-24"3]W/^[2/^_VR*ZK^TKK_ )^+
MG_OY2?VS=?\ /U<_]_*SIY_ED*?)]5-?[$S"<_:?6CS[?X@_:G\9Z#X/\%Z'
M^T1\%+^^N'DF\0^)OAC;S:1''';22>7*\D_[KS-GO^\\N.M'QW^SE\0OV.]9
MT?7/%GCCXG_'#1[\R6KZ+X*^&%F]U;/LPDLDD<_[N,?YQ76?VS=?\_5S_P!_
M*C_MFZ_Y^KG_ +^5G_;^6<G)]5+_ +$S#G]I]:..TKPQXG_:]\:Z=X=\#Q_'
MKX%R6L$]Y>:KXS^&5O+8W_\ J]D?F23_ "2#]<5)XV^!GCK]B[Q1I=UXT\4?
M%OX\:;KUG<I%8>!?AC;_ /$LGBDMOWL\D=Q^[_UC^7'_ ,M,R?\ /.NM_MFZ
M_P"?JY_[^5'_ &S=?\_5S_W\H_M_+/9^S^JA_8F8<_M/K1Q_ASX:^,/VRO'?
M]G^!]2^-WP'M=+T\7%R_C7X6VYM=3D,G_+.62X_UG_3/TI_B/X;^+/V-O&DN
MG^-K_P"-GQZBUBR2YM+CP3\,K<6NE$221R1R21W'^L(Y\OTQ76_VS=?\_5S_
M -_*C_MFZ_Y^KG_OY6?^LF6<GL_J0?V'F'/S_6CE/ GP#\=?MH>+M7N?!WBK
MXM_ S2=!M[.,Z?XY^%MNGVZ23S<R6\DD_P"\_P!7^\'_ "S_ '?_ #TJ'5?!
MGB;]D'QI?>'?'"?'KXZ27$$%Y9ZMX-^&5O'8Z?\ ZS?&9([CYY#Q],UUO]LW
M7_/U<_\ ?RH_[9NO^?JY_P"_E%3B3+.3D^I%_P!B9AS^T^M'/_#_ /9@^(7[
M8>L:YKGA;QY\3O@GH=C)';1Z+XV^%MG'=2GR\/)'))/^\C/Z>]4)DU;]EWQ-
MK?@_QIH/[1?QFU2QOHVC\2^%?AE;PZ/+');12".+R[C]YY9+^9)_ST+Q_P#+
M/%=?_;-U_P _5S_W\IDVL76/^/JY_P"_E9U.),LG#V?U(=/(\PY^?ZT8?PT_
M8V^)7[4MGJ7BCP_\6/'GPGTB:_>WM/#7B[X6V=OJEI%'L_YZ3_O(SO.)._-9
M-OKEW\"KN^\(^*O _P"TY\3-<T*^GM9/$FA_#..'3=4_>922W\N?_5_]-*ZW
M^V;K_GZN?^_E+-K%UC_CZN?^_E%3B3*90Y/J1=/),QA/G^MF5\,_V#OBE^T;
MX?F\6:7\9O&GPWTS5;^Y-IX:\5_#"RM]3TJW\Q_+BD_TCGK_ *S_ ):5A:)X
MW/PSM)O#OB+X<_M4^-]6T6XFLKO7M,^&<=O8ZKLDDQ);QQW'^K.>/6NM_MFZ
M_P"?JY_[^5'_ &S=?\_5S_W\K.?$F43AR3P0Z>09G#W_ *T5OAI_P3>^+GQ8
M\":7XB@_:"\1>%XM8B%U'I6O?#"RMM2L!_SSGC^T?NY*Y7P_\5H]/\'65CJ'
MPB_:]U/5H[*..XU/_A64<?VJXV8>Y\O[1^[S)^\\O^==?_;-U_S]7/\ W\H_
MMFZ_Y^KG_OY1B.),HG\>"+IY!FD/@Q9%!_P3.^,%[\.(?$C?M$:Y&LFF#4?[
M*?X867]IQ9C\S[/Y?VC_ (^ /D\O_GI7&ZM\2UN? 5Q96OPG_:YM=;ET][>/
M5S\+8Y/*N#'C[3]G^T?\]/WGEUV?]LW7_/U<_P#?RH_[9NO^?JY_[^5G4XHR
MB?QX$=/(,TA_S%B>,/\ @FG\6O ?P]NO%$_Q^U[Q!'IEJ=0DT;3?AC92:E??
M\M/L\<?VC_69XQ7,:_XTB\=:8^CZ)\,?VKO".KZI(EO::U?_  RCN;;2W>3F
M62/[1_JZZ3^V;K_GZN?^_E1_VS=?\_5S_P!_**G%&43^/ FE/A_-(?\ ,63_
M !)_X)R_%#X&>$[CQ9??'#Q-XYL=#D2YN/#WASX8V5QJ6J1^9'OBMX_M'4XS
M^=<GJ-Y)\9[C3_"?AGP-^U%\/-8U[4+*RB\0ZS\,H[K3=,\UXTDDN!)<?ZO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M117RQ]0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4=9FA'11169H1U'/4E1SUF:$=1U)5>LS0*CJ2HZ#0CGJ.I)ZCGK,T(Z^R_\
M@F?^SAH?PU\)Z]\0[.\U636_B9]G_M2WFDC-M:_8'N+>'R!L\P?(YW^9)(<C
MJ.<_&E?07_!'KXI>(O%WQ<^.'AO4M8N+SP_X3_L#^Q[*0?N[ W,5[)<>7_UT
MD&?PK]-\*_\ D;5/\'_R)^>^)"_X38?X_P!#[V'2B@=**_H,_$0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOU$^.6FSZ[\%/%EA:PR7%Y=:-=Q00J?GF=H9,(/<Y%?GF/V:OB W3PAX@_\
M %Z_$?%+ XC$8NC[&GS^Y_[<C]6\.<9AL-1K>VJ)>\CAZW/AIX_O/AAXTLM>
ML([>2ZT]Y'2.9"\?^K\OJ*WO^&9_B ?^9-\1?^ $E'_#,WQ!_P"A-\1?^"^2
MOR^EEN8TZGM*=.?_ (!/_P"1/TJMF&6U:7LJM2G;_&<;K&I2:QJEQ=2>7YEU
M))))Y=;GCOXHZA\0-,\/VMY#9QQ^&[%-,@\E)#YB1_W_ /IIQ6M_PS-\0/\
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M !-XB_X2;Q)?:A]FL]/^W3O<>3;1^7;1_P"Y76?\,S?$'_H3?$7_ (+Y*/\
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MWQ!_Z$WQ%_X+Y*/^&9OB#_T)OB+_ ,%\E']CX_\ Y\3_ / )_P#R(?VM@O\
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M\)!_PB/BK_CP_M#^S?[,D^W9\OS/*\O_ )Z_\L_+KQG_ (:<\1?]&]_M*?\
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M'/"N9L]1US/@CQIXS\;^*+/2O^%(_'32?[0?9]KU+PA<6UK$/^FDG_+.NO\
MBUX1\:?";P[;ZB_PY^(OB3S;C[-]DT+19+ZZB_=R?O/+_P">?R#\Q6=3AO,X
M5/9SH3-J>=X"=/G]O I43U@^ ->\8_$/QC9Z./@S\:M!^UEQ]KU?PI):V,11
M-X\R3W,>/K6Y\7_#/C;X3V%G._PP^)?B3[4^SR]!T"2^EB'_ $TK.IPWF4)^
MP]A/G"GG> Y.?V\"&BLWX8OXV^*OBC^S8_@]\8O#_P#H\DOVO7?#$EC:_P#7
M/S/^>E7/B_IOC;X37-FK_"KXJ>)!J$;_ +S0?#DE]Y6SIYG_ #SHJ<-YGS^P
M]A/G-/[?P'L^?V\!U1U#\)M*\;?%C4[N%?A+\6?#7V5/,$FO>')+&*7_ *YU
M'\6;#QM\)]9M[%OA%\7O$GVJW\W[1H/AB2^BB_Z9R2?\]*S_ -6\SY_8>PGS
MA_;^ Y.?V\":BCX3^'_&_P 67U%5^%?Q2\-G3]A(U[PZ]C]I#^9GR_\ GIC8
M/S%9/Q,D\;?#GQ/)I3?!OXS:Y\D;_:]%\*7%]:Y_ZZ5G_JWF?/[#V$^<T_U@
MP')S^W@:51SU>^%G@;QU\4M&N+Y/AA\1_#_V6Y\KR->T"2QEE_Z:1Q_\\ZY?
MX@7OCCP-XLO-'7X,_&K6/LI0?:](\*7%U:R[TWGRY/8\?6LZ?#>9SG["%"?.
M:?V_EL(<_MX&M4=:WPS^&WCSXF>'/[27X:_$+P_^]DA^R:UHDEC=9_YZ>7_S
MSKC/%>K>.O"GB.\TT_!'XZ:E]@N9(O/L?!]Q):RG_GI')_RTCHI\+YM.IR0H
M3-)\099&'M)UX&S4==#X#^$7CKXA^%+/5(_A[XXTDW1<?8]6TE[:ZB\N39^\
MC^G->>:SKWCC1=9O+'_A1?QWN/LMR\7GP>#+B2*79TDCD_YYFLZ?"^;3G.$*
M$S2?$&60ASSKP-Z>HZZKPM\#?B!XO\+V6I)\/_&FF_:TWBTO],DMKJ,^DD?_
M "SKRW_A)?'G_1!/V@O_  A[BL\/POFU;GA"A,)<299#XZ\#I*^WO^"</P+\
M.> /A?J'C;2;*:#Q%X^V?VW<-</(EW]B>>WMR$)Q'B,]$%?(I^"?CT>$_P"V
M/^$!\9?\>?VW['_9K_:ON;_+\O\ YZ9X\OUKU?\ X(VQ_$*3XA_&6X\6>&?B
M1X3\/W8T,^'['Q183V,,7[N\^T?9XY/W>?,V%_*X^>//:OT#PRRC&X?,IU*M
M/DAR'Q?B#FF#Q. A"C4O[Y]^BB@<"BOW0_'PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!N>:\P_:C\*>)
M?%7PSDD\(ZA-9:[ILZ7D"(__ !\[.L9^M>G%L$5SGQ-\<6/PU\ :OKVHMBST
MFVDNY3Z",5MA9SC6A*F<F-C"="<9GY0?MD^,+SPA^VC\*_$W@_4(;SQ!XC2X
MMM8CUR62RDM;^WC\R*.X\O\ U?EQ>9^\K[!_9C,_[1"Z"UOXSO?%6F^%[B.3
MQ'?P:I'<6-_J$?[SRXTC_P"FGER5\B_M\_"_0_VE5^$7BCQM'KEWXJU[XCZ=
M##H$FBW]G:MI\D4GF6\7F01F\Q'^\D\OS*]L_9/@A_8?NVN+#POXA\)Z3XP\
M;WC:OHK^'+RSTW2["\N3'ITAGDC^SQR11BWCD_>?\M#7O2BXUYPH_'_7](^;
M52,L'"IBO@_K^I'W9X]\>Z/\,_#%QK&O7T6FZ9:A2\TAXC^M<KX$_:B\!_%'
MQ"-)T/Q+8ZAJ<L;R)!&K]!U[5YC_ ,%6=;;1/V*?$5W@_N[S3SUZ?Z9%7G?B
MW]JKQ?\ !/\ 9HUKQ1XC^$]AX#BATJ.VTC5DU2WOI+ZXN#LC'EVX\Q/[]3E^
M30Q&$55?'.?)\45^&_4O'YU6H8[V:_APAS_#(^L?"'Q3T#QWK6I6.C:M8ZA<
MZ/)]GO4@DR;:3'0UA?$O]J+P/\(]8_L[Q!XAL;+4/+\S[.3ODC%?G)\+_P!H
M70_V./VB? EX/%T=_?:M"++QS9.TG_$N>X<'/F>7Y;^49$?$?_/*3UKZ!\5?
M"KXI?LS_ !Z\:>/--\":1\6O#'BB:34)"MW%#J&FQ_/)Y:"3/3?P(TD\SRX_
M]77I5N&<-A\1:<VX<ON?8YW>WVOP[GFT^)L=5H)TX6GS^_\ :Y('NS?M_P#P
MI X\56O_ 'YD_P *Z[X5?M!>$_CA+=Q^&M6CU*2P\O[0$C=/+W\BOCK]J[X^
M^$/CK^QUX-\;>&]+CT^.^\3VUE/#)!''-;R>9^\C(_C_  K[C\-:%8Z-H]NM
MA:V]JTT2%FAC\O?7FYI@<+A<(JG)-3;DK::<MO(]++,;CJV*<)SAR+E^S_,=
M%#_J:D/2H[?I4AZ5\YT/K#F_B-XN/@7P!K>N+#]H;1[">[$.['FF-"^/T_6O
ME,?\%2-0!_Y$^UQZ?;W_ /C5?2G[1O/P"\9_]@*^_P#2>2OR_K\C\1N(<;EM
M>C#!SY+Q9^D\ Y'@<?3JRQD.>Q]6_P##TO4_^A/M/_ ]_P#XU1_P]+U/_H3[
M3_P/?_XU7RE17YPN/,^>U;_T@^__ -2LE_Y\_B?5O_#TO4_^A/M/_ ]__C5)
M_P /2M0_Z$^U_P# ]_\ XU7RG11_KYGW_/[_ -(%_J5DO_/I_>?5O_#TO4_^
MA/M/_ ]__C5'_#TO4_\ H3[3_P #W_\ C5?*5%'^O>?_ //[\(!_J7DO_/K\
M?^"?5G_#TK4C_P R=9_^![__ !JC_AZ5J'_0GVO_ ('O_P#&J^4Z*'QUGZWK
M?A 2X+R1[4OQ_P""?5O_  ]*U/\ Z$ZT_P# ]_\ XU1_P]*U+_H3K3_P/?\
M^-5\I44?Z]Y]_P _O_2"O]2\E_Y]/[SZL_X>E:E_T)UG_P"![_\ QJC_ (>E
M:A_T)]K_ .![_P#QJOE.BC_7S/\ _G]^$"?]2LE_Y]?B?5O_  ]+U/\ Z$^T
M_P# ]_\ XU1_P]+U/_H3[3_P/?\ ^-5\I44?Z^9]_P _O_2"O]2\E_Y]/[SZ
MM_X>EZG_ -"?:?\ @>__ ,:I/^'I6H?]"?:_^![_ /QJOE.BC_7S/UHZW_I
MEP5DKU5%_>?5O_#TO4_^A/M/_ ]__C5'_#TO4_\ H3[3_P #W_\ C5?*5%'^
MON??\_O_ $@?^I.2_P#/E_>?5O\ P]+U/_H3[3_P/?\ ^-4G_#TK4/\ H3[7
M_P #W_\ C5?*=%'^OV??\_O_ $@/]2<E_P"?+^\^K?\ AZ7J?_0GVG_@>_\
M\:H_X>EZG_T)]I_X'O\ _&J^4J*/]?L^_P"?_P#Z0'^I.2_\^7]Y]6_\/2]3
M_P"A/M/_  /?_P"-4G_#TK4/^A/M?_ ]_P#XU7RG11_K]GW_ #^_](#_ %)R
M7_GR_O/JW_AZ7J?_ $)]I_X'O_\ &J/^'I>I_P#0GVG_ ('O_P#&J^4J*/\
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M+U/_ *$^T_\  ]__ (U2?\/2M0_Z$^U_\#W_ /C5?*=%'^OV??\ /[_T@/\
M4G)?^?+^\^K?^'I>I_\ 0GVG_@>__P :H_X>EZG_ -"?:?\ @>__ ,:KY2HH
M_P!?L^_Y_P#_ *0'^I.2_P#/E_>?5O\ P]+U/_H3[3_P/?\ ^-4G_#TK4/\
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M_#TO4_\ H3[3_P #W_\ C5)_P]*U#_H3[7_P/?\ ^-5\IT4?Z_9]_P _O_2
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M=*** #&:.E%% !UHZ444 &,T8Q110 =:,8HHH ,9HZ444 &,T=*** #%%%%
M!BBBB@ Q1110 8HHHH ,8HHHH ,8HQFBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BB
MB@ Q1M![444 &*-H/:BB@ Q1M![444 &*-H]*** #%&WVHHH ,4;1Z444 &*
M,444 %'2BB@ ZT8Q110 =:.E%% !UHZ444 '6CI110 8S1THHH ,9HZT44 &
M*,444 &**** $VCT'Y4N***+ %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN;7[$G[VTC?!^?9YG[S]/,KY3A>M@,-3G7QG_+SW/_DCZ#B:ACL55IX?!?\
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MY:UYM?,<'[&C4PW)^\J>_#^3X?\ R7FC_P" GH4,NQCG7AB^?]W#W'_/\?\
MY-9GT=XYM?$ME#K2>*O &BZ]X%:VG^R77AZW@>XLH\?NY$'F;_R%?'=?2GPU
M\7?#C]G?Q'<^(M"^(FNZQ9M#)Y&@I8R1BX/^W))\AQ^%?-]W-YUU))Y<<?FR
M>9LCKS^+)4IJG-3]_P!_[49_^31._A6G5@ZD)0]SW/YX?^22Z]WU(Z***^+/
ML0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBBG'<3V/U"_9S./@%X)_[ 5C_Z)2NV%<3^SF/^+!>"?^P%8_\ HE*[
M85_8F5_[G3_PQ_\ 24?RICO]YG_BE_Z42#I10.E%=YSA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 -!WUR?Q>^'D/Q7^'.M^&[B^U#3;?7+22S>[LI?
M+N81)U*'UKK!\JTG055.3C+GB9U*:FN5G@GP_P#^"='P?\ 6MI';^#=*O+BU
M@CC^T747FRW+Q_\ +1\_\M/>K'['?P0U#]G^7Q]H;1?9_#4GB22\\.0*_P"[
MAM)(XY/+3Z2^97N"'9PQSF@KG<.E=53,L5.G.%6?/S=SCIY?0ISC.G#E&T58
M'2BN,] KT58INR@"&BK%% $</^IJ0]**#S0!P7[1A\OX">,U^;_D!WW/_;"2
MOS K]7O&6D:?KWA74[/5C&NEW5K);W;/)Y8$+IA_G^AZUX./V9?V?\_\A#2?
M_"A/_P <K\J\0.&:^:5J%2C4A#D_GD?H'!/$5#+:=2-6$W>WP'PS17W-_P ,
MR?L__P#01TG_ ,*$_P#QRC_AF3]G_P#Z"6D_^% ?_CE? ?\ $.<=_P _Z?\
MX&?=?\1 P?\ SXG_ . GPS17W-_PS)^S_P#]!+2?_"@/_P <H_X9D_9__P"@
MEI/_ (4!_P#CE'_$.<=_S_I_^!A_Q$#"?\^)_P#@)\,T5]S?\,R?L_\ _02T
MG_PH#_\ '*/^&9/V?_\ H):3_P"% ?\ XY1_Q#G'?\_Z?_@8?\1 PG_/B?\
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M_CE'_$.<=_S_ (?^!A_Q$#"?\^)_^ GPS17W-_PS)^S_ /\ 02TG_P * _\
MQRC_ (9D_9__ .@EI/\ X4!_^.4?\0YQW_/^'_@8?\1 PG_/B?\ X"?#-%?<
MW_#,G[/_ /T$M)_\* __ !RC_AF3]G__ *"6D_\ A0'_ ..54?#G')I^WA_X
M&*7B!A&K>PG_ . GKW[.*D? /P9_V K'_P!)XZ[7O6)X+TO3] \):99Z28WT
MVUM8[>T9'\P&!$PGS_3O6Y_$:_HC!TW3P\(>1^%UY\]:<O,=111749!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#A_VCO^2">-O^P#>_\ HEZ_+NOU$_:._P"2">-O
M^P#>_P#HEZ_+NOP?Q<_WNA_@_P#;D?L7A?\ [O7_ ,2_])9)#-)9W4<\?^LB
MD\RO;_@G\;_$7Q:_:'\'1^(+Q+Q;"]EE@"VZ1F/S(O\ T77AE:7A3Q7J'@KQ
M':ZMILWV.^LW+PS>7')Y8/\ UTK\WRG,ZF$K0]_]WSP/OLTRFEC</-M?O.GS
M/I;PK\4+OX1?"+Q9X@LQYPM_B-<1W$/>X@V9=!_GM6MXU^'NC^&_@-XH\0>'
M+B*7PWXKU+3;^QCC'%L3<+YB?]_/YU\OZA\3==O_  S?:+->"33=2U+^U)X?
ML\>9)_\ GI4FF_%OQ)H_@.3PS!J;QZ%)/'=R6WE1RG?_ *W'_D.OKJ?%^'2Y
M*L/W?)[G]R?O?_)'RM3@_$<WM:<]7/7_  >[^3/?/VK/B!X T'X]Z]::Y\/[
MC7-3C$'GWL>N3VV\&WCQ^[C]!@?A6=\ /#VE^!OV9O$&L:UXB7PK-XXD&E6%
MZUF]SF"/_6>7&G]_YT_[9BO"/''C?4_B3XJN]:UJZ^V:E?>7Y\_EQQ^9Y<?E
M_P#+/_KG4GB?XDZUXM\/:3I>H7BW%CX?21+&#RXXOLT<G'_+.N-\4PECJN,<
M-N;D^Q\7\_+_ '3NAPM..$A@XU-^3VFO\G\G-_>\D?7EKH5EXP_:/^&/C[1;
MY=8LM6AN+"_OXK=XUENH+.;YQ&_^KW@2<?\ 3,<GK63\&M6L_P!I;Q)H%]<2
M1P^-/ .J,)Y& ']I6)D_]D_I_P!-*^;_  '^T!XM^&>BKINCZM]CLUNC=)']
MDMY/*G,?E^9^\CK)\&_$36OA[XN37=%U"2SU*/S 9DCCESYG_3.O4_UPPG-"
M?)[DY\\X?^ _!_V]'F/-?!^)<*D?:?![E/TO+2?RD>I?";C]O3_N8;W_ -#E
MK4_9C;9^WBQ/_00U/_T"YKQG2?B+K&A^/3XDM;[R];:>2\-WLCY>3_IG_JZD
M\-_$[7O!_CAO$EA??9]:9Y)#=>7')^\D_P!9^[_U?_+2OG\+G>'C.$_Y*W/\
MCVL1D^)E"<%;WZ')\SU3QK&\W[$NBB-/F_X2Z<_^0Y:=^QC-;Z;8_$B:^L9+
MZUC\+S23VI?R_M,>>8M__+/(R/;.>U</X#_:?\>?#/P__9.A:]]CT_S)+C9]
MCMY#YDG/_+2.K4?[6WQ C\7RZ\OB!?[7:U^P&?\ L^W_ -1OW[/+\O\ YZ5W
M4<XR^.)HXU\_/"')\']V4?YO[QQU,ES*>%KX%<EISY_C_O1_N?J.\?\ CWP#
MKGA2ZM=$^&\VA:E((Q!?'7KBX^S'S.OER58_90E\2:3X]U#4/"\.GZA=Z?I\
MTUUIUUG_ $ZU_=[XXR/^6G^KJ'Q/^UY\1/%OA^[TW4/$ N+&]@D@G3^S[>/S
M$DX_YYUP_A3QCJ7@37X=2TJ\GL+VW&$EA&01]*\^IFE".84\1"H_<_N1A_Z2
M=E/*<3]1J86HE_X'.:_0][T.V\(_&KP9XT?0= USX>ZSI6E-=77V6Z<:?<I&
M/^/>3'!_ZYX%7?BSJ7@#3_AW\+?^$LTOQ!J5U_PB]KY/]GS)''Y?E_Q\UY-X
M[_:B\>?$;0Y-/U;7WDLYAB2)+>.W,H_Z:>7'7+^*_'6K>-;728=2N?/CT2UC
ML+7]W''Y<$?_ "S_ '=>IB.)\(J<X8>'/4_P0_FYOA/-PO#.*]K"I6G9:_;?
M\O+\?Z=-CZ1^#WQ#TOXQ?&.+Q=>6</AWP5\,=&\NTCDE\[RR?W:;_P  3_VR
MCJO\0=,TGXQ_LRZPFF^*(_&&M>"[R36))X[%[>2."XD,DB?/[!W_ .V8KYVT
M_P"(VLZ'X+U+P[:WGEZ/JS(UU#Y<?[QTQL_>?ZSL/RJ7P#\2-:^&-]=S:+>?
M8Y+Z![2?,<<OF(_(C_>5-'BZG*G[#$4^?GY^?_M_^3[/N\L32MPM5IU/K&'J
M6]GR<B_STO[W-(]V\>^+X_#*^'?#_P 4_!-OXFDAL88['6M*G=6EAZ1[.[R>
MP(KK= TF\^ WQ+^)%]9ZE?:I-:^%H]4MVU&7S;B(;S^[<_6,5X+X+_:S^(/P
M_P!"CT[2O$#PV<4?EVZS6\=P8_\ <WQ\_C7//\9_%#W^O74FL7,MQXF@\C4Y
M)XXY)+E/^>?_ $S_ .V==7^M.#IJG.GS\_\ VY[GNR^U]K_MXY'PKC:EX^YR
M/S?\Z^Q]CY:'U9:Z%:?"CXBZK\0K!X?)^(=YIMGHG(_Y>Y8WN_S\O/X5S/C/
MQ%KO@.?XA7=WX?TOQAX(O?$1@U#3VD=KFVG\N+]X?W>$SA/_ "'@U\\WGQI\
M4WFD>'-/DU222T\)O]HTQ/+C_P!%D_\ :G_;2M+0?VD/&_ACQ3J>M6.N7$-]
MJ\GFW>8X_+N9/]SR_+JI<78.?[N'/#_[:/O?XO>^S_*1_JCC8_O)N$^F[^S;
MEU6J]U;_ ,QVGQF\*:%K7P$T[Q5X737- TF35/LK:->W4C6^_81Y\ D/Z]#S
MTKQ.NH^)7QL\4?&">%O$6K/J$=N<PP"...-#[QQUR]?)YYCJ&+Q'M,/_ %_V
MY]@^KR/!XG#8;V>)_P _QZ^H4445XI[(4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%%..X'Z@_LY_\D"\$_P#8"L?_ $2M=N.E<3^SH/\ BP7@
MG_L!6/\ Z(2NV'2O[$RO_<Z?^&/_ *2C^4\=_O,_\4O_ $HD'2B@=**[SG"B
MBB@ HHHH **** "BBB@ HHHH **,T9H **,T9H **,T9H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHSB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JA>Z]8Z:_EW%U;V\G97D
M\NK]9=_X6TO5[CSKK3=.N)@/OSVR2/\ G0 [_A*-*_Z"6G_^!"?XT?\ "4:5
M_P!!+3__  (3_&J__"O=!_Z >D_^ <?^%'_"O=!_Z >D_P#@''_A0!8_X2C2
MO^@EI_\ X$)_C1_PE&E?]!+3_P#P(3_&J_\ PKW0?^@'I/\ X!Q_X4?\*]T'
M_H!Z3_X!Q_X4 6/^$HTK_H):?_X$)_C1_P )1I7_ $$M/_\  A/\:K_\*]T'
M_H!Z3_X!Q_X4?\*]T'_H!Z3_ . <?^% %C_A*-*_Z"6G_P#@0G^-'_"4:5_T
M$M/_ / A/\:K_P#"O=!_Z >D_P#@''_A1_PKW0?^@'I/_@''_A0!8_X2C2O^
M@EI__@0G^-'_  E&E?\ 02T__P "$_QJO_PKW0?^@'I/_@''_A1_PKW0?^@'
MI/\ X!Q_X4 6/^$HTK_H):?_ .!"?XT?\)1I7_02T_\ \"$_QJO_ ,*]T'_H
M!Z3_ . <?^%'_"O=!_Z >D_^ <?^% %C_A*-*_Z"6G_^!"?XT?\ "4:5_P!!
M+3__  (3_&J__"O=!_Z >D_^ <?^%'_"O=!_Z >D_P#@''_A0!8_X2C2O^@E
MI_\ X$)_C1_PE&E?]!+3_P#P(3_&J_\ PKW0?^@'I/\ X!Q_X4?\*]T'_H!Z
M3_X!Q_X4 6/^$HTK_H):?_X$)_C1_P )1I7_ $$M/_\  A/\:K_\*]T'_H!Z
M3_X!Q_X4?\*]T'_H!Z3_ . <?^% %C_A*-*_Z"6G_P#@0G^-'_"4:5_T$M/_
M / A/\:K_P#"O=!_Z >D_P#@''_A1_PKW0?^@'I/_@''_A0!8_X2C2O^@EI_
M_@0G^-'_  E&E?\ 02T__P "$_QJO_PKW0?^@'I/_@''_A1_PKW0?^@'I/\
MX!Q_X4 6/^$HTK_H):?_ .!"?XT?\)1I7_02T_\ \"$_QJO_ ,*]T'_H!Z3_
M . <?^%'_"O=!_Z >D_^ <?^% %C_A*-*_Z"6G_^!"?XT?\ "4:5_P!!+3__
M  (3_&J__"O=!_Z >D_^ <?^%'_"O=!_Z >D_P#@''_A0!8_X2C2O^@EI_\
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M^3_XY1_Q*AB/YO\ R=?_ "(?\1WJ^7_@#_\ DCUC_AW_ /$[_H!VO_@;!_\
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M@_\ \%\G_P <H_X?/_&#_GU\'_\ @OD_^.5/_$J&)_F_\G_^U#_B.];R_P#
M'_\ )'JG_#O[XH?] .'_ ,#K?_XY4G_#O_XG?] .U_\  V#_ .+KR?\ X?/_
M !@_Y]?!_P#X+Y/_ (Y1_P /G_C!_P ^O@__ ,%\G_QRC_B5'$_S?^3_ /VH
M?\1VJ^7_ ( __DCUC_AW_P#$[_H!VO\ X&P?_%U'_P ._?BA_P! .U_\#8/_
M (Y7E?\ P^?^,'_/KX/_ /!?)_\ '*/^'S_Q@_Y]?!__ (+Y/_CE/_B5#$_S
M?^3_ /VH?\1WJ^7_ ( __DCU3_AW]\4/^@'#_P"!UO\ _'*D_P"'?_Q._P"@
M':_^!L'_ ,77D_\ P^?^,'_/KX/_ /!?)_\ '*/^'S_Q@_Y]?!__ (+Y/_CE
M+_B5#$_S?^3_ /VHO^(\5?+_ , ?_P D>L?\._\ XG?] .U_\#8/_BZC_P"'
M?OQ0_P"@':_^!L'_ ,<KRO\ X?/_ !@_Y]?!_P#X+Y/_ (Y1_P /G_C!_P ^
MO@__ ,%\G_QRC_B5#$_S?^3_ /VH_P#B.];R_P# '_\ )'JG_#O[XH?] .'_
M ,#K?_XY4G_#O_XG?] .U_\  V#_ .+KR?\ X?/_ !@_Y]?!_P#X+Y/_ (Y1
M_P /G_C!_P ^O@__ ,%\G_QRC_B5#$_S?^3_ /VH?\1WK>7_ ( __DCUC_AW
M_P#$[_H!VO\ X&P?_%U'_P ._?BA_P! .U_\#8/_ (Y7E?\ P^?^,'_/KX/_
M /!?)_\ '*/^'S_Q@_Y]?!__ (+Y/_CE'_$J&)_F_P#)_P#[4/\ B.];R_\
M '_\D>J?\._OBA_T X?_  .M_P#XY4G_  [_ /B=_P! .U_\#8/_ (NO)_\
MA\_\8/\ GU\'_P#@OD_^.4?\/G_C!_SZ^#__  7R?_'*/^)4,3_-_P"3_P#V
MH?\ $=ZW]0?_ ,D>L?\ #O\ ^)W_ $ [7_P-@_\ BZC_ .'?OQ0_Z =K_P"!
ML'_QRO*_^'S_ ,8/^?7P?_X+Y/\ XY1_P^?^,'_/KX/_ /!?)_\ '*/^)4,3
M_-_Y/_\ :A_Q'>M_4'_\D>J?\._OBA_T X?_  .M_P#XY4G_  [_ /B=_P!
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MW]0?_P D>L?\._\ XG?] .U_\#8/_BZC_P"'?OQ0_P"@':_^!L'_ ,<KRO\
MX?/_ !@_Y]?!_P#X+Y/_ (Y1_P /G_C!_P ^O@__ ,%\G_QRC_B5#$_S?^3_
M /VH?\1WK?U!_P#R1ZI_P[^^*'_0#A_\#K?_ ..5)_P[_P#B=_T [7_P-@_^
M+KR?_A\_\8/^?7P?_P""^3_XY1_P^?\ C!_SZ^#_ /P7R?\ QRC_ (E0Q/\
M-_Y/_P#:A_Q'>M_4'_\ )'K'_#O_ .)W_0#M?_ V#_XNH_\ AW[\4/\ H!VO
M_@;!_P#'*\K_ .'S_P 8/^?7P?\ ^"^3_P".4?\ #Y_XP?\ /KX/_P#!?)_\
M<H_XE0Q/\W_D_P#]J'_$=ZW]0?\ \D>J?\._OBA_T X?_ ZW_P#CE2?\._\
MXG?] .U_\#8/_BZ\G_X?/_&#_GU\'_\ @OD_^.4?\/G_ (P?\^O@_P#\%\G_
M ,<H_P")4,3_ #?^3_\ VH?\1WK?U!__ "1ZQ_P[_P#B=_T [7_P-@_^+J/_
M (=^_%#_ * =K_X&P?\ QRO*_P#A\_\ &#_GU\'_ /@OD_\ CE _X+0?& ?\
MNO@__P %\G_QRC_B5'$K7F_\G_\ M0_XCM6>G_MC_P#DC].O@YH-UX.^%'A?
M2KQ0EYINDVEI.F[[CQQ(CUUFS -?,/A?]K7Q1J?@?PY?21Z2+C4]%TW49Q]F
M?A[BSCGD_P"6G_/23'TJP/VK_% _ATK_ +\?_;*]BAPKBZ5)4XK2)\S4SJA.
M?.?30X%&:^8?^&M/%'_//2?_  'D_P#CE1_\-=^*/^>6D_\ @/)_\<KH_P!5
M\?V,_P"UJ'<^H<T9KY:_X; \6?\ /'2/_ >3_P".5'+^V#XL!_U>D_\ @/)_
M\<I_ZJX_L']K4.Y]545\H_\ #8WB[_GEI/\ X#2?_'*C_P"&S/&'_//0_P#P
M'D_^.57^J>8=C/\ MK#GUEFBODF;]M+Q@/\ EGHG_@/)_P#'*K_\-L>,_P#G
MGHO_ (#R?_'*?^J.8]@_MK#GU]17R!+^VYXR'_+/0_\ P'D_^.5'+^W%XR'_
M "ST/_P'D_\ CE7_ *GYCV_$/[:PY]?YHW5\<?\ #=7C?_GAHG_@')_\<IG_
M  WAXV_Y]]$_\ Y/_CE/_4G,_P"[]X_[:PY]E?A1^%?&/_#>7CC_ )XZ#_X!
MR?\ QRHY?V]_'8_Y8Z#_ . <G_QRM/\ 47-.T?O(_M_"'VE^%'X5\4_\-_>/
M/^>.@_\ @')_\<J/_AX)X\_YXZ#_ . <G_QRC_47-.T?O%_K!A.Y]M?A1^%?
M#O\ P\*\??\ /'0?_ .3_P".5'_P\/\ '_\ SQT#_P  Y/\ XY6G^H6:=H?>
M/_6#"'W/N;T-&YO0U\*?\/%?'W_/OX?_ / .3_XY47_#QKX@_P#/OX<_\ Y/
M_CE5_J#FG]S_ ,#)_P!8L)W/O'?_ )S1O_SFO@J7_@H]\0%_Y=_#?_@')_\
M'*C_ .'DGQ _Y]_#?_@')_\ '*U_XA[F_P#<_P# T3_K'A#[YW_YS1O_ ,YK
MX!_X>4?$/_GW\-_^ <G_ ,<IG_#ROXB?\^_AO_P#D_\ CE/_ (AYF_\ <_\
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M_P#X R__ !RC_B$V?=H?^!D_ZW8#N?JUG_.:-U?E#+_P65^+J_\ +KX/_P#
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M ,!TH_X1;3O^@;8_^ Z4 6/[8L_^?J#_ +^"C^V+/_GZ@_[^"J__  BVG?\
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M^V+/_GZ@_P"_@H_MBS_Y^H/^_@JO_P (MIW_ $#;'_P'2C_A%M._Z!MC_P"
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M $#;'_P'2C_A%M._Z!MC_P" Z4 6/[8L_P#GZ@_[^"C^V+/_ )^H/^_@JO\
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MP3V^)_[''Q2_:CTFU^$?PUUK0?'NGVUQ>V5]=6\D<<<?E>7)UN)/^6<F/N4
M?:'P<_; ^&?Q]\3:AHO@WQGH>O:QI<9EO+&UES<6D>_R\E/^N@QFG>)/VO/A
MGX1^,5G\/=1\9:';^.-0D@BM]&,O^E2/+_J\)[U^;_\ P51^&6L?\$U_VS?#
M/[2GPU^QVUGXEOWMM8TZ27RXI[ORSY\>SO'<Q>9S_P LY8_,_P">>.F_X(Q_
MLF:C^T'<>,OVD_B%??;?$GCR6_LM#N/^6EIYGF17%Y'_ ,\R?]5$/^6<<<G_
M #TH ^AO%W_!6#0QX[N=*\(Z/HWB*SCNQ!'?ZCXRTKP^=9_>>5_H$%Y()+F/
MS!)$),1Q2212;)#7N'PK_:G\'_%/X177C ZA_P ([8Z&\EOK<&N%+&X\/7$6
M/-@NQ)_JY(\]S7Y>>.? L6E:)J'A;QGX@TCX<ZWX)\'^&_"EYX4UFY^Q6OC?
M^SKV22X\N3R_,DCN8Y(Y(Y+:3S/,DD\ROIC5_P!A67_@I!\-_B)K6J:AXH^&
M&@?$3Q19Z[I=@;6/[5=6EGIL=G%/<0'[AED\R3R^O[N(T ?5?PD_;$^%O[0^
MO7&D^"O'OACQ)JEJOF2VMCJ$<DOE]-X0'+I[UZE7XA^%O"_PU\9_\%<?ACX;
M^ >FW'@'3OA_JD=KK%]J>IF-M9DL[F07'V??))YGF1_N]G'F>9GR^]?M=>:]
M8V4OES75O')_<>04 >7_ !!_;<^#_P *?&-YX?\ %'Q&\%Z#KFGE/M%A?ZI%
M#<Q%X_,&^/.?]6^:O?"S]L+X6?&OQ/\ V'X0^('A'Q+K'E//]DTW4X[J;RTZ
MOL0]*\"_;S_87_9O70/'7QN^)'@^?5;RULAJ-_/'K=Y;?;9(HTC@C01R"/?)
MB*('W%>+_P#! K]B.ST;0-4^/.H:<=-N_%,EQ9>&-.CDE\O2]/\ -'F<R?O'
M_>1F.,R=(X\_\M* /O?XY?M'^!?V:M"M-3\=>)--\,Z??7'V>WEO)-JRR??Q
M7=Q3+,@9?NFOPA_X*Y? WX[:=I>A_$;XW^(K&YO->U2XT[1_#UI)YD6C6_\
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MD<]5YZL3U7GK0".>J]6)ZKUH9D<]5YZL3U7GKH,SZ*_X)+?\GV^$_P#KA?\
M_I')7[$9R?PK\=_^"2O_ "?;X2_ZX7__ *1R5^Q ^]_P&OY?\8?^1[#_ *]K
M\Y'ZAP7_ ,B]_P"-_H34445^5GV 4444 %%%% !1110 4444 %%%% !1110
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MI?MQ>'_A)=_#/1_AEI.M+X5^'NI2:I/)J\D<=]JUQ(/+DW^7^[C_ '<DD?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ\'_ /A(WG_R/7Y@T4?\0MH_]!E?_P #7^0?ZT3_ .?$/_ #]/O^%[_L1?\
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M/1_PO?\ 8B_Y\?!__A(WG_R/7Y@T57_$+:/_ $&5_P#P-?Y!_K1/_GQ#_P
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MOS!HH_XA;1_Z#*__ (&O\@_UHG_SXA_X ?I]_P +W_8B_P"?'P?_ .$C>?\
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M #_\#%_:3_D@2?L^ZYXV_P"%BK_PM:Q_9M_X1/[.^_\ X1/2-9_M+S/^6?\
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MP7_ECS?*\R/S/(\S.,_O/+QFOF__ (2+XL?] W]B[_PG_$O_ ,;JU/5>M/\
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M=$^R?Z'_ ,(;X8UO[1]HW_\ +7[7!Y?E>7YG3G/M7A<]5YZZ/]1:7_056_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC?XN_P"%02ZI_:I\+I;_ +R23I_K/,\OS/+_ .6GE?\ ;.OTLHH ^-_V^/\
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M[H?9Y/\ IIY<GF5.;93E^$]I/$XN=.%7GGR6AZ3^PY&N%Q6(KJ"IT_X9ZMX
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M10 4444 %=]^S'\#+K]I#XYZ#X/AFDMX]3N/W\T:>9]F@C_>._XQUP-?7?[
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MFH4Y[:U'.TM9?W>NUI_<J&6X>%3_ !\\X?X.3^O_  $\=\3_  Z^ >G1:?\
MV3\1_%VI22W\$=XCZ%Y?E0?QR=/^6===>_\ !,O6Q^T?!X;AU2.3P!=6']N?
M\)<4 MH],_C?/^J\P_U\S_5U3^,WA_XF?&[0]-T5OV>="\%R3:I;[+[1_!T^
ME222/B)(Y+A_^6?S_G''7TO;OX;_ .%7-^R4?&%X/%:Z&<ZQYW^CB_\ ,^T?
M8/7R^V/^>7[O_65IC>(,?A:5)X>NW4?.I_!4Y(:?O+P6\>P8; X>I.?M(?\
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MZ1^D\%_[I/\ Q_Y$@Z44#I17Y(?9!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_&;Q_P" 8?B9IU_9^,]%3PMIOAU-(G0Z1-91R%)(YW_=R&.3[1)]?+Z\9R?
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M\$+O%H8C_A.?#O'_ $Z3_P"-=*?^"17Q+'PK/@C_ (67H/\ PBXU+^V/L/\
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MO#O_ (!24?\ $2.'?^@K_P!+_P#D0_U;S/\ D/A6BONG_AQ5XN_Z'CP[_P"
MD_\ C2_\.*_%O_0]>'?_  "DH_XB1P[_ -!7_I?_ ,B'^K>9_P A\*T5]V_\
M.+?%O_0\>'O_  !DIG_#BOQ;_P!#UX=_\ I*/^(D<._]!7_I?_R(?ZMYG_(?
M"M%?=/\ PXJ\7?\ 0\>'?_ 2?_&E_P"'%?BW_H>O#O\ X!24?\1(X=_Z"O\
MTO\ ^1#_ %;S/^0^%:*^[?\ AQ;XM_Z'CP]_X R4S_AQ7XM_Z'KP[_X!24?\
M1(X=_P"@K_TO_P"1#_5O,_Y#X5K3N_&>M7?A6WT&?6-6DT6QN/M$&G/=R?9K
M63_GI''_ *OS*^U?^'%?B[_H>/#O_@)/_C3O^'%?B[_H>/#O_@%)4R\0N&:G
MQ58?<_\ Y ?^K>9K[!\7^"_BAXE^'<5W'X=\1:UH,=]Y?G_V;?R6_P!I\O\
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M\$+?%RC_ )'CP[_X"3_XTJ_\$+O%CCCQQX=_\ I*R?'G"[G[=U8>TVO9[?\
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M *7_ /(A_JWF?\A\*T5]T_\ #BKQ=_T/'AW_ ,!)_P#&E_X<5^+?^AZ\._\
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M,4?T&EVXK8KQ?X:?#NW\&7WAN/4?VZO@_K&A:##:64FF>5HT?FP6Z1Q?9_M
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M5_VB_P#@G+X@\'VEOKEY^T#X+^%_A_\ X]Y'U;3K<VLMQ^\/^MGDC'<?N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU\5Z#J&@SWR;[=+I/+\U*5+ \.U:OU6E3H>T_P"W"ZE;,(4_:/G_ /)CO?\
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M?$?_ '\CH_X>#?&?_HHGB/\ [^1UXQ11_J[E7_0/3_\  (!_:F,_Y^3/9_\
MAX-\9_\ HHGB/_OY'2?\/!?C9_T47Q%_WW'7C-%'^KN5?] ]/_P" ?VIC/\
MGY,]G_X>%?&C_HHOB/\ [^1T?\/!OC/_ -%$\1_]_(Z\8HI_ZNY5_P! ]/\
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M\_"E\.?#^B_!S7)-4\'^&_"WA/4[JW^S276C:'965S-'_K/+\R./_5_NX_\
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MX+:G<7O@^WT/PG>72?9[B?1M'LK*26/_ )YR21QUGSU7GJ_['R__ )\0_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSS#8#$0E@&ZM2;J;PY->73X_Z[G3BJ>#JU*;5?W(?XSJOVDOC^WP2T7P_P#
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M6GVB6PM+B*2.22.,?\\Y?,C_ .N=;?A/1+GQ/X7\=S?!_P",G_"S%US2KO\
MM#PEXMBN3<R02#]Y*GF21[Y.H\SR\?O/>O&?"7_!1_6O"?A[X<QQZ#:7>M>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_)-'_$<)_P#0(O\ P/\ ^T#_ %&7_/\ /RQHK]3O^'VWPG_Z%_XA?^"^T_\
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M]%_*C_B-\_\ H$_\G_\ M _U&7_/Y_<?SRT5_0UY"^B_E1Y"^B_E1_Q&^?\
MT"?^3_\ V@?ZBK_G\_N/YY:*_H:\A?1?RH\A?1?RH_XC?/\ Z!/_ "?_ .T#
M_49?\_G]Q_/+17]#7D+Z+^5'D+Z+^5'_ !'"?_0)_P"3_P#V@?ZC+_G\_N/Y
MY:*_H:\A?1?RH\A?1?RH_P"(X3_Z!/\ R?\ ^T#_ %%7_/Y_<?SRT5_0UY"^
MB_E1Y"^B_E1_Q'"?_0)_Y/\ _:!_J,O^?S^X_GEHK^AKR%]%_*CR%]%_*C_B
M.$_^@3_R?_[0/]1E_P _G]Q_/+17]#7D+Z+^5'D+Z+^5'_$<)_\ 0)_Y/_\
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M2BOQ@_X++?M#^//CW^V5X@\(_#G4M:BT?X-^'Y+G5QIE[);@/^ZDO+B3R_\
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M/^NDE=97)ZC_ ,?]Q_UTDH KU^<_PE^/W@O]GO\ X+ _M"7WC3Q-I/ANSO\
M3[.VMY[^3RXI9/+MJ_1BO/\ QA^R7\*_B#XCN-8\0?#7P!K6L7__ !\7]_X?
ML[FZNO\ KI))'YE 'P?_ ,%AOVA-'^/WA+X-S^#O$?A_Q)\-Y?&$EEX@GDO)
M(]'^V1_9I(X[R2/]Y''Y<EQ_JZ\+U'0?$'@_X+?M.1^ /$7@&X\-W6GZ7_;&
MB^ ;S4+ZQTO_ $FV\R2.XN+?RY(Y8_M'F>7))_RT_P"6<=?KAIO[-_P]T?P)
M>>%;3P)X-MO"^J7'VF\TF#0[>.QNI/\ GI);^7Y<DG[N/_OW7/\ CS]EW38?
MV??$'@OX:_V;\*;C5$_T>_T;2XXXK63S/^6D?_+3S/\ 5R?],Y* /RWNX?@7
M9_M!_L?_ /"H9(_[<EUC1Y/%D<$DG_'Q]ILO+^T>9_R\>9]H_P!7_P#&ZXOX
MD:/_ ,+"\;_M"3^/]5^%VD^+(O$DD?V_Q9JFH1Z[8>7<_N_[/M[>.3S(_P#M
MG_J_^F=?<'P?_P""6WC[_A;_ ,.]8\?^)OAW_P (_P##34/[:L[3PGX?CTV7
M6;S]WY<EQY<<<?F>9''_ )DKZ\\8?LW_  \^(7C*W\0:YX#\):WX@M?]7J5_
MH]O<W7_?R2.@#\\_%7P?M_CS_P % _V6_#/Q&DC\71W7PSCDU23_ $B.+69(
MX[V2.23S(XY/WDD<<G[R..O#_BUH^I?"OX&?M<>$?!WVZQ\)Z-\2-+MKBT@D
MD\JUT_S+V/\ []^9'9Q_]LJ_92]^&/AW4?'EGXFNO#^AW/B32[?[-9ZM)I\<
ME]:Q_P#/..X_UD<?[R3_ +^U7L_@SX/TV7Q!):>%?#=M)XM_>:YY>EV\?]L_
M]?'[O_2/]9)_K/\ GI0!^7*:'\"?#O\ P4P_9SA^"$VFW%GL235'L;R2YC\S
MR_W?F?\ /.X\O_65^M5<%X5_96^&7@F\TNXT;X>^"=-N-'N)+G3Y+30[>.2P
MDD_UDD<GE_NY/W<?_?JN]H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K2\-?\?DG^X/YUFUI>&O\
MC\D_W!_.@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXI^!8/BA\,O
M$GAF>:2WM_$FEW&E2S1_ZR))XGB+CW^<U\;?\.+/"/\ T/?B3_P#BKZH_:ON
M9K3]EKXE7$,C6\T?A74Y8W1MKQR"SE(_&OQ-_P"%P>+O^AF\2?\ @?)_\<H
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MXD_\ XJ_/'_A<'B[_H9O$G_@?)_\<J3_ (7!XN_Z&;Q)_P"!\G_QR@#]"O\
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MQ_.@#[$HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N3U'_C_N/^NDE=97)ZC_Q_W'_722@"O111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<GJ/_'_<?]=)*ZRN3U'_ (_[C_KI)0!7KE_B=\;/!WP3
ML([KQCXJ\/\ A>WNO^/>35M0CMO-_P"N?F?ZRNHK\]_VM--M?@/_ ,%"=<^)
M7Q;^%>K?%'X9ZSH=G9:'?VFEQZO:^')(XX_,\RWD_=_ZSS)/,D_YZ?N_^6E
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MV?\ PCX.\.1^+?B)\1KS6++0[">X^S6L4<>HW,EQ<W$G_/./S* /T8HKY?\
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M'KBXDT?68X_]9'^\_>QR1^7)_GR_, /J"BOSW\*_\%/OCUXU_9:D^--C\,_
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M;O?_ (W0!YW17HG_  R-\6/^B7_$3_PF[W_XW1_PR-\6/^B7_$3_ ,)N]_\
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MN6NAWF@^,-"\+V?F7VEV\DDDEO)';^9^\DC\S]Y70:#9^*OVV/VW/"_Q-M_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO&VN>$?MFN_"FXN4UWPM]HDMY;?S8HTO.?\ 62?N_,_==O+QVH Z?Q'^WO\
M&[P?H5YJFH_L\ZE96&F0275Y/)JC^7%'&/,DD_U5<9\0O^"P/CKX6_V7_P )
M%\'?[(_MBW^V6GVO5'C^U1?WX_W=?//Q2TOP?I_P\UB;2_VHO$7BR_\ LTGE
MZ/)H>J6T.J?],O,DE\NOI_X_Z'H/[5OA+0O@O=QVNG^,[7P;I_B+PA?2_P#+
MW/Y9^T6__?N,?^C/^6= ":'_ ,%/_BKXEU?2].T_X%W%Y>:SI@UBSA35'S=V
MAX%Q'^[_ -6<BMSQ#^WQ\<?"FAWVJ:C^SSJ-G8Z9;R7-S.^J/Y<44<9DD?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT*W@;4/+_LN.X_U<GF>7^\\OR_\ IG7E-% 'I?P._:)_X4I\/OB)H?\ 8_\
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MBHKG?[9\1?\ 0!T__P &?_VNC^V?$7_0!T__ ,&?_P!KH Z*BN>_MKQ'_P!
M&R_\&G_VND_MGQ%_T =/_P#!G_\ :Z .BHKG?[9\1?\ 0!T__P &?_VNC^V?
M$7_0!T__ ,&?_P!KH Z*BN>_MKQ'_P! &R_\&G_VND_MGQ%_T =/_P#!G_\
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M_"CD_P#CE'_#LW]FW_GUM?\ PHY/_CE 'Y)T5^M?_#LS]FW_ )]8?_"CD_\
MCE+_ ,.S?V;?^?6U_P#"CD_^.4 ?DG17ZV?\.S?V;?\ GUM?_"CD_P#CE'_#
MLW]FW_GUM?\ PHY/_CE 'Y)T5^M?_#LS]FW_ )]8?_"CD_\ CE+_ ,.S?V;?
M^?6U_P#"CD_^.4 ?DG17ZV?\.S?V;?\ GUM?_"CD_P#CE'_#LW]FW_GUM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/[:OBOP#H/A^UMO!NBZ1<:EI>KO(_P!NO3'<6T7SQ](XY/,D<>WEUJ_M]?\
M!4*\_98^,'AOX9>!_!-W\2/B1XBMQ<QV$%QY<5M$_F^5G8'DDD_=N?+ &$_>
M9Q0!]DT5\G_\$Y_^"D5K^W(OBC0=2\,W7@?QWX,E\K4M&GN/-"H9)(S)'D))
M\DD9CDC(_=DQC/->'_%__@N%XDG\;>-;?X0?"*^^(?A7X>^9-KOB!YY!:K'&
M)/,<>7&?*C'ER'S)#]R//ET ?I!17RYX$_X*<^ _%'[!\_QZO8;[3=#T^-X]
M0T]F6:ZCO!*(_LT8S^\,LDB>6?\ GG(#\G2OFS1_^"]/BO0=4\+^(/'GP1U+
MPO\ "[Q?/Y>G:X;Z221T'WY$)B2.X_W/W9^M 'Z;457MYX[V*.2-DDCD^>-U
M[U8H **** "BBB@ HHHH **** "BBB@ HHHH YOXJ?\ )*O$O_8,O/\ T4]?
M$=?;GQ4_Y)5XE_[!EY_Z*>OB.@ HK0\*Z#_PE7BC3]-\Z.V^WW'V;S)/]5%5
MCQ)X)OO#GC*XT-T\R\BN/LW[O_EK_P \Z ,>BNZ\:? JY\%:9JUT^I6-U_9$
M]O;SQQ^9R\E:%G^SF\(L[74?$>BZ3J]]&DEO8S2?O?WE 'FM%=7HGP6UO6_&
MMYH)CCMKC2_^/N>>3_1K:/\ YZ>96KKWP(DL_#%YJFCZ_I.OQZ7_ ,?B6DG[
MR*@#S^BO1KO]GZUT>WLWU'Q9HNFW%_;QW$<,_F>9Y<E5=!^"L?B/Q%JEK:^(
MM)DL],L_MLE\GF>7Y= '!T5Z)/\  /[7H5_?:'XDT76Y+%/M%Q!;O^\\NL_X
M6_!34?BQ:ZI/8R1Q_88_XQ_K9/\ GG0!Q=%=!X/^'T_B^PUR:.>.V_L&SDO9
M(W_Y:US] !178?#WX3?\)WX=U#5)]8L])L]+DCCDDNQ_STJ3QA\%)O#?A/\
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MR5YW\)OVE]#^,OQ/^('A'2;/5K?4/AS>6]EJDEW''%%+))'YD?V?RY/^F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA^%_A^XU7PG)>>!_BY'X\U"2.XN/*ET_S/,\N/\ T?\ X^/_ "'_ --*]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!@_$'2)M=\":U96J[KB]L+BV1,]7D
MC('\Z^9?^&4?''_0-MO_  -CKZ>\=ZS)X=\%ZQJ%OY;7%C93W,>_IO2,D?RK
MYQ_X;)\6?\\]'_\  :3_ ..4 9__  RCXX_Z!MM_X&QT?\,H^./^@;;?^!L=
M:'_#9/BS_GGH_P#X#2?_ !RM^T^/?Q$N_ ,_B1++0_[-MGV._E]A_P!M/<4
M<A_PRCXX_P"@;;?^!L='_#*/CC_H&VW_ (&QUU7@+]H+XB?$6]DM-'T[2;F2
M*/S))#!Y<<7_ )$K4\7_ !:^)?@JWM[BZM/#\EK=/]GCG@_>1[_^_E ' _\
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M\,H^./\ H&VW_@;'1_PRCXX_Z!MM_P"!L=>K?\)'\5OL_G>7X2\O[GF;^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7)ZC_ ,?]Q_UTDKK*Y/4?^/\
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M$Z[XCNO$^NSZA>3?:+NYD\QW':@#U#XO_P#)W%G_ -A#3_\ VG3OBQ%\.?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?>$?$_A;P3K4,4>S7?$,_EV.EQ^9^\E_U<G[SR_]7_TTK\_+S]JVT^$OQ?\
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M)*CM/^"6%]XT_9H^(&C^-/%D=U\4/B-KL?B>\UVPMY/LVEZA;_\ 'O';Q_\
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M']BCX3^%;7Q-HFD_%CX0:Q<:UH^K0>9<Z9+))>R2?9I/,CCD\N2.2/S/W?\
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M^$1_Z>/_ "'1_P (C_T\?^0ZW** ,/\ X1'_ *>/_(=._P"$3_Z>/_(=;5%
M&'_PB/\ T\?^0Z/^$1_Z>/\ R'6Y10!A_P#"(_\ 3Q_Y#IW_  B?_3Q_Y#K:
?HH P_P#A$?\ IX_\AU8L= ^QS[O.WY3'*5J44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /2!6\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR'3/^3G=:_[!B?\ H$= &7\:-,BUKXC^"M,FDDCBNW\EGC.&4-(HR#ZUL?\
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M.<UZK0!E^''UJ30+1_$45K%JQ#>>EJ28U^8[<9)_AQGGKFO,/BQ_R4_X=?\
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MXR0"#R.HX% %O]HF"$^"=-NBJ_:8M218G[@,CE@/KM7\A3?CN\DGPMTEYO\
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M9/&([S:9KH @XE;D@D<$@87(_NTOQ(\,-XM\":EI<,8DNRGFVH) _>KR "<
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M(TQ9%M82Q7S'W-EF+')^I->.?%)[KXE^-(?!6@1PR'2HY+BYN6 ^63;]S=U
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M9P#@#.<5?T?X5:A<>)K/Q#XS\1RZU>69W6]NJ;(D8<@_3.#@ <@9R.*]/HH
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M_P 50![117B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\
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M17B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\ \-(^'/\
MH#:K_P"0_P#XJC_AI'PY_P! ;5?_ "'_ /%4 >T45XO_ ,-(^'/^@-JO_D/_
M .*H_P"&D?#G_0&U7_R'_P#%4 >T45XO_P -(^'/^@-JO_D/_P"*H_X:1\.?
M] ;5?_(?_P 50![117B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4
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M^&D?#G_0&U7_ ,A__%4 >T45XO\ \-(^'/\ H#:K_P"0_P#XJC_AI'PY_P!
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M_P 50![117B__#2/AS_H#:K_ .0__BJ/^&D?#G_0&U7_ ,A__%4 >T45XO\
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MB@#X=\;?\C[XB_["ES_Z-:L*MWQM_P C[XB_["ES_P"C6K"H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% 'P[XV_P"1]\1?]A2Y_P#1K5A5N^-O^1]\1?\ 84N?_1K5A4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%%,!<444520@HP*,4X#)JU!MV07
M&XJ1$+59MK1YW"J,DUT^F^#KJZVL1@'VKU*& ;]Z6QR5\73I+WF<]9V332
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M>L_L\?\ )2)O^P=+_P"AI0!]34444 %%%% !1110!\.^-O\ D??$7_84N?\
MT:U85;OC;_D??$7_ &%+G_T:U85 !1110 4444 %%%% !1110 4444 %%%%
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M3#7@57J?5(****YQA1110 4444 %%%% !1110 4444 %%%% !1110 4444T
MY>M=)X8M!<:@@(R,USB#FNO\'NL=\I)Q\U>UEL-;G!CY.-"5CW#1;(1VT<8&
M/E%=3:6@0BN=TN=/*1L@_**Z2&_B"@YK\BXJ>)GC)*2=CP,@="SE5:YKE?7U
M+6VQ1D\5R>G://+>@@$#/I7;/J-LP^8 U1EU9$XB0+]*\+"K$<O)"#U/O_\
M67"X.@X\R'ZF1#:I$.H%<AJR[D/O6U/<-.Q))_&LN[7S#@U^E\(X&IA).=72
MY^39KF*QN,]K'8Y1+8F<''>NMTY-D0^M9OV=4?-:EHPV@9K[G.&ZN&<8G!B*
MO,DS?M)@B_A3;RYW*16>DI7BFR2%J_$UE52.)YIK2YZ\LW7U;V<2M>R;8SCO
M7#ZO&9=QQGK7>21"5/>L34+%%C8D=C7[+DM6E"BJ2W/'P==1EYGC>L6^UR<5
M@2#!KM?$J1QNV".E<7*>:Z<>HVN?HN!FY4TR TE*:2OFI;GIA1114@%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 Y!DUW'@[3/M-PK$9Z?SKB$.
M&%>A^!=06&14(]/YU[V6:)M;GDYJYK#OD/7K"V$,2Q@=*ZG3%"+SQ7,VTX8!
MQ6G'J!C7 K\IXDHXS%8EQY=#YG),70PLG4JO4W'A@CE,K$9ZUAZI<B5S@\5%
M/J)<<FLB\OE5&/>HR'AW$U<1&I46B.S.<]6+I^QI;,S=5D!W#WKG7;YZOWMW
MYK&LMCEJ_=\/2]C",$>-AX<L;,TK1@6%=#9.,8KEK=L$5KV]R46L\50=:FXL
MPQ-/F5CJK6Z:!P0>];<&IHXR57=ZXKBH]14#!%78+Q2,J:_)<XX2J<SJ4T=>
M SC$X)<GV3H+L>?\V<UC31]5(!%3"[;&*J7-TL:%F->9DV79A0Q$8QC97%F.
M+P^+]Z/Q'G'CNWC7)  .3_*O*)1\U>C>.-36:5E4]S_*O.)#\U?K6,TIQ4M[
M'U&30E'#KF&,,"FTXG(IM?/R/>$HI:2LV@"O6?V>/^2D3?\ 8.E_]#2O)J]9
M_9X_Y*1-_P!@Z7_T-*0'U-1110 4444 %%%% 'P[XV_Y'WQ%_P!A2Y_]&M6%
M6[XV_P"1]\1?]A2Y_P#1K5A4 %%%% !1110 4444 %%%% !3XE#S(AZ,P!IE
M26__ !\Q?[X_G0![/XG^'_PL\(:L-,UC7O$$5T8UEVHB.-ISCD1^QKD?$>G?
M#*#0;F7P]K>MW.JKM\B*YB C;YANR=@_AW'KUQ7I_P 6O!WAO7?&:WFJ^-[/
M1KD6L:?99K?>VT%L-G>.N3V[5Y#XO\*Z!X?M+:72/%]KKDDLA5XH8/+,8QG)
M^8_2@#D:*]_\1:[H'P^\.^$KZV\*Z7>ZGJ.E0^8TT2A5144L< <NQ<Y/M7.Z
M/'HWAKP%<_$*^T2ROM1U6_DATVRFCS;6PRQ)V="!M;Z84#&2: /(J*]H\-7N
MF_%^'4M"U30M,L-<CMFN+"_T^#RLE<#8XR=PY'MC/0C-0^#8] T_X(:AX@U7
M0[34;FSU<^0LJ#YV*1A5=L9* L6*]#B@#QVNFTSP=+J'@+6_%9NTC@TV2*$0
M!26D9W0=>@ #Y[YKT?0M4T_XH>$?$UGJGAW1[*_TNQ:ZL[K3[?R2NT$[3R3C
M('&<$'ID9J?P?XLEL_@)KMV-'T>4Z;<00+'+:;DG!>,;I1GYV^;KQT% 'A=%
M=[X.UGP_8V^K:C<Z%'JWB6:7_B76#VQ>V0$Y9MHZXR<#_9&",YKTCPW9ZEX^
MTS5[#Q=X%M--@6R>2TU&+3S:O'(,8 )Y/7/''RD'.: /+M)\(6-_\*M>\523
MW"WNG744,4:E?+8,R EAC.?G/0CM7%UZIX<_Y-T\8_\ 80M__0X:\KH [?P1
M\/CXFLKS6]5U%-)\/6/%Q>R+DLW]U!W/(_,8!/%;UOHGP>U.Y33;77]?M+AS
MLCO+I$\DL>!N&T$#Z[?<U=\9C^S_ -GOP;:6H*P74YFG93PSX<X/KRQ_[Y'I
M7CM &_XR\(W_ (*\1S:/J!5V4"2&9/NRQG.&'IT(QV(-8%=9H$.J?$;QKH^D
M:KJEU/YK"$22N7,42@LP4'@<*?QKL=?^(NF>&/$-UH&@^#] ?1K&4VT@N[7S
M);DH<,2Y/J#@G/J<]* /(J*]6\8>%M%LO%?@[6]&MA%H_B%X9Q9N-PC;>F]>
M>V'''3KVQ71?$7Q?H7@CQ)J?A[2?!^C3-+$'N9IX%.V1T!4*H& JC:<=R3TZ
MD \M\1>#I?#OACPYJ\UVDK:U'+,L2*<1*NS&2>I._GCC'>N9KW3XG^+)?^%:
M^$1_8^C_ /$WL92W^B?\>N!'_J.?D^][]!4MYH=]\.=$TBR\.>"/[=UFYMQ<
M7VI3:=)=)&6_Y9I@?+CGTX )!)X /!J*]?\ &OAM=9^''_"83>&&\-ZS97*V
M]];+;-;QW"-@"148<<L!G_>R3@5)I.AZ=\6O!%M:Z;;6&G^*])=$F,<2Q+=0
M,0/,;:!DCJ?<'^\* /'**]#^)E]H&G?9/!_ARTM6M]+^6ZU$1+YUS/SNR^,X
M!)XSC/'0"O/* "BBB@ I:2GHCR-M168^@&:J(AM**D^RW'_/"7_O@TX6MQ_S
MPE_[X-;05P&IUJ_:2F-P15=;6?\ YX2?]\&K<%I<,P_<R?\ ?)KV\+[IS5;-
M:G2Z?J3J1@FNEL[AYP 2>:Y6PL)]P_<R=?[IKTSP'X<CU;5!;7@EC0Q,P9>"
M".G6O6554XNI+9'S6(I*4U""U9#:V)?!-:<.F<<UU5SX0O-,RT:BYA'\2#YA
M]5_PS6=@CC&*\+%YO+FM3V/E\:Z^'GR5(M%*&R5#FK1^7 '2GTA KY_%5JF(
M7OL\UU)2=V (Q2+UHP*51BO-H8?V<]!SJ.2*TT635.:$BM5ER:C:$-7U&'QJ
MIV3+A5L<;JV](V(]#7G>MW+[B,FO7]3L \+?+VKR[Q)8^6S_ "D<U])&LJM*
M\3ZO*:T)22.+E8DU 34\HP34!ZU\YB[W/MH;"4E+25YS- HHHI %%%%( HHH
MH **** "BBB@ HHHH **** %IZG%,%.Q753DUJ2R56S6EI_S3* >]9B+D5T'
MA^P:>Z0X.-PKW,'S.2./$R4:;;.Z\/::)55F4'(KO+6RB@0?(*S=!TY8+9"1
MVK=/) %<.;8^<?W5-ZGYICL2YU&DQ01V%+P*C:14XS30^\\5X].C5:YIGF\K
M>I/G-%)]T4W=6$ZBB[$V'<4TC!R*&&Y<BF*Q!P:N5%5:=T5%=4//3BLO5X/,
M@)]C6GTJ*YC$ENPJ<JE*AB5%['1"I::D>,^)( KR5Q[CBO1?%FGMND(!KSV>
M,JQ4]J^TQ2NKH_1\LJ*5)%0TPU(13"*^>JQ/:0VB@T5QO<H****0!1110 44
M44 %%%% !1110 4444 %%%% !2TE+5Q0#TZULZ/=&WN%;..:QT'-68V*$$5[
M6";B<U:"G%IGL&C>)B(E5W&,#K756VLI.HPWZUX?I]RY8 $_G7H>A!W"_-Z5
MW5\!A<2N:I!7]#XG'8&-)N2=CN!<;N0336F*BH8%PHS23R;17C0R_#PJ6IQ_
M ^=:N[;B_:7)ZTI;=R:S_.^:K,;Y6O4EA>57L:.G;8BF8@DBF17+(PYJ69>,
MUFSL4KOI4X5(69O"*DK&_#=JX 8BK VL,@UR\%RV[%;5K-P*\3'Y3!+F1S5L
M/RZHOYV#)-<WX@U1(86&X9P:T]0NBL)Q7E_B6^=V89/?O6V68)4H^T?0[<MP
M?M:B;.<UV^-S<'#<5S[G)JS,Q9B359NM1C9N1^D8>FJ<%%#*2EI*\22.H***
M*D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '+UK<T2\^S7*MNP
M.*PA4\;E3Q7JX&K[-F%:FJD7%GMNE>)8_* ,@K1?Q$"/E8?E7BUE?S1L!NXS
M77Z6\EQM!S7NQHT:SO**OZ'QN+RFG3?,SM1J\LQX/Z4]B\JY.:@L;'Y036IY
M(1>E;IT:'NP1XTW"#M%&#/;D$G%4RN&YKH)U4@\5DW$77%=*?/[QTTJEU8+;
M:6&:UHHD(&,5SV]HSFM"RO"3R:F;;CH%6#:NC5:WXX%0LTD/3-7X)%<4Z6 .
M.!7%]8M+EF<*G9VD8L^LS0#[QKG]1\23,K#S*VM6M (F..QKS_4PRNPK?EII
M7BD>S@:%*H[V,C5[QKF8DG/.:Q7/-7;G[QS5%^M>)CG<^TH148I(8:*#1VKQ
M&]3J$S1114 %>L_L\?\ )2)O^P=+_P"AI7DU>L_L\?\ )2)O^P=+_P"AI2 ^
MIJ*** "BBB@ HHHH ^'?&W_(^^(O^PI<_P#HUJPJW?&W_(^^(O\ L*7/_HUJ
MPJ "BBB@ HHHH **** "BBB@ J2W_P"/F+_?'\ZCHH ]6_:%_P"2EI_UX1?^
MA/7E-%% 'JOQB_Y O@+_ + <7_H*59\/6\?Q"^$$/A"QN88]?TB[:YMK::0)
M]IC8L2%)[_.WX@9P#7D- .#D=: /;? _AV[^$HU#Q=XO$5E(MLUO8V7FI)+/
M(Q!X"DC'&.O<DX YQ[ EOV:=6).2==!)_P" Q5Y;+-+.^^:5Y&QC<[$G'XTR
M@#U;X+_\>OC7_L!R_P C5OX<Z7/XI^#_ (M\-Z8\+:K-=031P/(%+*&0D\_[
MA_&O'J569&#*Q5AT(.#0![O\.[#4K+X<^(K'PH;:/QO!?&*Y5BGFB-2!A"W&
M.&Y/&<]\5O\ PZTSQ9::]>OXUUZ1M2O+&2*STJ:]$KD'#-)L4E5 V@#ZFOFJ
M.62&021.R..C*<$?C2,S.Q9F+,3DDG))H ]5\/HT?[._C-'4JZZC &5A@@[X
M>#7E-%% 'KWA"[TWQ[\-?^$ U#48;#5K*X-SI<UPV$ESN^0GU^=ACT((!VD5
M2L_@/XM-_MU7[%IVG1G,U[)<HRA!U( .>GKC\*\NJ5[F>2)8GFD:-/NHSD@?
M04 >LZEXU\+:)\6] NM LX(]'T91;375O$ UQE3&\A(&7 4C!/7!QU%,\3?!
M_P 0:UXKNM2\-BUU'1=2G:YAO8[I B*YW$-DYXR>@/ ]>*\DJ1)YHXWCCE=4
M<8=58@-]1WH ]>\9ZOIG_"3>!/">EW:WB>'Y(H)[B/[CREXPP'KC9^N.U<Y\
M;/\ DKNN_6#_ -$1UP%% 'M'BW0+WQ3\'/!^K:08;BVT6QG%]B4!H\!,\=\;
M&XZ]*W-?N?%?Q!T;2?$'@#7;L2):K!J.EV]_Y+Q2@GYL%@#G)&>,@*1GG'SX
M&8*5#$!NH!ZTZ*62&0212-&XZ,IP1^- 'J_CC3]9T#P*EKXJ\8:G=:_>S#_B
M4"^,T21 @@R#GG(R.<9(QG!-:%A.OP3\'VMX\$4GC#6=LAAE&?LUJ&!*GT+=
M#[G_ &*\69F=BS$LQ.22<DTE 'IWQ/\ #EE>6EIX^\.)_P 2?5N;F)1_QZW!
M^\#CH"<_CGU%>8T44 %%%% !6EHNNZIX=O3>Z1>RV=R4,9DC/.TX)'Z"LVEJ
MH@=A_P +4\<_]#+??]]#_"G#XI^.?^AEOO\ OH?X5QPIPKIIQ74EG:)\4?&Y
MZ^)+W_OH?X5?M/B5XSD<!O$5Z?\ @0_PK@8SS6IIYS*!]*]G#4Z;6L5]QRUY
M-1;3/5=+\:>*;AAOUN[;G^\/\*]&\*:_>F^#ZIJ,KP"-B1(<C/:O+/#UOG:<
M=Z[VS7$8^E:9@J5.C916ODCXK%YE6H55.,F[=+NQV&H>+7;,=C'L'_/1QD_@
M*YN65YY6DE<N[')8]346#FEKX]5&]SP,9C\1C)<U:5_+HOD+4;'FGD\4U!DU
MR8NOR1.:G#F=A.0,TY3FI"GRU$O&:Y\'7]K*R-:U%T]QQIIJM)=%6Q4L4OF"
MO9K8.HH\QDZ<DKL)P'A(]J\T\70<N<>E>G[?E(KAO%5NK1N?<5[V23;IN#/5
MRJIRU3QR<8=A[U5/6M&_39<./>LYJRQL;2/TZD[Q3$I,4M%>6]S83%&*6BEH
M E%%%)@%%%%( HHHH **** "BBB@ HHHH >!2@4"E'%>A"*(9/"N6 ]:]#\)
M6J^8AP.HKSV#EA7HOA-SN3GN*]_!VY3Q,V;]D['J%JH6U4#TJ8# -0V9)@7Z
M58/2OD<33_VIM]S\TG\3,R<MO[FK-H#MR:?Y(9LD5( %&%KLQ6,A&CRFLIIQ
MY4!^8T[9Q3DC)[5,(^*^#Q.-7M-SLH85RC>Q5'!P:0IDYJ61,4U3FO<P&,O&
MR.&M3E2E83&!B@C*$4II#RIKJC+]ZGU,5N<?XFME:)R0*\CU2,)<L!CJ:]<\
M3,_DO7D6J$_:6SZFONYO]S%GWN27Y=3,;O41J1C49KP:S1]6AII*4TE>;+<T
M"BBBI **** "BBB@ HHHH **** "BBB@ HHHH !3Q3:<.E=%):B9*@J=%)-0
MIVJ]:*&D ->YAXIG/4=E<U=(M6:0$BO3=%A$<:\8Z5R6B6@8J?:N\LX=D8KU
M7[M/4^,S2OS.Q?+D)P:IW$A(JRS@+525@:YL/3][F9X<%J4P7WU?@<X&:@10
M35N.+(&*Z\1**5F:U&AS'*UGW2$@\5I^6<5!+%D5S4:D4[(SA))F/"C"3I6S
M; X%5A& U7;<@<5MBYIPT-*LKHCO8]\1S7G/B*S +''K7I\P!CKB?$<((;Z&
MLL/-3A8ZLMJN,T>63KM8BJK=:TM03;.16:W6O*QBLS]!I.\4QAI*#17CR-Q*
M***Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !112TTK@**D0<TP5-'
M7HX>-V9R9I:?;&:1>.,UZ'H-D4"DBN-T4#<OU%>DZ/'F->*^GHI1C<^6S6LU
MH;D)"(*BGN,=ZG:/""LRZ)!K.DH5)MH^6II28K2;SUJ)DSVJ.-B6JT%)%=]D
MD=#]TH2VF[H*;%:,AXJ\P*]J%W>E-6+]H[%FU!2M2,@K69$&S5M&917D8R"D
M]&<-57(-1AWQ,/8UYYK-BPD;BO1YF+#FN8UB!"K&NF@O<LST,!5<)6/++Z(I
M(16:XYK?UE LIQZU@R#FO+QT5N?>X:7-!,B-)2T5X#6IV"4445 !7K/[/'_)
M2)O^P=+_ .AI7DU>L_L\?\E(F_[!TO\ Z&E(#ZFHHHH **** "BBB@#X=\;?
M\C[XB_["ES_Z-:L*MWQM_P C[XB_["ES_P"C6K"H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *6DIU:0$ IPIM.%=5,3'IQ6IICA9QGVK+6K,#;74UZN
M&E9G/6CS1:/7?#LJE5QCK7;VQ_=CZ5Y7X;O"'4$GK7IVGR^9 /I59K%RI<RZ
M'YSFM)QDRYFDSS3!UIPKXM5.8\.P$U)$N:B:IXC@5Y&92ER:'=@HISU)2ORU
M4QAR*ME\BJI^_7GY*ZGMO>.[,E#E7*9UR 'J6V8"EF@+O4D5OMY-?I\Z]-4;
M-GFRG'DL3.XV$BN+\2G,3BNR*!E(KD?$D6(W_"KR>4'>QT9=953Q_4UQ<O64
MPYK8U48N6K(;K58]*Y^H8=^XAAI,4[%)7C2B=(E%+25#0PHHHI %%%%( HHH
MH **** "BBB@ HHHH =2@TF**ZTW$DLPGFN^\)2@R)]17GD1P:[+PI<;;A!G
M^(5[V!GS)(\G,X7HL]IL3_HZ_2K(K/TN3?;K]*T.E?-X].&(D?E]96FT!'%$
M?!.:0MQ2QJ2W2O!S&<%3;;+PR;J*Q:C J1L 4Z"(GM4DD7%?G5:HG5>I]Q1H
MR5*]BA*14"59FC([55Y4U]AE%6"BM3Y3,82Y]4/:F@\TH4M2LFW%>J\9#VJB
MCA5"7+S'*>*=JP/7CFJ,#=N/0FO7_&#;;60UXK?R%KJ0Y[U^B<]L-%L^WR"-
MZ=RFQYIE*325X$YW9]:D(:2E-)7++<H****D HHHH **** "BBB@ HHHH **
M** "E%)2BG'<!:4445U15M229.U:%@/WHK,0\U?M)"LBX->QA))G-63Y6>A:
M$X&T>U=S;G<@XKA?#@5RN?2O1[.!#&*[\954*5V?G^9249E66,XK/E!!K;ND
M 0XK F+%\49?5YXW..A+F5RQ;H685M00#8":R[)/F!-;2?ZL5YN<8B</A,,3
M)K1#6B&TX%4IUP#Q6@":BN(P4S7E8#%N4TI'/3G9V9AR-@U) YS39T^<XIT"
M\U]A)Q]D>B[<I=(W1US>N6P:-C[&NE)"QBN9UZY"1-]#7'@[ZE82_M-#R[68
M=EP36'(,&MO6)C)/6+)UKDQR1^BX6_LU<A-)3B*2OGY1=SM$I:0TM388E%!H
MI, HHHI %%%% !1110 4444 %%%% !1110 4M)133L X&IHS4 J16(KNH5+,
MB2.BT:4>:JGL:]1T)P8UKR'2Y-MPG/<5ZCH$V(UY[5]12?-3/D\XIG8.!LK&
MOP.:T?/RG6LR\)8&LL)3<9L^8H1:96MEW/6Q#;[@.*S;*/YZZ*W0;1Q1CZ[I
M1T'B:G*4WM>.E0FV*GI6R57TJ&1%KSJ6.E\+.6-=E*(*O6IC/$HJK<ML'%40
MS2/U-=\<.JBYVS=4^;5EV:56SBN:UDG8U=*MO\N:YS7UV1M]*ZJ/)&-D=>$:
M51)'F^KG,I^M8<G6M?4Y"T[#/0UD.>:\O&M'W^&34$1XIM.--->'-([$%)2T
M5@T4)7K/[/'_ "4B;_L'2_\ H:5Y-7K/[/'_ "4B;_L'2_\ H:5 'U-1110
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M>Z AD4&O&[ALRL?4UW7C+4O,FD3=WK@I.3FOT?%^Y1C370^[R:A[*@KD7>G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:55H88*HW+4R2*8:E(J,BO'J1/;3('[4VGR#&*97BUU:HS9;!1116(PHHHH
M**** "BBB@ HHHH **** "E%)2BJAN \4X"FBG \UZ-,AC@*7% I^*[(Q70S
M;&X)IZ@TH6EZ5O&%B6R6)V7H:T8+MD')K+#[:-Y-=4:B1A.FI[G0+J7&-U(^
MH$_Q5AIN-38..36G.V<SPT$RZ]^?[U1F_/K5%^M1GK4N9K&A N27;,.#5%VR
M:"<"HV-<]2IH=$(*.PTGFFYIU)BN&5VS8**,4A.!2>BU ::0TIIN:Y9M%H*2
MEI#6#V&(:2E-)7/+<H****D HHHH **** "BBB@ HHHH ****  4X4T4X5K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGFO_ 'OTIE%+VU3^9_>/E0[>Q[TFX^M)14N<GNPL+DTE%%3=C"BBBD 5ZO\
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MB@#X;\9?\CQX@_["5Q_Z,:L2MOQE_P CQX@_["5Q_P"C&K$H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O5/V??^2FC_KRE_FM>5UZI^S[_P E-'_7E+_-: /JNBBB@ HHHH *
M*** /AOQE_R/'B#_ +"5Q_Z,:L2MOQE_R/'B#_L)7'_HQJQ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:'X<UCQ+>FTT;3I[V8#+")>%'JQ/ 'U-:'B#P!XJ\+VHNM9T6>VMR0/.!61
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M!%$F<9)]ST%:%UX1UNTTN^U26S!L+&\:QGG65"JS*0"H&<GJ.0,<T 8=%%%
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M^B*6''O]3T&:ZGX&W%I::?XVN;^W^TV<.E&2>#_GK& Y9?Q&1^-3?$#9\2O
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MKR2@ HHHH **** "BBB@ KU3]GW_ )*:/^O*7^:UY77JG[/O_)31_P!>4O\
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M:2WE65 XR"5((S[<5H>*?$=YXM\1W>N7\<$=U=;-Z0*0@VHJ# ))Z*.]8]%
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MR/'B#_L)7'_HQJQ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KU3]GW_DIH_Z\I?YK7E=>J?L^
M_P#)31_UY2_S6@#ZKHHHH **** "BBB@#X;\9?\ (\>(/^PE<?\ HQJQ*V_&
M7_(\>(/^PE<?^C&K$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O5/V??^2FC_ *\I?YK7E=>J
M?L^_\E-'_7E+_-: /JNBBB@ HHHH **** /AOQE_R/'B#_L)7'_HQJQ*V_&7
M_(\>(/\ L)7'_HQJQ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU3]GW_ )*:/^O*7^:UY77J
MG[/O_)31_P!>4O\ -: /JNBBB@ HHHH **** /AOQE_R/'B#_L)7'_HQJQ*^
MD]?_ &>+?6?$.H:I#XDDMDO+AY_):S$FPL2Q&[>,C)..*S?^&9D_Z&UO_!=_
M]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^
MAM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^
MAM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZ
MBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!
M=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!
M=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9
MF3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC
M_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@
M#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO
M_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H
M;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@
M?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:
M/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_
M]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^
MAM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^
MAM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZ
MBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!
M=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!
M=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9
MF3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC
M_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@
M#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO
M_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H
M;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@
M?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:
M/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_
M]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^
MAM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^
MAM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZ
MBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!
M=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!
M=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9
MF3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC
M_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@
M#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO
M_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H
M;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@
M?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:
M/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_
M]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^
MAM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^
MAM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZ
MBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!
M=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!
M=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9
MF3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC
M_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@
M#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO
M_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H
M;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@
M?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZBOH'_AF9/^AM;_P7?_;:
M/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!=_\ ;:/^&9D_Z&UO_!=_
M]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!=_\ ;: /GZBOH'_AF9/^
MAM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9F3_H;6_\%W_VVC_AF9/^
MAM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC_AF9/^AM;_P7?_;: /GZ
MBOH'_AF9/^AM;_P7?_;:/^&9D_Z&UO\ P7?_ &V@#Y^HKZ!_X9F3_H;6_P#!
M=_\ ;:/^&9D_Z&UO_!=_]MH ^?J*^@?^&9D_Z&UO_!=_]MH_X9F3_H;6_P#!
M=_\ ;: /GZBOH'_AF9/^AM;_ ,%W_P!MH_X9F3_H;6_\%W_VV@#Y^HKZ!_X9
MF3_H;6_\%W_VVC_AF9/^AM;_ ,%W_P!MH ^?J*^@?^&9D_Z&UO\ P7?_ &VC
M_AF9/^AM;_P7?_;: /GZO5/V??\ DIH_Z\I?YK76_P##,R?]#:W_ (+O_MM=
M?\._@W;^ ]?EU=M9?4)F@,,:?9_*"9())^9LGC'XF@#T^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+147VF'_ )ZK^='VF'_GJOYT 2T5%]IA_P">J_G1]IA_YZK^= $M%1?:8?\
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MJ_G2K/$Q 6123VS0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%K-ITR7%KHNE.MQ/$P9%EE; 3([XY_"O2*I:9I&FZ+:_9=+L+:R@SN\NWB"
MGU('4^]7: "JD !O[O(_N?RJW56#_C_N_P#@'\J +.U?0?E1M7T'Y4M% ";5
M]!^5&U?0?E2T4 )M7T'Y4;5]!^5+10 FU?0?E1M7T'Y4M% ";5]!^5&U?0?E
M2T4 )M7T'Y4;5]!^5+10 FU?0?E4,*CS)N!][^@J>H8?]9-_O_T% $NU?0?E
M1M7T'Y4M% ";5]!^5&U?0?E2T4 )M7T'Y4;5]!^5+10 FU?0?E1M7T'Y4M%
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MC:OH/RI:* $VKZ#\J-J^@_*EHH 3:OH/RHVKZ#\J6B@!-J^@_*C:OH/RI:*
M$VKZ#\J-J^@_*EHH 3:OH/RHVKZ#\J6B@!CJ/+;@=#38%'V>/@?=%/?_ %;?
M0TVW_P"/>/\ W10 _:OH/RHVCT%+10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'Q$\,6'B;0$35-:
MDTJRM)//DF4HH!'0DMTP>A'-=?7G/Q4^R&[\*)K1 \/-J>+_ 'G$>[8?*#]M
MN[KGB@#B]/D\-7=Y'I]K\9_$)F9@B"2=U4D] '8 ?K7MND6$FF:3;64M[<7L
MD*;6N;ALR2>['UKF_%%IX''A&Z.JPZ2FF"!MK*L8QQQY>/XO3;SFK/PX>^D^
M'.@-J(?[4;--V_.XK_"3GOMVT =11110 4444 %%%% !1110 4444 %58/\
MC_N_^ ?RJU56#_C_ +O_ (!_*@"U1110 4444 %%%% !1110 4444 %%%% !
M4,/^LF_W_P"@J:H8?]9-_O\ ]!0!-1110 4444 %%%% !1110 4444 %%%%
M!4,/^LF_W_Z"IJAA_P!9-_O_ -!0!-1110 4444 %%%% !1110 4444 %%%%
M !4-M_JS_OM_.IJAMO\ 5G_?;^= $U%%% !1110 4444 %%%% !1110 4444
M %0VW^K/^^W\ZFJ&V_U9_P!]OYT 34444 %%%% !1110 4444 %%%% !1110
M C?=/TJ.V_X]H_\ =%2-]T_2H[;_ (]H_P#=% $M%%% !1110 4444 %%%%
M!1110 4444 -?_5M]#3;?_CWC_W13G_U;?0TVW_X]X_]T4 24444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ0!NT444 %%%% !11535$NY-(O4T]PEZT#BW8]!)M.T_GB@"87,!N#;B>,S
M9,>\;L?3K3WD2)&>1U1%&2S' %?-.[PHW@NWTVQAN%^)(N50,"XN/M?F#<QE
M/R[<9[X_'FO2_$-JWBCXEZ#X4U@B>PM=+;5+RW4D1W$N[RUW =0&R0/>@#TN
M.6.:-9(G5T89#*<@_C3J\UTNRM_!OQ=CT728_L^D:SISW!M$)\N.XC;EE'09
M7@@5Z50 55@_X_[O_@'\JM52CE6._N\AN=G12>U %VBH?M*>C_\ ?!H^TIZ/
M_P!\&@":BH?M*>C_ /?!H^TIZ/\ ]\&@":BH?M*>C_\ ?!H^TIZ/_P!\&@":
MBH?M*>C_ /?!H^TIZ/\ ]\&@":BH?M*>C_\ ?!H^TIZ/_P!\&@":BH?M*>C_
M /?!H^TIZ/\ ]\&@":H8?]9-_O\ ]!1]I3T?_O@U'%.@DE.'Y;/W3Z4 6J*A
M^TIZ/_WP:/M*>C_]\&@":BH?M*>C_P#?!H^TIZ/_ -\&@":BH?M*>C_]\&C[
M2GH__?!H FHJ'[2GH_\ WP:/M*>C_P#?!H FHJ'[2GH__?!H^TIZ/_WP: )J
M*A^TIZ/_ -\&C[2GH_\ WP: )JAA_P!9-_O_ -!1]I3T?_O@U'%.@DE.'Y;/
MW3Z4 6J*A^TIZ/\ ]\&C[2GH_P#WP: )J*A^TIZ/_P!\&C[2GH__ 'P: )J*
MA^TIZ/\ ]\&C[2GH_P#WP: )J*A^TIZ/_P!\&C[2GH__ 'P: )J*A^TIZ/\
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M"CHIH LT5#]I3T?_ +X-*LZ,P #Y/JIH EHHHH **** "BBB@ HHHH ****
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M?\?]W_P#^56JJP?\?]W_ , _E0!:HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;_CVC_W14C?=/TJ.V_X]H_\ =% $M%%% !1110 4444 %%%% !1110 4444
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MADUZ#7;6TMKG3K[[.(K8DA1M!P6)^8C/48KM* "BBB@ HHHH **** "BBB@
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M_@3#VK[+[D9_D:I_S_0?]^/_ +*C[/JG_/\ P?\ @/\ _95H44?5H_S2_P#
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M]E$?RRL!E VT].<CGO6HL%Q\0O&.N6UWJ%[;>']%F6T2UM)S";F?;EVD9<'
MR !GW^M3X9^)=*T&QD\):K="UUJ'5)X5M9$;?)OD+*R\<@[NO3OTI]IJ]O\
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MFYVDK"TB (6QT!(Q7<:1K.GZ]IR:AI=RMS:.S*LJ@@,5.#C(YY!YH O4444
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MUOXN^'-+E?[=IFG:$=1@\TAUE=G$:NW9C@ @^O- 'H&DZWI>O6GVK2=0MKV
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MZ#\JL^<__/!_S%'G/_SP?\Q36&@W>I[S\_\ +;\!>UEM'3T_SW)0 H    Z
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MSG_YX/\ F* )J*A\Y_\ G@_YBCSG_P">#_F* )J*A\Y_^>#_ )BCSG_YX/\
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M  X ':EP,Y[T44 %%%% #0B!RX5=Y&"V.3044L&*@LO0D<BG44 &*  .E%%
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M[[?SH FHHHH **** "BBB@ HHHH **** "BBB@ J&V_U9_WV_G4U0VW^K/\
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M97#"0=VR.#DY/% &S7'WGAY=+\97'B0:U#9Z9J$0BU2SN0H2<JA5'5R?E(&
M1W KL*\ODT+2_%?Q5URU\5YNOL4<!TJPFD*Q&)DR\BKD;SN!!/.,?3 !FZ'X
M&UN\?2M+3Q7I=_X/TF]6[MQ;'?</M8LD;D#& 3US_3'L5>4^(_#6C^#O$GAN
M]\*1+I^K7>HQ6TEI;N=MU;$GS-R9Z*!G=CC\L>K4 %%%% !1110 4444 %58
M/^/^[_X!_*K558/^/^[_ . ?RH M4444 %%%% !1110 4444 %%%% !1110
M5##_ *R;_?\ Z"IJRWO9&N9[:R023[OF<_<CX[GU]JSJ58TU>7_!?H7&#D[(
MMW=]%9JH;+ROPD2#+.?8562QFO6$NHD; <K;*?E7_>/\1_2I[.P2U+2LQFN'
M^_,_4^P]![5;K!4I5=:VW\O^??TV]2^=0TAOW_R[?GZ     , =J***ZS$**
M** "BBB@ HHHH **** "H8?]9-_O_P!!4U0P_P"LF_W_ .@H FHHHH ****
M"BBB@ HHHH **** "BBB@ J&V_U9_P!]OYU-4-M_JS_OM_.@":BBB@ HHHH
M**** "BBB@ HHHH **** "H;;_5G_?;^=35#;?ZL_P"^W\Z )J*** "BBB@
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M&-55PV1QAN/>NXIH1%9F"J&;J0.30!P?PU_Y"'C?_L8[C_T%*+C_ )+U9?\
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M5Z+^OQ%:XFU1C%9L8K4'#W ZM[)_C5JQMXK59(84"HK<#\!5E55$"(H50,
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MR%6"GH&QTS_]8@')ZIXK\8Z-I4FI7OPKLTM8EWR,EY%(47N2JJ3CUXX[UO\
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MUQ_SS3_OK_ZU&ZX_YYI_WU_]:@":BH=UQ_SS3_OK_P"M1NN/^>:?]]?_ %J
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MKC_GFG_?7_UJ-UQ_SS3_ +Z_^M0!-14.ZX_YYI_WU_\ 6HW7'_/-/^^O_K4
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M'_/-/^^O_K4 345#NN/^>:?]]?\ UJ-UQ_SS3_OK_P"M0!-14.ZX_P">:?\
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M7/WB,<X]10!RGPXTC3M:^"&C6VIV4%Y L<LBQSH& 8228.#WY-)\'O"^A?\
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M4.H"[AQQQ^E:-E-J'PZ\0ZY'/HNHZAH.J7KZC!<Z?!YS02.!YB.@Y"Y'!_\
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M?\D[\-?]@NV_]%+70UA>"8)K7P'X>M[B)X9XM-MTDCD4JR,(U!!!Y!![5NT
M>3:\-&T[XFZE>^.]/6XTFZ@@CTF[NH/.M;?"XD1A@A&+<Y(Z=Q76S2:/X/\
MA]J>I^'(K864-M->0+"^^)GVDC;R1M) X'%0ZIXX33]0O-,U3PMKCQABL4MO
M9&YAN4([%>_JIK(\'>$;B?P1XETZ\LY-*L];N;E[2Q?&ZTAD4*N5Z*<\[>U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (RAE*L 5(P0>
M]>7S?!UY%_LE/%-]'X3,_G'1A&,#YMVP29R%SVQ[]>:]1K)OO$NE:=?:?9SW
M2>;?RM%#M((W!2QR>W - &#XS\):UXDM[31M-UB/2M!,?E7T44699$&,(A[#
M (Z_@1Q75Z=I]MI6FVVGV<8BM;:)8HD!SM51@"F7.K6%I:RW,UW (XD+L?,'
M  R>]1:%K5IXBT2TU:Q\S[+=)OC\Q=K8R1R/PH XWXO W.AZ'I<CM'8:GK=K
M:7K*<?N6))&>V2!S[5WEE96NFV4-G96\=O;0J$CBC7:J@=@*S?%/AJR\6^'K
MG1[_ "(YAE)%^]$XY5U]P?\ #O7$(/B_H,8LH8]#U^"/Y8KN9FBF8=BXW 9_
M,^YH F^)MI!I^O>#_$-HBQZL-:@LMZ##30R9#(?7@=^F3ZUZ57G>A>#O$>J^
M);7Q-XYOK26XL@38:;9 ^1;L1RY)Y+?GVYX 'HE !1110 4444 %%%% !56#
M_C_N_P#@'\JM55@_X_[O_@'\J +59^HZS;:9(B3QW+%QD>3;O(/QV@XK0HH
MPH/%VF7+*(4O7!;9D6DF <XY.*W:PO"?_()F_P"ORX_]&-6[0 4C,J*68@*!
MDD] *4G R:RCG69<#(T^-N3_ ,]V'_LH_6L:M7DLHJ\GLOZZ+J_U:-(0YM7L
M@C5M7F$T@(L4.8T/_+4_WC[>@K5H    & .@%%%*ER)MN\GN_P"NBZ+_ ((3
MGS:+9!1116QF%%%% !4,/^LF_P!_^@J:H8?]9-_O_P!!0!-1110 4444 %%%
M% !1110 4444 %%%% !4,/\ K)O]_P#H*FJ&'_63?[_]!0!-1110 4444 %%
M%% !1110 4444 %%%% !4-M_JS_OM_.IJAMO]6?]]OYT 34444 %%%% !111
M0 4444 %%%% !1110 5#;?ZL_P"^W\ZFJ&V_U9_WV_G0!-1110 4444 %%%%
M !1110 4444 %%%% "-]T_2H[;_CVC_W14C?=/TJ.V_X]H_]T4 2T444 %%%
M% !1110 4444 %%%% !1110 U_\ 5M]#3;?_ (]X_P#=%.?_ %;?0TVW_P"/
M>/\ W10!)1110 4444 %%%% !1110 4444 %%%% ',^/M=N?#_A*XGT\C^T[
METM+%< YGD;:N >#C);_ (#53X=:YJ.J:/>V&MSB;6M)O)+.[D"A?,P<HX
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M73H)!'P ?F89.3D\^M.TWXB>&M7U&"PL[J[>XF;:BOI]P@)QGEF0 ?B:ZDD
M9)P!0!Y5J(\9:-XQ\-Z/%XVGU&:_N3)<0/IT$:I;1\R,2!D9^Z.G)ZUV'B#3
M?%.J:E%#I6MP:1IBQ RS1VXFN)),G*C=\JKC'/)R36%X"SXF\2Z[XWD^:"=_
M[.TLGM;1'YF'L[Y/X5U?B!O$2VD9\.1:9)<[_P!X-0>14"X[; 3G.* .2L-1
M\1>%_B!I?AO6-7_MK3]8AF:UGD@6.:"2)=S*VSAE([D9R?;GT2O)=(N=2LOB
M;9W/C^V\O5;F-[;2)K5@;%,\LJ_Q"0],MUZ>E>M4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7E/C/X;?#;3'3Q!K,4>G6HN&DN0))<7+,#\@4
M-D<_-A!V]*]6KS3XMW6FZ5-X6UG5C')9V.HEY+5ADR@KC<HZ$H<-@^] '#BY
M_9]!R+5^/:\_QKV_PW<Z5=^'-/GT-572VA'V950H @X'!Y'2N6C^,OP],:E?
M$$:C' -K,,?ALKLM,U.SUG3+?4=/F$]I<+OBD"D;AZX(!H MT444 %%%% !1
M110 4444 %%%% !56#_C_N_^ ?RJU56#_C_N_P#@'\J +5%%% &%X3_Y!,W_
M %^7'_HQJW:PO"?_ ""9O^ORX_\ 1C5:N)I-0G:RM6*Q*<7$R]O]E??U]*RJ
MU537=O9=W_6[Z(N$.9^0DKMJTS6T+%;-#B:0?\M#_<'MZFM)$6-%1%"JHP .
M@%)##'!"L42!$48"CM3ZFE2<;SGK)[_Y+R7X[OR<YW]V.R_JX4445N9A1110
M 4444 %0P_ZR;_?_ *"IJAA_UDW^_P#T% $U%%% !1110 4444 %%%% !111
M0 4444 %0P_ZR;_?_H*FJ&'_ %DW^_\ T% $U%%% !1110 4444 %%%% !11
M10 4444 %0VW^K/^^W\ZFJ&V_P!6?]]OYT 34444 %%%% !1110 4444 %%%
M% !1110 5#;?ZL_[[?SJ:H;;_5G_ 'V_G0!-1110 4444 %%%% !1110 444
M4 %%%% "-]T_2H[;_CVC_P!T5(WW3]*CMO\ CVC_ -T4 2T444 %%%% !111
M0 4444 %%%% !1110 U_]6WT--M_^/>/_=%.?_5M]#3;?_CWC_W10!)1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)?\ Y[O^0H FHJ'R7_Y[O^0H\E_^>[_D* )J*A\E_P#GN_Y"CR7_ .>[_D*
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M2SMEB4ECU9SU9CU)JK;?Z7JD]T>8X/W$7U_B/\A^%:5<E']Y-UGZ+TZOYO\
M!(VG[L5!>K_KR_,PO"?_ ""9O^ORX_\ 1C5NUA>$_P#D$S?]?EQ_Z,:MVNLQ
M"BBB@ HHHH **** "BBB@ J&'_63?[_]!4U0P_ZR;_?_ *"@":BBB@ HHHH
M**** "BBB@ HHHH **** "H8?]9-_O\ ]!4U0P_ZR;_?_H* )J*** "BBB@
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M%%% !1110 5##_K)O]_^@J:H8?\ 63?[_P#04 34444 %%%% !1110 4444
M%%%% !1110 5#;?ZL_[[?SJ:H;;_ %9_WV_G0!-1110 4444 %%%% !1110
M4444 %%%% !4-M_JS_OM_.IJAMO]6?\ ?;^= $U%%% !1110 4444 %%%% !
M1110 4444 (WW3]*CMO^/:/_ '14C?=/TJ.V_P"/:/\ W10!+1110 4444 %
M%%% !1110 4444 %%%% #7_U;?0TVW_X]X_]T4Y_]6WT--M_^/>/_=% $E%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:HJK]@3_ )[7'_?TT?8$_P">UQ_W]- %JBJOV!/^>UQ_W]-'V!/^>UQ_W]-
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M@8$LX^DIH MT55^P)_SVN/\ OZ:/L"?\]KC_ +^F@"U157[ G_/:X_[^FC[
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MZH67.,@$],T :U%9VDZ]I&O1R2:3J5K?)$0KM;RAPI/0'%:- !1110 4444
M%%%% !1110 445#=75O8VLEU=SQ06\2[I)97"JH]23P* )J*R='\3Z%XA,BZ
M1J]G>M'RZ03!F4>I'7'O2:QXHT'P_)%'J^KV=E)+RB3S!2P]<>GOTH UZ*CM
M[B&[MX[BVFCF@E4-')&P974]""."*DH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*\2:C>?$JTT_0--\/ZS91M=Q3WUUJ-H8%MHT.2 3]YSQ@"@#U6BBB@ HHHH
M**** "BBB@ HHHH *CG$K6\JP.J3%"$9AD!L<$CZU)10!X_IWAN?0/C5H<E]
MJUSJNI7FG7,ES=3X4$C "H@X11V%;6M0QZW\;]&TN]C6:ST[2)-12%QE#*TG
MEAB#P2  1Z&KVJV%Y)\8_#]\EI.UG%IURDEPL9,:,2, MT!/I4?BNUO=%\<Z
M3XQM-/NM0MDM9-/OX;2/S)4C9MR.J#E@&Z@=J (/L\.A?&VU2PC2"#6=*D-S
M%&H57DB8%7P/XL$C->AUY_HB7GBGXC'Q0^G7=CI5A8&SM!>PF*6>1VR[A3R%
M &.1SFO0* "BBB@ HHHH **** "BBB@ JO?QW4NG74=E.L%V\3K!,Z;A&Y!V
ML1W .#BK%% 'DGACP\WASXYO#-J5UJ5W<^'&N+F[N3\TDAN%7@=%4!5 4= *
MG\>&[N?BCH,2>&;C78;+3YYD@"*(3)(=GSN_R# 7/.>2..:W#87G_"]%U#[)
M/]A_X1OR/M/EGR_,^T[MF[INQSCKBI?$7B+7_#?BF">32[G4?#,UOM<V%N99
M[>?/WF4')0CT'_UP"+P5KFDW6KW^D_\ ",Q^'==MHP\]IY48+Q$\,KH,.N<?
MB17<5Y[X=M[_ ,1_$FX\83:9=Z;IT&G#3K2.\C\N:<E][.4/*J.@SUZUZ%0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTI]0-I9BZCFND$6\SHISY>=PVY.#GGH.*Z:B@!%4(H50 H&  . *X27X;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^*]1BL)M?MVF:/5+F/3]%MUA:4;/F+7)C4;G) =P/[JKTW&ET^YOU\3:/\
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MB4%6C"HH4L0<[A@<DUH0:$-:^)FMWAU34XX].AAMD$5SM >3][(@XX7;Y/%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755628386224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 23, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,815,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Melville, New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627541744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 132,187<span></span>
</td>
<td class="nump">$ 151,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">135,567<span></span>
</td>
<td class="nump">154,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,627<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 3</a></td>
<td class="nump">4,835<span></span>
</td>
<td class="nump">7,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred grant income - Note 4</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">15,304<span></span>
</td>
<td class="nump">12,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 200,000,000 common stock, par value $0.001 per Issued and outstanding: 84,795,517 common shares (2023 - 82,066,511)</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">456,249<span></span>
</td>
<td class="nump">434,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(336,071)<span></span>
</td>
<td class="num">(293,069)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">120,263<span></span>
</td>
<td class="nump">141,852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 135,567<span></span>
</td>
<td class="nump">$ 154,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624393872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">84,795,517<span></span>
</td>
<td class="nump">82,066,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">84,795,517<span></span>
</td>
<td class="nump">82,066,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627111792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 11,039<span></span>
</td>
<td class="nump">$ 12,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">41,838<span></span>
</td>
<td class="nump">43,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">52,877<span></span>
</td>
<td class="nump">55,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(52,877)<span></span>
</td>
<td class="num">(55,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">7,320<span></span>
</td>
<td class="nump">6,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherFinancingExpense', window );">Other financing expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">189<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">9,875<span></span>
</td>
<td class="nump">8,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(43,002)<span></span>
</td>
<td class="num">(47,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EarningPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share, Basic</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share, Diluted</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, Basic</a></td>
<td class="nump">83,468,049<span></span>
</td>
<td class="nump">79,787,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, Diluted</a></td>
<td class="nump">83,468,049<span></span>
</td>
<td class="nump">79,787,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EarningPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EarningPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755619044624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NoncashFinancingRelatedCharges', window );">Non-cash financing related charges</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">9,438<span></span>
</td>
<td class="nump">16,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,305<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(2,460)<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,812)<span></span>
</td>
<td class="num">(27,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">11,284<span></span>
</td>
<td class="nump">27,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,975<span></span>
</td>
<td class="nump">29,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) Increase in cash and cash equivalents during the year</a></td>
<td class="num">(18,837)<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">151,024<span></span>
</td>
<td class="nump">149,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">132,187<span></span>
</td>
<td class="nump">151,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalFranchiseTaxes', window );">Cash paid for state and local franchise taxes</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalFranchiseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalFranchiseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NoncashFinancingRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NoncashFinancingRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755623309232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 387,977<span></span>
</td>
<td class="num">$ (245,564)<span></span>
</td>
<td class="nump">$ 142,491<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">&#160;Initial Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">27,872<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">3,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">&#160;Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">13,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">759,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(47,505)<span></span>
</td>
<td class="num">(47,505)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">434,839<span></span>
</td>
<td class="num">(293,069)<span></span>
</td>
<td class="nump">141,852<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2023</a></td>
<td class="nump">82,066,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">&#160;Purchase shares</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">11,281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">2,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">&#160;Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">5,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">273,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,438<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(43,002)<span></span>
</td>
<td class="num">(43,002)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 456,249<span></span>
</td>
<td class="num">$ (336,071)<span></span>
</td>
<td class="nump">$ 120,263<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Sep. 30, 2024</a></td>
<td class="nump">84,795,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755626257824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,505)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755619789968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624968608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUbZM51yn049" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_82B_zSWlR6NQYzu5">Business Description and Basis of Presentation</span>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755625491632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z6slE3KxRmT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2	<span id="xdx_823_z9L3pvings8g">Summary of Significant Accounting Policies</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p id="xdx_844_eus-gaap--UseOfEstimates_zgBJ5I211vml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_zAPlVc3iYYcf">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zSbQAInpEeXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_ztu82Co1Phn3">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBxoT8ehUmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zI70NBdVOwS5">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_c20240930_pp0p0" title="Federal deposit insurance corporation">250,000</span>, under current regulations. At September 30, 2024 and 2023, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8e6NUAU2tYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zesLA3jv5Q2k">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--RevenueRecognitionIncentives_zYOO7Un8ukSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zN9aksYH7Hu9">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;) through a program administered through the Australian Tax Office (the
&#8220;ATO&#8221;) and AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;).
The Australia R&amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#8217;s company tax rate in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), since the incentives
are not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_ecustom--LicenseFeesPolicyTextBlock_zvVTlse0Q7E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zgaDCnCdHYPa">License Fees</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"></p>








<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zWgq0UJnIPo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zDPBM6FA6BL3">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, diluted loss per share excludes
<span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_pdd" title="Loss per share for potentially dilutive common shares">15,047,754</span> potentially dilutive common shares (2023 &#8211; <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares">14,271,780</span>) related to outstanding options and warrants, as their effect was
anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z9ZlJF0Lwhif" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z19xBHj34mV5">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zuAFu9p1clul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_zVPWAmk5hIua">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zgEdj1w4tJSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zIbr3fjZhz78">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--GrantIncomePolicyTextBlock_zGwCAdk9hY0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zaw8i3Xa0wN7">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zXolNW64SI38" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zvqLWhRMJSC1">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zZYtdCIH7Uu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zzz8d0snS2Si">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. The Company&#8217;s historical share option exercise experience does not provide
sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the
expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid
any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist
of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. Changes
in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#8217;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOMteVA1jZv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_ziRWdPxOyJSl">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024 and 2023, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8PUyFNhGER7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zI4c0i94DpBe">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October 1, 2022, the Company
adopted Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832) &#8211; Disclosures by Business Entities about Government
Assistance, which requires business entities to disclose information about transactions with a government that are accounted for by applying
a grant or contribution model by analogy. For transactions within scope, the new standard requires the disclosure of information about
the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line
items affected by the transaction. The disclosure of the Company&#8217;s research and development tax incentive income and receivable
is detailed in Note 4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_847_ecustom--RecentAccountingPronouncementsPolicyTextBlock_z1SqSlbs2MCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_865_zX6GA3HUEZHd">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624990432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccuredLiabilitiesTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zEPbtC6j3LPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_827_zlLjSI9VItkl">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>


















<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zbwnkL2K0Ym1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B5_z2lzU6dypaQd" style="display: none">Schedule of principal components of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240930_z4WLWlnfqNq1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930_zSwhbt41fS56" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_zvn6pZIbv5Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,006</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,360</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FixedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTIC_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,295</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AB_z9vsAXyMD93i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccuredLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccuredLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624466928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_808_ecustom--OtherIncomeDisclosureTextBlock_zpl9acj2tuH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_82D_z4iq2194pL1b">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of September 30, 2024,
the Company had received a $<span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20231001__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zUqOPy8iSm9k" title="Research and development incentive income">1</span>.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) related to Parkinson&#8217;s
disease. Of the total, $<span id="xdx_906_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zsZM6XiZSJa7" title="Research and development incentive income">0.5</span> million was received during the year ended September 30, 2023 and $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_zNYa628sfExl" title="Research and development incentive income">0.5</span> million was received during the year
ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2024, the Company recognized $<span id="xdx_90F_ecustom--NonOperatingIncomeFromGrant_c20231001__20240930_pn5n6" title="Non operating income from grant">75,000</span> (2023: $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20221001__20230930_pn5n6" title="Non operating income from grant">25,000</span>) of this grant on its statements of operations within
grant income. At September 30, 2024 an amount of $<span id="xdx_900_ecustom--DeferredGrantIncome1_c20231001__20240930_pn5n6" title="Deferred grant income">0.8</span> million (2023: $<span id="xdx_902_ecustom--DeferredGrantIncome1_c20221001__20230930_pn5n6" title="Deferred grant income">0.9</span> million) of this grant is recorded as deferred grant income,
representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its
statements of operations as the related expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the year ended September
30, 2024, the Company recorded research and development incentive income of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930_zebZr3UeVuh" title="Research and development incentive income">2.3</span> million (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zalCwRRoaIzg" title="Research and development incentive income">3.5</span> million) (2023: $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930_zrnuLxk9QHT" title="Research and development incentive income">2.7</span> million (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zUS5vDVvJrPl" title="Research and development incentive income">4.1</span>
million)) in respect of the Australia R&amp;D credit for eligible research and development expenses incurred during the year. This amount
is included within Other income (expense) on the consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At September 30, 2024, Incentive
and tax receivables includes $<span id="xdx_909_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zS5nTIpYaJU6" title="Incentive and tax receivables">2.3</span> million (AUD <span id="xdx_908_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zNvZ2x4TOs3h" title="Incentive and tax receivables">3.3</span> million) (2023: $<span id="xdx_904_eus-gaap--OtherReceivables_iI_pn5n6_c20230930_znwGIkvLBIv6" title="Incentive and tax receivables">2.5</span> million (AUD <span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20230930__srt--CurrencyAxis__currency--AUD_zatHjCAGFLH2" title="Incentive and tax receivables">3.9</span> million)) relating to Australia R&amp;D credits
earned during the year that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2024 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624987776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_807_ecustom--EquityOfferingTextBlock_z8uH5AsWqi3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_821_z4UnVL811xpi">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zjBTw7sVBGf4" title="Value of shares obligated to purchase">150</span>.0
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zDtpzYyEJE34" title="Share issued for offering, shares">75,000</span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVEHO9Ok8nG3" title="Pro rata basic number of shares obligated to purchase">75,000</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zlvesVw4UA3k" title="Proceeds from issuance or sale of equity">150</span>.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_90C_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zJ9cx1I1Uf3j" title="Fair value of the initial commitment">0.8</span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_900_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zuQfWHsPplPj" title="Incurred expenses">0.1</span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2024, the Company
issued to Lincoln Park an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_z5XyHbAeGon5" title="Number of shares issued, shares">2,455,646</span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_z9eP1mwZKD7e" title="Number of shares issued, shares">2,450,000</span> shares
of common stock for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z3vDqP2N5m5a" title="Number of shares issued, value">11,283,200</span> and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zuZAWjOBzDX" title="Number of shares issued, shares">5,646</span> commitment shares. During the year ended September 30, 2023,
the Company issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zv8LrAnhBMp2" title="Number of shares issued, shares">3,288,943</span> shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_z4amQsG4Rn02" title="Number of shares issued, shares">3,275,000</span>
shares of common stock for aggregate proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zX7Y5ZjfAYx8" title="Number of shares issued, value">27.9</span> million and&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zvwZfCtAdAej" title="Number of shares issued, shares">13,943</span>&#160;commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024, an amount of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVFXJZstk14i" title="Amount of shares remain available">110.8</span> million
remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2020 Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;2020 Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company could offer and sell shares of common
stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended September 30, 2024 and 2023,
no shares were sold pursuant to the Offering. At September 30, 2023, an amount of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2020Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrSVeZj0Klw6" title="Amount of shares remain available">142.4</span> million was registered pursuant to an effective
registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2024, the Company terminated the 2020
Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624534688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsDisclosureTextBlock_zU3MKmk8tD6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_82E_zSxZDr5qZEec">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company leases office space under an operating lease with an initial term of <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zyt4oNkSylq3" title="Operating lease term">12</span> months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
operating lease costs were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_pn3n3_zo7TtWmPUcw5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zZE28QeKNvL9" style="display: none">Schedule of operating lease costs</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20231001__20240930_zy0nqCX3Sqqg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20221001__20230930_zOcdnZ1gajT9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zG2OCtLdwmZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z6qARMn5koC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company made matching contributions under the 401(k) plan as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zY74239U5rD7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zCLJmKfNvB4e" style="display: none">Schedule of contributions under the plan</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231001__20240930_zumtC3qVDoQk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221001__20230930_zkzgsKpX6ZJb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40C_eus-gaap--PensionContributions_zqnvDHsWLGQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">232</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zfRQyDHqkRy" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024. The complaint alleges violations
of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect to certain clinical trials for
ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. The complaint seeks unspecified damages, as well as costs, including counsel and
expert witness fees, on behalf of a class of investors.&#160;The Company believes the lawsuit is without merit and the Company denies
any liability or wrongdoing and has filed motions to dismiss the complaints, which is awaiting a decision by the Court. No amount has
been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes
that it is not probable that any loss will occur.</span></p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#8217;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett Syndrome. The Company believes this lawsuit is without merit and the Company denies any liability or wrongdoing.
The parties are currently due to file a proposed schedule for the anticipated motion to dismiss by the Company and the officer of the
Company (the other named defendants have not been served with the complaint) on or before January 15, 2025.&#160;No amount has been recorded
in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is
not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of the Company&#8217;s outstanding
share purchase warrants is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zVrXB8D2W2el" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zyucDNJtHIe6" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Balance, September 30, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsEaQiiCcKZf" style="width: 20%; text-align: right" title="Number of warrants outstanding">160,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zkOIgSWK3Ps2" style="width: 20%; text-align: right" title="Weighted average exercise price">3.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfWarrantsExpired_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9iODe9gm0d6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants expired">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceExpried_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zGiipVAva5fi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expried">3.17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Balance, September 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsLjle0jOCG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z8bylO1akFQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price">12.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zmbBBcE82K9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024, the Company had <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20240930_zRbUQoqcPBh4" title="Warrants outstanding">10,000</span> share
purchase warrants outstanding exercisable at $<span id="xdx_907_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20240930_zuT1PGPuBGF3" title="Warrants outstanding weighted average exercise price">12.00</span> per share until <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240930_zYam2lj5mBle" title="Expiry Date">April 21, 2026</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYy7f34kF64e" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20231001__20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zjyTf3HUI3qg" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zlkcZFkN32gj" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zaMq4gs0d8Dc" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At September
30, 2024, <span id="xdx_90F_ecustom--OptionIssued_pip0_c20231001__20240930_zf4vwFU8Ylt2" title="Option issued">5,267,500</span> options had been issued under the 2022 Plan and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zuhgSy4D4QU4" title="Option available issue">5,462,202</span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the years ended September 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_ztty77jTyIU6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zWT9kxCLd4y8" style="display: none">Schedule of stock option activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, October 1, 2022</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj2x0XX7LPE5" style="width: 10%; text-align: right" title="Number of options, Outstanding beginning balance">13,169,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuf1aIFtmA81" style="width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlhUTPvaW8Ag" style="width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">4.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlUHLENQXHdc" style="width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">62,267,309</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNoKqll9fo3h" style="text-align: right" title="Number of options, Granted">1,959,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zi1TwIf8oIff" style="text-align: right" title="Weighted average exercise price, Granted">9.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgzQ7JpYdPf6" style="text-align: right" title="Weighted average grant date fair value, Granted">6.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVgAZGD8r8Af" style="text-align: right" title="Number of options, Exercised">(759,753</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z06a8R6hHwP6" style="text-align: right" title="Weighted average exercise price, Exercised">2.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZP9O0acgU" style="text-align: right" title="Weighted average grant date fair value, Exercised">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziqPF6mfyqq6" style="text-align: right" title="Aggregate intrinsic value, Exercised">4,629,026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFy5pRVKYI99" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(257,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNQysIpp47ae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvNZk4PG8T94" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">6.74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRNBDwcTAcAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding beginning balance">14,111,780</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVCEf3tVsaM2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">7.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw26BK1vpFz2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTz4uUWMxZyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">22,290,069</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znZU3kVlHEO1" style="text-align: right" title="Number of options, Granted">1,860,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM2dLVlLPbD6" style="text-align: right" title="Weighted average exercise price, Granted">5.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z03F1sZBGRg4" style="text-align: right" title="Weighted average grant date fair value, Granted">3.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4ZomoYX4ICl" style="text-align: right" title="Number of options, Exercised">(273,360</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWjNVYMoyey4" style="text-align: right" title="Weighted average exercise price, Exercised">2.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqqUr0RdYOm9" style="text-align: right" title="Weighted average grant date fair value, Exercised">1.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdyGr0vXAN6f" style="text-align: right" title="Aggregate intrinsic value, Exercised">601,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0cHRJXMWav2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(661,166</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zALlzza5Em9d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">11.67</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhkSSkBQ8mua" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">5.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyLucyoiWRHl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance">15,037,754</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbAC367IhERd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">6.80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSsx5kNI3hI2" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">15,825,791</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, September 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0GduqcpBhGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">9,910,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlmzHQ6Ebou3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">5.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5tBnhyuxDb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">15,176,855</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zosVbZGmQpg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at September 30, 2024 by a range of exercise prices:</p>


















<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2YVgwyiK376" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B7_z68Fo18hTGsi" style="display: none">Schedule of summarizes information about stock options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">vested</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zKnsCyiAjbw7" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zqSFAzGAh9k4" style="width: 11%; text-align: right" title="Range of exercise prices, Upper range limit">3.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDdyTnQoyzci" style="width: 11%; text-align: right" title="Number of outstanding options">3,015,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjowsLPUAp12" title="Weighted average remaining contractual life">3.79</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zl8YkrHgTAhg" style="width: 10%; text-align: right" title="Weighted average exercise price">2.39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdwqQ4ozmBqd" style="width: 10%; text-align: right" title="Number of vested options">3,015,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjEnt80JFkO9" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.39</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zFs6okO3fwEd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zqBReWOji9Vj" style="text-align: right" title="Range of exercise prices, Upper range limit">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zH8xy90eCWLk" style="text-align: right" title="Number of outstanding options">2,267,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ziTWkBIVvmZ4" title="Weighted average remaining contractual life">4.01</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z1bYzPLt6MA3" style="text-align: right" title="Weighted average exercise price">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zv1CWYPyXMSd" style="text-align: right" title="Number of vested options">2,056,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_znR0tyhcDjdi" style="text-align: right" title="Weighted average exercise price options vested">3.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHErj6uIlhle" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">5.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvUdvToDrSr" style="text-align: right" title="Range of exercise prices, Upper range limit">9.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zefhqZJERt9e" style="text-align: right" title="Number of outstanding options">6,640,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHu9lRBkqU1b" title="Weighted average remaining contractual life">6.07</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zAwjOi5bd1He" style="text-align: right" title="Weighted average exercise price">6.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zhLOzuGk2cZa" style="text-align: right" title="Number of vested options">3,473,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zRLtybyWOCw3" style="text-align: right" title="Weighted average exercise price options vested">6.21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zwgjH4CudMMd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">9.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zHbXDbyucZag" style="text-align: right" title="Range of exercise prices, Upper range limit">13.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zAzTAGC3i8Hc" style="text-align: right" title="Number of outstanding options">1,649,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zjtL6f21Ij98" title="Weighted average remaining contractual life">7.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zfzOK1oMVFth" style="text-align: right" title="Weighted average exercise price">10.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zouJsfyRROXh" style="text-align: right" title="Number of vested options">760,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zJcbeYjhrGt8" style="text-align: right" title="Weighted average exercise price options vested">10.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUVTVmMIz5bg" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">13.01</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zTRX6VFAciHc" style="text-align: right" title="Range of exercise prices, Upper range limit">25.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKia0Yvbyx1b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,465,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRXry7ZoAYG3" title="Weighted average remaining contractual life">6.45</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXDhjTnxgqC" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zExs2DKoYFoc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">605,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z3Z0f4RuhDm6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.47</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7WiabqsG4Pl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options">15,037,754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzOS46JZKPbg" title="Weighted average remaining contractual life">5.48</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze3OZD5jIuyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price">6.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zv7ks6Ny45x1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options">9,910,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcbaT8u383oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested">5.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A6_zAufvJUNWIsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested at September 30, 2024 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zPGlJzsx1zL1" title="Weighted average grant date fair value of options vested">4.34</span> (2023: $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zUFUHnNr2KR6" title="Weighted average grant date fair value of options vested">3.94</span>). At September 30, 2024, the weighted average contractual life of options outstanding
was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zHLhZTyCnIo7" title="Weighted average contractual life of options outstanding">5.48</span> years (2023: <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zRvLLcf6qJWg" title="Weighted average contractual life of options outstanding">6.0</span> years) and for options exercisable was <span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zvCl9X5i0juj" title="Options exercisable">4.03</span> years (2023: <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_z6uUq3cqdtnh" title="Options exercisable">4.75</span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized share-based compensation
expense of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240930_zmUOLDM5C0Rg" title="Share based compensation">9.4</span> million during the year ended September 30, 2024 (2023: $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230930_zaAPC60VFCR9" title="Share based compensation">16.4</span> million) in connection with the issuance and vesting 	of
stock options in exchange for services. These amounts have been included in general and 	administrative expenses and research and development
expenses on the Company&#8217;s consolidated statements of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zi2FVOcwWNha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_z2tVgKm7mwUi" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp9OpXIsV36a" style="width: 12%; text-align: right" title="Total share based compensation">3,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFxQwPTmIz11" style="width: 12%; text-align: right" title="Total share based compensation">5,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyDyahjVnw1c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmVbu9HVINJa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">10,812</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zY0w9hpDCWCf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,438</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zqU4aiHPBqac" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">16,370</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A7_zU4EDeUl5dbl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20240930_zGXnFIkhKl2a" title="Remaining stock based compensation">8.4</span> million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_ztvANBNBKOd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zGx432uQE2A4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_zmVvhw0wUJUk" title="Risk-free interest rate">4.28</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zk9aeGxWv1f6" title="Risk-free interest rate">3.70</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zKcOrtuCNxVj" title="Expected life of options (years)">5.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zvMR7rgFHMMg" title="Expected life of options (years)">5.64</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_znTGYHoJmyzd" title="Annualized volatility">84.81</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zQyr91zB3pV3" title="Annualized volatility">85.13</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zDdrcqcPiXgc" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_zZxC4dNmLus5" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>


<p id="xdx_8A4_zWu897XZdev9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the years ended September 30, 2024 and 2023 was determined with reference to the quoted market price of the Company&#8217;s shares
on the grant date.</p>


















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755715137248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z8QYnm9qtxSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	 	<span id="xdx_827_zcEPileDpSC2">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s U.S. and foreign loss before income
taxes are set forth below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zHTmOjgJIYk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B1_z7HyZ8TCOyec" style="display: none">Schedule of loss before income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231001_20240930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221001_20230930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(39,195</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(41,198</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,300</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(43,002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(47,498</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p id="xdx_8AC_zPW5pZgLedye" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of net deferred income tax assets as of September 30, 2024
and 2023 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zRVU4M8bO6H5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zWHOKKQJ26yf" style="display: none">Schedule of components of net deferred income tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240930_zGRKXFJ26cP3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930_zlqiytEYB4ug" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">46,462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,713</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,593</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,219</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,559</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zG0mt9nm9ho3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_z6h5f6BjiZC5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(92,233</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(77,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zt8cAN4PUdM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2024
and 2023 is as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zs1csAl6SFD6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zLKUUUwRbwp9" style="display: none">Schedule of reconciliation of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20231001__20240930_zfSNRerA5OV6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20221001__20230930_zPiGwBdkJhzl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,975</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(601</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(276</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(860</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,122</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years&#8217; tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,186</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,098</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zXo4lZdi2t5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, the Company had U.S. federal
net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards">128.5</span> million (2023: $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards">126.3</span> million) of which <span id="xdx_905_ecustom--OperatingLossCarryforwardsDescription_c20231001__20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember" title="Operating loss carryforwards description">$37.7 million will begin to expire in
2025 and $90.8 million can be carried forward indefinitely</span>, state and local net operating loss carryforwards of approximately $ <span id="xdx_900_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pn5n6" title="Operating loss carryforwards">16.9</span> million
(2023: $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pn5n6" title="Operating loss carryforwards">16.6</span> million) which will begin to expire in <span id="xdx_90E_ecustom--OperatingLossCarryForwardsExpirationYear_c20231001__20240930" title="Operating loss carry forwards expiration year">2036</span>, and Research and Development tax credits of approximately $<span id="xdx_908_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20231001__20240930_pn5n6" title="Research and Development tax credits">4.3</span> million (2023:
$<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20221001__20230930_pn5n6" title="Research and Development tax credits">2.7</span> million) which will begin to expire in <span id="xdx_904_ecustom--ResearchAndDevelopmentTaxCreditsYear_c20231001__20240930" title="Research and development tax credits year">2029</span>. The calculation of the Research and Development tax credits, by their nature, involve
estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these credit
carryforwards would be disputed by the tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn5n6" title="Operating loss carryforwards">16.6</span> million (approximately
AU$<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_pn5n6" title="Operating loss carryforwards">23.9</span> million) (2023: $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn5n6" title="Operating loss carryforwards">12.9</span> million (approximately AU$<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_pn5n6" title="Operating loss carryforwards">20.1</span> million)) of net operating loss carryforwards in Australia, which have an
indefinite life, available to offset future taxable income in those jurisdictions.</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its valuation allowance requirements
based on available evidence. When circumstances change, and this causes a change in management&#8217;s judgment about the recoverability
of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income. Because management of the
Company does not currently believe that it is more likely than not that the Company will receive the benefit of these assets, a valuation
allowance has been established at September 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act of 2017 (TCJA) has modified
the IRC 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the TCJA, the Company
must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and
15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development costs in accordance
with IRC 174 has resulted in a gross deferred tax assets at September 30, 2024 of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_c20240930_pn5n6" title="Gross deferred tax asset">15.1</span> million (2023: $<span id="xdx_902_eus-gaap--DeferredTaxAssetsGross_iI_pn5n6_c20230930_z8yalo9nOo7j" title="Gross deferred tax asset">7.2</span> million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Uncertain Tax Positions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of the Internal Revenue Code,
the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducted a Section 382 study during the
year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership which resulted
in $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20150930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards">25.8</span> million of federal NOLs being subject to an annual limitation. During the year ended September 30, 2021, the Company reduced
its federal NOLs by $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zmd7nUtQtTa9" title="Operating loss carryforwards">12.1</span> million and its Research and Development tax credit carryforwards by $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20210930_z93tCgCjYeK5" title="Research and development tax credit carryforwards">0.8</span> million, which are the amount of tax
assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20210930_zmQtWtpoiQVj" title="Operating loss carryforwards">2.5</span> million of NOLs and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20210930_zZeW3liPXk17" title="Research and development tax credit carryforwards">0.8</span> million
of research and development credits and a corresponding reduction in the valuation allowance of $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20201001__20210930_zlq9EDiyUjZi" title="Decrease in valuation allowance">3.3</span> million, which was recorded in the
2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of the Company&#8217;s NOLs<span style="background-color: white">.
During the year ended September 30, 2024 and 2023 the Company determined that there were no changes in ownership pursuant to Section 382.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#8217; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624987488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zLlyvChHMtGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note
8	<span id="xdx_822_zpnru012Oyt9">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#8217;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no subsequent events or transactions that
required recognition or disclosure in the consolidated financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755618606944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_zgBJ5I211vml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_zAPlVc3iYYcf">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zSbQAInpEeXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_ztu82Co1Phn3">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBxoT8ehUmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zI70NBdVOwS5">Cash and equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#8217;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_c20240930_pp0p0" title="Federal deposit insurance corporation">250,000</span>, under current regulations. At September 30, 2024 and 2023, substantially
all of the Company&#8217;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8e6NUAU2tYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zesLA3jv5Q2k">Research and Development Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#8217;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#8220;CROs&#8221;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#8220;ASC&#8221;) 730, <i>Research and Development</i>, as these materials have no alternative future use outside of their intended
use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s
estimates. The Company&#8217;s historical accrual estimates have not been materially different from actual costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionIncentives', window );">Research and Development Incentive Income</a></td>
<td class="text"><p id="xdx_842_eus-gaap--RevenueRecognitionIncentives_zYOO7Un8ukSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zN9aksYH7Hu9">Research and Development Incentive Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#8220;Australia R&amp;D credit&#8221;) through a program administered through the Australian Tax Office (the
&#8220;ATO&#8221;) and AusIndustry, a division of the Australian Government&#8217;s Department of Industry, Innovation and Science (&#8220;AusIndustry&#8221;).
The Australia R&amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#8217;s company tax rate in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), since the incentives
are not linked to the Company&#8217;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (&#8220;IAS 20&#8221;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#8217;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LicenseFeesPolicyTextBlock', window );">License Fees</a></td>
<td class="text"><p id="xdx_84D_ecustom--LicenseFeesPolicyTextBlock_zvVTlse0Q7E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zgaDCnCdHYPa">License Fees</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.</span></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"></p>








<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zWgq0UJnIPo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zDPBM6FA6BL3">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, diluted loss per share excludes
<span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_pdd" title="Loss per share for potentially dilutive common shares">15,047,754</span> potentially dilutive common shares (2023 &#8211; <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares">14,271,780</span>) related to outstanding options and warrants, as their effect was
anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z9ZlJF0Lwhif" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z19xBHj34mV5">Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The book value of the Company&#8217;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zuAFu9p1clul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_zVPWAmk5hIua">Foreign Currency Translation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Reporting</a></td>
<td class="text"><p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zgEdj1w4tJSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zIbr3fjZhz78">Segment and Geographic Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p id="xdx_842_ecustom--GrantIncomePolicyTextBlock_zGwCAdk9hY0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zaw8i3Xa0wN7">Grant Income</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zXolNW64SI38" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zvqLWhRMJSC1">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zZYtdCIH7Uu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zzz8d0snS2Si">Share-based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based payments
and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. The Company&#8217;s historical share option exercise experience does not provide
sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the
expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid
any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist
of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. Changes
in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#8217;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#8220;net settled&#8221; in shares of the Company&#8217;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#8217;s treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
















<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOMteVA1jZv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_ziRWdPxOyJSl">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024 and 2023, the Company did not
have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8PUyFNhGER7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zI4c0i94DpBe">Recently Adopted Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October 1, 2022, the Company
adopted Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832) &#8211; Disclosures by Business Entities about Government
Assistance, which requires business entities to disclose information about transactions with a government that are accounted for by applying
a grant or contribution model by analogy. For transactions within scope, the new standard requires the disclosure of information about
the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line
items affected by the transaction. The disclosure of the Company&#8217;s research and development tax incentive income and receivable
is detailed in Note 4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_RecentAccountingPronouncementsPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_ecustom--RecentAccountingPronouncementsPolicyTextBlock_z1SqSlbs2MCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_865_zX6GA3HUEZHd">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LicenseFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LicenseFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_RecentAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_RecentAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624461216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of principal components of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zbwnkL2K0Ym1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B5_z2lzU6dypaQd" style="display: none">Schedule of principal components of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240930_z4WLWlnfqNq1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930_zSwhbt41fS56" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_zvn6pZIbv5Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,006</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,360</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FixedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,891</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTIC_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,295</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627312672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_pn3n3_zo7TtWmPUcw5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zZE28QeKNvL9" style="display: none">Schedule of operating lease costs</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20231001__20240930_zy0nqCX3Sqqg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20221001__20230930_zOcdnZ1gajT9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseCost_zG2OCtLdwmZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Schedule of contributions under the plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zY74239U5rD7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"><span id="xdx_8BC_zCLJmKfNvB4e" style="display: none">Schedule of contributions under the plan</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20231001__20240930_zumtC3qVDoQk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20221001__20230930_zkzgsKpX6ZJb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2024</td><td style="color: black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40C_eus-gaap--PensionContributions_zqnvDHsWLGQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">232</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zVrXB8D2W2el" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zyucDNJtHIe6" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Balance, September 30, 2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsEaQiiCcKZf" style="width: 20%; text-align: right" title="Number of warrants outstanding">160,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zkOIgSWK3Ps2" style="width: 20%; text-align: right" title="Weighted average exercise price">3.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfWarrantsExpired_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9iODe9gm0d6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants expired">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceExpried_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zGiipVAva5fi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expried">3.17</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Balance, September 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsLjle0jOCG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z8bylO1akFQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price">12.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_ztty77jTyIU6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zWT9kxCLd4y8" style="display: none">Schedule of stock option activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, October 1, 2022</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj2x0XX7LPE5" style="width: 10%; text-align: right" title="Number of options, Outstanding beginning balance">13,169,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuf1aIFtmA81" style="width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlhUTPvaW8Ag" style="width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">4.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlUHLENQXHdc" style="width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">62,267,309</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNoKqll9fo3h" style="text-align: right" title="Number of options, Granted">1,959,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zi1TwIf8oIff" style="text-align: right" title="Weighted average exercise price, Granted">9.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgzQ7JpYdPf6" style="text-align: right" title="Weighted average grant date fair value, Granted">6.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVgAZGD8r8Af" style="text-align: right" title="Number of options, Exercised">(759,753</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z06a8R6hHwP6" style="text-align: right" title="Weighted average exercise price, Exercised">2.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZP9O0acgU" style="text-align: right" title="Weighted average grant date fair value, Exercised">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziqPF6mfyqq6" style="text-align: right" title="Aggregate intrinsic value, Exercised">4,629,026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFy5pRVKYI99" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(257,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNQysIpp47ae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvNZk4PG8T94" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">6.74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRNBDwcTAcAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding beginning balance">14,111,780</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVCEf3tVsaM2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">7.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw26BK1vpFz2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTz4uUWMxZyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">22,290,069</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znZU3kVlHEO1" style="text-align: right" title="Number of options, Granted">1,860,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM2dLVlLPbD6" style="text-align: right" title="Weighted average exercise price, Granted">5.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z03F1sZBGRg4" style="text-align: right" title="Weighted average grant date fair value, Granted">3.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4ZomoYX4ICl" style="text-align: right" title="Number of options, Exercised">(273,360</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWjNVYMoyey4" style="text-align: right" title="Weighted average exercise price, Exercised">2.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqqUr0RdYOm9" style="text-align: right" title="Weighted average grant date fair value, Exercised">1.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdyGr0vXAN6f" style="text-align: right" title="Aggregate intrinsic value, Exercised">601,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0cHRJXMWav2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited">(661,166</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zALlzza5Em9d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">11.67</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhkSSkBQ8mua" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited">5.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyLucyoiWRHl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance">15,037,754</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbAC367IhERd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">6.80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSsx5kNI3hI2" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">15,825,791</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, September 30, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0GduqcpBhGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">9,910,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlmzHQ6Ebou3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">5.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5tBnhyuxDb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">15,176,855</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summarizes information about stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2YVgwyiK376" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B7_z68Fo18hTGsi" style="display: none">Schedule of summarizes information about stock options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">vested</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zKnsCyiAjbw7" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zqSFAzGAh9k4" style="width: 11%; text-align: right" title="Range of exercise prices, Upper range limit">3.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDdyTnQoyzci" style="width: 11%; text-align: right" title="Number of outstanding options">3,015,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjowsLPUAp12" title="Weighted average remaining contractual life">3.79</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zl8YkrHgTAhg" style="width: 10%; text-align: right" title="Weighted average exercise price">2.39</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdwqQ4ozmBqd" style="width: 10%; text-align: right" title="Number of vested options">3,015,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjEnt80JFkO9" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.39</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zFs6okO3fwEd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zqBReWOji9Vj" style="text-align: right" title="Range of exercise prices, Upper range limit">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zH8xy90eCWLk" style="text-align: right" title="Number of outstanding options">2,267,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ziTWkBIVvmZ4" title="Weighted average remaining contractual life">4.01</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z1bYzPLt6MA3" style="text-align: right" title="Weighted average exercise price">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zv1CWYPyXMSd" style="text-align: right" title="Number of vested options">2,056,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_znR0tyhcDjdi" style="text-align: right" title="Weighted average exercise price options vested">3.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHErj6uIlhle" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">5.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvUdvToDrSr" style="text-align: right" title="Range of exercise prices, Upper range limit">9.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zefhqZJERt9e" style="text-align: right" title="Number of outstanding options">6,640,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHu9lRBkqU1b" title="Weighted average remaining contractual life">6.07</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zAwjOi5bd1He" style="text-align: right" title="Weighted average exercise price">6.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zhLOzuGk2cZa" style="text-align: right" title="Number of vested options">3,473,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zRLtybyWOCw3" style="text-align: right" title="Weighted average exercise price options vested">6.21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zwgjH4CudMMd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">9.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zHbXDbyucZag" style="text-align: right" title="Range of exercise prices, Upper range limit">13.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zAzTAGC3i8Hc" style="text-align: right" title="Number of outstanding options">1,649,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zjtL6f21Ij98" title="Weighted average remaining contractual life">7.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zfzOK1oMVFth" style="text-align: right" title="Weighted average exercise price">10.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zouJsfyRROXh" style="text-align: right" title="Number of vested options">760,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zJcbeYjhrGt8" style="text-align: right" title="Weighted average exercise price options vested">10.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUVTVmMIz5bg" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit">13.01</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zTRX6VFAciHc" style="text-align: right" title="Range of exercise prices, Upper range limit">25.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKia0Yvbyx1b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,465,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRXry7ZoAYG3" title="Weighted average remaining contractual life">6.45</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXDhjTnxgqC" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zExs2DKoYFoc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">605,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z3Z0f4RuhDm6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.47</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7WiabqsG4Pl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options">15,037,754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzOS46JZKPbg" title="Weighted average remaining contractual life">5.48</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze3OZD5jIuyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price">6.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zv7ks6Ny45x1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options">9,910,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcbaT8u383oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested">5.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zi2FVOcwWNha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_z2tVgKm7mwUi" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp9OpXIsV36a" style="width: 12%; text-align: right" title="Total share based compensation">3,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFxQwPTmIz11" style="width: 12%; text-align: right" title="Total share based compensation">5,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyDyahjVnw1c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">5,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmVbu9HVINJa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">10,812</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zY0w9hpDCWCf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,438</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zqU4aiHPBqac" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">16,370</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_ztvANBNBKOd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zGx432uQE2A4" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_zmVvhw0wUJUk" title="Risk-free interest rate">4.28</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zk9aeGxWv1f6" title="Risk-free interest rate">3.70</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zKcOrtuCNxVj" title="Expected life of options (years)">5.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zvMR7rgFHMMg" title="Expected life of options (years)">5.64</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_znTGYHoJmyzd" title="Annualized volatility">84.81</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zQyr91zB3pV3" title="Annualized volatility">85.13</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zDdrcqcPiXgc" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_zZxC4dNmLus5" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755624468080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zHTmOjgJIYk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"><span id="xdx_8B1_z7HyZ8TCOyec" style="display: none">Schedule of loss before income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20231001_20240930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20221001_20230930" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(39,195</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(41,198</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,300</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(43,002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(47,498</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of net deferred income tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zRVU4M8bO6H5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zWHOKKQJ26yf" style="display: none">Schedule of components of net deferred income tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20240930_zGRKXFJ26cP3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930_zlqiytEYB4ug" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,134</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">46,462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,713</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,593</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,219</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,559</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zG0mt9nm9ho3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(254</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_z6h5f6BjiZC5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance of deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(92,233</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(77,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zs1csAl6SFD6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zLKUUUwRbwp9" style="display: none">Schedule of reconciliation of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20231001__20240930_zfSNRerA5OV6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20221001__20230930_zPiGwBdkJhzl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Income tax benefit at statutory federal rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,975</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(601</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Permanent differences relating to GILTI inclusion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(276</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development credits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(860</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,821</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,122</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustment to true up to prior years&#8217; tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in valuation allowances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,186</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,098</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755716061920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">15,047,754<span></span>
</td>
<td class="nump">14,271,780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627107184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedInvestigatorPayments', window );">Accrued investigator payments</a></td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 2,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MilestoneBasedContractAccruals', window );">Milestone-based contract accruals</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,835<span></span>
</td>
<td class="nump">$ 7,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedInvestigatorPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedInvestigatorPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MilestoneBasedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MilestoneBasedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755619756944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Non operating income from grant</a></td>
<td class="nump">$ 75,000.0<span></span>
</td>
<td class="nump">25,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome1', window );">Deferred grant income</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember', window );">Michael J Fox Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1', window );">Research and development incentive income</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627586736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FairValueOfInitialCommitment', window );">Fair value of the initial commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,283,200<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member] | Common Stock Including Commitment Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,455,646<span></span>
</td>
<td class="nump">3,288,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member] | Common Stock Excluding Commitment Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450,000<span></span>
</td>
<td class="nump">3,275,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member] | Commitment Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,646<span></span>
</td>
<td class="nump">13,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2020Member', window );">Purchase Agreement 2020 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FairValueOfInitialCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FairValueOfInitialCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avxl_CommonStockIncludingCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avxl_CommonStockIncludingCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avxl_CommonStockExcludingCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avxl_CommonStockExcludingCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avxl_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avxl_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755628344864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627586736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contributions to 401(k) plan</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755715092896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - Purchase Warrants 1 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NumberOfWarrantsExpired', window );">Number of warrants expired | shares</a></td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WeightedAverageExercisePriceExpried', window );">Weighted average exercise price expried | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageExercisePriceExpried">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageExercisePriceExpried</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627628048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - Equity Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding beginning balance</a></td>
<td class="nump">14,111,780<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding beginning balance</a></td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding beginning balance</a></td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding beginning balance</a></td>
<td class="nump">$ 22,290,069<span></span>
</td>
<td class="nump">$ 62,267,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">1,860,500<span></span>
</td>
<td class="nump">1,959,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 5.47<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(273,360)<span></span>
</td>
<td class="num">(759,753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted average grant date fair value, Exercised</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, Exercised</a></td>
<td class="nump">$ 601,407<span></span>
</td>
<td class="nump">$ 4,629,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="num">(661,166)<span></span>
</td>
<td class="num">(257,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 11.67<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted average grant date fair value, Forfeited</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 6.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding ending balance</a></td>
<td class="nump">15,037,754<span></span>
</td>
<td class="nump">14,111,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding ending balance</a></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding ending balance</a></td>
<td class="nump">$ 15,825,791<span></span>
</td>
<td class="nump">$ 22,290,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable</a></td>
<td class="nump">9,910,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">$ 15,176,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755619623312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">15,037,754<span></span>
</td>
<td class="nump">14,111,780<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">9,910,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,015,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,015,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,267,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,056,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">6,640,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,473,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, Lower range limit</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, Upper range limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">605,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627456224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 9,438<span></span>
</td>
<td class="nump">$ 16,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="nump">5,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 5,813<span></span>
</td>
<td class="nump">$ 10,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755721393120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 6)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">84.81%<span></span>
</td>
<td class="nump">85.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627663024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,267,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,462,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755625617952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (39,195)<span></span>
</td>
<td class="num">$ (41,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(3,807)<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (43,002)<span></span>
</td>
<td class="num">$ (47,498)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755716052848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 48,134<span></span>
</td>
<td class="nump">$ 46,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">4,203<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">21,091<span></span>
</td>
<td class="nump">18,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization', window );">Research and development capitalization</a></td>
<td class="nump">15,104<span></span>
</td>
<td class="nump">7,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredTaxAssetsUnpaidCharges', window );">Unpaid charges</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset costs</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(254)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance of deferred tax assets</a></td>
<td class="num">(92,233)<span></span>
</td>
<td class="num">(77,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsUnpaidCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsUnpaidCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755626535184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory federal rate</a></td>
<td class="num">$ (9,030)<span></span>
</td>
<td class="num">$ (9,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxed at other rates</a></td>
<td class="num">(61)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PermanentDifferencesRelatingToStockBasedCompensation', window );">Permanent differences relating to share-based compensation</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount', window );">Permanent differences relating to GILTI inclusion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="num">(276)<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet', window );">Research and development credits, net</a></td>
<td class="num">(860)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="num">(3,821)<span></span>
</td>
<td class="num">(4,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment to true up to prior years&#8217; tax provision</a></td>
<td class="num">(1,128)<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">15,186<span></span>
</td>
<td class="nump">14,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PermanentDifferencesRelatingToStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PermanentDifferencesRelatingToStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45755627062656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carry forwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and Development tax credits</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentTaxCreditsYear', window );">Research and development tax credits year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 128.5<span></span>
</td>
<td class="nump">126.3<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OperatingLossCarryforwardsDescription', window );">Operating loss carryforwards description</a></td>
<td class="text">$37.7 million will begin to expire in
2025 and $90.8 million can be carried forward indefinitely<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 23.9<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryforwardsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryforwardsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentTaxCreditsYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentTaxCreditsYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=avxl_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M"=_,26@<:HN_"K931_?(A/(LQ'?S<)]-O< P8B5;: -!X;)E<U:6!@EX_-V
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MA#X@7J$_<[%3M,K4W-. P5CRTOU\M\U\9& ^3- 74>E<H5^KC&7'!CP WWI
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MF1108CGB%3#])..BQ$I/1>[*2@!.;5))7=_S9FZ)"7.BI5W;BFC):T4)@ZU
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MHR1:$YJ [[4#,_H7VF#\Q>3VWU!+ P04    " #/@Y=9VY!E-B4<  #840
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MVP(BD @"E\I51("ZO;9C8RMA]6[0?3F-@>A$M'4(=;XIHCE@M;-@-(1MB0/
M4H1I<IJS:"J$/AJO:7RC\GA+NE43-. P.M\I5A<_R2X0+V0_!H S8.46V4],
M!6="8&:KID*4"[)S=$*'E,SH2;Z -<H=#5NH"D.,9&0K* 3#$=LMR9! -\B9
M8R(]E2;AGX( 7ZL6):I1W8]+GY\=?,E&OF7X*/1,R5&R&\^2:BK:+UE1M$ R
M&-U(RR+:)Q_[68@<.T X0)0&290OM#EB_U1.87FPP.@]UULF-K,T) R0+*(A
M721J.L>Y"<$;W\X<&9R)L,4"6M@H,H,JY9NQ%9)4F+!C<_,J0F4Z:D<8%2U)
M<BQVY5@[UL(ULO[")2&])O"MMDRW8#7>XUDTE%D20@ &DZ0 CB7"2TXM)3=Y
MU'&\C7DH^HM0^<16DI#)+B]#0.468-(HL]$K%+M> 3DI =0Y-H)@2$.6JRP.
M-SMQ^'8O"!=QQH_=45]48-6455- ?X+1P9O&P/[#7\OUYODK?2BZV$!?:=CZ
MENLH3W:(X><=@C[2NN]P+BRO5H35/KZ+$W-\/OJW78UA"-@1A#0^T_5LPC?P
M71UXBH;M%9*X0W!O:9ZW7>=N4Q2C.8^4K$AK!EH8&YMCHHB,;Y ,J*T@AU)"
M"P$8FE_$BK#ED'>YY(@SJLHWP(6"C^5 OKB#Y4ST+/958+Z?F2'%)&_HTI(I
MI?%5UDB1U0=R").S!F9WM?L;0/(!FHT;!\3_._F>89*&8]@<IF,81.'#*<?I
MMSIMVD D)?Q8=A'Q",83=$6D>@2,C 8RNR^.Y*LB@3AORZ8%>"R&3*R2[ '8
M8,.-9;L.+JU<$CI9(ET24NW$: OW1."N,W^^.)N? 42W4,U,MVO!S +PFO6"
M>&+$JL@0R1.#)!5\Z/EW\Z=_0>Y6=HI05TFN/#L5,16%[#EHR35)6)\8!;&E
MD5/H<$H<P\,J^B\J"NJ!#H1KR3M-LK*TB/BK+5)CPRK:A:D10HB-Y.<Q*](Z
MC@J1PA]I$J02)B"C0/"A$;PB<OR:,92I&<<O%2$-UKGK*_/1;2B2>?;D;!9M
M>_F%QOSS@ \^IB(S>!Q.%Q?J<950<3#+L9&X1LX?%XS88DR+(4ND#3C33Y].
M2>MN4  8/8$'TACP<@ )A\Q#X)HG*1:"D=V28[JWE]<79WD\A8>3_31O9&%V
M>HVO6H?L!J=.TS.7GK:?2PQ3L+=WI%.65=.B8@&*-QQ8L?T-L0I\PLF;ZX\/
MN6*B%B5&,FI<^82+"M 1JEV/?(N';PC9,9;,5@I7R(;^1J?'UXTD7?<I+/8I
M9/" 65JM4@53IPI#-!)6:0C;7#=T7%'XVLM**]+]!V<++VL0SOS]X_(P?\51
M_M@ RG$B!6C\4=+8,M+\2MLAK!^ ?0RMN/H7,Y\R5]&(O:Y$^X+=S\IV$ #$
MAL52!!ASM!P-OKVO5A?*BM!7IE!R ED)0\.B@AL%:(]_(2&1Q3>OK=1H8SHO
MY:NTD@GNI;;(Z4@*&RM]P'M'L'10% B-JD<P*><P=U?(;0@0;E5@&AUOIY*C
M;<-JC4]P-I9\!ENM.L>'#A8)9J#EH)B%HDF"D5CBQ91:CO'H+]^D""3-DUA!
M;FZ%Y&<MT3;+H( G+C=D9QAZ)]"1JM!1$[+8'SZICR'Q+L=9,)7Q+5(.K&X<
M7#.RKF1*BL-L3A,*D$B,A;+D1F26X]$;\M"-KL\)\<&'72-&R7'7'*0V" _+
M:J5)*764(D5;2'&:0MRM9/-O.24 B\;(7"3(E?E!XD>>/CD\+.S+EAAX2=14
M:A?;$7KT"\K#Y(;--9*,^D##?N/1"6K'#_E7A$2T#9R)!+50>AZ_V!; M"S\
MCN*7Z=!$ PHS.@?*U10&<,U'\W5WW,F#0 ?[1;B2XLH%+<M9FK2R.#[DSK!<
M!BHTNU $KOXE!LS_ P-^7(/8D_.'C"X#/Z?_$3\S<W+Q4()%\,6AG?16!%5&
MC9[SH@A7I0_$;6)MKKCC#"[L@P\S#ZBXCZ1)TC6PMN1BY!B</#ZZEF1AXQGA
MY(D^E)>'7I.>$5S=.&]3YD%VI(!HVZ!KL@MT/JJQU5:%C&P3R69L?/^J$O]R
MK*R6.V:1LOFYD'2<DH6M2M@Q&M7T@>\[3DT!Q]'RIV%I]M7HRK&;P?*>AMZH
M65AA=W:ES!?G3V=G3Y[-GCU]8LZ?S"Z>G<^>?7=F7L>"S]N.//JXCB52--:E
MRMZA>L6T6*1C9P57(3TCH^ 8=TJP7^U$B3AL4VXEN0PY[^<Q\_JBRB\5&8NO
M%QG9Y6?$S\VGC@,*UKD[*'5'&D!G0:## 4= >+?CI&TPP5D> RD7\BVDD34B
M')_U4G%=F^#$3,MU2-?V(432+ _]P_!25<K;PQ)GU:<CWYFK,-5'U,G;V-^
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MBQW(+PML^: = .T;A=_4?N,"M#^1^2]02P,$%     @ SX.765)5E9(+!@
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M(#4+/IX\^PE4F]//9"7>UX=*WRHELCAY]N5<O%&-VI:M^%3!HK%+]E!64DV
MAXOG.1QHRDW'U<?*:QQAQ8'V.#==^<+DI<*(=J_$CPU\T\!%G]6U:CJ%.!0J
MHF/<WEQ?*]@DJTK\'<XDPUK9(A!4FXI >5UM=.JU&%X+596[<@/GM5H<I&G+
MO#Q@H6 ?^[-J>2L&*Q#= RVFMWEG#( B+&1WK39 0PGP6&\9E@3W[+A"%A!2
MC-IUE23+K3/+V\\G(A8LAP[IO8HS:_D%2"B*DK9!)JIQOJ>0C7T,+#9BH_:R
MVI(SCZ^:W=@MXX#5LE /"1M,F2CXC7!\2!3)^"94OIT(@ O&2CP1Z7)-/V>I
M^"M\LF-WLC.]94%IT6<W_P3$:'->R;)V:5VI'1QX,#I7JF!(MGO9"FE*.P1?
M&[Q!BX89G;%LT*:S +6%_ZZZ?$\^:QF&AC;M%:&ANH6AN3(MJ$#(9[7T(L@E
MA44T6NPZ:21PH=R9?%37YKKF(R@@]B@<-0,8Q\9"Y26Y:BNOM9&;ZK9'81]%
M;8[R4&UUY5+NOLB 13:Z1:9> U#T6!FJ1[*@K%)";;?DLNZ@F_$1?_S#*DV6
M+RS%%?++0E)F(<TEJB.V4QXH+IW1. JBT,@T.F^#=$,>L)X!Z[QUBH%<%8R]
MQR+$:O^&RE"8$N<;%/S8B+])@[.3F4,<@B7L'J'<ZXJ "EVL9;ZDJ=X@=1#1
M5MP0]LL*<CU,I@4&K1.(A29O 9H66>(0?X4( P;-\3U,_P"V]@^P-;:W;(-&
MUJJ8Q)1>4!_A[F+ZXCB\Q7%J"]?)P>53/2&/TPL&_+D#8I+4$8B[:U%&U0[*
M7Y?:UZ3 'X7JW!GDEG)!>?\UWTMT0W'I+$C6LPQJ6 WWDA.XP14#>W";CEYW
ME887X>6A3TN7+' X^F).;9$B2Q7&!)<?+G]^_S\"I&&9O7 QNQ4K9T48(& H
MN)4TC\7'P@N<PL#?K?B+:AJ%\]_IFP:HHJ ?.G/0AM0?AW_J:ZS;0;QMCR*+
MH^N#,=H]R(L^&U&#*GECN]+'I+*:70!$B!H@;ME)3F4 6S/>X!:XL2ZM:P*#
M>1&U6_PNM]O>!'&-5&]:E*[J-O";^/32CMR",FC5KQVU*U\W<"+M]G;>.Y<S
M!.B5&R@:D-N1**)/%'BHO)8T2DR,\U:,7-5[Y9FD$@#JCO@.GCL/'T:WJYTU
M=P7KWP5W"]$;+4U!+]^5!FC26-EG9705/92,TQR\EH4D9$A4**3H:3C<R9@
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M$\;]UYC[T.H#_Z?61K>MKOG/O9(H>+0 [[<:-OH/=,#PKWNO_PU02P,$%
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M=\^RW)F%1[/X02 [[^BC-*U_]MC!JJEM(_U>W$GCX)G;:8Z'5UH+N$HYX?O
M+<3I5'P.B!?SSE33_MF,#P*=5N<:'*KV6WB#46A=K><-"2 5-'!IB2""04IW
M5S L-LHO$&!.R;'3<).\QCJ?/]B;J^,E%98QRVSKS:*AA^=R:9AO/$5T..64
MHP-QPUN2CYZF9L;[)6W1UO%&R_##6&[:#8QSP(79FJ;(R:=*WK-44_'+7#2D
MVSVD^^7I$/F\7>LX?.@*A:9&O0_)BUS1\D#=RYJ.MUIUAU1"2< ".4"ICHUE
MV ,'XM1KNK/.*]2UJI?\HIC8&3'YMZG[J_MWT5?^%>SAN'^1_9NLL3=94:@%
M1*/!9-03M7\Y[/\X4_$+V;EQSJSYYTI)< <=P/V%,6[WAPSLW]!?_@-02P,$
M%     @ SX.767GX2MP! P  ZP8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,38N>&ULC95=;]HP%(;O^156*E6;-)$0:,M:0"J,:;OH5)5]7$R[<))#8M6Q
M,_N$M/]^QPZD3 74F\0?[WG\'CL^F33:/-H" -E3*96=!@5B=1V&-BV@Y+:O
M*U TL]:FY$A=DX>V,L S'U3*,(ZBR[#D0@6SB1^[-[.)KE$*!?>&V;HLN7F>
M@]3--!@$NX$'D1?H!L+9I.(YK !_5/>&>F%'R40)R@JMF('U-+@=7,]'3N\%
M/P4T=J_-7":)UH^N\S6;!I$S!!)2= 1.KPTL0$H'(AM_M\R@6](%[K=W],\^
M=\HEX1866OX2&1;38!RP#-:\EOB@FR^PS>?"\5(MK7^RIM7&'P.6UA9UN0TF
M!Z50[9L_;?=A+V <'0F(MP&Q]]TNY%U^XLAG$Z,;9IR::*[A4_719$XH=R@K
M-#0K* YGJSJQ\+<&A6RYH:>=A$A8-QFF6\2\1<1'$(.8W6F%A65+E4'V/R D
M/YVI>&=J'I\DKJ#JLV'T@<51/#K!&W9)#CUO^-8DV>_;Q**A3^+/H7Q;VN@P
MS5V3:UOQ%*8!W0,+9@/![/QL<!G=G/ ZZKR.3M'?=B"G$=\T0F_,7F?]O0"V
MT&7%U3.##9<U1[!T'SL=M#J=IK4Q0N6]!+ !4 PILM06Z1ZF3IAPR54*K"T<
M&7$85YF7^8YKK(4BC>"26:2QTJ.Y(>6&"\D323+-$F#"VAHR)A33)@/C1C-
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M]">^2TBW^ #\OK)@*N4#3A#>F/W\_P!02P,$%     @ SX.76<[T!Q"G @
M%P8  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULG55=;YLP%'W/K[!H
M56U25H@)2=HF2,FV:I-6J6JZ[=F!FV#5V,PV3?OO=VT(RR0:37L!?YQ[[CDV
M]S+?*_UD"@!+7DHAS2(HK*VNP]!D!93,7*H*).YLE2Z9Q:G>A:;2P'(?5(J0
M1M$D+!F703KW:_<ZG:O:"B[A7A-3ER73KRL0:K\(1L%AX8'O"NL6PG1>L1VL
MP7ZO[C7.PHXEYR5(PY4D&K:+8#FZ7HT=W@-^<-B;HS%Q3C9*/;G)UWP11$X0
M",BL8V#X>H:/((0C0AF_6LZ@2^D"C\<']EOO';ULF(&/2OSDN2T6P2P@.6Q9
M+>R#VG^!UD_B^#(EC'^2?8--)@'):F-5V0:C@I++YLU>VG,X"IA%;P30-H!Z
MW4TBK_(3LRR=:[4GVJ&1S0V\51^-XKATE[*V&G<YQMETF66ZAIQ\XVS#!;<<
M#'GWR#8"S/MY:#&#PX59R[9JV.@;;"-*[I2TA2&?90[YWP0A2NOTT8.^%3W)
MN(;JDL31D-"(CD_PQ9W?V//%_^ZWSV9#,NXG<85R;2J6P2+ 2C"@GR%(+\Y&
MD^CFA,1Q)W%\BCU=8^'EM0"BMJ327&:\8H)DJJR4!&F-6V>M#7':QLE$_3;^
M,_L +\I"N0'M;FO@;LM=63PX'#B7SV LWS&K-*G8:^G)SLEL$N&3#K&)=%B7
M#>N>-74K<[(!"5N.^-$PH5-\QI-H<,M?/%9:C;7=B&+"D(NS&1W1&Q+/!G<<
MOV.+PC^XRNT#)XFCHY/I8"D$4;9  SWV$#.[&J',"1T/'I7%(^E#G9/Q<!8G
M^)X.Z55"^KZ&\*A82] [WY(,2JNE;>JV6^VZWK(I]C_PIF7>,;WCTA !6PR-
M+J=)0'33AIJ)594O_8VRV$C\L,#.#=H!<'^KE#U,7(+N7Y#^!E!+ P04
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M7@1X /;G36-W"U30_0LS^1M02P,$%     @ SX.768#)>+9O!   UPH  !D
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M+%E;FSNY_0EV_J06KY2U=K]DV[U-<Y^4K39RLQ-&"S9<=/_L<1>'GD 1OB!
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MY]B#53=&=1LC&S>Z+*3!0<@MUSAY@K(/\'XII=EOK(+#+#O]&U!+ P04
M" #/@Y=9O4,1NJH"  "[!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6RM56%OFS 0_2L6FZ96V@H!DE0=04K259NT3E&C;A^F?7#@"%:-S6PG:?_]
MSH;0M"+1-"T?@FWNO;MWMA_)3JH'70(8\EAQH2=>:4Q]Y?LZ*Z&B^D+6(/!-
M(55%#4[5VM>U IH[4,7], A&?D69\-+$K2U4FLB-X4S 0A&]J2JJGF; Y6[B
M#;S]PAU;E\8N^&E2TS4LP=S7"X4SOV/)605",RF(@F+B30=7\Z&-=P'?&>ST
MP9A8)2LI'^SD2S[Q EL0<,B,9:#XV,(<.+=$6,;OEM/K4EK@X7C/?N.THY85
MU3"7_ ?+33GQ+CV20T$WW-S)W6=H];@",\FU^R>[)G8<>23;:".K%HP55$PT
M3_K8]N$ ,!@= 80M('P-B(\ HA80.:%-94[6-34T393<$66CD<T.7&\<&M4P
M87=Q:12^98@SZ;+9/2(+LF1KP0J646'(-,OD1A@FUF0A.<L8:')V#88RKLDW
MJA2UW3\G'\C]\IJ<O3U/?(/56$X_:S//FLSAD<R#D-Q*84I-/HD<\I<$/LKH
MM(1[+;/P).,2Z@L2!>])&(1Q3T'SOX=')\J)NM9&CB\ZPM?7PY_3E38*S^ZO
MOH8U?'$_G[W/5[JF&4P\O+ :U!:\]-V;P2CXV"?V/Y&]D!YWTN-3[.D-Y* H
MQ_M42\T,84)O%!49D$RJ6MK3(T5?!QK:H:.U!K1-PV& O\3?'FH[F?T?M0T[
M;<.3VKY*K4D-Z(0E54#02$DM#>!&4\Z?2,[XQMX-5%I5Z%,N2O=I;=*,#K0.
MAD$\'@_C5VI[ N-P/!A?/K>E4>(?^$ %:NWL41-W#)MKU*UV#CQUQO-J?8;.
MW!CI,TUCZ[=4K7$W"8<"*8.+,1:G&JML)D;6SFU6TJ!WN6&)7Q=0-@#?%Q*;
MU4YL@NY[E?X!4$L#!!0    ( ,^#EUDCFPXDP (  &P(   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;*V676^;,!B%_XK%JJF5UD(@?+0C2&VJ:I-6
MJ6K:[=J!-\&JL9GM?/3?SP:*2* H%[L!&]YS_!S -O&.BS>9 RBT+RB3,RM7
MJKRQ;9GF4&!YQ4M@^LZ*BP(KW15K6Y8"<%:)"FJ[CA/8!2;,2N+JVI-(8KY1
ME#!X$DANB@*+]SN@?#>S)M;'A6>RSI6Y8"=QB=>P /5:/@G=LUN7C!3 ).$,
M"5C-K-O)S3PR]57!;P([V6DCDV3)^9OI_,QFEF. @$*JC /6IRW,@5)CI#'^
M-IY6.Z01=ML?[@]5=IUEB27,.?U#,I7/K,A"&:SPAJIGOOL!31[?^*6<RNJ(
M=G6M[ULHW4C%BT:L"0K"ZC/>-\^A(YA,/Q&XC< ]5> U J\*6I-5L>ZQPDDL
M^ X)4ZW=3*-Z-I5:IR',O,6%$OHNT3J5W*:IV$"&?A&\))0H A*=WX/"A,H+
M=(E>%_?H_.P"G2'"T$O.-Q*S3,:VTF,;!SMMQKFKQW$_&6<!Y17RG&_(==SI
M@'Q^NMP[E-LZ<1O;;6.[E9]W>NRA3+7)=-C$3+ ;6>(49I:>01+$%JSDZY=)
MX'P?2OB?S [R>FU>;\R]S4O8%J0B:ZRX0"5^U_-1#2:O[?S*SJP$VR0*G-C>
M=@/U:\S:T18=@$Y;T.E)H"DO]$(E<3W768:6P&!%AF%KRZ #,O'=\(AVH,CK
M1#J@]5M:?Y3V@>PK5J:$7H_TFJ3A,1UD'#4:?OMHZ"OR>S&\:#A$T(8(1D,\
M$JJ_"<[@TJR')\8)>AB^?_S$^S43-PB'8<,6-AS_/BA%7.4@:CJ-2\>G<-B'
MB*XG1Z3](C<PR]00:=221J.D+UQA>BIEU)M*T\CSCRC[1:%[[1]1VIV]P.S#
MCUBL"9.(PDK+G*M0ZT6]M]4=Q<MJ>UARI3>;JIGKWP$0ID#?7W&N/CIFQVE_
M,))_4$L#!!0    ( ,^#EUD.R+OZZ ,  "@3   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;+58;6_;-A#^*X16%"W062]^3VT!L;5B&>8N2-#M0]$/
MM'2VA%*D2])V]N]'4HIL*0J1>LJ'1!1U]_">A[K3F;,CX]]%"B#10TZHF#NI
ME+LKUQ5Q"CD6/;8#JIYL&,^Q5+=\ZXH=!YP8IYRX@>>-W!QGU EG9NZ6AS.V
MER2C<,N1V.<YYO\N@+#CW/&=QXF[;)M*/>&&LQW>PCW(+[M;KN[<"B7)<J B
M8Q1QV,R=:_\J\H?:P5C\G<%1G(V1IK)F[+N^N4GFCJ<C @*QU!!870ZP!$(T
MDHKC1PGJ5&MJQ_/Q(_HG0UZ166,!2T;^R1*9SIV)@Q+8X#V1=^SX.Y2$3( Q
M(\+\1\?"=CAV4+P7DN6ELXH@SVAQQ0^E$&<._N@9AZ!T")H.@V<<^J5#_Z4.
M@])A8)0IJ!@=(BQQ../LB+BV5FAZ8,0TWHI^1O6^WTNNGF;*3X9_R10XNJ$Q
MRP&]BT#BC CT&7..]8:\1[^B+_<1>O?F/7J#,HI6&2%JO\3,E6IUC>'&Y4J+
M8J7@F97\ *T8E:E O]$$DCJ J\*N8@\>8U\$5L1[V/50W_N  B\8M 2T?+E[
MO\4]>KF[;V'3KW:B;_#ZS^!%L%$S"5H 52.);@FF*,I$3)C8<T!?_U2/T8V$
M7'QK4[] '[2CZ_)Q)78XAKFCZH, ?@ G?/N+/_(^MBG7)5C4$5A-U4&EZL"&
M'MXI1,SC%&&:J'IP4(5NI\J65.]RK"[J%=<C]?*W26J%_EE)"["I =/5^!!Z
MO>',/9PK9;>I"3"L!!A:!?BLBJOZ2NATIMN2*]IPEJ,MQU2VT2X AV=1C(>>
MY]5C7196HS.KX*E59 WNPKT?5=1'5NHJHX!SE5*&J66?"QC?J^D^:?!M-9HV
MZ%H#NI#NN*([?KU7??R47=#K-R1H-1HW)+ &>:$$DTJ"B56"FXJIUD#B!]6:
MQ) =\)I ZR=K\A+:K4;-U+4&=B'M:45[:J5]K?H$CDF&/Z"($8)Y*U<KQL]6
MLR[!HH[ :MKYWJD#\E[UPUO"=R1LIVA15VAU:<^:2__U2E*)7<N[?C/OEFU6
M@Y[?R$Y[G)?J$)QT"+JM2R5>@WNS,)56TYI1\Y-D#^U2ZJ>NUK>V=^$JBU,,
M!/V!/K$'];>G"3:_^+ZN(%\#;T^I3IO93M&BKM#J>I[Z67_PNM6JTZ:V4[2H
M*[2ZM*=.V;>WRO^O6CWMFOUFNG;4#)=B==I:NV='"#GPK3F*$2A6^2J+7^35
M;'7<<VT..1KS"WT,9(XF3C#%&=(*\VU&!2*P49!>;ZP(\.)8IKB1;&<.*M9,
M2I:;80HX :X-U/,-8_+Q1B]0'8Z%_P%02P,$%     @ SX.768>_XZ&E!
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ME.KEB75FTX5J\N*%:/2A+RY+8BU<T&OR/.]U2U$G'UV8S()]]_]*K44=^N/
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M&BFCWCO,2#<3HS&LJGS3K93%%O;;$H<L:.> ]VNE[-YP ;JQG?T&4$L#!!0
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MM>IHD_(A?S(OV^$-4RN>:4AQ2:[-1I\"J[+%E!,C<_>L+Z2A)N&&"75E5-:
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MC] 25FP7R4_IX6\H";E9O""-1/X?'0I;SQNA8"=D&I?."D$<)L4O>RPGHN&
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M7EG\L,);)6AG@.]72MFGB;NW=/?4XA]02P,$%     @ SX.765T/PB_F P
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M1*4+9^J0!#:TRM4CW_\,C:"QQHMY+LTOV=>VXYE#XDHJ7C3.R*#(6/U/GYM
M'#GX48]#T#@$78=1CT/8.)C(N34S(^N.*KJ<"[XG0ELCFKXPL3'>J"9C>AM7
M2N#;#/W4\I[%O #R1)]!DO=WH&B62Q)\(!?DR^J.O'_[@;PE&2-/*:\D98F<
MNPJ7U<YNW"QQ4R\1]"SA!^0S9RJ5Y >60'(*X"+?EG1P('T3#"*NH+PDH?>1
M!%XPLA"Z_7[W<(!.V,8P-'CA/\:0W&4RSKFL!) _KM=2"4S3/VTAJQ%'=D1]
M=J]D26-8.'@X)8@=.,MW;_S(^V23^S^!G8@?M>)'0^@'\0K%KX'!)E.$*B(5
M597BXH5L( %!<R*H EL@:O2Q0=<U9[>\F'FA-W=WQPIM5K/)N+4ZH3YNJ8\'
MJ6,=P%/.,+T/$B#1Y+E*01C"UFRO0:-C+I'?X3NXL'U'R,!F1*VB:%#1 V!E
M8\ 42;+-!@2P&(^U@)RJC&V)XD2F5,"%+GP)0=78#235]=0F-#H7ZG<WQF(3
M>;Y]7R:MBLE_5/'3_2]/]WK?\DKVD!]<XKMVH!8X.1/H1SUY-VWU30?U_6KR
MJ[2IM"F9GH<XF$2=?3@W"B:AG>:LI3D;I/F(<:$B3@F6?>R,.VSY9:'YQ@*2
M3,F/A(&R$9Z=$YY&W<2Q&(43.V'?>VUFWB#E%98=,'QS'F/1T4?:WK$\R_+3
MH'N,;68C/PAZ>!XU77^0YW7R%[9V$TS,9B4J(%6I+TN1<4%>,.[RW1OD,_ED
M*FLI^"[KR_1FK=-SZ@?3KI9SL\"+>I0$KTJ"026W*65;T!/"CN85K4>S'(=#
MVI?.#>#)B1K[TVY"V\Q&WFS:0_BU5_N#W?"X7\&S+G_6KC0,\B_*1P-TW+FZ
M6>X>36\%B*T9:B56YXJI>B9JG[:#\[49%SO/;_1 ;:;"5YAZ&O],Q39CDN2P
M04CO<H)\1#W@UC>*EV9&7'.%$Z>Y3/&C (0VP/<;SM7A1B_0?F8L_P902P,$
M%     @ SX.769<B7]!X!0  GR0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&ULO9I=;]LV%(;O]RL(+QA:H+,ERI]98J"QE"U#LP7)NET4NV DVB8J
MB2Y)QPFP'S_J(Y(I*XRU'>0FMFR>A]1[*!Z^#L]V7'R5:TH5>DSB5)[WUDIM
M3@<#&:YI0F2?;VBJOUERD1"E+\5J(#>"DB@/2N(!=ISQ("$L[<W/\L]NQ/R,
M;U7,4GHCD-PF"1%/%S3FN_.>VWO^X):MUBK[8# _VY 5O:/J\^9&Z*M!18E8
M0E/)>(H$79[W/KJG ?:R@+S%GXSNY-Y[E-W*/>=?LXNKZ+SG9".B,0U5AB#Z
MY8$N:!QG)#V.;R6T5_69!>Z_?Z9?YC>O;^:>2+K@\5\L4NOSWK2'(KHDVUC=
M\MTOM+RA4<8+>2SSOVA7M!U->BC<2L63,EB/(&%I\4H>2R'V J;."P&X#,"-
M '?X0H!7!GC'!@S+@.&Q :,R(+_U07'ON7 ^461^)O@.B:RUIF5O<O7S:*T7
M2[.)<J>$_I;I.#6_2D.>4/0'>:02O?.I(BR6Z#<B!,DR^![]B#[?^>C=R7MT
M@EB*KED<ZP3+LX'2O6>,05CV=%'TA%_HR<7HFJ=J+5&01C0R 0,][&KL^'GL
M%]A*O*.;/O*<#P@[>-@RH,7QX5Y+N']\N-L2'AP=[HXL8GA5(KV<Y[W "Y9+
MFC]TJ$XINB6*HEL:\C1D,2/YH_GEDXY$5XHF\N^V+!;=#-N[R=:M4[DA(3WO
MZ85)4O% >_,?OG?'SD]M&8"$^9"P  AFY&I8Y6IHH\]_W]#L\4I7*.92HE _
M;4]ZS=\1$;4^6%9:UY1 POP"-LMA64UZF..^GLT/^TH#=6@H/:J4'G56&CU+
MC>CCAHGBJ7BB1+1);\=CQQNW:6R-ZJHQ)"P @AG)&%?)&%O5NM5$(L(U(FF$
M?/J@=RD;O>=02.FE*A0T8JIU^H\/)MFP[YF3;''8!O<G9AO?.KJN0@+!#"$G
ME9"3XX6,VH5\<4;;T;J8S=IFM#6JZXR&A 5 ,",1TRH14ZM:/XML5='[4BJT
MZKG\1$JJVG2?'LQ0=]1W&].X:.0Z>ZTF?=R8Q]8Q=94/"&;(-ZODF_W?>?QZ
M<;1VT;4X0L+\V6$RG?ZT41V!>C3T=YUZ]^]8,^!3+;/V6=G6_H'$VZ(8DEC[
M1Y*&M'67;R5V%1R4YI<T0W*O62L"J#Y-S?<<EVO5_))&>E,2HR_7-+FGHG43
M;D=T%AF2YH/2 BB:F0Q<)P._C6TJ^X'*&"3-!Z4%4#0S8[7/=:W6K+-Y*G%&
MX<73IDM9E,V,I</%X^;BX;?BFG4\:&F%1WMKOWGOM6]T_[MQU 54AH)MLMG:
MJH,=?>)-^A.4%#_OH)U^1?=TI<N"XH5/RFK$=WI[.,JK]<E,E[*J>4A2W3H?
M#]/[H')(.D!OC5C*%(V?6F<YJ!<%I050-#/3M6]U[<[R3F5K4*;T)Q[J8O'K
M5C 9L>+756OE@+2+"U":#TH+H&AFAFHSZX[?J') ^M(%*,T'I050-#-CM6MV
M[=ZV<^68'"[UX_ZL63@F+85CW!\WZP:HZ86BF4K6MM>U^]Y++BA;I?F4/WYE
M@O2M"U":#TH+H&AF=FI7[<[>:&4"]=:@-!^4%D#1S/]CU38<VVUXUY4)M_C<
MPS5GT=H,-U<PWSZXKE)"T4PI:W>-7W'7KRU-Z!_T<2N5=N",?$ ^CV,BVD4&
M]>"@-!^4%D#1S)35'AR_D0?'H!X<E.:#T@(HFIFQVH-C6 ^.6^RP=["3:FOE
M-*VU;Q]:9R%!_P\\V#N(D5"QRD_ :'WX-E7%N8;JT^J4S<?\;$GC\POWU"_.
MRM28XNC.-1':E4L4TZ5&.OV)=D&B. U37"B^R8][W'.E>)*_75,249$UT-\O
M.5?/%UD'U9FD^;]02P,$%     @ SX.765D$\3I& P  RA0   T   !X;"]S
M='EL97,N>&ULW5C1;MHP%/V5R%VG5IJ:0-I 5D#:D"I-VJ9*[</>*D,<L.0X
MF6,ZZ-?/-PX)4%_&^K#2!;6Q[_$Y]]B^(6X'I5X)=C=G3'O+3,AR2.9:%Q]]
MOYS.64;+B[Q@TB!IKC*J35?-_+)0C"8ED#+A=X,@\C/*)1D-Y"*[R73I3?.%
MU$/2:T*>O7U)AJ0371+/RHWSA W)P]G[GXM<7[_S[/WDP\E)\'!^O1L_JX!S
MXCM%KPX0O0@"7!A 3#PZ3'R?-B;=.TAZCS(FW-\6;H7^1(R=Q.!T@QJ<(N1>
MX""W3$OSZS(9#=)<MM42$ALPNC1CWB,50S*F@D\4!U9*,RY6-MR%P#07N?*T
M*5.3J .1\LG"'=N#"JYU,BYS5>6V&>SO23U\!UCWP" 7HC'8)38P&A14:Z;D
MC>E4@ZO@,\BKV_>KPCB<*;KJ=*](2ZAN)LDD5PE339H.68=& \%2L*/X; YW
MG1<^@%KGF6DDG,YR22L/:T;=,+)3)L0=/-X_TBWM9;JQ8]5^R:9I#-5-*V,[
MH+^I9K4W92]?I.L5_#'7GQ=F.K+J0V&S6\52OJSZR[0Q@*EW<'5:%&+U2?"9
MS)B=_,$)1P.ZYGGS7/$GDPU*96H"3!'OD2G-IYN17XH6]VRIU^6T3''/W3?H
M^=^N\XQ)IJC8-&UJ_YA7^<6.Z_?A:WBNOE9V'3M-AKWC]UB? 8[=9/063+Z)
M[>X?O\DP/GZ/]8GOR$WV7NV;?:])OSX);1RWM@Y;3=2#0^V0?(?#L6B3>I,%
M%YK+NC?G2<+DLS.7D==T8OY0V](WXQ.6TH70]PTX)&W[&TOX(HN;4;>P$/6H
MMOT5IM>)FA.UR<5EPI8L&===-9M43<\T3-;Z L(N<E-=;@3C6,R- (;EP1Q@
M',O"\OQ/\^FC\[$8YJWO1/HHIX]R+,N%C*L/EL?-B<WEGFD<AV$482LZ'CL=
MC+%UBR+X<:MAWH"!Y8%,?[?6^&[C%;*_#K ]W5<AV$SQ2L1FBJ\U(.YU T8<
MNW<;RP,,;!>PVH'\[CQ04VY.&,*N8MZP)QA'XAA#H!;=-1I%R.I$\''O#_:4
MA&$<NQ' W ["$$/@:<01S %XP) PK-Z#.^\C?_V>\MO_7HY^ U!+ P04
M" #/@Y=9EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M*&25*&25*&25*&25*&25_TG6#ZV7?_U7M%V36I7-P9]UOYYG7U!+ 0(4 Q0
M   ( ,^#EUD'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ SX.762([AK;M    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( ,^#EUD>IG_.MP(  '4(   8
M  " @<L4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #/
M@Y=9<D*F'-,$  #G$P  &               @(&X%P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ SX.76:F*5T=<!0  C!0  !@
M         ("!P1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( ,^#EUD7=>@0JP4  'PD   8              " @5,B  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #/@Y=9SZ#N'E,"  "L!0
M&               @($T*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ SX.76>9QJ^E, @  D@8  !@              ("!O2H  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,^#EUE 9E'<6@<
M #T1   8              " @3\M  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " #/@Y=9VY!E-B4<  #840  &0              @('/
M-   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,^#EUD
M;*4PNP(  % &   9              " @2M1  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ SX.765)5E9(+!@  D@X  !D
M     ("!'50  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,^#EUGI<ZA97AT  #U;   9              "
M@?=[  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ SX.7
M6<[T!Q"G @  %P8  !D              ("!C)D  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " #/@Y=9[!90P#8&  "1$0  &0
M        @(%JG   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( ,^#EUF R7BV;P0  -<*   9              " @=>B  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ SX.76;U#$;JJ @  NP8
M !D              ("!?:<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " #/@Y=9(YL.), "  !L"   &0              @(%>J@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,^#EUD.R+OZ
MZ ,  "@3   9              " @56M  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ SX.768>_XZ&E!   JQD  !D
M ("!=+$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #/
M@Y=9OF@XJ5\"  #"!0  &0              @(%0M@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,^#EUE0I;I<90(  ,L%   9
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M970S,"YX;6Q02P$"% ,4    " #/@Y=9%'(V5- "  #U!P  &0
M    @($2SP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M ,^#EUEXK5+S^ 4  /4F   9              " @1G2  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ SX.76=!7;Z:- @  R 8  !D
M             ("!2-@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " #/@Y=9R,,$4%X#  "S"@  &0              @($,VP  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,^#EUE=#\(OY@,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,^#EUF?$K8F70,  &<8   /
M      "  <?L  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #/@Y=9UOKY
ML7@!   #%@  &@              @ %1\   >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #/@Y=9ZXBZY94!  ""%@  $P
M    @ $!\@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +  L .L+  #'
%\P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>78</ContextCount>
  <ElementCount>234</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995612 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995613 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995614 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995616 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995618 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995619 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995620 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995621 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995622 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995623 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxes</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995624 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995626 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995628 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995629 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995630 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995631 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995632 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995633 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995634 - Disclosure - Commitments and Contingencies (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails6</Role>
      <ShortName>Commitments and Contingencies (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995636 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995638 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="e6219_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995639 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20240930.xsd</File>
    <File>avxl-20240930_cal.xml</File>
    <File>avxl-20240930_def.xml</File>
    <File>avxl-20240930_lab.xml</File>
    <File>avxl-20240930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="e6219_10-k.htm">e6219_10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="354">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e6219_10-k.htm": {
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "avxl-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avxl-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "e6219_10-k.htm"
     ]
    }
   },
   "keyStandard": 190,
   "keyCustom": 44,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 17,
   "hidden": {
    "total": 39,
    "http://anavex.com/20240930": 16,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://fasb.org/us-gaap/2024": 20
   },
   "contextCount": 78,
   "entityCount": 1,
   "segmentCount": 26,
   "elementCount": 429,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 354,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://anavex.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://anavex.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://anavex.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://anavex.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:NoncashFinancingRelatedCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://anavex.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "longName": "995612 - Disclosure - Business Description and Basis of Presentation",
     "shortName": "Business Description and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995613 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://anavex.com/role/AccruedLiabilities",
     "longName": "995614 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://anavex.com/role/OtherIncome",
     "longName": "995615 - Disclosure - Other Income",
     "shortName": "Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://anavex.com/role/EquityOfferings",
     "longName": "995616 - Disclosure - Equity Offerings",
     "shortName": "Equity Offerings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "avxl:EquityOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "avxl:EquityOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "longName": "995617 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://anavex.com/role/IncomeTaxes",
     "longName": "995618 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://anavex.com/role/SubsequentEvents",
     "longName": "995619 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995620 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "longName": "995621 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "longName": "995622 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://anavex.com/role/IncomeTaxesTables",
     "longName": "995623 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995624 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "longName": "995625 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "avxl:AccruedInvestigatorPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "avxl:AccruedInvestigatorPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "longName": "995626 - Disclosure - Other Income (Details Narrative)",
     "shortName": "Other Income (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "longName": "995627 - Disclosure - Equity Offerings (Details Narrative)",
     "shortName": "Equity Offerings (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "avxl:FairValueOfInitialCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "avxl:FairValueOfInitialCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "longName": "995628 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "995629 - Disclosure - Commitments and Contingencies (Details 1)",
     "shortName": "Commitments and Contingencies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "longName": "995630 - Disclosure - Commitments and Contingencies (Details 2)",
     "shortName": "Commitments and Contingencies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_custom_PurchaseWarrants1Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_PurchaseWarrants1Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "longName": "995631 - Disclosure - Commitments and Contingencies (Details 3)",
     "shortName": "Commitments and Contingencies (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "longName": "995632 - Disclosure - Commitments and Contingencies (Details 4)",
     "shortName": "Commitments and Contingencies (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "longName": "995633 - Disclosure - Commitments and Contingencies (Details 5)",
     "shortName": "Commitments and Contingencies (Details 5)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails6",
     "longName": "995634 - Disclosure - Commitments and Contingencies (Details 6)",
     "shortName": "Commitments and Contingencies (Details 6)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995635 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://anavex.com/role/IncomeTaxesDetails",
     "longName": "995636 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://anavex.com/role/IncomeTaxesDetails1",
     "longName": "995637 - Disclosure - Income Taxes (Details 1)",
     "shortName": "Income Taxes (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://anavex.com/role/IncomeTaxesDetails2",
     "longName": "995638 - Disclosure - Income Taxes (Details 2)",
     "shortName": "Income Taxes (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://anavex.com/role/IncomeTaxesDetailsNarrative",
     "longName": "995639 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2021-09-30",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6219_10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "currency_AUD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AUD",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r411"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "avxl_AccruedInvestigatorPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "AccruedInvestigatorPayments",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued investigator payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities - Note 3",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "avxl_AccuredLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "AccuredLiabilitiesTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Liabilities",
        "label": "AccuredLiabilitiesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r518",
      "r519",
      "r520",
      "r521",
      "r566",
      "r589"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r175"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r441",
      "r452",
      "r462",
      "r488"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r444",
      "r455",
      "r465",
      "r491"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r476"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r483"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r483",
      "r492",
      "r496",
      "r504"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r205"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share for potentially dilutive common shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75",
      "r86",
      "r102",
      "r130",
      "r134",
      "r142",
      "r143",
      "r147",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r249",
      "r251",
      "r265",
      "r290",
      "r354",
      "r404",
      "r405",
      "r411",
      "r422",
      "r531",
      "r532",
      "r583"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436",
      "r448"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436",
      "r448"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436",
      "r448"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r396"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r56",
      "r100"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) Increase in cash and cash equivalents during the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r56"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal deposit insurance corporation",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CashPaidForStateAndLocalFranchiseTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "CashPaidForStateAndLocalFranchiseTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local franchise taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r87",
      "r88",
      "r89",
      "r102",
      "r121",
      "r122",
      "r124",
      "r126",
      "r132",
      "r133",
      "r147",
      "r158",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r265",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r341",
      "r363",
      "r382",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r512",
      "r515",
      "r522"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "avxl_CommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "CommitmentShares",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "CommitmentSharesMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "CommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies - Note 6",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r70",
      "r292",
      "r340"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum number of common shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "avxl_CommonStockExcludingCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "CommonStockExcludingCommitmentSharesMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Excluding Commitment Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommonStockIncludingCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "CommonStockIncludingCommitmentSharesMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Including Commitment Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r518",
      "r519",
      "r521",
      "r566",
      "r588",
      "r589"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r341"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r341",
      "r360",
      "r589",
      "r590"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized: 200,000,000 common stock, par value $0.001 per Issued and outstanding: 84,795,517 common shares (2023 - 82,066,511)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r294",
      "r411"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r398"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense, current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r517"
     ]
    },
    "avxl_DeferredGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DeferredGrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred grant income",
        "label": "DeferredGrantIncome"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DeferredGrantIncome1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DeferredGrantIncome1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r81",
      "r517"
     ]
    },
    "us-gaap_DeferredRentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRentCredit",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income - Note 4",
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r581"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "avxl_DeferredTaxAssetsResearchAndDevelopmentCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "avxl_DeferredTaxAssetsUnpaidCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DeferredTaxAssetsUnpaidCharges",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance of deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of contributions under the plan",
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r389",
      "r412",
      "r414",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r67",
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r389",
      "r397",
      "r412",
      "r414",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ]
    },
    "avxl_DisclosureAccruedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DisclosureAccruedLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DisclosureEquityOfferingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "DisclosureOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436",
      "r448"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436",
      "r448",
      "r484"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "avxl_EarningPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "EarningPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r119",
      "r121",
      "r124",
      "r125",
      "r126",
      "r129",
      "r244",
      "r247",
      "r260",
      "r261",
      "r288",
      "r301",
      "r399"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r121",
      "r124",
      "r125",
      "r126",
      "r129",
      "r244",
      "r247",
      "r260",
      "r261",
      "r288",
      "r301",
      "r399"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r128"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences relating to GILTI inclusion",
        "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r560",
      "r562"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r408"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r408"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r83",
      "r94",
      "r95",
      "r96",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r118",
      "r131",
      "r148",
      "r149",
      "r150",
      "r172",
      "r235",
      "r236",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r300",
      "r304",
      "r305",
      "r306",
      "r319",
      "r382"
     ]
    },
    "avxl_EquityOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "EquityOfferingTextBlock",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity Offerings",
        "label": "EquityOfferingTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r441",
      "r452",
      "r462",
      "r488"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r438",
      "r449",
      "r459",
      "r485"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "avxl_FairValueOfInitialCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "FairValueOfInitialCommitment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the initial commitment"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "FederalMember",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_FixedContractAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "FixedContractAccruals",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r379"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "avxl_ForeignExchangeAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ForeignExchangeAndOther",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange and other",
        "label": "ForeignExchangeAndOther"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r492"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r492"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r492"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r492"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r492"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r365"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "avxl_GrantIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "GrantIncomePolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436",
      "r448"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r213"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails",
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before provision for income taxes",
        "label": "Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r72",
      "r74",
      "r289",
      "r298",
      "r401",
      "r404",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r213"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r262",
      "r263",
      "r264",
      "r302",
      "r303",
      "r366",
      "r395",
      "r409",
      "r587"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r262",
      "r263",
      "r264",
      "r302",
      "r303",
      "r366",
      "r395",
      "r409",
      "r587"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r214",
      "r215",
      "r223",
      "r231",
      "r408",
      "r564"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r214",
      "r215",
      "r223",
      "r231",
      "r408",
      "r564"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r210",
      "r214",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r237",
      "r238",
      "r239",
      "r240",
      "r318",
      "r408"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r211",
      "r212",
      "r224",
      "r225",
      "r229",
      "r233",
      "r312"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowances",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r408",
      "r560"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign income taxed at other rates",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r218",
      "r408",
      "r560"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit at statutory federal rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r408"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r562"
     ]
    },
    "avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other permanent differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r560",
      "r561"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to true up to prior years\u2019 tax provision",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and local taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r408",
      "r560"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive and tax receivables",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r513"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Incentive and tax receivables",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and deposits",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "avxl_IncurredExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "IncurredExpenses",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r483",
      "r492",
      "r496",
      "r504"
     ]
    },
    "avxl_InitialCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "InitialCommitmentShares",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_InitialCommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "InitialCommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r437",
      "r507"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r437",
      "r507"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r437",
      "r507"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r524"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r102",
      "r147",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r250",
      "r251",
      "r252",
      "r265",
      "r339",
      "r400",
      "r422",
      "r531",
      "r583",
      "r584"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r71",
      "r296",
      "r411",
      "r516",
      "r528",
      "r578"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LicenseFeesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "LicenseFeesPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r206",
      "r407",
      "r529",
      "r530"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r206",
      "r407",
      "r529",
      "r530"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "avxl_MichaelJFoxFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "MichaelJFoxFoundationMember",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_MilestoneBasedContractAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "MilestoneBasedContractAccruals",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone-based contract accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r58",
      "r73",
      "r84",
      "r91",
      "r92",
      "r96",
      "r102",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r123",
      "r147",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r244",
      "r247",
      "r261",
      "r265",
      "r299",
      "r362",
      "r380",
      "r381",
      "r420",
      "r531"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "NonOperatingIncomeFromGrant",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non operating income from grant"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "NonOperatingIncomeFromGrants",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "avxl_NoncashFinancingRelatedCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "NoncashFinancingRelatedCharges",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing related charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NumberOfWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "NumberOfWarrantsExpired",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r401",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r410"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r410"
     ]
    },
    "avxl_OperatingLossCarryForwardsExpirationYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "avxl_OperatingLossCarryforwardsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OperatingLossCarryforwardsDescription",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards description"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OptionIssued",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OptionPrice1Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OptionPrice2Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OptionPrice3Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OptionPrice4Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OptionPrice5Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r66",
      "r309",
      "r310"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "avxl_OtherFinancingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OtherFinancingExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other financing expense",
        "label": "OtherFinancingExpense"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "OtherIncomeDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income",
        "label": "OtherIncomeDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive and tax receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r349",
      "r405",
      "r586"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r443",
      "r454",
      "r464",
      "r490"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r446",
      "r457",
      "r467",
      "r493"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r446",
      "r457",
      "r467",
      "r493"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_PensionContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionContributions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions to 401(k) plan",
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "avxl_PermanentDifferencesRelatingToStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "PermanentDifferencesRelatingToStockBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences relating to share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r167"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r341"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r293",
      "r411"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r313"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "avxl_PurchaseAgreement2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "PurchaseAgreement2020Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "PurchaseAgreement2023Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "PurchaseWarrants1Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "avxl_RecentAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "RecentAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r438",
      "r449",
      "r459",
      "r485"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r173",
      "r282",
      "r283",
      "r291",
      "r297",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r359",
      "r361",
      "r385"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r173",
      "r282",
      "r283",
      "r291",
      "r297",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r359",
      "r361",
      "r385",
      "r582"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r395",
      "r404",
      "r585"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ResearchAndDevelopmentTaxCreditsYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ResearchAndDevelopmentTaxCreditsYear",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credits year"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r439",
      "r450",
      "r460",
      "r486"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r440",
      "r451",
      "r461",
      "r487"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r447",
      "r458",
      "r468",
      "r494"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r62",
      "r295",
      "r307",
      "r308",
      "r317",
      "r342",
      "r411"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r118",
      "r148",
      "r149",
      "r150",
      "r235",
      "r236",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r253",
      "r255",
      "r256",
      "r258",
      "r259",
      "r277",
      "r278",
      "r304",
      "r306",
      "r319",
      "r589"
     ]
    },
    "us-gaap_RevenueRecognitionIncentives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionIncentives",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Incentive Income",
        "documentation": "Disclosure of accounting policy for sales incentives."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of principal components of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of net deferred income tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r19",
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r408",
      "r560"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of general and administrative expenses and research and development expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of loss before income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarizes information about stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r63"
     ]
    },
    "avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment and Geographic Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r402",
      "r403",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "verboseLabel": "Total share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, Outstanding beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value of options vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annualized volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares of common stock available for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option available issue",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, Outstanding beginning balance",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding beginning balance",
        "periodEndLabel": "Number of options, Outstanding ending balance",
        "label": "Number of outstanding options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning balance",
        "periodEndLabel": "Weighted average exercise price, Outstanding ending balance",
        "label": "Weighted average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price options vested",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of warrants outstanding",
        "periodEndLabel": "Number of warrants outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price",
        "periodEndLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, Lower range limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, Upper range limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "verboseLabel": "Weighted average contractual life of options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of vested options",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedUnder2023PurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "SharesIssuedUnder2023PurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2023 Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning, shares",
        "periodEndLabel": "Balance at ending, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r101"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r87",
      "r88",
      "r89",
      "r102",
      "r121",
      "r122",
      "r124",
      "r126",
      "r132",
      "r133",
      "r147",
      "r158",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r265",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r341",
      "r363",
      "r382",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r512",
      "r515",
      "r522"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r47",
      "r48",
      "r83",
      "r94",
      "r95",
      "r96",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r118",
      "r131",
      "r148",
      "r149",
      "r150",
      "r172",
      "r235",
      "r236",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r300",
      "r304",
      "r305",
      "r306",
      "r319",
      "r382"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r131",
      "r278",
      "r286",
      "r311",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r415"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r131",
      "r146",
      "r278",
      "r286",
      "r311",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382",
      "r415"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r442",
      "r453",
      "r463",
      "r489"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r62",
      "r313",
      "r382",
      "r391"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r62",
      "r185"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r62",
      "r319",
      "r382",
      "r391",
      "r421"
     ]
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of shares remain available",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "avxl_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "StockOptionPlan2019Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "StockOptionPlan2022Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r62",
      "r316",
      "r382",
      "r393"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r62",
      "r319",
      "r382",
      "r393",
      "r421"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/BalanceSheets",
      "http://anavex.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r60",
      "r343",
      "r360",
      "r383",
      "r384",
      "r411",
      "r422",
      "r516",
      "r528",
      "r578",
      "r589"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://anavex.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r77",
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "ValueOfSharesObligatedToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r569"
     ]
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_WeightedAverageExercisePriceExpried": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240930",
     "localname": "WeightedAverageExercisePriceExpried",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price expried"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r126"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://anavex.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-11"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001731122-24-002041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-24-002041-xbrl.zip
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M]#:1A*4I^^T@'7>"TXWP\3]02P,$%     @ SX.76<TGPE=&"@  3',  !4
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M75R S$EUB_R^1M1BP.5*2:KI8]$#8ODYHTNECR-_TGUL2'(A'M\#KPB_+/P
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M3YKZM(VL;>X %_&^F/V9IE0#H][WJ0!GCV%8.*/$> **?<]EW[A6FM_*"A@
M9;T[5 'ROCADZY=">7]3)4(/#ZF"2 =-(BT+M_#$6A9OL:F/5:C 2FI0+V/5
MM:H@SJ&X.+PD*RUJ -P"KE8%28XZ2)*4;7F!E2_]?^QG3'^UTDI2"3,9?>P4
M!/.YFR<F#7.=B4T?X[XMHMM/MOV<3GC8_";[9CGS2;]X6.!DBD07[,\%;;[]
MB/RXVH<T<5W:';VH"[MP#8C3=&6T2SL:DPQW.B (CKK)*/39P4'(+._,CVMC
M(QF*UW49L@G!LU95IFK#C1+D=<N ;%F8,$OZLC7:76+AZP?WRU9(HAJ1!R8H
ML6W>$['E(S\3>?5$+*P^FU3Z:J?.;70560"H:I*YACE=')5@GJ9S<8@;(+E4
M3JHK@S9"&G6-102 >-G;76=B'D8U\&5QDTV05^W\5B4O%A+B;U\;?_P(&"?3
MB._IHA'BKI+T03IMQ=4K0$ESV\#MF(WKW9;GB#>VYUX$)_:S%_)#Q69"&K,I
M:%32V6D7 *1*&U>W_ @[0.Z930+NQM9&4GWZA[H>VS!V&I"#XY V6N"%4-W,
MK9SVX5 /'1VFUK60C>O)[J8V031WH-' 0CFI^234(@;;0D\.J@XT_)M4LQ>4
M1LC]$; :6)+]FX@X4YNB\1-!*#^/R:F;YQ;+;"X!'64 IUER*;G@>K']I1==
M A'@ $AMMM*;0$-:/AA$RWUTO<8:%]#[H=:Q]Q8]IVW1/8VX@_\-(AYVX[OP
M+4-Q4U9SR>HD <39D8F<@4U+0&33FU@W$2#:/LKMX@1'D/4:.CJ-&9_4*K23
M6M=1N0(J/E8W'V6S,!K907B/SUX1<3R*KB=Q"[N.;]5#BN]2A-ET=):DZ6A$
M%TN-C:1[09O#F$#CTK<?57"6!S;48@%XL!PW[TU_B_Z*/.J%Z Z1N>>@9/3C
M'HA/"44M<S?5-9MK0$,J +2XOOL+*UO<%0J3*SUY/Y"J>122&<]E%2VH^-PN
MPF\[)4%8-7^J<2[J'*PF\?\X/CX\&G'GJ.7-)?8A*\W*%1>[X<0%<B^08I&*
M/%JZ1;')";1?%B@MBB//%68M2[.6Q:D1IB'<30[X01EXFLTJY%.#L"X.3@[:
M81E:G-[*,JC!!$7%R>$Z*N-*\EBY3*J<']MCX^1P?BSCS.5/7=P*):@!71<^
M)P?R4QEDDMY*,ZAJYT LG1RPXVJ+SC)962Z=O5!#;[2WV[\WLG[)_E+FT]D:
M;2<GR4B@>[)^2?(K RP>>2>'O#+$-;8^Y3+ \7ERF"NC6+XQ*H>X8CR>G!R5
M0:V+_:<56(L:!FP(Y5@".9DJHV%M2T@+4 99)+!/#G1EJ,P/X;6JUK* ..7:
M0>Y7%+ _PAO?#I:@*_/TZL)",+NF?75GBMS(1]>3*DRZQ$G;G(&[%6.,KW G
M:LM[\GU49[QW\2WRN9/]C4W"MWO")+&=>%/IZUO^EV97XRYEZ/,[[D5?V>6H
MJ[(,\GW)0VSS@ZU+J\<[N8?*8<[,]5->C1R3/905$*C&5QDXHOCN.5,;^?\X
MQZ_G;'KHQEM.H%<ES]*00Y-+<D,;P,*XA^G0* ES[85]6K85]N'A)"*$K9&@
M 8DE*:98S^&F(@;88<G0?7:OWTFK3/2??5KJ/_OF8>S[*3R^2(%ZJRQY;>J!
M!Q-(H5@ JMK!8GCE&SE8]"=H@(LKW3GZ<=K$R8_3AX.!!P(1"R_K.H4)Z?:@
M;\</#+2WB")6_G0<N*=HCGS\S$TE%U*%;Y$1-GNXQS>(3#"9G6,2[R#0_-DE
MOPZ W!$P-LNMY&&DZ19+KW6L*ODA Y$\$;O"07HI/WA*MHS.F5J^,>206WE#
MCO5CKE48V?,S@ 8F &(=A!O7G "!&EM=TO53/"R%TEE9OU6DQ-;=M "56,UZ
M&80Z#8!3&%W&%,.]10[RYH4CHJH]E%.N):7U0H"3'QU.-J(O%.2.7"JG_F7O
M!'..7=[#I[R'3U% 4!S*=)+KFIO/,H#D9H=+:931H".(?'Q,-G2R*:V]_":_
M.=P:6J!K07H.+YIYP:N)9-XAABYZC=S14F\"@QZ#5&XR\^O-C<<@#3DT'8/T
M;6)86*B!UN!U*'8[D[&[,*.-HJ,@%CQ)D3((9CO#+O*2#I+]L>P7V8>'2_1D
M^V<!FY-#9U8L5261H=.-.JB#'$W!^DV@@.<@+$DQQ< 3@0:-80#A,.=-LC1J
MY-C;6>N##J5LH>5@/[BQR9_I+:SS*' O+T\:>_"67$,/J9#9XDZ(C=M!7?1_
M)[Y-:7K/4C#09C6+H=UX.W#C-B/S$-O\H^K2:@ZM"6H8MR(W;YFW&A=&#AC2
M^!IT(,E%C[P('#_B,;_*D1<:QQ3Q G0%!&QH$;BW'&"3DAR *P?K['5%?EH*
M>*BS+1/Y$9$#;#\*^.G$10U>31?'Q?4.8(9T?"A9QW&D  8TB4WXZ'M/W!/U
M'F<K=T#;;=D>1IHZ)+'P'6+P(0ZTC>Q)#QH'':E&G+I"+_%/;9&W6O,;S%T/
M.0;:\@,@Q8:V0 0YXHAE-IB7KD(8MZZ\(=A!R*7<9XLCY8_G7),[FSN(M\4#
M;L]K,',=99"]\ 1:T[GMD;2/K@2T!-I04Q:#]2\&'5*[]%BIL7.Q>_;*7: :
MPJ,6DQFNWGJXX 3+L,&]V']V'MN+V0UFJKL8$(-Z@Z("V&/WM7[LQ5G7F[F<
M"!!KN9BHPWGL-<0*:0CN4(F"TQ(L1'68AW8I1G5B5&+FB(EAC30*LE<CR'XE
M@(Z@('NZ/"GY.N5K.:A?[KC]Z]LRR8W]%KNE\/>2*TT0>!9AQ;)UA[YHE8%"
M0@B'Q5BY"G/\0Z49$QA/0Q(?QKNB)I!9!<T'BJ5D!EQAED40;I)3]D:*^FX4
ME'HI6>#R6PA7]@RUG92IJ4W/N6<]LS6OU2C2KDFGI>MO12:?V.JR-"V^MW_$
M_I$A'0FY>I92:_*Y5=K,:SQ!:Z1>OX$%4DD:\/UW1$/D,K7P'2<G/ECB7^5>
M_KJ*FAWLAT(P>)P#Y9/6(15GWOF@<NG_0-[3E*>9(V(_H>S!@QOB.4WK+JVX
MWHU<OCH'.E5-&MOU)!LU&&"/U%Y]CT,PU*?>'/[;A)1]K JPTF0=# [Q0(8$
M<FX66Z(""YRKFK0KOE^W#5N)_BVX#;NO:1OV>C*A*.2(QI3]005V5QNR: H"
M40+4L@$*)#=F,[.5DG)0B";QC=]O/$7$F\<A'2X"RH!PU=QZM.4^0W,N;;N1
MS53@#B(8MQY<PEV$C6&UM6WU-.?2L_$GI'B(*UAXD_;SY)-E\OZ:9$('"-;8
MV[$B6;RTA2:H)-6TKR;4;&H<*,K0C>L,5UU\#K@+5MVU.=)C#%VG-6H$W[CM
M*NW[4J([)C^?V;6J8W/ZM<0]>CG\TMC9[7YJ!ZE:KG PCW?<2DJ) U:>VB%:
M^/\JL%2)Z#;>C&7K2O9VG$D=[@6;U'AL#NNH,MRV*C?>&H44(+!ON%XF%C<E
M>A$DSL/?2.,;P0HJ^UG,"A(=,JB^-TTT^N?42JIHHB@/Q,88H&250(:I[[Z.
MU!:H8V[8#\C&&*@"M4!&:MJ5I.2F=&[#B68-KB&L?/>RUL94^DD&L?W1V"ZI
MK4_.Y-,]7';"L396-KQ6( O])#GXP5"24<CPX@ $PZ(PWNQTZ00RNF-CN\6N
M.KC'H>T/M0,B4KOQMCBT+IH\0-;3",\QF2 OY&]29L*KL[F:RGX6$X-$!RW*
MW!.+MKZ]1E1-\[V.2#;&%E7H!314R5[  PJG=MK7%8?QUJ=/*Z#MK>UY1"HD
M=V94[:Y2J<IX0U,J.&A+YFZOB,NIQU]%$,!/:'?]1]6^6RERK/&Q7?K'=NF+
M"ZBZ*)5YC2NI<ZUL3IT&0#/+;9Z8=!'HH.XBT%[/BT '[Q>!WB\"O5\$>K\(
M]'X1Z/TBD(%DO5\$>K\(]'X1J'DUG/A,C*-PBHGW;^3^8)--DA.(1PJB7]\*
M"ZQ;/G=N><1+165K,40J5+/QGNE"4E9E[!>$;<7*-+U@IM ZI-EA&T,FS1K6
MW1!-GJ.LM;$.&E$PQ<,A- <3K"8T*HZ@G.X!M\DK>SAK9V5/E)4]O>_S#4]+
M7F"0%W7$-+]Y7TUH5K@IE<3D!8:(.5!'S($H,6E"70<"PQ.3%Q@BYD@=,8>B
MQ*0)'S[]+,3D!8:(^;092Z9+_()(\I<W\^K>V%+!0JG6AY&F5U+E'#S+5 )D
M;INQ+OKQ_*S!VDJU_IS65JN$-=E;7),@0^MM5RM+;N;>X@HN&W!8FUO$>8D?
MRTZV]B/;OT=DMM=B;L."62^#U*$;<%MG _H_LR-CK95I#J4/<'6^KCUH$G ^
MBUR>S%S4=9%UM:V7H2D1'K*JM0V@ 3QCH-W+>C5<ZV6IFM4$;I>9Z2U[6.<M
MN]_36_90D[?L)::T *EB*-4FU91'3^=30=3B, NE-\9CMIV64OMMUH#Q/K,7
M 6MX:/DZ-:^$:[W1C:@QDS9WH!8FL+@(QFWD &C;'"-:LNGQM1'1O!!7YGJ_
MJ*#+9(\4R90:ZC7[#05L N6S2<G8G3&UTY#$#JE\XA50U.9)*Y1=D]N)6 O#
M_>0QKC>]110Q(%,&_13-D8^?N=""- IDUN6ETH=%47' 3M:PPXVNZ]&'CWJX
MZCS/;( O<,IITO+MJ&[Y=M!S^7;TMYR0 PMRQ=\.Y%U>G4"'/05:%*II7=I[
M/T)@_2JC;$V=C3-%;N2C="^P5T20EJ6QQ"J,64W+,Z9R;RB;#^,7ZMG;X,TK
M\V(J;4MQ^?3@!C&-FV#6O^,.LZ5W05ZKS'I]F[OD[J=RDQ?5G6D9]&I%R45J
M;W?4[  +IE= @= $'#!I+ H9['0DO]U=17'<4=''>E>E?11]K'+E*:KHO>;;
M*6#Z!TTGCST478 ,=AW:QM%K-N.P^2+I$K'9 >2,%/_(W9 :(BYU+>GAV"3O
M? D3YEX*$-A8&-8@3GR;TNO)'WR-'(37Y):+D7,*@@V@+>?&$2XDL.R9,]"U
MIB $W+> OE:\@,WAL8?<X%"IJ[UF^,>!&]M?7I#O=A@1+WSCS[_ [5:TA,WA
MO8_@X-"MK:/&LQD.XOG&B?WLA78229?RXP8R1^XY)N<1CXK+GXNQ@R8_LLY%
M;9PI]-, 9!/F/D$'Z2=SPQR[;LQ@)O_RUHZ"+>?V2C?.SE3K"K+(M76=+;YM
MILX5MEC/N]VUJP<RM;XOR#7>_TZ>/ .FKODDF\-<K620TM<OTGC1\7\\MSV?
MGT:P@3:V-87##5#CYEC.$(J"#%%OD/$^TK:^I9ZX_^M\_E0VQ'=35ZI9J&WH
M?5;N9[Y7O)'VKD&'38X<)IEVSY 3N1M=J:)4F?O@ '^2)J!'K](/JE=N%F,_
M+A>Y]?I/G8]AJQ7+OW%&U4%LD'-M)P%GLV<?OR%TA\B<&7:]"%<XF"?76;D^
M:/PJ:?[W$TS#*QS^$X6WR,%/ 6]$^7?%89,9I/J-L[CAM 8:;.X$8S@?]N0B
MQ;W]NG#UKO/P/BI[>"?9K#C?PJ%;F7]Z%>2H#N5'(936:$"<>W4X/XGAW!L0
M9Z-__[$87MWN_&>3"7*2]RQ2\6[9$,);8N!XOF>G>FOSW.]8C*8Q1@!DBQ-^
MAR*,<;+O17&YI^^J.N/]Y1>"I//M\$WD3GLUO38?^NZ4U%VQA11@D+=\%:C8
M1>FZ'#JOM(.J;N/%7*]Z>=28[&DOA;Y!O>_/D<OO7C?Z)Q?2:+U7WF#KN &O
M<1U5?+-Z'+B7K'3_'Q'QJ.LY7'_MCV@U9M3E,"[*3@<IP :@C;1S3)#WQ%:A
M41"2MS:FZE+KNB+>D1X0.G@L+Y<32L(<'^S3D@OVX>$D(@0%#C0+8TF**=9O
MWE41 1S/9>B=(N?#$Y[O.&F5B>ZS3TO=9]_P7=<4'K_!#@WC6?+:U //KB"%
M8@&H:N=2PRO?R/E3?X(&"/'3G:,?ITV<_#@=_,D.$0LOZSJ%";K :#L!6-Y
MXJ%/;$+>)IC$6\;P< SG>1AI>C]%QFY+FU@0>=*?1X-@G"+J$"_>GP?=&@7R
MKB=)'<63O4P1)NL\173V^NR16*1_(AM^@$@L^R91UB2ATKG92ELM19&O,#_
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MXLW3^BY/-;=/*:5\D<  L>&!0@0$%?2XAFRXR%$MBBK9$+=3]< JS!G\[HL
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M:(845IN4@A-O+%*USVJ'L!? .:5C&Z,(A76RHW/7>A&\,SJ^ >5FCM-=8J:
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M[_WJJ]45D)HV[_P$HL5E/,/VKB7"-&X3DMSBQ_(PE2_8T,CX#NLD>,/XKA4
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MQ3@[&5F MPG+7H:U<YA1VL%)N3=D-1WG(^'S ]?X'B?;%%\NY2L:C,_7[U.
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ME,5#N3)F/M.,U^UV\^A(>]TNF?.ZW8L\NVS.R55;='QM6%R@I*H3H[@W3CN
M;@EJD WN?1T!#CESP?<\V\.-]=8GKQZTXEIS/2I<)R!T;N-2>DJUG+^G@PTP
M=Z\%*X1@L,& 3#'N5ADAHM4G<A,S/4>PI]?41"L3?R/\$P?/K![[8PA[?@#*
M>#RG<<%&Y&F6"?D-(.2!S_UTLRI9S/M2H *DM/C7D8%&.PT^Q8V!-4$X=7@N
M$MWIS#0JUW=8BTW[XO(NY;NI.&'TK\_9JL88NXZWT=H5?CMRVQ1@C.*.*(<$
M^KDY 5"E3*"\T41EWIZ<#NYVQ*' LZ+8XN1XR]^?KXX:5<9>X"_B)YTS<E7V
MNA0YRJ#>&J239G!.[@57FG5LUW>8=MA)1$$'\^;W:""+GM(B5LY#7#7]G=$:
M9<KN])636G".C<<JO_67(S:GC="=>/(C&_(-IC=DJ&.,DX)/VKE]/'_TDMY$
M(OGY'UM2ZM[^<%'TZ07=#>EZ0+M6<&:.AJH@IE"LUEA(K8IRBHJH2DC'0GVN
MM*/=4R5G_!&O*&5SF34IUW(N@(.\OR0D!]B[7"2#<' "N2)47G;;GNKD]S61
M2E-DQE:J,W&&347XQG?2O VHLDB6\<8-';R6#T,!&!S0H%+, X789&?AYPK9
M^^/RN*!QJ L@8%>;XQ"O]Q6#<VT?M,[1NO!'H DI5EOVJ)):#PH1>V:XDE H
MO0@"=I%*"6_B]$B'?!2O(Y*AZ"$B*5\-"\Z_=L>MO5Y4M_2G$/2Z?*H%VEM
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M:B0C:XM7EKZK3-0<HPNCP@MHH\$L4=\5?@F/>VP!:I[LU?@E=)WP*N#W8RP
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MRC,)2M4>.YF_BX3TO*.+9JB' 9V+I&50NG\%<"Q.2(L;TKO<@4:7(.!^,XH
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M_"1^&RE4P[A2=H:^@"F>JBFO5I^*)S"4-R>D#?'!UZE/!6PI]0-?P]S/"X!
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M6>7FU.KE>F---X?F_IB;LV:7,4\YYK5:_>8TUGAS&H^V.3-5AK79IAQ#KS^
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M=0WLR:XU[(LKN[:[Y6[;%R?V]2\MVV!JFJ$UCZ[QZ]IA8T=3^2-1^$D8V<E
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M<759^8Z'N]6Z@R70W.VP9T=ZSK83V_%(=-'=Z-H>;'<2V]V!$\'/5F&'+,%
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MD&\:MTA6 5MS-LDG'Q^5:QK[E;\#Z .![<;CZU*6";91>+4@ILE8#U2ASOW
M+K*)(443+=?J]<:G+\.P>;#3/[J-=[J+:7G>N#.(NU8O(YQ<CK@;2Q+WZ?F)
M0=.JL]G!3NF@MEO:K>W/I&YI]"/+,8^$]_48V 2>FU5OE.SU)$=5AGM\<?3Q
MK'5^W;9/SQ'%^^*JB6VMWOUM7[5.6E<([[UNY=5ZZ[!F>OU.)E-'%]8AU:?6
M(;VV_T"!#E\_EXHD8PO4XE_;V!_KE?TAO!41O>ZUC= )O$GG(2[=\W*U1.JG
MU/KNQRER>D(@!M?-=Q]:V%?DZ.+\&IG.=VK\D,NW-/,KB_F7<BZYMH=Y4):'
MD3_"ATPFJ3 U36*ZR-<?5G^:-HJ").$[U!UFGQB7J(A< L_!SCCV($*Y^%_.
M)S#P7KR];%Y=VZ=O7CIS,>1KQ7F0!;3D1%Z\W9N%;_,MMO)!VV=^R-M78[Z4
MV[\ZJ';7K3.[5K'??6R?GK?:[9D[^;#=PS-[KKO74+O7K-A7I^W?[)/FT?7%
MU6-L8:/^3/=P1^WANXK]\?RJU;[X\ >W*#TYH5:AS')73Y//=4-WU88>5>RC
MO]^UKF2KK+\WF[C\)N[)3:Q7[,NKB\O6%78:>XP-;#S3#=R7&]BHV!]:[YL?
M<!N/6JWCT_/WFWV\QSX>R'W<J=AG()[M=O.D=?VW?7S:/OIPT?YX]3A4N?,,
M=G.*MGBHM,79ZN(/OFE32+!6E22X"R38O/JM=6V?7%S95ZWWIVULWW@M'7MM
MDM87YW;K]X\@;4KPQ(<F=QN_./KMEXL/QZTK&.#Z&B02-00_;;<_PD>7'Z^.
M?FFV6VVTL?BW1G?'S4$M?U!*F=^';3YOOF^AZJ0/!SG&1^JZ3IL/#WSXNWU*
MFWYR>MX\/SH%)@TF[C%WX\1G@+E\_'!-CZ (;%Y3R_;->2Q['LH\V&_:OV-+
MT]-KV,(_6K2W\,$'];?!S.WFNXN/U^J>H4WQ"!N^7WVF&ZYLB8.*0=-@25RW
MV%N,&]_^>'GY@?YN7H$<;5XW'V&'3\JU9[K%RKHX!.."NNZB#YXV%JBX^?ZJ
M);?ZS]/K7^SFT='%1]AH_ !Y"O\)*B#](#LB*14>@]2?ZSDH ^6P62''Y-7%
M!Z9OTK./'TDQ?+;;J<R5PW?VQ?4OH)6<GH.2<_98(N_9[J,R5PZ/#*F&NF+S
M"DT_U!Q;I^_/[5]!O6L?GU)[[[9]_4OS&@BW]0>P#MCY]B7W_=Y0\-*F32TS
M;1[#MME_IGZ>NK)M:E6@UZL6>6]+=NLOL#](-;LX.3D]4@:+#C7;[R_^:%VA
M]&IM-GOYS:ZIS:Y5C"T&J_&R==Y^-%:[_TQW4X=NZA5E+_]M7_QY#M3ZR^DE
M!2Q;5]=-T,[>M<Y;0,:H:?'W1,V9C2B-O9G6>N41CN7@F3KLZCHFU*CH Z"]
M18$&!]/.[38Z4-I-EG8EJ48S&P(Y>-R"BW'<>APN<_!,@W)U'5#:0=_]*5@8
MET#XANUQTFI)4[!U]0=P]\=0,PZ> ]>95#/JNTK-^.,Q-NW@&6S:-))4QEIM
M%P7?+Z?O3J_AMD]Q4=CMHU_ >/OP.#3Y7+=7&6^UO0H:&*C-E7^SVQ_/SII7
MCQ'U/#@T-G(U&!PKS'A:)@>OL4FWT^EV/U:^W7Q"ZX2^NYHT4._M21C=.I$+
MNQ]^]K![E2Y;!'W2FY$ZM[()/':>ZS5BY3:#('5\^TK#7,":A\Q]9!TW87+C
M-I1]W@8KJ]ZLV$T_7PTN*\\H+]&L$8=W)6&$7-;N.=TDII1S1U6>)?.G8O:(
MS8:UL)HFH@_#% M/@8E[(P9J2Y,TPIH'CV"(*9T\8NS@,!IC"86 Z00"T8EA
MI)+Z059K/@H9\Z:4U;%@#4 B^F,&_/4=K&8-7"LD4'/OALL!,C@0@LF1XX8C
MP6F9\"JL@"WLJ&WNZ/5 V+<A0N1(1,Z.\#V89Q'U<^B,BQ_!HKPAC*0^5_B?
MN-=>D$X,D6U9\1O$)@G<B?'O1K#4XJ?Q($S]B6>1K72=."G.910F6,KK^,4?
MC"+A>I.C=Z<-?HL?*I13_:'G^\7/XK3?%_'$H'AZ:EYXFK$').%$-BP0NU/+
M@\+B9($E53Z5C2 V$A\?[PZ#0'N(& ;W:>Z9M@D9>N8#ZJJ5"$PI3!/;APDQ
M@$;)?$Y3_.I[KTUG._=*UWT@/&I..$Z*1N#$BWHQ3N;*UJN5O5V02B_?3LFC
M/9B/[J:Z?,)&'#3RH)O35:^O+V2]"1'5W,=R/."&R,VX_DH6[P4:2X,K!V,+
M_NR+ )B*/XD*JM6YKR,/^K_& >WC,IAY9=[7#?E\>_(A\==A^N'F&EW@8KW4
MIXK*P$V[!.:DQ"$(<)"E@L17)B.3")@R-^# \4912+_K8@465J[%&TK;4%J!
MTB+'BX$_P8:CJ$(H,V<$<LM'[:WGW(01GHH%)M"0B0U9F#>$ TET$3%AYS-N
M46BPO@%HT8C/0=(YXX4;&MS08($&60XF@K!?(E3HL:B>P*24WFLYB'W1#SVJ
MJ ?3. HVA+0AI (A,3J0(!X$5H"@PG?D/RX0E1^.4 6WT') 1@6&%BMF6(F?
MNGV1;"AJ0U'3%2>9P&K2FBN&8&.20\$2B$7E=,>R5P@"SH_XO&*G)^!Y&!'A
M2#<$MB&P LL*.^A#([4J3D?L-^O9_Z;POIXG7"ON>N2=('@@WW<Z6!T<1AM5
M?D-*)BF5,O0^'[VBP(@(U1NQ342$_E!KY$0)Z%GP\TD#4SWD?1$*@&\Z(V2P
MOZ$SQFYOS@@AP 7#B<?.AK]MB'*"OVGG*FE:S.PR:]/:^"@V-#2=AB+A>P[&
M0$,*+D6NC0P,G0Q 00B?MHPO;$-,&V(J,"17] 2BX?6!$Q&Z%S,@(#9^QNKZ
MCC?<4,Z&<B:<\F#+]5/,)E#$(Q';01F*$&YN([PV5#/+P$/A-(1_H3_B%!T&
M:-A9&(CV$54?$R> &8U@4\A?D$AT_4TT9T-L2Q,;]W1BTP^_FDI=EN]U14!0
MHDX_$IR8L"&F#3'-UY18+V(L_XRJ+,VSO*"'0/Q$3AMJVE#3'-;$>3"4@T4F
MGFP>P3F!$GVWCPT< DK#P_0V^(?3%P$(S0VKVA!7D;BDOC1'YE%R/;HOHS#M
M4X)>PEF:OKNAIPT]43N:A+R2&W+8D /U3S"RT>/$B1)"?X=GW%1F@K/'D?L=
M8!LCCI#(V$D8<+8*/E-,9E\#Y^1W>/_BBJ&=3<60JABZ^:$*AC:L<VU9IRMB
M&%FSQ0(KM-: %6X(YWNH]$Z28&<16?A%;E.=%6,+D+GA6&QLP0WA,,?)4M)/
ML'/5=822GUF/PTUJ VI1Y8T2=# X;!V>'#=E$LNF"F=#29(%31:A&G6G<=H9
M>EQ>:'&'HWPU!3<R-7^AZ"MFERKE(<MH$+60FQ[;,>ME*2$K&F%%KANE?<SM
MRHC<,H@\?DT#;PAY0\@SJJF=>*#KHKDIH$QZR *5O93[=:FX8U;X7'G2E/4(
M=;1_"GO@P&WF/GT@9N)Y==^V#\,)?VS)(JAN&D7HMN:2:\-C +?]']U,N8.N
M2'D\JI0]N_K<O"X>P:.PD%LA![-[43BD+S]6VA7[) RYW]HQLH>F.P3=FC+3
ML?C8VI(5TR#L9,'T=HFS\2A?U&15:3((50?ZP.S;GL!*7)G\";.0]>R4!^KT
M>LKSFCV/)8NR^!ZFG_KLUC=KZ"=J\DMF?:,])Z>K5)A;((3+1??SCP?+OH%]
MX]8CN3M&!\'(BS_#N"G6%>$ET#O@Q'$ZY#YAV:F4[&DUWG14. ZJ'=W(ZS N
M@MS\*_C&QAY\812K2G8OL"[1K71:LD]ADG:MR9T'YP(IJ(7RJW!-08@T-G"0
M:F]$Q;Z@8XT5A2T>TI*UZV858(^G*EN.4@4_? W<,@8*U]H6G+D^Q_RAP$E3
MET'8T8I]%D8"HSDEI!TF JS AR.@'MW:]WHC2*9&SLAS,2T9)%X?#U$$-UX4
M4BRH0K<9%Z^G",<+]TY>":SIP;:IJK;'HZ[)N$7 ]F(/A8]B; ;. T40"+O
M=GR?AK?D\"7X<82"&>=.+2/C0@TD_D+-15Y]O2FR%2LP%_D:WD^4Z/P3ZM8*
M&]#QE)[:L_6;X7I973A7H?15>9=(D_#@WN$B$H&W K9+\@1LVIY#YJ"7S4$V
M^#M,;0: H'V*\(#3$6>>S  -06 %N6&*QG(LK&+_B<(FP/'P"L$78W@+L0_:
MCQL>!2^W%W73(7:)[ I$1^AAY$;H:OG9$[<0+(*RT+L#9$8N[F38[9+D<XL[
MQA0\=],D6U[FW16[=8<E/K X2S>^[Y"NY\M.H;YS&Q<8N<P60]Y"W\I Y\?
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M>1DE$Y8\JET<J]YHW.>H*-(S4\LV3VBGMKW&?&)V KBLPD3CI<0YYYA+Y=R
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M:87&DGA\(G!9B,L$MPF>RJ;4%D]T>\9,:=V40Q)0FT^$I[_#>:MJ+ TG9K1
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MT AETS?CCY3Y&F(B!/UD]@+7E_R6"&C5-@$M#&C5-@&M;Q+0:G<'WI=P-(A
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MH9N^\%5=T/6E--W#./\24"NW,K=R,\R\#(O'\#E:K!*;)972]>BK:Z)3*A=
M]@(9F>8FT<60 FYA6=/:[)E;AE6K+#[T89),F8[J8A1_FJKRVM+1:WMNC3MC
MJ]4.\BV%K(*(<;1-?'S>I V[@G\:Q<$J<]?,P96R?8)*%23(64C8J X<<:-4
MK58)&CE6G;S!A ("L[C9<!IT/(>*F]B7156:)5AY=X!6N5([0&6*T"3O<I9E
M HS5ZW.7NN;IMC+/"!.!QL>AS071X&;>NVJ,N\BC(U$]%3BTX1I0*/>R=ED!
MK)%^*]QE\>Y+C(B.QS+,AE*A0ED7)?5YB=//'',!*Z@@Y*EI-C.WI7N2.TM=
MQ(5%AF%@9?"A((K(0,"%JJD9W<51'1FJ66*96B=,$_N@^I,F&5W&CPJ=[]["
MYI7L:2U9S43ZK;,S;.],=?V9PKO5/#YJEYO''[9E#]E9E>T&Y<K";*G HI//
M"U+X*T_<BORIR2A;'23B4A"RZ-)."O!DE.$HLQE)UO4Y9S+&3%+0)&YI+T8C
MW^.=(0M"V8Q&?K#T?^*[>BD.,.$Q6-BY8ZF4SV6\"GA)<E&H[\"ROANOG+?#
MQ#90K #_Q':<GFP^GR,5G<9I=-Z@XG/)'SLO&S-QZD"94ZRZ)+DU$BMC7BK0
M8JL%I-V-L=4D^GV$R*';L1/W1I*YM PD<6,&2C:+TOV ]%0#@TS09V#QRU@.
MTY410>A"<U22H[QU@CM.$N<(F+#KT/Y8'P,""_L-:!]6P'MV+M!/XA/D U+T
M>S 6,96:I0Y5C+H$YW>=&3-T-K/<Q3)+."XP"NT[MK[:=UQ08'ZH:[=$H'5G
M$VC%0.O.)M#ZW0@XETML@H-Q$TY4.Y#'2BA<8C.6U#MB'0K0A4@D%Y GI/&B
MWAU%-_)(%K-PT0IR5BXQF(W7:W7$.)R/3S);-X#Q"YFP5$DGFZMT.=%0C#Q?
MC.)Q:4JNU GB%,#??UG9$,V@+WP"V,E&5849<=<7$99/R$K]%&QC1-G4GTO[
M^,[>NFX?;<_WO<SJ8FI-I-[YJK4'>4,RY<S3OCB%06L>?BZ:L+;V(YF)SA3(
MNUP6,.5&Z?8*U$)<GV,[.]H%F<$ZVY-2#<P\4*4D%-+1G!21+,GE'POO2UI4
M^:U[]'<M)''G/>ZP3(X"Z!>656! O9@<BY1H2QM6V"0+-NGDJOE7,VO=9[2C
M8+<WZNCZ1ACD7\S?6&(QG,.!/CL/V$S7 7O3Y[!"&82AA_U:B"<0C@;L7@_,
M4=CBK7?'YR?;9D0!;1/&YJ2.\["]^ B7MI6-YP8$;2V"7+HL:593ZA^,LHB,
M)5D&8K9\"Y=X2=3$88C*UA#-**VYDA]'W'4QOTW% +R 4&+Q3PI^$"CYO+V2
M5> :-,ZB=QMKXZ(I--C(/HR\3LI!7-XT19O3VC#+.F)C3VC*2^^)*UN4Q5QK
MI^\4(?M-D,JZ<QD=2IS8P20L$YXE:>CJ4L?6P]H1&U?)GHC:<5)YKFA/!%_&
M0^5ZO8-%RE9'9@J29?JER?L!\JXGTV_0=,*P9J'N;J)(<6KIYH(:HF=[Y//;
MAUF&\VM2/<A(9#&KI(-A]@)L<SC&HF]MM4\96IN@*E780MTN Q3,)=H]C$ E
M+H$F3IE5#/9*'Z@ [WIWC*-3#6G^0POW,8V :U =9X8X?G%YI!''\YT,X;T1
MI2!$-Z1+L9>42(YU'!. :2#\$=)^))"PN=25@M'X(;P#YXPYO\RCR4%GL&PD
M>B^.4\2 \-&=M=[4JP#8BN[S*<2\,*\G:XAJZCVH=LY1<N79@JZKCA;4G_81
MQ4<Y.5\-J@1)#C0T:\L;A;?) $NM@W3(;^N DM.'XTJ'7)[-PIQ!VZ3KMA.Z
M$@#>(907) 69WD+!>U,AF]B127TF:YFR,(%R5CJ$JHV6(<=)!0V8K:J'6E_*
M>].9UR9EO2$YEF]YHV"\#;#.//:UI$P&?IN"J&;?>$Z6!)65X4ZVQW$R+&15
M*T\8,A3D4)JOI?,.1# @Y-%<6I <6(8PF!?.SD231N/"#D 8$B^/\(Y'!&FN
MQ8@UF:B=.5A1F&2QE"Q%F#,6E2.#<018*Z+G@BF==2:7D/7:\0)KF78Z]OW;
MZ6#Z&\K:P<R&.F9^&$NA61UV%NVRUB1DGTC.F<A2[;#6E*%5IIYHAO- E  &
MF-/O1X0/%0:JK%>=5FSW,;))&7NJ?\32!/5UY+S&_+ YQ3LA[JA'NZL=-!1E
MG8_:1&*X+UPSDS#GQ.%4 8Z4.KED()(U)@0\&1>(M5.D[8RT*<=N=E9C!B&^
M='DY UQCBNLH\ORY]9#V/>HA:6^FAFE.KH_7F&Z.)\TX([UH[FX4M!=JM##4
MQX/5<\KWH#N5*(5ZBU,RE=&W37(*@^)=AY,=T+R7T'1:M5%D!>H9I@,1A'PB
MS8"*=3H->V()+ 9J'36[;B@_410&4C2H8+ZR;LW:<FM"T\O4XKSU+E,A\O8%
M722"2RIDR,YO#31A1EF/9.?;B^Q\5+J-;;(V-O]]*R=W-P$]#.CM;@)ZW[V]
M*+5\T"G-A33+L,>S6[*[5Q*&GSF!HI"8@55/%,>[3]Y%2?<ZU94\NE>@D7.9
M:Q5H9ZT"N1AE3JO"I4#XBTN6()=2EU+J_9R6@[,:#=Z_3Y\]LT^?-;5/GXG2
ML+AK'W:W6ZY/7TD!N3H2EK27HK6J^T-9G'5-\9-<?Z!K3N>Z@!=3$3Z)X]KK
M8I.<>[4 5@(#<;K6668\9DN1&:U$J-0/% %T>C$Z1OSC-A4QO0(3M83HCYR$
M))VTR#B*1K>$TQ8Z#N@_9%?PKG*7>=(!=3P=#.7,\)$9CU*+P@87ZX^JNS2G
M8U$4]BQ.0U!9I@\&'U=BSC/[B+ 1&LMMG<K ;(.!6?=F8)4U@0R<YV2ME7=6
MY63];OY47 ,[$'53<.[F5K$O#7YH,>@:%N\X?CY+9J+HD?UP*"V]BJB4E,45
M4V!)R&@4Y4)EIDXH 5G!(-JV9>-060>I_%)(\L!]0ZQ?'%+U:>)U4S\=EHK0
MJNAHFS :V4?K.D/RT!%YDZD6TX309\;*T13HNZ6*@7$C+=E%<6H]9M?!9"=1
M;A!,G30QR?)%RQ!/ +'WE7F8X<-N28$PE,BP:I>XS)'K(WE/-<Z^S/1(8P:9
M,EO84>H'OU;6<\-N9&438"AK7Z&LDY156K*I.C?N)7Q=SF PW8GP(^5WY."A
M;@)KS7&_K[%"<GD_%\<\TOEF"0J+'!=6P7&Q2598-NA6J^[M/<N@&RX,NX0.
MO3NA._J^Y'_6+8;RIO:-NO8O2X72U&RJL2PR'*Q3($JY\>*N8/Q"+Y@9AL%I
MD(6<U<)0_[#L$AJEO'-?441UUA$=4'! 7Z:P(8T/U!SKSN0**;-+=])3;OY_
M4K T=93>>*\UXNI]540;<@>N)7WXM-H\3 GE'\I\/G("AUT/(1@X% 5?#1 *
M5972$Y,@[--;JYB]AQ??IWJY&XWV'5+Z!ZP<IYGU,KT%%8]+G-T*]H_EB@X\
MAL@9R<!<)(8.!5E,O8!H ,YG$*8,$6$YV3;ECJ-D;*U/_QR,1VAW!Y1(A\$O
M?)]*M*1<DW^RMEN.$>6CY+\^&53 S;J<%2#3J&EP*DSYFB,!O2.-@KDG0.C\
MY*!1V\V06?D.-W _@5U6++8N*=54YH5+PBNF1L!YH8>35CPV8YSR:/L4"D C
M%4O_Z<XYN(-S[3I:$^])S[D).7HL'4?2".;9=YPDP3X)>7QAA<_U3!EZ8]]^
MIAP=5C:-86>Y-P0H$<8:,!)H%$-0&.KNHNLC(B@0,AT0IT"VR7 0P]CK#Q**
M&L&(]+P"*1-WE)*++(?RA#0*#?50+'2*1X0"*W""$(9V(G63IH'4F+^OF[]'
M]U_H>NF00!H"^GV":0=1;E"I\RNL:-,/)*\D*M(RWXH6H@TAK&.@U*A,U-&^
MH#HG.S(BEH'*"(FI-14+FL_8>8@[=_"&2C5>A0&9@7/+0KS?+R5/MO@QG?N0
MA(4T**PHH<)"GACG=.$E]H;#-$ 6A %H8D$(=:U23-KT&0YCMC*/Z:1\/%*5
MW!Q[;"IQUBV[(60_#TJB1%"^_+LYI$T],O0.&,8,S@TKAM'CRK^C[[#ISI3>
M**B?TIS&RL(2KI7K<&.,@27)F$7N,:P)XNP;74BTS1NX+PT*4HOIDF0I3%M;
M9@5+45DZQLO!@@)[*T#O51C!D"JUG+<#!2TGGC"#I@QS2:84@E">-DHK+32?
MR;*(\5BQ@(BR#Z2.+E/?/:X4S_J(D,4@$I 3#IF6,6R?HYK2Y(A0EDBCA,1V
M*;*RDM# .(>EF/]'K4O[7M9G)1<,MV0PO..CX_\&)^/'V[)V1^]7+F5TG27*
MXMCFWB:VB;'-O4UL\[OK (6.92(G !DQJ@ J9;00,\Q[68I'.$DP;!#:_=2A
M7"/IYR*KI"L5^CRP0Y"7NM*,H]Y\'0GDA"R>I:6<Q1HSB#\S@ G"Y>,J<)7Z
MQ6!=Z"OIIN0^9 %A9<8T[UM?FK;DPX^Z"JLC($BWD-MPZJQ-S)25,:N0VZ*A
M4U%Z0E5R$4CN[F<T88##8]S(*&Y @81"Q^G^FX)E967]LXBQ,\@*O"KEX!F8
M;S+R[,2HG6"/,& G&)%2Q:BW'H4OP$3!GCHXJ>F#(':Y+(W%A_JAL]95E%G_
MQ&N&9CG-"DG7OY/BG]QR6Y(&)_6J5EJR-ZHB8D(]X85;$A^X$X4.T#/2-N@=
MTD^OFAJJ:F([US91IQ>L<:^M(UEY<RXK;]I<>2,[/,3?:&$)F?ZD_HT<#,+^
M_*+Z@OX>H98K_Y9SN/7<9("3J/[T @7FFR127\%I$2JD>AO(Y!=2IB;N_=<@
MWU0_&-UE$T[<%8RX@R/F J\X1KGG##U__&K1*/1L['T1_%*<V^'>_N%K'8HV
MYBC_Y3%D^\S* 15V!2,%([H<=5(@3#2?O<HA8JCY:'@TAY@&#KR8KF^<HBE%
MI:UH!\P!RNUV0ZY7ECZVR4>;LI\RO&5"!:'@$LWE?K_3"XD-S2((4&QDB;$H
MEKJ.2F>:DX^O4B\PLY4F Z+G'_:=8@R&DK'0<JQ7=ZL5^TQD=?\2@Y/2.V 6
MH>N,V8/"^(R$>V=T>IX'.(Q=?T!GDE[I1&Z+D?M/5C7U(0(IFJ 4Y4PG!A$B
M]-M<=@9O"^MB</1IU%?=/;A]![;M(+\)A?&F ?IW$68*GIAQ0'KN60DA#2<2
M0IWF=9._*&L6PW+[L2Z#J<C#I8/_B1Z3-ZV$':T]!YJ-"J(XT,03-!?U%'D0
M-1EG^>K*N5 H1Z6[QO6*$0:HXU+6Q@M=%:Y.<(S]\+9$F'&(P(2$S5 >VF^I
M&[W3?!AJ-)>1(+T;3DS.]:"/69JY.#JWBF9O6G><S9@ %8"9$OX6)@N.J BE
M,@=")>N%CI,I N8YO1[H2@DGXA!48JVJ>?=(A%B9;*#F)>.1PKSW7-<79:IF
M(>Q-U.WA<_Z-[/8P:U(T%<G<<$9W(\T5X49W!_9_UVJ57;LCYT$LLGY8RDN%
M]W[8<?QC)W&>V>5?Y;WEJ4]>VQ^.F^0;JRD.DO\T*VK^J^Q[P6=Y@56%<PY"
ML=#,G5,0) 0?]8N6432\M[?.V+C;\E<Y=&%9N<=6:S?R1F;])T[+A^LNI\.V
M+\Z4DB0QULJIHV3/$)N+TI'&#^*J((R\PA)#=M J3H4!9[C7$56;X<)+.88Y
M/<^"%JEG@J,XZ?_/WKLVN6U<W<+?\2M0>?.<DNI@)KK9\N4YJ9KH$BN);1W)
MB4^=+Z= $IQ!1 (,0,Z(_O5OKWWKW2 X,[(EV9193SVQ9H8$&HWNW?NR]EH]
M6TXK?RXWZ](WJ[%:(";R-/]+15\(;VQ1]>R5E%[*_@(U%**:AA*Y4B60OSBO
MZ$N@;-^BU,P,W#06:C*7%R5RFSH&O% K6O,+*(ED/DQ\>#4]B&)[!3(MPU#@
M[2 '& Q0!TIL@I$S82 Q3$VWISD4D60X-!!N#.>QR(>*P?(:OBC7%EOXH@S?
MJ2+Q>-:A-%&>BWHQ,V.*E/;7>C%Y/QT$Z9GSI]!YJ;O$W5M5Y9NPM,K%&S;<
M)4IJBZI:R4(,3BF8LZRIG3Z$GE%RAN.%D"TE-%I84=!(&4@7*N]V(NV#$=VG
MV:2GNW\/M+PG]S\C=EZ9SD_,FA]=N3_\.4'HYB<I8E<<-9"W]VL))6@D3-<>
M+$XY6; , RWQX!0TQ&Y*%,=4\FVOY H4-P7+'88VKZC<9?(HUM8M"U.VV8-'
MU[@[9J!I/ ].OQA^UB'%B]V8]4=<*?^&JJOY]ZY09_9WERJCJRRT"^X=T"_]
M5Y'X28,^&L\=-,*CEU&"1CZ2F"FTOUN$)SPODV_E=V!F 6Y=0[KLWRU%8S C
MW",4'-595UZ!X)T8!1'F]7<+WP6>=/.'ZTD[O9@]@78"_=TPZPN?8SPRIBL]
M6980U;A+54Y"D(J(##6]E*YN*9ZKB_(*G?=%3? B^EC2NL"+AH;3K[O-.0XC
MI*S#/)+64+5<+=HM5Q46S#G@4% \TK# 49:ASGF,YJ)>@;> @$V[8Z)B[J1*
M:0SH$E30H/(NCT?>0I':Q/SA(Z*JEB>38)T;RI5YNRM7VD-4QM)P>$^?W3OY
M_-Y_B71VQ1T.E"$HF5T;VR5R#8(OP8\$)]NF"<NV6G&.SBLF',WP)V>&(Y^;
M^K^[#&_YG>?_Y_5=)*P8)=\3Z;2HGZB#10R@8<TF=14RU.P=D)W=K('&)O^E
MVRS-<RRDB0Y"X-'I@4-WFI^I  -NN^M]1K*Z(@^CW/%@#8!,'4VJ2S34H%5:
M#HY1-4R^8)<:<$3"+,1^+0)>BUUB6X$#03)T5CO0J5'1EI@$L'TK7$IALP(]
MQU'Q@_ 2Q+E[_NVK^^(B^X&-'1-F=B$-8XI$6@$Q*(AZ_*DZTRG-G=$ISJJU
M><;@(8UT^>+ZK2\ G$3;$,R@DDNB%LBV*GO3B)Q,]1::6I(H1<H.!S.Q.L4L
M,#=ID=>/OI_HI8=!G>:O!:BH.8J8A;6DX)A?F=__ZA%<R(S]<0S[_E>?)TXE
M'\9\K+MD1_'H'OF@:GXC$Z,&#*#5_#^O3P>F*OPO+&92/KFQZ<8W_]R,Y'A\
M1'( R?'X<)$<^Q;$L2!V@(?GT\J:KO3T=+^B&(8)JSB[T<XYR=EV$TH=Q[#B
MG>($G 3GE.@D1*BH,0*21\"]F$--2DN21'UP7U.H-!9*HSZ\E][_;$$*(=_R
MA=2ZGZ+Y'Z*31$&5=%G,":"Q2\M+HI2=9(?!*]"48CXGBW;Z9K(!(1128,VL
M/Z7Q?-->(0W +:;\#6'V6[/2'R,KZ1MXQ*N2>\D6@#?@)APW$)9R+XD-B5*@
M;91%>7:F\%/S<X_)XP_P%I\)P[SM?/L%[7N6++)>$Y\GUHK4'FI,HE*E@'+3
M8*&V;QR=I.G862:N$UP38:R!?NH-8>RJP<KM5("X6E*Y4FP-3C&-$G4O2PP;
M=$YV#Z6I@S,^-%-/Z*SGG200DOR)M*,0\0<WJ6I[ZX-[]S\S;O[H3ST\?<26
M<0@0"(^+.G?D\\^I!Q Y(,]*,MFL*4)&$7DF0?'2E<XY^PX=(T'[L(1RSN"S
M,'T6/).^+=\L[$!^4Z0(&-D]3ES5+OVX& _+9OL'146M%ZQ#Q=RF,;^-C'/A
M*NBQ7LXW1RY=TRD^ 4X/RDKL>Y]A9_SY3>/_M(S?X03YO\SK'F=W^$5C_<ZU
M-;Y$IDQ-W8^5"*>2P2@7Y^ ':;ND#W*E:L*Q!Y* NFNO(.<8(Y'N8N5O[KV(
M?>9* >P[ $[S[_3.N"Q%;Y;().-$R!@*Z*ANQ.@;ZM"P6TUDG]80)ZWZ),DF
M^JC:[D:?=R8EA*6(\JDI+=H9:?*<XH:)*(FJK?& ";IL5?,Y(FRFYJ%Z#INH
M+;=/2$]'"-B11B'M0-[/.YY+?^K7E.TKC4E_T5ZF_WM( =*H @[]LJ:$Z5?Y
MR?TOTO#H%]-5/*%FD??/?'&,N7X_MNQ;NC0\_&^#^6G"=R)D*#@-'&F0&'G>
MOZFU2PX*"OJ]I7X/R7UJAFNG4P*2RY^8'G]./7OJ-H5P9J&M"GFUK4[S;W<O
MB.!K@[(!Q2,<RW#@" \,><LX(FYBZY7C32,PD4N&A]$Q& & I<M2-82X\RG8
MX]F_-Z .CE]%/W3XJ+"4+#=-:\6%,!JX%6R?Y;<#'[#F"'4:G*LS$B(-UWO1
M3$\9XV#A[<@LCD-]T,.'__[Q\2[6Y[=LX(ZFY/=C2EYJIS*?2Y%SRAWV2R@%
M6TNS;%UR[;5.(K\CQTCA/[$IBK\(/H?S11GM"?+64,'H6F)^ICHND(JG.A9V
MFM [8ZV7/U6QP=)&M+^WLA -7H <!58\:1O)H"]"2 G.PADB42)S=JSD;+^&
M#XVPR^]PR\N02T3W^./]>Z?W_6XG8PG(]'PD.S5(2^7/-Z+I<30.1^/PZQN'
MR%PP, \OAYP&FB#6H[&IF&\LZIKS5C%.&)&6?8WMM0,9^/P!U:R21H0=&@7K
M<@RG^GG3]D3U$8:Q#5N)*[3)-3^3.E@IRN3T;6#A/-:01UMWYC+M]FE(.D=G
MY'4[K2L4'5]3:2Y$,+-:FM/#YI?]#1 O$'4A1N-Z,SX3:W_B/BB5A.3#5_LR
MU/LGP]NC/SX\?3SP.AY_0,/RJS8%@@FF6E/.Z/ [ :DXCN,(?:PMHR13,"YQ
M*_3KCC*(^$ VU0FXK(J1+"SS#7$7JXERKJOI14/*"0#B(EWGA#&8Q&35U<!;
M;@??1?VZ5\Z.LX;X;G"&9XYG@1:WM+[VFRGRM,J#R<VO:0-N&"HKO/&3B/9,
M];;FOFD^F4FZA%(S5_$W?"=\59(54==&' W6?3_-T3KJ6GY;DH_=-,S-9X5Q
M%3T*]ZD V>(R3\TBWSK/H-/8^R Z'3PTHH6C!(HAJ K!!U17Z/=QF"0FOZ</
M3]OFLFHH$=ZRX[$ *!#>ATJHE)).\G?3*9?!'7"[[X\ICP<9<U3]Q XGYG"G
MQRKS_6'L'#[Y[G54=.!T=1^5A=V+Y85B0L"8S1:?CJU>)['5RX95CRA(9#>0
M^1&D/,D:"@LDG9+<;5[M,.I@LS;Z/=[@)EK#%*1 -ZMDQ7X-L"+3KR64 KK^
MX=)1<Q 3@2IDG"&F*'6^^NZ,TN\IJ)]G3PFYPBJ>U]UR0&E'VUI5SLI,S\Q+
MI_".OYCH3(64X:+N+^B(9XY3'?L2P_!RJ]@$MIDWHH7+)F! XNNJ&^T\0U.@
MTL HG)+AZKO]!0G+3#^@V0'I0L+G!FW$FOO]P)8*Q"8UL/=ZXIL4DG!!501\
M0MOI/'S"I8"O[X,<6>=T<$1066S(V-]/A:^DFM391.GS"(PL!'?TZN/$'["E
MN056Z8LC5@E8I2\.%ZMT.,OQ;,UQS+J&=/70ZRC)3U. *6WY#%:3*C<I,_Z4
M^1$K5S,NX=!0+*/.I?<M'>4$RQ.I^;SYP+7.QW%#I!0WT(Z,PRH78-$"FH:@
MY"TU8E,V>@Z1CVGTZOF@+J=E.*J(R*('>UP$<9[C41J&P)X#)P[F.2HFUR/A
M)A]BQ)EQP&;K^\'*@*-"?F5*:G>.]P:\*L&/(.P4+'9855-^*\GARF#@:153
M= A,"\;?KVL&('6:K!I$)?#?FPTDO8D[.14D'F-#*C+VVEVF$&$"J:M,]/@5
MLFVB)S6L$W<Q8&Q"P<9_HB=@9UBQ)<G6P<I*XHL-22R&878;)E=D3E:]]W\V
M8<[G@(_UD>*/%C)")X9/4U-.4P&,HA-)% "IH ,XX'IA@Z3\0ZK+ *Z @6^2
M* S#&R#Z('K<SK/$6!3'[A;XJ\G+[-##)M$29A6_F*-JXDF,3O/7RW*Q@+O5
M<0/@"3%497&/$G41)HXF6.R"]V[<#.^D6]E5F[:+$(^U2G#=$0A]*4F8\!:X
M1D18;+<6;0@'O$6?DS2'@5DB,96FQ;JZ?],[$$'F;!Y:%*O\!7KW[Y\IN/Y5
M^$+^/.PQ!"H"L#_<^>'LS<MRS<U//W2P[Z1\BM7PPG=?O!16J\//[X0SCLB.
MVRL0CEW4*]I\;Z=H;(-@"QA#Z0!>7X5IV9[,$4G>>?#976K#@P'AV7)_SH=_
M]AQ1<O@J3^C+)S_P#4_V?5XZP]A/&.'0#':["D?Y+&D"(< 7MK,<]?Q-.RO,
MXAST>P,9;=L U]9OPC/["<3QL :QK6S4Z\3*Z3 ,BYF9,(+!#.L!E*T@-J4S
MEDA(<6210];73EH"$T]QXT#*MM!N&^ZIGRZ"JR?83;L"4#A$1GV3FCI3@ NL
M200H"'2W#4L6YY:B0)VV@E'\,JA/^X)F8;Y6U4_UPH6H>Y\7IS:PWC2EV:"<
M'OY==^0L_&T3WL&#>P_!S33IN>]IJR^"6H6$EYZ/5N]#S"IHAOQ^5B&]SFFW
M#0?K G.>K]K%=MEVJPN_,GJW-.(RH]\B.T)[&V)]M,*HN5?6EUR929I(6'[>
M5=6$6&B89VF^"4_$FGJ+=9'-VA[!&3)KX@^E50[\0=NSDM4P!%?XU4#R@P^_
M?.?5D'TJJV%.)) [RR',&%*3W&S,+TQW-H@#_;+@%W*]66"<CLIH"7\UW5IO
MEZZ*6U]X9%DDBQ/P:'')_:6ON^)P&:?]'?O#5Q80!D_&.ZZ^SW^V+:)9%3BS
M3FLV-JV#K;)OBLJ=^;]I^O=.5G;M9.4V6<E8;CUQ;,1O,7'9-1.WOJB[V?7+
M\8/-6_;S%ME[GK?L9RTX3!2X7ZZ;./$VZ&QX0[M/G);=#7Z=V<AN]5S?AY@&
M34V_:"\=M"5G'";T#H@E8\R>DUP#M\MDMMI&[3)?8_2%2EG FUPJ1!"@@#@=
MN!]'&]?<YY+MLFBO3B#-DKG.BWXKT4+B!%8U7(BO\COUW>M6"N,VT?S,+B5@
M7Y/@*J[WVOK[7Y[<?_3H:S@;=^KZ;G;MQT8M[6"BE##9^\_6HB(3DT!5H>A&
MTY%HX62LKG/CQ%PS(3SF0A_M^H]=I]&J>W#'5HXND=*_<+_>N##(B0F8K:XF
M*W:+)[AN^&Q'^1G#I]+YOD90Z%9/_37''"M.OZ ]0=]N'']<QNG;RO"V3M$^
M.IBG(09PU()]]CNT8+<HHWUY+*.AC/;EL8SV<0_4O?'1OM#(SL)K* *MQI!8
M4#MCDR.UO.Y"(&)=K&O0<_331=5!(X<$2.O.4L.3ND5K@]52E.0%/TH[+.&8
MZ+R NNE).S_1#^V2M5P_',!2Y#@C,NM]QRH'#S=8?VG@O4Y&]T[)C1H#*(7(
M"87?+FL 4=;M=0.Y2X^>./>2MV KGCBX^XWXW\IF@UI),.*/]QGQ[-,UXHDR
MT]6UN2:W=Y*$X3 @8FH[Z921Y>?TP*Q_\H;,PRU"B.?5I,/+RP"T_QV>P-[D
M@35B]YTQ.FHG2Y/=E*71S7SK/ T%M^^0!I(;_,R(^OWG:O:D' YW;7@YFO>T
MJ:=E-ZO+:3[;]G;27*>8^0X[6=_4%S\_R7%F=5?P'LI30RMEY*EW1!R9_*UO
MEPVZP<OF+3#^.&"R\EQ(''>C;A;5'8^X_;SIA;GOF2Y]X[S==,QF-Q^SMYSZ
MU^'LK982QWPQ$C.//:9&C61(DO"J 7JVX$?=WC*Z>T]^Q2T33SMK[7=T8OQ"
MJU"Z%&%,'P6K'\(UT2+6F>.<Y_NS#%^&)?\S\^VCEN'F)\_]DZ<YY;1^$2;C
MSLG=O$(C%)!Y-Y5;CZ?7S\B.WGEX=S2B$X<RV^]00KCYW5.F23A'K:%,!@1.
M<:3$>7W?^9_[LV'AMED-_HXN,:KR G_>[4ZNO5WN;\?)/RFMZXJ^H1H[\.YB
MTN_ZQ[3[WI@]R^+R_@XDOK_C L#S_8?9K1R :P["XKI$*5X864':8 0@/2?Q
M26J!$CK8%!\4WM89^L_"(P3OZ$G9E#/\]R*<[$7V#+"0J@B!]*H4:NQOVG"%
MO[? A#(Z94_XS7TE2)\>\'O\$2=&6)C!.;XFJGUX\OB^GCW9./AKS%--,U9H
MD#&12G\Z4:/J_AO'\#L-MS*S. H6LT:2V#FR&X31D(@LN%Q6PZ38_DS+6; F
MBUQ"]3 .EWFY5V3^V7Y^:=V?&V.SK.D''6W;)2L],^#\R):X;A?D@UWP]S;,
M;$&+ZO]6)5@0BOP5H* E/_OK=@/_?X[6XK%-DNW+4=T[Y)WB7HX2..R"$1U8
M+M.W@!QXN):]-K_VH]L51J+XI"(!%A5 -0DL4O'8HE/>-K8?K*\4R&?B-36_
M,7.=LEAY<![#?ZAQLYTKQ!KE,@>;/.PW)1;-MK6!^4:U9S/98B7<AF[5$@*L
M[/L*R'PCW1'W&[BSY8K:W%"K6Z*%%N:$A'1W:-A-WC9*#9&/%.9\ J\('00B
M\[O-HMDB^V1:]$G;@@-1,@K][6K12I2OKW-\"/R4B9X]J>[6T/, =G[&C0;9
M'I7?L.G!B\1=G=9_?<T-.>76S%GX&.H'C4G%(VV_K$H&\X'$B/NM(X-\ELC9
MHV5YT\@V,UJG/CB TE/A+BTR(TQFPOV2R3"4$[]IFQ. W!=MCXIQ>1Y<OZ6M
M%]I')-Z1:<(%)P8304), ZCV*#-I7U9MBJ:-O^26W!X'0[O8K*OD)7+S:[RY
M;F BSU-@3[ 889Y[ZQ(G_YJ4N>T!"F6FF]8K.B;BGPYX,]]<IWUP[UBG#8_]
MX-ZQ3ONAE^/7^22L'8@O-+.3:;MHNZ_@_JRK 8_-WD]]O^GV6%>-7"&$\T:4
M%@C*%IQ(US%I?48%4B^;)@+S9P+OL<:JM_DBG(*+00M86!7]VJR:2-HMP2V!
M]BC^1G!UFRDJO.P0;QKTX(4KSUAHC1P';\KYM*4D.T20*I+<D)X*(\6 0AOW
MM5M/2%]5V4BGD/8&A,=Z"?+1%X7U%5'V(SSX&:L OZHP<.CS/H>=O'_OY.^1
M-.:C+X'WR+O)K49_C7VB$BV\7\J8#V^]W1,X]V&TS36<VL0OE,VK&83@BYS)
MS(C\K,727< -$D=86C- WD@*\A);46PI<P4.MR5B>2&@1:>CH 2UT:=(72OM
M]'2MH56145_E>JNTUX5U=H+['K0*U#T:%@5I3&'8P8$\#W?'F=W-3MZPF!]Y
M;LM6')09,8KU]/L9@'CU9,-_BIVBXMUAA4.$C7>I<-TPAXKR9G"K,IS3KG)N
M9G!>B7V&Q0G".R$I%6T^%0?I^=,SZWW$S]^%GRFY$_ZK/:["IE%3A)%-*K83
MT)VEP<:VZ^2-<D!+.N,3J"' )&BH?CZVM'MQKIK*E><(U>GZQ#5BJ5>8^H-V
M;>H_4[*$V/R>#G217MFLY+SC#_4IQQG4=.7I7NV5;QULS"1V]9S-0+#L[:R@
M.>*=_Z3MEZ3M=#9=&P2WUDYBUX1-"^J.G"_/GSXYDW/E+F>8;]V_G5FTL9GT
MY%5Q&_&B)H$,QHBLF'\*!BNU7X48+X)!22( ?]AHB[4?;5>A;;H2^29*W=")
M"2+:<',<T6B)!]<"7U"[Y'/KD@]'=%DO"/?+[>.+;=Q'DJH J0NM/+F?!#V<
ML:*+SZ@I7OO<*37@]Z#,79'I),79[.#)K&WVA%&+]S\PQCR"AHR!1R&3*D)8
M-<'-H1;TDDOT479!?R%T.4*[2R=&6$@6B"&0A) W+L^6;C0K7'A]18$_FUD7
M2RN7 A6HM;NC%Q9RK1TMET6%)K2^,$HQ<.8M%O$7'IW> K;6=B8%V&_ZE>0#
MHTVGG[K!D5 W_Q;$ E)#2!H4.CA:O\Z8:FC:4TY2:2?HC#EONW.)1L/)65_6
M-)II1ZQAX 8(_XO3F4G2B)ABF[R3"BX?TZH1YATB&U$_#'R* .!AK>-TZY4G
M+*-ZZ@';Z>^QS<M!7S'<;TXH$.7"//(<D"^1U=3>B*"?-U$UY)/(B;N R3V:
M_$5SB5^?EP*3Q&#I7#B+B]:,V8OOGJHM$RJY/$01C0R#'1S7-9B<G6Y+GX)_
M.QE6;]M**!!@""$WN"FM\=)2A0!X@M8/2_LM:=FID=/4I6>%R"1GNDL1AO66
MAT?*B3\+\04\E6 SEO5:O;7-(E+E#N>2]M9Y19=G_1%/[)$$*G"C2I!E<\$P
MO,>RT H$3B/23(AR!Q@46=&&GWC(QT5U43]H2A#K%):4Y6E#C !5O[)F1]&Y
MI)EW25LRD?5E9<^Y0['!S*1=B/MY726D-^&RM7!><:IJ7C&#.2.%:K)CRH:N
MU'Y(/V;! M"^E0O*ZP:-R 7M;KM ?#+B^@ICF_K5<9J_1L9J;*DS52).YPVG
MKJ1XII-<AVBT7B"^_$%^$Z*%%B^-A1J8*[%WJJZH#X?GN_/PWMWP&K>]7!!@
MW#KL^.C;%L&E("Y"^QEK1-S5A_=.9J4<>=!L#9Y&MEJ4TZH?>0,(,P<GP6G^
MQ/\HI"W*$X-J=.IG^R-6?&K8#5ZH@_>=B:"6O$G2\.U089BT&X2\YZT5VUN^
MT> "Q*;2-B=#7\64,=C_BAY 7"!R 3C[4.:85,$^,EY9WF$(N^J%/5;X#*P@
M3YIN"..+)?H($R9;U.%%'3*1$5 "PYG6V$HL17@7456DWX25Q9ED]%GYXDMD
M[*G-_+>=$.@@=HPO#=-\'CQA+X6*,SC\74^%OSYY::="^EHERZ.[-W-_%;*M
MQ2*27XBW%A/1C.UG.TI4-TW/W63Y5<=$1'+LU.+<4 *:=/B8\S.=KKAILANF
M3^UG'PWH'ELI!F[6$N"#G-$9NUWJ>\:*&<U#KV4$J;.&EV-VT/Q]WGD"W4N,
M9K[/:)[FSTHF$&'+KX_&QYDK>(\?-PPIAGT(5D_NWU&2J[_A4C+F="%Q0QQ'
MW/C$IK'BMOEHEURTP!D<><K"NWE57=9AC_RE12'-/(]7?[$U%M9-Q5RB]C7_
M^KGF/&)&Z3DZOKH17P>37B43Q^8Q*W>^S:R[2\IMBX7Q(R",@)W%>FW^U%C&
M,IYNCL$J?CRN=P:+<IE5WH1L$"[D$MLK7<@F@5UMY"OQG["@.;W:55'&^)($
M<.GHYC47?**MF%=.X]++THS75=TSW95&==BY+JH+[\<'E =L9K_9A"_M&%K2
MW#/]IF@O:@':91*@U\Q(WGO"901)BY+XB\C62&<K4D[:*(XO?'6X<W:+6MG]
M8ZT,M;+[QUK9AU^.+[$!\_M?D5-O("[$S6 QIQU<(Z7.#,[AGVVF=+T7M/O-
M$^$25B]@&CD8K;]GW2ZJ#JX2(:_:;B6)=.G'[Y=IBEV/_:[2GPH0I@<?NJ^#
M#45 F)V70FE,U(!UHT)SA#18]ZDS0(B*);)>4V8/E>?+90)&K5BT763']<$O
MVT4P_A7U:ZHB;\9\]VL_BY,*AU>,U>I^O"VDQQ7(XPR>9G4"(XGJ&ZG9&=NI
MEA%,1H+(#5EE#P<-&+R19]/07P*<==MRZ$_G'Z0'Z>.Q&1._WWVP0HY7GB-^
MTSY03!Q!\BE, X/3F!D34AM!"0<F#&B!.B#%'SWA)]:T@L,Z"OLKNK+[W@N6
MH/Z1W4#Y8;(;^]-?LMV_#(ZHLH8+023?Q"U.$T_+MLA?_IUIRMC-PX)C<LG.
M*2;KPTMPO6\\F:Z$R$E.3D>_Z;KV'+_77SK]@9U&6POJZ^&L1S5%E7$TK*6?
M_4-V.'AJ'WPE[0T7S/6F%?6=E1+"*.@M"!R30'FK=J4E&Z@M<7)P:X9ED!;M
M_<LG9DU*1077D'4<B#'97JND;?CUI&D\*N3'%T1[@]$_(R](Z0Z5ZGYH0J-'
M+M4,_L#!O]>'7\G>>3BZ82G>7)=O8.C:3(DW;/9UQ]I7[54,-C!PN\'OGXVN
MBD+T?\DNK,,/()E<J=D,[POTO"Z/DSDV7F,('B8%69*YJ^95UTF;4Z]\>JOZ
M$D4'Q5.TG?Y!WC[E=_6ONXR^A/((5Y\)HE?I;CD&OZ0GH94;?**FFM<AJL-S
M6O[2P[8E5**3UBTOXG0N9\'_(ML%M0*5,J.3QLI(A *0:OL!+\8?)%S7:$^3
MQU0D0SEHE@\CWLPG#8-IL0HZ05 2F01\;%XW$M>6ECT?Y'6H!B76'2]9?(FW
MG$7$"FK"ABBGX#6@J)+/\ RO.IQ#S&] ./>& LXIN6H\>CQ8U;$.37Q[*+ -
M WFH$E/!(<;N]5CB6[6+>93F&60C23)*HG"&0FJ!KKP)AD>^/A5R+"$Y/ 1C
MCJ2PW GZC"@72]&Y3B3\OBSR#^PD!:4R0T:_(L KVMS#=L),P33@%:XP.3$1
MR-SE&.UYV:@BDELJ1?ZFH89YZF*%4!=;G\SE_R>4LF%Z"<H45:?YTTJKH)AG
M-(R%9UK#V2,\U>Y7<M;EX9=9P0<DDUBZ-,P2F96P6Z_P7=)2!-,V];--+ZH0
M-Z[:&C,/@DWRY$H25J+C1R)N>@+32.3TX.'N;CYA'NE1\TBKX2>V$=S20'XJ
M2WQ=+F%(H9$J&9>5!4L>%R17TS/A-D>!C$B-O;?Q)'$/ 5B*>2+_-RW%FN)B
M]X8263<Q(I+GT\."F$Q4)";&3A0FZ8O'ML?&=5 05!O"I,_4W0EWIX2=*.]0
MD+)S=C/IF7@WD5N?;8Z6*P;T^[X$>KB+[6F$: Q*O*6!O@HU&V3HLW,$K!P2
M[BB*$6M"M8Z&-+P276#X [4(P-);?TGCKK"UZ-/*/RVA\].T*]6N,IG_\T[@
M-PZ9HOB''6=$+T]HM=8UN5S6%/<WLYT1:$I<OM)1AM9P]AD+*X>I>KL6;Q]1
M39S)G8>G'"+I3@??A9]04$'+VFCR2RIE*Y91I50EMACQWKK,E*H(>0=0[V*M
M*I"6ZG=A;8PMA>PXCC"]*?ZI-Y;M(DHJFS#OPR%E6F5G;XWRTY 5:V)B0=S)
MO8ZTNAQ;$YLBF<=^LV(,H]N9//.\2$_S;^,#"$R XW8Y0:DQ9;.BM#W!ESE(
M28&%=O58;CW@S?VD;<)"ZUQ/_V#A.+4<70^9U@N<$<?."(N)D#X\LU01WA%I
M,W7 :/YW]BW[9HKZD ;L;5]/(]=7U'($Z7J?M='A*@RP1J*#I2'&YN3_>L2&
M1YT1(-1$$(.?!,IP@1"/N7\>"B8SF/T5==-ODUN\E.)I! A.__KM>/F4,0GI
M"'7L5 BBEB4HQ$&_AL<MI=U@%B?E.LP.MZNJZTD9QWW09 <]%E")OINDV;XR
MI4E)-" ?"NV[YARB!GI[>DD;%;,G=#6!O7C?)?19/N@W-',L.E+Y5$I1G(KE
M-XJ@L*9[J8K>;C479B>*]M$PTFJJR>[J;=EVBSVS0'+65AP+4+A^WJ91"CFK
M=2LB-:06!4>WOZ@6<\I^'K ]X):R")<1SMDBGJ-:)>XW2ZAM_00BO %X2C$C
M.TX4]\(-K8(Z8$ "U=ADN-R")8&3FXY4IF$ST$T2/IT1LRRU:W!\'ZO6O((
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M:.TFKT,F*PVY%<-&]3%9E[T&+BY/1\3D7;L@WX&;+!W.,K:%[P'/%DJ,HRE
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M\]VHT <B'$')]#/Q3\=C XEW,Q5)]JIA*61YNBS5=< LL?<RWTA#;GM%/OR
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M^6_P,4EL?5EQ-H":\BLN.&K&=^NWI:@DFDJ9-<\6Z-Y@#0 DK$>6U:JKT&P
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MF%JX86Z&CJ"U5E)+L'9M.9$%UV,2G =KU<'?:Y$OUCXTJ=/8]T'G8@29S4B
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MU0DG^.4T(PYOD6^*+G9ZQM&'[CRX*\%&+Y)BPZ,PK+QNG?_%)1WE=]E3ZEA
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MP77Y&X3 /SQ"X &!?WB$P!\-[(<NNK&C:I:J7PF3&@QN0PQ>13ASIZQY683
MJ3OG(WKZGTW=UZ+_].^V#D?_97@W&Z;VRIRP$244"5Y V<=-(YS6@^[-,5?C
MYK@^9AQ_@[;UN"1O#YJC3O2Y,K,ER4"<[X,3&J^^>@LB0\&+.RD[DN0LJ'RG
M3<)6"J8:",32CZOE8%?+"ZN5Q8IK7\Z#EU5VD4/?J/V->WUHXA@!&1D$." 1
MPV0K1HS,L?;_":V@)TP4X)1)B'Y@LH@R=4@)-TPAX#XB@+6].4&AQN,B13RH
M3"[.494.Q7 Y%RT!"9;JK"NO@$(',)-REO0!HZ_:)3^-VA+4E\9EY:PT7;5E
MTGAT7+Z'NWQ9T(0H<J4E9BZ:9<^?GC'/[.MG3QSUHB,M);F+NC*J<BKPKE7\
M4?^(59=)V(OK,W$/;A=7+!=X<3/7>2-G=U)*">'\-@6A-]4Y)8;29K1C_??@
ME^:/A@G.ST!_7"(1XI??WH0BB+J6X2POW^*?</@)0(4%WI_F_Q#MU9*R?NS&
M32_B)W4Y"]! U]< 8"!)_6G97^3S17MERG"VC\(MY$/[.]:Z%A;WN$H/=Y5^
M;VC/Q%8QZ5_)9_D"HM@=^*A)# (9:Z:4\G;L&G HM20>+=KAKY4T2Z&$:>"&
MC*!ADH;&<MF& _.*=,3(L@1C-D4CUGKPQQWG+:,D1GEL4CWHM?)-Y(!GQ7>"
M:T;I0S8:2=["-.*<3'M4D!N(Q9B'7V1*40LN35-4WU$CY\.KIHM<5(K<2RK<
MX9!K6)O"ZU78G8ZK\6!78U11$+9D_]H3:2\3M;M&Q\(WX7@!I8RE%PHLYMB,
M'P]5$1P<1@"C;!3VI2/OPR>P_IP J&"0J4M0&\%FU7\VU&;1LI2(6$NOM+9?
M#*- C=8X5#(OX3$H*PC&CUF3$]#-K&+QFN$WCHW0G]Q2?-'WE.USJ;H^F#D&
M'@,0BO3ONIV^488]S>V1C'=8QIXPLGI;,W* OG'1+D@9'44ON'614Y<OR$))
M$%@-1O T/\.R@RJ=8I#]I\0T1H/HRV-$0J7Z.U=M]X;H386)BIT%,:F9NT*T
MI*?YJW )2A914K)<LT@/W[L7I#[1X1-)!IZZB@_;6OAL,.OCACC8#?']8.4!
M9#4AD%4+IV!1>28T^UU"HFNPZ63_\%<XE7-196OPQK-*;2XR:OT%6E#Z_VRJ
MZJ=*!-6.*^E@5U(*)W!]W@ZORI4UK ))L2Q88J-=D&9WPD)&,DB &B0=;)D6
M^LII<&99YD-8PL=IS-K.4MOSKMQPWP@PAM,0JU,2D ?0:T?3M)J1<IC>4[]-
M &_(-*.3)*NZCD1!.M#ST>DA5S\C>FJZ>9$>#*X7)=QS#OVWJ5G_./"8K%]M
M)B#>]U.1M%)URRQQEC6'&>+!&2.+14)PN#F/N^Q@=]G+DAJAP+-GV:.P=-2'
M1O6/Q<03]#D+U?9"XM_LE5>RBGH6*^KBLO,Q()LZ<E+31EXL*DY 0#PZ3-Q6
M!Z&Z7OM\]R%"GK>(H^4:<!F.B.'UP=<711[L*(Y5N:@O$C\#_REI?4TOOT=O
M+TQSQJJ09=T="Z8'O'MV(6]A#3#C"%QD5_>OFSTKVS!P'OI+>M\F;!8.EVZS
MXNL(O,1LM!<R[^.M^:K4;'M5^9,"(JW=NMR[T;KZ_&+M=V[$PF1J";C9C4\<
MP.=<XP:.B@H0F:Y:#P O<LR8M,=O<-G_!B'+CXZ094"6'QTART?[_0'L]Z@-
MK)LY\,F<*F34)[E&HZGEA%F;:1?- ^ LN'0T_0;MW7&9O"OQF$/%R<(0?7(G
MOUCD1)^YP"E+1_D^!4C"E%QU;7/./-N;G@GO))BL9LDIFT!*"7CG^Y>TJ3,9
MR? .^>X=(&A.:MO^X,X8UU>3A'=8S7K%8V;N4UC$E$.KF\MV<<G2:"@I;VHF
MQ[!H#^)HS)M.44RY5L>4<PFCWN-O<'5\N)O_X<_?3X0P*0EF%?W#4^8BUXRM
M $$<AZU\A@1BOG*. N"KBPIR!+IANOG*BJD\S1UN4_X67JGC,:\['[1F@Z!^
M-T+]&@_T$2;PN(]__CZV%E+W)J\+Z7(!\MXF<+,5E8VM*(5]T.6@>A:)4L1*
M4.93%NDJK'-'DB%5^]-/RU+L6=\O(H:? G>QG/$85UW*1.4W2T5^UXD@)PD5
MJL!E?Z$A=53$A.]1,Y5$'57IAHC$< I0.9' KGHY+"O!N3IQD$S!%RF75K%+
M;8F&OF"^9EA6>X02DGRV%Q2-SU11>3[8Q$GPJZ_0$(CEG&G^7=<@>JT\3%+:
M&:08_V_JI,F%%U;@<2>+MGW#]=7P/;*Q83RQ<KM'V5.S]CU1H&=OFO:J8<1>
M86[7E5<.UU<@2J;U4H=9<!BQZ$<1+>\RHYF;T1?<W$:ODA^A12VC> ^O*S:8
M>$"J]"F%V<T@I"R4:V%_A*U]FO^3>MEI--.ZFVZ6X/^85DQK.5Y+D):JV#P@
MI6S.MT+T%?-FK%LHP93,-K=ELZ?\6P>O?/Z*WM\K)/4J8],7-K'#%T#G9U0^
MD(LRA!\W:K06&1>I?KE4:UIE/CW\Z7Q=<\$/9/O,H,[LZJ_#S]5R$G;APWM%
M_N#>@T>%$JMG*',N-[R\RK#/4';A,CHP3V_K)9= __CPX>=Y\%069&%^)!71
M\"G8W/!JRK[?=.2\JO$C= LIF+*9J8S+<;'U1I(^ISBHC$M(EZYQ8O".\A]:
MJ A4-O[<2YG.O-QI'Y4&/#3E-C+ ?0:\UII6USG]J^-59J5.7E.SG[?0TA(N
M+AC>=2GI)092]H1IL-/97S[\.Y8"8O^):S71%BVD.?NJ8L6/B*00_5?1[: 6
M/@*YX6T-,O1+>(J91(CV EFC-JK;C0G7$?*'S36[%-9'KXR-E\%?95*KQN7(
M<)R06 37&%"%9 3>.B-4TUA+K@*6))3:_?XX16WU-IPRZU25G%2BPL%4OA%Z
MHC42N+%7)R46 "<;VGS;9A89#J08&G[?4YF_!>N5XY5,0KJPH.'NL:(!17R+
M+>.I;]9*9Q0CG=S(S[A%?K@6S X$:B!M@!F'_Q3YV/$Z4MQPMK=_BB65M@8P
M^@"*RD9EE7UPD>@\$8G^ 0H\>=WO6M_,]9^Y=LD!W%#P^3=K0N?OH@G]"9RA
M-ZP]OZ;T_,GVG#]K/JO\9W<7Q&G^;3#3+=G>^"(0P7' $;.X-S&D92HDX$B]
MVXZL9_Q-$:^WE^TDGMV3V,5-IPHH="G'D"+W1;N,C)U-AJ<_U2F)&X8.VP^\
M23)YERY'+V*1.!UCQ9RCO(%""%H[KW*J8X;0I*]<5T(1OKNFTT3W^[HM--*:
M!VLO!V^CH-G,F_S"&,/ ";KO'52UY 9200I');;+55)X+K+PP6##D)4Q@HD4
M&J"28'IBS>K>3KS>R"T6@%5V;$*)&E(O6\WB:U<KHBFH'8=A:#NR<=MQJ#;C
M%F7[SXYE>Y3M/_M=E>U_;2?JW02HLY\C0)U(Z?YR >I/P('8B5 QX4)RZORQ
M<*B$*]7!PY H/0N_N:1 .>S]2AE.J7P;#H_UUB7%"HOLZ^#Z43(-GY5&$^:.
MQ!'W<A-F&U;V3)%D?+;] Q0(BR9LS.Y-_D3>\//PO2+_QS^>9'<$/^\_)O#Y
MN_EJT^&6=)I&7@[)2-&"FH63+IRVR4W@,^A@]O3#=.@37!OE<9<EP&[^J]"[
M6;JV( >'O08<A.C]TZD!JTWOB#3EH<KU21CPB>H#((,1=H,\'A-\-HT@2S%9
M&1[O;%G1.\3"?571[6?Y:](3&$SMDS U8>$_K]<_G:.N,<O_1[E<?1TFZ)2^
M_?I??\G_4>&>;S#7^1U<7H:F%X27H/-=V(1G-N$&X./\"\78U6)OH]%P8O-;
M3*QDS^NEJ=G:,B7.%S=2BD5L 9@^-R/%AW,4YO=OF[#FD8.Z919!;175JJ2]
M-/@73;NLIS'KG10K+"F25BIV>IS<G=BTF;E#\HP0T$:,/2\OV\X@RS$)"Y>W
M),@^/<^["ZS#K8:S'>ZZ#>91TQU\Q7\&YW A<<'U%RHR2^%<63LN\96MZWZ^
MW6$EP0/WMEG$Q% +PF2MZ8;F7%-]8S')R'O"V\R&R9W=? R:&N0!4:M0;+ET
MBXDTD5VC<"14XDC/=D\;4ITA^O!VCCMD[NQIZ# B__4FI?CD*#K4(^B:TL%?
M)!@X_'.6'_)96/U.TVJ@ Y/&N5D:8^W+"^YJJIEFJ#+=6S_PGDM<NU,1_-RN
M1Z W5PM6<A1MN-N/M*]R)VQN="G*_.L6HG2\FNT0;RQ9_7RQN'&S(%FJ-#4$
M07"^X">8&CJ+4[(W;L<B5,E0-,C.VREC[)K\]8N_?GOVZK[,%_H@M?M+\K[4
M%LGJ69RP$)922\$(&X+K+)>L'AE%UC#JB07?U;#EY66#E^=9%D93#".:EP5J
M&U=P-<I^;'N$#W"4IB>6M<17RV#J&Z>"6&07F_ *1/B7$DGNR=*D35>?MQW
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MX<S1+K>4*43Z-#QBOC\IN?^\..Z6XV[Y2+NEDKK;C2FMFTIEG+FN6#:H]JT
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MBZ6FXT9WOFSLQ0NG.*(E6M4.@4F027&0<,#LCN[P'"\T@6IL63WS*I-P;+B
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M,"P?5)"/@='@FT=1@Y'39KWF,!<_" %0$*V3S9=G4H/XS$4^0L-7H@S7@']
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MG"OT9LV!P5*2)E3"JY: M=M4!C-> ]2.W/C%^V 6DX0_I7\(V5H:$B(1-)!
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MCH8!>6O:%"]42396W.M#%E2\S@SP/?-*'O M.DA?(#Z<0S.YPYH'$ )2) -
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MI9^26"-U.$:5V-Z5,F?N-\\NGXUWY8XF<Z$3.#%@D# RZ5G D3Z@($<:2)1
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M(ET/ZB'=#VA;IL0?_TR8TU$+ON1K.T==VH,77KJWD]1!W'AB*5W;4;I8JJ]
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M3*[O7W;.Y@W$T(#PP6*2@QI7F;RU&LB#JKJN901PN6*=P<;W],W:C]5X/*I
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MO@*KXHP4%*9DR5G16A9-]2OENTY8HKE34G"(F3.*9F6VSR.3&S*8K74A-,>
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M0V51J4Y/#!011T)'U/8(+ILR7(S[72P1*V2Z&<60M)3>$8$TIB"WLXITM<5
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M]%2P(?H,-^755\%_F5>B\6=#$_O4@T%6X-=N<+$)X[,]F ^*B-2;SUG?%4Q
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M?3-3>)1#X9'RNN3ZWWP 0F[,2JNAVLE#W+0.=F_4>ULIU8Q*M654ZO5W"S$
M9Z]ZXS_1)=ID& ^5<U;8%?X01 <\)3T?#M.(GSY_2>L_Z0<<LTI25O+FPQ\9
MSRQ78A_'4;3T:,M&NYE@@YFO2.?QIUA[Q:C7*DNO_2&\])VA(2PI0;*9)E95
M(O8VZTCS$BCE ,M5H]%LS/I@V@-7M9B246DD.'%U)'R0.,A'S6Y&$F;%)UDW
M6N7J^E"U54[<T<V[F*>BL'R,K1C*W8R]8KZ>S*D;\Q[Z(L_A1*DVZSE6GW\)
M&[3U=KN G:^YV+F87<J0BWLKV_5EB(A?TP=N0,W_7"I^P:=P*M;*1JO:RK6'
MY;EXS8^@:C3+S4*.0+"S#.=L9!?7?I:9S6KN>W>BJT?O Z@%%"9H@"H*P*+H
M-?L9ONR&)I1>?>577WE3?.64CB#KGC ^?_-A1GI$]@@]N3-:;AKUYO+.Z-.N
MO4T=Z=*S<J27XBC(F,0X:D5N$57>M83]\D0N6L5H)(7;1AO '=L. 7"C*G_E
M(95ZXAX]$5D7C.NLXR5F3G=F_'3C_?!Z*7'O7HH?7DWJRN?JB#^0?]?;#4W/
M'[PH3SP]#5&,)[[6CO@"32)YFGJQC!1[G&37E9BXH+981:L^#3;1"$IF> =9
MN:)T-:1UB[$._CL^)5U.=<C7IQ7VT=[P>F*P+_BK,ILN1*]YK*LLM28YI>M"
M3W1=8(X>RXXA00_PA#8,(\#!MC;TRM(?V#K$X]AWUZP?:74MD GS?VC2D[E[
M/_ME.#("*,RFFOF$Y"B;$-58LK2+S1'FT'LV?)P#.<"L E/@X<B2+%Z@'AO)
MY5"J!:9HAYCAL/ J+LI^W?Z5=>].KNA[+9/U2H?3A_BK.4[4Q#8=Q.H)?ZO/
M+T34SDSOE^7XD,%"+XF7XRY]V@AP!6<6KH@>RM02];?0K#=C32@?3/W ,T<P
ML^4?/5[FAO<73YX?*+:$4CO@A@/9PJ0+69\I (V4:DH5E4*L[!J0*9X.G.0I
MQ#=O<D9SG#(I#BMTR/1=@;!8BZWF25N^3P E2CT+H4)F-]"#POBCO=W6E):[
MB.9J;5>EXHIV2<_67&H]?F1=\$8^U,C4J4K8 D4A%*@SXA HJ)5*H59"Z.B1
M8]V'%:%*32KN,=[/A[%'N$B6PRO>L39,@&SJG9%'F)!YBX,,([W)[PQ-;9N.
M]A?(,2]\2[%^:PXY!BK6])E\QG\ 9,NU:3-A)XX@^F0.]W4#*!KB+9J'[8JX
M1RS(G=/#^PQ!(985Y:SS6HMW7C,8<DJB/RH*=\]J 0*<. <M0T9R0T"K*%/S
M.@'88P QD@W!%#Z'TAS12;@AASB\8KPD/NWBU.! D@X?A89<'6$T>G(6\+^J
M\K?U0X??#<#0,/(L1A$9:B\3"H?*=E,]HNSU5+/6@Z"1XJK0F^;15\JQE=$1
MI0GC!0P6O/'R= W9<1E!6)C;1)=HW*0/C4QADR9L=KL=K$/T\A5O;80"1YO5
MS\>GR8EZ>?10^'9A8%L";  A#4/[434ZZ$4@0']A7#!\\0@O:^$$,L8?#!$T
M/MI.K 5-)F5T._(P8'$9R"XJ(=?97EDQ# HH:]OU-P>/9146DSB$!/@*BIU:
M-?28<4 ;M0;J%6U"^-0V(V*FF+HCGI9LC*HUPU9P\:A&29>/2M@UZ^6/KL1:
MG=\MTGCM%H%ND<:+ZA99=[;M?3BRJ!4]0.A#&&)J3@ #%* EJ>\,*'-KZ_FM
MS@7^[GJ(CBT.(UHQ]&3N<)9ZV<C2HK2JEM=:H4VN%9I5$/3FPRZ/E'9\GR33
M84]1#E.M&_5&HK9R0VIYZC6CVDHD_Y^RF">9+$WE?<$'1Q:U#VQLCM_@!'>Y
M;E1?;GJ_7#'JU2)VOUK!E),S8UK_\>F2+U,]CR308)7H"UISCBQDY] N4"^R
MWF1F?G[).,)C!$TB[^A,4SN[<<+90/^C7*U$(;DB$78M$F%7D+T89&NYKD*8
MFBEOFN7Z;\H)?F>9 V<0#_;!H$+,\7(WP9,^$P106,Y5BR2!>6P/PB.SDK X
MQ2P[%RP!83C HGY#)9<NIA'=X5\0X(@H 48M96KBQ)JPB@*(_(!,70$T=FYR
M+3[':A'OR?JP"XQ]@!T@S']ZBD6H_MNC>H^):+KP&\0TC@.)*8'!?P8I<0=5
M"8*I 50+SG"(9ZAF0[,A)+(0)%8^6>RU]R9_[TUNA[1(UW@%+]V\CIC=\#X%
M/DO+*0,I)'K8&CB<;ZNI+=XSWY& RWJ*=5>:1K.5:(3.L^YUK)57&(;7%P\@
M[RN+/5*89E4M$% 2G#C7IVIN:1N->OE9=;>\W>.V]KM(/0MHX.4.,W%STFY+
MN66TJHF8V(RK7?P:J!?76+*K)=-A*W"LV2P3=IG7+&#$R<L_1UD\P=*>+/U_
M@4-*;Y(E96BJSCHG '[]0\F)IQ9Z\'H\!Z96VM&*/"C!2;P5DN:L-"T<FC0$
M>,6I^4M6SIG]/A4F4SF]3,NJ*#=FX46FX97*VJMUJV9[M)LQ7RN^I-N!YS+O
M2.+5EE@M OT5FBSQ .[S+)S@,,3FC6IB @]R/2]_&H1U3Y;O!ZP8?BAP=9#;
M882/?FUZV/C BS3I*\#/I'J6,WVDO%2+EY?2O<CB4O0S_R@IE75R*9/ @R5,
M)4ST+4#K,FQ6G#(F9@&NVYU9-\X0Y8OM[6869U2:2H'Q@SDD@Q'".F,<O?>'
M.JAI\ZF^T@@4J^T_$*3.D(8K7<(35;ED<-"+*FXY=?0#TO,"B!%767C>4&'W
M68$_6DQ8 ?A'N5XR2B7\GS819V>&8AB^"^6ZE=)?&>>+?RW_]8Z5-A]!S;+M
MZ-!@)(MK#N@U-_2CHUW]+7^6^C'Q $/>:(VNC0-;*TNGKV5#8\")8%U=-I_F
M0>4+RA_UL2R$'ED/->;<'CTQ,5) ;-C0@PEK.:R7E*9%*AJOH9H/! H,#.$R
MB_ZTRX18%Z4,$W/0D &""/Z+)IT)I>F$;&$/ C?HV/3S&(4:1=1.KOHJ+E\3
MV7RMB82:R.:+JHE\(G:DX@\D12_P830'M2#-.]$^^5.4\A-O:H+S2+_C8OX#
MJN[9C)*HJ!S3+[.QSU$IH@@.+C<J3(!F"8BW.'U;?(>^A0O!<S(*;"H<A$SU
MA23<UL I-<?H0H(3J,<_BHN37BFSHN3.+*\?C/TI6%P^;Q[F P94*UST>*A+
M_4O:BX9^Y=X0*L<,;7IE1D] SFX!6\Z:8L\%$ZM@G['%P $F%DW/ATILQX5^
MVSZ!7J):*&ZY)RX^*]?(#E6+'^H-_1;U#*+[H_]SL-G:Q(G#,:\#'@:4"+T3
M_ Y*;!SVC /NE*XVWC27X:/@@CV"X\$=5[>M,2@)5XR?08 (62Z?.$2DX,2\
MB[!39(=S;>-M[="1@W@,W1HFU"5C7S+(9F!LR@] CTINBRS"A*-$\QX[W!,D
M!2= &V%S$KUL=!'37/=&F4+-7HPGS^^%V>\3&Z(YS,B/W V\SN)SRD/"KVCA
M11/?(29T<E$%3K ?AYHI:915#G9S%?+%C)9-SJ$I4Y@T8/[PLB6X(&9:P<_E
MNM$H-8Q:I9'Q)6BBFT ?G8-1N7)[N]W^CQ ZX5?B(DB#2>]30'F"+D%&)L![
M$I_-VES@V"#QWUKO='6P.,;/KJ$-#6P_D(_,]&,F(\[9I5?388)!W %/A_%"
MV-=FPH39D2*.0(+Q ><XEP&EQKSSFGN5H<\5RD9<CXM&1B:;RF /1-];&$&%
MG7^N#P>3*<'%D9V8_L#\+2UP-NA*M\9C,K!8+'$"CC2>,G;ZW9)^@/)[#P^;
M'L$.>R4_ 3'+\8$K"(% KHF^(_3TGGGGYU[<,[V=E/Q0U.->6;W8+673LYE(
MA2/)EJI4[&?<8%0.KB]N'C1"4I%MCNCK1V'[MRGQUM(?HZ&"[1&'#"U ;H$Q
M@3<.BRY%5B5F+ (L@PTTA3>Z@3T0+:=4 ,_Y E5@U[#;\&WX+AP59VA4F^)N
MZ2<@7NY:#IO\9D&?,:"GR)M=4^4.KI]-B%;E3)8$@\9^T^X'MM!%,N#49?V\
M6KGZ=O!./)W^,O!86&W_E@_3[?11J9;;53;:F_H%#MI7L./S@"Z^7!UL5>'[
M'D$YL<'\C5W4C@^86,P8A.L^!U,@-*BBYC=*Z$%"E#;KLTQM-%*86<JZ;PF)
MQ# 8](>M?H0]29C>&D\1S4.!8!5\&"A1] ES!Z)+I%=:IZ=AZF^A=HA-NZ7W
M!N\; WW(6)*A*0O/7+"XR7!_AD;TK(1@ &Z;IDY?'%C4UB7,?H2_1R,@H7S0
MPO=O,'ONY:-M+<*(6@8CFLKQ !]6C%J=VD2U+'MHOA&@X@;!TU2G,N'_(&*.
MNH2DY\2R.)*6E$/8^A*\M*WG/)DJX\DY5S1^,E6CTFH9[5JUD).A3V,73,N*
MQ^4XF6@6@YY,N8H+3!R- C" "^1W.WEI^6HV^':<.JE7 8Y2^H:4I4IA+D;S
MR)A9U*&;.-]K76$TLN# >_9K=NG#/!#G WW_=P"=M:?#(=-R7?0(BDX_/.V.
M*6L<4Z^^C#Q1PM:":"+!T3O,KF%F#:&6%;CBL;.(IQ-*\<.*YA)VJ:WE0BYK
M>C\"%#_J^)OCR5_TMF_C:[K?=O0C J?^BR47E*>+!T-;@U25FFK!2?2-/MJE
M+M"/!0OANF?(%BI1!/",B'/IA'Z3S;!G?^6F#QX!,T+B"0)-!:U15QK90F>Z
M17_:XHZ3X"\9(]Q<07/BBN-%'!8?<I$QLRM1;JXER\TCDB;!2BR<*#05)=G8
M<EC>)^,+X+?^'5#+#(0>'Y"ZJ2?,8=Z&PZT=T\;,>_>*4";J>!XX)8@=6&"/
M^^+]["MXVW=H=[K&4"R]RUL]OG$?-VXJ&V>Q6/BL!I:"1WC1%U5?=[IM_0+K
MG%Y4?)@IX1]#&!]VWX%=H,$F1#&5>01#9[X?+ZY(^;M'KHD3$![OX65D&G.-
M4>CP:C;,2=@"O<&0;4C1X<&I[4FP1]@;5(XA#A/=$H-*E,&Q51HKCZ>*E1?,
M2D.V7M.0D(9LO:8AGQ9]1.W2PD]0>\'QH<?OO1Y,Z+7O4VL9E]AA46:!'+L+
MD26HT^JPVE)0EV>4-_M8\@C[**K?:C7;44_\J2#,ED:<.PT\+93DTK3S612H
MWV=F!I#$<2%V"9*7-VAB&A$^X@U0(:%IRW&IJ::!S-4$[!(S)"LO1[:9!@&#
MY2OU-\$<@A?[V]H9/IJ5,J<LRH.>7E -# L7K1M$QOU%M1<]G#'&5QFFKA^,
M694<5QE,N6&=#0%\.U@9S]!!]@.A/4 G26@'T%NHS?"!0INA^>7/>AT<$7L;
MBQ^':RT*)5 SPQN$BU=.F%\<Q/GK$=NB6V '@%:E# S#.?1,WV++IP8D&  \
MVIN]-<NY=NUK'E3'B$DXSMOT 530%_VYJ?2CK^N+V\Z\J^BJ9GQW^P7B WYG
M50!X)A$. WZ41*(\<$6],]?#8P4^]2S0?5AARI,>JO%THS"&"Y4&TDHD:NG
M-D3X V9[H?4&Z>]KJ.Y"MP_6%*Z! ]@JYF&D6(,ZJ"Y<JCX]CY'M]F"=U&IT
MQ^PW',M>5K>$A2MZN(>AV:=[I(Q]"L8>/3IK2#<,&<:07='DM445'&+54]-(
MWI,;M):G/CN9]:RA?82.$Q1029&1X [XG'+0&C]2GON6IYIY8]%1'<-H0Y5<
M3,CXZ4M@U/,%]92/0/!31;K74I'N?2ZT,N<<\$^]**I37_5<A?W=4TYMGY_:
M[+;^52XM#ZS ^ME-YUELB!-S\.IP5D-\?P%>+*T'R:P<KU?V(;"&*7^JUI"
M"5:8[3#Q7/HV,F4P[5EC(X903A09^ "5"P(+Q)_2W\%38^@@!A@[ 4AJ%O7"
MC1@Z&4]L]XY@40FU[M@=U5C^>YKOPB+&-C7!J0G'AQ3YRMJ(&& T>PZ&3Q08
M:1[F5.(G&D]=6MX 48IAH:Q\Q@_?+M_@>B/3L>Y9,$-_J]"G4EJ>/KOGI[[Z
MJ/+RCWIG:)02W)@5I( *[BMB#@2?2O4J]&9HYQ[+.2T3\X[9;V-S0 16MXQ
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M-^8[/9LGA!:F89$$2Q<QA7BI]9I1;356+&:>/DBZMO&JM5I,JF8H*YKA*!Q
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MX]^G&?F>,WWM9CI#KSI(R*H$R9?3.[4B2F3K%:/5?(YYZD?2._EH.4?7U(K
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M9Y]>Y^FM?IY>>+6?8%VO@_-6\*0U.IP%A>9#!^>1U\%YSW5PWE.3;:VO>?K
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M*D[Q+K?'$J- OE#3V:"^3.I3L<<2;TQUUF&$,<%[@QL@7LP>Q)@H;;6NHYG
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M\9%N6'+[(NW1PMF!SZ!]!0%9K@[8Y]%ZP'ZLJ.7!HB.>8NWY6O8V%66K1#+
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M7J,>./F(Q 0''7%FQ(<(=9JR,%N8=#RJ7$MI8+I*\(6>+2$>T'>C6>NV-D7
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M/^6;M>%]ZS5]>VP<79HK\Y^(0%<O=\X*^Y7"SFGV!TZN:+#PI=X#&8*)\I"
M$7'-7\&GHC2@ =3__(02OE](@ ;.5:9U.V!(0_  250?")!I1K_ 4)W05P-M
MA_DS?*,W>74+G60)(3MP)8@$>WVU_6^F840V,-R?,6/(<X$?W$P;$!/8@-WK
MP&)_9GYASI?O9VNA_:3$G](OBB2"?2'NAW;OY%X6=('$*B) !--FJF;7[6TB
MO&&]$[BN-G\RS,RQ>\3)H7TI.ZK3-JF']C,[]EVT9LEUWQ!8SS[D+][?)RY0
MMV=U35OUP-WT1 0@K<[%B9X"<=T:K+(VY5^VZ"X;,]:3WTK!40BD8A$PM\+
M]WPZ;&KL2NIJ0P87F]8-L7V_8=D"Y/K(Z[?XJU<4#UM2Q&1Y8T/PP$=+HU.<
M[&&2L^.RA7!]>L%W:U0(Y3GAO7$X>^RDX5;;13&6Z8R]\"7CJV?/9M+I3*WF
M5;8KBEO7?AI<&3CRD4P7D-QI=>Z)+/U'[%O<=V_GTNF8-?)'Y_N^VOAKMJ],
M/I7.%5/%?&Y<A7P,\A#-!3WNN546/N3<4@Y9<@\YN^F'+-%#QN...F)IL2/.
MI:1B)E4LC6V"\,N?=/!?4E%ZFJ>N?;I3AHJ6U:O-9=O$N70N;!/ORYJ%N2;?
MC,\CG+W5\3IBA2SCO(_]8WV_-BP_Z<?[Z=.WMM9<F8&<J0TSY?>=P^=LKG.7
M__&/YU+Z%O@5K&((2==-\\5K@A2%E GVRF#D2>$T'LUVV,"31D0SLJF-QUV$
M1E<>T"I@,'I&"T[]K9B80'K]F(3I_9@PC^E;_+9X:U!8#QB ;V!A&D1ITN$;
MFAV5,( AC0@*X*'ZT"@0]1W,0P5"%K9O0 ,VZ5-M)\7:KC1PB <#XS$\/OD/
MHDZ8?6>KT13_-*JF,*)J3(OX%<8NH]"-KY5AQ5#P1]:H9K)C[C>QYGYF;=BK
M[/?*W0RY[%8W0:)<&]Y=WE<Z+_GV44\F*HDN7^3K%WTK_BJ:J=DS&FR4CB<\
M(W-XX,?;:U$Q=5VVMH4STZ!-031BL4.2#2;>8L]+V@FHR0CK/A&L)H<1%S]$
M)-A]'M:%JWQ"I87IMJZE@O.,<!N'H3(162 BL@ [ =*1MJ:QU0DN)_2RB0]W
M<WEL9@#V4N)Y4NPY8-9UZ(^$=HO;6D7<#^U0\-. I4KG6 X?<>4)$NX45*D+
MF&QA$S&R,M8CR:_:!/?;?!XH^LJH"6D;!U]&ER'=.%",0H4UWS UP@D-LL$-
M!CG%20='2(#@]=6-[(P[KHGM""0)6M*ZY0!!(?HL%\U(G/=:Q4815[RS U7]
MDR^5M'] 5)SOUX:M/>4Y\Y9SCJ_5A>=#17>I/JI;V>;S4WM8+$'6H-7AC00.
M5(!'=HF8B.XJD[\O5GT;7+@S^&R5M_JP5'>DG$S#GD35\F$_AH!Y8^PGA3XQ
M51PV'4^$TZV)YL'Z >IN@CKSUT3@EU1O, X+AT*'H:9O)*#BSF^77R ,:KF_
MV:)S88269?:Z*=J"I$&CL6WS#0$Z.H#R$&GB#B@TZ"V%X!36>0371VZ7(("D
MKZEOMG\^(?==J>E*_^3BHXG7"IV2S# 9^5QW+32 %9N'NI/)#1-F*CHXQ%[S
MX6I],YJ@._KY]<HGMB];@V32 7 = L%I<<)DG2%YX+KQWX%Y(;L5Y:7<?DPG
M#S 9ISSV:D/YK:1E'^3TVWGQQS^XOL]=F$FWR$T*Q&!3X+W"#3A?<U]J8 I8
M*A $Q+OH=O!1==UKB=D/0-4]8#JT?K.;&MADK(3 17^CK]?RR@>\!FHR&Y>%
M>H#BO 5>,<-[GTT>]^6!>]%.HO&NT5Y7/BKP&=?^-+NOO7]@R)) >S!UB&5(
MB&/#YC$"'C35\,T8#I<M XCF#+H :=,'?H@:M3JG[(8.X6;&[6?1*U+8,J$"
M>"._3U8L_B:WX[Y2&SZ8^OE](7=]E%W*T*E(O;);&_9?3^_;5V?'U[N9'Z$:
MKJ_AL/++N6G2/MX,4$GKE6U>ZX95;BB@@CONT'7S I/A!CR-"29-L#R):3,'
MR LN&"^/&?^05-08/\RF!@)MENK7#.XL=8ICQ?ITLA6&D0/OV+&T>L_AF62B
M,J!ALC48.^(M<H (;\8N^*8J8@\K=+(GCLS3+'^!'2P01PMNB]7HW8KAW78P
M;PR=--'B4@WL+2?P"E.;%2ZPXHANEU7V!*L'F?8;J#).RG;U+U2+1-.$]\C@
M3ZZ[B&/J#)/U0D4&UWCCL#U2;5@9/AQKCWJU("T#HC][!Z!]Z(]S?GI5.LA6
M[I?1E&@!$&PI/0X$2_27O/?GJM/^LY,=Z%\.!)M)SXF"+=:&A1WU\;;4.S^[
M+6P0"K92&QZWC@8-PY(JS\L8XC*[Y.P0'KRH9-+%L\;E4R1V?M.QIH7:4!F<
MOC^<'9"'Y]9DAZOHG55^?SEN-';[;_?Y-=GU5*QI9AZL*7$O+V\O3@Y[<KU>
M6H97N]+N63,9=5XAD1 RUKQN6UA$&K3= FV#H+,3>DG^XG!BB>!@"A;G'V]&
M^=S5#M&[Q+![@6:?V)\#<I2T5HD^R2W;MLEF:1U0KXN-RF7,%?B"7OZF#XB'
MNX9T:G!9U$OCJ\>6O\0]QEO$T0>":V110 6=QV [OFI1M-QH*W4:_R:;:)%+
MQ$'#EFP@G_Y+9!LB'Z^K0%PW\8!+=TNWJ.U$*]EH+W3<A.!VKJ  0SR>'AL?
M0VRMEIL!=XG$?7WBJZI]F0^BWA8K7IVU-[/<;<OJ-?#U6OZX@45?Q)&V%!H=
M8H5Q>S["^BW4HYD-YX$7P(\0YPL=!<NT\\;T*7?8GL^P#WQ%"'\%NX$ Q\B0
M9"$[P3,EBDGK8BR!MMHU>PXP,BN79@7;F+,.Q%1YG5F*=H%P.XV(ADI-7QHS
MH.$!059 ^EB ('JY(SM$(;)5]T$B?0AO-C^@,1G9;: L:H3B@ "=&/<0@L.E
MH^,>W[#)J8K3I\HX&@*)V26NEHYN&(L$P17,A]-X.M)-6;+3<I]!/Y)"<+-.
M&"PUO01\7%!K]' %/%P8!(!8E.B%DS=BJ_ 4#U*YI>I1&)8H;@MDCC]-V%S*
MC"3> *"W \IPUS<58]^TFJH&D84IP Y_Q<6LCZH-GQX=9??HL'C;6UDTK%0;
M#H<E)6T;U]*U1HPMWUP0_[*_6F0LT)('@^@^PO#1#W@=R6_$EO(W?O'%Z&E
M:\-S_\&<PSA:!'JI"GPJA6:Y8Q!ZV-;#]LTIH- 0/K_"C3'Y4HD\2@^'0%O5
MH,UCN1U=*>W]X:D^8MBH@H7.?[AH=P8+6S1;1XJUCH/Q:1";,RG"ENA'J-'
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MD.1S\%MO8",%S\&3:(TWP[&V0 X1[H!T-[L,&<P&40(<&N"O^$<9[#VL1HD
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MF/!E26%$FT.R"3_7LSD>@5X&UXVVJ4,&F3X24#?P@8ZIJ#J3*?8<FB*&/XY
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M6Q7.[>C[^VOGT(O_;9Q;*)RONRUJHOO*'M US'E6&@Q,;W%V*>:2<2^\W-G
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M&)38B>.36 </D633J/P$ G>?'+5WPM H\.G@WA=AU'-!C<,5@C",KV(N(HB
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MTKT;3C.$?%=N'(UM*M&H Q#&8(-M6CV7Y#B%GM8@ &T'[9)!:,K&.#$9:=T
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MQE8(6/P@+P7UL C\'B83@.I[4KXH/V?(V>+^IN_NG6B%I ,<$OH?;&6 Y<@
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M;L;ZULVX1DQV4D:7G?L1V&R'3-46F:I'Y#9%+=HP-%$<;=X;*'9B<%90=T0
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MX^_[C$US2G$]!F$2.W)_)$O 9:I!/VL8T(W>#),!DB .RYT*!-1C#3.4HB@
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MZY7LIM$(FFNY;\KVGYSPQL4U^\Y7(?V141O4=,RVMD)Q"T!"$1U]>(YMZG%
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M7]ESB;XV]7U]</0LK(RYOVP&C%ETG6A\F<C7\HS-,=+SUZ5X,RO#9SBY*2X
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M<=Q\D7V<L.5\)9^TM$HZNHUA:IO,AE_-PS'R8D\4A\!',6B:Z2Z2AT).I#S
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MQN:LO6?#A$?ZBJQ6=MTBSF:L9AM/N67%6QS>[-5L(RLWA@L_#CP<E.I;Q-V
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MA(&T'4AH20#(/48EOZ,!%2F3_'L<S7G-">-W"/Y(.ET?70<HW[DHG='\Z 6
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M53F=;LP3S5C T=.M!NMCX4MIT,LN&I@OFB]VZI67R';Q_-TV2YU9JQ8AG+E
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MU$^][]C*8XQ(T\JA=MAL3C6: &Z F$5L*H]$''O<^4Z"AWS#]64"^DO>J),
M37-(T(0I6P)4C7E@8A-:$$[HSI:B("*?BWYMN@<WMM'-  ?O=/JNCS5O0M&Q
MX(@U*2BA!3DE#/AX1WCB%CT1=$58ZR7P([?E>JB7(0B1L]B-8R&8 N0,7G0A
MK4P#,W-&FPOU6#%L$V_U%JU@"'+\%OR*W1)C-"<YGL+/KN.&>!1?16S?H9B
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MG4<GZ@6#O@)9B;WX]:'"BE ]!7O24XXLO'@JY_P$*R6NHR*#.KXB@W/ZJHU
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MLK8/Q&7\YG"9!9H^3N( ES&*9<E_^\H (^4+H/+^WJ*OHG+%-%9K1 I2OWY
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M2424?:+YAB;2H *3F+JH#55;<H>'1+<J*T8C+ H:+G93&ZC(91GUXWO$9MC
M)IID SLULCDSEE]6;V72O52#0&-NW#@<B??Q87_O=V+EU8UZ!\M3$F))1D;(
M_^H6ZA^Y.99DU@$_A89D1Z2EW:KQ6A%'!HP$599K?)%/=*[ X&"L#'^%#I_$
M+E<)N(V^FX+!4@N1M:QZ\1?X;\H+[ZG%HX<V"\"L$ )TZE51;I..5SR831%,
MZAV1G+ D0T%.G)H22%'0>]"@K$-RK^WQH[Q+H'KHI8X<Z<D%K9D"2Q."VW;A
M9AE8NLB=6=@+G4:+]1%O'Z\?BG%>?59*D\T@_>;Y <^@G$A]UAF#GX:NP1'4
MZ :N4'KHBER:^S':K0NH_8GTYH;4/:;,8Y"Z+E)LM9@UFWKK.@5BH?WVUI5V
M/X7^9*,PL8E8;N'NCF)^TMF"66C,] _I!A0)<IA/\)!)QR# T%"O,71I3E8X
M?"PJ\R\/=^-H_J&-0T.==S=Z&YC>FD>D=9*U6T)AD2AO9RUS!AF8!'QQ.;/
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MB?5B([599XYE]P/EKK]&NWF'C'#IMGO>2QP\R=R6L86AO!)VJ[NM^']6'IV
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MWX96U_*@KE5JNMHU#B&.J'+L\6W;G'6J^D#?,]LNZ8 P241&M3>V7=/V8#P
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M'0]W)+^]JD_>)+1_N4@\9U%XSDUXK'D'IZ2FBUV^Z:4+X2]02P,$%     @
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MM18#:1+-T1.GB\YQN%DM@-/DWJRX>X#G^\+SEP,\R9/>PDK^69LOJ;K"'N(
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M3N?[?-?I+>\R[6GN:371BV;NS3-Z0>T/4$L#!!0    ( ,^#EUE>AF\/, 8
M ((;   0    938R,3E?97@S,BTQ+FAT;=59ZV_:2!#_CL3_,,?IHD0RKZ2M
M&J!(YI$&'0T(W%/[<;'7>._,KKM>AW!__<WX02#)]?J M!=%@/<Q\YO9V7FY
M<^V\&W?+I<[UT![@-]!?QQDYXV&W4\^^<;:>3W=ZD\%'F#L?Q\,W%5])TX)F
M(S+@B!6/X8:O8:963%K9@ 5SKH5?P8VX=5KL6S&]%+(%C0JRF&:3OU2K<"5X
MZ+5@EH2\.F5+#M5JMS,8_;&_KVI4A%S/(].&?&2AC%&K%ES0V%IX)B!8C=\J
M>]L);C46?W.<I(4+I3VN,W*]D+E_ =*$6(7"VTX6E+/Y9C%?Z9[(11RU.W6D
MW\T_=T2H[\GPK](71*8/EAA^9ZHL%$M<IL4RV$J:Z:S7'7ZX'O5&#ER<UYJ=
M>J_[F,07</G2X]MAWH9=:"Z7ANL44'\X<T97H[[MC"8W,'T_F[^W;QQP)D^C
M.R3KYFMX7YO7^C68#_LI^^;%R\;Q^=ISL >3J3,</*^\A927C5<PN0+G>@AS
M>]:S;X;SZN3#>/@1[+Y#,^>-QOGQX136=10^?R:Q$?ZFTAU)<)64W#5"2;SB
M)@ 3<+"E3%@(,QXI;4#Y.,!N^1V,A<_+I;DKN'21;5_IJ :GM.,D]#XEJMU7
MJXC)S8E.G\X B5XIO4*LU=_!5SJE[HO81>H;SC1PZ0FY1+B1X:L%UW#1L%##
MYR^ Q;@PY-X]JCEW$RV,0,Y,>N72\,X-F$1?@%Q7(HY)!/RGI1XS' *N.6+?
MQ9=)5,"S@#,W(/EH22+1,\6H'^Y9(#(Z+HN8NV6Y1UT@<A=_() %#]7:2ODM
M-GB(FI1K093H.&'2@%&P<YMR9=-MLDA*YBD4WMM;7BPB8\SAS9E>,,GCZN0N
MY!NPW?1@R!@MG&>F7,)]M'#!XW0J$#&@QA$5_"75&E6YY*UC&M,#A^C8O?$0
M^L/Q>#ZU^Z.;MV\JC4KZ/+4'@^(Y1[$776CSK)BY)76BO13L,*YD*P9?+T'.
MY25%L*L).I;=$.:SE0@WK?^BL1OND&6E>]H\Z]2)&@7VP3ZTG.'E83DZ>,KY
MW?23,$23PVL7DI%N[XKFGQ*A^0H=2DS&<&]UI^R,S*+Y\M0[V]K6_<W:7JK<
MP)J7%R_:9/RYC' X,0I[N=<=?LR.=?KW_(I#VATX+N<#&MOY8V,[L&4)B8YZ
MQ5)SP>!@F$"/6#C$PNR8T&AWD>8Q65CJ+UD8HHO ^"70N>-$A"876[G'ETRZ
M-(X$/9&2)G^*JY(P,U 5<9WRC NCS&-)[3D-KYXZK>_WD =SAMN,V55AR*(8
M92A^?;6?++Q?XZ#.:(!'WH(!=[/X?7Z1Q>]RZ;&6GP'-]_F4HP(Y/H=O<6*?
M+\@RML_MY#JC;CVN0S_0(D;$E,&\P_PNQ$RQ4Q]U?WZE_@BE/:4M"Z;!X.=5
MUT&E%]S'Y 43&2-N.4Q\7V BC@K &",\#%*TU]7<,+V!TZD6&(\B%E(5\6#/
M6:>72H"&EOX@4YQCM-(,>HI++%Z"DU\OV\]JB<<*?O_C;.YPR!\<K@7]J8T?
M;^V?]^;\2'5M[PY<;=.Z[75S-&=QHKFFN[-SSW;64N)GNZY*I*'2?WOK?HBR
MCY;P':&^IN0<4W.^5*2WK,U +0C*IK'67W :]A.-5AQ@QHX!G(>;M"W 7#=+
MIG=S^*?;$R<QINWMHCN!1X64I3(%];0C0XT<W!VIF.\7EZ\_4U"62SL59=;X
MP.K4HV;+#AO$LJ 2Q%5(7E-[!18;K!-\KJGGA#,D#@J"2 C0?JU@P3K@AB+@
MBGG4"2%U4;7+?*Q+MKV;<BEK#5E(>,FT%_(XE8/H+KG$0B3<@4"2A2A!0FUG
MK'/BQ UR]C6P(>L8(1.!AX<;4T0HS1KE-QR7&^1(=7A1DZ<2Y2HKERX;KRQ"
MJ%+8GG*3="U+\%F:]'@ICF-6EO=PTL=BPUK$/&L@D3)(/H+##-[ M"D$+(HX
MTW%:OFVB[.Q6:9L@+^AXB$BTDL(MEVZI_T5-M*\1 5() D8&B&LCK6XQWGJ0
M=Z/RDTG/>"VP1%Q0<R(O*A>;1VNV]KOM9^VW_>#)KI\&@64DXO1]2"(<(: \
M-K5G['<=@<,WO\:Y..9;G.]Y2W,L[9,KIW=HV4LU>O?V#U!+ P04    " #/
M@Y=9P *M*O9L P#$= 0 #0   &EM86=E7S P,2YJ<&?LO'E8$]G6+EZ(BHH:
M41"5(:V@."$-,CB$E+8B(&K$"65**RHB(B(B 4+*&00A @H"0E1$M!$0&45,
M9(PT*#+/A"3(/%080D$JE5O8?<[WG>'>[G.^>__X_9Y34,\#2>V]AKW6N]ZU
M-T'6*.L %NW=8[D'D).3 W[&OP 9'UAE1G,Y"P#[]P/K 0"8@[^W&)#'?Y+#
MO[Y?LA9@%S!#3F[Z^_=+?I;\]#5[YDSY60JS%12F[SES%>?.F3-OCH+"O 7S
MYBG.QR^%N0L)"^8OG/YY>I+IX=.C\._Y<Q3FS/^7+]E'0&F._$$%3%YN%3!#
M24Y>24Y6#!!Q76?)?;^ WR^Y&?(S9\W&59JGB#^0M0A77UY^!J[LK)DS\7?]
M\?>!F4JS%J_4WSE[B?5)A54>R@;7PY[.T?HIO4#E4!6LO?G4Y1MSYRU57;9\
MQ>HU.FO7K3<T,C;9LG7;KMUF>\PM+/<>/G+TF,WQ$[9.I\^<=3[G<M[SBM=5
M;YJ/[\U;M^\$!-X-"H]X\# RZE%TS+.$YXDODEZ^^N5M1F96=D[NN[S"HN*2
M4NZGLE^K:VKKZAL:FYKY F'GMZ[NGMX^T<CHV+AX IF<FK9+#I"7^\OU3^U2
MPNV:@:_!3(5IN^1F>$\_H#1SUDK]V8MW6BN<]%BRRN#Z'.6?PIZF%\S5VGP(
M5CEUN6K>4FU#_FK1M&G?+?MSAMWXMRS[JV'_95<S,%]>#E\\>24 !*3HLZ"U
MP/^%6QYT9+LJ$K<J5)P.49!.!'U]S5*1 9\(6+NN#!B[X)6R8Y:R]7_N_Z_=
M]  9,$M'FD#R?(I4\ED%G-N^M]E,865P5(.^#+BP-]Y=;'0[WR?^"'&T)E<<
MNG=JA*TL VX\;;=G?)$!6>8?.<T+73>4#\]%%@Z-[A9IV99TE26UM)=\,_=@
M2EQTA&^@\KT Y2X([^?<Y<U!-72"L,6H-\)-H9M7.4EVVT)WO9#AS$JE3S_2
MWVE%E >!FT%N6%@#F)]&1Z02RSXP(VG [#5]K^ALK.LS),H<1KUM5ESPG/Q:
M\HOELM#MT&;,5J?YM,6HO=Z@!FZ)/6(.)W283021=(5Z<VDUQ:H'EV4N4-M?
MZ_3N'2<_(K#:0D ^9=[EY*-UC5"=3Q0/-^1[2MQI 1TZ'WUTQV2  JVHN!Z"
MXQ V<<-@_=3,8Z(R,:V3,NDBJ=+V(Z"9(SWRWMC<$R)S@7DA+\2754B\Y[A&
MI'#7J'(IS8DBZ@Y('4\NN[CI6>CQ!-7($Q%AWSXQ.F1 _&4;@L2-T<!2!L\R
MD?7[)P(-[3Y#MHA'!V]![Q0SB&08==G23<KRT&OJ?!?*DQX/W^JXN<M+!F0S
MSN@,ML#>PH"!DC1$01PH<BYV( JT68I&M,5]O -PJ^^^FY1W]\T]HBS)].YR
MKI2T8CSM3D8/I"H#.MXXDL_8[7<MBE^'[#S;D><31K6UM[<;&P^UX"4";C*@
M8 _;U,$*?B_V%YE?HUN_:NDEZR,L/L)N>MZWN&4!A?(N2$!9AW+&P\HDG+8R
M>Y-29D#\&ND+3L=K; WBRUE*UJ6I%<50BB3^5]>2U@DLK_1\YC8[!0_]S*W>
M.YDF#H$#@D G0BBD* .<)8U#7GIW1NG'JU#G#M.]/J3*MTUWSX0*RK$F2P\B
M=D\&1#X<*WTEBBH$Y7'=<S4-ZNA. BH!L:&\0ZCN;@OJDWU4'AAP6MP>KYF<
M4XZ&JT.V0(#@+$NDA<UU%VWXR%@5)4@*8:RCKQ.Y!_X =W%."OH+_/T3RSR*
M;?3MO480J"VL=B';>4BZP08)%FR $%WC:/ZY_)TI4.%FD\+*P76&[MGE8F(6
MY&));"978FD5(\@H.$\D Y"UT""1#R)K%8+(*^@+D:.O3R MA^OR;5Q>]WLW
M6TB.1H8DV?G$GWYK64$?KI1FC(=O&PMQP@XW/(>:B.#4Y<AKI "QFC0:/2&Y
MT$-4RM^?0H>D3TB@1P(R?*3JPJ A=9FERKUC(I]#YI)WI,K)7L</DHUT*R1$
M8L)HB6)ER(!BRE)'=%>UEYL\MEAO#BU(ZF0G4K[L<]G.7JDBW%\&M$,UX)1+
M(#J*S;64V*";$16X4I =):00$:O"J<<\9:/RXHS:<8O!U#/!2V5 _D@GV1G-
M@,I'+MZ6_'0.S.2ARDDV2-.S_:LK"RE-D@+5R(;XE2.=H?530Q;?PBT&94!W
MTM!S'._]T4\],Z)099ZPL@1<QJB:ZF+!4<7-]<&N$A+M%+B,%K;QXO,@WI'<
M\*YF2KJ]N3HKGSE@7:X3I2,U3$LQ&EQ"D;*A,]""/D<-450(23$)^45Q__D%
MN)*L1J\M['VQD*%\GS57HB+B#*R6&-!I2#E<5$)<:LBY&Z\!'Z9[UVXR2CF\
MEPT_\,T/MXM>';JE(MP22RZ'VK@R@-29MA<'IZW]MCD?-9P%-@,-@N2>8:.T
MV[[1^=4Z^I/4BS6;(+^N55<U3\<[2_._*CQ"O,4'1<>R<.18+=(IR)$^XYSK
M0;<F(,;@$N[5^"T1@]6MEI[*#"I%K[R8-?IKGGN+'S\GD+R0)A2?1*R<1<G"
MI=$)R$V;^L%Q=R5.T+> 8VRF5-."7>4I W1)G,WES(I>Q[L=6C) 32CB2L/]
M(*EN=JH.IDA\2@.+69EI ^^=1,O'&O.7>"7W*_4-OW3PCVGX-#+ J;=\T#3Y
M5<$U 2H@C<7Z.]:42U^#YX*YHX=/$T0+M])Y4\Y8*KLF[09]'>PGEH/U@JZT
MN5O4LQ<U]N69=GIGV\B7.OW8:JX7K?ZXU6D5Q7'#\)87)^X;2&MV$/Y,L=<I
M@4;P-,P)AJ1J&J['S(,YG7B5H.^4 0E.*;[ VF=!?[TWC$X(S8LJES!JJ/ Q
M: G=E!I,7)J_@/]9AR]EOU?65!9IYUTY*QS4+YGXT:EW->.Z33>Q9+CIYDYI
M,M21I;G^*\GL%2UX?V8ZXN'VLF1-R"]63EZ<07US["W84?Q SKOX:OPV?%%]
ML6;>+/KV)/1G$;>8HX@>X43LK<T$EYTG-GO7!TPX#>J7%2@Q-\N E3*@?&^%
M-!:;T<_+-N<.-R_>[RUD<IF*MHBY0 .+2'3!EHON11J_:;FK7>QH'_9)09J1
M]@)T=D?6@(74IF3!!EJ11?6XFUV)=<FWG;_TYSV.>5CWFA$6#=9A*B/4@009
M,!-!K"1G&%^)F5U/182BQ>>G4J-$>D<S,M\S#^?F1-:;A.^[IA5Q4@9<OSGV
M9.%H!_$>2I'@JA7L'V/>](5*TE3H]C 41#(E)[XT%RPP,[(;5FPU[UJ&EL?/
M&27E^S@3^\'^N$M@>E)!B+GX?182+2 L9513U>DZWL\0&7"DZO5K0XZF:4CF
M,8_ 3N;$91_6:#6^-A?ZG^">\J;936?!1:PY?B4R2^"F:FF)VKX][SA?]"33
M(C6K!1QG.<4?&#'_5B8#W/#(?!'6$(D5<^9"9ZB:MO3C>4B;%XSQ2M+I%O5:
M.5B+2$]\IK)1!GA]PX8'E;#ABM&U\D-ZUUES#*'&[@)LJ^@T;QEY#?U@]>NQ
MRAQ'J) BH X^KUG<O%7[?D%-N8\"%JS2 ;X=_D@)9,&'9, =-Y&3 "QQOZLY
MMQJU]KB$+8,;;AJQ!EK\-WW92LKMC)KP":>V=8^"(S7ES'HV 5TNC:>;P]L%
MK"+H6C/W!KM*Z#9#T'+DIEG#[,1O/MG5=N;:K/R(<FZTHP^^,F^DN>@2N$%\
MKH:A@NX1+8V )W!@F'^:958[QEO4SDWRN:L>/GEYS\A];<V#&@3XX*PQ.(>;
MUI0@]I,^S20LI278BFQNHT8=G\T/PN:A+]@6XYE0NM7*(*HN6FFPSF<Q#'EQ
M9\WPJT27<(OS D+ D\.W\UZDOZ2>;X[#C1O<I*>GEZHI$'3M(AJ0F.7=J:[=
ME8%X(EW BSFAD-<<; 6G1KCZP4D%F%R=FUO^D9F/ZKSDSVQ"\+"*O+Q'(;H&
MBY8!E0>VN2,Z28,YL/M'5CJA\#/1'GG5H;'!ICK?Q-G-V]E'H'ANR.WY"-89
M-OE [JFH2* :>(6%;*@LH,YOZ6^NXP1XN<\_'V62=\2[VMS):Z-'J\]E$GC9
M4B'-^GHOU:A(<H4F$9_'@R0&/52+4EXC-X\@6@IW=='-R;J?.Z.68LJ1 CV#
MYJZU,N#;8^A]!%X)![&,\K0+R"N!&U@*P<=E0%/WT6KW%"\-DR/P@20/5R\W
MG5B-BLMF'JLLPA=JDB#]$U"&:N$">>'PH)'D @YVD3,D9J*E[Q(;VU;^X&P\
M032 :G8+**EKY;^"KLS YJZ;. C/DCZ\$J?J6+<Q4T_9GG;K_-+LO%OIC7U5
M7&?WC8X7/+ ABIXVM\M[3>YPT[ XL8ZQ##T@S2"9">)<[1L,P3LQC[VW,:*]
M7I+"FLTULBI8SCFC6Y@53<1LB[18-J&=UL^GH,I<L0^B(13'3/7S%V"Y,9I9
M*X7'JX8W<K[*@&%>4R?S-P39-LZ\S5.XR#FGIXSQVA5K8L!!O47GPUI.3+)&
M16+7""*V>^X.-4Z&^T"("*>1B,D+]""2*$H6!-P>UUMF+DUX=HX]OQYZ>Z5M
MQ1<*,E'!H ZO'IG4GFIXCQ5B2Y$J.+6[5%,)2? !@S--%XH4;I-L2#WN6<$F
M9?HX$BPG?<(H[18&!S!:&D[#;[A#!;O)*UH8OY)5X:A[^78)--52*L'P$[K]
M=2]9.Y^Y_]WU@6=*[E*^IO.0<%?8P18<:XZEDBSA"&%#L=MFLQS*'7"A4VAE
M8<Q _&EW@>E/NY4F&?:LD0K[?%JOY)W3EB>$Y=)7'-?ANXL8#9H_(CE\SB+7
M?ACJT+N;R9S7'V.4V'J#>\)RWZN7%C@=2@X_GAB^108,/C\Z9H(NW2SH2N_@
M- ;5%),51<9IS^P=7:>H8:_.Y0R[:;^QTJ$8@)/./W"['9=+\#$%!MB6/B@=
M1%?IB5R+\C9=%ZWY/.[F;9X'T[VCB.<^A&A2#+HK1N>S/+MQ9#J5'ROP+GW/
M4X$*-%)1><$K$F<9JB2J"[@U'MA.&?=HL2\3^X#]K"ABE RXV'4-='J91DR7
M<MBS^U3KQ=D<5?:*5GL'RV_FR@SM# ,+&3 Q\N'&M7EKG_WA#6XE:]!51>:#
M$9(K6%6>8Z(H21AP<XPSHV_JBJTCBP^I6#JY*7N6K//X%K8&K),!LS<D(DH"
M@B;C$P\^K*'3D=)0S%.A'X:=[Y$V355 <#A%W';XI]S@"LG$LK)0RD9A*+UR
MRMF>6.#>F%;(R>*@RIO%21'%,3GW,BL'-#SWXBRMT;8XQCVVJZ7U+JE23^H\
ME2>1%_^,1X,_74]Z?[S-R@9F,/$F8>[L=&*8]^OS-N&./,HR[A!:1J#</ZAP
M%W<V$3JO1EF$<2]]%E8&1DZP5V$MM5KAE$6NV)GA!ZLUJ2C=LLN'UAM3BQ!%
M;(F @*KT"\X&.PGZVSP+\J ;&X=>7] =!S-=[K=&ZQ:'[[E><>H Y0=O(X$,
M@"V(C6H=$X,*$B)7H+>"#E:1=J9:I?4M'7%HFXQW"=T*>>,,:"U\-.<:SN;C
M>; UIUG^T-<K=D0"XEP(*@Z.6[QVPXY_BZC()A_OOZD=;PNU[ 4"Q!/2%Y@.
M#ZMK-Q39%/E#MCDP9:#<_;FE8,&:4O&1+)'ZA(GFF>)#>UCO(\H#YU1&8Z]+
M=/U?27:@/NPJZ!2T!+6 YVE<',643AA)YSQ?0]EBFAZYCL01=@0T\9:E!7&<
MF(V'A1PF>&;!X:/4($P#;F-Q=^>*UG!>.")DT[VN:8-S9$"H=P28S^SFHAFC
M&[QQXOZ<[BDQPDI!/)RXS]+ND;49GYOO18JG7'W"9,!YE\L'3H?NQN'[T0CV
MU6DZ:M<#I=(X\AS.H(L$/($4X<N;5++@L)#\ZKEBTP4WU$'=>)L_5OEC4UF2
M#'@=VFHIX115I,:*,>2FZ&81!%/2;A'A1_W-#47#=U<TA!I^5BNV8:C5DTL,
MN#HM6@9S=3M'9(#/"G.=*+Q'$69YQNO#W0-$R0FZMKO&^17<&YAF?\-2R"W>
M3>_(B@/I+UJA\GTGF./A/H\]ETP^&G9T$A658*NF"\[,2XB6G^C D'BJ?53@
M\)AXL8Y:GL>N!FL20NV8KZ&1&LPGL/,)X1>0W[X-E&I,#"Z7 0&K0,R$ZD#;
MOD,&W-I5F.<8V1#5_+8W.\Q.FBVF&'?U//-A7&"BE\%#?EUL-;PD>DY3$AGP
ME<(G8*H&T(B#?V4'3ZF7\2-<RGIUSCLR)C3"WTVC)+'N]3-7OT -@]#0+5=^
M@#UW$!6A@E.<<VDA[0N1DT(WD"^^^8IF7L!>GI')LA.5MTOC!3VMENH>+2X"
ML'V^Y2J?\(7M/TO;%:(G3(IBH_+AV0&D+R.6:UCR^2%X)&Y>!DI])WF8XE$9
ML/83@CO>44R<\LA*>\I> 95M@X>E-_ F9^S0086=9LH'Y?[5FQHC S)L!F2
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M9( SY<7[?*I;U>E<;K/3\-L?3T=@[^;TX?Q5GE$(+</F4^D_5=$M^: \<G.
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M[8?\>/MT[<B)=#2@(0;HXKCJ-1:5R("WQ &)@!K8KB)]P=ZZP*G0V.V5N;N
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M5N3<)7$,'%2MF(R):U=&G^N7W9,!E61]E@'91.@^H"32$GLA;J_H.Q ;T:A
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M;JFGT=1*OEZ+>\=$*+K?.:&'JIPO__K\U.-XAY3;28&ZB7EY]Z&9'@%EX%X
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M,0GW\2_C+P6+N%FN4?\01T3X[6D9\-2I&/]E+E$&J#]9^$O0-XA_IGQZ28+
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ME%F5[NO3#Q6VJY?>7/6.\@^"@C&UY +>:.]?[:[ [;XF [[+=<Z">(80STC
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M[D-\<>)/G;*:MS8U[0"R3J!KP[_=<&]EIKQ91JPK:_/$<]])2%S-T2TZV=>
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M]>'RQP]&*_*>Y:]7-U5II>T2^XB(P>AVI]=[LHUMKR9>A7<:M7&CNBXP*WS
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MB9?P%6PS%>(5M*?DL 7X@[%DR\E]QHY%F9LCGTJRZDHH4PC.,J-M"2K77.9
M.'PIP>\+@8_V^H'#6=3]TL&A6UE$5K _/D16J0@Y3U*5+=VR?>:R>XOM;XPO
M"W!9>#EC3U-=QBN6(\FCG0B%9,#K&LWJQHX?OCAT8([XR)E0GMD]PU?2X0[D
MK6R_.^]U %P5'G15DD*VTDY-2SLZ1B#E3_#,BRF-/W]D-QBC?=R97..Q9KHS
M-*\3>\7^K-W=2^MJ#[0R!JT"?%6_'B:G'8:$[\*BREKZ/;Q<#\>YQ/[ZEFQ%
M7ML5=FV'[NS-T(V5<0ZZ;M"^GPSCPD;)4Y!J!EXFN6(9'*N?3O(Y/10]TO:8
M3E(55D L::(;M$<!##K;*(EM/:$H#7-ACH&(_-;VYPMW_$[$GKDGS4@C/Z]C
M%Y^Q-7'>)?#>]3U>L$_R7+\^J.'8Y= ^^X2PN.PW#[W#XL+05V$U/5'/&&44
M>;"WO@83UJ_!.%M9C/HQYRFK5'I@Y5<:6=W/4>,+.%^>]%**:;X:S))M;#%X
MDUP.;]5@XA^#[WCK7"DHM)<< OW&U'=XA]CSO=Q;5QD.QR0BL]O63EDXWR5N
MZ8T@/NO4TD3IMHG7/$>@(P/E^!74EFQ%#N3UH$0DB>T8OM+E'!RP]T12?)+_
M5; ..'=DQ%GN$V.C%KH?Y7S%"@0UPCD04,I[G?Z.=QZ8S]454W7[*',&@Z?;
MXF;YK2LL#[%;5QO*]LL>L10G?F*.!U8:L\=J><XH$7L-ZI_E70>E3HF=U4O(
M=BZR7^\2TTYI?^[.7TJ!6C28*8L@_6<P3F;"B:0;K4OLK#S;<N&Q5_&;B%6!
M7DK?CT+C1.51PJ<C$?YE-KAOB8J8!K CGK@8LLBBS3S =7W<+_4Z/E_L4=>E
M\HIL53]R@@5 U6;C%-^).MAGKO9:II3,B[&7P'/8BLO2R;1G?61H'V@"VZ7W
MD;54,?-(PGI>J ;C9?DXL8J%W''I 07VX\/0NCQ:!V0G.[CUZ*],K[P$$C@Q
MGE 4)8Z"]5-&%-<UF(ON-"-1WJM#,]DRHQ*B$5I$LNVXNR,2=^;GQ6VPA#^@
M.-==&8G3XI3;,N"<Q3O@"/9;LB)*?1OH2*$8P2NH'<X!]'#QU<&!T:=F#:,:
M##2>!*SL%(/-A *XH(N.79M8>YX(UMM2)Z'>12WI+V"VKY7QKL/6H@@KQR6=
M5251[@U+ZN@MMU%=Z3='\!K,?I_\!.?5:)WW'Q! =BS% PWF<KK*^@0%._S$
MSY8<97<[WU*#L;11)<A)&@RC>T0\,:V/-^"".@$/^1Q2K?_.D[XA&"P=+[>(
MQ$\\(F6V\DU>C6!9LU2._"3PG)GVTC8&]>E]#68V<(@,K8R!8D6<2T<*H*4<
MU).^WNL;%JWQD[K,9?A6!@+-1^1#AZ^/J 1MLH;S! U&L8L;A4S/UV"F<F22
M\]0G3%<IJ7QYUM+L$'5;SNI*)!F-;@:OUK(_")DF>DA6_<80:C +T/*0N7LA
M/CNNT\42)^C7;P6?:R\7[ZK J7.S5(AN)+KX;EG^8, S&K9"J#LZOX&[*Y5D
MQ7JZT62LZ.:5.N+).:&)E0O4K4]VK&6WWYW01Z935<O;&'S<*\X5KO5S]TQV
MC!6];8_7K[2NBM:H(2JSB^AY>'V),<[J/&##P-)]H&RI+S*C4K7Q!$4'GNXG
M'F2,N#5:<E99$02C_N @:I-0Y#6@]$/+C?"CJE_QLSJ=YR>(T6 ,.[X@*V'C
M.CI69/ ZQ3UXO9WR8B"2!4!00O'^UVH6Z,]I8BJ4$$^V5D0MLS0XD"M[DOZ,
M1 U\?J(Y-,;?)5:00UK$' S\$#7NA[PN/@]-DB4J>NJ1-=_7H0Y@Z$/+^"4)
MGF!Y>\0:N6!PUY9L;6-37DIFCS[ 3M%@(J]P;44"U#YS$4/855I3M"Y2YNV1
MN,#%>NQU2\N(R1#8G5RQ6,Z'1T> WOMA.-BH3AI>8A@U4-?),=#]/H9N@):^
MLZ!N;/0>HBA%[9[/?\SN)PB4?O%H08-J(%W4],-0IFH/6/*K+?,:)<?W<L H
MB.W%$Z,>>E+<^W[^8+8^/\_TUP2LE?580BB['\_']:^ASU='(JO!$D=>QZ/"
MN#=27ND(+;F#&?OXJJT%;2S9P7W5;PG;E>'F\?CXP<=H3(<*<94-SGH8UTXT
M1\SSKW-7/W--ZS.=])6XV)L&;J^SH4RF\3;Q:@>'SAX?[;]Z:E77?6M\C%-W
MDSG+G-5#,K^%,TT9/(0N];M4R*=&%?:\46WV*W2+)NSJO+Z7%KDSIG2BYSU_
MT^HF?L \[AD2GO%;S/I*;38E)3B%N37NDW'@^211U'M.'"[[*_-"\:SC!H8Y
M##-N8*=#=*Z#P_SY@1=>MZB7. F&C]![T)YK%:_E 3810 NI*>J.$B]>QP.V
M'JPCS7M7V0%>#M)_2DM:VH2[<?1:%=X7"<5F\XTI([7.CE,COJI^0<_?2YR&
M5*$^HW*-Q%0#3S_&DMK4ZT.6=21NP>SI9G-(J@_BU2-&DDSZ%I4);*@N 'R8
M4]PAMQ*4U,/Z3[[+O1>.Z;[AY+RQYJ L]+4SL4E5UHW83IC(R(J9T$99_GN6
MJ9DLI$R#T8.B/(N=Q 4\;O[(TAM;4PXR-IU?+VRQ4%1]1J8Q2N]RWNLMS1RS
M'HQ8HLO4K;3!R<8"0Q>H;"[@NS28%R,_@2,U:[V/HF;U4B=T0+XJ:[LX OGD
M>(H=5,G;_]4JZXIR:<Z-GN65HTGK1M".R#54=3$;Z'B%>Q553FZV[K NHT2Q
M9Q#6Y-_]\4(&E9L?A[1_M%S7WMXRH(#T*TVE9DF[HB=\9)P<B33@&62D^J'&
MXS[QZTE&R90D3G?UR8O JE J/'-]B>(!5H"%5DI*F/J,:LIK9C3!3&HN\HY*
MA]?*C.?T%6^HSSPDM(V.<^+RK#;@)>.!)EVD1=? H,P(M-Y.B2R6.O('YG4\
M)T=-W&_G/.I=$AZ>,1Q07!TR3_RQT6#UAWL#ZBZNWK"*9YW8(E93.MP&A=+8
M$@8 N?C\!,XEK!7[%N29+J\?NSUD]2@_:;5QBB?+P/2H=D1#][WX2@UF>_\@
M""TS&/ -5LU JO839]9S+,>L9WE[5S[KDQ^\YA%[=4K@ +-Y?><UQMQ)HY?_
MY\,E[FHG^OP](E$'JR*!*"O-5Y^G@J,NC=UMC$>,+T+Y+W" !O.;D5 ]9TP9
M0HF$WB#CFV&<Z@QP6,I3M_,@%I)0:=.V+N(PTMXPK2NALP\E46A93'KMUF;H
M=MF2OCC\ 1THD&$ONY6]_+[&SS[I7G/,EO"@X--;\4ZK^8)Q!V2TLWB%%'?M
M&!0NMK1SS\O-YK)WW!/\X/D$*D]YSRHWW5!/<!7'<F95VR5F>+>I7Q) ^4?R
MVD_J-CH3*SE S[O7(Q+8LR?0DG,R8FM$8F?0MAM/TBMWL)&D<.Q5KE%P!Z[)
MHKQY:6=/!-K(;^;!8^IR$.CW=I.FBDZER:+>YQ4N2UXXDO7CD9"%<<THT)K%
MC,9J,"V)Y0=;#61]IH921_F)H+3N4L]>>97Q:Y)QH/+>![#[7F ]$:?.M^5-
M;_-R3H-<WMF#+0]F[4AJWAO/7XF=D)BK;;(&SIDM+3^\W*5%D& J*4',!"6B
MD6OK3%\X1O%V3Z"E.^KA0QFU,R_YH>LCV$[J(2ZS=^W:BG3KV&<*[ZCX-S08
M 8">1>A/4S]] NWRE0D]*;,/0IVNQR/8@T#3L$[3B(*F.#GBH 0;N(U[U1F2
MKS;*0;$4*//8@"=;"W*_<-_\/C^<=\?3MP*X:B><SPV-Z-3;=2B_WM;:^I/+
MT2;<D%@^P9Z0[+O6.6/&VKW*E4$%$<PSLZ+LQB,GET%7M\U\IMB_1\6 >Y38
M+,+^"0IL8UT!#I+SP2/L:>;-Q _Z@Z:DF\7'JC48_K4Q<7J8,OW]#=A"@[ET
M< 29W40(5>?>1@3JAPIR-IK5:LF=;F1$3;ES\#/CF^D22O3=QNB>.JY=:&#6
M 5)Z6XNK/SY)SL>IUXZL9%_E^?D17!]Z'0!+]:5H^?G\H3@X*\:L@'F-ZFR'
MRLH<^4DUZ5JZQ5Z$&J>OVMT[;!QZBG1;]*RT7[GN?K$ITCOJ:=BJG8$7[+K)
M>DP!ZA77F0XK>Q<RY]U#%J 5][UE>.<8=R?:% J/?SYAZ&26-B8<XB."'K#Q
MH-1(@VF.+;=#5A4WX/.^($WA#]$4X(:CO0]3V8MDJX_NJ@>.XV918*LO7%.A
M#U+YQ:JB:T[HF= $\2=U*YN+DC+5QUZZ&^OQ35Y*4!2$\,?4=0ND6<"=7/CE
M)12%&^7$^] 3.@'+QT+;'G_EO78=2NPQ<?!M!K]NZ1X8 4+0>GRZ400%*0:-
MD%D2V8N[+,4M7K+Z55<$FZI&;9G$/I.;"9ZDSMZ2"25,]&^19KTH7DXS'6J?
M>.\<\"'_&LGT UP3MA^X!AQO8<[S>]\ Z-"P+C<JC5^U]DZ0FX:6R+O0%I:J
MR#K9XOCN<,*]E:#=-S; 7T'WY&]U2^A9[U9IJ\$D9I$OD [(^R(FRW1$OF64
MJT#ND]0G_8:-T:O@G0*JV:9K\=I)]L>854["A0)62[_W"I433)%AKS%6T%*=
M$VI<9SIN"P\/SW2$>6LHZ*J?"\V17R?<#&38SKP,F5FG8V.LU;7Y817E\97)
M9DM(QO%\-+E\D:9ZH0%C=1_.D+[QQ\SG+7[GQK^\NT%09.#!XW*T@T<)T;AZ
MZNEC=&?2O!V9]KBWXTHT_+##)DUN>@UE]:GV&@S7NZ99?56#.3MN;42K*B':
MR-K9N')_:WT:MO/'1)-"Q[%K\97^QO&(8@/0G1:J,V@GNN]?RC/*38X(VLD\
M4)_/Q[.**2S%);GX&^%5KZE_:JT&$P#.>G:P\MEQ[]FR^1E/^-W-)PR3DGN\
MMV@PDT> 6Z'I<?2C3^F_REP;<I][OAAOS#+Y-A.M9*WBZ3%E6<XJ9S23S<V1
MJ8JCUL.&1^[L6(N-9GPY:'R=[HGR#IWF2W0F69WC*^?Z=RC-4%8:LX.OK/(6
MBOR.O)&QSY^RM5[C&@;^T*;.;3WL[/;S[2ID&?D]=RD*>=6GPL,G6U^&=8)#
MGW@L?6'@9K\WP?/]580SGN)+/G0@#\C5B;$L-F^C%?8.Y%H>E%>/BB3I0YWY
MC!3/P,97,Q>]^UQ>PUT93O:K5#!F;JY.VGS;K;2N3&53Q"9R5??9E[F4U&:&
MH-A8.EQ.Q9[X IWK#(^M-MI;9\[\!'"5R,8ZM6]1B+?.9]P.J%'*VI4K,^%?
MI2\DA"1-+'\35?4F>W:+<[$=82$P:W6W6PR\7IV>RYD$ <CLWM$BW?+FGZR+
M'2R]&P=GMP#JM1GIZDS"+J \0*<\94=<5-FN2M/D]#(=EN^I!%*WLSR4K=J=
MA(U^.3M]>GV&]$P$$VQCCT0\U6"L"_=;+.+O>*R^:4\>; OO=R5^XB6GVA(B
ML"5!+_K:]VHP<W@Y]*81]NO0<!6*[/:CG*:1C?7$N?0?:L=<3/S+)F9F=F;N
MUU6">=;%%9(#)<OH!1I,_P/<^-!!.1I;_F^&C_KA1,.E37BPW6GX8;!V..U[
M^EZH*(/N_J:.LC/_U2NF\RL7W0.69@GKQ4[::PA!?&*5--?\>M2PN?K#-ISJ
M;&P*B5E1NL"O_6<$%@,(*6/8>[FT(4/JJ^!3]2' F3+;SS[WTMW:C3_)7IS9
MN(SXI;M2.![U:53=%>PB:H_MT&"N)O1'BI(R.32W<E;AR4'BG:<O0O:/OT1Y
M-'4)^7-*;O>$P>#F3L[,[\4&N;G^^,324QK,H3=HO_;8!06T%_F)XRD4E@;S
M_O))?V'>NC<9O2%Y$^<B1;B9WB=>W1[FY&2NYP<&H]D$^Y_PW)B440/ZB+NZ
M$%K$577BRCLSCXD^U$J@#<J)C>H"_^J'S;0\W*1JE0/=&@7[!O(\$A(5K" /
M@&8J[1<Q=[03K,J0Y6#I"O4;'+R8T[G"1F F0;[)D3H)Z@$ S?*LMY8ZBI=?
M<RA3_>Q-!%?H"[/<OP?FG+O^S(]S1D956(6-9U$ZTRON$%>Z^.-3<-*L*(6)
M!B/7>:DRN(-VT>1VM\248PNV>QN->]Y#)-_&$9RD!Q5-)IM5O2HX21YV>Q/:
M7_/&CMK1_:;RRY9Y,OZWR__DAW/A=C ^%1L40Z$J>R$MAK__\ZAC2 6K=][-
MYHKQ>&P\=='(#V +>5VA/]K6;G[":&/,ENDE>[3Y$==<Z90=O7 I/J<WP$H=
M!PPF:V_&H0MD^N*9SV46&Z5#]R/TTHK85P(8?-^ISYQ-@=Y4M&X>/>N-43_C
M;I%J,!NE@Y?3\IBAN"NG'K]]&?X4G^#$_="E'7+N/@Z$FMM.K-.-EG];_IM$
MNCF!CO:-414H90R_2U&N4/981 49QCU9@C/9$0&\440,WP3G\-_I5N^N4G!0
MD'O=3NM*/+BZ-:#7DG=')8"C/(??%RU%G7P<.[?)+U#Y). $K0/5D\(^CE8Y
MD^!L1K/IHER/][4Y.!W:F:$)P,JE;>VVID -)D)YF[-!2KF>Q<6*/2Q/+3C$
M+:SK6?O(\WXO/DHER:4=@+WUOER9<Y_LIZH!SRND-,^0_(SK&>0F9#BAD5CW
M&;;P$^EY;(9 NVB"I08SK2MLRMVMJ>G$!S?:6]L\?21.@<QQ'4J[(8JKE[Q7
M%*A9#%W_+R?.R80>3;0:U[6[KJ(LE!F-SV=^,AL9<>SOX<RB27;*K..LN)MM
MVO>G!88H2O!_,<ESX%SPA%=0IR3*ZNQS-; YG[FSV*7W<=X5I^Y;8NUM*BGL
MD4]N=:1KI\_==]K3=6_#3:(0+45R0&G#3-%@]LK\G@6-B^QT $H?Y4(_.*=8
MKP6V4=]#%KD^;HW@;)1-;;C_]+B<9)[<4X)_]A,H:2C2>==N$"F:8CI5>O]]
MOBC9<8.-4BR;SPYGQ+=Y"\[>F>S;"'@BMJB.RZ ?;Q;-3=3&N\R];[VS-I.:
MRLOWJ$\@6U0E;"#PQMA]Y='^B=!E<=OFSI X:^[&#"YXJOZ>@U)G=3G:=Q^!
MLJT?/8PN+1...PI4C-WL,3B5^=,QV^2'WHSNKF'AEFD:C)?@'!30D6%C/1MV
MA=8^=5KJM<V@H)8N4 Y$?6(BR%8?0/&A ;S^B!K)FXS@: #B.$:9(S2/MJ6A
M?4AZTE'37\$'&@QOGP0Q5S_F;NP$8PSM8M/SZWYK.+O7Z<O#.*>*AII'Y/:S
M+]A7*0O&F#&\.;@*P_0FI+7X0,QZ_=45W8UZ]/%).ZZ)-T.LKBC(G @B]:-/
MNVY7-EYZA2O+)S2.*T-!E4\+[\11:(\Y/R*8N[7=$6FVI"J8 VC$1K !7Z:6
M@FIYE]H?JUAS++)3&-U<<9]HRO=?_W7'<PV&R./*88'2ES<1>HN9A307LJ*#
M=;CU!*RT<2?WQJ$A\R^F[FD:3-[E_OLRYJ#%"UIVB1T#EU_+!41JN]V%*J]F
MO_E4JN(.T)LN0%X@0X7]$AHNZ\7)$Q%O=GR^A$;:A2HTB7]8_U*YSF<,]VQ'
M<F/KV[OLFEG=O(>]O%P@EEIL O\F58^>:QA/F6Q(C7_4W%S9W5+EAS?U[$50
M.@>#+?:?9*S!8)^(XZRPW7VLXL6Y:_EIK=XEQH'?90+CP$ICD/![RFDP\1:?
M>J"VY][T16CD+^LS(8Z[QE#M:T)KR3D'-)C&#03!1*\& UJD2/G1CZ6LJR]L
MG1;G%R1N3W&([K@+K-E ?Z/E/+0:/+O!? ]VSW@P("?W#Z2D&$0=&J-MGDT>
MOXE&-D.H?C6,&!070;/]GL&;9!4#"31!>0.9FNZ78#WQ:_($V0:45P/GB!MO
M_!S>R.H',?@O1!/<++#4O>-Y=/GL5M!W<T8H"S6[!A.2C6:0^PCRJ!#MHIL+
MTZ]9-??OE5+*KF_J%<LO9?NM<397PPG;9'=#&WQ9];GV #=*7:1+5G;#K:65
MKP>"E_75JUO1HEKYI'"S*JJ UM[-F(9\LC>-]$>8'/HOY$%'[U]Q1?-Y\E+@
M Q.^>E"838EA;8<J152(G GO+!Q=7>8O*OHR+;-V.N&#6(@3-O'W> ,R4F?Q
M0UF(^\O"^D6O\Q*WOW0EMEG.<1++Q5DM96">7;2-GI%+?J*SM#TCXF&+FKVC
M?O@DH:K*2<9,(*_)*Y44'!"_:=NQ[717USC(FKC)*S\44[DZH42^]:XB,2B(
MW@ I$-[-5YW#3<]W?H7=.W4S-U<@DUX7>FT;$.@UI"G"HQ(_:3 ']E1I'ZPW
MR)Z>LX$QA68A0E+:%TG?QTK>]C6KDS*>IA55EP=M]7%2^$B61_&FBN;)!H57
MASCPOF6YH=U]!KN]U*]!!_6^3VC)57W\#-V1X79#;\0.F?[[Y#Z%!4T+G&X^
M#GP?/Z!N @[>XT6O@4VVW8Z9ZZC!R-  N7WOU&9FQ9[T*^5[U<V(Q,,#'AMU
M'"[CZ6%+ 0/ZJ5HS9O ];Z."!('.4,DB7W)5O"=O8/72<F2E;,OULM72@;LF
M7^KC>5\GLS48"O+KBVIK19ULZ?5/:UT?T_QWQY_E##@3&_WQ[%.1:EX[0QI8
MA]QM *^!)X2S:*Q2N[LF<2P1^Z?>?/[1YN-Y1%(SVJA2'2TR)0NW^Y?-CLJ0
M!JGNL6L.O[Y7>SK%,--654,&DY4SWW;DOUL F\C<2@V+)+%TW8SRPFOX)O<3
MX/$"[24U-_G)3."R7;8W' Y5F<C.Y;)<OFZIT6!$ZF%<&EWV^,3:XP?O%XV]
MJ/5H/UAI4O$V'7Z=8#\J,$(:BA?)HJ[D6LQ^# 4Y%S2(XQP/JG;DR(>"ET_0
MY6[+/%(Z5I0B@B8YF:U\HV[?\QR7X//,):DO/<>3!84Z#ODT,!9["3=K,%-G
M2[GGWE9P_0),[J)] 1'9. (,LB<^]A$-Z$;U#$/HF;C<%/<ZK]Z:Z]SI-\>9
M_EW,W%:[>T2BDDCB.P6M)DZCDA(;L 5;?G?=91_CL)"H4[81Z^I4Q#J/E,9/
M]0$HS*:$]]<05G>&<V;0WKHV/)1WO:T[)>:2"<B0NUGB)W5W&*5_*V43+Q\Q
MSV$#$%&_FO63^/E.!76<46-\7YWVIF@F7Y$EO3Y^B6$/7> \FJY."UD*XPAG
M0F\0$J8DSI,$IXEQ\SVAQHK"I.Q0X\"V$XW4<[(2A$._E4R9>G=_>O3[O<]=
M.B1$\?+4_7'S[Z]\^VWYHYA.QW_&(VS_*7^<TY"#!H/O)Z-HSIY8LTTZ,8Z-
MY,EWY&@P*C\-)A7/"5J$;!!+*.](SEOFNGW#+9N[:\NQ*6?_O+LQS'>@^Y$Z
M1;)?-C?!O=3F&[':S[9N(%:0B-P%V6.W/M/2RU[[KZ&9E0,GL^NM3@X/#E@_
MR4T>G%TY B=0-1B@W__C45F1!%X4#S'6#XI?C2!-^&@V-UZ#Z4WSE-I5>&U^
M-Q'0=NO%NI!9GA]8*/KC4_;&(_)BMF[RH16?TR]E2,%!#6;V2 &7,V_W"YF-
M!O/T)$4VRDKBF7*2R:%SH+Y??M%_J[S)SHG9Q%L0?"RJ0#L)-BO%,_@$M1G8
M:W^/=>,[8I3/NP'R/QZ -9AQX1W/[87EC6'#BNN-$P'E^3B_1 $*.;D5<>6'
MU/=Z2T%C9<T]GNY5Q<N,W?>+[A%'VN'9QX1Z7$>1/VY0SYSL=W],S]NBA6WE
MSOT0$R&0B<?!@^^E5Q+M2K$+(%GF*^3"DZ**!XRM@N)(96,BU/+>+L5!9MQ\
M2\*2>&(>V0!OHV>TUR-V?1-)K*5<::_<V>J^^@Y>A1]9BE(+\ 5GCPJ<KL%<
M1+"P#MJ<Y!%ZCR[(;(2YD 8C-:NUL?[I&W1E>+_LW*WH@=S,F;VGT#Z('<Y+
M!.7 +9)4LB-9)"SCS!S\:A-@-;+WK>L.M746]RH^$@E]#_3?#P4N$E><8$RN
M&]-UL,ZN]']JQ7<6Y!$^]''BX(!0F8Y'G%SN0.NZ/F=:[=Q/@4N,[P(-/^%7
ME'(7#VLPGIW(N_(=S],WJ-A?F22/XXPYR)?=+:_YZJC.:3$8\&NE'E^#"7CF
M9FJ<V,$N8\[-$:L=#KQ-=,I)1&Z#QFR!/,N@7(.9-4SW>-B[+L09#8TY3H1H
M\U\_)9"N,4;DSW%SBBW[V/H548KT)@WF\YXCC$V^*(5Y<JMDS[K2/9?: %40
M(H1JH*.TJ,I!'&J-04'D<%\(>Z%1Z8\J%&DN7>!N40P/'"=P!L0Z28>5V@>
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MXG(MPR@YE<_Z7Q\TBK5PQA<D;#2JQ*><3-E[AH0;2DU4>X4UP@9O%3%LT?@
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MB0(\R-7>Y3E6^X8WCU&/3);N* I-.W%0TI2K.YWP-AHULCF:JC?ZOPL@9RM
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M0,?JZLYFXF"+.,[OH.WIUN>76Z-N+6H\FLDHUV!FTDDJTC?8L_@S'8W?,$_
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M* ZTO_?J^K8#76M< A6TUAYG/*MJ^Y;&V7%C$U52EP[S2VC+!URY2XV$C=)
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M_"L^T/F\"8'">#7?..P(BWTLIAVP(@+=G>(T/Z0>K4BCS.9&1/=Y!^7*^+G
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M8P9\J* -45?=KXA3HZ+PH@FZXIL/H1?M"K0CUF(6LYYY?9LD3]7;ZF?DZ>'
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MZ%_4P53@&#\RR%4I>I(]Y$^!)5_""D$?%AC/]8,9/!4]#Z%=,U7%]WEC9F;
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MNR)C49.5U8,$FS=.Y")5N?D3+[/$VZ$'HGML^;5'U[]_[!.B*'&B]8=&+#]
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M$.P!Z\\^4%*<7-]ZT!S<Y(S)8#;&S[,=D-IJ=B]7S5*CG@47\S/"^%5A4=0
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MJ_J2\M7RW\O(_X\]3OT?;G?6&JZ__\,7O\H>5; Q2BGFMLL>RT-ZOOO/@S?
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MT;,XTR"*';1:L>M<Q?JR_/>4>1]#(UWB&Q1.TTI3^^#"= 53+C#U)_NJ<BA
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MVNJ .S9[#L\X7[[2&#4M^6N,C#U 8 <3I'_POD/*H5[&C ]?3;^S BVU*O\
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ML7ZBV%',M X2M9BP6:9R5<>V*1\958[R6+)FYFE?KQ<RWK3@LTQGIJ#G9(F
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M+ G(,55LK%"=G"=U+Q!8 PP2=')#]:SG>AUW'<I97Q(-E/D>Z)*ZR9[[$F/
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M2-($.CKH5(I1H1",V<VR>DS(=G^WSHZ-2G/R]B4X%N_??7RT.=5*>J-HIOR
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M,6VV[6/F #T<WA@@X7X4)?73(NT59W0IV^C<Z+&3H#HJ&F:I^V5:B+19[>5
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ME?E)P('5';#PB8+3T<Q_/ZU3/!*Z_L_LC?OT8^]J<_U%!*E.GR:"5)Y(M"?
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M.('WX4#:,Z*@G8%&F)%[&SC=GPFK)2'12J9D3)#)5,2S9SM!H<I>Q1YLZ6.
MI_4KH)!!ASR($7+4G)$[L"! 0I>2C4 "A^?KP7 7/Q\Q!/-3H%02 9\B2LW*
M]:126C\E JPZ3P:0\18B&F#<HT(>M C.W$%%?5N^UP:%$&\Y:G8*(]X#5A^N
M!'',5BSDP8A@?"\S=Q[DYE&TP):NK.^#3_513.^%1L4IE#,N!"@<0FQS$>FE
MDH-@%@[_B'1D%0'RQ$30_B5BAZ)7CJ!4C/0*(U02T)C[YT!8C<F=EBFE("/=
M2!-TTA"W,')3,0GT9K7OEO^&^O=)4?7(8-=QD!D#]"!,%O&?HK>0HB.(O58Y
M2$V0D3$4(\M@'%0LM-TNW\]KFD'6&T_M"LA'@L;2.61J^5RF;*V:0AY8Y2A%
MR&]ZU=^UC!1WSYL!F%PE1^FBH?  C%@,?)(=%N1,;NAG:'B*%IT3>08'%Q<'
M_)-^O#UL*<95U;%2IDIFJ2>E/%GD41([J?*97Z^?')65I+)X9/B*;+G^7)P2
M;U5WQ:J %('$AF+)?VJ74+6KYM5NO1"L.+'57$44T;SLGS.'_V\_*^+--RX1
M1DA5'3X'13P ^I$8-MJ@DYOEL<F_)#+UU ^G,+(UMDT<@7F(R:<@1I675G._
M;BKO0U[#EX&T,;:)?OXY0.SN1=)+&O*XTV>[V!!(KD>BD1U&6H@ ^G-D*ZX7
M4)NF];'-S]HD6+;_;+BU9YX=JS&:=^A'X\-S6^.)3XC*0'\R#<-PH6]R]B"^
M1>):098@=9+#)H1C"P;VV==S5OK#L7HRW\0%VIAL36C[9U[F+JU*D?'/[0NF
MR=/GP,_;*C1&U6C5)^:V'4SB,J+43KSI,,)NM2)Y>6ND7?_8FY6,ON62&#@#
M>W^I_4LZ($?=VTO>VO4,^?G,[5'L+6%]/W'2LE,SR/)MWW #9D%T8GR.!:^4
M#-#9)&+G@5A@H"O4UTN;4'+OB%&3?2V/V?@^T7]:.W[K^\0>FN%>YQH!7W13
M@*"!R#2LT#9B3M_ID).P]YM_4 UOPY/<%24"GZ2%0+112%"VFD\V0.%.'E'=
M-FA;9E- %?9<$F)%6I&=]JYQO#C;]4[9P@_O6?GY3?QDOOCR3%8<%OO7J*:#
MX'=(KW]ZJ9-5AKM]V!2-2UO;9^_P63,MTT^4;\@;:'R_B4>$H#@KE*R_3[M>
M7.W7/![+5<**GG[TI*\+V 6HUO-&:BJ>^-&[ZT(,GHR^,:_YP$! 6%IH8QYF
M!8+.5 )\/ONG7.=$S'L&-V!^[!TANE5TN)2%C_%.+=',"(3B. LNLFO>(OJ?
MB[7&&P8/FV8?DZ,F)@5,+B:2/I\/'!70'^ F#9T.G7TTX%#:H35,*'SVZ"^C
MM&'"_H;($W>.TK ]:?H!=D9@-&5+!\YNH!=M05P%C7D9BF#>7\.">A=_U^"-
M=^YT81#\8+>Q@IBLXUV'F<J:/4R_ "D+9B\+2%'DLWZY]N*]G,_/+9<FQ392
MEZ68ZZV4HVSVST\Z>V+O%WOV$-=A'_CFH7^4HRHO9CBZE]1:C[N]\DMU'#Y1
ML'M@0[W>8^TX*R!0TKQ".IOO=-,I'7BGU99^\(.@H=\_5.J/SS6(B+PU;X>=
M-\6;J%O'7EWL,XF)W$^Y\C9V,,Y4R)34:T?ZS:M0A8M=7*62SU\&6'/$2;Z6
M1MM$44V<P;$3DT70E$M"0^-[*FPZ&'<"X4())P9GM<=31BM^)!\6+L_D,L.<
MMY93)S<T:&7F><S>.KZW/G#Y^:7"I7$/:^L%)G7VARJ/&*F#*_L\5%-*(HIB
MC2WO+3::7]_Q\7/@CQ77ZZ2S1Q!RQ2[,?>Q2:HATO#O ]1<(VV_"*'8756P-
MIJ[JY;!E90'SP:.&AE,BAV_I:80]?8XG72+]'A%Z1<.E=&7I7EGJ5!$1+7Y'
MT4UHKJW4WSE1U'V@SVLNUX+YSL$!86"%" 4$]J9]'"^M@!QXUNCP-Z^"<$GL
M,.J#:UWF?][N$7<='!99@7>N)3;,KE&<GF3B]PH3SOA1:G<]?RPE591H^L3S
M$KSM_9[B]O7U7CN&6A+ZCJSZ @8.4<4W3KETX3I -Q=QW>0NS8@J] -@C52]
M7W;,=+F7F0V+1Y/8_Q_LO0E44U?W-YQ6K77$";$(Q J*BDA%$,' K:6*D6(4
M5&1,+2H"8HJ($ BY=0(!(1I$%(2H3")3%3""@90Q(DAD%A!"PA!FD@!)2&YN
MOANL;6W_ZWV?YUWO^K[UK559+A6SS]G#;^_]VR'WG*!S6XW6W^GK=L7*WWDD
MF;VBV@Z 3^8Z/I2J\98F"@V^#^G:2$R-_*J[@[N13NUV\3K$[:6:;U^_B^V'
M!X+RQ:#034S)V#(4'"Y#7R,!)X=\02W'];QZR9L7D>:8^@VB>C-:+)S@^(3\
MQFI^,P/-3?(J--RB1&%#'9P2Q)L($U737,I)OQ3V.NKWDVIW=CS[SB*DJ8)G
M4)^QX=L,\VDSX,S$S+KD?QX;A_[KL7'"/ WPX[%Q8SI_.3;.R;\BX?O@\9<9
M[VH""*>T6RHOPB35LZ630']JW-320OD7N5>$<\IDEOR('T70'GF1_=>E_+'E
MG5@]*C*H(ASB(DTB*KT8YK6U/V9_']5\O:+OO(W[&_E&R+J-X2D_&+3/TN58
ML^F7W&(&8BZ?N$.WT[9DA"<E#*^D_5IMG>Q_7RV7AQY;8SVRQDGTW;)[GA4<
ME-5:J;P*$,0,PKM;5[I1L88]D2,'%.^?V4B/@9>1JK!D;X]=R'%A_'53;76&
M96[-(\S%.[0S,[U5P7F_<6Z4HH7,RI+ O?D"]C62/F_(JD$1G5F6$:'!GA@
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MD )K)\UFA/H?&3'L'H!TPR:U?R7_E?Q7\E_)_X\E-62]2$%C2T/9$&5U ]E
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MM+(Y[-0:]G)(Q=;-]:OSOG(CD@.CH,/Z=^1-Y!R @U0PI^,:P27BE,R:T(
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MATIY_!-X!Y3.9<XLD_6OA4YCIK6F\Y"E=8I42[NHEDX'R^?E@F_7'D.V-S<
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M=?U(6,X'XQ+GN+BA['0AF0_UA*6FH'S2+@Z6W#Z@0MAM^ZU1ZOB9]Q(UH2'
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MHYAG,GPT<774@,CJ4A7BP67D;NNO>M^B=Z@]L&2_)!V07E*K3?=T+O.[H/V
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MIL0=<J6/J1!RM[7L@5Q^]:OHM-^/8-:$X.@JQ+=;7VY.^T3(:\T><$@/4R3
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ME8@YNF(956%4"FW;@U_X#B_]!K::QC'4+,SE=Z@0OY)/M^+S>$)&H,G"-Z.
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MF/;'KL#=:=5A?W1^L\$D6-A)(AK"-AF&YF2FF ]?GRN1JYE](TH2--G*.)K
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MC^S15N&PD=PX+%?*&HB-;<1MRA_[3MZT.WW7<I+WUA2%>NXX<NW3Q:+Q)(2
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MN6:*F1*T'!:SKX;S7WP*)\^965_]"*\NG&/G,'HL?2O\TGMU!-GKM1A(9BR
M6;!Y!VXY'Y.2ZU F7IV;]XAHVA ;&_[]&##^.2]]9)]L<7DFF:D:L>9_@VJI
MBM7HBY1E"I!W_!:4R%A):)3$>L/O)?.''SRMCXZ.O#UTV&Z1AP5Y2A9X3\U_
MAZEJV/9:8@W/2>!BS$<)\P-V27S3Z)8\;+R+@[]Q F^/R;ZTW@/J%9&SZZ)@
MP?N,BU%2:U6CV\GI0U!W&)<E#]$LO;-?W%\E3J@!YWYC+R<[5,3AWV8ZB4]U
MFD1JR[7'ZR(]Y8BZJE)#5$TI;74"DHP3-$@FGS%-\K@Z.&]TRX7AI[RM0A'V
M?GF:ZYW;_,X\*3\=KPP=TJ%V:F?INYK,J!='O$7W?%?+BRY(0M009>NUUEA;
MCP.=T><8&4?2/%I'R*"4/6=(&12$*WZ[]'TC,H0HGJT(X+-G%*3 :P,43JRL
MF_U;KB,9\56E0])9.Z_/_/0^S;-& 7,0B<9U^@_^8:2 1H/'\-V8M_(@ W%?
M6L*6!WSF_ !.WV,=:HNBMQ&;*36QAB]XZX_^'HM#:CCSX"Y ?)"9MH^\LVT#
M>7^HF+6KI50T[VO/'W%_-/2[-D5LX?'?W2!1CM[8KG\"9]@8MB=*'O )#$//
M&,TQ2*0YAKGNP?J5=OV:L2=SZZ#3EI%-(\UIVTIHBJ[%ZNTZU%MWC;V$SXMG
MIB'H64P4<+O2CI:81@DHB]KK4SN$%<!8@7M $HJ/V=;UR_WI\M4*)S%;#E8I
M4KG M?[UE1T/RKMR9#YB274:CU,3LWF>(?'&RG0'=X*F% O3GM3'S2>LT/@C
M5QY=*Y;)ETH*:CGQWKP4JC'Q#]7\'\//Q$5_WX$5?:BS%F9EG8U.PY'261;S
M;B;]%-R<82V(0(]R/JO<BFC95M")>$L9!O:/_ &S!-GTYLE$G(TZC-*1:]1Y
MS)BQL5)R1]!2NZHNRS\P'FX>U:%V\]/T37#'?)@#U96IJ4A,'PWA+M-4T982
MV769QD&8EU38_<P9,D=YPHW?#,I;JS/D!<@V+RC,Y(\DE&Q>82%M$1%@F;J0
M#@59BQGWS_7MM0*D[ _+^]W+4L08>,Z5 >95CK&0',=#&Q%E/##-0:&IFA_0
MX/^Z_5&;@=;UP;*TB[A9Z&Z;MV I2V-LPLMGUME:=-4;7T!?_A9E7E27/OM1
M[@X^M5DY6ZB_'SY+'J.]Y6ZF"41V\01N]2'FU:@PB:O$=X,PI:T.U3O[70L-
M_1ZU)=SF]>E0,;<UB?QE!DV<M,TVXUA#2E,/^@I2_E*7D@^5T3L>20RNGQ/L
MV:+J#Z&.>YM7:+M3<<R-P/- K0U?-(=2UP69ZU #CYBE68G/<5X2>V[U,+0E
MP?CF<^*I\=&"?9=WK7-OP=R6W)ZPU'ZA, )OPK]8&*@]0ELTSMH4'>ITQ#65
M&0+^V>C+Y/ \\)=M5>1#F)/5R;M23B(RZ>Y9K];J)KE8>YUB ;/<#16&O B4
MX@*KEK(.*1&.H/%QA]JF?/WO'B#EGJS(@/U)N83#KCDJ,S_DLH^2'=N9Q^+"
M!OKH_9;%XHEJ8D[FTS\\8E94-N2?M[.L4/^4M<AKC3+*]&QP@P$_*$6]E])T
M 2,\R*6A1RFKZ!W/[B-C0GEF,6V/TIQ7ORZ7X4HSFE-96>K:FYHGTWFTY"WN
M\Q4EZK.:0_K#M.\F:3U ?>:)WAV=$[@]3T?E% MQ\TW6D#:W26@$;Y[,:$Z9
MBI95U_0I(N Y]NK]Q/.[=IQ+B4/STK=%/.XY$O>X;6>]D)8='H'5E*:Y00)W
MQBW54CY3L0:=H/&6W*F#-XLY==AD:/X$_3>!=>(&^J:B_%NO\M<B^K!BTVM?
M'>KP.\&PMZ#A.*0Q&N%2,L0F/(/:(_8')+E9W(A$W\Z<U*%*0D#3&LB6?O.=
M^T?I#R.+EK4U(UKKDT$JI9]3G%4+=1N\A;XC>PQ@%G03(^I=G.I2$?N>:/]5
M!3OCV/9LQ+S*7+_&=*:731,SE-8=YJ%]2G;C?L#6F>047;=8WC6N\3RI.G?S
M4?J77F6NO_?P=GZ3EOM.) S*^P%CC(39(N9@LCYZ7Q8_![]6G1JA; Y;QQ<I
M;-,NA3W<_*7\,L64H$/5>%H9P&YUT$FI<%!SQG80J9<O5R8" ]?=C5H=W<[P
MMRNJ)>K:5Q?D3]V+2(]'+3:D-30<1FC7CUPA%'P&CG,^.W&GQC.X'TZQ:UXY
M<7HLK)P[)E.W?_TRYI_=8&]5_74Z#U2LX8R'BU5M\!P\27*0[AP2*_E.70M;
M9[H=GFJ,#E-7]6+MW"\LRV/A^>X='(^GO3W([JM<!T_R4\D&\M/R10C,X.NT
M9\ )4;=O+52"'N?GDVU;AML=J?-"BX_T3O^C]&Q@H%<4+OW=2U)D0T+V(/\7
MOHP&Z5#<1G#!L#B?<V58,E+?B)OF7)'>5%-0=[OU6^/JCU;) #9C"778:Y@$
MT8?Q]ODHDE<-9\9)9BE'6"3V?8-(NV?",MIL!7[@3!;MY 5S*2G3J>?JM:V/
M7J<#DV<I@E3H6Y-C!_R>,P.'$1O AD<D9AYBM_S<K,='R$[4_1"^=-FKMN=6
MU:]DEFF;ZDC:+W=<*')JKP[UQMU($<#C7%4!272,Y$?T7(7'#]2]+8S5BO5R
MSRZ'Y0_KMO='1B!RPW+'H,R-_'8%*%B?I5G4)"<3D0C&)Q*6.APQY!G?&[@C
M-+:=R_I94IIN'E4WE>YM_J%^/#=$A"L>8F'<6+3L'RP*$5'^MHOV#:M84U W
MJSATE1/^:-AOHSW6C'*.4H<JU#_R[1WX-OA<&#"-\@Z<0X;6N*%K*&YB3;K^
M<4_<\C2;Q%KX*0$/=T#33C-/$;I[&P"T:%"-HZQMR^U9]WYDO&OZ5*94&WS+
M$JRA5\G/BOL@889ZOOXI?LD]\]I.N>  <;+BCYH!W-FXE^^4A-"TO4#GZ32>
M_@:)W"O]%]WP\B() DKU>HU'QYG'R:ZNA'FG%F?O@D6PVR-1$(+1&9?;K-L0
MSKN+F<.O\$32P<M'M[S4BP*;OJ=<]9W%$7MB9XWYDTTMGDH\^.?+!@((V/?B
M?&1U7-^&V2JO(24XIBWLA[?"C94F#="5"Q&7\MKIG@-]!CO2>W;MYZ8\*LYT
M*.=MW1P<.<1_M79Z/1!&NPK,99Y&]X#>8C=6DH8P0$@-6O ),=6WU-B?,G>9
MY;],_S%^45 Z108?UNI0D[<15KA50TMS=T. BX,!S1;Q5)K[]X<UQQ0Q$AL"
MM=98=F24UQ389G=<G8[&:H^!OAEP=Q<R8QEM?.8  <'[OI;)\%_W1-7"Z\5(
M DP*2:0#L7+SO2V;O;>M7=$09Y.IL$4,P11GU8 IIKYI&@^>*)&S%'?X?H-D
M-*O?OE.'*OV8)5A-I_C5Y7Z;)B*8N*_T(Z]2'.3AEYXB2-'BANS(PD"PRY78
MK&]O0&-'I'#0-/H<'6K6E")'[<?26%EL>54NH12O1*ZERS2M*#Q*Y645B6#5
M9@Q,X;R8E2"Y0$A.)?%T*/,?F,:VXT)'5Z(H+S;<Q0;$#I9<9ZEI&[V2[)GN
M1Y_SY:G:VSA7]1X*VX55Z_8K_T"KQOE9P-MP:[E/7=9"UHR;C9BL82^KX-M\
M?A-NG\%'T)!Y5(=*\\^JQ2[X$*8^1'S9T,_?_2I]K6_-^0-Q]W!/D)0)ORQ&
M$)"O0BQ<TPMTK^'756IRFHC!O!,)X86"\DC6&;M'L&LV,'07'.O?.6X+#E![
M@K+"5FRD? +*9E8_VZ3<SS)),[),<@/X_=7VA[57<99\=+<?V5(2/95,CWM0
M^(Z_7V)<(*_^Y=UQDB58^KR68;]F(3^QH6;V?4.,^,">LUVUX N@7ITRFI>\
M'+?Z26\$J!Q%V+U>A[II;E.+.SCP6<0<N"CY/%:LI.!K"F-;T^Y9I;UW3:S0
MH9XGWBI"].V,('%0B6,\-9EA33XEZ;I:^IJ7B9X7QK!6[T6T^4 Z@"W01FWJ
M\D)B=N6G"'@=V4[,><.<$^!]G"3QW4?=75%9?F7*90'U='"FE ^3'EO^E+:5
MO>#8&]$/%D_51H*NW+7:5,;B,?]+H8YF(H-1$]]%&X>]K5XF9FG".@JM:_H7
MOQ3[QI^K-ML3'SY^+M;O6=%BF.1E2CH)K.^\_UWRVO_6:_JR^]*U#R_B+&3R
M$QV.(@,RJ>4QHVU AXI_2L)E+O)BX%^R[#+"CJO9CV[L(-+LN\!CG.3<M1)&
M-C_E*]TPA,=&<TZ6'!X]KZK_DNDDZ69%K[@S\0&Z8Y M;P2&?F>.U<<E)6_R
M?_932T%I2+W[,NT5#:7'-W6PXPS.,BR.1YLE<)GWV^%^ML-O1_I/93DE)<2>
M6[,R_1+SRDV89AY3H*4RK/R)_1\_=@K>2A1!@*GU]<'V>&W=A=\/@">TU'%)
MKQ9ZCV1Q-=L>*9U?14\R/,WB?;O66+1 LQ4&\)RW_#V8/9++7_PT0$N$HP@%
MQ!^K+&Z?F#C>Y8@N)27LJ^)$6+#M#;;*\%+:+@EGO(A?2.BQ@8U]$XZ)<_-)
MP7''HT(?G_*/K[\>L^EQ5M3QK>D\&Q*.'I='!JLR@&\?&7E?UCG98I__C#[)
MOJY9A6!#(\F\R<4F&I?[%UP;IDMH\:>_/4G&1P[Y!WD](?1[=P*3X&BBY8VS
M..;D0?D6*$R^:VWPF>+[.^^XZU#Y*#5\ZYY_1NY@5&#TDOT'+!.T>;5@S17)
M?<RWZ0PV/%U_O]K8%)5,0%_2F!>&^<Z6!HP:1QUYES0UN(/?_X.F<.0V<^!Q
M_Z)41!I>!>L(MY@ZU K:>\V/[S<NJVRW3JV/G?[-PK"Y9-YJ%VC_ R$V3(E9
MW$((!VL_:M9!2I-H'>H]!PGA_4A]Y"HNT!I6ZE!#$3H4RV: V4%/@*]M1(@$
MC?S13P:I]#UIV$DG::] [@AEJ0[U("9(4Z1#*88P8AESK@[UJ8I&.:1#:<YF
MJ6@WD'\V8!3(D$[<"'P1D$;Q3MD(:0H2)Q[X>J1+A[(!86<O#4Y4 WVS$^A0
M?^X[3QOP#OP:C-:@" +C*(3N,$IGB>U2.5O_/B;R/LY?;X,M8K@$E4FTZ*^]
MPX6#P+=-"3 *([#XQRC'I?*N_YQ=/PRO^N<U^^A0AUYB5,N0?(?"J%AWD1T;
MP'O)NSSC2OZT!@VQQM2?QD#$8\(]A2\<WQ<K+=>A^+\S.\A_VV8F7#P"?)NF
M0V5 B_?_;5<=ZL<)IC) AY*\!Q!++=%;BO"WI<;Z/?2-%\&!Z8A-2_ZR*<*/
MF$4MA-,Z%#+:1C^Z^E^C_\W.8PS]Z+7@P#2X..2_L2PP&;%*W]03$$\#GY%8
M6A0X.%)7ZML+_(?CJ'K_@(A_F'KW[-+ZOF/^Z0[@O^'$ KCHG^[XKSOQ@ YU
M4(I1+??X=V?L\8PK^T]H_N4-'\0;X%_>T*'^"=7IVE\_@E\1VUJ[KW[(Z/Y/
MOX'_86#"_]2@__+CM'\!X+_J0\^_1G[WOT;5$]HKYG^NH7<.B/@&_LLW__*A
MOG\#^[_H1*]_Q2+B^K]'M?OV$OYC]G]W*OZ?D?@OU_O;"*%_G_K?/9K_?Q&'
MTK_C$#U)==:A[J,U=Q69R>J0_PCT_PC+=> ?2K1V'B)!+AK\WT F^'\ F7_W
M_'\O!E'_<SK]_UWX/W3ANO]7%_X?0_!O3_A(,)JEP6\MEHK['_S1]]7B>_6:
MK(C5S<-;'W(MJ<TPDK^7* )6/_7I;FL&I3]:UW73 :)8;[/4I2)W0VV!#A4F
M,E=@?I(L@,+4F[?<X]EN;CM8P@E_3KILF$*<6-RL'2'8X9M]VR!Q=72$XN!K
MF-V*%+].<//'3=;R$'G"+1T*=&</RW0H-QR3$M;YE/MQ 49FKD.E6T2HM$F0
MI@9$*G\Q^N,?-E_9"@+P*D2C@IN!J9% '8HG^ I9D&,ZD G]3V'$US^/0N+;
M<9<]"NYY$M1.PDM;%Y% NE3ST>VD#I48=07QF4AS ^@:#]%^]\])1\.G\\N%
M%QR; &$ H9N&##-*>562XK>81)!^\F+L)EWIKV[B$U@1B\IK]^QGF'W^:MVP
M:^C>5N(-;^T=:#/@]$$-B( .)5)H/<[U$WEI/.YBM ;@X"68&0Q\78QX3-]C
M-[:%X$/>JA"H?P9K8O,P)OXPFRE.T1;-*M2F+J#)AQ$O9D(A,DR3S$#K0 M4
M*"6<!E!,LP+FCN.0V)Q#@):EP(O**DPCLMC9.I2%#D67&>1C) M^ [_I;66@
MTEY'+@^O@>!I2K5GW!'Q%3Y-Z*A#&6*16ODJW#6 U:P:$^G]-?N;?X'\-GZ#
M\@10"F3.N7%?.U)T 2U<)>'S[(G!>$0E>Q0H+-410FCT"E) G#1FADC9*F8)
M+&N6S3L'UCF_13 < >_ ".3V\"5 "BH,:I;X(B&)HN#@3TT24T#A?QZ<B?AD
ML1H7S[K*:P=*KT)2-NQN)=64"(Y@A>LD'%[!YV]1X@M=W)XO<S!J'WCQVN?-
MVX$^)1BB-IO2CJC8V_XRY"P=ZD]+;E$5P,C64(HSR6IK>:1"*!D@\@2P\1"M
MQHA;'&P9@#:H!^6B5Q'4ID5Q#S1,FR89^CF9<8HCM)5T\7T$.1&:=;WX^*?Y
MI8O,?R"^MY']]E*':K+'=&.TAR<=P+JM_[JH+3K4!*0$---YE39":G<AG]G@
MV>Y(500:,^?Y<XZ!W1YOB_OG(&Q&&C:DEC$C^OA-DW]@2F-8$6E,\9T>L.9A
MF0()OMF]?@U=T^LE!&V5,/=8[B_4<=&0\D=@@VJD>9BJ2-@*J!;H&R!J*0T$
M;=M?*"&'>\;5JAW)9$61W.TH8Y._QM7) ED0%%_SC!F:K5\Q+D]([372H0HG
M'9LTYQ2(J[%U=VB*0^>9,Q"#HZ5\]4H)S@629V4/P6)O>8Q4;,4?U9L2,630
MW^N!GZS_M*72-%E=B]A2R></W&$K CJ#D!U=S5!O@S^25ZW0H8X:YP92#H.E
M0/;P<MS;4?@YO9>7Q=*A>F)A8SNDY)WM";W!*WZ"/P$O&UX;/]4^LOQ6(1V4
M:MBJ$63%+_][%)"+/>.T8K3\JN22(M9(D7^4&R\A0"LS8*/H"OB#5"&5R*G]
MI-P.?I"+]CYPJE[24$JV#U/CD+IZ:[0A=9PFW%H&EAOB-VHAH46 DA*2N:]Q
M2/(!(T'_AOEF]E<4I/XC"F2.2U5&XECYY<XL[JLL)(0FTZC(SX0L:SFDL118
MRT]F-+OBF,#4E2G*8>T(N>O2&%#J)+R,'5';0N.MX750E>S[3EPMAJ9Z#_ L
MD.KQJ_XAI.A)-;+2#W\"9,3%YIM'+5CJ*=,X(Z3VZMGI+B1@?DD<P_R"D=BJ
M0S)Q;"S"?]V:9OUC";&S&$@RN9:@?0F,L.7'=2BFR\B?B6;5Q'3X"JCO5DLH
M9GZ;@V1;_3$<Z2'3PY'=@SE B(^!NL^;DB1,>2!T3.UW(Q3JL3B,F%D9*H^R
M0VN^204C:J#'3/Y&?0XX5:+-\:SR5K/M;(.;$9QPWK/_FI_YG_-'(?-3UL$M
M+I!FI2E+LU)%09AXCF]W8QM0?@@_SG$J[\$Q^TG@Y$?ZXAH=JM1+>(Q\Y+$.
M=<:?\C'X)Z>;*;*CQL7R_'(90!I24H?T#[UOT:$63B%J81M3N1*D^;%5,_^6
M_EM:"!0R4?L0MX\S'PMP#W\FGB/6-E/'07%& OQAW3!%UJQV54)C2AX]BQLB
M-%+OI296 IHUG81I ,(B7IH]VQ.,GT1;8O*9V?HF/UT[$8\,Z5!_4I\)7!UL
M"X_^?5E''C+$VOO@2;89>AJ"U;F/:VN8X@SM\XW\^C#@LSL;*:IA-TZSS*!1
MV75'LU3[4-\44.*U"S!Z1C& 9J'MA4A>2*W_ PRE]C4.*<&3(#:;7/(1C!G6
M-[>=POZ50T!!YS^X[_TWWUZHE"HTDV!A(ZT]O$2;<,GL9_MWCM/XLR?F?0\,
M2.'&->1:4:!H7(M<"3&%]1*LZ2Q6_(C#RIVD>GIT_W(&B$&NAE6KU"-Q4-\D
M-A9![*<8/1_]<Z%WI;[=S-)R(482+2H%%3YRS/Q?R[NMY06:-9%!RPT1.ML4
M(?<2)>A0AW_6H4*P/7B^#_&Q&C:>I-9D?>ILVP**$Q".S(L<!IL\?H,)64,B
M7-2-_\-BK';?ST!IA-!:DD_V"4;L>*V6BY>;^9\0$QE(/BHS3-5:;D$(C1)4
M*T@_I4.--ZJ]-0?G/W=JV -P.9HJ'0H95+/<' F;7.BDVJN' []64@A:!SW<
M"0A$.']#9,;?$#%I(1PFQVGS&0 FL16L*6J#YR,36,N)<O32^B=@Z')PJ$ 3
MBWCDUTIF-U.>H[C(,&X'N&="X7GP%_6)#0C[+4SCCR.YBJ5BZRF+=/E_!8F!
M:O)Z&?ST;Y!\_Y#Q2-&EW@6W7.&E/:&L0, S(^&R#/,9X*Y.^1EN ZJHS3+W
MCS!AD3*!J@P9ZGI(83-+IZXSN3,R8..RA'B0:ZT.O&00_STT/HNCOU&3C*RX
MHE$Y%QPS_D>P!15#_PPVDX>,=,5-]7Y*&XO5P])\?PB# KDFZF-0M\=AZL_J
MW_3I'SRI)T]$7^X6?&;,@=M48D78X_*Z(_9>""LWTFN?4.>SK.6_N!_+)63)
M$V2DE":VUD&&J+XG?NB_<\F%?W*[PBY995;/+#,0^N7:MC-?C(,A5Q[:#EY^
MPZE_%O>D5]]>%%>.< @VUZ:/80RWEPO%?W8GNLK?@R0C[GJ_:1W "X002OP)
MJJ/#0#9BQZZ=3=IM;\"_@>+T-U":H!?<H^H#"GS$D2Z"RCN2D#=&V5]Q-DRF
M!4^!O=\!507P!YMO"7^)M<*('H8,7MH.GFSC$8S-@:EX8- 4BV,P!3AVB?*N
M_DF=V+N^7\GK\-,RN.Y%D]!),M;HYX83%5"1RXH<?Q8]9'0[Y992K4/-#U8?
M!=D)XXCLH$Q"L#/!@S@B?\$ KU52-98Y<;<EX&>.&C<&2.>K0[+4Q=99UME#
MR[=.TA "\]O,46JH:/5B,TT"@X(IPB0("-]]Q90E"$.UY2<J;V6-CYW3\YV\
M)-3BQ6HI<^@^E7Q;9E =F]# [&$' O.CURBB"T8!<38V2WL7MP.C=D!DH/T'
MA,'N_G2L81/"O07:7YN $3'X*Y\YTOW-EZMJ45#*Q(1+0!B^)P5>G+I,D<,:
M,-%8YNV[HO91;W'S$38T-ZHY)<IT$N7H=6=JLR"H2B*25TL.*+[#*PZJ*!=S
M;=0_40Y+=I\%3]Q6R@!^/]Z^.1\N/@[)E 9R.U<E.A^I)CJIM9.T>'@AI8M0
M&JFX]0@)(#!$[ $OG$S'"P&%5UX'4%I#"FG:I'V@>;$[WD#D%O8)0*1QCXR5
MR@T'X*46$->QR[T[A:W8;5FA7E?^I^YC(K%T;9.7JCX39 ]B/E>(E/*X_0I*
M*6(ZLH_84,Y03"(R\SM$]9F"-1A$#[#7((6%)Q_A-2L]K"42ZZRAG*_,4&RO
M(>^ 'V*X@F\ZU'>LR.%&[6-RB#DK\U=^DQKX/"A* CHOS 4Z-Y3 X$JXG@6R
M2P1[.",.9W0H9UH*0FE@KP'_%TE]MZ*X0(,%YZ<L-_U"=$?8J#RNI/EOW;>6
M-8P)5)([H!XO^3M%M44U8I>:!VWPBOR$[D'X$P+P&E>V/9*/,T\ )4Q5R=^7
M%:J]0H4]QN/^L5J:#G4"ZK7DU1 $&'&% U)NG>T=IZJQ\,)WM!F7D'KM/B0\
M>UZY::@3%)JI@\FG+;:6 G-*$>T\RBT)75ZA7\?60\@)DUG)9H A(+9)+WVA
MS=3)%(2IH'? B\BI\E7RQ^#'T"B1JNL=6!(AO"6Q?59V17(%+]Z=I5=]D/B:
M5^004L#(W%ODC8  4C%] ID-.E0OP)=J?J(CBX44:)!*X*I'$W4<$O_NA= D
M*9<@0F()D4762P&!W6$="K@!_L(7G?&8</L60?L=V4NO5T/"6Q-(_*J4,Z^1
MAQ<:(()7G.CE7/R_R3T!3X<2/E5O!VL^=)B],07?(FH/5Z<VT%AM.@7UG+!?
MAJ0:1&+J4)US9N)5'Q"ZT -D*R+9W65]L-",V4?+A+^C]##6 &@^LMT'^5]!
M\:VXA_B-Q"!G]S>6?Z,C>]A4HD.9PST$Q( ::].WXH_WQ!C8B"-$-!]3N-:1
M4&X(;%02]/S8?'GS-3PV'SN9M_Y?=E3-"-#F.&$FX#*9%Z+C>R\HR"YM(->]
M=1RALHTG[YX"Q%0[!\Y&P,(7LKZ-Y%JHW_?R*:#<0'A<KH2;'B.(_>*M9F[F
M');M!J>DD*KM%LA&,I<OLBW9$/0P&QAOR8 _D+L&J+V4XXK0 K!F3WX#^9<-
M;>H?1I'LM8A3]KO^0;#'<D.RAB,%!#<=JC:2TJE_4H[V'BAJ*/OS&*!HN:\&
MW@;3A@G(G'D(ZW@KT!\9)[N ,X>SN/$C\C,W('$.>+Q1CB][[, 6HFVF3NSV
M'HZ[VZ1#A>,8%[K8G81R+^$O6+[ZT!TU+@6TG\H]PB@9GJU_)#-&$'00<?6E
MWX;U??3Q+63P;@M5EJ,LX&4)NS:*];WZ9P=1332KP1"@.SB0:OP=0464#LIP
M3-5(D"$WHK=$#KE;(\K/0701_'Q""@BG'YU5*'\0@4BSILW>>G57]/<:R8%.
MV4SE6?:G<4A^$O$RF29IDLLZ(>Z' 478H]%B!?-/89=>;RT_P=Y(NH8O:1P&
M"T>2I81XJ+Q B-1-AH8[W1U:X;E@S3HY59$#_MH[!IW9I K0LU^(]EP^7#8$
MR.!I<-$PB%CJ?@"S+R]&728E"&>JR<3;"F- <=#%/0F3!'=;2'@5@VJ#;AA$
M1!UR-1\7RVC.BG5J,IF,P"T['TKLP=<L)UO,NZ9#P49/'#'"3>JG."96N(@$
M"G E.E2@IA:O#7L/CFBF:P,15AAI<E>]D>=-[V$X:?/ ",Z*+0F/G6J.6->$
M/3%+4!,EYWS1<UD:"]_N1^S;<7,</\!LJ%S4<%6"H+NFO14V8<;7YRE!<;(7
M,:N!_Z<N0!1+R!1T(Q]^=1PC@V>"A<[W:./XJO-Q@,L6Y*4HE"/0N7R)O+WO
M 71%!5Q&9!.5*HSB6[W.@$E:"$%P< 9<2<H-P?=U@N,B_7VLBC*3)!&3>^8K
M0OE6+<9M6T)J-O7;ME3(@*&"GF-2#7.#,[]B";-S_ X,O@$Z[K9VR3>HLT+:
M9(^04.W3"+A@CQ,\=['$CYC+0CB?*I:Z&179DQ#U?RZ&>LX.QU8>EX<B5FI:
M2YK8<Y+R 13O@Q)[RTHD5[S$NR&)2'N#;)JU29^L2Y%R-!WL K!-@B1$2 :\
MC% BVD.'.A2%5TK9K[9 GGFAW_P5UGR19HD]/T1C+05K7K12EA9<A=D6M;R4
MN!]WR:PU2-13D?4V^.Y1.^M0;STTD1:I3Z&42J_XP7;W3] O%D;)W*,GJ:'N
M;6O([*/)!,'Y/8B 7(C5^GZPU1C'Y2&AN1P8[QHI;Z IUD*L2Q*GGR,27(":
MK1HS=<E1Y+(VF%+EV=IV2DBVG(1CK):A,5)VDYLWS4.!%"LSETAF4*8CLNYQ
MRL-&WI68E7B%9_#-#11]8R$=BL]#$NU6\'V!-J*1.:(Q@ N'_^2$X&.(-MJ.
M5SLJ6R08>*ZMVA.LB7N&F1,*SF#'PUW6<E]Y&>.IG!N!S *W#"$H2("SNYZ3
M31%G7^_;)N;O!HP<=H7BCO4?;?>ZAL G*4+5_1<RH3'-"W"T('O42\7]?]A[
M\[ FLJUO-+8#[8BHB ,0%105 151P9!J!T2D-8VHR)A65$#4- (2(*141!"$
M"*B(:-(*B(H0$9#11,:(H)%90 E)@,@D"8&D0I+*5\%NVWZ_<^_[GG//>>[P
MW#^JJ JU]UY[K;77^JW:M?9.!-G09"ZI R;E#KSD[-T29BSVK0*$#O3V7XGT
M V<T[:&% =N#ESV3A[UX+'F(Q&)!O<'^2&"<Q%Y$#X"\D-X978-FVB,^HG$G
M".V-*+2Z77\,8=[&\;)>NUXDN&O(4/K7@)]73(*?G.0@_3KR9?R7I7WX9$ X
M@FO/A"_B<X?AR;YH!9D1_@(A_98++=)!F;&C"+\0](*%::#(1(>*QX]1O=0;
MVOKTB*.!5DP2?&D9NC_[-+.G%INW+;<]D79*@;BMR%OD9@01*VE,H>81Q$=$
MCVL@OPH=D6NN:__DBI %M7S-'.:'.>EHA3VYQ:!O K3)[H8@@-1](WY\^@5F
M,P;AQ,_CW0$/=J-=%#7O@:Z'0)Y 4D63W(H7+OL0]@#(3[$/^\6^!ZS=KB^_
M%AS>R1B%%HL&=D!R;FY8ZD=7F600V_RKV&9E\ZWCUW=[Q4[?(+NTL8_ZH.3<
M1Q7*E(5KXQJO>=W-.EXX:&@I6M]MO2C@0;1Q!^;9_W#]RO^[C\F1RE2$LY>(
M'?"K+<SQE0,C7Y@.@/>P;!D5<?+/9@_#5T,4)?0RA;L*%7(?UE06H7.(>'@8
MKT!4Q.ZHC=O[T_RF_(ZMZKU^ _UTSSDYR'=!:!SD*4HZ4K_I?7GUFUT?5B76
M)6YT91G!3?1:SZ2F .PSQN11'T\?V_EC'B\(7PID=]VUQ\CWY-I$G"N4R+\W
M_43)<XIM[C.KTT._@8'6E>?"5"A9GU@6V.TQ"=+6>P51?.D[_::E<_56^=ZN
M-QS8&*1"/8QOS7>][->4@:/!'NK4M$C*SICUAWR:NM7N-I'J:A,VG:^>ES:
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M'M#MJBFB[9MSXQ<K!_Q[+]Y_;@.O_RL'V1MF,U_H#*7+O4FV4!=GE@K%O1U
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M/2/K7ZOF_Q6&^2]GBNZ'@U6H[2J4;+G$Z&\=JO_;$ D4<21C7^G@U/SW51F
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M"W]ELPHE6D==8\(,15P*>5CI*?-#AMK/R'C##&3!;6J.9'Y5C].?0';SA(3
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M4^*WPJ;$_#->!DD_I7!S&D?[PRR,WKZ6(_0=;\TU2$:^8P8G:_UD'W"!]0H
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M@9J?Y#_(']829U"-T:+#X/0JDS=+R]!:#W2=UA5H>!:6'CTYD'^,_"F6+$L
MA94*P-9&_&R;O \2Q*!W=ULZ;!_8&?B0_[]^&,W_FY?*#IXKLWPL]!?$"?9+
MA\\*9/L;SDQ4VZ[K''U/-NW3,#X0VIQ7+$XWWG%HW[Z-_;<2]GC[W$M4$RH
M5.VC$"I:]N9.&VR^AYV;?64K^C% *WY]M?+K)0X4-W2^H%=",\W4/Z-DW.DS
M6I\1,^-;1FQASUP%D'^C?G=W=#7I:>')X"OZ#S?4GC9)*$T../CAE6/*UD-,
MT-PO,I'\P\-NRW.]NCN/Z*_)V%1G\O'P=_EKOM%96[YDAM[7MZIAZIMG%-,_
MAE;#:MUF4YP>U1"N_&44YWN3B> *YUU,%M7),;/IMD]RAW,5Y0+7^/Y,TP<0
M\\O%EJN,SS%2B(M<V\Q$UI 4@![K/7L[/VXJV7OIFL9K%F"BS1<]S;*#&UL#
M# ]K!N84T3;M#*E1 /.K9"!63-K88BG\-:R8?0_R8T$,7:;5O$!X/PZU(,]0
M (OZ];&J%(/S+L\.J&Q[\>]3IXU+-SNU\X0?F!B0R6=F8735,;I)J':T%%(
MC^Y'*X#K6.ONNU"9127$G8;@Y5CK$NA_O#$,=1U3 !HJJK]/AV;._TCV@THW
MTKD80"ZNAX2/0.2\<LT0%NW0*\XD= GV9*3#7PO^M;W:?Z\]!I>70Y$?YQLK
M%PT _UGQ=DK%7_I'BK=!K!\&8D5XRA^MIYCH-__]UO#_>.M0=#9.M.A[IG(E
M@9JP9NFD.;+)>%CY&F;'>DR-<U64TZ>QA/2$G(GESZN>*@#^=@CNQ8D6^O(D
M*//_5VO<O\!<_A7#_3^LM#_%_E/L/\7^4^P_Q+[G(.S7BZ-W8HV3!;,UG@>K
M*1NSZ+5K;8K V="GN<K,M#NCI> X%6_7,*ZNYG7_HFW$>)O+D9$1;=R'V3/W
M&G/'QUR893[3AJKV#:4E!C;\@'ZN\WF)_LXE3@Z__!]XX?G_[.6Q^1\<AWX.
M*_#^[KV3_$=Y$J?G"K4-+3+G3*\:$H]R5$7G[8^GMDTIMP0JY5]S+&WA2/#R
M5=>7^OU0YRG:E^^9XCP%G2[,C>P$-Y+PDU%.+X9PK_!A67@-V+MB5% [!]GQ
MNOW#F,&9LT:11XT8U0RY9TRO<L>;FG-'W<V7DEJ/\6M#4).-15V#P>OV<G6>
M%&RRE\<$%/@5=1JWK!M=/ZI;JG.]_/:;-+W$$Q7?W[!A\/K-N+ =?P$WG*X_
M6+CRQF#G5O_XW'6=JCAV#/<7&[F/\]M]1&;F)'AK+"KS]NQ"M+;2>&>P31CG
M1 B^^&)9Z]ETD6[)!:WF;OS,-O8G3F^*GRM4PKKLQ--"U[13/6TYV5';R$1;
M,\#<99@TY:4 SBA7^D FSK$&'G-_*:TE(HC TXY0U)CBJ,&5<4BPJOK.P#S\
ML"QMD(D#^4!N;DYF8T29M(1_PV.;8=0.8[DL,HG999#^##G'*,IY;>.96A4@
MW=U_[$&?!&RJ8DSUNW(^4]N"]]F(Q%!;GP)H/6+2QASV4P!MH0MV!JM>Y9S<
M!FG[+/:"A _A"]RCLI#R%&GPF(P4JQ=E,\2<\G14_[R,YR#*9H2.\PRHE/V-
M+%.C-U%S5&+/L'-[HDB;5-'8J8#/I%")=BDS!O-2K+B.I$Q<79\R:C$ULCX?
M,;[]T>T42YC8OQMV]!%4F3Z*:NX^$+*IJG+,_.F)H%AD[5@Q_@I%%*< #D>8
M^=@OXUF_TIK4;+]=9IAA29V_]]6B4C%=['ER;^4\';\R/W141\]LZ4#B.ECC
M,36XU-SI#4>#@/_5U:6R+SD]C;*Q&WW;U8(7,OF[DD7A%0Y?\GZ^+WQ3F1C4
M#YEN.V$=&K0F[5[WL9LWM&UXS-@EF>O,]CB69<MR@X[T?6$=%CD-L]\0YS4&
M<-5A5FFA:?9'F]B067>O?LC9MP_E^'V3X4)_?_@7JH]UHQE%'Z;LB'9_%8G.
M.3M9OL(6(/B-N3$'I1[<JFH8PZHH"ZAY?DY4NP*XQM5_D@_=5 #?F'%##0@-
M-'##ZT;CYMN4%-+)U?#88EM"KO0@!Z< /.6DKH7YGAZ0WX(>YVNS!9W4&Y^4
M9P<'5#M^5^EX;7 ?3K7"_T#-]TO7.J;L\YD,5=T9O/"JS/#YESRWBH)NW +8
M<W_+(]OA=6?C)S.-F(.3_:-T?3@5F2?3\T%-X?@,>)_/\P7@ 2&BT4ZX_>Q(
M3^3>J6!P[:#RA#'2^;DX[=#ITOON$!M67_DDCWL#FI--"L-IKA!F[?AY++;'
MUL A^HS2KSI-,NJA$]55V93%D)=/'I'Q!'8?&M9R3FY6 *9.W9.^E0\#ET;B
M5E4ZA5IMU3WN]V+6W,3:IP@JJ3J=(1-,%IEPK^>Y)_Q:_*L7?47=A)?!5K-Y
MWX&!['%;J^>7,_3.:BZ]EC8LFC]4<ORTP"O8=4LQAMX@(3^!\/PE!C5^U;GG
M,[!;#EQ3_OO\64L<; CYH6N',;S1$X_J_5]Y9&NM4[N%D\?$/*D_*/J)K:D
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MR(*KRI7)F%2E7XC?0UP6]J>0;/SUM38.%%U%0V@XY0Y@H/*-^-KE#*P"J%(
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M-'I!IBNG7"20,Y]Q THD/6S?ZX%$C.H- KS:DP@FIUFJWV48U;S$RFE!7;H
M7$3:W3)9'-X:-E;4YV;WU*[6-E12+P^6[QB"*X6!51K4V@J<.)BWB+I%DEP0
M\NI2SPS9+3KCR%"^M0;E ZD =; 74[ADPV]9QW;Q=O>E,-6DN7>6,#N+/3%,
M2M_E<)CAE0!+TY^XO;];99>]ODR)17!P_1 \7CG_ VUAA8M$A_7>;/@Y3Q01
M9.+5+AJJJ%3^0+N8:&.L'J1>B+P;)]'[#;&1"R&'-_E\J)YGDV=>-+I+L(QX
MHW\?*=%$+2:(O*&ORJ[Z@P].VM@K'HM>VXB[EH!\],;]+_LN'74Q_L75.(0L
MQ9D#%I]?@T)F^+JH';DD! =][T];& HN+KH10<[,\A2N>6R,EZAFEV";-*BG
MQ]^7BVD?@WN-O(J?5&>_QIEG7=SU9[]1R9M$04.BNU3AMY,\)<E)K^GP2*M,
MCG-IX^!O>+V73Y6>_#Q&?T?B$OT<GH09Z[&^800;(_7$2;>(&7J/@-)C5TN3
MJ32HSQ6=$8K+S!6RAY985PTJ)2;I0=;$>.1.F_$*V;D(NGV$DXU/1'Q$(G)]
M^7FZ@SA>(_.)&+4PHN:P3YF\GNZ\>X$X;JO]=]3"E'UR)$>O@RC<8\H^RCZ&
M.\KV_@GY]^]Z0E<G_,O?2.&.^^.5_A>=[-VIN;B3(_G1%J-TR+A$10N^K4$)
M[VA0VJFO@M7U*E,)%UYHJD&9]/(P"AZH065<<Y_8H^2*U\!X20SL]$:#H@=.
M)RAB?M2@/E5J4''P[?:CCN1343?_N_>_^K]UN0_15/J1_"69ROWP%PUJ(>B'
M7MP4V^3[6TE[V#Q:GZ-]#<VO9"?(L89;3-1%\<SCFY_I?M*@>O;#"RY(@+WJ
MM.*-28*I>Q5A+PDFN*2CK2I,>-97).P9 GVL8(.41"<#)'H8@.63IC$=S$OS
M)-/P@ODY_N&<Q;O+Q%->;3-;5-7*^FWP%^/") 0L LIP2R5")LGN< ?SC8PK
MFJ]!_9 %F4I,JGYK0M=@[L ZK?2@P6+^L*+*SC\C<8/0&(%0"'*A3;=6T."%
MODIG2K<3O#!;N9_0LNFTS-6SU\Y^.Y4SNY1X0\T<2DL,5FR@]SS8/$\2"R]L
M0>I.@)Y(P@=^I-68S1-0[CNL0*^]OS&9=;BD=!H3)$AT%A#/Q_,!"YL_U,;
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M,GX*&,N,<+_%#,;\+*0:0'Y$@5!W&9X@X+W,,TA^G_GG+RYRX9(6MG&BTWT
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M'*M"K]6;GJ@]<JV)^_3,M? ;+:"S5&Q3) &EDS08%<H4,X!SVP'!MZ^;77Q
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M:,4BN@;U.UVJ*WL!3O/1T'>**"0T<N6_:E TM-;COX&(F?\@$/D?+4ZJ?3W
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M5*R0!IC,)K!"T+15\:U8,&<:F)HJ)AUUO [6V#2,_W;U=>^3 .41^RS'H+Q
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M^0[*Z'"0,KC@[@R.(Y1K#,@%)A:),C/C&>^ARXU=7$Y,_;1K%!_?TW')K,/
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MC&K6K/F?*TV&=V&1>/[9'HZ5HSZ&+13$R5$[!5F;YHG2HP7(,#,2$OU1U]/
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MT.H_B%8VT_7D<;:YSR?ND!59K(%B+//)7T<2+T>ZBA@]BM8^DV8?Q[[*46Y
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M"1"<H;<;*/-]D2EU3.G_H37*8<0A3GTWV-/@3[C'E;#[%*+#AD#$F''W7?9
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M :['_IFH(X-_8TN]Q6:Z.7Y4*=]38VV9XGOV)4W"YZ%O3HA"3IR&TFZE(RB
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M1\/9 *9^!FCK2'[(>W9B^[W,7\,$(XVJXV+S!OVR[F\_Y6J;;-KY4$)H I>
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MT04&7#1AUO<.S*'1&$4Q]\NPCN*/S_G8(R\M#P,8*@HWNCN[D.HF Z[;@F'
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M0?';-(V#.Y/5P9GH,T;_1S9F)8NK.'./4XAY#2,%R!+QX69 T5D3^4)14FK
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M4N;[L_:TD!=F^/27NK_BJ]?&RC>G:4G??8Q[K8O!+"%_[!6&J\MQPB\Q>?!
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M%UT YXM.>-#E@<\-N.5>QPM/'0>_4YM>_*S1@,L+X(WSU?H>=,0H2N"  EO
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MO/LW#";Z^_I/+!1;M['JL,X0Z:U>L ZKNP_\U0RH\ ;':L[D2@-N/J!*>6;
M*<Y,N:V2* J?J>(4+AD)^6Z*PA9E3G<9H'U%WX@<.04V.=F(,'NN5^!GP%O5
M_GES.3*G,](50+L#.)>64;LJ)LP:SD^JX]+&?@(EN[I!6:)P+=A @F(,N,OO
M1S /)PU=MD(N1A88<-?XD$<G9L1*<9V03'\B(D7A>2% ]=-RSRLP0;9TF-*
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MK?2\W?RN9X0N>G4P89[KHZ!Q(1%#<-UZVV@>$52/6,-E;"WFM14:/\3HC;^
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MW'OOQ(A>;'Q27Z FH+-6*!B7T=5)KFK'BJ6C?KLVRV\HA\>H"5O-;XN'![N
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M&[-Q!?*>I56[NZO8?)7V<(H[DEGF*L?&E.?6\T%S_%QZ_I8,9(.6R*L39*#
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MSA)I#I*'6G5M?6DO14[ZGZ/=Q)O)%8,3"HU?2-I3;("8@Z3!V^9<KX2CEC\
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MP;CS2N,EL0"Y!G2E*<R$#WMIB/4B0LSL_]4BP/\[?_Z90+&0"T>;5G'>!,]
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M&+\3:-])T O^<:*RT:]\I*21V:5FPO,/_4TE+E;PWD:)6J6H#@Z]98/MC"&
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MV&>7#[C08039-]IQ)XE9I1S.LR6HPX8'3$=YYO9D[^.E%Y'9X\) ^H53'JC
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M+N!8:#W'E =+:(B<N&&KC.OP\VR<F96(,42*'J^%B[ U,"6 PY)\.J1_;L\
M&CP?;]--JGQ;:HY*$A\HZVNVSX>I+>@<5WC:THTLOHLF'RV_R'][@$+'CX>O
MB<%P1P3ZKF5N41>LNU@.-?L9 Z?>7EGFY6KBL0\05D@490C!IV3VQ ,=&[;)
M4 8;^(!?;", F%R"4]HS8A/L_$0T!:4-OD0"N6_/O!9R@2M<Q;$_PA]V/N)C
MFK*LW$0?H2F3\>WQ^%GR??/TO4&OO!W3,P^K\T^>G]D1COXD'6$CM33](<U'
M1.M@L+_W-\GI.#W[.5P16K-S'C_T)91KX6J]3E#=2JJJP&A>8].!"ZEZAU;7
M1V9DG28\4(]T)]N"O$>O='V@]I@.)7==]L/[@&)K6WG6JAU:<21R*7X!\P]>
M8#.>A<%IL+*K#-B0.WH\%4^%,"WBR!--2AUPGC/GE^;U[[I3*1RFLHA8T\ ?
MZDR\4//CY]6GH$7#4T+!H?,7FH4+P1)J8#<!>Q^'!F?4DH77_9O/T#0-;OU'
MO6)8(;=%^/+%\9>T8>#>25B6&Y[_"[ELLT7N"QYF@V&M9T>8R(U;Z;+HR:^1
M%VJ01T,Y6R 6,3RM-1V;=@G8-&RR_!(TH(R%Q4)9?RG.A+D';@LYL(D%/FQF
MJ.E7MH$M%_'Y#V+B!;$3#4J4BX"QIYUA*6O[+3<_5^=_\<N7*OJ@?#X*NFCF
M4_C-EXB</T0Y\[4 '"XA@^&_,VJ\WVQ%5[.UTC3?L!/ U*/(.@E297</\4<6
M/39/,V4-AZN"D^RWUIWIB#*4/R<O&5-G9TOD6**N_V0XD&H\X^PNPBDD\D_0
M@)1'>=0ZN1X[H_$SF4T-IP+(G1/E,(OAKK"$%NP0!S7^D-PW24V5!L_Q,"PQ
M!^#.TP_<2INLT)3H'G1,%AY6\NR(( 5^&7DBFA .^K?:_=$]SN 4T 8?)L[H
MV8R?]U:HG9H#1!!T^/@1GOQM;CP7"UU'^19YW;@,+Z)7 %+&X /;/-SBTTB-
M(W_S>B?'Y''KCL>2H2\3T_H"8\=Y,@*X4.4-.^Z1^4/JWH]_5@%SWJ$5>-63
MUO^Y1]T!!:+TTU?L ^@/?DZF](AR$;X5U"#I*@5=.C>W8DW$B?CWLSCK'U&I
MF#:SH(Z@@B];*XJ/F=CM.>S%PR K K!ML+/'*LL)+[+-F-5$9P'3OZ.CAXR]
M:[E'U@QX^![4[JQ(P4Y@OU8VP43)</5-//?G<JMS"+I\SY)KND-[2]Q7QL&/
M&Q$KR/ 4X]_].G.LL!2'G4*:\@ONIUJ6XFC),KUIIQ0ZUT)G?>C+GZ -0U^Q
MOZ:RW*DW1IZ:P/)P4PH;6'^]1M88DF;Z#'6(/?6I$YRX<0YW;ZI?T<9$>89R
MF79LT(I]%\*KWK7(\].NM59=L!8DJH>2$3&QY4VZ:X%:D3VT^00J$\&S>M[4
M(4+VFV+C Y;&; I72E5=6'+N1A8=FOK3Q8R VE=MXPFW\4C8-@B EA[" ?QL
MAF5^,H,1'8RB2:QZ=_NQ#1KR,=$.*,QBHA!]<1"]'L7U"H/,TN$B@ +C]@>D
ME >.#SNG6#(X#]]NC06MPN9<3N<FKQPN=WC"R)@?A.;]*:\\MJ309YSI!4X(
MSC9UQ%;%]\,9%Z0Y7E/U1[>Z$:R9''$[EW48@>]$^5,]+CDB_0^JF  B=['Z
MA"%SIH4>@Z)U9RK3Q.6%E*X=O$3Q&KSAL#]-8C6-\G92:8;:F-P..JGA)&E*
M X<#* :QA\9Q,'8HLM;<-5KV V&2,M71',3DJR4F$ 3]_ =>$2%+5P:FIWO]
M0+WB74=V8CH=5J54A2,\%\N!C8JSD<BC?)@QL!,_!8N&\@]]21M"_[YVJYTO
M.=QNL$HHD'2V*DJY%0CN#(LV5O\9#U>L#%9>WAG.YIES;!1A%!V;- Q!GY39
M4FB49G-=>/1PW>YD!?'-N%3'TB<NWY*C2RAH7\U[7%V3@!J*X9Y9REGJ#FHM
MXFXYC5\#*DPII:<[MB@)DM:]EF*W,T8"^VKJ#KN>9CRMJC(?<;.ABG',@T8M
M4!QI6(JO3&%;\;Y%:["I/USAWSS.)>T1=UWW#&_&0 #>.O0A*I7,E^^OG?XP
MK@]F!19&M(3@#^LG>'/7U0TW-M,$-!91CDM>X"^'BS'=R?ISF?^F]I'A])5>
MN+':VUDY=QW;-L^L<!(.;"M$O8\>]B-KKH?M)>X^0P!2W?H6<=Z]U \$/Q0F
M+[Y]%ZP\9>8FD*V,KWXE2^^=:$LXF\P9?5\ ?[P/# 0"RN -IYC!23\WUO*E
MVEWA7K)T#:9NB=)/86$#XHED5)4]SN\^76:Z;&TB[88K,^,504^OZB<_Y2YO
M;F=61+(;";1TH7$6=,S,ATM^?:!"'NB__*K_F+IJ(8 1 Y-M-[K7!=QSO$)!
ME"R1WZ:_LZ:?OK1"JK0>WDWJD/):7<8?^>&T,+B)TN7L[$_T +O/6G]C^8S[
M-L>/PO1R-<V8#@TB7Y\ 6:;'MQCH/TWE6R1F46VIB45)]D?A4;Q]C?R8PN\<
M1)Z<K6&$M;AIO<)97MYQ>)"<#%,YDQ0")S&-K&D?&0NM%N".4-@X*PQ5-Q7(
M(8#K9 Y1%TFA;2G4TW0)7!FU:#[&1CU34%1'84_(-^6&9S!R$L_C!X%%P8ZI
M0)*5"!>%>9+P;[KXQ9]W[C_)TJW(DVB"_J\!*>[W#A/VZ>(2T[C50>:[,NC%
MP;IH$1XO6'&8HH>^HBP_/J1FF/PG2V8Q[ACSE@2^VA7M#%V'P^ YLNHV+550
MKQ;\U$\G3/SF^7I\@9+:[:@R:Z<4A'/*VPTWV&B^1\\'[-C#;57EM'!5\.>(
M]<+K_DM3N.C.JCN?>421LP59O= =6^L,]B'9FHERPH=/^7Z,6Q<R@3^@JP^T
MKY&)P0;PK!D@;.5Q2TI0@X0">$=DL&'-6M#"&+C<=I(P]<&"G'735-RG*"01
M-#MF>IOUUA?<,Z.G3@+VWC_H7QJ)BBAS-&J=7G;2:PK(DG)YU(4N&OB1E4H:
MFWTP,@IT^+JJN"BP VEPKA?9/A^ZTT Z;&Y8H[O5[@GC/SM[51O$=AXQ<9"N
M+!WNJPLZ^(P )@9-$<!J4_\?3<XJ*'W,*5S=#K=N>N^^6IXWEVIR:W#*70&3
M5E%**MIS]I\-GJU$?C<72OXZEZP*]S[_ILDVV48L6?66[4P.Y?,#UT&A^57[
M3^PKB3J5_8?E8[T%YFZ76\R*34%V3KK2!LE[/K,Z$M"X$QWM/)P7,F.ZX)V@
MU]YF)KT7A\YU8OVFF7A"$D^CJ($%9@<I5(6Z1;JT.M<9Z+5G[J;A^%ZBRL6,
M ?&W%D3&&I7^)@9-K1K\8/#DZV*UB,X/&,BL$1/GIBN#4NAZD)5P[I8?UBLG
M[8Z"B3:7I..H'<Q53-=%V ^8$-KLB*+>^,F'AU]FXTTR:V4;))5C  "2F@G&
MES,U_X  6"7JPE;Y9*XPCE=JQKUG?HO]<'X8>(< BA1E*<.H!,=;&^(>L!:>
MIBN!N\-8"@1B-.?9QJ5;&Q$ %OH+F4NZE1#_#HN'I_6PN\&NS68HTT!N6[[=
MP7?'6]!9Z:5><"L1.RO*+K0@_*I!O0C P3%(A LB@/25'03PYRCLRJK!OH$/
M(A,M-$T/KDBX#CI^0I9?*>;LV+,D;6_!A(7)E&*JB4J_1K6I"*'-'.3DEZM\
MDD$;H4\)A\A07=U3W7"KOOS<%QZ%.]+C^8DN6J[R^I3HZW NZ69*Y1-GD\H;
MZ85(B1BZK7#%C@:&>4&9> 2 9Y.A.L?0N'(5/E)T64AG'D+2E3ECBJ3@M9$N
M*S784W9-G_1<$?DEY#<H#M5N*Q&B8"'ZYU*UY#4"()94!)O)Z$&E3JAX\FV>
MY3C>\ CPT7Y$@9?2T$[Y_Q*;#JP#[& >UU6"V(I0$OU&IV&1@JS2G)5]"8_T
ML%C*@WKG*6FNL D-F \"L$)! '.-*^7^!0<FS9#KQ0?:SS%W>F9]\CW?"$VX
MD&W3T;$S%KT;R*!D&5"WX:Z'=[5F, V-Y!!&*T%,TD4KTQC<F*G2'0YQZW"I
MBA'QDU!*R&A)G2JQ2EOJ!Q1GN/HLOE4Z?Q 6Q"*6GK!'I$BCVKF/,>@NA>#(
M,X,K;=V5<"PO6J?@H% -E;9FM8<\9$==70@%6AYK55&$P3W2$S%<=+9)@>Y:
MR%MA?KUP'S/S$&*) /JMPZ6](#+#,_B_I*6AKLW!O*CE59[FN*EGEF6K>S'^
M6\LS2<$R-F#Z-4Z5!9]HW\;N)MQ6TT\NE;LXUP-V(SZA2)#0FA+X2VA,2>5A
MVE"%A2DE-S-/4H^;-8:F,@T=# %@TQ/#,:N/;P,MXGJ$^.4;#M5SAE+[G*(Z
M< KX\?PE"<8$00:C%AAPJC[LQ=W&>9O&KM;6=']71M^-VGA#!^9=&LN#QI.
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MB2Q=L328'42G-72%)GPP!#E_"W[T\*BLQ7,IY@(<^2XNE&A#U($ ED,$$)T
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M!:@B%7C.HV[6WNJHA,4Y/V35F5@A1#M9S.&7::)UB/>%9N%;ZI>5\L_OF-+
MGS8&^'9:7WZ-W\Q6L12M/3PUEBYNK(E>>&%HD-AF'U!:9<:GE18/K=;V<-#V
M(TK4!F>0)L0]KDZ9)5&\L4K,L^)X]G^_L*2"RF;<BG:#G50V(JF@X10X. S!
M]7Z!RSJ;S1PWN%_0N%__PH;SZH4QP2'>ZF3NU:&E=[>B()0@^62,X$Z;PF.M
MR[_%PG!:;8V"\Z'6P&'1>GE,9.53R#>QDH'R-).57+4TVVAPDSD9.JJZ^_*
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M#"0M[UM+7ZH3D'Z'Z9%/F]X9D-*C=9DAG0QQ7";+A^ A&1M>>D ]2T^"L@J
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MV'G:H;F$+/4#/R0) 43V* JG5)+Z:C+'V-XUC7K%T.5CC%GC6AH8%;VH#E:
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M+]^N?(I>A6U0LL;4*RP_R%"E4C*^KNQ#J69JFA$CSO<N?(9J"9TWU6OJ3+,
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MRUB8N.1\)NB0Y6.BF?$(,%U]!(!\3;UC[8YP!/MO>;K:AG_S;,P*:?Z4A9?
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MF(C3(GJ@G[%IEFI]$_4@-9TH\;8Q'IW,A2.6^)7;1IY&DD9KJIZWF>QIH?!
MHV7M>\[$)5WBOI4=XAZ BR$9NNCKFM';KX^ ;%JH8;3A"9_%(^ "-? 1(!';
M?*P[<TZ%NW^ZWPCM6WA?L+@M7Z'J,HW!]QFPAM1>Y/P(P+-:86P./M9JNOT$
M;Z]%U"6&A4[%/B= 6CJ=\>,L_+LL*TFT3E;?GO(4Y/05=_PJK(MU#7W>WV7[
M 8<<<:P=O\8BPQ*6GH60?KKV;H:.[]K$P2/@K\\9?2_HI#I3>O<(@%LZ_U5"
MG?AM67V/EK3Y(P!=Z1]CM1\!_^?@(OP>RE=/=^)M(?KG+S=*CR8^V&'F5V3F
M'9[V'JE=N!!SI5\&6DW$3N&4+<ZIU7E;B,!%4N&!/%9&-&'J]3M7:'>T_UXP
M\/0=FW(@]O3,KLYP8M^E R>1/K2F(F;)FV56+4<C+FBA+?41P#7878!>7&2P
M(G\77>2L[RLGL[)<:\ K0;KFYSTJ?G< -I-E=)'IME!Z@<YWI^#0R /=?DON
MJ$^GE(8[-MNW4X\^'M)4+,++WJ?>;81?'"L/>C_K>F^A'RFIT$ZH3ZXZG*:Y
ME0Q639#GFOZI@1O4)XCAW\\=*TJ(Z^"A61#8+CN?,]IC3%MLK/=E BFC&G]T
M6%(2."@5@J*Y^.4;D-ZBVNNNY=JS$%ID0/>9?=380!86/DX7';BD:5Z^;U'8
MSK[K.9NX?YGA=(@$:[T(>KN^ZYZI&[O^[CHBA8SAYRCW!3_W(()%82 31/@E
M-SL..,00CBQ)H/'I66S$N$KOO\K(P1N7E3<H-GFBJ<O5(V3!%)'J!.<'^MPF
ML#\1VW$:YJ[KR]]Z.V0I6":K6R1M7YE$@3I*&9C>=I0KP)<1? -GY8I0/MC;
M^9R-4R\"YUAAE&_SA+;/^0D_D*#$!.  K9AXSLL'N X)<ACBE=#>%Q?]GG#A
MA>K20+G\6/!81G*@+*LFSN6!B1@EB7TK$R,6G>EE.HU)-!5E9)!$W;1I*9L=
MQCQO2J6D$<43Z4&SZ^]6>T28'9J.FAPPK*_&_@DRQSH"-3?BN%V:B5>!&N]I
M 8J<H OR*B12@FEM5D6A.I3]$=EDTJ/1!=ODG5808>-T2EH3GI).Z;)5A5W*
MTCW1=W[J;&[5.E6+LK>#O3 91[ I?U%-E_J*37P ^&UI\+_."XOU5Z=H=WZ;
MFT<X3C% E!>Z-J55A-=4N$=#7S%IX>JCZK_+,LGM+>_A?U9.5I7<P^"HO^)?
M5)R &F)U6014$:K4H>* K+LG3 A_(#HE(/W1C6HRM_\"$<$.!<;SK<V.PKZ=
M,XTLKHLPY/%+26CY*\HR1: +?8ZI^1BOY\PPN) HU &.W!RA?8;Z89B%V<VM
MSBV.F+7;>?ESI4T1J;@Z8QJJT&S5A[3%BFF4E2!6J4U),LV, X]@V&JD$V1Y
M?:'+V?U/#K_[BU&HA\HEK?$^YS#PW,SKY+6#58E:F5MA-! VF\0E4HO1'Q6;
M(<D-/MUY;I&\P"6>6R:K3_!T^V;L_]952: "GL" &<'2<B!R#K/.W''T<=(=
M:"N-+<^N<J .5B!5A503/WR#&2(-H3M]$3=N3^Q,S^W>FFQV4,A$#746UO2D
MKA7&QK&FLYR53O>5M13EY[A*[I2[*@B$98P/F$[?^>MV&BT-Z4#;6X[P=;/#
M+:5I4>WEFR"QD3CM/4%21SU<54R,X$XUFVS63563+]E%9&56-=/;M$(SB)_F
M+B!2A<J,"N?0?LKS'=+FGDU:X/C^Y35:ILZ&'?TI/2,0N!U;*5+R[N=0D92B
MPD=)N7/<<DBWSLZ$]%<.67DIELBRGC IBQS"U/K_%X#3_]W&-+7@;(G$7J""
MH;,?U,WG5(#QA1LQXBRM0KS%!W28,8K%Q%<+4B!Y4Z5?;3+)F:8J[?O3ZCFO
M7L6!05C^/OJ[+T3EA+_:3OH'"*?W%A891&Q%:I8UOG.\VDPYX0]&&JF-V0>O
M102/"#IJOK:!43XW/"_9@Z$^7-T=;(/@/;PLW7#ZX&Z)C[\C3B^C4#4R]HS(
M27N][;6\$=<SWMNE&/"NT[)#(DD,MA,&8ME!S1B'4^V3@>L1Q\;HT*@)Y!AM
MG8Q\63ZK+3N[Y;G(Z3\K!(FA-Y\H=4FTJ[6F@>YLQ'Z;#\# -^\<E+@OK$\4
MI!3<D\%IMYFJ4O&6O>.TM 232HS<709ZT[4"G^/C25FB/F7E9H-'*OY+$/)_
M<B2COZ6P*"C<;N'KJ)4PBDJ@\1?3<=,Y8YJT&*@$&1&)ZR>&N1A_#=S3DQ%4
M!&GT/@(&@;O*24P[QF]O93)Z\O=1"LF";"69^UO<R]_^FG6)&2@K49I5AZ,#
M1R*&]F"$1T4(K>96V67:2NJHX-18JSPH;+#&=$>-I#RFVY0-R#KH=J06OD6N
M.#WD5.HMK:%%&,^.3%EM10K)-4_31"[=;TI>C_0FTDZ8R*-TARK)HP8D:!M(
MU$!M<M\ANYZ7D5X8O_L>!VFQ=]SFV '*M)LP$AZ,G++BU'8J1Q*8UP/),,8\
MI9'SU-SZ&9H7I@QV2M +*@S [CJ6Q&7HDCFZ,37T_$VJH-$B!.>8LB1A<N>_
M<S(7_D'VR\LEJ%DD_(FDB +^I'($S;''RXE9J7GW7H<!6?B 29'98A&39>(G
M3QW_?H>L=D90GM4A@<FLOGE)"5*:9H+6$K/_J::XI1> V.HLZ=UTKE?M^V>I
M<V??IPA;1 6J*/8SY=9@4Z%4'@6D_>*7!QC)&([S&>_@KP7=V=2@*K'V!WK?
M,][8'4/\:V"K?7*)&.DB>1)L$('4\+% Z->5@S=()(2![E NY--9+L^BIH8N
MTGV'[T0A)4%#>AGY,P7%U_ZM-8-Z<B8.EI6*QY?)$+]:4$ -*%,^I(M9KI]X
M.U5>UL"K9NKHU5D^J7T^Z781*\8'4CD=.5AL@Y&RG"4+P[_-]<].8XI?UYU,
M^-[W^6UVXV1K=RP3T(@)@YUZ^@NSI'!);02$*[9A3'N?GN-4XSZ_5(K]O*NW
MFW2BU@7%T:":69!2BO;EZZ(EAF)%SG-+("'?$,8&+)5X._]628AT64VHZ"ON
MDH0W"84DW<UW.0'P!M'U#W-1J*3PM2],--VPAD.+K'\O4S/:=850YT!%.F(]
MR.$]5UP:1/E;NP.(]_-A%"KK9ZLZP3# S0QRQ8A>4YRC.M&!@0N#>5-(?@X9
M;L5 /JFJ A"F;GTD+F7YMLR4A8"5GB"!U4^S]&&4ZD2%X4E-.;7=D&K&_:U#
MP_A_548+<HM ZDJZSB0^.=.'[1^J_F6[.MT5'(KD*DB*T"]AQC-)W.,SZ3'Z
MLC_ZT&A*>[QI< >*<P@.-1#Q2:K\4N\==5BU9P-D[JPV/08>KLM<DAAGZM0A
M_%M!!6PAGQL''A"Y<9I+;6ZSG!0M"DPQH0>:1Q&M>2^3;(^]NOQ _+\5,!T_
MC3A,%WEC#SI-$?X(@?(DM1 .3H\$\^I\+2)-!L5FLV+F%I#:N)^R/NF9S__%
M./ZG=8-$740P9907Z4YX,-&<$>Q 1U+@J-*#;AN_$PKUB,D_=&Q@F2N3S>*G
MV-,RRN$_TI:MKZPV[;?5)_X"V:U>_EB$4N, _F:UW+R%HW.0IUX5ARNN0%E4
M &)^9;I_=S-Q='N^75L7D0/5\9:LI03E(UH61%S<'1P;BDI [^2_7I7QG-SG
M.09"=!=[8T)'S/%'OAI4>= N=WZE512(ZWOS?N! =X;H@"8"W%$;.D!=UJ90
M^P:I0)*WOB).60=W:9Y:$<UJN]Q([0>L2;"^/V*6OI#QMU*+I;K%UX#"I1I.
MF7S2>' $&+'_\6*2VF=JP2N0.%\S7%\GA^>_X7\*7A-2]<L'?Q.:S?D4S(>A
M]YGIJJR_QXG+VA:]H)#[IZ6'!B(HS#J1T707)/6R5GR@]->MQ8J"LU2V%'Y^
M0<,86UXOKXI(EA)"@]06R(/-#RP0-.?J$N<\6,T\5C.[NYE^?:"<4<-F5O'S
MV6:2=5>@FGZE!>.S'&.]<V8+IP\8@EB,$%O+J>0R$OVJ+]D1*OC^LKLU2/D_
M)B"VH$0;HH#8Q!\S.%]#__(9.0XY/*'!HG^)>@C6%0C6==H_?2LH8Q;XQ@=<
M5(@=8%?@EP0J :D/].&R^R9]Y<_+%]L(Q=3"&";UI[:,,6*VI6*2H^(#UFZF
ME7AI?@B#''%,=#V#^W3\?CO.I/ZPZ+4@!7\L8ML84?P0_]LJ3%")H,V"VB@\
M[$G3<-V?JFNIAUA#_!LU*6P4ZRU"M1P5:'*MOI8SERI^YP2KRNJ]R\J.!8='
ML,SXFD=?,^'[S@D8WF.Q#)3\A]_,8C>0?Q(QG! A*PFWXVXZ)X'T@4= /U3+
MN6[C_36ED/@CX"M+]#WQ=-C_O+QH-@5Z@DD+U($<^_/<[$RA)K^CHP/IY)7J
M!:9;V4NC2HIM7BBEL<>D1<&1^7+0CT< \!'0<J-R/>'K>5:X6W!4[,MUV]D?
M-QIWNYI'Z96Y<L\L\/9BVC?E?GVP"<_]Y&E4SC_^DY:D7"D_%6WFU_SZ\$0G
MG[J'?0TG4B3?@U2OD[5Q3JEFSW)/R6;/\L>E:S)/V2O)]:,]%/IF8L&*#IZ_
M?ID]O>^FOV(C_/X=V/KF((CQ+3WI5^$NU%@GU\6HTK3_G,28&",SE)LGC\59
MYA% ^P!4!,\>)#P"4F(.?\ZEEZ5',U>O"K>@2DK*=\]X]I=I7="?+HZI!DU&
M^5MAO-6"#%FR;^F'%Q4K!@8I=5,A"GB@@LYJ=]%7TQC,#TVA#R[2%04M80M_
MI/G?6+9Z>F" P2'@TLNX]['"X=_V.=L="D/VL:PD8(N[FB^QVF X5S.HA""R
M4-TG7&I(R[2^IP2+'-GSTO9F[P CG:'=@41L5-Q;3_JND!^ 4F [BE#/D:>!
MU,&D\2+$<\E+'(?5DUR4G3G9E6[@<G?2DY_#6Q5IJA;9%?%IZ?/B_RBG]"^D
M(8M<69+[$+F.E!=B0^@S 2HL%1T1"4AC_'I'DYT--6*&)C<HBRZDWI;(7B0^
M[!9:%-\LVVUCRUPPW$IX8*!VX:P38A%X6]6=HC&SLIZ6?Y3#N@NYTB@>5S\?
M? 0,*U6%&'4T.<ZI^DRL!/S,+CAP;DLN>SJ6%],3PS(YXVFN<=W3OA;\RHQI
MWJCOGYJDY/M2]3_DA7%/<_C1K_3U4W9<N?*?/A-!^]P1>D)L!\^*.;UQB!R3
M(_M_+2SH6<2XI*!? [>M2'6\ZG;L/G+=KV/Y[;;+-CE30KG2F1%P?]SO_VLQ
MHDI+BMIH7F>ND)=4O%^@?[C<?7O[L6WU_FDNHG9_];.ISZ4>J>)LW*.^7V1\
M>#*=S!AO;WH,MWW='*0K.!J3SWW'5'W&F1[>CZDY*9^#VX8?X%O11DHB2L<^
M\1F@O]9QOK+\HMJ#^65T O9*7PO#QH&LI'Q:QN&[O^1*;?D?.R*$^X^ JLF@
MJP1JT9Z"0;3[LY ;S7C-8I_1MA-5Z7MW^;L9/Y&2_V#-VTA\^Q$PG%MT/=_=
MWE*Y1432730E]9,Q3^A[B+#J_I];P.E_Y]:B>N']"(B%B!X,&F[7;#GO9U8=
MW\6//P(,5)Y4719.\>X_!QK9]1J>"+D%/G1J4MUPE.#5WID^J96^4-%#>OM'
M0 YIQ?\'BL?]_Z25J]UG^F[F1]^<)%U#W?4]"@YO'P'TW+ZS\6TC%LC[C?_,
MZ,G^)AW0OTG/_S1"_[][8YD6-5^]9LIY:,Y[ !EH&A3=BCP"!A2HSK?>G^H
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M'BE&TLK"AWQ&2-[#AMM&P'/>;^A%4A!EJ1+ 6\'"+;"=DAG>4M@XXZ1]!!U
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ME25M+%:YE4BH=!>.4U-[)L6)]FL4A.77!4I?\0(WWM9&L'S26D/!0>*_Z+5
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M0?"DS1H;Z5I/SJA..#3UL4;J,;[&#A=>Q>_^XII&J)K1</!4B(X8_E&,@_N
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MB8\IF*D92@^_N]LPN6"EIG=9&76^9H;F,3V"9;X !0RR<U_"%Y?E)L@/E5
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M(QPW[WRY2N!+_5ZP@V0?0G#2$-MZAFLK/6(G^G"G)MPR32+#[U%4L,DA+^@
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M4+ZI#W%ECI&BP3+2(L$@>9C?361NPG.;R[%G92(K(Q2P?LI%DW^ A5':D\7
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MF%*;X?MZ]TMOD2340[6Q!>6Q+.&'V),?+W<U5#D^IM9OPG612CHP\W$HZ3_
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M5V=,S^Q,MJ@TP[JTD[VP>W!]W6HDK-0J[#$1CK#/"-\JS_,*9UC@602PY4J
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M'K?.?/1;$A:WP!_=LEWH,KT,*46!>FP."C(]3I36KH%"F]:7JE6UMT_YT:;
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M^?[Z]%+JLLI%.V\F2+5_X-S @3*IO<W<WU*E"MSJFG[MF8>(E:NK5,E?$S>
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MW;_\P/<7/1)=]J.QH0HI+:LLM9TLM?$N76A9G\[<DR%_IG4-@"C9M@VA_[(
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MNH>W4& <0 BPFL6ZSV+#/TLR@M>OB)KDW4'4VDT-T0'QM[5XZ[,D#(*<-X-
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MC?5B5G"I?!MH%3 (G8Z&M'Y F[T&['I\5"]#*ZH5:OU!\0;[ :W=!E[I(M=
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M_V\" %!+ 0(4 Q0    ( ,^#EUE$DE9@, P  !!_   1              "
M 0    !A=GAL+3(P,C0P.3,P+GAS9%!+ 0(4 Q0    ( ,^#EUG-)\)71@H
M $QS   5              "  5\,  !A=GAL+3(P,C0P.3,P7V-A;"YX;6Q0
M2P$"% ,4    " #/@Y=9^$44VNT7   A= $ %0              @ '8%@
M879X;"TR,#(T,#DS,%]D968N>&UL4$L! A0#%     @ SX.768$W!$R730
MDW($ !4              ( !^"X  &%V>&PM,C R-# Y,S!?;&%B+GAM;%!+
M 0(4 Q0    ( ,^#EUG"#FT:3C4   YO P 5              "  <)\  !A
M=GAL+3(P,C0P.3,P7W!R92YX;6Q02P$"% ,4    " #/@Y=9 6#1\TJ] @#\
MCQ, #@              @ %#L@  938R,3E?,3 M:RYH=&U02P$"% ,4
M" #/@Y=9;A+_NKH5   @;   $               @ &Y;P, 938R,3E?97@Q
M.2TQ+FAT;5!+ 0(4 Q0    ( ,^#EUES^(9-: (  -8.   0
M  "  :&% P!E-C(Q.5]E>#(Q+3$N:'1M4$L! A0#%     @ SX.761P4O.C&
M @  %PH  !               ( !-X@# &4V,C$Y7V5X,C,M,2YH=&U02P$"
M% ,4    " #/@Y=9GV.J'/@'  !F/P  $               @ $KBP, 938R
M,3E?97@S,2TQ+FAT;5!+ 0(4 Q0    ( ,^#EUD=15S#^@<  *<V   0
M          "  5&3 P!E-C(Q.5]E>#,Q+3(N:'1M4$L! A0#%     @ SX.7
M65Z&;P\P!@  @AL  !               ( !>9L# &4V,C$Y7V5X,S(M,2YH
M=&U02P$"% ,4    " #/@Y=9P *M*O9L P#$= 0 #0              @ '7
MH0, :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( ,^#EUDH>95!90H! .UP 0 -
M              "  ?@.!P!I;6%G95\P,#(N:G!G4$L%!@     .  X <0,
' (@9"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>e6219_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20240930"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20240930.xsd" xlink:type="simple"/>
    <context id="From2023-10-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-12-23</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_MichaelJFoxFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockIncludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommonStockExcludingCommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avxl:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_PurchaseAgreement2020Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-03-242022-03-25_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2015-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_FederalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-10-01to2024-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-10-01to2024-09-30" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-10-01to2024-09-30" id="Fact000005">0001314052</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2023-10-01to2024-09-30"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-10-01to2024-09-30"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2023-10-01to2024-09-30"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-09-30"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-01to2024-09-30"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:FixedContractAccruals
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-10-012023-09-30"
      id="xdx2ixbrl0868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2023-10-01to2024-09-30"
      id="xdx2ixbrl0873"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-10-01to2024-09-30"
      id="xdx2ixbrl0891"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-10-01to2024-09-30" id="Fact000011">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-10-01to2024-09-30" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-10-01to2024-09-30" id="Fact000013">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-10-01to2024-09-30" id="Fact000014">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-10-01to2024-09-30" id="Fact000015">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-10-01to2024-09-30" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-10-01to2024-09-30" id="Fact000017">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-10-01to2024-09-30" id="Fact000018">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-10-01to2024-09-30" id="Fact000019">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-10-01to2024-09-30" id="Fact000020">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-10-01to2024-09-30" id="Fact000021">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-10-01to2024-09-30" id="Fact000022">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-10-01to2024-09-30" id="Fact000023">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-10-01to2024-09-30" id="Fact000024">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2023-10-01to2024-09-30" id="Fact000025">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2023-10-01to2024-09-30" id="Fact000026">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-10-01to2024-09-30" id="Fact000027">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-10-01to2024-09-30" id="Fact000028">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-10-01to2024-09-30" id="Fact000029">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-10-01to2024-09-30" id="Fact000030">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-10-01to2024-09-30" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-10-01to2024-09-30" id="Fact000032">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-10-01to2024-09-30" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-10-01to2024-09-30" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-10-01to2024-09-30" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-10-01to2024-09-30" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-10-01to2024-09-30" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-10-01to2024-09-30" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-10-01to2024-09-30" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-10-01to2024-09-30" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-10-01to2024-09-30" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-03-31"
      decimals="-6"
      id="Fact000042"
      unitRef="USD">412000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-12-23"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">84815517</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2023-10-01to2024-09-30" id="Fact000044">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-10-01to2024-09-30" id="Fact000045">Melville, New York</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2023-10-01to2024-09-30" id="Fact000046">248</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">132187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">151024000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">2449000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">2709000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">931000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">653000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">135567000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000064"
      unitRef="USD">154386000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">9627000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">4322000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">4835000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">7295000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCredit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">842000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">917000</us-gaap:DeferredRentCredit>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">15304000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">12534000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000087"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000089"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000091"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000093"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000099"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000101"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000103"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000105"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000107"
      unitRef="Shares">84795517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">84795517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000111"
      unitRef="Shares">82066511</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000113"
      unitRef="Shares">82066511</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">85000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">82000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">456249000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">434839000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">-336071000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">-293069000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">120263000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">141852000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">135567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">154386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">11039000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">12039000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">41838000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">43717000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">52877000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">55756000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">-52877000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">-55756000</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">75000</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">2291000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">2718000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">7320000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">6519000</us-gaap:InterestIncomeExpenseNet>
    <avxl:OtherFinancingExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">964000</avxl:OtherFinancingExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">189000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000162"
      unitRef="USD">-40000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">9875000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">8258000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">-43002000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">-47498000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000179"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000181"
      unitRef="USDPShares">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000183"
      unitRef="USDPShares">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000185"
      unitRef="USDPShares">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">83468049</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">83468049</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000194"
      unitRef="Shares">79787596</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000196"
      unitRef="Shares">79787596</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">845000</avxl:NoncashFinancingRelatedCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">9438000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">16370000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">-260000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">-484000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">278000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">299000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">5305000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">497000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">-2460000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000226"
      unitRef="USD">1350000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:DeferredGrantIncome
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">75000</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">-473000</avxl:DeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">-30812000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-27785000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">11284000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">27875000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">691000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">1776000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">11975000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">29651000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">-18837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">1866000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">151024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">149158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">132187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000253"
      unitRef="USD">151024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">300000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">136000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000266"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">387977000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">-245564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">142491000</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">845000</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">845000</avxl:InitialCommitmentShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">3275000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">3000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">27872000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">27875000</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">13943</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">759753</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">1000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">1775000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">1776000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">16370000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">16370000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">-47505000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000316"
      unitRef="Shares">82066511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">434839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">-293069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">141852000</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000328"
      unitRef="Shares">2450000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">3000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">11281000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">11284000</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000335"
      unitRef="Shares">5646</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2023-10-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000342"
      unitRef="Shares">273360</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">691000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">691000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">9438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">9438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000351"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">-43002000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">84795517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">456249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000356"
      unitRef="USD">-336071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">120263000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000361">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zUbZM51yn049" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 	&lt;span id="xdx_82B_zSWlR6NQYzu5"&gt;Business Description and Basis of Presentation&lt;/span&gt;
&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Business&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s focus is on developing innovative
treatments for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and the instructions to Form
10-K and have been prepared under the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The
actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development programs and the level of
financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future
clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000363">&lt;p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_z6slE3KxRmT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 2	&lt;span id="xdx_823_z9L3pvings8g"&gt;Summary of Significant Accounting Policies&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zgBJ5I211vml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zAPlVc3iYYcf"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zSbQAInpEeXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztu82Co1Phn3"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBxoT8ehUmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zI70NBdVOwS5"&gt;Cash and equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#x2019;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_c20240930_pp0p0" title="Federal deposit insurance corporation"&gt;250,000&lt;/span&gt;, under current regulations. At September 30, 2024 and 2023, substantially
all of the Company&#x2019;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8e6NUAU2tYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zesLA3jv5Q2k"&gt;Research and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#x2019;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#x201c;CROs&#x201d;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#x201c;ASC&#x201d;) 730, &lt;i&gt;Research and Development&lt;/i&gt;, as these materials have no alternative future use outside of their intended
use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s
estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--RevenueRecognitionIncentives_zYOO7Un8ukSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zN9aksYH7Hu9"&gt;Research and Development Incentive Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#x201c;Australia R&amp;amp;D credit&#x201d;) through a program administered through the Australian Tax Office (the
&#x201c;ATO&#x201d;) and AusIndustry, a division of the Australian Government&#x2019;s Department of Industry, Innovation and Science (&#x201c;AusIndustry&#x201d;).
The Australia R&amp;amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Australia R&amp;amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#x2019;s company tax rate in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;), since the incentives
are not linked to the Company&#x2019;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to the Australia R&amp;amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 &lt;i&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt; (&#x201c;IAS 20&#x201d;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--LicenseFeesPolicyTextBlock_zvVTlse0Q7E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zgaDCnCdHYPa"&gt;License Fees&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;/p&gt;








&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zWgq0UJnIPo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zDPBM6FA6BL3"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2024, diluted loss per share excludes
&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_pdd" title="Loss per share for potentially dilutive common shares"&gt;15,047,754&lt;/span&gt; potentially dilutive common shares (2023 &#x2013; &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares"&gt;14,271,780&lt;/span&gt;) related to outstanding options and warrants, as their effect was
anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z9ZlJF0Lwhif" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z19xBHj34mV5"&gt;Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The book value of the Company&#x2019;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#x2019;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zuAFu9p1clul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zVPWAmk5hIua"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zgEdj1w4tJSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zIbr3fjZhz78"&gt;Segment and Geographic Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--GrantIncomePolicyTextBlock_zGwCAdk9hY0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zaw8i3Xa0wN7"&gt;Grant Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zXolNW64SI38" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zvqLWhRMJSC1"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zZYtdCIH7Uu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zzz8d0snS2Si"&gt;Share-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for all share-based payments
and awards under the fair value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. The Company&#x2019;s historical share option exercise experience does not provide
sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the
expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid
any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist
of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. Changes
in these assumptions can materially affect the fair value estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#x2019;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#x201c;net settled&#x201d; in shares of the Company&#x2019;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#x2019;s treasury.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOMteVA1jZv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_ziRWdPxOyJSl"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2024 and 2023, the Company did not
have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8PUyFNhGER7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zI4c0i94DpBe"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On October 1, 2022, the Company
adopted Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832) &#x2013; Disclosures by Business Entities about Government
Assistance, which requires business entities to disclose information about transactions with a government that are accounted for by applying
a grant or contribution model by analogy. For transactions within scope, the new standard requires the disclosure of information about
the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line
items affected by the transaction. The disclosure of the Company&#x2019;s research and development tax incentive income and receivable
is detailed in Note 4.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--RecentAccountingPronouncementsPolicyTextBlock_z1SqSlbs2MCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zX6GA3HUEZHd"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-10-01to2024-09-30" id="Fact000365">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zgBJ5I211vml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zAPlVc3iYYcf"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000373">&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zSbQAInpEeXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztu82Co1Phn3"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000375">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBxoT8ehUmTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zI70NBdVOwS5"&gt;Cash and equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;The Company considers only
those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to
be cash equivalents&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Highly
liquid investments that are considered cash equivalents include money market&#160;accounts, money market&#160;funds&#160;and&#160;certificates
of deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The Company&#x2019;s
investment policy allows for investments in domestic money market certificates, certificates of deposit, money market funds, bonds or
commercial papers, and establishes diversification and credit quality requirements and limits investments by maturity and issuer. The
Company currently maintains its investments at one large well known financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the
Federal Deposit Insurance Corporation (FDIC) up to $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_c20240930_pp0p0" title="Federal deposit insurance corporation"&gt;250,000&lt;/span&gt;, under current regulations. At September 30, 2024 and 2023, substantially
all of the Company&#x2019;s cash balances were in excess of these federally insured limits. The Company mitigates this risk by maintaining
the majority of its cash balances in a large well-known financial institution. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000377"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-10-01to2024-09-30" id="Fact000379">&lt;p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_z8e6NUAU2tYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zesLA3jv5Q2k"&gt;Research and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed as incurred.
These expenses are comprised of the costs of the Company&#x2019;s proprietary research and development efforts, including preclinical studies,
clinical trials, manufacturing costs, employee salaries and benefits and share-based compensation expense, contract services including
external research and development expenses incurred under arrangements with third parties such as contract research organizations (&#x201c;CROs&#x201d;),
facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when
the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification
(&#x201c;ASC&#x201d;) 730, &lt;i&gt;Research and Development&lt;/i&gt;, as these materials have no alternative future use outside of their intended
use.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods
are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs
incurred in relation to external CROs, and clinical site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes
progress of the trials and studies including the phase or completion of events, invoices received and contracted costs. Judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s
estimates. The Company&#x2019;s historical accrual estimates have not been materially different from actual costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the Company incurs expenses in respect
of intellectual property costs relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the underlying patent and trademark costs is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the drugs subject to the underlying patents
and trademarks will ever be successfully commercialized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to these risks and uncertainties, the patent and
trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionIncentives contextRef="From2023-10-01to2024-09-30" id="Fact000387">&lt;p id="xdx_842_eus-gaap--RevenueRecognitionIncentives_zYOO7Un8ukSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zN9aksYH7Hu9"&gt;Research and Development Incentive Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is eligible to obtain certain research
and development tax credits, including, through its wholly owned subsidiary Anavex Australia, the Australian research and development
tax incentive credit (the &#x201c;Australia R&amp;amp;D credit&#x201d;) through a program administered through the Australian Tax Office (the
&#x201c;ATO&#x201d;) and AusIndustry, a division of the Australian Government&#x2019;s Department of Industry, Innovation and Science (&#x201c;AusIndustry&#x201d;).
The Australia R&amp;amp;D credit program provides for a cash refund based on a percentage of eligible research and development activities
undertaken in Australia by Anavex Australia. Anavex Australia is also eligible under the Australia R&amp;amp;D credit program to receive the
cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses
are pre-approved by AusIndustry pursuant to an advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Australia R&amp;amp;D credit program is available
to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period at a rate
of 18.5% above the claimant&#x2019;s company tax rate in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax incentives are available on the basis of specific
criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company
has accounted for the incentives outside of the scope of ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;), since the incentives
are not linked to the Company&#x2019;s taxable income and can be realized regardless of whether the Company has generated taxable income
in the respective jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With respect to the Australia R&amp;amp;D credit, as there
is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant
by analogy to IAS20 &lt;i&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt; (&#x201c;IAS 20&#x201d;). The Company
recognizes the research and development incentive income as it incurs costs eligible for reimbursement under the Australia R&amp;amp;D credit
program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when
the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in
relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry,
pursuant to an approved advanced overseas finding application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Anavex Australia and Anavex Canada incur
Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia
and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services
provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund
it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance
sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionIncentives>
    <avxl:LicenseFeesPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000389">&lt;p id="xdx_84D_ecustom--LicenseFeesPolicyTextBlock_zvVTlse0Q7E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zgaDCnCdHYPa"&gt;License Fees&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recovery of the amounts
paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense
or capitalized based on management&#x2019;s assessment regarding the ultimate recoverability of the amounts paid and the potential for
alternative future use. The Company has determined that the technological feasibility for its product candidates is reached when the requisite
regulatory approvals are obtained to make the product available for sale.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;/p&gt;








</avxl:LicenseFeesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000398">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zWgq0UJnIPo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zDPBM6FA6BL3"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2024, diluted loss per share excludes
&lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240930_pdd" title="Loss per share for potentially dilutive common shares"&gt;15,047,754&lt;/span&gt; potentially dilutive common shares (2023 &#x2013; &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230930_pdd" title="Loss per share for potentially dilutive common shares"&gt;14,271,780&lt;/span&gt;) related to outstanding options and warrants, as their effect was
anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000400"
      unitRef="Shares">15047754</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">14271780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-10-01to2024-09-30" id="Fact000404">&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z9ZlJF0Lwhif" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z19xBHj34mV5"&gt;Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The book value of the Company&#x2019;s financial instruments,
consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value
due to the short-term maturity of such instruments. Unless otherwise noted, it is management&#x2019;s opinion that the Company is not exposed
to significant interest, currency or credit risks arising from these financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000406">&lt;p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zuAFu9p1clul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zVPWAmk5hIua"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company is the US dollar.
Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date
and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency
denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from
the translations are credited or charged to income in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that the functional currency
of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000408">&lt;p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zgEdj1w4tJSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zIbr3fjZhz78"&gt;Segment and Geographic Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are defined as components of an
enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making
group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as
one operating segment, which is the business of developing novel therapies for the management of CNS diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <avxl:GrantIncomePolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000410">&lt;p id="xdx_842_ecustom--GrantIncomePolicyTextBlock_zGwCAdk9hY0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zaw8i3Xa0wN7"&gt;Grant Income&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Grant income is recognized at the fair value of the
grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance
of the specific research and development costs to which they relate are deferred and recognized in the consolidated statements of operations
and comprehensive loss in the period they are earned, typically when the related research and development costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:GrantIncomePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000412">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zXolNW64SI38" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zvqLWhRMJSC1"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740, which
requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying
amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the provisions of ASC 740 regarding
accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more
likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently
measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax
authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information.
The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions
and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically
adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements
of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest and penalties related
to current income tax expense on the interest income, net line, in the accompanying consolidated statements of operations and comprehensive
loss. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000421">&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zZYtdCIH7Uu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zzz8d0snS2Si"&gt;Share-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for all share-based payments
and awards under the fair value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of all share-based payments are expensed
over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the
case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation costs for share-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested awards
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted share purchase option awards
that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit service period
for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service period
when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates as appropriate its
estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement
of the performance criteria.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option valuation
model to calculate the fair value of share-based awards at the date of the grant. This model requires the input of subjective assumptions,
including the expected price volatility and expected life of each&#160;award. The Company uses the U.S. Treasury daily treasury yield
curve rates for the expected term of the option as the risk-free rate. The expected term represents the period that options granted are
expected to be outstanding using the simplified method. The Company&#x2019;s historical share option exercise experience does not provide
sufficient basis for estimating the expected term. Expected volatility is based on the average of the daily share price changes over the
expected term. The Company does not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid
any dividends on its common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist
of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. Changes
in these assumptions can materially affect the fair value estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price of share-based compensation awards
may be paid in cash or, if approved by the Company&#x2019;s compensation committee (or in the case of warrants by the Board of Directors)
in advance, &#x201c;net settled&#x201d; in shares of the Company&#x2019;s common stock. In a net settlement of an share-based award, the
Company does not receive payment of the exercise price from the holder but reduces the number of shares of common stock issued upon the
exercise of the award by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise
price for the option shares covered by the instrument exercised. Shares issued pursuant to the exercise of options and warrants are issued
from the Company&#x2019;s treasury.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
















</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000429">&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zOMteVA1jZv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_ziRWdPxOyJSl"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair
value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes
the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities that the Company has the ability to access at the measurement date;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2024 and 2023, the Company did not
have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000431">&lt;p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8PUyFNhGER7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zI4c0i94DpBe"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On October 1, 2022, the Company
adopted Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832) &#x2013; Disclosures by Business Entities about Government
Assistance, which requires business entities to disclose information about transactions with a government that are accounted for by applying
a grant or contribution model by analogy. For transactions within scope, the new standard requires the disclosure of information about
the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line
items affected by the transaction. The disclosure of the Company&#x2019;s research and development tax incentive income and receivable
is detailed in Note 4.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:RecentAccountingPronouncementsPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000433">&lt;p id="xdx_847_ecustom--RecentAccountingPronouncementsPolicyTextBlock_z1SqSlbs2MCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zX6GA3HUEZHd"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:RecentAccountingPronouncementsPolicyTextBlock>
    <avxl:AccuredLiabilitiesTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000435">&lt;p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zEPbtC6j3LPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 3	&lt;span id="xdx_827_zlLjSI9VItkl"&gt;Accrued Liabilities&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consist of (in thousands):&lt;/p&gt;


















&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zbwnkL2K0Ym1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_z2lzU6dypaQd" style="display: none"&gt;Schedule of principal components of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240930_z4WLWlnfqNq1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930_zSwhbt41fS56" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_zvn6pZIbv5Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued investigator payments&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,360&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FixedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0452"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone-based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,835&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;7,295&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AB_z9vsAXyMD93i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt"&gt;&#160;&lt;/p&gt;

</avxl:AccuredLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000444">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zbwnkL2K0Ym1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_z2lzU6dypaQd" style="display: none"&gt;Schedule of principal components of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240930_z4WLWlnfqNq1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930_zSwhbt41fS56" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedInvestigatorPayments_iI_pn3n3_zvn6pZIbv5Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued investigator payments&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,360&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FixedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0452"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone-based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTIC_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,835&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;7,295&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedInvestigatorPayments
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">860000</avxl:AccruedInvestigatorPayments>
    <avxl:AccruedInvestigatorPayments
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">2006000</avxl:AccruedInvestigatorPayments>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">1527000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000450"
      unitRef="USD">1360000</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">38000</avxl:FixedContractAccruals>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">557000</avxl:MilestoneBasedContractAccruals>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">1267000</avxl:MilestoneBasedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">1891000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">2624000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">4835000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">7295000</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000464">&lt;p id="xdx_808_ecustom--OtherIncomeDisclosureTextBlock_zpl9acj2tuH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 4	&lt;span id="xdx_82D_z4iq2194pL1b"&gt;Other Income&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of September 30, 2024,
the Company had received a $&lt;span id="xdx_905_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20231001__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zUqOPy8iSm9k" title="Research and development incentive income"&gt;1&lt;/span&gt;.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant
will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 (blarcamesine) related to Parkinson&#x2019;s
disease. Of the total, $&lt;span id="xdx_906_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zsZM6XiZSJa7" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year ended September 30, 2023 and $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_zNYa628sfExl" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year
ended September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the year ended September 30, 2024, the Company recognized $&lt;span id="xdx_90F_ecustom--NonOperatingIncomeFromGrant_c20231001__20240930_pn5n6" title="Non operating income from grant"&gt;75,000&lt;/span&gt; (2023: $&lt;span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20221001__20230930_pn5n6" title="Non operating income from grant"&gt;25,000&lt;/span&gt;) of this grant on its statements of operations within
grant income. At September 30, 2024 an amount of $&lt;span id="xdx_900_ecustom--DeferredGrantIncome1_c20231001__20240930_pn5n6" title="Deferred grant income"&gt;0.8&lt;/span&gt; million (2023: $&lt;span id="xdx_902_ecustom--DeferredGrantIncome1_c20221001__20230930_pn5n6" title="Deferred grant income"&gt;0.9&lt;/span&gt; million) of this grant is recorded as deferred grant income,
representing the amount of this grant which has not yet been amortized to other income. The Company will recognize this income on its
statements of operations as the related expenditures are incurred to offset the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#x2019;s annual income tax return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the year ended September
30, 2024, the Company recorded research and development incentive income of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930_zebZr3UeVuh" title="Research and development incentive income"&gt;2.3&lt;/span&gt; million (AUD &lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240930__srt--CurrencyAxis__currency--AUD_zalCwRRoaIzg" title="Research and development incentive income"&gt;3.5&lt;/span&gt; million) (2023: $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930_zrnuLxk9QHT" title="Research and development incentive income"&gt;2.7&lt;/span&gt; million (AUD &lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__srt--CurrencyAxis__currency--AUD_zUS5vDVvJrPl" title="Research and development incentive income"&gt;4.1&lt;/span&gt;
million)) in respect of the Australia R&amp;amp;D credit for eligible research and development expenses incurred during the year. This amount
is included within Other income (expense) on the consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;At September 30, 2024, Incentive
and tax receivables includes $&lt;span id="xdx_909_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zS5nTIpYaJU6" title="Incentive and tax receivables"&gt;2.3&lt;/span&gt; million (AUD &lt;span id="xdx_908_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zNvZ2x4TOs3h" title="Incentive and tax receivables"&gt;3.3&lt;/span&gt; million) (2023: $&lt;span id="xdx_904_eus-gaap--OtherReceivables_iI_pn5n6_c20230930_znwGIkvLBIv6" title="Incentive and tax receivables"&gt;2.5&lt;/span&gt; million (AUD &lt;span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20230930__srt--CurrencyAxis__currency--AUD_zatHjCAGFLH2" title="Incentive and tax receivables"&gt;3.9&lt;/span&gt; million)) relating to Australia R&amp;amp;D credits
earned during the year that are expected to be reimbursed upon filing of the Company&#x2019;s annual claim under this program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Australia R&amp;amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;amp;D activities are eligible and (iii) if the individual R&amp;amp;D expenditures have nexus to such R&amp;amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#x2019;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#x2019;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#x2019; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Currently, the Company&#x2019;s
tax incentive claims from 2020 to 2024 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2023-10-012024-09-30_custom_MichaelJFoxFoundationMember"
      decimals="-5"
      id="Fact000466"
      unitRef="USD">1000000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000468"
      unitRef="USD">500000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2020-10-012021-09-30"
      decimals="-5"
      id="Fact000470"
      unitRef="USD">500000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="Fact000472"
      unitRef="USD">75000000000</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000474"
      unitRef="USD">25000000000</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome1
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="Fact000476"
      unitRef="USD">800000</avxl:DeferredGrantIncome1>
    <avxl:DeferredGrantIncome1
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000478"
      unitRef="USD">900000</avxl:DeferredGrantIncome1>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="Fact000480"
      unitRef="USD">2300000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-09-30_currency_AUD"
      decimals="-5"
      id="Fact000482"
      unitRef="USD">3500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000484"
      unitRef="USD">2700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-09-30_currency_AUD"
      decimals="-5"
      id="Fact000486"
      unitRef="USD">4100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000488"
      unitRef="USD">2300000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-09-30_currency_AUD"
      decimals="-5"
      id="Fact000490"
      unitRef="USD">3300000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000492"
      unitRef="USD">2500000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-09-30_currency_AUD"
      decimals="-5"
      id="Fact000494"
      unitRef="USD">3900000</us-gaap:OtherReceivables>
    <avxl:EquityOfferingTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000503">&lt;p id="xdx_807_ecustom--EquityOfferingTextBlock_z8uH5AsWqi3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 5	&lt;span id="xdx_821_z4UnVL811xpi"&gt;Equity Offerings&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board of Directors&#160;(the &#x201c;Board&#x201d;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2023 Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zjBTw7sVBGf4" title="Value of shares obligated to purchase"&gt;150&lt;/span&gt;.0
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zDtpzYyEJE34" title="Share issued for offering, shares"&gt;75,000&lt;/span&gt; shares of common stock as a commitment fee (the &#x201c;initial commitment shares&#x201d;)
and agreed to issue up to an additional &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVEHO9Ok8nG3" title="Pro rata basic number of shares obligated to purchase"&gt;75,000&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion,
the $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zlvesVw4UA3k" title="Proceeds from issuance or sale of equity"&gt;150&lt;/span&gt;.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $&lt;span id="xdx_90C_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zJ9cx1I1Uf3j" title="Fair value of the initial commitment"&gt;0.8&lt;/span&gt; million with
reference to the closing price of the Company&#x2019;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $&lt;span id="xdx_900_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zuQfWHsPplPj" title="Incurred expenses"&gt;0.1&lt;/span&gt; million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2024, the Company
issued to Lincoln Park an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_z5XyHbAeGon5" title="Number of shares issued, shares"&gt;2,455,646&lt;/span&gt; shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_z9eP1mwZKD7e" title="Number of shares issued, shares"&gt;2,450,000&lt;/span&gt; shares
of common stock for an aggregate purchase price of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z3vDqP2N5m5a" title="Number of shares issued, value"&gt;11,283,200&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zuZAWjOBzDX" title="Number of shares issued, shares"&gt;5,646&lt;/span&gt; commitment shares. During the year ended September 30, 2023,
the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockIncludingCommitmentSharesMember_zv8LrAnhBMp2" title="Number of shares issued, shares"&gt;3,288,943&lt;/span&gt; shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommonStockExcludingCommitmentSharesMember_z4amQsG4Rn02" title="Number of shares issued, shares"&gt;3,275,000&lt;/span&gt;
shares of common stock for aggregate proceeds of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zX7Y5ZjfAYx8" title="Number of shares issued, value"&gt;27.9&lt;/span&gt; million and&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--CommitmentSharesMember_zvwZfCtAdAej" title="Number of shares issued, shares"&gt;13,943&lt;/span&gt;&#160;commitment shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2024, an amount of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20231001__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVFXJZstk14i" title="Amount of shares remain available"&gt;110.8&lt;/span&gt; million
remained available under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2020 Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;2020 Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company could offer and sell shares of common
stock registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended September 30, 2024 and 2023,
no shares were sold pursuant to the Offering. At September 30, 2023, an amount of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20221001__20230930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2020Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrSVeZj0Klw6" title="Amount of shares remain available"&gt;142.4&lt;/span&gt; million was registered pursuant to an effective
registration statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2024, the Company terminated the 2020
Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:EquityOfferingTextBlock>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-6"
      id="Fact000505"
      unitRef="USD">150000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000507"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000509"
      unitRef="Shares">75000</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-6"
      id="Fact000511"
      unitRef="USD">150000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:FairValueOfInitialCommitment
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000513"
      unitRef="USD">800000</avxl:FairValueOfInitialCommitment>
    <avxl:IncurredExpenses
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000515"
      unitRef="USD">100000</avxl:IncurredExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000517"
      unitRef="Shares">2455646</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000519"
      unitRef="Shares">2450000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">11283200</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember"
      decimals="INF"
      id="Fact000523"
      unitRef="Shares">5646</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockIncludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000525"
      unitRef="Shares">3288943</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommonStockExcludingCommitmentSharesMember"
      decimals="INF"
      id="Fact000527"
      unitRef="Shares">3275000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000529"
      unitRef="USD">27900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember_custom_CommitmentSharesMember"
      decimals="INF"
      id="Fact000531"
      unitRef="Shares">13943</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-10-012024-09-30_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000533"
      unitRef="USD">110800000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-10-012023-09-30_custom_PurchaseAgreement2020Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000542"
      unitRef="USD">142400000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000544">&lt;p id="xdx_805_eus-gaap--CommitmentsDisclosureTextBlock_zU3MKmk8tD6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 6	&lt;span id="xdx_82E_zSxZDr5qZEec"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company leases office space under an operating lease with an initial term of &lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zyt4oNkSylq3" title="Operating lease term"&gt;12&lt;/span&gt; months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
operating lease costs were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_pn3n3_zo7TtWmPUcw5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zZE28QeKNvL9" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20231001__20240930_zy0nqCX3Sqqg" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20221001__20230930_zOcdnZ1gajT9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseCost_zG2OCtLdwmZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z6qARMn5koC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company made matching contributions under the 401(k) plan as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zY74239U5rD7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zCLJmKfNvB4e" style="display: none"&gt;Schedule of contributions under the plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20231001__20240930_zumtC3qVDoQk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20221001__20230930_zkzgsKpX6ZJb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PensionContributions_zqnvDHsWLGQd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zfRQyDHqkRy" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024. The complaint alleges violations
of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect to certain clinical trials for
ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Rett syndrome. The complaint seeks unspecified damages, as well as costs, including counsel and
expert witness fees, on behalf of a class of investors.&#160;The Company believes the lawsuit is without merit and the Company denies
any liability or wrongdoing and has filed motions to dismiss the complaints, which is awaiting a decision by the Court. No amount has
been recorded in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes
that it is not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#x2019;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett Syndrome. The Company believes this lawsuit is without merit and the Company denies any liability or wrongdoing.
The parties are currently due to file a proposed schedule for the anticipated motion to dismiss by the Company and the officer of the
Company (the other named defendants have not been served with the complaint) on or before January 15, 2025.&#160;No amount has been recorded
in these consolidated financial statements for any loss contingencies associated with this lawsuit as the Company believes that it is
not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#x2019; interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the status of the Company&#x2019;s outstanding
share purchase warrants is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zVrXB8D2W2el" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zyucDNJtHIe6" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsEaQiiCcKZf" style="width: 20%; text-align: right" title="Number of warrants outstanding"&gt;160,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zkOIgSWK3Ps2" style="width: 20%; text-align: right" title="Weighted average exercise price"&gt;3.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfWarrantsExpired_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9iODe9gm0d6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants expired"&gt;(150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageExercisePriceExpried_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zGiipVAva5fi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expried"&gt;3.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsLjle0jOCG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z8bylO1akFQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zmbBBcE82K9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2024, the Company had &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20240930_zRbUQoqcPBh4" title="Warrants outstanding"&gt;10,000&lt;/span&gt; share
purchase warrants outstanding exercisable at $&lt;span id="xdx_907_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20240930_zuT1PGPuBGF3" title="Warrants outstanding weighted average exercise price"&gt;12.00&lt;/span&gt; per share until &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240930_zYam2lj5mBle" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2015 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYy7f34kF64e" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20231001__20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zjyTf3HUI3qg" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zlkcZFkN32gj" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zaMq4gs0d8Dc" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At September
30, 2024, &lt;span id="xdx_90F_ecustom--OptionIssued_pip0_c20231001__20240930_zf4vwFU8Ylt2" title="Option issued"&gt;5,267,500&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20240930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zuhgSy4D4QU4" title="Option available issue"&gt;5,462,202&lt;/span&gt; options were available for issue under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock option
activity during the years ended September 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_ztty77jTyIU6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zWT9kxCLd4y8" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, October 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj2x0XX7LPE5" style="width: 10%; text-align: right" title="Number of options, Outstanding beginning balance"&gt;13,169,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuf1aIFtmA81" style="width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;6.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlhUTPvaW8Ag" style="width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;4.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlUHLENQXHdc" style="width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;62,267,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNoKqll9fo3h" style="text-align: right" title="Number of options, Granted"&gt;1,959,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zi1TwIf8oIff" style="text-align: right" title="Weighted average exercise price, Granted"&gt;9.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgzQ7JpYdPf6" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVgAZGD8r8Af" style="text-align: right" title="Number of options, Exercised"&gt;(759,753&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z06a8R6hHwP6" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;2.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZP9O0acgU" style="text-align: right" title="Weighted average grant date fair value, Exercised"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziqPF6mfyqq6" style="text-align: right" title="Aggregate intrinsic value, Exercised"&gt;4,629,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFy5pRVKYI99" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited"&gt;(257,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNQysIpp47ae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvNZk4PG8T94" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;6.74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRNBDwcTAcAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding beginning balance"&gt;14,111,780&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVCEf3tVsaM2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;7.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw26BK1vpFz2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;5.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTz4uUWMxZyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;22,290,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znZU3kVlHEO1" style="text-align: right" title="Number of options, Granted"&gt;1,860,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM2dLVlLPbD6" style="text-align: right" title="Weighted average exercise price, Granted"&gt;5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z03F1sZBGRg4" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;3.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4ZomoYX4ICl" style="text-align: right" title="Number of options, Exercised"&gt;(273,360&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWjNVYMoyey4" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;2.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqqUr0RdYOm9" style="text-align: right" title="Weighted average grant date fair value, Exercised"&gt;1.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdyGr0vXAN6f" style="text-align: right" title="Aggregate intrinsic value, Exercised"&gt;601,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0cHRJXMWav2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited"&gt;(661,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zALlzza5Em9d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;11.67&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhkSSkBQ8mua" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;5.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyLucyoiWRHl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance"&gt;15,037,754&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbAC367IhERd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance"&gt;6.80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSsx5kNI3hI2" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance"&gt;15,825,791&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0GduqcpBhGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable"&gt;9,910,590&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlmzHQ6Ebou3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;5.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5tBnhyuxDb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;15,176,855&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zosVbZGmQpg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at September 30, 2024 by a range of exercise prices:&lt;/p&gt;


















&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2YVgwyiK376" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B7_z68Fo18hTGsi" style="display: none"&gt;Schedule of summarizes information about stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zKnsCyiAjbw7" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zqSFAzGAh9k4" style="width: 11%; text-align: right" title="Range of exercise prices, Upper range limit"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDdyTnQoyzci" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,015,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjowsLPUAp12" title="Weighted average remaining contractual life"&gt;3.79&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zl8YkrHgTAhg" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdwqQ4ozmBqd" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,015,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjEnt80JFkO9" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zFs6okO3fwEd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zqBReWOji9Vj" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zH8xy90eCWLk" style="text-align: right" title="Number of outstanding options"&gt;2,267,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ziTWkBIVvmZ4" title="Weighted average remaining contractual life"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z1bYzPLt6MA3" style="text-align: right" title="Weighted average exercise price"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zv1CWYPyXMSd" style="text-align: right" title="Number of vested options"&gt;2,056,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_znR0tyhcDjdi" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHErj6uIlhle" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvUdvToDrSr" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zefhqZJERt9e" style="text-align: right" title="Number of outstanding options"&gt;6,640,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHu9lRBkqU1b" title="Weighted average remaining contractual life"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zAwjOi5bd1He" style="text-align: right" title="Weighted average exercise price"&gt;6.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zhLOzuGk2cZa" style="text-align: right" title="Number of vested options"&gt;3,473,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zRLtybyWOCw3" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zwgjH4CudMMd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zHbXDbyucZag" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zAzTAGC3i8Hc" style="text-align: right" title="Number of outstanding options"&gt;1,649,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zjtL6f21Ij98" title="Weighted average remaining contractual life"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zfzOK1oMVFth" style="text-align: right" title="Weighted average exercise price"&gt;10.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zouJsfyRROXh" style="text-align: right" title="Number of vested options"&gt;760,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zJcbeYjhrGt8" style="text-align: right" title="Weighted average exercise price options vested"&gt;10.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUVTVmMIz5bg" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zTRX6VFAciHc" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKia0Yvbyx1b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,465,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRXry7ZoAYG3" title="Weighted average remaining contractual life"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXDhjTnxgqC" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.18&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zExs2DKoYFoc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;605,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z3Z0f4RuhDm6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.47&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7WiabqsG4Pl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;15,037,754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzOS46JZKPbg" title="Weighted average remaining contractual life"&gt;5.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze3OZD5jIuyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price"&gt;6.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zv7ks6Ny45x1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;9,910,590&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcbaT8u383oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested"&gt;5.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A6_zAufvJUNWIsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average per share fair value of options
vested at September 30, 2024 was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zPGlJzsx1zL1" title="Weighted average grant date fair value of options vested"&gt;4.34&lt;/span&gt; (2023: $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930_zUFUHnNr2KR6" title="Weighted average grant date fair value of options vested"&gt;3.94&lt;/span&gt;). At September 30, 2024, the weighted average contractual life of options outstanding
was &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zHLhZTyCnIo7" title="Weighted average contractual life of options outstanding"&gt;5.48&lt;/span&gt; years (2023: &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_zRvLLcf6qJWg" title="Weighted average contractual life of options outstanding"&gt;6.0&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zvCl9X5i0juj" title="Options exercisable"&gt;4.03&lt;/span&gt; years (2023: &lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930_z6uUq3cqdtnh" title="Options exercisable"&gt;4.75&lt;/span&gt; years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;	The Company recognized share-based compensation
expense of $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240930_zmUOLDM5C0Rg" title="Share based compensation"&gt;9.4&lt;/span&gt; million during the year ended September 30, 2024 (2023: $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230930_zaAPC60VFCR9" title="Share based compensation"&gt;16.4&lt;/span&gt; million) in connection with the issuance and vesting 	of
stock options in exchange for services. These amounts have been included in general and 	administrative expenses and research and development
expenses on the Company&#x2019;s consolidated statements of 	operations as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zi2FVOcwWNha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B8_z2tVgKm7mwUi" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp9OpXIsV36a" style="width: 12%; text-align: right" title="Total share based compensation"&gt;3,625&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFxQwPTmIz11" style="width: 12%; text-align: right" title="Total share based compensation"&gt;5,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyDyahjVnw1c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;5,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmVbu9HVINJa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;10,812&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zY0w9hpDCWCf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,438&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zqU4aiHPBqac" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;16,370&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zU4EDeUl5dbl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20240930_zGXnFIkhKl2a" title="Remaining stock based compensation"&gt;8.4&lt;/span&gt; million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2027.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;The fair value of each option and
warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_ztvANBNBKOd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zGx432uQE2A4" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_zmVvhw0wUJUk" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zk9aeGxWv1f6" title="Risk-free interest rate"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zKcOrtuCNxVj" title="Expected life of options (years)"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zvMR7rgFHMMg" title="Expected life of options (years)"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_znTGYHoJmyzd" title="Annualized volatility"&gt;84.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zQyr91zB3pV3" title="Annualized volatility"&gt;85.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zDdrcqcPiXgc" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_zZxC4dNmLus5" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zWu897XZdev9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the years ended September 30, 2024 and 2023 was determined with reference to the quoted market price of the Company&#x2019;s shares
on the grant date.&lt;/p&gt;


















</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-09-30" id="Fact000546">P12M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000548">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--LeaseCostTableTextBlock_pn3n3_zo7TtWmPUcw5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zZE28QeKNvL9" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20231001__20240930_zy0nqCX3Sqqg" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20221001__20230930_zOcdnZ1gajT9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseCost_zG2OCtLdwmZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000551"
      unitRef="USD">118000</us-gaap:OperatingLeaseCost>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000553">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zY74239U5rD7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; color: black; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BC_zCLJmKfNvB4e" style="display: none"&gt;Schedule of contributions under the plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20231001__20240930_zumtC3qVDoQk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20221001__20230930_zkzgsKpX6ZJb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="color: black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; color: black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PensionContributions_zqnvDHsWLGQd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; color: black; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:PensionContributions
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">279000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">232000</us-gaap:PensionContributions>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000565">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zVrXB8D2W2el" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zyucDNJtHIe6" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsEaQiiCcKZf" style="width: 20%; text-align: right" title="Number of warrants outstanding"&gt;160,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zkOIgSWK3Ps2" style="width: 20%; text-align: right" title="Weighted average exercise price"&gt;3.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfWarrantsExpired_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z9iODe9gm0d6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants expired"&gt;(150,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageExercisePriceExpried_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zGiipVAva5fi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price expried"&gt;3.17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zsLjle0jOCG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_z8bylO1akFQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000569"
      unitRef="USDPShares">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <avxl:NumberOfWarrantsExpired
      contextRef="From2023-10-012024-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000571"
      unitRef="Shares">-150000</avxl:NumberOfWarrantsExpired>
    <avxl:WeightedAverageExercisePriceExpried
      contextRef="From2023-10-012024-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000573"
      unitRef="USDPShares">3.17</avxl:WeightedAverageExercisePriceExpried>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000575"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000577"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000579"
      unitRef="Shares">10000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000581"
      unitRef="USDPShares">12.00</avxl:WarrantsOutstandingWeightedAverageExercise>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2024-09-30" id="Fact000583">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000585"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2023-10-012024-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      id="Fact000594"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000596"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-03-242022-03-25_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000598"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">5267500</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">5462202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000604">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_ztty77jTyIU6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zWT9kxCLd4y8" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 39%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, October 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj2x0XX7LPE5" style="width: 10%; text-align: right" title="Number of options, Outstanding beginning balance"&gt;13,169,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuf1aIFtmA81" style="width: 10%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;6.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlhUTPvaW8Ag" style="width: 10%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;4.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlUHLENQXHdc" style="width: 10%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;62,267,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNoKqll9fo3h" style="text-align: right" title="Number of options, Granted"&gt;1,959,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zi1TwIf8oIff" style="text-align: right" title="Weighted average exercise price, Granted"&gt;9.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgzQ7JpYdPf6" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVgAZGD8r8Af" style="text-align: right" title="Number of options, Exercised"&gt;(759,753&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z06a8R6hHwP6" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;2.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZP9O0acgU" style="text-align: right" title="Weighted average grant date fair value, Exercised"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziqPF6mfyqq6" style="text-align: right" title="Aggregate intrinsic value, Exercised"&gt;4,629,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFy5pRVKYI99" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited"&gt;(257,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zNQysIpp47ae" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvNZk4PG8T94" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;6.74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRNBDwcTAcAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Outstanding beginning balance"&gt;14,111,780&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVCEf3tVsaM2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;7.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw26BK1vpFz2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;5.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTz4uUWMxZyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;22,290,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znZU3kVlHEO1" style="text-align: right" title="Number of options, Granted"&gt;1,860,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zM2dLVlLPbD6" style="text-align: right" title="Weighted average exercise price, Granted"&gt;5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z03F1sZBGRg4" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;3.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4ZomoYX4ICl" style="text-align: right" title="Number of options, Exercised"&gt;(273,360&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWjNVYMoyey4" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;2.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqqUr0RdYOm9" style="text-align: right" title="Weighted average grant date fair value, Exercised"&gt;1.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdyGr0vXAN6f" style="text-align: right" title="Aggregate intrinsic value, Exercised"&gt;601,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pip0_di_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0cHRJXMWav2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Forfeited"&gt;(661,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zALlzza5Em9d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;11.67&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhkSSkBQ8mua" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;5.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyLucyoiWRHl" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding ending balance"&gt;15,037,754&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbAC367IhERd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance"&gt;6.80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSsx5kNI3hI2" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance"&gt;15,825,791&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0GduqcpBhGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable"&gt;9,910,590&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlmzHQ6Ebou3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;5.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5tBnhyuxDb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;15,176,855&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000606"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000608"
      unitRef="USDPShares">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000610"
      unitRef="USDPShares">4.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000612"
      unitRef="USD">62267309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">1959000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000616"
      unitRef="USDPShares">9.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000618"
      unitRef="USDPShares">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000620"
      unitRef="Shares">759753</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000622"
      unitRef="USDPShares">2.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000624"
      unitRef="USDPShares">0.95</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000626"
      unitRef="USD">4629026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000628"
      unitRef="Shares">257083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000630"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000632"
      unitRef="USDPShares">6.74</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000634"
      unitRef="Shares">14111780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000636"
      unitRef="USDPShares">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000638"
      unitRef="USDPShares">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">22290069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">1860500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000644"
      unitRef="USDPShares">5.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000646"
      unitRef="USDPShares">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000648"
      unitRef="Shares">273360</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000650"
      unitRef="USDPShares">2.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000652"
      unitRef="USDPShares">1.11</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000654"
      unitRef="USD">601407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000656"
      unitRef="Shares">661166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000658"
      unitRef="USDPShares">11.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000660"
      unitRef="USDPShares">5.00</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000662"
      unitRef="Shares">15037754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000664"
      unitRef="USDPShares">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000666"
      unitRef="USD">15825791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">9910590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000670"
      unitRef="USDPShares">5.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000672"
      unitRef="USD">15176855</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000681">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2YVgwyiK376" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B7_z68Fo18hTGsi" style="display: none"&gt;Schedule of summarizes information about stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zKnsCyiAjbw7" style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zqSFAzGAh9k4" style="width: 11%; text-align: right" title="Range of exercise prices, Upper range limit"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zDdyTnQoyzci" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,015,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjowsLPUAp12" title="Weighted average remaining contractual life"&gt;3.79&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zl8YkrHgTAhg" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdwqQ4ozmBqd" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,015,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zjEnt80JFkO9" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zFs6okO3fwEd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zqBReWOji9Vj" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zH8xy90eCWLk" style="text-align: right" title="Number of outstanding options"&gt;2,267,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_ziTWkBIVvmZ4" title="Weighted average remaining contractual life"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z1bYzPLt6MA3" style="text-align: right" title="Weighted average exercise price"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zv1CWYPyXMSd" style="text-align: right" title="Number of vested options"&gt;2,056,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_znR0tyhcDjdi" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHErj6uIlhle" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvUdvToDrSr" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zefhqZJERt9e" style="text-align: right" title="Number of outstanding options"&gt;6,640,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zHu9lRBkqU1b" title="Weighted average remaining contractual life"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zAwjOi5bd1He" style="text-align: right" title="Weighted average exercise price"&gt;6.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zhLOzuGk2cZa" style="text-align: right" title="Number of vested options"&gt;3,473,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zRLtybyWOCw3" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zwgjH4CudMMd" style="padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zHbXDbyucZag" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zAzTAGC3i8Hc" style="text-align: right" title="Number of outstanding options"&gt;1,649,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zjtL6f21Ij98" title="Weighted average remaining contractual life"&gt;7.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zfzOK1oMVFth" style="text-align: right" title="Weighted average exercise price"&gt;10.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zouJsfyRROXh" style="text-align: right" title="Number of vested options"&gt;760,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zJcbeYjhrGt8" style="text-align: right" title="Weighted average exercise price options vested"&gt;10.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUVTVmMIz5bg" style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Range of exercise prices, Lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zTRX6VFAciHc" style="text-align: right" title="Range of exercise prices, Upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKia0Yvbyx1b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,465,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRXry7ZoAYG3" title="Weighted average remaining contractual life"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXDhjTnxgqC" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.18&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zExs2DKoYFoc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;605,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_z3Z0f4RuhDm6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.47&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7WiabqsG4Pl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;15,037,754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzOS46JZKPbg" title="Weighted average remaining contractual life"&gt;5.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze3OZD5jIuyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price"&gt;6.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zv7ks6Ny45x1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;9,910,590&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcbaT8u383oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested"&gt;5.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000683"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000685"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000687"
      unitRef="Shares">3015700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      id="Fact000689">P3Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000691"
      unitRef="USDPShares">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">3015700</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000697"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000699"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000701"
      unitRef="Shares">2267500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      id="Fact000703">P4Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000705"
      unitRef="USDPShares">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000707"
      unitRef="Shares">2056250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000709"
      unitRef="USDPShares">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000713"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000715"
      unitRef="Shares">6640554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      id="Fact000717">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000719"
      unitRef="USDPShares">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">3473639</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000725"
      unitRef="USDPShares">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">13.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">1649000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      id="Fact000731">P7Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000733"
      unitRef="USDPShares">10.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">760000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000737"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000739"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000741"
      unitRef="USDPShares">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">1465000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      id="Fact000745">P6Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000747"
      unitRef="USDPShares">18.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000749"
      unitRef="Shares">605001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000751"
      unitRef="USDPShares">18.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000753"
      unitRef="Shares">15037754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      id="Fact000755">P5Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000757"
      unitRef="USDPShares">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">9910590</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000761"
      unitRef="USDPShares">5.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000763"
      unitRef="USDPShares">4.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-10-01to2024-09-30" id="Fact000767">P5Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-09-30" id="Fact000769">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-10-01to2024-09-30" id="Fact000771">P4Y10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-09-30" id="Fact000773">P4Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="Fact000775"
      unitRef="USD">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000777"
      unitRef="USD">16400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000779">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zi2FVOcwWNha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B8_z2tVgKm7mwUi" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zp9OpXIsV36a" style="width: 12%; text-align: right" title="Total share based compensation"&gt;3,625&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFxQwPTmIz11" style="width: 12%; text-align: right" title="Total share based compensation"&gt;5,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyDyahjVnw1c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;5,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmVbu9HVINJa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;10,812&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240930_zY0w9hpDCWCf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,438&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230930_zqU4aiHPBqac" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;16,370&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000781"
      unitRef="USD">3625000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000783"
      unitRef="USD">5558000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000785"
      unitRef="USD">5813000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000787"
      unitRef="USD">10812000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000789"
      unitRef="USD">9438000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000791"
      unitRef="USD">16370000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000793"
      unitRef="USD">8400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000795">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_ztvANBNBKOd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zGx432uQE2A4" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240930_zmVvhw0wUJUk" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230930_zk9aeGxWv1f6" title="Risk-free interest rate"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240930_zKcOrtuCNxVj" title="Expected life of options (years)"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230930_zvMR7rgFHMMg" title="Expected life of options (years)"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240930_znTGYHoJmyzd" title="Annualized volatility"&gt;84.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230930_zQyr91zB3pV3" title="Annualized volatility"&gt;85.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240930_zDdrcqcPiXgc" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230930_zZxC4dNmLus5" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000797"
      unitRef="Pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000799"
      unitRef="Pure">0.0370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-10-01to2024-09-30" id="Fact000801">P5Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-10-012023-09-30" id="Fact000803">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000805"
      unitRef="Pure">0.8481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000807"
      unitRef="Pure">0.8513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="Fact000809"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-012023-09-30"
      decimals="INF"
      id="Fact000811"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000820">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_z8QYnm9qtxSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 7	 	&lt;span id="xdx_827_zcEPileDpSC2"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s U.S. and foreign loss before income
taxes are set forth below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zHTmOjgJIYk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_z7HyZ8TCOyec" style="display: none"&gt;Schedule of loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20231001_20240930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221001_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(39,195&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(41,198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,807&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,300&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(43,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(47,498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zPW5pZgLedye" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of net deferred income tax assets as of September 30, 2024
and 2023 are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zRVU4M8bO6H5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zWHOKKQJ26yf" style="display: none"&gt;Schedule of components of net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240930_zGRKXFJ26cP3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930_zlqiytEYB4ug" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;48,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;46,462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Unpaid charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible asset costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zG0mt9nm9ho3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign exchange and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(254&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_z6h5f6BjiZC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance of deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(92,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(77,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zt8cAN4PUdM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of income tax expense at the statutory
federal income tax rate and income taxes as reflected in the consolidated financial statements for the years ended September 30, 2024
and 2023 is as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zs1csAl6SFD6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zLKUUUwRbwp9" style="display: none"&gt;Schedule of reconciliation of income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20231001__20240930_zfSNRerA5OV6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20221001__20230930_zPiGwBdkJhzl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Income tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(9,030&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(9,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign income taxed at other rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(601&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to GILTI inclusion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(276&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development credits, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(860&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;State and local taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,122&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Adjustment to true up to prior years&#x2019; tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,186&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,098&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zXo4lZdi2t5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2024, the Company had U.S. federal
net operating loss carryforwards of approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"&gt;128.5&lt;/span&gt; million (2023: $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"&gt;126.3&lt;/span&gt; million) of which &lt;span id="xdx_905_ecustom--OperatingLossCarryforwardsDescription_c20231001__20240930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember" title="Operating loss carryforwards description"&gt;$37.7 million will begin to expire in
2025 and $90.8 million can be carried forward indefinitely&lt;/span&gt;, state and local net operating loss carryforwards of approximately $ &lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pn5n6" title="Operating loss carryforwards"&gt;16.9&lt;/span&gt; million
(2023: $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pn5n6" title="Operating loss carryforwards"&gt;16.6&lt;/span&gt; million) which will begin to expire in &lt;span id="xdx_90E_ecustom--OperatingLossCarryForwardsExpirationYear_c20231001__20240930" title="Operating loss carry forwards expiration year"&gt;2036&lt;/span&gt;, and Research and Development tax credits of approximately $&lt;span id="xdx_908_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20231001__20240930_pn5n6" title="Research and Development tax credits"&gt;4.3&lt;/span&gt; million (2023:
$&lt;span id="xdx_90A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20221001__20230930_pn5n6" title="Research and Development tax credits"&gt;2.7&lt;/span&gt; million) which will begin to expire in &lt;span id="xdx_904_ecustom--ResearchAndDevelopmentTaxCreditsYear_c20231001__20240930" title="Research and development tax credits year"&gt;2029&lt;/span&gt;. The calculation of the Research and Development tax credits, by their nature, involve
estimates and subjectivity. If examined by the U.S. federal and state tax authorities, it is possible that some portion of these credit
carryforwards would be disputed by the tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company had approximately $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn5n6" title="Operating loss carryforwards"&gt;16.6&lt;/span&gt; million (approximately
AU$&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20240930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_pn5n6" title="Operating loss carryforwards"&gt;23.9&lt;/span&gt; million) (2023: $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pn5n6" title="Operating loss carryforwards"&gt;12.9&lt;/span&gt; million (approximately AU$&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_c20230930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_pn5n6" title="Operating loss carryforwards"&gt;20.1&lt;/span&gt; million)) of net operating loss carryforwards in Australia, which have an
indefinite life, available to offset future taxable income in those jurisdictions.&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates its valuation allowance requirements
based on available evidence. When circumstances change, and this causes a change in management&#x2019;s judgment about the recoverability
of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income. Because management of the
Company does not currently believe that it is more likely than not that the Company will receive the benefit of these assets, a valuation
allowance has been established at September 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Tax Cuts and Jobs Act of 2017 (TCJA) has modified
the IRC 174 expenses related to research and development for tax years beginning after December 31, 2021. Under the TCJA, the Company
must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and
15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development costs in accordance
with IRC 174 has resulted in a gross deferred tax assets at September 30, 2024 of $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_c20240930_pn5n6" title="Gross deferred tax asset"&gt;15.1&lt;/span&gt; million (2023: $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsGross_iI_pn5n6_c20230930_z8yalo9nOo7j" title="Gross deferred tax asset"&gt;7.2&lt;/span&gt; million).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Uncertain Tax Positions&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files income tax returns in the U.S. federal
jurisdiction and various state and local and foreign jurisdictions. The Company&#x2019;s tax returns are subject to tax examinations by
U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire.
The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the provisions of the Internal Revenue Code,
the net operating loss (&#x201c;NOL&#x201d;) carryforwards are subject to review and possible adjustment by the Internal Revenue Service
and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may become subject to an annual
limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over a three-year period,
as well as similar state tax provisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company conducted a Section 382 study during the
year ended September 30, 2021 and determined that, during the year ended September 30, 2015, there was a change in ownership which resulted
in $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20150930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_pn5n6" title="Operating loss carryforwards"&gt;25.8&lt;/span&gt; million of federal NOLs being subject to an annual limitation. During the year ended September 30, 2021, the Company reduced
its federal NOLs by $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zmd7nUtQtTa9" title="Operating loss carryforwards"&gt;12.1&lt;/span&gt; million and its Research and Development tax credit carryforwards by $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20210930_z93tCgCjYeK5" title="Research and development tax credit carryforwards"&gt;0.8&lt;/span&gt; million, which are the amount of tax
assets that will expire unutilized pursuant to the Section 382 study. This resulted in a reduction of $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20210930_zmQtWtpoiQVj" title="Operating loss carryforwards"&gt;2.5&lt;/span&gt; million of NOLs and $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20210930_zZeW3liPXk17" title="Research and development tax credit carryforwards"&gt;0.8&lt;/span&gt; million
of research and development credits and a corresponding reduction in the valuation allowance of $&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20201001__20210930_zlq9EDiyUjZi" title="Decrease in valuation allowance"&gt;3.3&lt;/span&gt; million, which was recorded in the
2021 fiscal year. Subsequent ownership changes in future years could trigger additional limitations of the Company&#x2019;s NOLs&lt;span style="background-color: white"&gt;.
During the year ended September 30, 2024 and 2023 the Company determined that there were no changes in ownership pursuant to Section 382.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2024, the Company did not provide
any foreign withholding taxes related to its foreign subsidiaries&#x2019; undistributed earnings, as such earnings have been retained and
are intended to be indefinitely reinvested to fund ongoing operations of the foreign subsidiaries. It is not practicable to estimate the
amount of taxes that would be payable upon remittance of these earnings, because such tax, if any, is dependent upon circumstances existing
if and when remittance occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000822">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zHTmOjgJIYk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_z7HyZ8TCOyec" style="display: none"&gt;Schedule of loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20231001_20240930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221001_20230930" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(39,195&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(41,198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,807&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,300&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(43,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(47,498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">-39195000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000825"
      unitRef="USD">-41198000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">-3807000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000828"
      unitRef="USD">-6300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000830"
      unitRef="USD">-43002000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">-47498000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000833">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zRVU4M8bO6H5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zWHOKKQJ26yf" style="display: none"&gt;Schedule of components of net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240930_zGRKXFJ26cP3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20230930_zlqiytEYB4ug" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;48,134&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;46,462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsResearchAndDevelopmentCapitalization_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Unpaid charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Intangible asset costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ForeignExchangeAndOther_iNI_pn3n3_di_zG0mt9nm9ho3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign exchange and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(254&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_z6h5f6BjiZC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance of deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(92,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(77,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">48134000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000836"
      unitRef="USD">46462000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000838"
      unitRef="USD">4203000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">2713000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">21091000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">18593000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000844"
      unitRef="USD">15104000</avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">7219000</avxl:DeferredTaxAssetsResearchAndDevelopmentCapitalization>
    <avxl:DeferredTaxAssetsUnpaidCharges
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">3197000</avxl:DeferredTaxAssetsUnpaidCharges>
    <avxl:DeferredTaxAssetsUnpaidCharges
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">1559000</avxl:DeferredTaxAssetsUnpaidCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000850"
      unitRef="USD">758000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">593000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <avxl:ForeignExchangeAndOther
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000853"
      unitRef="USD">254000</avxl:ForeignExchangeAndOther>
    <avxl:ForeignExchangeAndOther
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">-49000</avxl:ForeignExchangeAndOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000856"
      unitRef="USD">92233000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">77188000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000862">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_pn3n3_zs1csAl6SFD6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zLKUUUwRbwp9" style="display: none"&gt;Schedule of reconciliation of income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20231001__20240930_zfSNRerA5OV6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20221001__20230930_zPiGwBdkJhzl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Income tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(9,030&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(9,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Foreign income taxed at other rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(601&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Permanent differences relating to GILTI inclusion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(276&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development credits, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(860&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;State and local taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,821&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,122&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Adjustment to true up to prior years&#x2019; tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,186&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,098&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000864"
      unitRef="USD">-9030000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000865"
      unitRef="USD">-9975000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">-61000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000870"
      unitRef="USD">-10000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <avxl:PermanentDifferencesRelatingToStockBasedCompensation
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000871"
      unitRef="USD">-601000</avxl:PermanentDifferencesRelatingToStockBasedCompensation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">165000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">-276000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000877"
      unitRef="USD">273000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">-860000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000880"
      unitRef="USD">-37000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">-3821000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000883"
      unitRef="USD">-4122000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">-1128000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">206000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-10-01to2024-09-30"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">15186000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000889"
      unitRef="USD">14098000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-10-012023-09-30"
      decimals="-3"
      id="Fact000892"
      unitRef="USD">7000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_custom_FederalMember"
      decimals="-5"
      id="Fact000894"
      unitRef="USD">128500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-09-30_custom_FederalMember"
      decimals="-5"
      id="Fact000896"
      unitRef="USD">126300000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryforwardsDescription
      contextRef="From2023-10-012024-09-30_custom_FederalMember"
      id="Fact000898">$37.7 million will begin to expire in
2025 and $90.8 million can be carried forward indefinitely</avxl:OperatingLossCarryforwardsDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact000900"
      unitRef="USD">16900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-09-30_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact000902"
      unitRef="USD">16600000</us-gaap:OperatingLossCarryforwards>
    <avxl:OperatingLossCarryForwardsExpirationYear contextRef="From2023-10-01to2024-09-30" id="Fact000904">2036</avxl:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="Fact000906"
      unitRef="USD">4300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000908"
      unitRef="USD">2700000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <avxl:ResearchAndDevelopmentTaxCreditsYear contextRef="From2023-10-01to2024-09-30" id="Fact000910">2029</avxl:ResearchAndDevelopmentTaxCreditsYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact000912"
      unitRef="USD">16600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="-5"
      id="Fact000914"
      unitRef="USD">23900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-09-30_us-gaap_ForeignCountryMember"
      decimals="-5"
      id="Fact000916"
      unitRef="USD">12900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="-5"
      id="Fact000918"
      unitRef="USD">20100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000927"
      unitRef="USD">15100000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000929"
      unitRef="USD">7200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2015-09-30_custom_FederalMember"
      decimals="-5"
      id="Fact000931"
      unitRef="USD">25800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-09-30_custom_FederalMember"
      decimals="-5"
      id="Fact000933"
      unitRef="USD">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2021-09-30"
      decimals="-5"
      id="Fact000935"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-09-30"
      decimals="-5"
      id="Fact000937"
      unitRef="USD">2500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2021-09-30"
      decimals="-5"
      id="Fact000939"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2020-10-012021-09-30"
      decimals="-5"
      id="Fact000941"
      unitRef="USD">3300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-10-01to2024-09-30" id="Fact000943">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zLlyvChHMtGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note
8	&lt;span id="xdx_822_zpnru012Oyt9"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#x2019;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There were no subsequent events or transactions that
required recognition or disclosure in the consolidated financial statements.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-07-012024-09-30" id="Fact000944">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-07-012024-09-30" id="Fact000945">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-07-012024-09-30" id="Fact000946">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-07-012024-09-30" id="Fact000947">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
